{"id": "1_1", "text": "Tremor, muscle stiffness, and slowness of movement are symptoms of Parkinson's disease.", "tags": [{"end": 6, "start": 0, "tag": "SignOrSymptom"}, {"end": 24, "start": 8, "tag": "SignOrSymptom"}, {"end": 63, "start": 55, "tag": "SignOrSymptom"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 30, "tag": "SignOrSymptom"}]}
{"id": "1_7", "text": "Our results can be used to mathematically study the mechanisms behind these diseases.", "tags": [{"end": 47, "start": 42, "tag": "ResearchActivity"}]}
{"id": "2_2", "text": "This process preserves mitochondrial health.", "tags": [{"end": 36, "start": 23, "tag": "CellComponent"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}]}
{"id": "2_3", "text": "However, defective mitophagy triggers the accumulation of damaged mitochondria, causing major neurodegenerative disorders.", "tags": [{"end": 121, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 66, "tag": "CellComponent"}, {"end": 78, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 9, "tag": "CellOrMolecularDysfunction"}]}
{"id": "2_4", "text": "This review introduces molecular mechanisms and signaling pathways behind mitophagy regulation.", "tags": [{"end": 94, "start": 74, "tag": "CellFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 66, "start": 48, "tag": "CellFunction"}, {"end": 43, "start": 23, "tag": "CellFunction"}]}
{"id": "4_6", "text": "Olfactory dysfunction is present in both premanifest and manifest patients with HD, showing a progressive decline over time with more severe deficits at advanced stages.", "tags": [{"end": 21, "start": 0, "tag": "PathologicFunction"}, {"end": 65, "start": 57, "tag": "SignOrSymptom"}, {"end": 168, "start": 153, "tag": "TemporalConcept"}, {"end": 82, "start": 66, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 119, "tag": "TemporalConcept"}, {"end": 149, "start": 134, "tag": "Finding"}, {"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "Finding"}]}
{"id": "9_2", "text": "Also emerging are the roles of other polyglutamine disease proteins in DNA damage repair mechanisms.", "tags": [{"end": 50, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "CellFunction"}]}
{"id": "10_0", "text": "There has been substantial progress in the development of regenerative medicine strategies for CNS disorders over the last decade, with progression to early clinical studies for some conditions.", "tags": [{"end": 108, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 157, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "TemporalConcept"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 79, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}]}
{"id": "10_3", "text": "Furthermore, clinical trials that incorporate principles of efficient design and disease-specific outcomes are urgently needed (particularly for those undertaken in rare diseases, where relatively small cohorts are an additional limiting factor), and all processes must be adaptable in a dynamic regulatory environment.", "tags": [{"end": 28, "start": 13, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "HealthCareActivity"}, {"end": 178, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 203, "tag": "PopulationGroup"}, {"end": 106, "start": 81, "tag": "HealthCareActivity"}]}
{"id": "11_5", "text": "Spectral-domain Optical Coherence Tomography (SD-OCT) was used to evaluate the macular thickness and peripapillary retinal nerve fiber layer (pRNFL).", "tags": [{"end": 147, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 79, "tag": "ClinicalAttribute"}, {"end": 140, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}, {"end": 44, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "11_11", "text": "Age and disease duration were negatively correlated with macular thickness in HD patients.", "tags": [{"end": 24, "start": 8, "tag": "TemporalConcept"}, {"end": 74, "start": 57, "tag": "SignOrSymptom"}, {"end": 89, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}]}
{"id": "11_14", "text": "It can support the hypothesis that the retina may be a potential biomarker for monitoring the neurodegenerative process in HD.", "tags": [{"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "Cell"}, {"end": 74, "start": 55, "tag": "ClinicalAttribute"}, {"end": 119, "start": 94, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "HealthCareActivity"}]}
{"id": "12_0", "text": "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 129, "tag": "BiologicFunction"}, {"end": 191, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "BiologicFunction"}, {"end": 68, "start": 63, "tag": "PathologicFunction"}, {"end": 125, "start": 90, "tag": "ClinicalAttribute"}]}
{"id": "12_3", "text": "Cumulative evidence indicates that melatonin has a wide range of neuroprotective roles by regulating pathophysiological mechanisms and signaling pathways.", "tags": [{"end": 19, "start": 0, "tag": "Finding"}, {"end": 130, "start": 90, "tag": "BiologicFunction"}, {"end": 119, "start": 101, "tag": "PathologicFunction"}, {"end": 153, "start": 135, "tag": "CellFunction"}, {"end": 86, "start": 65, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 35, "tag": "Chemical"}]}
{"id": "13_3", "text": "There are currently still no treatments available for HD, but approaches targeting the HTT levels offer systematic, mechanism-driven routes towards curing HD and other neurodegenerative diseases.", "tags": [{"end": 39, "start": 26, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "TemporalConcept"}, {"end": 39, "start": 29, "tag": "HealthCareActivity"}, {"end": 39, "start": 29, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}]}
{"id": "14_9", "text": "Conclusions Provision of primary palliative care for HD in an interdisciplinary clinic is feasible.", "tags": [{"end": 21, "start": 12, "tag": "HealthCareActivity"}, {"end": 48, "start": 25, "tag": "HealthCareActivity"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 62, "tag": "HealthCareRelatedOrganization"}]}
{"id": "27_8", "text": "As an ideal biorecognition element for neurodegenerative disease detection, the chapter summarizes recent advances on aptamers and their application in the detection of neurodegenerative diseases.", "tags": [{"end": 126, "start": 118, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 165, "start": 156, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "Finding"}, {"end": 105, "start": 99, "tag": "TemporalConcept"}, {"end": 195, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 39, "tag": "DiseaseOrSyndrome"}]}
{"id": "28_1", "text": "The disease is inherited in an autosomal dominant fashion by an increased number of CAG repeats on the short arm of chromosome 4p16.3 in the Huntingtin gene.", "tags": [{"end": 95, "start": 84, "tag": "MolecularSequence"}, {"end": 49, "start": 31, "tag": "CellFunction"}, {"end": 49, "start": 41, "tag": "CellFunction"}, {"end": 24, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 141, "tag": "GeneOrGenome"}, {"end": 133, "start": 103, "tag": "CellComponent"}]}
{"id": "28_5", "text": "There is no cure for the disease, and there is a high rate of neuropsychiatric symptoms including depression, and aggressive behavior.", "tags": [{"end": 133, "start": 114, "tag": "IndividualBehavior"}, {"end": 16, "start": 9, "tag": "Finding"}, {"end": 87, "start": 62, "tag": "SignOrSymptom"}, {"end": 108, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 54, "tag": "TemporalConcept"}]}
{"id": "36_0", "text": "Substantial evidence indicates that oxidative/nitrosative stress contributes to the neurodegenerative diseases.", "tags": [{"end": 64, "start": 36, "tag": "NaturalPhenomenonOrProcess"}, {"end": 20, "start": 12, "tag": "Finding"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}]}
{"id": "45_0", "text": "There is a growing body of evidence that prionoid protein behaviors are a core element of neurodegenerative diseases (NDs) that afflict humans.", "tags": [{"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 142, "start": 136, "tag": "Eukaryote"}, {"end": 116, "start": 90, "tag": "DiseaseOrSyndrome"}]}
{"id": "47_1", "text": "The neuronal damage caused by these diseases may be associated with abnormal alterations of connexins in glia.", "tags": [{"end": 88, "start": 68, "tag": "Finding"}, {"end": 76, "start": 68, "tag": "Cell"}, {"end": 101, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 105, "tag": "Cell"}, {"end": 12, "start": 4, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "InjuryOrPoisoning"}]}
{"id": "76_6", "text": "In Huntington's disease male mice, we revealed an inefficiency of FMT engraftment, which is potentially due to the more pronounced changes in the structure, composition and instability of the gut microbial community, and the imbalance in acetate and gut immune profiles found in these mice.", "tags": [{"end": 62, "start": 50, "tag": "Finding"}, {"end": 69, "start": 66, "tag": "HealthCareActivity"}, {"end": 184, "start": 173, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 215, "start": 196, "tag": "Organism"}, {"end": 245, "start": 238, "tag": "Chemical"}, {"end": 269, "start": 238, "tag": "ResearchActivity"}, {"end": 234, "start": 225, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 24, "tag": "OrganismAttribute"}, {"end": 81, "start": 70, "tag": "ResearchActivity"}, {"end": 81, "start": 70, "tag": "HealthCareActivity"}, {"end": 33, "start": 29, "tag": "Eukaryote"}, {"end": 289, "start": 285, "tag": "Eukaryote"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 131, "tag": "Finding"}]}
{"id": "78_6", "text": "We put special emphasis on intricate We not only describe aberrant changes in p53 level/activity observed in CNS regions affected by particular diseases but, most importantly, put special attention to the complicated reciprocal tuning connections prevailing between p53 and molecules considered in pathological hallmarks of these disorders.", "tags": [{"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 269, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 266, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 58, "tag": "PathologicFunction"}, {"end": 320, "start": 311, "tag": "Finding"}, {"end": 283, "start": 274, "tag": "Substance"}, {"end": 112, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 188, "tag": "BiologicFunction"}, {"end": 74, "start": 67, "tag": "Finding"}]}
{"id": "86_5", "text": "Based on our systematic review, treatment with stem cells significantly improves neurological and behavioral outcomes in animal models of HD.", "tags": [{"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 30, "start": 13, "tag": "HealthCareActivity"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 41, "start": 32, "tag": "HealthCareActivity"}, {"end": 41, "start": 32, "tag": "ResearchActivity"}, {"end": 134, "start": 121, "tag": "ResearchActivity"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 81, "tag": "Finding"}, {"end": 140, "start": 121, "tag": "ExperimentalModelOfDisease"}]}
{"id": "102_2", "text": "We introduce the first case of a HD patient with CVT, iron-deficiency anemia and neutropenia.", "tags": [{"end": 27, "start": 23, "tag": "ManufacturedObject"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 49, "tag": "PathologicFunction"}, {"end": 69, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 33, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 81, "tag": "AnatomicalAbnormality"}]}
{"id": "271_4", "text": "This work investigates the potential of classifying patient disease severity based on individual footstep pressure data using deep learning techniques.", "tags": [{"end": 105, "start": 86, "tag": "OrganismAttribute"}, {"end": 76, "start": 60, "tag": "ClinicalAttribute"}, {"end": 76, "start": 60, "tag": "Finding"}, {"end": 119, "start": 115, "tag": "ResearchActivity"}, {"end": 59, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 97, "tag": "ClinicalAttribute"}, {"end": 150, "start": 126, "tag": "MachineActivity"}]}
{"id": "342_3", "text": "Since the retina is an extension of the brain and shares a common embryological origin with the central nervous system, there has also been intense interest in leveraging the expanding armamentarium of retinal imaging technology to understand, diagnose and monitor neurological diseases.", "tags": [{"end": 86, "start": 66, "tag": "EmbryonicStructure"}, {"end": 228, "start": 202, "tag": "HealthCareActivity"}, {"end": 264, "start": 257, "tag": "HealthCareActivity"}, {"end": 264, "start": 257, "tag": "ManufacturedObject"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 265, "tag": "DiseaseOrSyndrome"}]}
{"id": "629_2", "text": "We used mutant Huntingtin (mHTT) expressing bacterial artificial chromosome Huntington's disease mice to determine if they exhibit electrocardiogram (ECG) abnormalities involving cardiac conduction that are known to increase risk of sudden arrhythmic death in humans.", "tags": [{"end": 25, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 44, "tag": "Bacterium"}, {"end": 197, "start": 179, "tag": "BiologicFunction"}, {"end": 31, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 8, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 256, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 260, "tag": "Eukaryote"}, {"end": 101, "start": 97, "tag": "Eukaryote"}, {"end": 148, "start": 131, "tag": "HealthCareActivity"}, {"end": 148, "start": 131, "tag": "ManufacturedObject"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "ManufacturedObject"}, {"end": 229, "start": 225, "tag": "Finding"}, {"end": 96, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 44, "tag": "ManufacturedObject"}, {"end": 101, "start": 44, "tag": "ExperimentalModelOfDisease"}, {"end": 168, "start": 155, "tag": "Finding"}]}
{"id": "1066_1", "text": "Previous literature has focused on the direct effects of the air pollution components on neuronal and glial cells, as well as on involvement of oxidative stress and neuroinflammation on microglia and astrocyte reactivity.", "tags": [{"end": 56, "start": 46, "tag": "PathologicFunction"}, {"end": 74, "start": 61, "tag": "EnvironmentalEffectOfHumans"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}, {"end": 113, "start": 102, "tag": "Cell"}, {"end": 97, "start": 89, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 160, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 209, "start": 200, "tag": "Cell"}, {"end": 85, "start": 75, "tag": "CellComponent"}, {"end": 140, "start": 129, "tag": "Finding"}, {"end": 182, "start": 165, "tag": "PathologicFunction"}, {"end": 195, "start": 186, "tag": "Cell"}, {"end": 220, "start": 200, "tag": "CellFunction"}, {"end": 220, "start": 210, "tag": "CellFunction"}, {"end": 195, "start": 186, "tag": "CellFunction"}]}
{"id": "1084_0", "text": "People living with HIV (PLH) have significantly higher rates of cognitive impairment (CI) and major depressive disorder (MDD) versus the general population.", "tags": [{"end": 119, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 137, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 22, "start": 19, "tag": "Virus"}, {"end": 155, "start": 145, "tag": "PopulationGroup"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "Finding"}, {"end": 27, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}]}
{"id": "1266_7", "text": "The development of high-resolution technologies to profile individual cells has greatly contributed to our understanding of microglia heterogeneity and function under normal and pathological conditions.", "tags": [{"end": 147, "start": 134, "tag": "OrganismAttribute"}, {"end": 201, "start": 178, "tag": "PathologicFunction"}, {"end": 75, "start": 70, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "Cell"}, {"end": 120, "start": 107, "tag": "BiologicFunction"}, {"end": 173, "start": 167, "tag": "Finding"}, {"end": 47, "start": 19, "tag": "ResearchActivity"}]}
{"id": "1266_8", "text": "Gene expression profiling technologies have evolved from whole tissue RNA sequencing toward single-cell or nucleus sequencing.", "tags": [{"end": 38, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 70, "tag": "ResearchActivity"}, {"end": 125, "start": 115, "tag": "ResearchActivity"}, {"end": 103, "start": 92, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "Chemical"}, {"end": 114, "start": 107, "tag": "CellComponent"}, {"end": 84, "start": 57, "tag": "ResearchActivity"}, {"end": 125, "start": 107, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}]}
{"id": "1266_9", "text": "Single microglia proteomic profiles are also increasingly generated, offering another layer of high-resolution data.", "tags": [{"end": 35, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 95, "tag": "ResearchActivity"}]}
{"id": "1266_10", "text": "Here, we will review recent studies that have employed these technologies in the context of MS and their respective advantages and disadvantages.", "tags": [{"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 27, "start": 21, "tag": "TemporalConcept"}, {"end": 73, "start": 61, "tag": "BiomedicalOccupationOrDiscipline"}]}
{"id": "1266_11", "text": "Moreover, recent developments that allow for (single) cell profiling while retaining spatial information and tissue context will be discussed.", "tags": [{"end": 29, "start": 17, "tag": "BiologicFunction"}, {"end": 29, "start": 17, "tag": "CellFunction"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "TemporalConcept"}, {"end": 68, "start": 45, "tag": "ResearchActivity"}]}
{"id": "1267_0", "text": "We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models.", "tags": [{"end": 143, "start": 137, "tag": "Eukaryote"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 157, "start": 144, "tag": "PathologicFunction"}, {"end": 107, "start": 92, "tag": "CellFunction"}, {"end": 164, "start": 158, "tag": "ResearchActivity"}, {"end": 107, "start": 61, "tag": "CellFunction"}, {"end": 50, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 137, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1267_1", "text": "We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 82, "start": 72, "tag": "Chemical"}, {"end": 87, "start": 84, "tag": "Chemical"}, {"end": 218, "start": 177, "tag": "ExperimentalModelOfDisease"}, {"end": 223, "start": 220, "tag": "ExperimentalModelOfDisease"}, {"end": 118, "start": 111, "tag": "Chemical"}, {"end": 149, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 127, "start": 120, "tag": "Chemical"}]}
{"id": "1267_2", "text": "Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes.", "tags": [{"end": 57, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 75, "tag": "Chemical"}, {"end": 238, "start": 226, "tag": "PathologicFunction"}, {"end": 30, "start": 22, "tag": "ExperimentalModelOfDisease"}, {"end": 20, "start": 12, "tag": "PopulationGroup"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 244, "start": 239, "tag": "CellComponent"}, {"end": 270, "start": 254, "tag": "Cell"}, {"end": 166, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 202, "tag": "CellComponent"}, {"end": 99, "start": 92, "tag": "Chemical"}, {"end": 186, "start": 180, "tag": "InjuryOrPoisoning"}]}
{"id": "1267_3", "text": "T3 and Sob also protected cultured oligodendrocytes against cell death.", "tags": [{"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 7, "tag": "Chemical"}, {"end": 34, "start": 26, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "CellFunction"}, {"end": 51, "start": 35, "tag": "Cell"}]}
{"id": "1267_4", "text": "Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.", "tags": [{"end": 62, "start": 57, "tag": "CellFunction"}, {"end": 56, "start": 41, "tag": "Cell"}, {"end": 158, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 123, "tag": "CellFunction"}, {"end": 77, "start": 64, "tag": "PathologicFunction"}, {"end": 88, "start": 82, "tag": "CellComponent"}, {"end": 101, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 57, "tag": "PathologicFunction"}, {"end": 62, "start": 57, "tag": "BiologicFunction"}]}
{"id": "1268_0", "text": "Inside the adult CNS, oligodendrocyte progenitor cells (OPCS) are able to proliferate, migrate and differentiate into mature oligodendrocytes (OLs) which are responsible for the production of myelin sheet and energy supply for neurons.", "tags": [{"end": 60, "start": 56, "tag": "Cell"}, {"end": 112, "start": 99, "tag": "CellFunction"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 118, "tag": "Cell"}, {"end": 54, "start": 22, "tag": "Cell"}, {"end": 146, "start": 143, "tag": "Cell"}, {"end": 234, "start": 227, "tag": "Cell"}, {"end": 215, "start": 209, "tag": "NaturalPhenomenonOrProcess"}, {"end": 16, "start": 11, "tag": "PopulationGroup"}]}
{"id": "1268_1", "text": "Moreover, in demyelinating diseases, OPCs are recruited to the lesion areas where they undergo differentiation and myelin synthesis.", "tags": [{"end": 41, "start": 37, "tag": "Cell"}, {"end": 35, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 63, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 95, "tag": "CellFunction"}, {"end": 131, "start": 115, "tag": "CellFunction"}]}
{"id": "1268_2", "text": "Serotonin (5-hydroxytryptamine, 5-HT) is involved in OLs' development and myelination, but so far the molecular mechanisms involved or the effects of 5-HT on mitochondria function have not yet been well documented.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 11, "tag": "Chemical"}, {"end": 30, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 32, "tag": "Chemical"}, {"end": 154, "start": 150, "tag": "Chemical"}, {"end": 213, "start": 203, "tag": "HealthCareActivity"}, {"end": 170, "start": 158, "tag": "CellComponent"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 69, "start": 58, "tag": "BiologicFunction"}, {"end": 69, "start": 58, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "Cell"}, {"end": 122, "start": 102, "tag": "CellFunction"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 150, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1268_3", "text": "Our data show that 5-HT inhibits migration and proliferation committing cells toward differentiation in an immortalized human oligodendrocyte precursor cell line, M03-13.", "tags": [{"end": 23, "start": 19, "tag": "Chemical"}, {"end": 161, "start": 107, "tag": "Cell"}, {"end": 77, "start": 72, "tag": "Cell"}, {"end": 100, "start": 85, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 60, "start": 47, "tag": "CellFunction"}, {"end": 42, "start": 33, "tag": "CellFunction"}, {"end": 156, "start": 126, "tag": "Cell"}, {"end": 125, "start": 120, "tag": "Eukaryote"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 163, "tag": "Cell"}]}
{"id": "1268_4", "text": "Migration blockage is mediated by reactive oxygen species (ROS) generation since antioxidants, such as Vit C and Cu-Zn superoxide dismutase, prevent the inhibitory effects of 5-HT on cell migration.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 108, "start": 103, "tag": "Chemical"}, {"end": 139, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 175, "tag": "Chemical"}, {"end": 197, "start": 183, "tag": "CellFunction"}, {"end": 93, "start": 81, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 50, "tag": "OrganismAttribute"}, {"end": 57, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 34, "tag": "Chemical"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "Chemical"}, {"end": 163, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 164, "tag": "PathologicFunction"}, {"end": 74, "start": 64, "tag": "TemporalConcept"}, {"end": 179, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1268_5", "text": "5-HT inhibits OPC migration and proliferation and increases OL phenotypic markers myelin basic protein (MBP) and Olig-2 via protein kinase C (PKC) activation since the inhibitor of PKC, bis-indolyl-maleimide (BIM), counteracts 5-HT effects.", "tags": [{"end": 4, "start": 0, "tag": "Chemical"}, {"end": 119, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 227, "tag": "Chemical"}, {"end": 73, "start": 63, "tag": "OrganismAttribute"}, {"end": 177, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 168, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 168, "tag": "Chemical"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "GeneOrGenome"}, {"end": 17, "start": 14, "tag": "Cell"}, {"end": 62, "start": 60, "tag": "Cell"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 27, "start": 18, "tag": "CellFunction"}, {"end": 102, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 74, "tag": "ClinicalAttribute"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 186, "tag": "Chemical"}, {"end": 207, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 209, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 209, "tag": "Chemical"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1268_6", "text": "NOX inhibitors as well, reverse the effects of 5-HT, indicating that 5-HT influences the maturation process of OPCs by NOX-dependent ROS production.", "tags": [{"end": 51, "start": 47, "tag": "Chemical"}, {"end": 73, "start": 69, "tag": "Chemical"}, {"end": 147, "start": 133, "tag": "CellFunction"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 133, "tag": "Chemical"}, {"end": 115, "start": 111, "tag": "Cell"}, {"end": 99, "start": 89, "tag": "BiologicFunction"}, {"end": 14, "start": 4, "tag": "Chemical"}, {"end": 14, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1268_7", "text": "Finally, 5-HT increases mitochondria function and antioxidant activity.", "tags": [{"end": 13, "start": 9, "tag": "Chemical"}, {"end": 70, "start": 50, "tag": "CellFunction"}, {"end": 36, "start": 24, "tag": "CellComponent"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1268_8", "text": "The identification of the molecular mechanisms underlying the effects of 5-HT on maturation and energy metabolism of OPCs could pave the way for the development of new treatments for autoimmune demyelinating diseases such as Multiple Sclerosis where oligodendrocytes are the primary target of immune attack.", "tags": [{"end": 77, "start": 73, "tag": "Chemical"}, {"end": 216, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 96, "tag": "BiologicFunction"}, {"end": 306, "start": 300, "tag": "Finding"}, {"end": 266, "start": 250, "tag": "Cell"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 91, "start": 81, "tag": "BiologicFunction"}, {"end": 160, "start": 149, "tag": "BiologicFunction"}, {"end": 160, "start": 149, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "CellFunction"}, {"end": 178, "start": 168, "tag": "HealthCareActivity"}, {"end": 178, "start": 168, "tag": "ResearchActivity"}, {"end": 243, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 306, "start": 293, "tag": "BiologicFunction"}]}
{"id": "1269_0", "text": "Generation of oligodendrocytes in the adult brain enables both adaptive changes in neural circuits and regeneration of myelin sheaths destroyed by injury, disease, and normal aging.", "tags": [{"end": 115, "start": 103, "tag": "BiologicFunction"}, {"end": 133, "start": 119, "tag": "CellComponent"}, {"end": 115, "start": 103, "tag": "HealthCareActivity"}, {"end": 98, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 0, "tag": "CellFunction"}, {"end": 79, "start": 63, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 168, "tag": "Finding"}, {"end": 153, "start": 147, "tag": "InjuryOrPoisoning"}, {"end": 43, "start": 38, "tag": "PopulationGroup"}, {"end": 180, "start": 175, "tag": "BiologicFunction"}, {"end": 180, "start": 175, "tag": "CellFunction"}]}
{"id": "1269_1", "text": "This transformation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes requires processing of distinct mRNAs at different stages of cell maturation.", "tags": [{"end": 19, "start": 5, "tag": "Finding"}, {"end": 172, "start": 157, "tag": "CellFunction"}, {"end": 60, "start": 56, "tag": "Cell"}, {"end": 54, "start": 23, "tag": "Cell"}, {"end": 95, "start": 67, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "TemporalConcept"}, {"end": 133, "start": 128, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 133, "start": 128, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_2", "text": "Although mislocalization and aggregation of the RNA-binding protein, TDP-43, occur in both neurons and glia in neurodegenerative diseases, the consequences of TDP-43 loss within different stages of the oligodendrocyte lineage are not well understood.", "tags": [{"end": 67, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 202, "tag": "Cell"}, {"end": 170, "start": 159, "tag": "CellOrMolecularDysfunction"}, {"end": 137, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 103, "tag": "Cell"}, {"end": 98, "start": 91, "tag": "Cell"}, {"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 40, "start": 29, "tag": "ResearchActivity"}, {"end": 194, "start": 188, "tag": "TemporalConcept"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 52, "tag": "CellFunction"}, {"end": 51, "start": 48, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1269_3", "text": "By performing stage-specific genetic inactivation of Tardbp in vivo, we show that oligodendrocyte lineage cells are differentially sensitive to loss of TDP-43.", "tags": [{"end": 59, "start": 53, "tag": "GeneOrGenome"}, {"end": 111, "start": 82, "tag": "Cell"}, {"end": 49, "start": 37, "tag": "CellFunction"}, {"end": 36, "start": 29, "tag": "HealthCareActivity"}, {"end": 158, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 140, "start": 131, "tag": "PathologicFunction"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 152, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_4", "text": "While OPCs depend on TDP-43 for survival, with conditional deletion resulting in cascading cell loss followed by rapid regeneration to restore their density, oligodendrocytes become less sensitive to TDP-43 depletion as they mature.", "tags": [{"end": 174, "start": 158, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "Cell"}, {"end": 131, "start": 119, "tag": "BiologicFunction"}, {"end": 231, "start": 225, "tag": "TemporalConcept"}, {"end": 131, "start": 119, "tag": "HealthCareActivity"}, {"end": 100, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 216, "start": 200, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 32, "tag": "CellFunction"}, {"end": 196, "start": 187, "tag": "PathologicFunction"}, {"end": 27, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 200, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_5", "text": "Deletion of TDP-43 early in the maturation process led to eventual oligodendrocyte degeneration, seizures, and premature lethality, while oligodendrocytes that experienced late deletion survived and mice exhibited a normal lifespan.", "tags": [{"end": 18, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 105, "start": 97, "tag": "SignOrSymptom"}, {"end": 105, "start": 97, "tag": "Finding"}, {"end": 185, "start": 177, "tag": "CellOrMolecularDysfunction"}, {"end": 231, "start": 223, "tag": "TemporalConcept"}, {"end": 154, "start": 138, "tag": "Cell"}, {"end": 42, "start": 32, "tag": "BiologicFunction"}, {"end": 24, "start": 19, "tag": "TemporalConcept"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 120, "start": 111, "tag": "TemporalConcept"}, {"end": 130, "start": 121, "tag": "Finding"}, {"end": 176, "start": 172, "tag": "TemporalConcept"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 222, "start": 216, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 12, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_6", "text": "At both stages, TDP-43-deficient oligodendrocytes formed fewer and thinner myelin sheaths and extended new processes that inappropriately wrapped neuronal somata and blood vessels.", "tags": [{"end": 179, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 33, "tag": "Cell"}, {"end": 89, "start": 75, "tag": "CellComponent"}, {"end": 154, "start": 146, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "TemporalConcept"}, {"end": 22, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_7", "text": "Transcriptional analysis revealed that in the absence of TDP-43, key proteins involved in oligodendrocyte maturation and myelination were misspliced, leading to aberrant incorporation of cryptic exons.", "tags": [{"end": 169, "start": 161, "tag": "PathologicFunction"}, {"end": 116, "start": 106, "tag": "BiologicFunction"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 46, "tag": "Finding"}, {"end": 200, "start": 187, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 200, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 90, "tag": "Cell"}, {"end": 132, "start": 121, "tag": "CellFunction"}, {"end": 63, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1269_8", "text": "Inducible deletion of TDP-43 from oligodendrocytes in the adult central nervous system (CNS) induced the same progressive morphological changes and mice acquired profound hindlimb weakness, suggesting that loss of TDP-43 function in oligodendrocytes may contribute to neuronal dysfunction in neurodegenerative disease.", "tags": [{"end": 28, "start": 10, "tag": "CellOrMolecularDysfunction"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 162, "tag": "SignOrSymptom"}, {"end": 288, "start": 268, "tag": "CellOrMolecularDysfunction"}, {"end": 50, "start": 34, "tag": "Cell"}, {"end": 249, "start": 233, "tag": "Cell"}, {"end": 229, "start": 206, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 122, "tag": "Finding"}, {"end": 86, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 148, "tag": "Eukaryote"}, {"end": 276, "start": 268, "tag": "Cell"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 317, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 28, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 214, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 277, "tag": "PathologicFunction"}]}
{"id": "1270_0", "text": "Brain and spinal cord oligodendroglia have distinct functional characteristics, and cell-autonomous loss of individual genes can result in different regional phenotypes.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 158, "tag": "OrganismAttribute"}, {"end": 21, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 22, "tag": "Cell"}, {"end": 124, "start": 84, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1270_1", "text": "However, a molecular basis for these distinctions is unknown.", "tags": []}
{"id": "1270_2", "text": "Using single-cell analysis of oligodendroglia during developmental myelination, we demonstrate that brain and spinal cord precursors are transcriptionally distinct, defined predominantly by cholesterol biosynthesis.", "tags": [{"end": 26, "start": 6, "tag": "ResearchActivity"}, {"end": 154, "start": 137, "tag": "CellFunction"}, {"end": 214, "start": 190, "tag": "CellFunction"}, {"end": 201, "start": 190, "tag": "Chemical"}, {"end": 201, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 67, "tag": "CellFunction"}, {"end": 121, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 53, "tag": "BiologicFunction"}, {"end": 66, "start": 53, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 30, "tag": "Cell"}]}
{"id": "1270_3", "text": "We further identify the mechanistic target of rapamycin (mTOR) as a major regulator promoting cholesterol biosynthesis in oligodendroglia.", "tags": [{"end": 118, "start": 94, "tag": "CellFunction"}, {"end": 105, "start": 94, "tag": "Chemical"}, {"end": 105, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 46, "tag": "Chemical"}, {"end": 61, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 57, "tag": "GeneOrGenome"}, {"end": 61, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 122, "tag": "Cell"}]}
{"id": "1270_4", "text": "Oligodendroglia-specific loss of mTOR decreases cholesterol biosynthesis in both the brain and the spinal cord, but mTOR loss in spinal cord oligodendroglia has a greater impact on cholesterol biosynthesis, consistent with more pronounced deficits in developmental myelination.", "tags": [{"end": 47, "start": 38, "tag": "Finding"}, {"end": 72, "start": 48, "tag": "CellFunction"}, {"end": 205, "start": 181, "tag": "CellFunction"}, {"end": 59, "start": 48, "tag": "Chemical"}, {"end": 192, "start": 181, "tag": "Chemical"}, {"end": 59, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 120, "start": 116, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 265, "tag": "CellFunction"}, {"end": 110, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 251, "tag": "BiologicFunction"}, {"end": 264, "start": 251, "tag": "TemporalConcept"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 141, "tag": "Cell"}, {"end": 247, "start": 239, "tag": "Finding"}, {"end": 125, "start": 116, "tag": "CellOrMolecularDysfunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 37, "start": 25, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1270_5", "text": "In the brain, mTOR loss results in a later adult myelin deficit, including oligodendrocyte death, spontaneous demyelination, and impaired axonal function, demonstrating that mTOR is required for myelin maintenance in the adult brain.", "tags": [{"end": 96, "start": 91, "tag": "BiologicFunction"}, {"end": 96, "start": 91, "tag": "PathologicFunction"}, {"end": 96, "start": 91, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 178, "start": 174, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 110, "tag": "PathologicFunction"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 138, "tag": "CellComponent"}, {"end": 213, "start": 202, "tag": "BiologicFunction"}, {"end": 48, "start": 43, "tag": "PopulationGroup"}, {"end": 226, "start": 221, "tag": "PopulationGroup"}, {"end": 23, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 63, "start": 49, "tag": "PathologicFunction"}]}
{"id": "1271_0", "text": "Oligodendrocyte precursor cells (OPCs) are essential for developmental myelination and oligodendrocyte regeneration after CNS injury.", "tags": [{"end": 132, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "CellFunction"}, {"end": 102, "start": 87, "tag": "Cell"}, {"end": 125, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 57, "tag": "BiologicFunction"}, {"end": 70, "start": 57, "tag": "TemporalConcept"}, {"end": 115, "start": 103, "tag": "BiologicFunction"}, {"end": 115, "start": 103, "tag": "HealthCareActivity"}, {"end": 31, "start": 0, "tag": "Cell"}]}
{"id": "1271_1", "text": "These progenitors express calcium-permeable AMPA receptors (AMPARs) and form direct synapses with neurons throughout the CNS, but the roles of this signaling are unclear.", "tags": [{"end": 17, "start": 6, "tag": "Cell"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "CellFunction"}, {"end": 124, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 148, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "Cell"}, {"end": 58, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1271_2", "text": "To enable selective alteration of the properties of AMPARs in oligodendroglia, we generate mice that allow cell-specific overexpression of EGFP-GluA2 in vivo.", "tags": [{"end": 58, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 20, "tag": "Finding"}, {"end": 95, "start": 91, "tag": "Eukaryote"}, {"end": 157, "start": 150, "tag": "ResearchActivity"}, {"end": 77, "start": 62, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 139, "tag": "Chemical"}, {"end": 149, "start": 144, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1271_3", "text": "In healthy conditions, OPC-specific GluA2 overexpression significantly increase their proliferation in an age-dependent manner but did not alter their rate of differentiation into oligodendrocytes.", "tags": [{"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 42, "tag": "CellFunction"}, {"end": 56, "start": 42, "tag": "Finding"}, {"end": 196, "start": 180, "tag": "Cell"}, {"end": 26, "start": 23, "tag": "Cell"}, {"end": 155, "start": 151, "tag": "TemporalConcept"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 99, "start": 86, "tag": "CellFunction"}, {"end": 109, "start": 106, "tag": "OrganismAttribute"}, {"end": 10, "start": 3, "tag": "OrganismAttribute"}]}
{"id": "1271_4", "text": "In contrast, after demyelinating brain injury in neonates or adults, higher GluA2 levels promote both OPC proliferation and oligodendrocyte regeneration, but do not prevent injury-induced initial cell loss.", "tags": [{"end": 57, "start": 49, "tag": "PopulationGroup"}, {"end": 81, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 61, "tag": "PopulationGroup"}, {"end": 139, "start": 124, "tag": "Cell"}, {"end": 32, "start": 19, "tag": "PathologicFunction"}, {"end": 195, "start": 188, "tag": "TemporalConcept"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "InjuryOrPoisoning"}, {"end": 179, "start": 173, "tag": "InjuryOrPoisoning"}, {"end": 152, "start": 140, "tag": "BiologicFunction"}, {"end": 119, "start": 102, "tag": "CellFunction"}, {"end": 152, "start": 140, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1271_5", "text": "These findings indicate that AMPAR GluA2 content regulates the proliferative and regenerative behavior of adult OPCs, serving as a putative target for better myelin repair.", "tags": [{"end": 40, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 81, "tag": "BiologicFunction"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 171, "start": 165, "tag": "BiologicFunction"}, {"end": 171, "start": 165, "tag": "HealthCareActivity"}, {"end": 111, "start": 106, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 94, "tag": "BiologicFunction"}, {"end": 76, "start": 63, "tag": "BiologicFunction"}, {"end": 146, "start": 131, "tag": "Finding"}, {"end": 164, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1272_0", "text": "Neural-derived signals are crucial regulators of CNS vascularization.", "tags": [{"end": 45, "start": 27, "tag": "Finding"}, {"end": 68, "start": 49, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "Cell"}]}
{"id": "1272_1", "text": "However, whether the vasculature responds to these signals by means of elongating and branching or in addition by building a feedback response to modulate neurodevelopmental processes remains unknown.", "tags": [{"end": 32, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 51, "tag": "CellFunction"}, {"end": 183, "start": 155, "tag": "BiologicFunction"}]}
{"id": "1272_2", "text": "In this study, we identified bidirectional crosstalk between the neural and the vascular compartment of the developing CNS required for oligodendrocyte precursor cell specification.", "tags": [{"end": 122, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 136, "tag": "Cell"}, {"end": 88, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}
{"id": "1272_3", "text": "Mechanistically, we show that neural progenitor cells (NPCs) express angiopoietin-1 (Ang1) and that this expression is regulated by Sonic hedgehog.", "tags": [{"end": 83, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 61, "tag": "CellFunction"}, {"end": 53, "start": 30, "tag": "Cell"}, {"end": 59, "start": 55, "tag": "Cell"}]}
{"id": "1272_4", "text": "We demonstrate that NPC-derived Ang1 signals to its receptor, Tie2, on endothelial cells to induce the production of transforming growth factor beta 1 (TGF beta 1).", "tags": [{"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 37, "tag": "CellFunction"}, {"end": 66, "start": 62, "tag": "GeneOrGenome"}, {"end": 150, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "Cell"}, {"end": 23, "start": 20, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 152, "tag": "GeneOrGenome"}, {"end": 162, "start": 152, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1272_5", "text": "Endothelial-derived TGF beta 1, in turn, acts as an angiocrine molecule and signals back to NPCs to induce their commitment toward oligodendrocyte precursor cells.", "tags": [{"end": 83, "start": 76, "tag": "CellFunction"}, {"end": 123, "start": 113, "tag": "BiologicFunction"}, {"end": 162, "start": 131, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "Cell"}, {"end": 71, "start": 52, "tag": "Substance"}, {"end": 30, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 20, "tag": "GeneOrGenome"}, {"end": 11, "start": 0, "tag": "Cell"}]}
{"id": "1272_6", "text": "This work demonstrates a true bidirectional collaboration between NPCs and the vasculature as a critical regulator of oligodendrogenesis.", "tags": [{"end": 90, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 118, "tag": "BiologicFunction"}, {"end": 70, "start": 66, "tag": "Cell"}, {"end": 57, "start": 30, "tag": "Finding"}, {"end": 114, "start": 96, "tag": "Finding"}]}
{"id": "1273_0", "text": "The myelin sheath, which is wrapped around axons, is a lipid-enriched structure produced by mature oligodendrocytes.", "tags": [{"end": 48, "start": 43, "tag": "CellComponent"}, {"end": 60, "start": 55, "tag": "Chemical"}, {"end": 115, "start": 99, "tag": "Cell"}, {"end": 115, "start": 92, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellComponent"}, {"end": 98, "start": 92, "tag": "TemporalConcept"}, {"end": 10, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1273_1", "text": "Disruption of the myelin sheath is observed in several neurological diseases, such as multiple sclerosis.", "tags": [{"end": 31, "start": 18, "tag": "CellComponent"}, {"end": 76, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 0, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1273_2", "text": "A crucial component of myelin is sphingomyelin, levels of which can be increased by ABCA8, a member of the ATP-binding cassette transporter family.", "tags": [{"end": 89, "start": 84, "tag": "GeneOrGenome"}, {"end": 146, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 33, "tag": "Chemical"}, {"end": 46, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 107, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1273_3", "text": "ABCA8 is highly expressed in the cerebellum, specifically in oligodendroglia.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 43, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1273_4", "text": "However, whether ABCA8 plays a role in myelination and mechanisms that would underlie this role remain unknown.", "tags": [{"end": 22, "start": 17, "tag": "GeneOrGenome"}, {"end": 50, "start": 39, "tag": "CellFunction"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1273_5", "text": "Here, we found that the absence of Abca8b, a mouse ortholog of ABCA8, led to decreased numbers of cerebellar oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes in mice.", "tags": [{"end": 68, "start": 45, "tag": "GeneOrGenome"}, {"end": 108, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 142, "tag": "Cell"}, {"end": 175, "start": 152, "tag": "Cell"}, {"end": 140, "start": 109, "tag": "Cell"}, {"end": 183, "start": 179, "tag": "Eukaryote"}, {"end": 41, "start": 24, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 35, "tag": "GeneOrGenome"}]}
{"id": "1273_6", "text": "We show that in oligodendrocytes, ABCA8 interacts with chondroitin sulfate proteoglycan 4 (CSPG4), a molecule essential for OPC proliferation, migration, and myelination.", "tags": [{"end": 39, "start": 34, "tag": "GeneOrGenome"}, {"end": 89, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 91, "tag": "GeneOrGenome"}, {"end": 96, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 101, "tag": "Substance"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 127, "start": 124, "tag": "Cell"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 152, "start": 143, "tag": "CellFunction"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1273_7", "text": "In the absence of Abca8b, localization of CSPG4 to the plasma membrane was decreased, contributing to reduced cerebellar CSPG4 expression.", "tags": [{"end": 47, "start": 42, "tag": "GeneOrGenome"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 55, "tag": "CellComponent"}, {"end": 120, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 121, "tag": "GeneOrGenome"}, {"end": 126, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 7, "tag": "CellOrMolecularDysfunction"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 18, "tag": "GeneOrGenome"}]}
{"id": "1273_8", "text": "Cerebellar CSPG4+ OPCs were also diminished, leading to decreased mature myelinating oligodendrocyte numbers and cerebellar myelination levels in Abca8b(-/-) mice.", "tags": [{"end": 10, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "GeneOrGenome"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 135, "start": 124, "tag": "CellFunction"}, {"end": 100, "start": 66, "tag": "Cell"}, {"end": 162, "start": 158, "tag": "Eukaryote"}, {"end": 162, "start": 146, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1273_9", "text": "In addition, electron microscopy analyses showed that the number of nonmyelinated cerebellar axons was increased, whereas cerebellar myelin thickness (g-ratio), myelin sheath periodicity, and axonal diameter were all decreased, indicative of disordered myelin ultrastructure.", "tags": [{"end": 92, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 198, "start": 192, "tag": "CellComponent"}, {"end": 98, "start": 93, "tag": "CellComponent"}, {"end": 81, "start": 68, "tag": "CellComponent"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 174, "start": 161, "tag": "CellComponent"}, {"end": 167, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 133, "tag": "ClinicalAttribute"}, {"end": 207, "start": 192, "tag": "ClinicalAttribute"}, {"end": 274, "start": 242, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1273_10", "text": "In line with disrupted cerebellar myelination, Abca8b(-/-) mice showed lower cerebellar conduction velocity and disturbed locomotion.", "tags": [{"end": 33, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 122, "tag": "BiologicFunction"}, {"end": 45, "start": 34, "tag": "CellFunction"}, {"end": 107, "start": 88, "tag": "BiologicFunction"}, {"end": 98, "start": 88, "tag": "NaturalPhenomenonOrProcess"}, {"end": 45, "start": 13, "tag": "PathologicFunction"}, {"end": 63, "start": 59, "tag": "Eukaryote"}, {"end": 132, "start": 112, "tag": "PathologicFunction"}, {"end": 63, "start": 47, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1273_11", "text": "In summary, ABCA8 modulates cerebellar myelination, in part through functional regulation of the ABCA8-interacting protein CSPG4.", "tags": [{"end": 17, "start": 12, "tag": "GeneOrGenome"}, {"end": 38, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 123, "tag": "GeneOrGenome"}, {"end": 128, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 39, "tag": "CellFunction"}, {"end": 17, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 97, "tag": "GeneOrGenome"}, {"end": 122, "start": 103, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1273_12", "text": "Our findings suggest that ABCA8 disruption may contribute to the pathophysiology of myelin disorders.", "tags": [{"end": 31, "start": 26, "tag": "GeneOrGenome"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 65, "tag": "PathologicFunction"}, {"end": 80, "start": 65, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 26, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1274_0", "text": "Background: When aiming to restore myelin tolerance using antigen-specific treatment approaches in MS, the wide variety of myelin-derived antigens towards which immune responses are targeted in multiple sclerosis (MS) patients needs to be taken into account.", "tags": [{"end": 51, "start": 42, "tag": "Finding"}, {"end": 177, "start": 161, "tag": "BiologicFunction"}, {"end": 177, "start": 161, "tag": "CellFunction"}, {"end": 212, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 226, "start": 218, "tag": "PatientOrDisabledGroup"}, {"end": 84, "start": 75, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 138, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1274_1", "text": "Uncertainty remains as to whether the myelin reactivity pattern of a specific MS patient can be predicted based upon the human leukocyte antigen (HLA) class II haplotype of the patient.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 159, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "OrganismAttribute"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 184, "start": 177, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 146, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1274_2", "text": "Methods: In this study, we analyzed the reactivity towards myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) peptides using direct interferon (IFN)-gamma enzyme-linked immune absorbent spot (ELISPOT).", "tags": [{"end": 94, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "GeneOrGenome"}, {"end": 122, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 154, "tag": "GeneOrGenome"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 167, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 204, "tag": "ResearchActivity"}, {"end": 248, "start": 241, "tag": "ResearchActivity"}, {"end": 203, "start": 181, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1274_3", "text": "Next, the HLA class II haplotype profile was determined by next-generation sequencing.", "tags": [{"end": 32, "start": 23, "tag": "OrganismAttribute"}, {"end": 85, "start": 59, "tag": "ResearchActivity"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 22, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 10, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1274_4", "text": "In doing so, we aimed to evaluate the possible association between the precursor frequency of myelin-reactive T cells and the HLA haplotype.", "tags": [{"end": 80, "start": 71, "tag": "Cell"}, {"end": 129, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 130, "tag": "OrganismAttribute"}, {"end": 90, "start": 81, "tag": "TemporalConcept"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 110, "tag": "Cell"}]}
{"id": "1274_5", "text": "Results: Reactivity towards any of the analyzed peptides could be demonstrated in 65.0% (13/20) of MS patients and in 60.0% (6/10) of healthy controls.", "tags": [{"end": 150, "start": 134, "tag": "PopulationGroup"}, {"end": 141, "start": 134, "tag": "OrganismAttribute"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 47, "start": 39, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 9, "tag": "Finding"}]}
{"id": "1274_6", "text": "At least one of the MS risk alleles HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02 was found in 70.0% (14/20) of patients and in 20.0% (2/10) of healthy controls.", "tags": [{"end": 35, "start": 28, "tag": "GeneOrGenome"}, {"end": 164, "start": 148, "tag": "PopulationGroup"}, {"end": 155, "start": 148, "tag": "OrganismAttribute"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 23, "tag": "Finding"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 71, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1274_7", "text": "No difference in the presence of a myelin-specific response, nor in the frequency of myelin peptide-reactive precursor cells could be detected among carriers and non-carriers of these risk alleles.", "tags": [{"end": 196, "start": 189, "tag": "GeneOrGenome"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 188, "start": 184, "tag": "Finding"}, {"end": 157, "start": 149, "tag": "PopulationGroup"}, {"end": 174, "start": 162, "tag": "PopulationGroup"}, {"end": 29, "start": 21, "tag": "Finding"}, {"end": 99, "start": 92, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1274_8", "text": "Conclusion: No association between HLA haplotype and myelin reactivity profile was present in our study population.", "tags": [{"end": 38, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "OrganismAttribute"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 98, "tag": "PopulationGroup"}, {"end": 78, "start": 71, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "Finding"}]}
{"id": "1274_9", "text": "This complicates the development of antigen-specific treatment approaches and implies the need for multi-epitope targeting in an HLA-unrestricted manner to fully address the wide variation in myelin responses and HLA profiles in a heterogeneous group of MS patients.", "tags": [{"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 231, "tag": "OrganismAttribute"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 265, "start": 257, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 21, "tag": "BiologicFunction"}, {"end": 32, "start": 21, "tag": "CellFunction"}, {"end": 250, "start": 245, "tag": "PopulationGroup"}, {"end": 225, "start": 213, "tag": "ResearchActivity"}, {"end": 62, "start": 53, "tag": "HealthCareActivity"}, {"end": 62, "start": 53, "tag": "ResearchActivity"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 99, "tag": "ResearchActivity"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1275_0", "text": "Extrinsic inhibitors at sites of blood-brain barrier disruption and neurovascular damage contribute to remyelination failure in neurological diseases.", "tags": [{"end": 63, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 124, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 149, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1275_1", "text": "However, therapies to overcome the extrinsic inhibition of remyelination are not widely available and the dynamics of glial progenitor niche remodelling at sites of neurovascular dysfunction are largely unknown.", "tags": [{"end": 152, "start": 141, "tag": "BiologicFunction"}, {"end": 152, "start": 141, "tag": "CellFunction"}, {"end": 190, "start": 179, "tag": "PathologicFunction"}, {"end": 72, "start": 59, "tag": "CellFunction"}, {"end": 140, "start": 118, "tag": "Cell"}, {"end": 55, "start": 45, "tag": "CellFunction"}, {"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 178, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1275_2", "text": "By integrating in uiuo two-photon imaging co-registered with electron microscopy and transcriptomics in chronic neuroinflammatory lesions, we found that oligodendrocyte precursor cells clustered perivascularly at sites of limited remyelination with deposition of fibrinogen, a blood coagulation factor abundantly deposited in multiple sclerosis lesions.", "tags": [{"end": 273, "start": 263, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 263, "tag": "PharmacologicSubstance"}, {"end": 273, "start": 263, "tag": "BiologicallyActiveSubstance"}, {"end": 301, "start": 277, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 277, "tag": "PharmacologicSubstance"}, {"end": 301, "start": 277, "tag": "BiologicFunction"}, {"end": 243, "start": 230, "tag": "CellFunction"}, {"end": 80, "start": 61, "tag": "ResearchActivity"}, {"end": 184, "start": 153, "tag": "Cell"}, {"end": 100, "start": 85, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 112, "tag": "PathologicFunction"}, {"end": 344, "start": 326, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 104, "tag": "TemporalConcept"}, {"end": 137, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 352, "start": 345, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 23, "tag": "HealthCareActivity"}]}
{"id": "1275_3", "text": "By developing a screen (OPC-X-screen) to identify compounds that promote remyelination in the presence of extrinsic inhibitors, we showed that known promyelinating drugs did not rescue the extrinsic inhibition of remyelination by fibrinogen.", "tags": [{"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 59, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 102, "start": 94, "tag": "Finding"}, {"end": 240, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 230, "tag": "PharmacologicSubstance"}, {"end": 240, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 149, "tag": "PharmacologicSubstance"}, {"end": 86, "start": 73, "tag": "CellFunction"}, {"end": 226, "start": 213, "tag": "CellFunction"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "CellFunction"}]}
{"id": "1275_4", "text": "In contrast, bone morphogenetic protein type I receptor blockade rescued the inhibitory fibrinogen effects and restored a promyelinating progenitor niche by promoting myelinating oligodendrocytes, while suppressing astrocyte cell fate, with potent therapeutic effects in chronic models of multiple sclerosis.", "tags": [{"end": 55, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 13, "tag": "GeneOrGenome"}, {"end": 87, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 225, "tag": "Finding"}, {"end": 17, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 267, "start": 248, "tag": "Finding"}, {"end": 195, "start": 167, "tag": "Cell"}, {"end": 39, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 56, "tag": "PharmacologicSubstance"}, {"end": 64, "start": 56, "tag": "HealthCareActivity"}, {"end": 224, "start": 215, "tag": "Cell"}, {"end": 55, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 307, "start": 289, "tag": "DiseaseOrSyndrome"}, {"end": 278, "start": 271, "tag": "TemporalConcept"}, {"end": 285, "start": 279, "tag": "ResearchActivity"}, {"end": 98, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 122, "tag": "Cell"}]}
{"id": "1275_5", "text": "Thus, abortive oligodendrocyte precursor cell differentiation by fibrinogen is refractory to known promyelinating compounds, suggesting that blockade of the bone morphogenetic protein signalling pathway may enhance remyelinating efficacy by overcoming extrinsic inhibition in neuroinflammatory lesions with vascular damage.", "tags": [{"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 79, "tag": "SignOrSymptom"}, {"end": 228, "start": 215, "tag": "CellFunction"}, {"end": 45, "start": 15, "tag": "Cell"}, {"end": 183, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 149, "start": 141, "tag": "HealthCareActivity"}, {"end": 293, "start": 276, "tag": "PathologicFunction"}, {"end": 202, "start": 184, "tag": "CellFunction"}, {"end": 272, "start": 262, "tag": "CellFunction"}, {"end": 301, "start": 294, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 315, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 237, "start": 229, "tag": "Finding"}]}
{"id": "1276_0", "text": "Efficient strategies for neuroprotection and repair are still an unmet medical need for neurodegenerative diseases and lesions of the central nervous system.", "tags": [{"end": 40, "start": 25, "tag": "CellFunction"}, {"end": 156, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 119, "tag": "InjuryOrPoisoning"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "HealthCareActivity"}, {"end": 114, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 65, "tag": "Finding"}]}
{"id": "1276_1", "text": "Over the last few decades, a great deal of attention has been focused on white matter as a potential therapeutic target, mainly due to the discovery of the oligodendrocyte precursor cells in the adult central nervous system, a cell type able to fully repair myelin damage, and to the development of advanced imaging techniques to visualize and measure white matter lesions.", "tags": [{"end": 236, "start": 227, "tag": "Cell"}, {"end": 52, "start": 43, "tag": "BiologicFunction"}, {"end": 148, "start": 139, "tag": "ResearchActivity"}, {"end": 187, "start": 156, "tag": "Cell"}, {"end": 264, "start": 258, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 284, "tag": "BiologicFunction"}, {"end": 295, "start": 284, "tag": "CellFunction"}, {"end": 223, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 372, "start": 365, "tag": "InjuryOrPoisoning"}, {"end": 257, "start": 251, "tag": "BiologicFunction"}, {"end": 257, "start": 251, "tag": "HealthCareActivity"}, {"end": 85, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 364, "start": 352, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 315, "start": 308, "tag": "HealthCareActivity"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 200, "start": 195, "tag": "PopulationGroup"}, {"end": 119, "start": 101, "tag": "Finding"}]}
{"id": "1276_2", "text": "The combination of these two events has greatly increased the body of research into white matter alterations in central nervous system lesions and neurodegenerative diseases and has identified the oligodendrocyte precursor cell as a putative target for white matter lesion repair, thus indirectly contributing to neuroprotection.", "tags": [{"end": 328, "start": 313, "tag": "CellFunction"}, {"end": 134, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 135, "tag": "InjuryOrPoisoning"}, {"end": 272, "start": 266, "tag": "InjuryOrPoisoning"}, {"end": 279, "start": 273, "tag": "BiologicFunction"}, {"end": 279, "start": 273, "tag": "HealthCareActivity"}, {"end": 96, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 265, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 197, "tag": "Cell"}, {"end": 173, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 62, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "Finding"}]}
{"id": "1276_3", "text": "This review aims to discuss the potential of white matter as a therapeutic target for neuroprotection in lesions and diseases of the central nervous system.", "tags": [{"end": 101, "start": 86, "tag": "CellFunction"}, {"end": 155, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 112, "start": 105, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 63, "tag": "Finding"}]}
{"id": "1276_4", "text": "Pivot conditions are discussed, specifically multiple sclerosis as a white matter disease; spinal cord injury, the acute lesion of a central nervous system component where white matter prevails over the gray matter, and Alzheimer's disease, where the white matter was considered an ancillary component until recently.", "tags": [{"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 63, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "InjuryOrPoisoning"}, {"end": 102, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 263, "start": 251, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 316, "start": 308, "tag": "TemporalConcept"}, {"end": 239, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}]}
{"id": "1276_5", "text": "We first describe oligodendrocyte precursor cell biology and developmental myelination, and its regulation by thyroid hormones, then briefly describe white matter imaging techniques, which are providing information on white matter involvement in central nervous system lesions and degenerative diseases.", "tags": [{"end": 126, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 302, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 133, "tag": "TemporalConcept"}, {"end": 8, "start": 3, "tag": "TemporalConcept"}, {"end": 86, "start": 75, "tag": "CellFunction"}, {"end": 268, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 231, "tag": "Finding"}, {"end": 276, "start": 269, "tag": "InjuryOrPoisoning"}, {"end": 74, "start": 61, "tag": "BiologicFunction"}, {"end": 74, "start": 61, "tag": "TemporalConcept"}, {"end": 162, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 18, "tag": "Cell"}, {"end": 181, "start": 163, "tag": "HealthCareActivity"}, {"end": 56, "start": 49, "tag": "BiologicFunction"}]}
{"id": "1276_6", "text": "Finally, we discuss pathological mechanisms which interfere with myelin repair in adulthood.", "tags": [{"end": 91, "start": 82, "tag": "TemporalConcept"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 43, "start": 20, "tag": "PathologicFunction"}]}
{"id": "1277_0", "text": "Insufficient remyelination due to impaired oligodendrocyte precursor cell (OPC) differentiation and maturation is strongly associated with irreversible white matter injury (WMI) and neurological deficits.", "tags": [{"end": 12, "start": 0, "tag": "Finding"}, {"end": 171, "start": 152, "tag": "Finding"}, {"end": 176, "start": 173, "tag": "Finding"}, {"end": 203, "start": 182, "tag": "Finding"}, {"end": 78, "start": 75, "tag": "Cell"}, {"end": 110, "start": 100, "tag": "BiologicFunction"}, {"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 164, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 43, "tag": "Cell"}, {"end": 73, "start": 59, "tag": "Cell"}]}
{"id": "1277_1", "text": "We analyzed whole transcriptome expression to elucidate the potential role and underlying mechanism of action of lipocalin-2 (LCN2) in OPC differentiation and WMI and identified the receptor SCL22A17 and downstream transcription factor early growth response protein 1 (EGR1) as the key signals contributing to LCN2-mediated insufficient OPC remyelination.", "tags": [{"end": 124, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "GeneOrGenome"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 159, "tag": "Finding"}, {"end": 267, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 273, "start": 269, "tag": "GeneOrGenome"}, {"end": 273, "start": 269, "tag": "AminoAcidPeptideOrProtein"}, {"end": 293, "start": 286, "tag": "CellFunction"}, {"end": 31, "start": 18, "tag": "MolecularSequence"}, {"end": 235, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 138, "start": 135, "tag": "Cell"}, {"end": 340, "start": 337, "tag": "Cell"}, {"end": 354, "start": 341, "tag": "CellFunction"}, {"end": 154, "start": 139, "tag": "CellFunction"}, {"end": 154, "start": 135, "tag": "CellFunction"}, {"end": 190, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 199, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 191, "tag": "GeneOrGenome"}, {"end": 273, "start": 269, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 236, "tag": "AminoAcidPeptideOrProtein"}, {"end": 314, "start": 310, "tag": "AminoAcidPeptideOrProtein"}, {"end": 314, "start": 310, "tag": "BiologicallyActiveSubstance"}, {"end": 314, "start": 310, "tag": "GeneOrGenome"}]}
{"id": "1277_2", "text": "In LCN-knockdown and OPC EGR1 conditional-knockout mice, we discovered enhanced OPC differentiation in developing and injured white matter (WM); consistent with this, the specific inactivation of LCN2/SCl22A17/EGR1 signaling promoted remyelination and neurological recovery in both atypical, acute WMI due to subarachnoid hemorrhage and typical, chronic WMI due to multiple sclerosis.", "tags": [{"end": 29, "start": 25, "tag": "GeneOrGenome"}, {"end": 29, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 298, "tag": "Finding"}, {"end": 321, "start": 309, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 332, "start": 322, "tag": "PathologicFunction"}, {"end": 332, "start": 322, "tag": "Finding"}, {"end": 357, "start": 354, "tag": "Finding"}, {"end": 142, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 21, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "Cell"}, {"end": 383, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 234, "tag": "CellFunction"}, {"end": 273, "start": 252, "tag": "BiologicFunction"}, {"end": 273, "start": 252, "tag": "HealthCareActivity"}, {"end": 224, "start": 196, "tag": "CellFunction"}, {"end": 99, "start": 84, "tag": "CellFunction"}, {"end": 353, "start": 346, "tag": "TemporalConcept"}, {"end": 138, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 80, "tag": "CellFunction"}, {"end": 192, "start": 180, "tag": "CellFunction"}, {"end": 290, "start": 282, "tag": "Finding"}, {"end": 297, "start": 292, "tag": "TemporalConcept"}, {"end": 29, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "GeneOrGenome"}, {"end": 16, "start": 7, "tag": "ResearchActivity"}, {"end": 55, "start": 51, "tag": "Eukaryote"}, {"end": 50, "start": 30, "tag": "ResearchActivity"}]}
{"id": "1277_3", "text": "This potentially represents a novel strategy to enhance differentiation and remyelination in patients with white matter injury.", "tags": [{"end": 126, "start": 107, "tag": "Finding"}, {"end": 89, "start": 76, "tag": "CellFunction"}, {"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 119, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1278_0", "text": "White matter deficits are a common neuropathologic finding in neurologic disorders, including HIV-associated neurocognitive disorders (HAND).", "tags": [{"end": 82, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 94, "tag": "Virus"}, {"end": 133, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 35, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 139, "start": 135, "tag": "DiseaseOrSyndrome"}]}
{"id": "1278_1", "text": "In HAND, the persistence of white matter alterations despite suppressive antiretroviral (ARV) therapy suggests that ARVs may be directly contributing to these impairments.", "tags": [{"end": 24, "start": 13, "tag": "Finding"}, {"end": 92, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 170, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "HealthCareActivity"}, {"end": 87, "start": 73, "tag": "HealthCareActivity"}, {"end": 7, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 41, "tag": "Finding"}, {"end": 120, "start": 116, "tag": "PharmacologicSubstance"}]}
{"id": "1278_2", "text": "Here, we report that a frontline ARV, bictegravir (BIC), significantly attenuates remyelination following cuprizone-mediated demyelination, a model that recapitulates acute demyelination, but has no impact on already formed mature myelin.", "tags": [{"end": 36, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 38, "tag": "Chemical"}, {"end": 54, "start": 51, "tag": "Chemical"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 237, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 82, "tag": "CellFunction"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 186, "start": 173, "tag": "PathologicFunction"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 230, "start": 224, "tag": "TemporalConcept"}, {"end": 115, "start": 106, "tag": "Chemical"}, {"end": 172, "start": 167, "tag": "TemporalConcept"}, {"end": 49, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "PharmacologicSubstance"}]}
{"id": "1278_3", "text": "Mechanistic studies utilizing primary rat oligodendrocyte precursor cells (OPCs) revealed that treatment with BIC leads to significant decrease in mature oligodendrocytes accompanied by lysosomal deacidification and impairment of lysosomal degradative capacity with no alterations in lysosomal membrane permeability or total lysosome number.", "tags": [{"end": 113, "start": 110, "tag": "Chemical"}, {"end": 226, "start": 216, "tag": "Finding"}, {"end": 239, "start": 230, "tag": "CellComponent"}, {"end": 293, "start": 284, "tag": "CellComponent"}, {"end": 143, "start": 123, "tag": "Finding"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 73, "start": 42, "tag": "Cell"}, {"end": 170, "start": 147, "tag": "Cell"}, {"end": 41, "start": 38, "tag": "Eukaryote"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "ResearchActivity"}, {"end": 302, "start": 294, "tag": "CellComponent"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 211, "start": 186, "tag": "CellFunction"}, {"end": 260, "start": 230, "tag": "CellFunction"}, {"end": 280, "start": 269, "tag": "Finding"}, {"end": 315, "start": 294, "tag": "CellFunction"}, {"end": 333, "start": 325, "tag": "CellComponent"}]}
{"id": "1278_4", "text": "Activation of the endolysosomal cation channel TRPML1 prevents both lysosomal deacidification and impairment of oligodendrocyte differentiation by BIC.", "tags": [{"end": 77, "start": 68, "tag": "CellComponent"}, {"end": 108, "start": 98, "tag": "Finding"}, {"end": 150, "start": 147, "tag": "Chemical"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 143, "start": 128, "tag": "CellFunction"}, {"end": 46, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 68, "tag": "CellFunction"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 147, "tag": "PharmacologicSubstance"}]}
{"id": "1278_5", "text": "Lastly, we show that deacidification of lysosomes by compounds that raise lysosomal pH is sufficient to prevent maturation of oligodendrocytes.", "tags": [{"end": 83, "start": 74, "tag": "CellComponent"}, {"end": 49, "start": 40, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 126, "tag": "Cell"}, {"end": 122, "start": 112, "tag": "BiologicFunction"}, {"end": 62, "start": 53, "tag": "Chemical"}, {"end": 62, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 21, "tag": "CellFunction"}, {"end": 86, "start": 74, "tag": "CellFunction"}]}
{"id": "1278_6", "text": "Overall, this study has uncovered a critical role for lysosomal acidification in modulating oligodendrocyte function and has implications for neurologic diseases characterized by lysosomal dysfunction and white matter abnormalities.", "tags": [{"end": 77, "start": 54, "tag": "CellFunction"}, {"end": 161, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 231, "start": 205, "tag": "PathologicFunction"}, {"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 116, "start": 92, "tag": "CellFunction"}, {"end": 200, "start": 179, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1279_0", "text": "Huperzine A (HupA) is a natural acetylcholinesterase inhibitor (AChEI) with the advantages of high efficiency, selectivity as well as reversibility and can exhibit significant therapeutic effects against certain neurodegenerative diseases.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 17, "start": 13, "tag": "Chemical"}, {"end": 62, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 111, "tag": "CellFunction"}, {"end": 147, "start": 134, "tag": "TemporalConcept"}, {"end": 52, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 53, "tag": "Chemical"}, {"end": 195, "start": 176, "tag": "Finding"}, {"end": 109, "start": 94, "tag": "Finding"}, {"end": 238, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 17, "start": 13, "tag": "PharmacologicSubstance"}]}
{"id": "1279_1", "text": "It is also beneficial in reducing the neurological impairment and neuroinflammation of experimental autoimmune encephalomyelitis (EAE), a classic model for multiple sclerosis (MS).", "tags": [{"end": 33, "start": 25, "tag": "Finding"}, {"end": 128, "start": 87, "tag": "ExperimentalModelOfDisease"}, {"end": 133, "start": 130, "tag": "ExperimentalModelOfDisease"}, {"end": 61, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 66, "tag": "PathologicFunction"}, {"end": 151, "start": 146, "tag": "ResearchActivity"}, {"end": 174, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}]}
{"id": "1279_2", "text": "However, whether HupA can directly regulate oligodendrocyte differentiation and maturation and promote remyelination has not been investigated previously.", "tags": [{"end": 21, "start": 17, "tag": "Chemical"}, {"end": 59, "start": 44, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "BiologicFunction"}, {"end": 116, "start": 103, "tag": "CellFunction"}, {"end": 75, "start": 60, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "PharmacologicSubstance"}]}
{"id": "1279_3", "text": "In this study, we have analyzed the potential protective effects of HupA on the demylination model of MS induced by cuprizone (CPZ).", "tags": [{"end": 72, "start": 68, "tag": "Chemical"}, {"end": 130, "start": 127, "tag": "Chemical"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "ResearchActivity"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 64, "start": 46, "tag": "Finding"}, {"end": 72, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 80, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1279_4", "text": "It was found that HupA significantly attenuated anxiety-like behavior, as well as augmented motor and cognitive functions in CPZ mice.", "tags": [{"end": 22, "start": 18, "tag": "Chemical"}, {"end": 128, "start": 125, "tag": "Chemical"}, {"end": 55, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "BiologicFunction"}, {"end": 69, "start": 61, "tag": "IndividualBehavior"}, {"end": 69, "start": 61, "tag": "ResearchActivity"}, {"end": 133, "start": 129, "tag": "Eukaryote"}, {"end": 121, "start": 102, "tag": "BiologicFunction"}, {"end": 22, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 125, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1279_5", "text": "It also decreased demyelination and axonal injury in CPZ mice.", "tags": [{"end": 56, "start": 53, "tag": "Chemical"}, {"end": 61, "start": 57, "tag": "Eukaryote"}, {"end": 31, "start": 18, "tag": "PathologicFunction"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 42, "start": 36, "tag": "CellComponent"}, {"end": 61, "start": 53, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1279_6", "text": "Moreover, in CPZ mice, HupA increased mRNA levels of the various anti-inflammatory cytokines (Arg1, CD206) while reducing the levels of different pro-inflammatory cytokines (iNOS, IL-1 beta, IL-18, CD16, and TNF-alpha).", "tags": [{"end": 27, "start": 23, "tag": "Chemical"}, {"end": 98, "start": 94, "tag": "GeneOrGenome"}, {"end": 105, "start": 100, "tag": "GeneOrGenome"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 196, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 191, "tag": "GeneOrGenome"}, {"end": 202, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 198, "tag": "GeneOrGenome"}, {"end": 82, "start": 65, "tag": "BiologicFunction"}, {"end": 82, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 189, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 217, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 217, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "Chemical"}, {"end": 189, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 163, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "Eukaryote"}, {"end": 162, "start": 146, "tag": "PathologicFunction"}, {"end": 42, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 82, "start": 70, "tag": "PathologicFunction"}, {"end": 162, "start": 150, "tag": "PathologicFunction"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 13, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 198, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1279_7", "text": "Mecamylamine, a nicotinic acetylcholinergic receptor antagonist, could effectively reverse the effects of HupA.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 63, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 106, "tag": "Chemical"}, {"end": 110, "start": 106, "tag": "PharmacologicSubstance"}]}
{"id": "1279_8", "text": "Therefore, we concluded that HupA primarily exerts its therapeutic effects on multiple sclerosis through alleviating demyelination and neuroinflammation.", "tags": [{"end": 33, "start": 29, "tag": "Chemical"}, {"end": 152, "start": 135, "tag": "PathologicFunction"}, {"end": 96, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 117, "tag": "PathologicFunction"}, {"end": 74, "start": 55, "tag": "Finding"}, {"end": 33, "start": 29, "tag": "PharmacologicSubstance"}]}
{"id": "1280_0", "text": "Oligodendrocytes are the myelinating cells of the central nervous system.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "Cell"}, {"end": 72, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 25, "tag": "CellFunction"}]}
{"id": "1280_1", "text": "The physiological importance of oligodendrocytes is highlighted by diseases such as multiple sclerosis, in which the myelin sheaths are degraded and the axonal signal transmission is compromised.", "tags": [{"end": 144, "start": 136, "tag": "Finding"}, {"end": 48, "start": 32, "tag": "Cell"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 117, "tag": "CellComponent"}, {"end": 159, "start": 153, "tag": "CellComponent"}, {"end": 179, "start": 160, "tag": "CellFunction"}]}
{"id": "1280_2", "text": "In a healthy brain, spontaneous remyelination is rare, and newly formed myelin sheaths are thinner and shorter than the former ones.", "tags": [{"end": 53, "start": 49, "tag": "TemporalConcept"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 72, "tag": "CellComponent"}, {"end": 12, "start": 5, "tag": "OrganismAttribute"}]}
{"id": "1280_3", "text": "The myelination process requires the migration, proliferation, and differentiation of oligodendrocyte precursor cells (OPCs) and is influenced by proteins of the extracellular matrix (ECM), which consists of a network of glycoproteins and proteoglycans.", "tags": [{"end": 217, "start": 210, "tag": "PopulationGroup"}, {"end": 217, "start": 210, "tag": "CellFunction"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 117, "start": 86, "tag": "Cell"}, {"end": 182, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 67, "tag": "CellFunction"}, {"end": 187, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 239, "tag": "AminoAcidPeptideOrProtein"}, {"end": 252, "start": 239, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 46, "start": 37, "tag": "CellFunction"}]}
{"id": "1280_4", "text": "In particular, the glycoprotein tenascin-C (Tnc) has an inhibitory effect on the differentiation of OPCs and the remyelination efficiency of oligodendrocytes.", "tags": [{"end": 157, "start": 141, "tag": "Cell"}, {"end": 104, "start": 100, "tag": "Cell"}, {"end": 126, "start": 113, "tag": "CellFunction"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 66, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 127, "tag": "Finding"}, {"end": 42, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 56, "tag": "Finding"}, {"end": 31, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 19, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_5", "text": "The structurally similar tenascin-R (Tnr) exerts an inhibitory influence on the formation of myelin membranes in vitro.", "tags": [{"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 100, "tag": "CellComponent"}, {"end": 109, "start": 93, "tag": "CellComponent"}, {"end": 35, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 25, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_6", "text": "When Tnc knockout oligodendrocytes were applied to an in vitro myelination assay using artificial fibers, a higher number of sheaths per single cell were obtained compared to the wild-type control.", "tags": [{"end": 34, "start": 18, "tag": "Cell"}, {"end": 74, "start": 63, "tag": "CellFunction"}, {"end": 62, "start": 54, "tag": "ResearchActivity"}, {"end": 188, "start": 179, "tag": "ResearchActivity"}, {"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 104, "start": 87, "tag": "ManufacturedObject"}]}
{"id": "1280_7", "text": "This effect was enhanced by adding brain-derived neurotrophic factor (BDNF) to the culture system.", "tags": [{"end": 97, "start": 83, "tag": "ResearchActivity"}, {"end": 68, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 70, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_8", "text": "Tnr(-/-) oligodendrocytes behaved differently in that the number of formed sheaths per single cell was decreased, indicating that Tnr supports the differentiation of OPCs.", "tags": [{"end": 25, "start": 9, "tag": "Cell"}, {"end": 170, "start": 166, "tag": "Cell"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 130, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_9", "text": "In order to study the functions of tenascin proteins in vivo Tnc(-/-) and Tnr(-/-) mice were exposed to Cuprizone-induced demyelination for a period of 10 weeks.", "tags": [{"end": 113, "start": 104, "tag": "Chemical"}, {"end": 87, "start": 83, "tag": "Eukaryote"}, {"end": 60, "start": 53, "tag": "ResearchActivity"}, {"end": 135, "start": 122, "tag": "PathologicFunction"}, {"end": 52, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 155, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 142, "tag": "TemporalConcept"}, {"end": 52, "start": 35, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_10", "text": "Both Tnc(-/-) and Tnr(-/-) mouse knockout lines displayed a significant increase in the regenerating myelin sheath thickness after Cuprizone treatment.", "tags": [{"end": 47, "start": 33, "tag": "ResearchActivity"}, {"end": 140, "start": 131, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 101, "tag": "CellComponent"}, {"end": 32, "start": 27, "tag": "Eukaryote"}, {"end": 150, "start": 141, "tag": "HealthCareActivity"}, {"end": 150, "start": 141, "tag": "ResearchActivity"}, {"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1280_11", "text": "Furthermore, in the absence of either tenascin, the number of OPCs was increased.", "tags": [{"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 62, "tag": "Cell"}]}
{"id": "1280_12", "text": "These results suggest that the fine-tuning of myelin regeneration is regulated by the major tenascin proteins of the CNS.", "tags": [{"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 53, "tag": "BiologicFunction"}, {"end": 65, "start": 53, "tag": "HealthCareActivity"}, {"end": 65, "start": 46, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "Finding"}, {"end": 109, "start": 92, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1281_0", "text": "Remyelination is a key aspect in multiple sclerosis pathology and a special effort is being made to promote it.", "tags": [{"end": 82, "start": 76, "tag": "BiologicFunction"}, {"end": 82, "start": 76, "tag": "Finding"}, {"end": 51, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "PathologicFunction"}, {"end": 61, "start": 52, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 13, "start": 0, "tag": "CellFunction"}]}
{"id": "1281_1", "text": "However, there is still no available treatment to regenerate myelin and several strategies are being scrutinized.", "tags": [{"end": 90, "start": 80, "tag": "BiologicFunction"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 37, "tag": "HealthCareActivity"}, {"end": 46, "start": 37, "tag": "ResearchActivity"}]}
{"id": "1281_2", "text": "Myelination is naturally performed by oligodendrocytes and microRNAs have been postulated as a promising tool to induce oligodendrocyte precursor cell differentiation and therefore remyelination.", "tags": [{"end": 68, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 38, "tag": "Cell"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 166, "start": 151, "tag": "CellFunction"}, {"end": 150, "start": 120, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}]}
{"id": "1281_3", "text": "Herein, DSPC liposomes and PLGA nanoparticles were studied for miR-219a-5p encapsulation, release and remyelination promotion.", "tags": [{"end": 31, "start": 27, "tag": "Chemical"}, {"end": 88, "start": 75, "tag": "ResearchActivity"}, {"end": 88, "start": 75, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Chemical"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 74, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 8, "tag": "Chemical"}, {"end": 97, "start": 90, "tag": "Finding"}]}
{"id": "1281_4", "text": "In parallel, they were compared with biologically engineered extracellular vesicles overexpressing miR-219a-5p.", "tags": [{"end": 60, "start": 37, "tag": "ResearchActivity"}, {"end": 98, "start": 84, "tag": "CellFunction"}, {"end": 83, "start": 61, "tag": "CellComponent"}, {"end": 110, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 110, "start": 99, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1281_5", "text": "Interestingly, extracellular vesicles showed the highest oligodendrocyte precursor cell differentiation levels and were more effective than liposomes and polymeric nanoparticles crossing the blood-brain barrier.", "tags": [{"end": 163, "start": 154, "tag": "Chemical"}, {"end": 149, "start": 140, "tag": "Chemical"}, {"end": 177, "start": 154, "tag": "ManufacturedObject"}, {"end": 37, "start": 15, "tag": "CellComponent"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 87, "start": 57, "tag": "Cell"}, {"end": 210, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1281_6", "text": "Finally, extracellular vesicles were able to improve EAE animal model clinical evolution.", "tags": [{"end": 31, "start": 9, "tag": "CellComponent"}, {"end": 69, "start": 53, "tag": "ExperimentalModelOfDisease"}, {"end": 88, "start": 70, "tag": "ClinicalAttribute"}]}
{"id": "1281_7", "text": "Our results indicate that the use of extracellular vesicles as miR-219a-5p delivery system can be a feasible and promising strategy to induce remyelination in multiple sclerosis patients.", "tags": [{"end": 59, "start": 37, "tag": "CellComponent"}, {"end": 177, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 186, "start": 178, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 90, "start": 75, "tag": "ManufacturedObject"}, {"end": 131, "start": 113, "tag": "Finding"}]}
{"id": "1282_0", "text": "Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS).", "tags": [{"end": 94, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}]}
{"id": "1282_1", "text": "While most of the current treatment strategies focus on immune cell regulation, except for the drug siponimod, there is no therapeutic intervention that primarily aims at neuroprotection and remyelination.", "tags": [{"end": 78, "start": 56, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "HealthCareActivity"}, {"end": 186, "start": 171, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "ResearchActivity"}, {"end": 147, "start": 123, "tag": "HealthCareActivity"}, {"end": 99, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 204, "start": 191, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 109, "start": 100, "tag": "Chemical"}, {"end": 109, "start": 100, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1282_2", "text": "Recently, nimodipine showed a beneficial and remyelinating effect in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.", "tags": [{"end": 20, "start": 10, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 110, "start": 69, "tag": "ExperimentalModelOfDisease"}, {"end": 115, "start": 112, "tag": "ExperimentalModelOfDisease"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 45, "tag": "CellFunction"}, {"end": 20, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 131, "start": 126, "tag": "ResearchActivity"}, {"end": 137, "start": 120, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1282_3", "text": "Nimodipine also positively affected astrocytes, neurons, and mature oligodendrocytes.", "tags": [{"end": 10, "start": 0, "tag": "Chemical"}, {"end": 84, "start": 61, "tag": "Cell"}, {"end": 55, "start": 48, "tag": "Cell"}, {"end": 46, "start": 36, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "PharmacologicSubstance"}]}
{"id": "1282_4", "text": "Here we investigated the effects of nimodipine, an L-type voltage-gated calcium channel antagonist, on the expression profile of myelin genes and proteins in the oligodendrocyte precursor cell (OPC) line Oli-Neu and in primary OPCs.", "tags": [{"end": 46, "start": 36, "tag": "Chemical"}, {"end": 125, "start": 107, "tag": "ResearchActivity"}, {"end": 231, "start": 219, "tag": "Cell"}, {"end": 197, "start": 194, "tag": "Cell"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 162, "tag": "Cell"}, {"end": 79, "start": 72, "tag": "Chemical"}, {"end": 79, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 136, "tag": "GeneOrGenome"}, {"end": 211, "start": 204, "tag": "Cell"}]}
{"id": "1282_5", "text": "Our data indicate that nimodipine does not have any effect on myelin-related gene and protein expression.", "tags": [{"end": 33, "start": 23, "tag": "Chemical"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 104, "start": 86, "tag": "CellFunction"}, {"end": 33, "start": 23, "tag": "PharmacologicSubstance"}]}
{"id": "1282_6", "text": "Furthermore, nimodipine treatment did not result in any morphological changes in these cells.", "tags": [{"end": 23, "start": 13, "tag": "Chemical"}, {"end": 92, "start": 87, "tag": "Cell"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 23, "start": 13, "tag": "PharmacologicSubstance"}]}
{"id": "1282_7", "text": "However, RNA sequencing and bioinformatic analyses identified potential micro (mi)RNA that could support myelination after nimodipine treatment compared to a dimethyl sulfoxide (DMSO) control.", "tags": [{"end": 23, "start": 9, "tag": "ResearchActivity"}, {"end": 133, "start": 123, "tag": "Chemical"}, {"end": 176, "start": 158, "tag": "Chemical"}, {"end": 182, "start": 178, "tag": "Chemical"}, {"end": 116, "start": 105, "tag": "CellFunction"}, {"end": 85, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 134, "tag": "HealthCareActivity"}, {"end": 143, "start": 134, "tag": "ResearchActivity"}, {"end": 133, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 28, "tag": "ResearchActivity"}]}
{"id": "1282_8", "text": "Additionally, we treated zebrafish with nimodipine and observed a significant increase in the number of mature oligodendrocytes (* p <= 0.05).", "tags": [{"end": 50, "start": 40, "tag": "Chemical"}, {"end": 34, "start": 25, "tag": "Eukaryote"}, {"end": 127, "start": 104, "tag": "Cell"}, {"end": 50, "start": 40, "tag": "PharmacologicSubstance"}]}
{"id": "1282_9", "text": "Taken together, nimodipine seems to have different positive effects on OPCs and mature oligodendrocytes.", "tags": [{"end": 26, "start": 16, "tag": "Chemical"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 103, "start": 80, "tag": "Cell"}, {"end": 26, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 51, "tag": "Finding"}]}
{"id": "1283_0", "text": "NG2-glia, also known as oligodendrocyte precursor cells (OPCs), have the potential to generate new mature oligodendrocytes and thus, to contribute to tissue repair in demyelinating diseases like multiple sclerosis (MS).", "tags": [{"end": 163, "start": 150, "tag": "BiologicFunction"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 189, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 24, "tag": "Cell"}, {"end": 213, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 99, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "Cell"}]}
{"id": "1283_1", "text": "Once activated in response to brain damage, NG2-glial cells proliferate, and they acquire a reactive phenotype and a heterogeneous appearance.", "tags": [{"end": 141, "start": 117, "tag": "Finding"}, {"end": 42, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 92, "tag": "OrganismAttribute"}, {"end": 59, "start": 44, "tag": "Cell"}]}
{"id": "1283_2", "text": "Here, we set out to investigate the distribution and phenotypic diversity of NG2-glia relative to their ontogenic origin, and whether there is a clonal NG2-glial response to lesion in an experimental autoimmune encephalomyelitis (EAE) murine model of MS.", "tags": [{"end": 151, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 235, "tag": "Eukaryote"}, {"end": 63, "start": 53, "tag": "OrganismAttribute"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 228, "start": 187, "tag": "ExperimentalModelOfDisease"}, {"end": 233, "start": 230, "tag": "ExperimentalModelOfDisease"}, {"end": 247, "start": 242, "tag": "ResearchActivity"}, {"end": 253, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 174, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 152, "tag": "Cell"}, {"end": 85, "start": 77, "tag": "Cell"}, {"end": 73, "start": 64, "tag": "Finding"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 253, "start": 235, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1283_3", "text": "As such, we performed in utero electroporation of the genomic lineage tracer, StarTrack, to follow the fate of NG2-glia derived from single progenitors and to evaluate their response to brain damage after EAE induction.", "tags": [{"end": 151, "start": 140, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 198, "start": 186, "tag": "InjuryOrPoisoning"}, {"end": 208, "start": 205, "tag": "ExperimentalModelOfDisease"}, {"end": 69, "start": 54, "tag": "GeneOrGenome"}, {"end": 119, "start": 111, "tag": "Cell"}, {"end": 46, "start": 22, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "Chemical"}, {"end": 218, "start": 205, "tag": "ResearchActivity"}]}
{"id": "1283_4", "text": "We then analyzed the dispersion of the NG2-glia derived clonally from single pallial progenitors in the brain of EAE mice.", "tags": [{"end": 116, "start": 113, "tag": "ExperimentalModelOfDisease"}, {"end": 121, "start": 113, "tag": "ExperimentalModelOfDisease"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 121, "start": 117, "tag": "Eukaryote"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 96, "start": 70, "tag": "Cell"}]}
{"id": "1283_5", "text": "In addition, we examined several morphological parameters to assess the degree of NG2-glia reactivity in clonally-related cells.", "tags": [{"end": 127, "start": 105, "tag": "Cell"}, {"end": 90, "start": 82, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "Finding"}]}
{"id": "1283_6", "text": "Our results reveal the heterogeneity of these progenitors and their cell progeny in a scenario of autoimmune demyelination, revealing the ontogenic phenomena at play in these processes.", "tags": [{"end": 36, "start": 23, "tag": "OrganismAttribute"}, {"end": 57, "start": 46, "tag": "Cell"}, {"end": 122, "start": 98, "tag": "PathologicFunction"}, {"end": 80, "start": 68, "tag": "Cell"}, {"end": 157, "start": 138, "tag": "Finding"}]}
{"id": "1284_0", "text": "Multiple sclerosis (MS) is characterized by a targeted attack on oligodendroglia (OLG) and myelin by immune cells, which are thought to be the main drivers of MS susceptibility.", "tags": [{"end": 85, "start": 82, "tag": "Cell"}, {"end": 155, "start": 148, "tag": "ManufacturedObject"}, {"end": 155, "start": 148, "tag": "PopulationGroup"}, {"end": 176, "start": 159, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "Finding"}, {"end": 113, "start": 101, "tag": "Cell"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 65, "tag": "Cell"}]}
{"id": "1284_1", "text": "We found that immune genes exhibit a primed chromatin state in single mouse and human OLG in a non-disease context, compatible with transitions to immune-competent states in MS.", "tags": [{"end": 89, "start": 86, "tag": "Cell"}, {"end": 143, "start": 132, "tag": "Finding"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "CellComponent"}, {"end": 75, "start": 70, "tag": "Eukaryote"}, {"end": 85, "start": 80, "tag": "Eukaryote"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 26, "start": 14, "tag": "GeneOrGenome"}]}
{"id": "1284_2", "text": "We identified BACH1 and STAT1 as transcription factors involved in immune gene regulation in oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 19, "start": 14, "tag": "GeneOrGenome"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "Cell"}, {"end": 124, "start": 93, "tag": "Cell"}, {"end": 19, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 67, "tag": "CellFunction"}]}
{"id": "1284_3", "text": "A subset of immune genes presents bivalency of H3K4me3/H3K27me3 in OPCs, with Polycomb inhibition leading to their increased activation upon interferon gamma (IFN-g) treatment.", "tags": [{"end": 86, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "GeneOrGenome"}, {"end": 164, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 67, "tag": "Cell"}, {"end": 97, "start": 87, "tag": "CellFunction"}, {"end": 175, "start": 166, "tag": "HealthCareActivity"}, {"end": 175, "start": 166, "tag": "ResearchActivity"}, {"end": 24, "start": 12, "tag": "GeneOrGenome"}, {"end": 43, "start": 34, "tag": "Finding"}, {"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 115, "tag": "Finding"}, {"end": 157, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 141, "tag": "PharmacologicSubstance"}]}
{"id": "1284_4", "text": "Some MS susceptibility single-nucleotide polymorphisms (SNPs) overlap with these regulatory regions in mouse and human OLG.", "tags": [{"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 69, "start": 62, "tag": "TemporalConcept"}, {"end": 99, "start": 81, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 119, "tag": "Cell"}, {"end": 60, "start": 56, "tag": "MolecularSequence"}, {"end": 7, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 103, "tag": "Eukaryote"}, {"end": 118, "start": 113, "tag": "Eukaryote"}, {"end": 54, "start": 23, "tag": "MolecularSequence"}, {"end": 22, "start": 5, "tag": "ClinicalAttribute"}]}
{"id": "1284_5", "text": "Treatment of mouse OPCs with IFN-g leads to chromatin architecture remodeling at these loci and altered expression of interacting genes.", "tags": [{"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 53, "start": 44, "tag": "CellComponent"}, {"end": 18, "start": 13, "tag": "Eukaryote"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 44, "tag": "CellFunction"}, {"end": 91, "start": 87, "tag": "Finding"}, {"end": 114, "start": 96, "tag": "Finding"}, {"end": 135, "start": 118, "tag": "GeneOrGenome"}]}
{"id": "1284_6", "text": "Thus, the susceptibility for MS may involve OLG, which therefore constitutes novel targets for immunological based therapies for MS.", "tags": [{"end": 31, "start": 10, "tag": "ClinicalAttribute"}, {"end": 47, "start": 44, "tag": "Cell"}, {"end": 124, "start": 95, "tag": "HealthCareActivity"}, {"end": 31, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}]}
{"id": "1285_0", "text": "Cholesterol is essential for myelin formation, but may also modulate mechanisms involved in adaptive immune responses.", "tags": [{"end": 117, "start": 92, "tag": "CellFunction"}, {"end": 117, "start": 92, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "Chemical"}, {"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 29, "tag": "CellFunction"}]}
{"id": "1285_1", "text": "It is unclear whether lack of remyelination in multiple sclerosis (MS) results from an insufficient capacity of oligodendrocyte precursor cells to differentiate or from cholesterol insufficiency.", "tags": [{"end": 108, "start": 87, "tag": "Finding"}, {"end": 180, "start": 169, "tag": "Chemical"}, {"end": 180, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 112, "tag": "Cell"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 65, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 30, "tag": "CellFunction"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 194, "start": 181, "tag": "Finding"}]}
{"id": "1285_2", "text": "Several studies have assessed the potential association of lipid profile and its metabolism with demyelination, disability, and disease progression.", "tags": [{"end": 91, "start": 81, "tag": "BiologicFunction"}, {"end": 91, "start": 81, "tag": "CellFunction"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 110, "start": 97, "tag": "PathologicFunction"}, {"end": 147, "start": 128, "tag": "PathologicFunction"}, {"end": 64, "start": 59, "tag": "Chemical"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 122, "start": 112, "tag": "Finding"}, {"end": 72, "start": 59, "tag": "ResearchActivity"}]}
{"id": "1285_3", "text": "The aim of the present study was to measure cholesterol levels in plasma and cerebrospinal fluid (CSF) of patients with relapsing remitting MS (RRMS) or with clinically isolated syndrome (CIS), and to inves-tigate whether there is an association between cholesterol levels and disease characteristics.Sixty-two patients with CIS and 46 patients with RRMS were included in the study.", "tags": [{"end": 139, "start": 130, "tag": "TemporalConcept"}, {"end": 55, "start": 44, "tag": "Chemical"}, {"end": 265, "start": 254, "tag": "Chemical"}, {"end": 55, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 300, "start": 277, "tag": "ClinicalAttribute"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 120, "tag": "TemporalConcept"}, {"end": 148, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 354, "start": 350, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 328, "start": 325, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 319, "start": 311, "tag": "PatientOrDisabledGroup"}, {"end": 344, "start": 336, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 381, "start": 376, "tag": "ResearchActivity"}, {"end": 96, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 44, "tag": "ClinicalAttribute"}]}
{"id": "1285_4", "text": "All patients had low EDSS and were medication-free at assessment.", "tags": [{"end": 20, "start": 17, "tag": "Finding"}, {"end": 64, "start": 54, "tag": "HealthCareActivity"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "HealthCareActivity"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 45, "start": 35, "tag": "HealthCareActivity"}]}
{"id": "1285_5", "text": "Forty-eight subjects within the same age range served as controls.", "tags": [{"end": 65, "start": 57, "tag": "PopulationGroup"}, {"end": 40, "start": 37, "tag": "OrganismAttribute"}, {"end": 20, "start": 12, "tag": "PopulationGroup"}]}
{"id": "1285_6", "text": "Cholesterol concentrations were measured in plasma and in CSF by the same enzymatic - colorimetric method, and were related to clinical status, disease activity in magnetic resonance imaging (MRI) and presence of oli-goclonal bands in CSF (OBs).Significantly lower levels of plasma and CSF cholesterol were found in patients compared to controls.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 290, "tag": "Chemical"}, {"end": 105, "start": 74, "tag": "ResearchActivity"}, {"end": 301, "start": 290, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 281, "start": 275, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 289, "start": 286, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 144, "tag": "HealthCareActivity"}, {"end": 345, "start": 337, "tag": "PopulationGroup"}, {"end": 190, "start": 164, "tag": "HealthCareActivity"}, {"end": 209, "start": 201, "tag": "Finding"}, {"end": 324, "start": 316, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 192, "tag": "HealthCareActivity"}, {"end": 142, "start": 127, "tag": "ClinicalAttribute"}, {"end": 231, "start": 213, "tag": "ResearchActivity"}]}
{"id": "1285_7", "text": "Patients with OBs showed significantly lower levels of CSF cholesterol but not plasma cholesterol compared to OBs-negative patients.", "tags": [{"end": 17, "start": 14, "tag": "GeneOrGenome"}, {"end": 70, "start": 59, "tag": "Chemical"}, {"end": 97, "start": 86, "tag": "Chemical"}, {"end": 70, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 123, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 79, "tag": "ClinicalAttribute"}, {"end": 70, "start": 55, "tag": "ClinicalAttribute"}]}
{"id": "1285_8", "text": "A positive correlation of plasma cholesterol with age and of CSF cholesterol with EDSS was found.Our results suggest that low CSF cholesterol in MS patients with positive OBs might reflect extensive demy-elination and a more aggressive disease course associated with an increased humoral immune response against membrane components.", "tags": [{"end": 44, "start": 26, "tag": "ClinicalAttribute"}, {"end": 125, "start": 122, "tag": "Finding"}, {"end": 303, "start": 280, "tag": "BiologicFunction"}, {"end": 303, "start": 280, "tag": "CellFunction"}, {"end": 250, "start": 236, "tag": "TemporalConcept"}, {"end": 44, "start": 33, "tag": "Chemical"}, {"end": 76, "start": 65, "tag": "Chemical"}, {"end": 141, "start": 130, "tag": "Chemical"}, {"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "HealthCareActivity"}, {"end": 156, "start": 148, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 331, "start": 312, "tag": "CellComponent"}, {"end": 76, "start": 61, "tag": "ClinicalAttribute"}, {"end": 22, "start": 2, "tag": "Finding"}, {"end": 141, "start": 126, "tag": "ClinicalAttribute"}]}
{"id": "1286_0", "text": "The differentiation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes is the prerequisite for remyelination in demyelinated disorders such as multiple sclerosis (MS).", "tags": [{"end": 159, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 56, "tag": "Cell"}, {"end": 54, "start": 23, "tag": "Cell"}, {"end": 186, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 4, "tag": "CellFunction"}, {"end": 95, "start": 67, "tag": "Cell"}, {"end": 54, "start": 39, "tag": "Cell"}]}
{"id": "1286_1", "text": "Epigenetic mechanisms, such as DNA methylation, have been suggested to control the intricate network of transcription factors involved in OPC differentiation.", "tags": [{"end": 125, "start": 93, "tag": "CellFunction"}, {"end": 125, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "CellFunction"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 157, "start": 138, "tag": "CellFunction"}]}
{"id": "1286_2", "text": "Yet, the exact mechanism remains undisclosed.", "tags": []}
{"id": "1286_3", "text": "Here, we are the first to identify the DNA-binding protein inhibitors, Id2 and Id4, as targets of DNA methylation during OPC differentiation.", "tags": [{"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "GeneOrGenome"}, {"end": 113, "start": 98, "tag": "CellFunction"}, {"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 140, "start": 121, "tag": "CellFunction"}, {"end": 69, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1286_4", "text": "Using state-of-the-art epigenetic editing via CRISPR/dCas9-DNMT3a, we confirm that targeted methylation of Id2/Id4 drives OPC differentiation.", "tags": [{"end": 65, "start": 46, "tag": "ResearchActivity"}, {"end": 125, "start": 122, "tag": "Cell"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "CellFunction"}, {"end": 41, "start": 23, "tag": "ResearchActivity"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "GeneOrGenome"}, {"end": 114, "start": 111, "tag": "GeneOrGenome"}]}
{"id": "1286_5", "text": "Moreover, we show that in the pathological context of MS, methylation and gene expression levels of both ID2 and ID4 are altered compared to control human brain samples.", "tags": [{"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 116, "start": 113, "tag": "GeneOrGenome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 149, "tag": "Eukaryote"}, {"end": 69, "start": 58, "tag": "CellFunction"}, {"end": 168, "start": 161, "tag": "Substance"}, {"end": 168, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 108, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1286_6", "text": "We conclude that DNA methylation is crucial to suppress ID2 and ID4 during OPC differentiation, a process that appears to be dysregulated during MS.", "tags": [{"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "GeneOrGenome"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 137, "start": 125, "tag": "PathologicFunction"}, {"end": 32, "start": 17, "tag": "CellFunction"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "CellFunction"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1286_7", "text": "Our data do not only reveal new insights into oligodendrocyte biology, but could also lead to a better understanding of CNS myelin disorders.", "tags": [{"end": 69, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 61, "start": 46, "tag": "Cell"}, {"end": 130, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 140, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "BiologicFunction"}]}
{"id": "1287_0", "text": "White matter (WM) is a highly prominent feature in the human cerebrum and is comprised of bundles of myelinated axons that form the connectome of the brain.", "tags": [{"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 55, "tag": "Eukaryote"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1287_1", "text": "Myelin is formed by oligodendrocytes and is essential for rapid neuronal electrical communication that underlies the massive computing power of the human brain.", "tags": [{"end": 36, "start": 20, "tag": "Cell"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 148, "tag": "Eukaryote"}, {"end": 97, "start": 64, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 117, "tag": "Finding"}]}
{"id": "1287_2", "text": "Oligodendrocytes are generated throughout life by oligodendrocyte precursor cells (OPCs), which are identified by expression of the chondroitin sulphate proteoglycan NG2 (Cspg4), and are often termed NG2-glia.", "tags": [{"end": 165, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 171, "tag": "GeneOrGenome"}, {"end": 176, "start": 171, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 81, "start": 50, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}, {"end": 208, "start": 200, "tag": "Cell"}, {"end": 124, "start": 114, "tag": "CellFunction"}, {"end": 176, "start": 171, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1287_3", "text": "Adult NG2+ OPCs are slowly proliferating cells that have the stem cell-like property of self-renewal and differentiation into a pool of 'late OPCs' or 'differentiation committed' OPCs(COPs) identified by specific expression of the G-protein-coupled receptor GPR17, which are capable of differentiation into myelinating oligodendrocytes.", "tags": [{"end": 5, "start": 0, "tag": "PopulationGroup"}, {"end": 257, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 88, "tag": "CellFunction"}, {"end": 9, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 6, "tag": "Cell"}, {"end": 146, "start": 136, "tag": "Cell"}, {"end": 183, "start": 179, "tag": "Cell"}, {"end": 46, "start": 20, "tag": "Cell"}, {"end": 120, "start": 105, "tag": "CellFunction"}, {"end": 167, "start": 152, "tag": "CellFunction"}, {"end": 301, "start": 286, "tag": "CellFunction"}, {"end": 335, "start": 307, "tag": "Cell"}, {"end": 257, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 258, "tag": "GeneOrGenome"}, {"end": 263, "start": 258, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 258, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 61, "tag": "Cell"}, {"end": 188, "start": 184, "tag": "Cell"}]}
{"id": "1287_4", "text": "In the adult brain, these reservoirs of OPCs and COPs ensure rapid myelination of new neuronal connections formed in response to neuronal signalling, which underpins learning and cognitive function.", "tags": [{"end": 197, "start": 179, "tag": "BiologicFunction"}, {"end": 174, "start": 166, "tag": "BiologicFunction"}, {"end": 44, "start": 26, "tag": "Cell"}, {"end": 78, "start": 67, "tag": "CellFunction"}, {"end": 94, "start": 86, "tag": "Cell"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 7, "tag": "PopulationGroup"}, {"end": 53, "start": 49, "tag": "Cell"}, {"end": 106, "start": 86, "tag": "CellComponent"}, {"end": 148, "start": 129, "tag": "CellFunction"}]}
{"id": "1287_5", "text": "However, there is an age-related decline in myelination that is associated with a loss of neuronal function and cognitive decline.", "tags": [{"end": 129, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 44, "tag": "CellFunction"}, {"end": 24, "start": 21, "tag": "OrganismAttribute"}, {"end": 107, "start": 82, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1287_6", "text": "The underlying causes of myelin loss in ageing are manifold, but a key factor is the decay in OPC 'stemness' and a decline in their replenishment of COPs, which results in the ultimate failure of myelin regeneration.", "tags": [{"end": 46, "start": 40, "tag": "BiologicFunction"}, {"end": 97, "start": 94, "tag": "Cell"}, {"end": 31, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 185, "tag": "Finding"}, {"end": 215, "start": 196, "tag": "CellFunction"}, {"end": 36, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 99, "tag": "Finding"}, {"end": 153, "start": 149, "tag": "Cell"}, {"end": 122, "start": 115, "tag": "Finding"}, {"end": 145, "start": 132, "tag": "Finding"}]}
{"id": "1287_7", "text": "These changes in ageing OPCs are underpinned by dysregulation of neuronal signalling and OPC metabolic function.", "tags": [{"end": 23, "start": 17, "tag": "BiologicFunction"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 84, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 89, "tag": "CellFunction"}]}
{"id": "1287_8", "text": "Here, we highlight the role of purine signalling in regulating OPC self-renewal and the potential importance of GPR17 and the P2X7 receptor subtype in age-related changes in OPC metabolism.", "tags": [{"end": 37, "start": 31, "tag": "Chemical"}, {"end": 139, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 174, "tag": "CellFunction"}, {"end": 79, "start": 63, "tag": "CellFunction"}, {"end": 139, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "OrganismAttribute"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 31, "tag": "CellFunction"}]}
{"id": "1287_9", "text": "Moreover, age is the main factor in the failure of myelination in chronic multiple sclerosis and myelin loss in Alzheimer's disease, hence understanding the importance of purine signalling in OPC regeneration and myelination is critical for developing new strategies for promoting repair in age-dependent neuropathology.", "tags": [{"end": 92, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 171, "tag": "Chemical"}, {"end": 62, "start": 51, "tag": "CellFunction"}, {"end": 224, "start": 213, "tag": "CellFunction"}, {"end": 103, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 287, "start": 281, "tag": "BiologicFunction"}, {"end": 287, "start": 281, "tag": "HealthCareActivity"}, {"end": 152, "start": 139, "tag": "BiologicFunction"}, {"end": 13, "start": 10, "tag": "OrganismAttribute"}, {"end": 294, "start": 291, "tag": "OrganismAttribute"}, {"end": 47, "start": 40, "tag": "Finding"}, {"end": 319, "start": 305, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 319, "start": 305, "tag": "PathologicFunction"}, {"end": 131, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 171, "tag": "CellFunction"}, {"end": 108, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 208, "start": 192, "tag": "CellFunction"}]}
{"id": "1288_0", "text": "Oligodendrocyte precursor cells (NG2 glia) are uniformly distributed proliferative cells in the mammalian central nervous system and generate myelinating oligodendrocytes throughout life.", "tags": [{"end": 88, "start": 69, "tag": "Cell"}, {"end": 128, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 182, "tag": "TemporalConcept"}, {"end": 170, "start": 142, "tag": "Cell"}, {"end": 105, "start": 96, "tag": "Eukaryote"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 41, "start": 33, "tag": "Cell"}]}
{"id": "1288_1", "text": "A subpopulation of OPCs in the neocortex arises from progenitor cells in the embryonic ganglionic eminences that also produce inhibitory neurons.", "tags": [{"end": 15, "start": 2, "tag": "PopulationGroup"}, {"end": 40, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 69, "start": 53, "tag": "Cell"}, {"end": 144, "start": 126, "tag": "Cell"}, {"end": 107, "start": 77, "tag": "EmbryonicStructure"}]}
{"id": "1288_2", "text": "The neuronal fate of some progenitor cells is sealed before birth as they become committed to the oligodendrocyte lineage, marked by sustained expression of the oligodendrocyte transcription factor Olig2, which represses the interneuron transcription factor Dlx2.", "tags": [{"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "GeneOrGenome"}, {"end": 262, "start": 258, "tag": "GeneOrGenome"}, {"end": 197, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 197, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 257, "start": 237, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 161, "tag": "Cell"}, {"end": 12, "start": 4, "tag": "Cell"}, {"end": 42, "start": 26, "tag": "Cell"}, {"end": 121, "start": 98, "tag": "Cell"}, {"end": 65, "start": 60, "tag": "BiologicFunction"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}, {"end": 153, "start": 143, "tag": "CellFunction"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 236, "start": 225, "tag": "Cell"}, {"end": 262, "start": 258, "tag": "BiologicallyActiveSubstance"}, {"end": 262, "start": 258, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1288_3", "text": "Here we show that misexpression of Dlx2 alone in postnatal mouse OPCs caused them to switch their fate to GABAergic neurons within 2 days by downregulating Olig2 and upregulating a network of inhibitory neuron transcripts.", "tags": [{"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 123, "start": 106, "tag": "Cell"}, {"end": 155, "start": 141, "tag": "CellFunction"}, {"end": 161, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "GeneOrGenome"}, {"end": 178, "start": 166, "tag": "CellFunction"}, {"end": 188, "start": 181, "tag": "PopulationGroup"}, {"end": 188, "start": 181, "tag": "CellFunction"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 221, "start": 210, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 58, "start": 49, "tag": "TemporalConcept"}, {"end": 209, "start": 192, "tag": "Cell"}, {"end": 31, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 156, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1288_4", "text": "After two weeks, some OPC-derived neurons generated trains of action potentials and formed clusters of GABAergic synaptic proteins.", "tags": [{"end": 130, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 22, "tag": "Cell"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 79, "start": 62, "tag": "CellFunction"}]}
{"id": "1288_5", "text": "Our study revealed that the developmental molecular logic can be applied to promote neuronal reprogramming from OPCs.", "tags": [{"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 92, "start": 84, "tag": "Cell"}, {"end": 41, "start": 28, "tag": "BiologicFunction"}, {"end": 41, "start": 28, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 106, "start": 93, "tag": "ResearchActivity"}]}
{"id": "1289_0", "text": "The differentiation of oligodendroglia from oligodendrocyte precursor cells (OPCs) to complex and extensive myelinating oligodendrocytes (OLs) is a multistep process that involves large-scale morphological changes with significant strain on the cytoskeleton.", "tags": [{"end": 257, "start": 245, "tag": "CellComponent"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 75, "start": 44, "tag": "Cell"}, {"end": 19, "start": 4, "tag": "CellFunction"}, {"end": 136, "start": 108, "tag": "Cell"}, {"end": 141, "start": 138, "tag": "Cell"}, {"end": 38, "start": 23, "tag": "Cell"}, {"end": 213, "start": 192, "tag": "Finding"}]}
{"id": "1289_1", "text": "While key chromatin and transcriptional regulators of differentiation have been identified, their target genes responsible for the morphological changes occurring during OL myelination are still largely unknown.", "tags": [{"end": 50, "start": 24, "tag": "CellFunction"}, {"end": 184, "start": 173, "tag": "CellFunction"}, {"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 19, "start": 10, "tag": "CellComponent"}, {"end": 172, "start": 170, "tag": "Cell"}, {"end": 110, "start": 98, "tag": "GeneOrGenome"}, {"end": 152, "start": 131, "tag": "Finding"}]}
{"id": "1289_2", "text": "Here, we show that the regulator of focal adhesion, Tensin3 (Tns3), is a direct target gene of Olig2, Chd7, and Chd8, transcriptional regulators of OL differentiation.", "tags": [{"end": 50, "start": 36, "tag": "CellComponent"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 95, "tag": "GeneOrGenome"}, {"end": 106, "start": 102, "tag": "GeneOrGenome"}, {"end": 116, "start": 112, "tag": "GeneOrGenome"}, {"end": 144, "start": 118, "tag": "CellFunction"}, {"end": 166, "start": 148, "tag": "CellFunction"}, {"end": 59, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "GeneOrGenome"}, {"end": 91, "start": 80, "tag": "GeneOrGenome"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1289_3", "text": "Tns3 is transiently upregulated and localized to cell processes of immature OLs, together with integrin-beta 1, a key mediator of survival at this transient stage.", "tags": [{"end": 63, "start": 49, "tag": "CellComponent"}, {"end": 156, "start": 147, "tag": "TemporalConcept"}, {"end": 79, "start": 76, "tag": "Cell"}, {"end": 138, "start": 130, "tag": "CellFunction"}, {"end": 75, "start": 67, "tag": "BiologicFunction"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 110, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 118, "tag": "Finding"}]}
{"id": "1289_4", "text": "Constitutive Tns3 loss of function leads to reduced viability in mouse and humans, with surviving knockout mice still expressing Tns3 in oligodendroglia.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 111, "start": 98, "tag": "ResearchActivity"}, {"end": 128, "start": 118, "tag": "CellFunction"}, {"end": 81, "start": 75, "tag": "Eukaryote"}, {"end": 152, "start": 137, "tag": "Cell"}, {"end": 70, "start": 65, "tag": "Eukaryote"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 133, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 129, "tag": "GeneOrGenome"}]}
{"id": "1289_5", "text": "Acute deletion of Tns3 in vivo, either in postnatal neural stem cells (NSCs) or in OPCs, leads to a twofold reduction in OL numbers.", "tags": [{"end": 22, "start": 6, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 117, "start": 108, "tag": "Finding"}, {"end": 117, "start": 108, "tag": "NaturalPhenomenonOrProcess"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 123, "start": 121, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 51, "start": 42, "tag": "TemporalConcept"}, {"end": 69, "start": 52, "tag": "Cell"}]}
{"id": "1289_6", "text": "We find that the transient upregulation of Tns3 is required to protect differentiating OPCs and immature OLs from cell death by preventing the upregulation of p53, a key regulator of apoptosis.", "tags": [{"end": 162, "start": 159, "tag": "GeneOrGenome"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 114, "tag": "CellFunction"}, {"end": 91, "start": 71, "tag": "Cell"}, {"end": 26, "start": 17, "tag": "TemporalConcept"}, {"end": 108, "start": 96, "tag": "Cell"}, {"end": 192, "start": 183, "tag": "CellFunction"}, {"end": 39, "start": 27, "tag": "CellFunction"}, {"end": 155, "start": 143, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 43, "tag": "GeneOrGenome"}, {"end": 179, "start": 166, "tag": "Finding"}]}
{"id": "1289_7", "text": "Altogether, our findings reveal a specific time window during which transcriptional upregulation of Tns3 in immature OLs is required for OL differentiation likely by mediating integrin-beta 1 survival signaling to the actin cytoskeleton as OL undergo the large morphological changes required for their terminal differentiation.", "tags": [{"end": 236, "start": 218, "tag": "CellComponent"}, {"end": 83, "start": 68, "tag": "CellFunction"}, {"end": 210, "start": 201, "tag": "CellFunction"}, {"end": 326, "start": 311, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 120, "start": 108, "tag": "Cell"}, {"end": 155, "start": 137, "tag": "CellFunction"}, {"end": 242, "start": 240, "tag": "Cell"}, {"end": 200, "start": 192, "tag": "CellFunction"}, {"end": 96, "start": 84, "tag": "CellFunction"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 191, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 176, "tag": "GeneOrGenome"}, {"end": 282, "start": 261, "tag": "Finding"}]}
{"id": "1290_0", "text": "Introduction Several experimental studies have suggested the potential remyelinating effects of vitamin D (VitD) supplements regardless of the presence of VitD deficiency.", "tags": [{"end": 41, "start": 21, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "Finding"}, {"end": 105, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 143, "tag": "Finding"}, {"end": 84, "start": 71, "tag": "CellFunction"}, {"end": 111, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 159, "start": 155, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 96, "tag": "PharmacologicSubstance"}]}
{"id": "1290_1", "text": "This study aims to analyze neurogenesis in a model of toxic demyelination in order to evaluate the effects of VitD on demyelination and remyelination.", "tags": [{"end": 59, "start": 54, "tag": "InjuryOrPoisoning"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 73, "start": 60, "tag": "PathologicFunction"}, {"end": 131, "start": 118, "tag": "PathologicFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 39, "start": 27, "tag": "BiologicFunction"}, {"end": 114, "start": 110, "tag": "PharmacologicSubstance"}]}
{"id": "1290_2", "text": "Material and methods We used 24 male Wistar rats that had received surgical lesions to the corpus callosum and were injected with lysolecithin.", "tags": [{"end": 48, "start": 37, "tag": "Eukaryote"}, {"end": 83, "start": 67, "tag": "InjuryOrPoisoning"}, {"end": 142, "start": 130, "tag": "Chemical"}, {"end": 142, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 32, "tag": "OrganismAttribute"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1290_3", "text": "Rats were divided into three groups: Group 1 included eight rats with lesions to the corpus callosum but not lysolecithin injections (sham group), group 2 included eight rats with lesions to the corpus callosum that were injected with lysolecithin (lysolecithin group), and group 3 included eight rats with lesions that were injected with lysolecithin and received VitD (VitD group).", "tags": [{"end": 369, "start": 365, "tag": "PharmacologicSubstance"}, {"end": 369, "start": 365, "tag": "BiologicallyActiveSubstance"}, {"end": 375, "start": 371, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "Eukaryote"}, {"end": 174, "start": 170, "tag": "Eukaryote"}, {"end": 301, "start": 297, "tag": "Eukaryote"}, {"end": 132, "start": 122, "tag": "HealthCareActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 187, "start": 180, "tag": "InjuryOrPoisoning"}, {"end": 314, "start": 307, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 109, "tag": "Chemical"}, {"end": 247, "start": 235, "tag": "Chemical"}, {"end": 261, "start": 249, "tag": "Chemical"}, {"end": 351, "start": 339, "tag": "Chemical"}, {"end": 121, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 247, "start": 235, "tag": "PharmacologicSubstance"}, {"end": 261, "start": 249, "tag": "PharmacologicSubstance"}, {"end": 351, "start": 339, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 132, "start": 122, "tag": "ResearchActivity"}, {"end": 375, "start": 371, "tag": "PharmacologicSubstance"}]}
{"id": "1290_4", "text": "We analyzed neurogenesis both in the subventricular zone and at the lesion site.", "tags": [{"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 74, "start": 68, "tag": "InjuryOrPoisoning"}, {"end": 24, "start": 12, "tag": "BiologicFunction"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1290_5", "text": "Results Administration of VitD promotes the proliferation and differentiation of neural stem cells in the subventricular zone and the migration of these cells to the lesion site in the corpus callosum; these cells subsequently differentiate into oligodendrocyte lineage cells and produce myelin basic protein.", "tags": [{"end": 30, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 8, "tag": "HealthCareActivity"}, {"end": 240, "start": 227, "tag": "CellFunction"}, {"end": 158, "start": 153, "tag": "Cell"}, {"end": 213, "start": 208, "tag": "Cell"}, {"end": 294, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 166, "tag": "InjuryOrPoisoning"}, {"end": 275, "start": 246, "tag": "Cell"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 57, "start": 44, "tag": "CellFunction"}, {"end": 143, "start": 134, "tag": "CellFunction"}, {"end": 308, "start": 288, "tag": "AminoAcidPeptideOrProtein"}, {"end": 308, "start": 288, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 81, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1290_6", "text": "This phenomenon was not caused by microglial activation, which was less marked in rats receiving VitD.", "tags": [{"end": 86, "start": 82, "tag": "Eukaryote"}, {"end": 55, "start": 34, "tag": "CellFunction"}, {"end": 101, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1290_7", "text": "Megalin expression did not increase at the lesion site, which suggests that VitD is internalized by other mechanisms.", "tags": [{"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 76, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 18, "start": 8, "tag": "CellFunction"}]}
{"id": "1290_8", "text": "Conclusion Our results support the hypothesis that regardless of the presence of VitD deficiency, treatment with VitD may contribute to remyelination by promoting the proliferation of oligodendrocyte precursor cells.", "tags": [{"end": 117, "start": 113, "tag": "PharmacologicSubstance"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 86, "tag": "Finding"}, {"end": 215, "start": 184, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "Finding"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 180, "start": 167, "tag": "CellFunction"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 81, "tag": "PharmacologicSubstance"}]}
{"id": "1291_0", "text": "Demyelinating injuries and diseases, like multiple sclerosis, affect millions of people worldwide.", "tags": [{"end": 60, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 22, "start": 0, "tag": "InjuryOrPoisoning"}]}
{"id": "1291_1", "text": "Oligodendrocyte precursor cells (OPCs) have the potential to repair demyelinated tissues because they can both self-renew and differentiate into oligodendrocytes (OLs), the myelin producing cells of the central nervous system (CNS).", "tags": [{"end": 161, "start": 145, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 166, "start": 163, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 225, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 190, "tag": "Cell"}, {"end": 88, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "BiologicFunction"}, {"end": 67, "start": 61, "tag": "HealthCareActivity"}]}
{"id": "1291_2", "text": "Cell-matrix interactions impact OPC differentiation into OLs, but the process is not fully understood.", "tags": [{"end": 35, "start": 32, "tag": "Cell"}, {"end": 51, "start": 36, "tag": "CellFunction"}, {"end": 60, "start": 57, "tag": "Cell"}, {"end": 51, "start": 32, "tag": "CellFunction"}, {"end": 24, "start": 0, "tag": "Finding"}]}
{"id": "1291_3", "text": "Biomaterial hydrogel systems help to elucidate cell-matrix interactions because they can mimic specific properties of native CNS tissues in an in vitro setting.", "tags": [{"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 47, "tag": "Cell"}, {"end": 151, "start": 143, "tag": "ResearchActivity"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 136, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 28, "start": 0, "tag": "ManufacturedObject"}]}
{"id": "1291_4", "text": "We investigated whether OPC maturation into OLs is influenced by interacting with a urokinase plasminogen activator (uPA) degradable extracellular matrix (ECM).", "tags": [{"end": 115, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 38, "start": 28, "tag": "BiologicFunction"}, {"end": 153, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "Cell"}]}
{"id": "1291_5", "text": "uPA is a proteolytic enzyme that is transiently upregulated in the developing rat brain, with peak uPA expression correlating with an increase in myelin production in vivo.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 78, "tag": "Eukaryote"}, {"end": 27, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "CellFunction"}, {"end": 171, "start": 164, "tag": "ResearchActivity"}]}
{"id": "1291_6", "text": "OPC-like cells isolated through the Mosaic Analysis with Double Marker technique (MADM OPCs) produced low-molecular-weight uPA in culture.", "tags": [{"end": 86, "start": 82, "tag": "ResearchActivity"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 87, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 80, "start": 36, "tag": "ResearchActivity"}, {"end": 137, "start": 130, "tag": "ResearchActivity"}, {"end": 14, "start": 9, "tag": "Cell"}, {"end": 105, "start": 102, "tag": "Finding"}]}
{"id": "1291_7", "text": "MADM OPCs were encapsulated into two otherwise similar elastin-like protein (ELP) hydrogel systems: one that was uPA degradable and one that was nondegradable.", "tags": [{"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 5, "tag": "Cell"}, {"end": 98, "start": 82, "tag": "ResearchActivity"}, {"end": 98, "start": 82, "tag": "ManufacturedObject"}, {"end": 75, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1291_8", "text": "Encapsulated MADM OPCs had similar viability, proliferation, and metabolic activity in uPA degradable and nondegradable ELP hydrogels.", "tags": [{"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "CellFunction"}, {"end": 83, "start": 65, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "ResearchActivity"}, {"end": 133, "start": 124, "tag": "ManufacturedObject"}, {"end": 123, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 120, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1291_9", "text": "Expression of OPC maturation-associated genes, however, indicated that uPA degradable ELP hydrogels promoted MADM OPC maturation although not sufficiently for these cells to differentiate into OLs.", "tags": [{"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 109, "tag": "ResearchActivity"}, {"end": 17, "start": 14, "tag": "Cell"}, {"end": 117, "start": 114, "tag": "Cell"}, {"end": 28, "start": 18, "tag": "BiologicFunction"}, {"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 196, "start": 193, "tag": "Cell"}, {"end": 170, "start": 165, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 99, "start": 90, "tag": "ResearchActivity"}, {"end": 99, "start": 90, "tag": "ManufacturedObject"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1292_0", "text": "The pathology of fetal alcohol syndrome and the less severe fetal alcohol spectrum disorders includes brain dysmyelination.", "tags": [{"end": 39, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 108, "tag": "PathologicFunction"}, {"end": 59, "start": 53, "tag": "Finding"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 4, "tag": "PathologicFunction"}, {"end": 13, "start": 4, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 92, "start": 60, "tag": "AnatomicalAbnormality"}]}
{"id": "1292_1", "text": "Recent studies have shed light on the molecular mechanisms underlying these white matter abnormalities.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 58, "start": 38, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 88, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 76, "tag": "PathologicFunction"}]}
{"id": "1292_2", "text": "Rodent models of fetal alcohol syndrome and human studies have shown suppressed oligodendrocyte differentiation and apoptosis of oligodendrocyte precursor cells.", "tags": [{"end": 39, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 44, "tag": "ResearchActivity"}, {"end": 125, "start": 116, "tag": "CellFunction"}, {"end": 160, "start": 145, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "Cell"}, {"end": 160, "start": 129, "tag": "Cell"}, {"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 13, "start": 7, "tag": "ResearchActivity"}, {"end": 39, "start": 0, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1292_3", "text": "Ethanol exposure led to reduced expression of myelin basic protein and delayed myelin basic protein expression in rat and mouse models of fetal alcohol syndrome and in human histopathological specimens.", "tags": [{"end": 7, "start": 0, "tag": "Chemical"}, {"end": 7, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 160, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 174, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 201, "start": 192, "tag": "Substance"}, {"end": 201, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 92, "tag": "CellFunction"}, {"end": 117, "start": 114, "tag": "Eukaryote"}, {"end": 78, "start": 71, "tag": "TemporalConcept"}, {"end": 173, "start": 168, "tag": "Eukaryote"}, {"end": 127, "start": 122, "tag": "Eukaryote"}, {"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 128, "tag": "ResearchActivity"}, {"end": 66, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "InjuryOrPoisoning"}]}
{"id": "1292_4", "text": "Several studies have reported increased expression of many chemokines in dysmyelinating disorders in central nervous system, including multiple sclerosis and fetal alcohol syndrome.", "tags": [{"end": 69, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 153, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 73, "tag": "DiseaseOrSyndrome"}]}
{"id": "1292_5", "text": "Acute ethanol exposure reduced levels of the neuroprotective insulin-like growth factor-1 in fetal and maternal sheep and in human fetal brain tissues, while ethanol increased the expression of tumor necrosis factor alpha in mouse and human neurons.", "tags": [{"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 13, "start": 6, "tag": "Chemical"}, {"end": 13, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 98, "start": 93, "tag": "EmbryonicStructure"}, {"end": 150, "start": 131, "tag": "EmbryonicStructure"}, {"end": 165, "start": 158, "tag": "Chemical"}, {"end": 165, "start": 158, "tag": "PharmacologicSubstance"}, {"end": 221, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 103, "tag": "PopulationGroup"}, {"end": 248, "start": 241, "tag": "Cell"}, {"end": 80, "start": 74, "tag": "BiologicFunction"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 240, "start": 235, "tag": "Eukaryote"}, {"end": 230, "start": 225, "tag": "Eukaryote"}, {"end": 60, "start": 45, "tag": "CellFunction"}, {"end": 89, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "Eukaryote"}]}
{"id": "1292_6", "text": "White matter lesions have been induced in the developing sheep brain by alcohol exposure in early gestation.", "tags": [{"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 13, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 46, "tag": "EmbryonicStructure"}, {"end": 88, "start": 72, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 98, "tag": "BiologicFunction"}, {"end": 97, "start": 92, "tag": "TemporalConcept"}]}
{"id": "1292_7", "text": "Rat fetal alcohol syndrome models have shown reduced axon diameters, with thinner myelin sheaths, as well as reduced numbers of oligodendrocytes, which were also morphologically aberrant oligodendrocytes.", "tags": [{"end": 26, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 128, "tag": "Cell"}, {"end": 203, "start": 187, "tag": "Cell"}, {"end": 96, "start": 82, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "Eukaryote"}, {"end": 88, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "CellComponent"}, {"end": 33, "start": 4, "tag": "ExperimentalModelOfDisease"}, {"end": 203, "start": 162, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1292_8", "text": "Expressions of markers for mature myelination, including myelin basic protein, also were reduced.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 77, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 34, "tag": "CellFunction"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1292_9", "text": "The accumulating knowledge concerning the mechanisms of ethanol-induced dysmyelination could lead to the development of strategies to prevent dysmyelination in children exposed to ethanol during fetal development.", "tags": [{"end": 86, "start": 72, "tag": "PathologicFunction"}, {"end": 156, "start": 142, "tag": "PathologicFunction"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 187, "start": 180, "tag": "Chemical"}, {"end": 187, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 195, "tag": "BiologicFunction"}, {"end": 26, "start": 17, "tag": "Finding"}, {"end": 116, "start": 105, "tag": "BiologicFunction"}, {"end": 116, "start": 105, "tag": "CellFunction"}, {"end": 63, "start": 56, "tag": "Chemical"}, {"end": 63, "start": 56, "tag": "PharmacologicSubstance"}]}
{"id": "1292_10", "text": "Future studies using fetal oligodendrocyte- and oligodendrocyte precursor cell-derived exosomes isolated from the mother's blood may identify biomarkers for fetal alcohol syndrome and even implicate epigenetic changes in early development that affect oligodendrocyte precursor cell and oligodendrocyte function in adulthood.", "tags": [{"end": 26, "start": 21, "tag": "EmbryonicStructure"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 179, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 281, "start": 267, "tag": "Cell"}, {"end": 78, "start": 48, "tag": "Cell"}, {"end": 281, "start": 251, "tag": "Cell"}, {"end": 276, "start": 251, "tag": "Cell"}, {"end": 301, "start": 286, "tag": "Cell"}, {"end": 323, "start": 314, "tag": "TemporalConcept"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 217, "start": 199, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 227, "tag": "BiologicFunction"}, {"end": 238, "start": 227, "tag": "CellFunction"}]}
{"id": "1292_11", "text": "By combining various imaging modalities with molecular studies, it may be possible to determine which fetuses are at risk and to intervene therapeutically early in the pregnancy.", "tags": [{"end": 109, "start": 102, "tag": "EmbryonicStructure"}, {"end": 177, "start": 168, "tag": "BiologicFunction"}, {"end": 62, "start": 45, "tag": "ResearchActivity"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}]}
{"id": "1293_0", "text": "Development of pharmacotherapies that promote remyelination is a high priority for multiple sclerosis (MS), due to their potential for neuroprotection and restoration of function through repair of demyelinated lesions.", "tags": [{"end": 32, "start": 15, "tag": "HealthCareActivity"}, {"end": 78, "start": 70, "tag": "TemporalConcept"}, {"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 101, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 187, "tag": "BiologicFunction"}, {"end": 193, "start": 187, "tag": "HealthCareActivity"}, {"end": 217, "start": 197, "tag": "PathologicFunction"}]}
{"id": "1293_1", "text": "A novel preparation of clean-surfaced, faceted gold nanocrystals demonstrated robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute lysolecithin rodent animal models.", "tags": [{"end": 199, "start": 193, "tag": "Eukaryote"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 159, "start": 152, "tag": "TemporalConcept"}, {"end": 192, "start": 180, "tag": "Chemical"}, {"end": 192, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 107, "start": 85, "tag": "CellFunction"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 213, "start": 200, "tag": "ResearchActivity"}, {"end": 179, "start": 174, "tag": "TemporalConcept"}, {"end": 64, "start": 47, "tag": "ManufacturedObject"}, {"end": 143, "start": 137, "tag": "Chemical"}]}
{"id": "1293_2", "text": "Furthermore, oral delivery of gold nanocrystals improved motor functions of cuprizone-treated mice in both open field and kinematic gait studies.", "tags": [{"end": 26, "start": 13, "tag": "HealthCareActivity"}, {"end": 72, "start": 57, "tag": "BiologicFunction"}, {"end": 117, "start": 107, "tag": "ManufacturedObject"}, {"end": 136, "start": 132, "tag": "OrganismAttribute"}, {"end": 98, "start": 94, "tag": "Eukaryote"}, {"end": 144, "start": 122, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "Chemical"}, {"end": 117, "start": 107, "tag": "ResearchActivity"}, {"end": 47, "start": 30, "tag": "ManufacturedObject"}]}
{"id": "1293_3", "text": "Gold nanocrystal treatment of oligodendrocyte precursor cells in culture resulted in oligodendrocyte maturation and expression of myelin differentiation markers.", "tags": [{"end": 61, "start": 30, "tag": "Cell"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 137, "tag": "CellFunction"}, {"end": 72, "start": 65, "tag": "ResearchActivity"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 160, "start": 153, "tag": "ClinicalAttribute"}, {"end": 16, "start": 0, "tag": "ManufacturedObject"}, {"end": 126, "start": 116, "tag": "CellFunction"}, {"end": 111, "start": 85, "tag": "CellFunction"}]}
{"id": "1293_4", "text": "Additional in vitro data demonstrated that these gold nanocrystals act via a novel energy metabolism pathway involving the enhancement of key indicators of aerobic glycolysis.", "tags": [{"end": 152, "start": 142, "tag": "Chemical"}, {"end": 100, "start": 83, "tag": "BiologicFunction"}, {"end": 174, "start": 156, "tag": "CellFunction"}, {"end": 108, "start": 101, "tag": "CellFunction"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 134, "start": 123, "tag": "Finding"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 66, "start": 49, "tag": "ManufacturedObject"}]}
{"id": "1293_5", "text": "In response to gold nanocrystals, co-cultured central nervous system cells exhibited elevated levels of the redox coenzyme nicotine adenine dinucleotide (NAD+), elevated total intracellular ATP levels, and elevated extracellular lactate levels, along with upregulation of myelin-synthesis related genes, collectively resulting in functional myelin generation.", "tags": [{"end": 74, "start": 69, "tag": "Cell"}, {"end": 189, "start": 176, "tag": "CellComponent"}, {"end": 193, "start": 190, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 193, "start": 190, "tag": "PharmacologicSubstance"}, {"end": 193, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "CellFunction"}, {"end": 45, "start": 34, "tag": "ResearchActivity"}, {"end": 358, "start": 341, "tag": "CellFunction"}, {"end": 157, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 157, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 268, "start": 256, "tag": "CellFunction"}, {"end": 32, "start": 15, "tag": "ManufacturedObject"}, {"end": 152, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 236, "start": 229, "tag": "Chemical"}, {"end": 236, "start": 229, "tag": "PharmacologicSubstance"}, {"end": 302, "start": 272, "tag": "GeneOrGenome"}]}
{"id": "1293_6", "text": "Based on these preclinical studies, clean-surfaced, faceted gold nanocrystals represent a novel remyelinating therapeutic for multiple sclerosis.", "tags": [{"end": 34, "start": 15, "tag": "ResearchActivity"}, {"end": 144, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 96, "tag": "CellFunction"}, {"end": 77, "start": 60, "tag": "ManufacturedObject"}]}
{"id": "1294_0", "text": "Cytokines, demyelination and neuroaxonal degeneration in the central nervous system are pivotal elements implicated in the pathogenesis of multiple sclerosis (MS) and its nonclinical model of experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 192, "tag": "ExperimentalModelOfDisease"}, {"end": 238, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 157, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 83, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 171, "tag": "ResearchActivity"}, {"end": 135, "start": 123, "tag": "PathologicFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 11, "tag": "PathologicFunction"}]}
{"id": "1294_1", "text": "Phycocyanobilin (PCB), a chromophore of the biliprotein C-Phycocyanin (C-PC) from Spirulina platensis, has antioxidant, immunoregulatory and anti-inflammatory effects in this disease, and it could complement the effect of other Disease Modifying Treatments (DMT), such as Interferon-beta (IFN-beta).", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 20, "start": 17, "tag": "Chemical"}, {"end": 36, "start": 25, "tag": "Chemical"}, {"end": 75, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 82, "tag": "Bacterium"}, {"end": 256, "start": 228, "tag": "HealthCareActivity"}, {"end": 287, "start": 272, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 272, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 289, "tag": "AminoAcidPeptideOrProtein"}, {"end": 297, "start": 289, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 146, "tag": "PathologicFunction"}, {"end": 218, "start": 212, "tag": "Finding"}, {"end": 118, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 107, "tag": "CellFunction"}, {"end": 166, "start": 159, "tag": "Finding"}, {"end": 158, "start": 141, "tag": "BiologicFunction"}, {"end": 158, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 120, "tag": "BiologicFunction"}]}
{"id": "1294_2", "text": "Here, our main goal was to evaluate the potential PCB benefits and its mechanisms of action to counteract the chronic EAE in mice.", "tags": [{"end": 53, "start": 50, "tag": "Chemical"}, {"end": 121, "start": 118, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 125, "tag": "Eukaryote"}, {"end": 117, "start": 110, "tag": "TemporalConcept"}]}
{"id": "1294_3", "text": "MOG(35-55)-induced EAE was implemented in C57BL/6 female mice.", "tags": [{"end": 22, "start": 19, "tag": "ExperimentalModelOfDisease"}, {"end": 61, "start": 57, "tag": "Eukaryote"}, {"end": 49, "start": 42, "tag": "Eukaryote"}, {"end": 56, "start": 50, "tag": "OrganismAttribute"}, {"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1294_4", "text": "Clinical signs, pro-inflammatory cytokines levels by ELISA, qPCR in the brain and immunohistochemistry using precursor/mature oligodendrocytes cells antibodies in the spinal cord, were assessed.", "tags": [{"end": 14, "start": 0, "tag": "Finding"}, {"end": 159, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 9, "tag": "SignOrSymptom"}, {"end": 142, "start": 126, "tag": "Cell"}, {"end": 118, "start": 109, "tag": "Cell"}, {"end": 142, "start": 119, "tag": "Cell"}, {"end": 178, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 32, "start": 20, "tag": "PathologicFunction"}, {"end": 64, "start": 60, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 143, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "PathologicFunction"}, {"end": 42, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 82, "tag": "ResearchActivity"}, {"end": 58, "start": 53, "tag": "ResearchActivity"}]}
{"id": "1294_5", "text": "PCB enhanced the neurological condition, and waned the brain concentrations of IL-17A and IL-6, pro-inflammatory cytokines, in a dose-dependent manner.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 85, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 100, "tag": "PathologicFunction"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 96, "tag": "PathologicFunction"}, {"end": 75, "start": 61, "tag": "BiologicFunction"}, {"end": 122, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 90, "tag": "GeneOrGenome"}, {"end": 39, "start": 17, "tag": "BiologicFunction"}, {"end": 85, "start": 79, "tag": "GeneOrGenome"}]}
{"id": "1294_6", "text": "A down- or up-regulating activity of PCB at 1 mg/kg was identified in the brain on three (LINGO1, NOTCH1, and TNF-alpha), and five genes (MAL, CXCL12, MOG, OLIG1, and NKX2-2), respectively.", "tags": [{"end": 24, "start": 11, "tag": "CellFunction"}, {"end": 40, "start": 37, "tag": "Chemical"}, {"end": 96, "start": 90, "tag": "GeneOrGenome"}, {"end": 104, "start": 98, "tag": "GeneOrGenome"}, {"end": 104, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 138, "tag": "GeneOrGenome"}, {"end": 141, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 143, "tag": "GeneOrGenome"}, {"end": 149, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 161, "start": 156, "tag": "GeneOrGenome"}, {"end": 173, "start": 167, "tag": "GeneOrGenome"}, {"end": 79, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 167, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1294_7", "text": "Interestingly, a reduction of demyelination, active microglia/macrophages density, and axonal damage was detected along with an increase in oligodendrocyte precursor cells and mature oligodendrocytes, when assessed the spinal cords of EAE mice that took up PCB.", "tags": [{"end": 260, "start": 257, "tag": "Chemical"}, {"end": 238, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 243, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 231, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 183, "tag": "Cell"}, {"end": 171, "start": 140, "tag": "Cell"}, {"end": 199, "start": 176, "tag": "Cell"}, {"end": 93, "start": 87, "tag": "CellComponent"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 171, "start": 156, "tag": "Cell"}, {"end": 165, "start": 140, "tag": "Cell"}, {"end": 73, "start": 62, "tag": "Cell"}, {"end": 243, "start": 239, "tag": "Eukaryote"}, {"end": 61, "start": 52, "tag": "Cell"}, {"end": 26, "start": 17, "tag": "Finding"}, {"end": 26, "start": 17, "tag": "NaturalPhenomenonOrProcess"}, {"end": 43, "start": 30, "tag": "PathologicFunction"}, {"end": 100, "start": 94, "tag": "InjuryOrPoisoning"}]}
{"id": "1294_8", "text": "The studies in vitro in rodent encephalitogenic T cells and in vivo in the EAE mouse model with the PCB/IFN-beta combination, showed an enhanced positive effect of this combined therapy.", "tags": [{"end": 185, "start": 169, "tag": "HealthCareActivity"}, {"end": 78, "start": 75, "tag": "ExperimentalModelOfDisease"}, {"end": 30, "start": 24, "tag": "Eukaryote"}, {"end": 160, "start": 154, "tag": "Finding"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 185, "start": 178, "tag": "HealthCareActivity"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 90, "start": 79, "tag": "ResearchActivity"}, {"end": 160, "start": 145, "tag": "Finding"}, {"end": 55, "start": 48, "tag": "Cell"}, {"end": 103, "start": 100, "tag": "Chemical"}, {"end": 112, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 104, "tag": "PharmacologicSubstance"}]}
{"id": "1294_9", "text": "Overall, these results demonstrate the anti-inflammatory activity and the protective properties of PCB on the myelin and support its use with IFN-beta as an improved DMT combination for MS.", "tags": [{"end": 102, "start": 99, "tag": "Chemical"}, {"end": 150, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 44, "tag": "CellFunction"}, {"end": 56, "start": 44, "tag": "PathologicFunction"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 39, "tag": "BiologicFunction"}, {"end": 56, "start": 39, "tag": "PharmacologicSubstance"}, {"end": 150, "start": 142, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1295_0", "text": "The most challenging aspect of secondary progressive multiple sclerosis (SPMS) is the lack of efficient regenerative response for remyelination, which is carried out by the endogenous population of adult oligoprogenitor cells (OPCs) after proper activation.", "tags": [{"end": 77, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 227, "tag": "Cell"}, {"end": 71, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 204, "tag": "Cell"}, {"end": 194, "start": 184, "tag": "PopulationGroup"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 203, "start": 198, "tag": "PopulationGroup"}]}
{"id": "1295_1", "text": "OPCs must proliferate and migrate to the lesion and then differentiate into mature oligodendrocytes.", "tags": [{"end": 99, "start": 83, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 70, "start": 57, "tag": "CellFunction"}, {"end": 47, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 99, "start": 76, "tag": "Cell"}, {"end": 82, "start": 76, "tag": "TemporalConcept"}]}
{"id": "1295_2", "text": "To investigate the OPC cellular component in SPMS, we developed induced pluripotent stem cells (iPSCs) from SPMS-affected donors and age-matched controls (CT).", "tags": [{"end": 49, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 19, "tag": "Cell"}, {"end": 153, "start": 145, "tag": "PopulationGroup"}, {"end": 136, "start": 133, "tag": "OrganismAttribute"}, {"end": 94, "start": 64, "tag": "Cell"}, {"end": 101, "start": 96, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "Cell"}, {"end": 128, "start": 122, "tag": "PopulationGroup"}]}
{"id": "1295_3", "text": "We confirmed their efficient and similar OPC differentiation capacity, although we reported SPMS-OPCs were transcriptionally distinguishable from their CT counterparts.", "tags": [{"end": 124, "start": 107, "tag": "CellFunction"}, {"end": 96, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 60, "start": 45, "tag": "CellFunction"}, {"end": 60, "start": 41, "tag": "CellFunction"}, {"end": 69, "start": 61, "tag": "Finding"}]}
{"id": "1295_4", "text": "Analysis of OPC-generated conditioned media (CM) also evinced differences in protein secretion.", "tags": [{"end": 47, "start": 45, "tag": "Chemical"}, {"end": 94, "start": 77, "tag": "CellFunction"}, {"end": 15, "start": 12, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 43, "start": 26, "tag": "Chemical"}, {"end": 73, "start": 62, "tag": "Finding"}]}
{"id": "1295_5", "text": "We further confirmed SPMS-OPC CM presented a deficient capacity to stimulate OPC in vitro migration that can be compensated by exogenous addition of specific components.", "tags": [{"end": 32, "start": 30, "tag": "Chemical"}, {"end": 25, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 26, "tag": "Cell"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 99, "start": 90, "tag": "CellFunction"}, {"end": 63, "start": 55, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}]}
{"id": "1295_6", "text": "Our results provide an SPMS-OPC cellular model and encouraging venues to study potential cell communication deficiencies in the progressive form of multiple sclerosis (MS) for future treatment strategies.", "tags": [{"end": 120, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "Cell"}, {"end": 166, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 73, "tag": "ResearchActivity"}, {"end": 46, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 139, "start": 128, "tag": "TemporalConcept"}, {"end": 40, "start": 32, "tag": "Cell"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 89, "tag": "CellFunction"}, {"end": 203, "start": 183, "tag": "HealthCareActivity"}, {"end": 203, "start": 183, "tag": "ResearchActivity"}]}
{"id": "1296_0", "text": "Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) leading to demyelination and neurodegeneration.", "tags": [{"end": 57, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 105, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 87, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1296_1", "text": "Life expectancy and age of onset in MS patients have been rising over the last decades, and previous studies have shown that age affects disease progression.", "tags": [{"end": 32, "start": 20, "tag": "TemporalConcept"}, {"end": 86, "start": 79, "tag": "TemporalConcept"}, {"end": 156, "start": 145, "tag": "PathologicFunction"}, {"end": 156, "start": 145, "tag": "TemporalConcept"}, {"end": 128, "start": 125, "tag": "OrganismAttribute"}, {"end": 108, "start": 101, "tag": "ResearchActivity"}, {"end": 47, "start": 39, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 137, "tag": "PathologicFunction"}, {"end": 15, "start": 0, "tag": "TemporalConcept"}]}
{"id": "1296_2", "text": "Therefore, age appears as one of the most important factors in accumulating disability in MS patients.", "tags": [{"end": 14, "start": 11, "tag": "OrganismAttribute"}, {"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 76, "tag": "Finding"}]}
{"id": "1296_3", "text": "Indeed, the degeneration of oligodendrocytes (OGDs) and OGD precursors (OPCs) increases with age, in association with increased inflammatory activity of astrocytes and microglia.", "tags": [{"end": 50, "start": 46, "tag": "Cell"}, {"end": 44, "start": 28, "tag": "Cell"}, {"end": 163, "start": 153, "tag": "Cell"}, {"end": 76, "start": 72, "tag": "Cell"}, {"end": 96, "start": 93, "tag": "OrganismAttribute"}, {"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 177, "start": 168, "tag": "Cell"}, {"end": 70, "start": 56, "tag": "Cell"}, {"end": 149, "start": 128, "tag": "CellFunction"}]}
{"id": "1296_4", "text": "Similarly, age-related neuronal changes such as mitochondrial alterations, an increase in oxidative stress, and disrupted paranodal junctions can impact myelin integrity.", "tags": [{"end": 141, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 160, "tag": "IndividualBehavior"}, {"end": 31, "start": 23, "tag": "Cell"}, {"end": 106, "start": 90, "tag": "CellOrMolecularDysfunction"}, {"end": 61, "start": 48, "tag": "CellComponent"}, {"end": 141, "start": 112, "tag": "PathologicFunction"}, {"end": 14, "start": 11, "tag": "OrganismAttribute"}, {"end": 159, "start": 153, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 153, "tag": "CellFunction"}]}
{"id": "1296_5", "text": "Conversely, once myelination is complete, the long-term integrity of axons depends on OGD supply of energy.", "tags": [{"end": 65, "start": 56, "tag": "IndividualBehavior"}, {"end": 89, "start": 86, "tag": "Cell"}, {"end": 106, "start": 90, "tag": "BiologicFunction"}, {"end": 106, "start": 100, "tag": "NaturalPhenomenonOrProcess"}, {"end": 74, "start": 69, "tag": "CellComponent"}, {"end": 28, "start": 17, "tag": "CellFunction"}, {"end": 55, "start": 46, "tag": "TemporalConcept"}]}
{"id": "1296_6", "text": "These alterations determine pathological myelin changes consisting of myelin outfolding, splitting, and accumulation of multilamellar fragments.", "tags": [{"end": 98, "start": 89, "tag": "SignOrSymptom"}, {"end": 143, "start": 104, "tag": "Finding"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1296_7", "text": "Overall, these data demonstrate that old mature OGDs lose their ability to produce and maintain healthy myelin over time, to induce de novo myelination, and to remodel pre-existing myelinated axons that contribute to neural plasticity in the CNS.", "tags": [{"end": 52, "start": 48, "tag": "Cell"}, {"end": 167, "start": 160, "tag": "BiologicFunction"}, {"end": 234, "start": 217, "tag": "CellFunction"}, {"end": 245, "start": 242, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "CellFunction"}, {"end": 197, "start": 181, "tag": "CellComponent"}, {"end": 47, "start": 41, "tag": "TemporalConcept"}, {"end": 103, "start": 96, "tag": "OrganismAttribute"}, {"end": 19, "start": 15, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 116, "tag": "TemporalConcept"}, {"end": 71, "start": 64, "tag": "OrganismAttribute"}]}
{"id": "1296_8", "text": "Furthermore, as observed in other tissues, aging induces a general decline in regenerative processes and, not surprisingly, progressively hinders remyelination in MS.", "tags": [{"end": 159, "start": 146, "tag": "CellFunction"}, {"end": 48, "start": 43, "tag": "BiologicFunction"}, {"end": 48, "start": 43, "tag": "CellFunction"}, {"end": 165, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1296_9", "text": "In this context, this review will provide an overview of the current knowledge of age-related changes occurring in cells of the oligodendroglial lineage and how they impact myelin synthesis, axonal degeneration, and remyelination efficiency.", "tags": [{"end": 78, "start": 69, "tag": "Finding"}, {"end": 53, "start": 45, "tag": "ResearchActivity"}, {"end": 229, "start": 216, "tag": "CellFunction"}, {"end": 152, "start": 128, "tag": "Cell"}, {"end": 210, "start": 191, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 85, "start": 82, "tag": "OrganismAttribute"}, {"end": 120, "start": 115, "tag": "Cell"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "TemporalConcept"}, {"end": 189, "start": 173, "tag": "CellFunction"}, {"end": 240, "start": 230, "tag": "Finding"}]}
{"id": "1297_0", "text": "Promoting remyelination is considered as a potential neurorepair strategy to prevent/limit the development of permanent neurological disability in patients with multiple sclerosis (MS).", "tags": [{"end": 119, "start": 110, "tag": "TemporalConcept"}, {"end": 143, "start": 120, "tag": "SignOrSymptom"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 106, "start": 95, "tag": "BiologicFunction"}, {"end": 106, "start": 95, "tag": "CellFunction"}, {"end": 23, "start": 10, "tag": "CellFunction"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 133, "tag": "Finding"}, {"end": 73, "start": 53, "tag": "HealthCareActivity"}]}
{"id": "1297_1", "text": "To this end, a number of clinical trials are investigating the potential of existing drugs to enhance oligodendrocyte progenitor cell (OPC) differentiation, a process that fails in chronic MS lesions.", "tags": [{"end": 133, "start": 102, "tag": "Cell"}, {"end": 138, "start": 135, "tag": "Cell"}, {"end": 199, "start": 192, "tag": "InjuryOrPoisoning"}, {"end": 155, "start": 140, "tag": "CellFunction"}, {"end": 133, "start": 118, "tag": "Cell"}, {"end": 133, "start": 129, "tag": "Cell"}, {"end": 90, "start": 85, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 25, "tag": "ResearchActivity"}, {"end": 188, "start": 181, "tag": "TemporalConcept"}]}
{"id": "1297_2", "text": "We previously reported that oligodendroglia express GABA(B) receptors (GABA(B)Rs) both in vitro and in vivo, and that GABA(B)R-mediated signaling enhances OPC differentiation and myelin protein expression in vitro.", "tags": [{"end": 193, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "CellFunction"}, {"end": 80, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "Cell"}, {"end": 145, "start": 136, "tag": "CellFunction"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 174, "start": 155, "tag": "CellFunction"}, {"end": 43, "start": 28, "tag": "Cell"}, {"end": 204, "start": 194, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "ResearchActivity"}, {"end": 213, "start": 205, "tag": "ResearchActivity"}, {"end": 126, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 100, "tag": "ResearchActivity"}, {"end": 69, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 52, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1297_3", "text": "Our goal here was to evaluate the pro-remyelinating potential of GABA(B)R agonist baclofen (Bac), a clinically approved drug to treat spasticity in patients with MS.", "tags": [{"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 134, "tag": "SignOrSymptom"}, {"end": 81, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 156, "start": 148, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 120, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 92, "tag": "PharmacologicSubstance"}]}
{"id": "1297_4", "text": "We first demonstrated that Bac increases myelin protein production in lysolecithin (LPC)-treated cerebellar slices.", "tags": [{"end": 30, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 70, "tag": "Chemical"}, {"end": 82, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 114, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 3, "tag": "TemporalConcept"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 27, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 84, "tag": "Chemical"}, {"end": 87, "start": 84, "tag": "PharmacologicSubstance"}]}
{"id": "1297_5", "text": "Importantly, Bac administration to adult mice following induction of demyelination by LPC injection in the spinal cord resulted in enhanced OPC differentiation and remyelination.", "tags": [{"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "Chemical"}, {"end": 143, "start": 140, "tag": "Cell"}, {"end": 118, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 144, "tag": "CellFunction"}, {"end": 159, "start": 140, "tag": "CellFunction"}, {"end": 45, "start": 41, "tag": "Eukaryote"}, {"end": 177, "start": 164, "tag": "CellFunction"}, {"end": 82, "start": 69, "tag": "PathologicFunction"}, {"end": 40, "start": 35, "tag": "PopulationGroup"}, {"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 31, "start": 17, "tag": "HealthCareActivity"}, {"end": 89, "start": 86, "tag": "PharmacologicSubstance"}]}
{"id": "1297_6", "text": "Thus, our results suggest that Bac repurposing should be considered as a potential therapeutic strategy to stimulate remyelination in patients with MS.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 134, "tag": "PatientOrDisabledGroup"}, {"end": 130, "start": 117, "tag": "CellFunction"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 83, "tag": "HealthCareActivity"}, {"end": 34, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 31, "tag": "HealthCareActivity"}]}
{"id": "1298_0", "text": "Multiple sclerosis (MS) is an autoimmune disorder characterised by demyelination of central nervous system neurons with subsequent damage, cell death and disability.", "tags": [{"end": 106, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 144, "tag": "BiologicFunction"}, {"end": 149, "start": 144, "tag": "PathologicFunction"}, {"end": 149, "start": 144, "tag": "CellFunction"}, {"end": 114, "start": 107, "tag": "Cell"}, {"end": 49, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "CellFunction"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 67, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 154, "tag": "Finding"}, {"end": 137, "start": 131, "tag": "InjuryOrPoisoning"}]}
{"id": "1298_1", "text": "While mechanisms exist in the CNS to repair this damage, they are disrupted in MS and currently there are no treatments to address this deficit.", "tags": [{"end": 143, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 66, "tag": "PathologicFunction"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "TemporalConcept"}, {"end": 119, "start": 109, "tag": "HealthCareActivity"}, {"end": 119, "start": 109, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 37, "tag": "BiologicFunction"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}, {"end": 55, "start": 49, "tag": "InjuryOrPoisoning"}]}
{"id": "1298_2", "text": "In recent years, increasing attention has been paid to the influence of the small, non-coding RNA molecules, microRNAs (miRNAs), in autoimmune disorders, including MS.", "tags": [{"end": 97, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 28, "tag": "BiologicFunction"}, {"end": 126, "start": 120, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 107, "start": 98, "tag": "Substance"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 17, "tag": "Finding"}, {"end": 97, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 109, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 109, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1298_3", "text": "In this review, we examine the role of miRNAs in remyelination in the different cell types that contribute to MS.", "tags": [{"end": 45, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 62, "start": 49, "tag": "CellFunction"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "Cell"}]}
{"id": "1298_4", "text": "We focus on key miRNAs that have a central role in mediating the repair process, along with several more that play either secondary or inhibitory roles in one or more aspects.", "tags": [{"end": 145, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 65, "tag": "BiologicFunction"}, {"end": 71, "start": 65, "tag": "HealthCareActivity"}]}
{"id": "1298_5", "text": "Finally, we consider the current state of miRNAs as therapeutic targets in MS, acknowledging current challenges and potential strategies to overcome them in developing effective novel therapeutics to enhance repair mechanisms in MS.", "tags": [{"end": 48, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 101, "tag": "HealthCareActivity"}, {"end": 196, "start": 184, "tag": "HealthCareActivity"}, {"end": 71, "start": 52, "tag": "ResearchActivity"}, {"end": 38, "start": 33, "tag": "PopulationGroup"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 100, "start": 93, "tag": "TemporalConcept"}, {"end": 136, "start": 126, "tag": "ResearchActivity"}, {"end": 136, "start": 126, "tag": "BiologicFunction"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 208, "tag": "BiologicFunction"}, {"end": 214, "start": 208, "tag": "HealthCareActivity"}]}
{"id": "1299_0", "text": "Multiple sclerosis (MS) is the most demyelinating disease of the central nervous system (CNS) characterized by neuroinflammation.", "tags": [{"end": 49, "start": 36, "tag": "PathologicFunction"}, {"end": 57, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 111, "tag": "PathologicFunction"}]}
{"id": "1299_1", "text": "Oligodendrocyte progenitor cells (OPCs) are cycling cells in the developing and adult CNS that, under demyelinating conditions, migrate to the site of lesions and differentiate into mature oligodendrocytes to remyelinate damaged axons.", "tags": [{"end": 32, "start": 0, "tag": "Cell"}, {"end": 234, "start": 229, "tag": "CellComponent"}, {"end": 205, "start": 189, "tag": "Cell"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 176, "start": 163, "tag": "CellFunction"}, {"end": 115, "start": 102, "tag": "PathologicFunction"}, {"end": 220, "start": 209, "tag": "CellFunction"}, {"end": 158, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 205, "start": 182, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 188, "start": 182, "tag": "TemporalConcept"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 52, "tag": "Cell"}, {"end": 85, "start": 80, "tag": "PopulationGroup"}]}
{"id": "1299_2", "text": "However, this process fails during disease chronicization due to impaired OPC differentiation.", "tags": [{"end": 77, "start": 74, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 93, "start": 74, "tag": "CellFunction"}, {"end": 57, "start": 35, "tag": "Finding"}]}
{"id": "1299_3", "text": "Moreover, OPCs are crucial players in neuro-glial communication as they receive synaptic inputs from neurons and express ion channels and neurotransmitter/neuromodulator receptors that control their maturation.", "tags": [{"end": 133, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "CellFunction"}, {"end": 124, "start": 121, "tag": "Chemical"}, {"end": 154, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 10, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "BiologicFunction"}, {"end": 108, "start": 101, "tag": "Cell"}, {"end": 63, "start": 38, "tag": "CellFunction"}, {"end": 179, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 80, "tag": "CellFunction"}]}
{"id": "1299_4", "text": "Ion channels are recognized as attractive therapeutic targets, and indeed ligand-gated and voltage-gated channels can both be found among the top five pharmaceutical target groups of FDA-approved agents.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 42, "tag": "ResearchActivity"}, {"end": 186, "start": 183, "tag": "HealthCareRelatedOrganization"}, {"end": 202, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 113, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 74, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1299_5", "text": "Their modulation ameliorates some of the symptoms of MS and improves the outcome of related animal models.", "tags": [{"end": 80, "start": 73, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "SignOrSymptom"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 92, "tag": "ResearchActivity"}]}
{"id": "1299_6", "text": "However, the exact mechanism of action of ion-channel targeting compounds is often still unclear due to the wide expression of these channels on neurons, glia, and infiltrating immune cells.", "tags": [{"end": 141, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 42, "tag": "Chemical"}, {"end": 189, "start": 164, "tag": "Cell"}, {"end": 73, "start": 64, "tag": "Chemical"}, {"end": 73, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 113, "tag": "CellFunction"}, {"end": 158, "start": 154, "tag": "Cell"}, {"end": 152, "start": 145, "tag": "Cell"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 42, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1299_7", "text": "The present review summarizes recent findings in the field to get further insights into physio-pathophysiological processes and possible therapeutic mechanisms of drug actions.", "tags": [{"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 36, "start": 30, "tag": "TemporalConcept"}, {"end": 167, "start": 163, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 95, "tag": "PathologicFunction"}, {"end": 113, "start": 95, "tag": "PathologicFunction"}]}
{"id": "1300_0", "text": "Oligodendrocyte precursor cells (OPCs) undergo an extensive and coordinated migration in the developing CNS, using the pre-formed scaffold of developed blood vessels as their physical substrate for migration.", "tags": [{"end": 165, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 184, "tag": "Chemical"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 207, "start": 198, "tag": "CellFunction"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 107, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1300_1", "text": "While OPC association with vasculature is critical for dispersal, equally important for permitting differentia-tion and proper myelination of target axons is their appropriate and timely detachment, but regulation of this process remains unclear.", "tags": [{"end": 38, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 187, "tag": "BiologicFunction"}, {"end": 197, "start": 187, "tag": "PathologicFunction"}, {"end": 197, "start": 187, "tag": "Finding"}, {"end": 154, "start": 149, "tag": "CellComponent"}, {"end": 9, "start": 6, "tag": "Cell"}, {"end": 138, "start": 127, "tag": "CellFunction"}]}
{"id": "1300_2", "text": "Here we demonstrate a correlation between the developmental formation of astro-cytic endfeet on vessels and the termination of OPC perivascular migration.", "tags": [{"end": 103, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 131, "tag": "Cell"}, {"end": 130, "start": 127, "tag": "Cell"}, {"end": 59, "start": 46, "tag": "BiologicFunction"}, {"end": 59, "start": 46, "tag": "TemporalConcept"}, {"end": 153, "start": 144, "tag": "CellFunction"}]}
{"id": "1300_3", "text": "Ex vivo and in vivo live imaging shows that astrocyte endfeet physically displace OPCs from vasculature, and genetic abrogation of endfoot formation hinders both OPC detachment from vessels and subsequent differentiation.", "tags": [{"end": 103, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 166, "tag": "BiologicFunction"}, {"end": 176, "start": 166, "tag": "PathologicFunction"}, {"end": 176, "start": 166, "tag": "Finding"}, {"end": 189, "start": 182, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 220, "start": 205, "tag": "CellFunction"}, {"end": 32, "start": 20, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 44, "tag": "Cell"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}]}
{"id": "1300_4", "text": "Astrocyte-derived semaphorins 3a and 6a act to repel OPCs from blood vessels at the cessation of their perivascular migration and, in so doing, permit subsequent OPC differentiation by insulating them from a maturation inhibitory endo-thelial niche.", "tags": [{"end": 76, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 103, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 229, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 162, "tag": "CellFunction"}, {"end": 125, "start": 116, "tag": "CellFunction"}, {"end": 32, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1301_0", "text": "Oligodendrocyte progenitor cells (OPCs) are responsible for generating oligodendrocytes, the myelinating cells of the CNS.", "tags": [{"end": 32, "start": 0, "tag": "Cell"}, {"end": 87, "start": 71, "tag": "Cell"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 105, "tag": "Cell"}, {"end": 104, "start": 93, "tag": "CellFunction"}]}
{"id": "1301_1", "text": "Life-long myelination is promoted by neuronal activity and is essential for neural network plasticity and learning.", "tags": [{"end": 114, "start": 106, "tag": "BiologicFunction"}, {"end": 54, "start": 37, "tag": "CellFunction"}, {"end": 45, "start": 37, "tag": "Cell"}, {"end": 21, "start": 10, "tag": "CellFunction"}, {"end": 90, "start": 83, "tag": "PopulationGroup"}, {"end": 90, "start": 83, "tag": "CellFunction"}, {"end": 4, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 76, "tag": "BiologicFunction"}]}
{"id": "1301_2", "text": "OPCs are known to contact synapses and it is proposed that neuronal synaptic activity in turn regulates their behavior.", "tags": [{"end": 118, "start": 110, "tag": "BiologicFunction"}, {"end": 118, "start": 110, "tag": "IndividualBehavior"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 68, "tag": "CellFunction"}]}
{"id": "1301_3", "text": "To examine this in the adult, we performed unilateral injection of the synaptic blocker botulinum neurotoxin A (BoNT/A) into the hippocampus of adult mice.", "tags": [{"end": 118, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 150, "tag": "Eukaryote"}, {"end": 140, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 23, "tag": "PopulationGroup"}, {"end": 149, "start": 144, "tag": "PopulationGroup"}, {"end": 63, "start": 54, "tag": "HealthCareActivity"}, {"end": 110, "start": 88, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 112, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 112, "tag": "InjuryOrPoisoning"}]}
{"id": "1301_4", "text": "We confirm BoNT/A cleaves SNAP-25 in the CA1 are of the hippocampus, which has been proven to block neurotransmission.", "tags": [{"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 26, "tag": "GeneOrGenome"}, {"end": 33, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 100, "tag": "CellFunction"}, {"end": 67, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 11, "tag": "InjuryOrPoisoning"}, {"end": 17, "start": 11, "tag": "PharmacologicSubstance"}]}
{"id": "1301_5", "text": "Notably, BoNT/A significantly decreased OPC density and caused their shrinkage, as determined by immunolabeling for the OPC marker NG2.", "tags": [{"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 131, "tag": "GeneOrGenome"}, {"end": 78, "start": 69, "tag": "Finding"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 123, "start": 120, "tag": "Cell"}, {"end": 130, "start": 124, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 9, "tag": "InjuryOrPoisoning"}]}
{"id": "1301_6", "text": "Furthermore, BoNT/A resulted in an overall decrease in the number of OPC processes, as well as a decrease in their lengths and branching frequency.", "tags": [{"end": 19, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 137, "tag": "TemporalConcept"}, {"end": 51, "start": 43, "tag": "Finding"}, {"end": 105, "start": 97, "tag": "Finding"}, {"end": 72, "start": 69, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 69, "tag": "CellComponent"}]}
{"id": "1301_7", "text": "These data indicate that synaptic activity is important for maintaining adult OPC numbers and cellular integrity, which is relevant to pathophysiological scenarios characterized by dysregulation of synaptic activity, such as age-related cognitive decline, Multiple Sclerosis and Alzheimer's disease.", "tags": [{"end": 81, "start": 78, "tag": "Cell"}, {"end": 274, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 225, "tag": "OrganismAttribute"}, {"end": 254, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "PopulationGroup"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 153, "start": 135, "tag": "PathologicFunction"}, {"end": 42, "start": 25, "tag": "CellFunction"}, {"end": 112, "start": 94, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "Finding"}, {"end": 215, "start": 198, "tag": "CellFunction"}]}
{"id": "1302_0", "text": "Multiple sclerosis (MS) is a complex inflammatory, degenerative, and demyelinating disease of the central nervous system.", "tags": [{"end": 63, "start": 51, "tag": "PathologicFunction"}, {"end": 120, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 37, "tag": "PathologicFunction"}]}
{"id": "1302_1", "text": "Although treatments exist, MS cannot be cured by available drugs, which primarily target neuroinflammation.", "tags": [{"end": 64, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 89, "tag": "PathologicFunction"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 9, "tag": "HealthCareActivity"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}]}
{"id": "1302_2", "text": "Thus, it is feasible that a well concerted polypharmacological approach able to act at multiple points within the intricate network of inflammation, neurodegeneration, and demyelination/remyelination pathways would succeed where other drugs have failed.", "tags": [{"end": 240, "start": 235, "tag": "PharmacologicSubstance"}, {"end": 199, "start": 186, "tag": "CellFunction"}, {"end": 166, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 185, "start": 172, "tag": "PathologicFunction"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 208, "start": 200, "tag": "CellFunction"}, {"end": 71, "start": 43, "tag": "HealthCareActivity"}]}
{"id": "1302_3", "text": "Starting from reported beneficial effects of a-linolenic acid (ALA) and valproic acid (VPA) in MS, and by applying a rational strategy, we developed a small set of codrugs obtained by conjugating VPA and ALA through proper linkers.", "tags": [{"end": 85, "start": 72, "tag": "Chemical"}, {"end": 90, "start": 87, "tag": "Chemical"}, {"end": 199, "start": 196, "tag": "Chemical"}, {"end": 41, "start": 23, "tag": "Finding"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 45, "tag": "Chemical"}, {"end": 61, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "Chemical"}, {"end": 66, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 204, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 204, "tag": "Chemical"}, {"end": 207, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 164, "tag": "PharmacologicSubstance"}]}
{"id": "1302_4", "text": "A cellular profiling identified 1 as a polypharmacological tool able not only to modulate microglia polarization, but also to counteract neurodegeneration and demyelination and induce oligodendrocyte precursor cell differentiation, by acting on multiple biochemical and epigenetic pathways.", "tags": [{"end": 154, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 172, "start": 159, "tag": "PathologicFunction"}, {"end": 99, "start": 90, "tag": "Cell"}, {"end": 230, "start": 215, "tag": "CellFunction"}, {"end": 214, "start": 184, "tag": "Cell"}, {"end": 289, "start": 270, "tag": "CellFunction"}, {"end": 230, "start": 184, "tag": "CellFunction"}, {"end": 112, "start": 90, "tag": "CellFunction"}, {"end": 63, "start": 39, "tag": "HealthCareActivity"}, {"end": 20, "start": 2, "tag": "ResearchActivity"}]}
{"id": "1303_0", "text": "Oligodendrocytes, myelin-forming cells in the brain, are vulnerable to oxidative stress.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 33, "tag": "Cell"}, {"end": 87, "start": 71, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1303_1", "text": "Recent work indicates that air pollution causes demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 40, "start": 27, "tag": "EnvironmentalEffectOfHumans"}, {"end": 70, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 97, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}]}
{"id": "1303_2", "text": "However, little is known about the mechanism of toxicity of ultrafine particulate matters (PMs) to oligodendrocytes.", "tags": [{"end": 94, "start": 91, "tag": "Substance"}, {"end": 115, "start": 99, "tag": "Cell"}, {"end": 56, "start": 48, "tag": "InjuryOrPoisoning"}, {"end": 89, "start": 60, "tag": "Substance"}]}
{"id": "1303_3", "text": "Here, we aimed to determine whether oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes (mOLs) are more vulnerable to ultrafine urban PMs (uf-UPs) than other types of brain cells and damage to adult OPCs and mOLs in the mouse brain exposed to uf-UPs.", "tags": [{"end": 108, "start": 104, "tag": "Cell"}, {"end": 152, "start": 133, "tag": "Substance"}, {"end": 227, "start": 223, "tag": "Cell"}, {"end": 193, "start": 182, "tag": "Cell"}, {"end": 102, "start": 86, "tag": "Cell"}, {"end": 73, "start": 69, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Cell"}, {"end": 67, "start": 36, "tag": "Cell"}, {"end": 102, "start": 79, "tag": "Cell"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 67, "start": 52, "tag": "Cell"}, {"end": 61, "start": 36, "tag": "Cell"}, {"end": 246, "start": 241, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 240, "start": 235, "tag": "Eukaryote"}, {"end": 213, "start": 208, "tag": "PopulationGroup"}, {"end": 160, "start": 154, "tag": "Substance"}, {"end": 204, "start": 198, "tag": "InjuryOrPoisoning"}, {"end": 264, "start": 258, "tag": "Substance"}]}
{"id": "1303_4", "text": "For in vitro experiments, following exposure to various concentrations (2, 20, and 200 mu g/mL) of uf-UPs, we measured survival rates, the amount of reactive oxygen species (ROS), and the total antioxidant capacities (TACs) of brain cells isolated from neonatal Sprague-Dawley rats.", "tags": [{"end": 238, "start": 227, "tag": "Cell"}, {"end": 24, "start": 13, "tag": "ResearchActivity"}, {"end": 281, "start": 262, "tag": "Eukaryote"}, {"end": 172, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 149, "tag": "Chemical"}, {"end": 177, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 174, "tag": "Chemical"}, {"end": 261, "start": 253, "tag": "PopulationGroup"}, {"end": 261, "start": 253, "tag": "TemporalConcept"}, {"end": 205, "start": 194, "tag": "PharmacologicSubstance"}, {"end": 205, "start": 194, "tag": "CellFunction"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 127, "start": 119, "tag": "CellFunction"}, {"end": 70, "start": 56, "tag": "BiologicFunction"}, {"end": 105, "start": 99, "tag": "Substance"}, {"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 216, "start": 188, "tag": "CellFunction"}]}
{"id": "1303_5", "text": "For animal experiments, after a four-week exposure to a uf-UP suspension (20 mu L, 0.4 mg/mL), we enumerated the number of damaged cells and typed damaged cells in the white matter of the cerebellum of uf-UP-exposed mice.", "tags": [{"end": 22, "start": 4, "tag": "ResearchActivity"}, {"end": 72, "start": 62, "tag": "Substance"}, {"end": 22, "start": 11, "tag": "ResearchActivity"}, {"end": 180, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 37, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "Cell"}, {"end": 160, "start": 155, "tag": "Cell"}, {"end": 220, "start": 216, "tag": "Eukaryote"}, {"end": 61, "start": 56, "tag": "Substance"}, {"end": 130, "start": 123, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 147, "tag": "InjuryOrPoisoning"}, {"end": 207, "start": 202, "tag": "Substance"}]}
{"id": "1303_6", "text": "MTT assays and Hoechst staining demonstrated that OPCs and mOLs were more vulnerable to uf-UP-induced damage than astrocytes and cortical neurons at 2, 20, and 200 mu g/mL of uf-UPs examined in this study (p < 0.05).", "tags": [{"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 145, "start": 129, "tag": "Cell"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 204, "start": 199, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 145, "start": 138, "tag": "Cell"}, {"end": 137, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 114, "tag": "Cell"}, {"end": 31, "start": 15, "tag": "ResearchActivity"}, {"end": 93, "start": 88, "tag": "Substance"}, {"end": 108, "start": 102, "tag": "InjuryOrPoisoning"}, {"end": 181, "start": 175, "tag": "Substance"}]}
{"id": "1303_7", "text": "Damage to OPCs and mOLs depended on uf-UP concentration.", "tags": [{"end": 23, "start": 19, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "Cell"}, {"end": 55, "start": 42, "tag": "BiologicFunction"}, {"end": 41, "start": 36, "tag": "Substance"}, {"end": 6, "start": 0, "tag": "InjuryOrPoisoning"}]}
{"id": "1303_8", "text": "DCF assays and DHE staining indicated that the amount of ROS generated in OPCs and mOLs was significantly higher than in other brain cell types (p < 0.05).", "tags": [{"end": 18, "start": 15, "tag": "Chemical"}, {"end": 27, "start": 15, "tag": "ResearchActivity"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 137, "start": 127, "tag": "Cell"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 78, "start": 74, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 143, "start": 133, "tag": "Cell"}]}
{"id": "1303_9", "text": "In contrast, TAC values in OPCs and mOLs were significantly lower than those of other brain cell types (p < 0.05).", "tags": [{"end": 40, "start": 36, "tag": "Cell"}, {"end": 96, "start": 86, "tag": "Cell"}, {"end": 31, "start": 27, "tag": "Cell"}, {"end": 102, "start": 92, "tag": "Cell"}]}
{"id": "1303_10", "text": "Fluoro-Jade B (FJB)-positive cells in the cerebellar white matter of the uf-UP-exposed group were significantly greater in number relative to the control group.", "tags": [{"end": 65, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 146, "tag": "PopulationGroup"}, {"end": 65, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 87, "tag": "PopulationGroup"}, {"end": 159, "start": 154, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "Cell"}, {"end": 13, "start": 0, "tag": "Chemical"}, {"end": 18, "start": 15, "tag": "Chemical"}, {"end": 78, "start": 73, "tag": "Substance"}]}
{"id": "1303_11", "text": "Double immunofluorescence indicated that FJB-positive cells are NG2-positive adult OPCs and carbon anhydrase II-positive mOLs.", "tags": [{"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 59, "start": 54, "tag": "Cell"}, {"end": 82, "start": 77, "tag": "PopulationGroup"}, {"end": 25, "start": 7, "tag": "ResearchActivity"}, {"end": 44, "start": 41, "tag": "Chemical"}, {"end": 125, "start": 121, "tag": "Cell"}, {"end": 111, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 92, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1303_12", "text": "Taken together, our findings suggest that oxidative stress induced by uf-UPs in the brain impairs adult OPCs and mOLs, causing demyelination and reducing the capacity for remyelination.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 108, "start": 104, "tag": "Cell"}, {"end": 89, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 166, "start": 158, "tag": "Finding"}, {"end": 184, "start": 171, "tag": "CellFunction"}, {"end": 140, "start": 127, "tag": "PathologicFunction"}, {"end": 103, "start": 98, "tag": "PopulationGroup"}, {"end": 76, "start": 70, "tag": "Substance"}]}
{"id": "1304_0", "text": "Oligodendrocytes are a type of glial cells that produce a lipid-rich membrane called myelin.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 31, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "CellComponent"}, {"end": 42, "start": 31, "tag": "Cell"}, {"end": 63, "start": 58, "tag": "Chemical"}]}
{"id": "1304_1", "text": "Myelin assembles into a sheath and lines neuronal axons in the brain and spinal cord to insulate them.", "tags": [{"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 50, "tag": "CellComponent"}, {"end": 84, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "Cell"}]}
{"id": "1304_2", "text": "This not only increases the speed and efficiency of nerve signal transduction but also protects the axons from damage and degradation, which could trigger neuronal cell death.", "tags": [{"end": 77, "start": 52, "tag": "CellFunction"}, {"end": 105, "start": 100, "tag": "CellComponent"}, {"end": 48, "start": 38, "tag": "Finding"}, {"end": 133, "start": 122, "tag": "NaturalPhenomenonOrProcess"}, {"end": 163, "start": 155, "tag": "Cell"}, {"end": 174, "start": 169, "tag": "BiologicFunction"}, {"end": 174, "start": 169, "tag": "PathologicFunction"}, {"end": 174, "start": 169, "tag": "CellFunction"}, {"end": 174, "start": 164, "tag": "CellFunction"}, {"end": 174, "start": 155, "tag": "CellFunction"}]}
{"id": "1304_3", "text": "Demyelination, which is caused by a loss of myelin and oligodendrocytes, is a prominent feature of many neurological conditions, including Multiple sclerosis (MS), spinal cord injuries (SCI), and leukodystrophies.", "tags": [{"end": 184, "start": 164, "tag": "InjuryOrPoisoning"}, {"end": 189, "start": 186, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 71, "start": 55, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 139, "tag": "DiseaseOrSyndrome"}]}
{"id": "1304_4", "text": "Demyelination is followed by a time of remyelination mediated by the recruitment of endogenous oligodendrocyte precursor cells, their migration to the injury site, and differentiation into myelin-producing oligodendrocytes.", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 222, "start": 189, "tag": "Cell"}, {"end": 222, "start": 206, "tag": "Cell"}, {"end": 126, "start": 95, "tag": "Cell"}, {"end": 195, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 143, "start": 134, "tag": "CellFunction"}, {"end": 126, "start": 111, "tag": "Cell"}, {"end": 120, "start": 95, "tag": "Cell"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 157, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 52, "start": 39, "tag": "CellFunction"}]}
{"id": "1304_5", "text": "Unfortunately, endogenous remyelination is not sufficient to overcome demyelination, which explains why there are to date no regenerative-based treatments for MS, SCI, or leukodystrophies.", "tags": [{"end": 166, "start": 163, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 114, "tag": "TemporalConcept"}, {"end": 121, "start": 117, "tag": "TemporalConcept"}, {"end": 187, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 144, "tag": "HealthCareActivity"}, {"end": 154, "start": 144, "tag": "ResearchActivity"}, {"end": 39, "start": 26, "tag": "CellFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 70, "tag": "PathologicFunction"}]}
{"id": "1304_6", "text": "To better understand the role of oligodendrocytes and develop cell-based remyelination therapies, human oligodendrocytes have been derived from somatic cells using cell reprogramming.", "tags": [{"end": 157, "start": 144, "tag": "Cell"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 182, "start": 164, "tag": "CellFunction"}, {"end": 49, "start": 33, "tag": "Cell"}, {"end": 120, "start": 104, "tag": "Cell"}, {"end": 103, "start": 98, "tag": "Eukaryote"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 86, "start": 73, "tag": "CellFunction"}, {"end": 96, "start": 87, "tag": "HealthCareActivity"}]}
{"id": "1304_7", "text": "This review will detail the different cell reprogramming methods that have been developed to generate human oligodendrocytes and their applications to disease modeling and cell-based remyelination therapies.", "tags": [{"end": 56, "start": 43, "tag": "CellFunction"}, {"end": 56, "start": 38, "tag": "CellFunction"}, {"end": 167, "start": 151, "tag": "ResearchActivity"}, {"end": 124, "start": 108, "tag": "Cell"}, {"end": 107, "start": 102, "tag": "Eukaryote"}, {"end": 176, "start": 172, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 196, "start": 183, "tag": "CellFunction"}, {"end": 206, "start": 197, "tag": "HealthCareActivity"}]}
{"id": "1304_8", "text": "Recent developments in the field have seen the derivation of brain organoids from pluripotent stem cells, and protocols have been devised to incorporate oligodendrocytes within the organoids, which will also be reviewed.", "tags": [{"end": 57, "start": 47, "tag": "HealthCareActivity"}, {"end": 76, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 82, "tag": "Cell"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 219, "start": 211, "tag": "HealthCareActivity"}, {"end": 219, "start": 211, "tag": "ResearchActivity"}, {"end": 76, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 7, "tag": "BiologicFunction"}, {"end": 19, "start": 7, "tag": "CellFunction"}, {"end": 169, "start": 153, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 104, "start": 94, "tag": "Cell"}]}
{"id": "1305_0", "text": "The molecular mechanisms that govern the maturation of oligodendrocyte lineage cells remain unclear.", "tags": [{"end": 24, "start": 4, "tag": "CellFunction"}, {"end": 51, "start": 41, "tag": "BiologicFunction"}, {"end": 78, "start": 55, "tag": "Cell"}, {"end": 84, "start": 79, "tag": "Cell"}]}
{"id": "1305_1", "text": "Emerging studies have shown that N-6-methyladenosine (m(6)A), the most common internal RNA modification of mammalian mRNA, plays a critical role in various developmental processes.", "tags": [{"end": 179, "start": 156, "tag": "BiologicFunction"}, {"end": 116, "start": 107, "tag": "Eukaryote"}, {"end": 121, "start": 117, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 33, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 54, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 87, "tag": "CellFunction"}]}
{"id": "1305_2", "text": "Here, we demonstrate that oligodendrocyte lineage progression is accompanied by dynamic changes in m(6)A modification on numerous transcripts.", "tags": [{"end": 49, "start": 26, "tag": "Cell"}, {"end": 141, "start": 130, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 104, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 99, "tag": "CellFunction"}]}
{"id": "1305_3", "text": "In vivo conditional inactivation of an essential m(6)A writer component, METTl14, results in decreased oligodendrocyte numbers and CNS hypomyelination, although oligodendrocyte precursor cell (OPC) numbers are normal.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 19, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 20, "tag": "CellFunction"}, {"end": 80, "start": 73, "tag": "GeneOrGenome"}, {"end": 150, "start": 135, "tag": "Finding"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 93, "tag": "Finding"}, {"end": 191, "start": 161, "tag": "Cell"}, {"end": 196, "start": 193, "tag": "Cell"}, {"end": 186, "start": 161, "tag": "Cell"}, {"end": 118, "start": 103, "tag": "Cell"}, {"end": 216, "start": 210, "tag": "Finding"}, {"end": 54, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1305_4", "text": "n vitro Mettl14 ablation disrupts postmitotic oligodendrocyte maturation and has distinct effects on OPC and oligodendrocyte transcriptomes.", "tags": [{"end": 15, "start": 8, "tag": "GeneOrGenome"}, {"end": 104, "start": 101, "tag": "Cell"}, {"end": 61, "start": 46, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 72, "start": 62, "tag": "BiologicFunction"}, {"end": 139, "start": 125, "tag": "MolecularSequence"}, {"end": 15, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 8, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1305_5", "text": "Moreover, the loss of Mettl14 in oligodendrocyte lineage cells causes aberrant splicing of myriad RNA transcripts, including those that encode the essential paranodal component neurofascin 155 (NF155).", "tags": [{"end": 29, "start": 22, "tag": "GeneOrGenome"}, {"end": 56, "start": 33, "tag": "Cell"}, {"end": 113, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 101, "start": 98, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 57, "tag": "Cell"}, {"end": 87, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 22, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1305_6", "text": "Together, our findings indicate that dynamic RNA methylation plays an important regulatory role in oligodendrocyte development and CNS myelination.", "tags": [{"end": 90, "start": 80, "tag": "GeneOrGenome"}, {"end": 60, "start": 49, "tag": "CellFunction"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "CellFunction"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 48, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 115, "tag": "BiologicFunction"}, {"end": 126, "start": 115, "tag": "CellFunction"}]}
{"id": "1306_0", "text": "BackgroundPeptidylarginine deiminase 2 (PAD2) mediates the post-translational conversion of arginine residues in proteins to citrullines and is highly expressed in the central nervous system (CNS).", "tags": [{"end": 44, "start": 40, "tag": "GeneOrGenome"}, {"end": 88, "start": 59, "tag": "CellFunction"}, {"end": 109, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 151, "tag": "CellFunction"}, {"end": 136, "start": 125, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 10, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1306_1", "text": "Dysregulated PAD2 activity has been implicated in the pathogenesis of several neurologic diseases, including multiple sclerosis (MS).", "tags": [{"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 54, "tag": "PathologicFunction"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1306_2", "text": "In this study, we sought to define the cellular and regional expression of the gene encoding for PAD2 (i.e.", "tags": [{"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 84, "tag": "BiologicFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 71, "start": 61, "tag": "CellFunction"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 101, "start": 97, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1306_3", "text": "PADI2) in the human CNS using publicly available datasets and evaluate whether anti-PAD2 antibodies were present in patients with various neurologic diseases.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 14, "tag": "Eukaryote"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 30, "tag": "ResearchActivity"}, {"end": 99, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 79, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1306_4", "text": "MethodsA total of 491 study participants were included in this study: 91 people with MS, 32 people with neuromyelitis optica (NMO), 281 people with post-treatment Lyme disease (PTLD), and 87 healthy controls.", "tags": [{"end": 129, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 199, "tag": "PopulationGroup"}, {"end": 40, "start": 28, "tag": "PopulationGroup"}, {"end": 198, "start": 191, "tag": "OrganismAttribute"}, {"end": 27, "start": 22, "tag": "ResearchActivity"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 79, "start": 73, "tag": "PopulationGroup"}, {"end": 98, "start": 92, "tag": "PopulationGroup"}, {"end": 142, "start": 136, "tag": "PopulationGroup"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 148, "tag": "DiseaseOrSyndrome"}]}
{"id": "1306_5", "text": "To measure PADI2 expression in the CNS from healthy individuals, publicly available tissue and single cell RNA sequencing data was analyzed.", "tags": [{"end": 16, "start": 11, "tag": "GeneOrGenome"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 95, "tag": "ResearchActivity"}, {"end": 63, "start": 52, "tag": "PopulationGroup"}, {"end": 51, "start": 44, "tag": "OrganismAttribute"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 17, "tag": "CellFunction"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 122, "tag": "ResearchActivity"}, {"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1306_6", "text": "Anti-PAD2 antibodies were measured in the serum of study participants using anti-PAD2 ELISA.", "tags": [{"end": 69, "start": 57, "tag": "PopulationGroup"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1306_7", "text": "Clinical and demographic variables were compared according to anti-PAD2 antibody positivity for the MS and PTLD groups and correlations between anti-PAD2 levels and disease severity were examined.", "tags": [{"end": 34, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 81, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 165, "tag": "ClinicalAttribute"}, {"end": 135, "start": 123, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "ClinicalAttribute"}, {"end": 181, "start": 173, "tag": "Finding"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 144, "tag": "ClinicalAttribute"}]}
{"id": "1306_8", "text": "ResultsPADI2 expression was highest in oligodendrocytes (mean +/- SD; 6.4 +/- 2.2), followed closely by astrocytes (5.5 +/- 2.6), microglia/macrophages (4.5 +/- 3.5), and oligodendrocyte precursor cells (3.2 +/- 3.3).", "tags": [{"end": 55, "start": 39, "tag": "Cell"}, {"end": 202, "start": 171, "tag": "Cell"}, {"end": 151, "start": 140, "tag": "Cell"}, {"end": 23, "start": 13, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "Cell"}, {"end": 114, "start": 104, "tag": "Cell"}, {"end": 12, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "GeneOrGenome"}]}
{"id": "1306_9", "text": "There was an increased proportion of anti-PAD2 positivity in the MS (19.8%; p = 0.007) and PTLD groups (13.9%; p = 0.057) relative to the healthy controls (5.7%), and these antibodies were not detected in NMO patients.", "tags": [{"end": 57, "start": 47, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 146, "tag": "PopulationGroup"}, {"end": 145, "start": 138, "tag": "OrganismAttribute"}, {"end": 217, "start": 209, "tag": "PatientOrDisabledGroup"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1306_10", "text": "There was a modest inverse correlation between anti-PAD2 levels and disease severity in people with MS (tau = -0.145, p = 0.02), with levels being the highest in those with relapsing-remitting disease.", "tags": [{"end": 182, "start": 173, "tag": "TemporalConcept"}, {"end": 84, "start": 68, "tag": "ClinicalAttribute"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "PopulationGroup"}, {"end": 84, "start": 76, "tag": "ClinicalAttribute"}, {"end": 84, "start": 76, "tag": "Finding"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 12, "tag": "ResearchActivity"}, {"end": 63, "start": 47, "tag": "ClinicalAttribute"}, {"end": 200, "start": 173, "tag": "DiseaseOrSyndrome"}]}
{"id": "1306_11", "text": "Similarly, there was a modest inverse correlation between anti-PAD2 levels and neurocognitive score (tau = -0.10, p = 0.027) in people with PTLD, with difficulty focusing, memory changes, fatigue, and difficulty finding words contributing most strongly to the effect.", "tags": [{"end": 144, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 151, "tag": "Finding"}, {"end": 219, "start": 212, "tag": "Finding"}, {"end": 195, "start": 188, "tag": "SignOrSymptom"}, {"end": 104, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 266, "start": 260, "tag": "Finding"}, {"end": 134, "start": 128, "tag": "PopulationGroup"}, {"end": 178, "start": 172, "tag": "BiologicFunction"}, {"end": 178, "start": 172, "tag": "Finding"}, {"end": 99, "start": 79, "tag": "ResearchActivity"}, {"end": 186, "start": 179, "tag": "Finding"}, {"end": 74, "start": 58, "tag": "ClinicalAttribute"}]}
{"id": "1306_12", "text": "ConclusionPADI2 expression was observed in diverse regions and cells of the CNS, and anti-PAD2 autoantibodies were associated with less severe symptoms in subsets of patients with MS and PTLD.", "tags": [{"end": 191, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 166, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "Cell"}, {"end": 26, "start": 16, "tag": "CellFunction"}, {"end": 151, "start": 143, "tag": "SignOrSymptom"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 136, "tag": "Finding"}, {"end": 15, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 10, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 85, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1306_13", "text": "These data suggest that anti-PAD2 antibodies may attenuate inflammation in diseases of different etiologies, which are united by high PADI2 expression in the target tissue.", "tags": [{"end": 139, "start": 134, "tag": "GeneOrGenome"}, {"end": 139, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 150, "start": 140, "tag": "CellFunction"}, {"end": 171, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 129, "tag": "Finding"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 44, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 97, "tag": "Finding"}, {"end": 139, "start": 134, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1307_0", "text": "Remyelination is a refractory feature of demyelinating diseases such as multiple sclerosis (MS).", "tags": [{"end": 63, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 29, "start": 19, "tag": "SignOrSymptom"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}]}
{"id": "1307_1", "text": "Studies have shown that promoting oligodendrocyte precursor cell (OPC) differentiation, which cannot be achieved by currently available therapeutic agents, is the key to enhancing remyelination.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 154, "start": 136, "tag": "HealthCareActivity"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 64, "start": 34, "tag": "Cell"}, {"end": 125, "start": 116, "tag": "TemporalConcept"}, {"end": 193, "start": 180, "tag": "CellFunction"}]}
{"id": "1307_2", "text": "Bu Shen Yi Sui capsule (BSYSC) is a traditional Chinese herbal medicine over many years of clinical practice.", "tags": [{"end": 71, "start": 48, "tag": "HealthCareActivity"}, {"end": 87, "start": 82, "tag": "TemporalConcept"}, {"end": 108, "start": 91, "tag": "HealthCareActivity"}, {"end": 14, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 71, "start": 48, "tag": "PharmacologicSubstance"}]}
{"id": "1307_3", "text": "We have found that BSYSC can effectively treat MS.", "tags": [{"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 19, "tag": "PharmacologicSubstance"}]}
{"id": "1307_4", "text": "In this study, the effects of BSYSC in promoting OPCs differentiation and remyelination were assessed using an experimental autoimmune encephalomyelitis (EAE) model in vivo and cultured OPCs in vitro.", "tags": [{"end": 152, "start": 111, "tag": "ExperimentalModelOfDisease"}, {"end": 157, "start": 154, "tag": "ExperimentalModelOfDisease"}, {"end": 53, "start": 49, "tag": "Cell"}, {"end": 190, "start": 186, "tag": "Cell"}, {"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 164, "start": 159, "tag": "ResearchActivity"}, {"end": 199, "start": 191, "tag": "ResearchActivity"}, {"end": 29, "start": 19, "tag": "PathologicFunction"}, {"end": 172, "start": 165, "tag": "ResearchActivity"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 185, "start": 177, "tag": "ResearchActivity"}, {"end": 26, "start": 19, "tag": "Finding"}, {"end": 35, "start": 30, "tag": "PharmacologicSubstance"}]}
{"id": "1307_5", "text": "The results showed that BSYSC reduced clinical function scores and increased neuroprotection.", "tags": [{"end": 92, "start": 77, "tag": "CellFunction"}, {"end": 29, "start": 24, "tag": "PharmacologicSubstance"}]}
{"id": "1307_6", "text": "The expression of platelet-derived growth factor receptor alpha (PDGFR-alpha) was decreased and the level of 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) was increased in the brains and spinal cords of mice as well as in OPCs after treatment with BSYSC.", "tags": [{"end": 63, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 233, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Eukaryote"}, {"end": 253, "start": 244, "tag": "HealthCareActivity"}, {"end": 253, "start": 244, "tag": "ResearchActivity"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 193, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 259, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1307_7", "text": "We further found that BSYSC elevated the expression of miR-219 or miR-338 in the serum exosomes of mice with EAE, thereby suppressing the expression of Sox6, Lingo1, and Hes5, which negatively regulate OPCs differentiation.", "tags": [{"end": 156, "start": 152, "tag": "GeneOrGenome"}, {"end": 164, "start": 158, "tag": "GeneOrGenome"}, {"end": 174, "start": 170, "tag": "GeneOrGenome"}, {"end": 112, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 206, "start": 202, "tag": "Cell"}, {"end": 222, "start": 207, "tag": "CellFunction"}, {"end": 103, "start": 99, "tag": "Eukaryote"}, {"end": 86, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 148, "start": 138, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 27, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 156, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 170, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1307_8", "text": "Therefore, serum exosomes of BSYSC-treated mice (exos-BSYSC) were extracted and administered to OPCs in which miR-219 or miR-338 expression was knocked down by adenovirus, and the results showed that Sox6, Lingo1, and Hes5 expression was downregulated, MBP expression was upregulated, OPCs differentiation was increased, and the ability of OPCs to wrap around neuronal axons was improved.", "tags": [{"end": 75, "start": 66, "tag": "HealthCareActivity"}, {"end": 75, "start": 66, "tag": "Finding"}, {"end": 170, "start": 160, "tag": "Virus"}, {"end": 204, "start": 200, "tag": "GeneOrGenome"}, {"end": 212, "start": 206, "tag": "GeneOrGenome"}, {"end": 222, "start": 218, "tag": "GeneOrGenome"}, {"end": 256, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 253, "tag": "GeneOrGenome"}, {"end": 374, "start": 369, "tag": "CellComponent"}, {"end": 100, "start": 96, "tag": "Cell"}, {"end": 289, "start": 285, "tag": "Cell"}, {"end": 344, "start": 340, "tag": "Cell"}, {"end": 305, "start": 290, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "Eukaryote"}, {"end": 368, "start": 360, "tag": "Cell"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 129, "tag": "CellFunction"}, {"end": 233, "start": 223, "tag": "CellFunction"}, {"end": 267, "start": 257, "tag": "CellFunction"}, {"end": 251, "start": 238, "tag": "CellFunction"}, {"end": 336, "start": 329, "tag": "OrganismAttribute"}, {"end": 25, "start": 17, "tag": "CellComponent"}, {"end": 34, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 117, "start": 110, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 117, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 121, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 204, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 206, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 272, "tag": "CellFunction"}, {"end": 156, "start": 144, "tag": "ResearchActivity"}]}
{"id": "1307_9", "text": "In conclusion, BSYSC may exert clinically relevant effects by regulating microRNA (miR) levels in exosomes and thus promoting the differentiation and maturation of OPCs.", "tags": [{"end": 86, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 81, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 164, "tag": "Cell"}, {"end": 160, "start": 150, "tag": "BiologicFunction"}, {"end": 145, "start": 130, "tag": "CellFunction"}, {"end": 58, "start": 51, "tag": "Finding"}, {"end": 106, "start": 98, "tag": "CellComponent"}, {"end": 20, "start": 15, "tag": "PharmacologicSubstance"}]}
{"id": "1308_0", "text": "The brain's endogenous capacity to restore damaged myelin deteriorates during the course of demyelinating disorders.", "tags": [{"end": 70, "start": 58, "tag": "Finding"}, {"end": 57, "start": 43, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 23, "tag": "Finding"}]}
{"id": "1308_1", "text": "Currently, no treatment options are available to establish remyelination.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 23, "start": 14, "tag": "ResearchActivity"}, {"end": 72, "start": 59, "tag": "CellFunction"}]}
{"id": "1308_2", "text": "Chronic demyelination leads to damaged axons and irreversible destruction of the central nervous system (CNS).", "tags": [{"end": 73, "start": 62, "tag": "HealthCareActivity"}, {"end": 44, "start": 39, "tag": "CellComponent"}, {"end": 103, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 8, "tag": "PathologicFunction"}]}
{"id": "1308_3", "text": "We identified two promising therapeutic candidates which enhance remyelination: oncostatin M (OSM), a member of the interleukin-6 family, and downstream mediator tissue inhibitor of metalloproteinases-1 (TIMP-1).", "tags": [{"end": 92, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "PharmacologicSubstance"}, {"end": 136, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 210, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 18, "tag": "Finding"}, {"end": 136, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 142, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1308_4", "text": "While remyelination was completely abrogated in OSMR beta knockout (KO) mice, OSM overexpression in the chronically demyelinated CNS established remyelination.", "tags": [{"end": 57, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 82, "tag": "CellFunction"}, {"end": 128, "start": 116, "tag": "PathologicFunction"}, {"end": 132, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 48, "tag": "ExperimentalModelOfDisease"}, {"end": 19, "start": 6, "tag": "CellFunction"}, {"end": 158, "start": 145, "tag": "CellFunction"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1308_5", "text": "Astrocytic TIMP-1 was demonstrated to play a pivotal role in OSM-mediated remyelination.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "PharmacologicSubstance"}]}
{"id": "1308_6", "text": "Astrocyte-derived TIMP-1 drove differentiation of oligodendrocyte precursor cells into mature oligodendrocytes in vitro.", "tags": [{"end": 9, "start": 0, "tag": "Cell"}, {"end": 81, "start": 50, "tag": "Cell"}, {"end": 110, "start": 87, "tag": "Cell"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 18, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1308_7", "text": "In vivo, TIMP-1 deficiency completely abolished spontaneous remyelination, phenocopying OSMR beta KO mice.", "tags": [{"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 16, "tag": "Finding"}, {"end": 105, "start": 101, "tag": "Eukaryote"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 105, "start": 88, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1308_8", "text": "Finally, TIMP-1 was expressed by human astrocytes in demyelinated multiple sclerosis lesions, confirming the human value of our findings.", "tags": [{"end": 84, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 85, "tag": "InjuryOrPoisoning"}, {"end": 65, "start": 53, "tag": "PathologicFunction"}, {"end": 38, "start": 33, "tag": "Eukaryote"}, {"end": 114, "start": 109, "tag": "Eukaryote"}, {"end": 49, "start": 39, "tag": "Cell"}, {"end": 29, "start": 20, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1308_9", "text": "Taken together, OSM and its downstream mediator TIMP-1 have the therapeutic potential to boost remyelination in demyelinating disorders.", "tags": [{"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 89, "tag": "HealthCareActivity"}, {"end": 135, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 64, "tag": "HealthCareActivity"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 54, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 28, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1309_0", "text": "Myelination is an essential process that consists of the ensheathment of axons by myelin.", "tags": [{"end": 78, "start": 73, "tag": "CellComponent"}, {"end": 88, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 78, "start": 57, "tag": "CellFunction"}]}
{"id": "1309_1", "text": "In the central nervous system (CNS), myelin is synthesized by oligodendrocytes.", "tags": [{"end": 78, "start": 62, "tag": "Cell"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1309_2", "text": "The proliferation, migration, and differentiation of oligodendrocyte precursor cells constitute a prerequisite before mature oligodendrocytes extend their processes around the axons and progressively generate a multilamellar lipidic sheath.", "tags": [{"end": 181, "start": 176, "tag": "CellComponent"}, {"end": 84, "start": 53, "tag": "Cell"}, {"end": 141, "start": 118, "tag": "Cell"}, {"end": 49, "start": 34, "tag": "CellFunction"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 28, "start": 19, "tag": "CellFunction"}, {"end": 239, "start": 211, "tag": "CellComponent"}]}
{"id": "1309_3", "text": "Although myelination is predominately driven by oligodendrocytes, the other glial cells including astrocytes and microglia, also contribute to this process.", "tags": [{"end": 64, "start": 48, "tag": "Cell"}, {"end": 87, "start": 76, "tag": "Cell"}, {"end": 122, "start": 113, "tag": "Cell"}, {"end": 108, "start": 98, "tag": "Cell"}, {"end": 20, "start": 9, "tag": "CellFunction"}]}
{"id": "1309_4", "text": "The present review is an update of the most recent emerging mechanisms involving astrocyte and microglia in myelin production.", "tags": [{"end": 31, "start": 25, "tag": "TemporalConcept"}, {"end": 114, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "Cell"}, {"end": 90, "start": 81, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "TemporalConcept"}]}
{"id": "1309_5", "text": "The contribution of these cells will be first described during developmental myelination that occurs in the early postnatal period and is critical for the proper development of cognition and behavior.", "tags": [{"end": 199, "start": 191, "tag": "BiologicFunction"}, {"end": 199, "start": 191, "tag": "IndividualBehavior"}, {"end": 199, "start": 191, "tag": "ResearchActivity"}, {"end": 76, "start": 63, "tag": "BiologicFunction"}, {"end": 76, "start": 63, "tag": "TemporalConcept"}, {"end": 113, "start": 108, "tag": "TemporalConcept"}, {"end": 123, "start": 114, "tag": "TemporalConcept"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 173, "start": 162, "tag": "BiologicFunction"}, {"end": 173, "start": 162, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}, {"end": 186, "start": 177, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}]}
{"id": "1309_6", "text": "Then, we will report the novel findings regarding the beneficial or deleterious effects of astroglia and microglia, which respectively promote or impair the endogenous capacity of oligodendrocyte progenitor cells (OPCs) to induce spontaneous remyelination after myelin loss.", "tags": [{"end": 100, "start": 91, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Cell"}, {"end": 268, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 180, "tag": "Cell"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 176, "start": 168, "tag": "Finding"}, {"end": 114, "start": 105, "tag": "Cell"}, {"end": 255, "start": 242, "tag": "CellFunction"}, {"end": 87, "start": 80, "tag": "Finding"}, {"end": 273, "start": 262, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1309_7", "text": "Acute delineation of astrocyte and microglia activities and cross-talk should uncover the way towards novel therapeutic perspectives aimed at recovering proper myelination during development or at breaking down the barriers impeding the regeneration of the damaged myelin that occurs in CNS demyelinating diseases.", "tags": [{"end": 70, "start": 60, "tag": "CellFunction"}, {"end": 271, "start": 257, "tag": "CellOrMolecularDysfunction"}, {"end": 313, "start": 291, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 237, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 249, "start": 237, "tag": "HealthCareActivity"}, {"end": 290, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 179, "tag": "BiologicFunction"}, {"end": 190, "start": 179, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "Cell"}, {"end": 171, "start": 160, "tag": "CellFunction"}, {"end": 132, "start": 102, "tag": "Finding"}]}
{"id": "1310_0", "text": "Introduction: AQP4 (aquaporin-4)-immunoglobulin G (IgG)-mediated neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that affects the central nervous system, particularly the spinal cord and optic nerve; remyelination capacity in neuromyelitis optica is yet to be determined, as is the role of AQP4-IgG in cell differentiation.", "tags": [{"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "ResearchActivity"}, {"end": 103, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 266, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 338, "start": 335, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 338, "start": 335, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 338, "start": 335, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 118, "tag": "PathologicFunction"}, {"end": 192, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 262, "start": 254, "tag": "Finding"}, {"end": 253, "start": 240, "tag": "CellFunction"}, {"end": 362, "start": 342, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 334, "start": 330, "tag": "GeneOrGenome"}, {"end": 334, "start": 330, "tag": "BiologicallyActiveSubstance"}, {"end": 334, "start": 330, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1310_1", "text": "Material and Methods: We included three groups-a group of patients with AQP4-IgG-positive neuromyelitis optica, a healthy group, and a sham group.", "tags": [{"end": 8, "start": 0, "tag": "Substance"}, {"end": 139, "start": 135, "tag": "Chemical"}, {"end": 66, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 114, "tag": "OrganismAttribute"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 127, "start": 122, "tag": "PopulationGroup"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 76, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 72, "tag": "GeneOrGenome"}]}
{"id": "1310_2", "text": "We analyzed differentiation capacity in cultures of neurospheres from the subventricular zone of mice by adding serum at two different times: early and advanced stages of differentiation.", "tags": [{"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 152, "tag": "TemporalConcept"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 27, "start": 12, "tag": "CellFunction"}, {"end": 186, "start": 171, "tag": "CellFunction"}, {"end": 147, "start": 142, "tag": "TemporalConcept"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 97, "tag": "Eukaryote"}, {"end": 117, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 28, "tag": "Finding"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "TemporalConcept"}]}
{"id": "1310_3", "text": "We also analyzed differentiation into different cell lines.", "tags": [{"end": 32, "start": 17, "tag": "CellFunction"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "Cell"}]}
{"id": "1310_4", "text": "Results and Conclusions: The effect of sera from patients with NMOSD on precursor cells differs according to the degree of differentiation, and probably affects oligodendrocyte progenitor cells from NG2 cells to a lesser extent than cells from the subventricular zone; however, the resulting oligodendrocytes may be compromised in terms of maturation and possibly limited in their ability to generate myelin.", "tags": [{"end": 68, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 199, "tag": "GeneOrGenome"}, {"end": 308, "start": 292, "tag": "Cell"}, {"end": 350, "start": 340, "tag": "BiologicFunction"}, {"end": 407, "start": 401, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 161, "tag": "Cell"}, {"end": 138, "start": 123, "tag": "CellFunction"}, {"end": 87, "start": 72, "tag": "Cell"}, {"end": 267, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 208, "start": 203, "tag": "Cell"}, {"end": 238, "start": 233, "tag": "Cell"}, {"end": 43, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 29, "tag": "Finding"}, {"end": 388, "start": 381, "tag": "OrganismAttribute"}]}
{"id": "1310_5", "text": "Furthermore, these cells decrease in number with age.", "tags": [{"end": 24, "start": 19, "tag": "Cell"}, {"end": 52, "start": 49, "tag": "OrganismAttribute"}, {"end": 33, "start": 25, "tag": "Finding"}]}
{"id": "1310_6", "text": "It is very unlikely that the use of drugs favoring the migration and differentiation of oligodendrocyte progenitor cells in multiple sclerosis would be effective in the context of neuromyelitis optica, but cell therapy with oligodendrocyte progenitor cells seems to be a potential alternative.", "tags": [{"end": 218, "start": 206, "tag": "HealthCareActivity"}, {"end": 200, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 88, "tag": "Cell"}, {"end": 256, "start": 224, "tag": "Cell"}, {"end": 84, "start": 69, "tag": "CellFunction"}, {"end": 64, "start": 55, "tag": "CellFunction"}, {"end": 41, "start": 36, "tag": "PharmacologicSubstance"}]}
{"id": "1311_0", "text": "This article reviews the wealth of papers dealing with the different effects of epidermal growth factor (EGF) on oligodendrocytes, astrocytes, neurons, and neural stem cells (NSCs).", "tags": [{"end": 103, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 179, "start": 175, "tag": "Cell"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "HealthCareActivity"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 129, "start": 113, "tag": "Cell"}, {"end": 173, "start": 156, "tag": "Cell"}, {"end": 150, "start": 143, "tag": "Cell"}, {"end": 141, "start": 131, "tag": "Cell"}, {"end": 76, "start": 69, "tag": "Finding"}]}
{"id": "1311_1", "text": "EGF induces the in vitro and in vivo proliferation of NSCs, their migration, and their differentiation towards the neuroglial cell line.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 58, "start": 54, "tag": "Cell"}, {"end": 135, "start": 115, "tag": "Cell"}, {"end": 102, "start": 87, "tag": "CellFunction"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 75, "start": 66, "tag": "CellFunction"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}]}
{"id": "1311_2", "text": "It interacts with extracellular matrix components.", "tags": [{"end": 38, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 39, "tag": "CellComponent"}]}
{"id": "1311_3", "text": "NSCs are distributed in different CNS areas, serve as a reservoir of multipotent cells, and may be increased during CNS demyelinating diseases.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "ManufacturedObject"}, {"end": 86, "start": 69, "tag": "Cell"}, {"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "Finding"}]}
{"id": "1311_4", "text": "EGF has pleiotropic differentiative and proliferative effects on the main CNS cell types, particularly oligodendrocytes and their precursors, and astrocytes.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 119, "start": 103, "tag": "Cell"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 146, "tag": "Cell"}, {"end": 61, "start": 40, "tag": "Finding"}, {"end": 88, "start": 78, "tag": "Cell"}]}
{"id": "1311_5", "text": "EGF mediates the in vivo myelinotrophic effect of cobalamin on the CNS, and modulates the synthesis and levels of CNS normal prions (PrPs), both of which are indispensable for myelinogenesis and myelin maintenance.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 59, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 176, "tag": "CellFunction"}, {"end": 201, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 90, "tag": "BiologicFunction"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "Finding"}, {"end": 213, "start": 202, "tag": "BiologicFunction"}, {"end": 24, "start": 17, "tag": "ResearchActivity"}, {"end": 124, "start": 118, "tag": "Finding"}, {"end": 39, "start": 25, "tag": "CellFunction"}, {"end": 131, "start": 125, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1311_6", "text": "EGF levels are significantly lower in the cerebrospinal fluid and spinal cord of patients with multiple sclerosis (MS), which probably explains remyelination failure, also because of the EGF marginal role in immunology.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 190, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 187, "tag": "GeneOrGenome"}, {"end": 218, "start": 208, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 113, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 61, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 190, "start": 187, "tag": "PharmacologicSubstance"}]}
{"id": "1311_7", "text": "When repeatedly administered, EGF protects mouse spinal cord from demyelination in various experimental models of autoimmune encephalomyelitis.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 142, "start": 91, "tag": "ExperimentalModelOfDisease"}, {"end": 60, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 43, "tag": "Eukaryote"}, {"end": 79, "start": 66, "tag": "PathologicFunction"}, {"end": 33, "start": 30, "tag": "PharmacologicSubstance"}]}
{"id": "1311_8", "text": "It would be worth further investigating the role of EGF in the pathogenesis of MS because of its multifarious effects.", "tags": [{"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 55, "start": 52, "tag": "CellFunction"}, {"end": 55, "start": 52, "tag": "GeneOrGenome"}, {"end": 75, "start": 63, "tag": "PathologicFunction"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 110, "tag": "Finding"}]}
{"id": "1312_0", "text": "Oligodendrocytes are glial cells located in the central nervous system (CNS) that play essential roles in the transmission of nerve signals and in the neuroprotection of myelinated neurons.", "tags": [{"end": 131, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 151, "tag": "CellFunction"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 70, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 132, "tag": "CellFunction"}, {"end": 32, "start": 21, "tag": "Cell"}, {"end": 122, "start": 110, "tag": "Finding"}, {"end": 188, "start": 170, "tag": "Cell"}]}
{"id": "1312_1", "text": "The dysfunction or loss of oligodendrocytes leads to demyelinating diseases such as multiple sclerosis (MS).", "tags": [{"end": 43, "start": 27, "tag": "Cell"}, {"end": 75, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 53, "tag": "PathologicFunction"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 19, "tag": "CellOrMolecularDysfunction"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}]}
{"id": "1312_2", "text": "To treat demyelinating diseases, the development of a therapy that promotes remyelination is required.", "tags": [{"end": 31, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 9, "tag": "PathologicFunction"}, {"end": 48, "start": 37, "tag": "BiologicFunction"}, {"end": 48, "start": 37, "tag": "CellFunction"}, {"end": 61, "start": 54, "tag": "HealthCareActivity"}, {"end": 89, "start": 76, "tag": "CellFunction"}]}
{"id": "1312_3", "text": "In the present study, we established an in vitro method to convert human fibroblasts into induced oligodendrocyte-like cells (iOLCs) in 3 days.", "tags": [{"end": 84, "start": 73, "tag": "Cell"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 72, "start": 67, "tag": "Eukaryote"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 124, "start": 90, "tag": "Cell"}, {"end": 142, "start": 138, "tag": "TemporalConcept"}, {"end": 55, "start": 49, "tag": "ResearchActivity"}, {"end": 55, "start": 49, "tag": "HealthCareActivity"}, {"end": 131, "start": 126, "tag": "Cell"}]}
{"id": "1312_4", "text": "The induced cells displayed morphologies and molecular signatures similar to oligodendrocytes after treatment with valproic acid and exposure to the small molecules Y27632, SU9516, and forskolin (FSK).", "tags": [{"end": 65, "start": 45, "tag": "ResearchActivity"}, {"end": 128, "start": 115, "tag": "Chemical"}, {"end": 171, "start": 165, "tag": "Chemical"}, {"end": 179, "start": 173, "tag": "Chemical"}, {"end": 194, "start": 185, "tag": "Chemical"}, {"end": 199, "start": 196, "tag": "Chemical"}, {"end": 164, "start": 149, "tag": "Chemical"}, {"end": 93, "start": 77, "tag": "Cell"}, {"end": 17, "start": 12, "tag": "Cell"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "ResearchActivity"}, {"end": 164, "start": 155, "tag": "Substance"}, {"end": 40, "start": 28, "tag": "ClinicalAttribute"}]}
{"id": "1312_5", "text": "To pursue the development of a cell-free remyelination therapy in vivo, we used a cuprizone-induced demyelinated mouse model.", "tags": [{"end": 62, "start": 41, "tag": "HealthCareActivity"}, {"end": 112, "start": 100, "tag": "PathologicFunction"}, {"end": 91, "start": 82, "tag": "Chemical"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 25, "start": 14, "tag": "CellFunction"}, {"end": 35, "start": 31, "tag": "Cell"}, {"end": 62, "start": 55, "tag": "HealthCareActivity"}, {"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 124, "start": 113, "tag": "ResearchActivity"}, {"end": 124, "start": 82, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1312_6", "text": "The small molecules (Y27632, SU9516, and FSK) were directly injected into the demyelinated corpus callosum of the mouse brain.", "tags": [{"end": 27, "start": 21, "tag": "Chemical"}, {"end": 35, "start": 29, "tag": "Chemical"}, {"end": 44, "start": 41, "tag": "Chemical"}, {"end": 19, "start": 4, "tag": "Chemical"}, {"end": 90, "start": 78, "tag": "PathologicFunction"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 10, "tag": "Substance"}, {"end": 119, "start": 114, "tag": "Eukaryote"}]}
{"id": "1312_7", "text": "This combination of small molecules rescued the demyelination phenotype within two weeks as observed by light and electron microscopy.", "tags": [{"end": 35, "start": 20, "tag": "Chemical"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 109, "start": 104, "tag": "NaturalPhenomenonOrProcess"}, {"end": 71, "start": 62, "tag": "OrganismAttribute"}, {"end": 133, "start": 114, "tag": "ResearchActivity"}, {"end": 35, "start": 26, "tag": "Substance"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 133, "start": 123, "tag": "ResearchActivity"}, {"end": 109, "start": 104, "tag": "ResearchActivity"}]}
{"id": "1312_8", "text": "These results provide a foundation for exploring the development of a treatment for demyelinating diseases via regenerative medicine.", "tags": [{"end": 132, "start": 111, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 79, "start": 70, "tag": "HealthCareActivity"}, {"end": 79, "start": 70, "tag": "ResearchActivity"}]}
{"id": "1313_0", "text": "Oligodendrocyte precursor cells (OPCs) originate in localized germinal zones in the embryonic neural tube, then migrate and proliferate to populate the entire central nervous system, both white and gray matter.", "tags": [{"end": 209, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 84, "tag": "EmbryonicStructure"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 181, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 62, "tag": "EmbryonicStructure"}]}
{"id": "1313_1", "text": "They divide and generate myelinating oligodendrocytes (OLs) throughout postnatal and adult life.", "tags": [{"end": 36, "start": 25, "tag": "CellFunction"}, {"end": 53, "start": 37, "tag": "Cell"}, {"end": 53, "start": 25, "tag": "Cell"}, {"end": 58, "start": 55, "tag": "Cell"}, {"end": 80, "start": 71, "tag": "TemporalConcept"}, {"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 90, "start": 85, "tag": "PopulationGroup"}]}
{"id": "1313_2", "text": "OPCs express NG2 and platelet-derived growth factor receptor alpha subunit (PDGFR alpha), two functionally important cell surface proteins, which are also widely used as markers for OPCs.", "tags": [{"end": 74, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 5, "tag": "CellFunction"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "GeneOrGenome"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 186, "start": 182, "tag": "Cell"}, {"end": 177, "start": 170, "tag": "ClinicalAttribute"}, {"end": 138, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 117, "tag": "CellComponent"}, {"end": 74, "start": 21, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1313_3", "text": "The proliferation of OPCs, their terminal differentiation into OLs, survival of new OLs, and myelin synthesis are orchestrated by signals in the local microenvironment.", "tags": [{"end": 167, "start": 151, "tag": "NaturalPhenomenonOrProcess"}, {"end": 25, "start": 21, "tag": "Cell"}, {"end": 57, "start": 42, "tag": "CellFunction"}, {"end": 66, "start": 63, "tag": "Cell"}, {"end": 87, "start": 84, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 109, "start": 93, "tag": "CellFunction"}, {"end": 137, "start": 130, "tag": "CellFunction"}, {"end": 76, "start": 68, "tag": "CellFunction"}]}
{"id": "1313_4", "text": "We discuss advances in our mechanistic understanding of paracrine effects, including those mediated through PDGFR alpha and neuronal activity-dependent signals such as those mediated through AMPA receptors in OL survival and myelination.", "tags": [{"end": 65, "start": 56, "tag": "BiologicFunction"}, {"end": 119, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 209, "tag": "Cell"}, {"end": 141, "start": 124, "tag": "CellFunction"}, {"end": 159, "start": 152, "tag": "CellFunction"}, {"end": 220, "start": 212, "tag": "CellFunction"}, {"end": 52, "start": 39, "tag": "BiologicFunction"}, {"end": 236, "start": 225, "tag": "CellFunction"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 205, "start": 191, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1313_5", "text": "Finally, we review recent studies supporting the role of new OL production and adaptive myelination in specific behaviours and cognitive processes contributing to learning and long-term memory formation.", "tags": [{"end": 122, "start": 112, "tag": "Finding"}, {"end": 146, "start": 127, "tag": "BiologicFunction"}, {"end": 171, "start": 163, "tag": "BiologicFunction"}, {"end": 63, "start": 61, "tag": "Cell"}, {"end": 185, "start": 176, "tag": "TemporalConcept"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 99, "start": 88, "tag": "CellFunction"}, {"end": 192, "start": 186, "tag": "BiologicFunction"}, {"end": 192, "start": 186, "tag": "Finding"}, {"end": 202, "start": 176, "tag": "BiologicFunction"}]}
{"id": "1313_6", "text": "Our article is not intended to be comprehensive but reflects the authors' past and present interests.", "tags": [{"end": 100, "start": 91, "tag": "BiologicFunction"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 78, "start": 74, "tag": "TemporalConcept"}]}
{"id": "1314_0", "text": "Oligodendrocytes are extensively coupled to astrocytes, a phenomenon ensuring glial homeostasis and maintenance of central nervous system myelin.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 78, "tag": "Cell"}, {"end": 137, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 95, "start": 84, "tag": "BiologicFunction"}, {"end": 54, "start": 44, "tag": "Cell"}]}
{"id": "1314_1", "text": "Molecular disruption of this communication occurs in demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 75, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 29, "tag": "HealthCareActivity"}, {"end": 42, "start": 29, "tag": "CellFunction"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1314_2", "text": "Less is known about the vulnerability and reconstruction of the panglial network during adult demyelination-remyelination.", "tags": [{"end": 37, "start": 24, "tag": "ClinicalAttribute"}, {"end": 56, "start": 42, "tag": "MachineActivity"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 121, "start": 108, "tag": "CellFunction"}, {"end": 107, "start": 94, "tag": "PathologicFunction"}, {"end": 93, "start": 88, "tag": "PopulationGroup"}, {"end": 80, "start": 64, "tag": "CellFunction"}]}
{"id": "1314_3", "text": "Here, we took advantage of lysolcithin-induced demyelination to investigate the expression dynamics of the oligodendrocyte specific connexin 47 (Cx47) and to some extent that of astrocyte Cx43, and whether this dynamic could be modulated by grafted induced pluripotent stem cell (iPSC)-neural progeny.", "tags": [{"end": 143, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 293, "tag": "PopulationGroup"}, {"end": 284, "start": 280, "tag": "Cell"}, {"end": 192, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 278, "start": 274, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "CellFunction"}, {"end": 187, "start": 178, "tag": "Cell"}, {"end": 122, "start": 107, "tag": "Cell"}, {"end": 278, "start": 249, "tag": "Cell"}, {"end": 60, "start": 47, "tag": "PathologicFunction"}, {"end": 99, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 278, "start": 269, "tag": "Cell"}, {"end": 143, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 292, "start": 286, "tag": "Cell"}]}
{"id": "1314_4", "text": "Our data show that disruption of Cx43-Cx47 mediated hetero-cellular gap-junction intercellular communication following demyelination is larger in size than demyelination.", "tags": [{"end": 29, "start": 19, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "OrganismAttribute"}, {"end": 108, "start": 81, "tag": "CellFunction"}, {"end": 108, "start": 95, "tag": "HealthCareActivity"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 132, "start": 119, "tag": "PathologicFunction"}, {"end": 169, "start": 156, "tag": "PathologicFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 80, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1314_5", "text": "Loss of Cx47 expression is timely rescued during remyelination and accelerated by the grafted neural precursors.", "tags": [{"end": 111, "start": 94, "tag": "Cell"}, {"end": 12, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 13, "tag": "CellFunction"}, {"end": 62, "start": 49, "tag": "CellFunction"}]}
{"id": "1314_6", "text": "Moreover, mouse and human iPSC-derived oligodendrocytes express Cx47, which co-labels with astrocyte Cx43, indicating their integration into the panglial network.", "tags": [{"end": 63, "start": 56, "tag": "CellFunction"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 55, "start": 39, "tag": "Cell"}, {"end": 135, "start": 124, "tag": "CellFunction"}, {"end": 135, "start": 124, "tag": "MachineActivity"}, {"end": 105, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "Eukaryote"}, {"end": 100, "start": 91, "tag": "Cell"}, {"end": 15, "start": 10, "tag": "Eukaryote"}, {"end": 161, "start": 145, "tag": "CellFunction"}]}
{"id": "1314_7", "text": "These data suggest that in rodents, full lesion repair following transplantation occurs by panglial reconstruction in addition to remyelination.", "tags": [{"end": 34, "start": 27, "tag": "Eukaryote"}, {"end": 47, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 80, "start": 65, "tag": "HealthCareActivity"}, {"end": 54, "start": 48, "tag": "BiologicFunction"}, {"end": 54, "start": 48, "tag": "HealthCareActivity"}]}
{"id": "1314_8", "text": "Targeting panglial elements by cell therapy or pharmacological compounds may help accelerating or stabilizing re/myelination in myelin disorders.", "tags": [{"end": 43, "start": 31, "tag": "HealthCareActivity"}, {"end": 144, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 47, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 113, "tag": "CellFunction"}]}
{"id": "1315_0", "text": "The regeneration of myelin is known to restore axonal conduction velocity after a demyelinating event.", "tags": [{"end": 95, "start": 82, "tag": "PathologicFunction"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 4, "tag": "BiologicFunction"}, {"end": 53, "start": 47, "tag": "CellComponent"}, {"end": 73, "start": 54, "tag": "BiologicFunction"}, {"end": 64, "start": 54, "tag": "NaturalPhenomenonOrProcess"}, {"end": 16, "start": 4, "tag": "HealthCareActivity"}, {"end": 64, "start": 54, "tag": "BiologicFunction"}]}
{"id": "1315_1", "text": "Remyelination failure in the central nervous system contributes to the severity and progression of demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 121, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 21, "start": 14, "tag": "IndividualBehavior"}, {"end": 51, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 95, "start": 84, "tag": "TemporalConcept"}, {"end": 79, "start": 71, "tag": "ClinicalAttribute"}, {"end": 79, "start": 71, "tag": "Finding"}]}
{"id": "1315_2", "text": "Remyelination is controlled by many signaling pathways, such as the Sonic hedgehog (Shh) pathway, as shown by the canonical activation of its key effector Smoothened (Smo), which increases the proliferation of oligodendrocyte precursor cells via the upregulation of the transcription factor Gli1.", "tags": [{"end": 27, "start": 17, "tag": "Finding"}, {"end": 27, "start": 17, "tag": "HealthCareActivity"}, {"end": 165, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 295, "start": 291, "tag": "GeneOrGenome"}, {"end": 295, "start": 291, "tag": "AminoAcidPeptideOrProtein"}, {"end": 290, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 290, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 241, "start": 210, "tag": "Cell"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 206, "start": 193, "tag": "CellFunction"}, {"end": 54, "start": 36, "tag": "CellFunction"}, {"end": 96, "start": 68, "tag": "CellFunction"}, {"end": 262, "start": 250, "tag": "CellFunction"}, {"end": 295, "start": 291, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "GeneOrGenome"}]}
{"id": "1315_3", "text": "On the other hand, the inhibition of Gli1 was also found to promote the recruitment of a subset of adult neural stem cells and their subsequent differentiation into oligodendrocytes.", "tags": [{"end": 41, "start": 37, "tag": "GeneOrGenome"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 165, "tag": "Cell"}, {"end": 159, "start": 144, "tag": "CellFunction"}, {"end": 122, "start": 105, "tag": "Cell"}, {"end": 33, "start": 23, "tag": "CellFunction"}, {"end": 104, "start": 99, "tag": "PopulationGroup"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1315_4", "text": "Since Smo is also able to transduce Shh signals via various non-canonical pathways such as the blockade of Gli1, we addressed the potential of non-canonical Smo signaling to contribute to oligodendroglial cell maturation in myelinating cells using the non-canonical Smo agonist GSA-10, which downregulates Gli1.", "tags": [{"end": 9, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "GeneOrGenome"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 305, "start": 292, "tag": "CellFunction"}, {"end": 310, "start": 306, "tag": "GeneOrGenome"}, {"end": 310, "start": 306, "tag": "AminoAcidPeptideOrProtein"}, {"end": 277, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 210, "tag": "BiologicFunction"}, {"end": 170, "start": 143, "tag": "CellFunction"}, {"end": 103, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 95, "tag": "Chemical"}, {"end": 209, "start": 188, "tag": "Cell"}, {"end": 241, "start": 236, "tag": "Cell"}, {"end": 47, "start": 40, "tag": "CellFunction"}, {"end": 82, "start": 60, "tag": "CellFunction"}, {"end": 9, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 284, "start": 278, "tag": "PharmacologicSubstance"}, {"end": 284, "start": 278, "tag": "Chemical"}, {"end": 269, "start": 266, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1315_5", "text": "Using the Oli-neuM cell line, we show that GSA-10 promotes Gli2 upregulation, MBP and MAL/OPALIN expression via Smo/AMP-activated Protein Kinase (AMPK) signaling, and efficiently increases the number of axonal contact/ensheathment for each oligodendroglial cell.", "tags": [{"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 217, "start": 203, "tag": "CellFunction"}, {"end": 150, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "GeneOrGenome"}, {"end": 161, "start": 152, "tag": "CellFunction"}, {"end": 144, "start": 112, "tag": "CellFunction"}, {"end": 261, "start": 240, "tag": "Cell"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 107, "start": 97, "tag": "CellFunction"}, {"end": 76, "start": 64, "tag": "CellFunction"}, {"end": 49, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 218, "tag": "CellFunction"}, {"end": 49, "start": 43, "tag": "Chemical"}, {"end": 96, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 90, "tag": "GeneOrGenome"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "GeneOrGenome"}]}
{"id": "1315_6", "text": "Moreover, GSA-10 promotes the recruitment and differentiation of oligodendroglial progenitors into the demyelinated corpus callosum in vivo.", "tags": [{"end": 115, "start": 103, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 131, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 65, "tag": "Cell"}, {"end": 139, "start": 132, "tag": "ResearchActivity"}, {"end": 16, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 16, "start": 10, "tag": "Chemical"}]}
{"id": "1315_7", "text": "Altogether, our data indicate that non-canonical signaling involving Smo/AMPK modulation and Gli1 downregulation promotes oligodendroglia maturation until axon engagement.", "tags": [{"end": 97, "start": 93, "tag": "GeneOrGenome"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "BiologicFunction"}, {"end": 58, "start": 49, "tag": "CellFunction"}, {"end": 137, "start": 122, "tag": "Cell"}, {"end": 159, "start": 155, "tag": "CellComponent"}, {"end": 112, "start": 98, "tag": "CellFunction"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "Finding"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1315_8", "text": "Thus, GSA-10, by activation of this signaling pathway, represents a novel potential remyelinating agent.", "tags": [{"end": 97, "start": 84, "tag": "CellFunction"}, {"end": 103, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 53, "start": 36, "tag": "CellFunction"}, {"end": 12, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 12, "start": 6, "tag": "Chemical"}]}
{"id": "1316_0", "text": "Glial subtype diversity is an emerging topic in neurobiology and immune-mediated neurological diseases such as multiple sclerosis (MS).", "tags": [{"end": 60, "start": 48, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "Cell"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 14, "tag": "Finding"}]}
{"id": "1316_1", "text": "We discuss recent conceptual and technological advances that allow a better understanding of the transcriptomic and functional heterogeneity of oligodendrocytes (OLs), astrocytes, and microglial cells under inflammatory-demyelinating conditions.", "tags": [{"end": 160, "start": 144, "tag": "Cell"}, {"end": 233, "start": 220, "tag": "PathologicFunction"}, {"end": 111, "start": 97, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 219, "start": 207, "tag": "PathologicFunction"}, {"end": 140, "start": 127, "tag": "OrganismAttribute"}, {"end": 89, "start": 76, "tag": "BiologicFunction"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 17, "start": 11, "tag": "TemporalConcept"}, {"end": 55, "start": 47, "tag": "Finding"}, {"end": 200, "start": 184, "tag": "Cell"}]}
{"id": "1316_2", "text": "Recent single cell transcriptomic studies suggest the occurrence of novel homeostatic and reactive glial subtypes and provide insight into the molecular events during disease progression.", "tags": [{"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 113, "start": 90, "tag": "Cell"}, {"end": 64, "start": 54, "tag": "TemporalConcept"}, {"end": 186, "start": 175, "tag": "PathologicFunction"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 41, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 186, "start": 167, "tag": "PathologicFunction"}]}
{"id": "1316_3", "text": "Multiplexed RNA in situ hybridization has enabled 'mapping back' dysregulated gene expression to glial subtypes within the MS lesion microenvironment.", "tags": [{"end": 37, "start": 0, "tag": "ResearchActivity"}, {"end": 149, "start": 133, "tag": "NaturalPhenomenonOrProcess"}, {"end": 132, "start": 126, "tag": "InjuryOrPoisoning"}, {"end": 111, "start": 97, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 77, "start": 65, "tag": "PathologicFunction"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 51, "tag": "ResearchActivity"}]}
{"id": "1316_4", "text": "These findings suggest novel homeostatic and reactive glial-cell-type functions both in immune-related processes and neuroprotection relevant to understanding the pathology of MS.", "tags": [{"end": 132, "start": 117, "tag": "CellFunction"}, {"end": 40, "start": 29, "tag": "BiologicFunction"}, {"end": 59, "start": 54, "tag": "Cell"}, {"end": 172, "start": 163, "tag": "PathologicFunction"}, {"end": 172, "start": 163, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 158, "start": 145, "tag": "BiologicFunction"}, {"end": 69, "start": 60, "tag": "Cell"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}]}
{"id": "1317_0", "text": "Demyelinating disorders show impaired remyelination due to failure in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature myelin-forming oligodendrocytes, a process driven by microglia-OPC crosstalk.", "tags": [{"end": 23, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "IndividualBehavior"}, {"end": 176, "start": 160, "tag": "Cell"}, {"end": 125, "start": 109, "tag": "Cell"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 131, "start": 127, "tag": "Cell"}, {"end": 211, "start": 208, "tag": "Cell"}, {"end": 125, "start": 93, "tag": "Cell"}, {"end": 221, "start": 212, "tag": "CellFunction"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 151, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 207, "start": 198, "tag": "Cell"}, {"end": 89, "start": 74, "tag": "CellFunction"}]}
{"id": "1317_1", "text": "Through conducting a transcriptomic analysis of microarray studies on the demyelination-remyelination cuprizone model and using human samples of multiple sclerosis (MS), we identified molecules involved in this crosstalk.", "tags": [{"end": 44, "start": 21, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "ManufacturedObject"}, {"end": 193, "start": 184, "tag": "Substance"}, {"end": 101, "start": 88, "tag": "CellFunction"}, {"end": 111, "start": 102, "tag": "Chemical"}, {"end": 220, "start": 211, "tag": "CellFunction"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 133, "start": 128, "tag": "Eukaryote"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 117, "start": 74, "tag": "ResearchActivity"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 74, "tag": "PathologicFunction"}, {"end": 141, "start": 134, "tag": "Substance"}, {"end": 141, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1317_2", "text": "Differentially expressed genes (DEGs) of specific regions/cell types were detected in GEO transcriptomic raw data after cuprizone treatment and in MS samples, followed by functional analysis with GO terms and WikiPathways.", "tags": [{"end": 104, "start": 90, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 190, "start": 171, "tag": "HealthCareActivity"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 196, "tag": "GeneOrGenome"}, {"end": 89, "start": 86, "tag": "ResearchActivity"}, {"end": 68, "start": 58, "tag": "Cell"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 129, "start": 120, "tag": "Chemical"}, {"end": 113, "start": 90, "tag": "ResearchActivity"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 139, "start": 130, "tag": "ResearchActivity"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 15, "tag": "CellFunction"}]}
{"id": "1317_3", "text": "Additionally, microglia-OPC crosstalk between microglia ligands, OPC receptors and target genes was examined with the NicheNet model.", "tags": [{"end": 95, "start": 83, "tag": "GeneOrGenome"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 68, "start": 65, "tag": "Cell"}, {"end": 37, "start": 28, "tag": "CellFunction"}, {"end": 132, "start": 118, "tag": "ResearchActivity"}, {"end": 23, "start": 14, "tag": "Cell"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1317_4", "text": "We identified 108 and 166 DEGs in the demyelinated corpus callosum (CC) at 2 and 4 weeks of cuprizone treatment; 427 and 355 DEGs in the remyelinated (4 weeks of cuprizone treatment + 14 days of normal diet) compared to 2- and 4-week demyelinated CC; 252 DEGs in MS samples and 2730 and 12 DEGs in OPC and microglia of 4-week demyelinated CC.", "tags": [{"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 70, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 246, "start": 234, "tag": "PathologicFunction"}, {"end": 249, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 338, "start": 326, "tag": "PathologicFunction"}, {"end": 341, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 298, "tag": "Cell"}, {"end": 66, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 26, "tag": "GeneOrGenome"}, {"end": 129, "start": 125, "tag": "GeneOrGenome"}, {"end": 259, "start": 255, "tag": "GeneOrGenome"}, {"end": 294, "start": 290, "tag": "GeneOrGenome"}, {"end": 30, "start": 26, "tag": "ResearchActivity"}, {"end": 129, "start": 125, "tag": "ResearchActivity"}, {"end": 259, "start": 255, "tag": "ResearchActivity"}, {"end": 294, "start": 290, "tag": "ResearchActivity"}, {"end": 101, "start": 92, "tag": "Chemical"}, {"end": 171, "start": 162, "tag": "Chemical"}, {"end": 206, "start": 195, "tag": "Finding"}, {"end": 233, "start": 229, "tag": "TemporalConcept"}, {"end": 325, "start": 321, "tag": "TemporalConcept"}, {"end": 111, "start": 102, "tag": "HealthCareActivity"}, {"end": 181, "start": 172, "tag": "HealthCareActivity"}, {"end": 111, "start": 102, "tag": "ResearchActivity"}, {"end": 181, "start": 172, "tag": "ResearchActivity"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}, {"end": 265, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 137, "tag": "CellFunction"}, {"end": 191, "start": 187, "tag": "TemporalConcept"}, {"end": 315, "start": 306, "tag": "Cell"}]}
{"id": "1317_5", "text": "At this time point, we found 95 common DEGs in the CC and OPCs, and one common DEG in microglia and OPCs, mostly associated with myelin and lipid metabolism.", "tags": [{"end": 18, "start": 8, "tag": "TemporalConcept"}, {"end": 53, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 140, "tag": "CellFunction"}, {"end": 156, "start": 140, "tag": "BiologicFunction"}, {"end": 145, "start": 140, "tag": "Chemical"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 104, "start": 100, "tag": "Cell"}, {"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 43, "start": 39, "tag": "ResearchActivity"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 12, "start": 8, "tag": "TemporalConcept"}, {"end": 82, "start": 79, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "ResearchActivity"}]}
{"id": "1317_6", "text": "Crosstalk analysis identified 47 microglia ligands, 43 OPC receptors and 115 OPC target genes, all differentially expressed in cuprizone-treated samples and associated with myelination.", "tags": [{"end": 123, "start": 99, "tag": "Finding"}, {"end": 58, "start": 55, "tag": "Cell"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 184, "start": 173, "tag": "CellFunction"}, {"end": 136, "start": 127, "tag": "Chemical"}, {"end": 18, "start": 10, "tag": "ResearchActivity"}, {"end": 123, "start": 114, "tag": "CellFunction"}, {"end": 42, "start": 33, "tag": "Cell"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 81, "tag": "GeneOrGenome"}]}
{"id": "1317_7", "text": "Our differential expression pipeline identified demyelination/remyelination transcriptomic biomarkers in studies using diverse platforms and cell types/tissues.", "tags": [{"end": 151, "start": 141, "tag": "Cell"}, {"end": 75, "start": 62, "tag": "CellFunction"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 101, "start": 76, "tag": "ClinicalAttribute"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 159, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1317_8", "text": "Cellular crosstalk analysis yielded novel markers of microglia ligands, OPC receptors and target genes.", "tags": [{"end": 75, "start": 72, "tag": "Cell"}, {"end": 18, "start": 0, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "ResearchActivity"}, {"end": 62, "start": 53, "tag": "Cell"}, {"end": 49, "start": 42, "tag": "ClinicalAttribute"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 90, "tag": "GeneOrGenome"}]}
{"id": "1318_0", "text": "Low-density lipoprotein receptor-related protein 1 (LRP1) is a large, endocytic cell surface receptor that is highly expressed by oligodendrocyte progenitor cells (OPCs) and LRP1 expression is rapidly downregulated as OPCs differentiate into oligodendrocytes (OLs).", "tags": [{"end": 50, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 258, "start": 242, "tag": "Cell"}, {"end": 168, "start": 164, "tag": "Cell"}, {"end": 222, "start": 218, "tag": "Cell"}, {"end": 236, "start": 223, "tag": "CellFunction"}, {"end": 162, "start": 130, "tag": "Cell"}, {"end": 263, "start": 260, "tag": "Cell"}, {"end": 189, "start": 179, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "GeneOrGenome"}, {"end": 178, "start": 174, "tag": "GeneOrGenome"}, {"end": 56, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 80, "tag": "CellComponent"}, {"end": 214, "start": 201, "tag": "CellFunction"}, {"end": 126, "start": 117, "tag": "CellFunction"}, {"end": 50, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 93, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1318_1", "text": "We report that the conditional deletion of Lrp1 from adult mouse OPCs (Pdgfr alpha-CreER :: Lrp1(fl/fl)) increases the number of newborn, mature myelinating OLs added to the corpus callosum and motor cortex.", "tags": [{"end": 47, "start": 43, "tag": "GeneOrGenome"}, {"end": 206, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 145, "tag": "Cell"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 189, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 129, "tag": "TemporalConcept"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 58, "start": 53, "tag": "PopulationGroup"}, {"end": 39, "start": 19, "tag": "ResearchActivity"}, {"end": 103, "start": 71, "tag": "ResearchActivity"}]}
{"id": "1318_2", "text": "As these additional OLs extend a normal number of internodes that are of a normal length, Lrp1-deletion increases adult myelination.", "tags": [{"end": 60, "start": 50, "tag": "CellComponent"}, {"end": 88, "start": 82, "tag": "ResearchActivity"}, {"end": 23, "start": 20, "tag": "Cell"}, {"end": 39, "start": 33, "tag": "Finding"}, {"end": 81, "start": 75, "tag": "Finding"}, {"end": 131, "start": 120, "tag": "CellFunction"}, {"end": 119, "start": 114, "tag": "PopulationGroup"}, {"end": 103, "start": 90, "tag": "CellFunction"}]}
{"id": "1318_3", "text": "OPC proliferation is also elevated following Lrp1 deletion in vivo, however, this may be a secondary, homeostatic response to increased OPC differentiation, as our in vitro experiments show that LRP1 is a direct negative regulator of OPC differentiation, not proliferation.", "tags": [{"end": 49, "start": 45, "tag": "GeneOrGenome"}, {"end": 58, "start": 50, "tag": "CellOrMolecularDysfunction"}, {"end": 184, "start": 173, "tag": "ResearchActivity"}, {"end": 113, "start": 102, "tag": "BiologicFunction"}, {"end": 155, "start": 136, "tag": "CellFunction"}, {"end": 253, "start": 234, "tag": "CellFunction"}, {"end": 17, "start": 0, "tag": "CellFunction"}, {"end": 272, "start": 259, "tag": "CellFunction"}, {"end": 230, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 164, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 199, "start": 195, "tag": "GeneOrGenome"}, {"end": 199, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 195, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1318_4", "text": "Deleting Lrp1 from adult OPCs also increases the number of newborn mature OLs added to the corpus callosum in response to cuprizone-induced demyelination.", "tags": [{"end": 13, "start": 9, "tag": "GeneOrGenome"}, {"end": 29, "start": 19, "tag": "Cell"}, {"end": 77, "start": 74, "tag": "Cell"}, {"end": 73, "start": 67, "tag": "TemporalConcept"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 122, "tag": "Chemical"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 153, "start": 140, "tag": "PathologicFunction"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 9, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1318_5", "text": "These data suggest that the selective blockade of LRP1 function on adult OPCs may enhance myelin repair in demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 77, "start": 73, "tag": "Cell"}, {"end": 129, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 38, "tag": "Chemical"}, {"end": 103, "start": 90, "tag": "CellFunction"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "PopulationGroup"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}
{"id": "1319_0", "text": "The main obstacle to remyelination in demyelinating diseases, such as multiple sclerosis, is the inability of oligodendrocyte precursor cells (OPCs) to differentiate into mature oligodendrocytes (OLs) in the demyelinating region.", "tags": [{"end": 34, "start": 21, "tag": "CellFunction"}, {"end": 60, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 110, "tag": "Cell"}, {"end": 147, "start": 143, "tag": "Cell"}, {"end": 194, "start": 171, "tag": "Cell"}, {"end": 199, "start": 196, "tag": "Cell"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}]}
{"id": "1319_1", "text": "Consequently, promoting OL differentiation and myelin remodeling is a key goal in the search for treatments.", "tags": [{"end": 42, "start": 24, "tag": "CellFunction"}, {"end": 64, "start": 47, "tag": "CellFunction"}, {"end": 107, "start": 97, "tag": "ResearchActivity"}, {"end": 107, "start": 97, "tag": "HealthCareActivity"}]}
{"id": "1319_2", "text": "Rho GTPases play diverse and important roles throughout the development of neuronal axons and the formation of the myelin sheath.", "tags": [{"end": 11, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 75, "tag": "CellComponent"}, {"end": 128, "start": 115, "tag": "CellComponent"}, {"end": 71, "start": 60, "tag": "BiologicFunction"}, {"end": 71, "start": 60, "tag": "CellFunction"}, {"end": 44, "start": 29, "tag": "Finding"}]}
{"id": "1319_3", "text": "The current study aimed to investigate the direct protective effects of catalpol on demyelination damage induced by myelin oligodendrocyte glycoprotein (MOG) immunization and to explore whether the GEF-Cdc42/Rac1 signaling pathway contributes to the regeneration effect induced by catalpol.", "tags": [{"end": 68, "start": 50, "tag": "Finding"}, {"end": 80, "start": 72, "tag": "Chemical"}, {"end": 104, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 151, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 198, "tag": "CellFunction"}, {"end": 289, "start": 281, "tag": "Chemical"}, {"end": 269, "start": 263, "tag": "Finding"}, {"end": 262, "start": 250, "tag": "BiologicFunction"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}]}
{"id": "1319_4", "text": "In the MOG-induced experimental autoimmune encephalomyelitis (EAE) mouse model of demyelination, we observed that catalpol significantly promoted OL development by enhancing the expression of glutathione S-transferase pi (GST-pi) in the affected brain.", "tags": [{"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 19, "tag": "ExperimentalModelOfDisease"}, {"end": 65, "start": 62, "tag": "ExperimentalModelOfDisease"}, {"end": 95, "start": 67, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 114, "tag": "Chemical"}, {"end": 160, "start": 146, "tag": "CellFunction"}, {"end": 220, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 222, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 222, "tag": "BiologicallyActiveSubstance"}, {"end": 251, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 178, "tag": "CellFunction"}]}
{"id": "1319_5", "text": "By Luxol fast blue staining and myelin basic protein (MBP) expression assessment, catalpol was found to increase MBP expression and promote myelin repair.", "tags": [{"end": 27, "start": 3, "tag": "ResearchActivity"}, {"end": 52, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 54, "tag": "GeneOrGenome"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 59, "tag": "CellFunction"}, {"end": 80, "start": 70, "tag": "ResearchActivity"}, {"end": 80, "start": 70, "tag": "HealthCareActivity"}, {"end": 90, "start": 82, "tag": "Chemical"}, {"end": 127, "start": 113, "tag": "CellFunction"}, {"end": 153, "start": 140, "tag": "CellFunction"}]}
{"id": "1319_6", "text": "Furthermore, catalpol promoted OL differentiation associated with the upregulation of Cdc42/Rac1 expression and activation in vivo.", "tags": [{"end": 21, "start": 13, "tag": "Chemical"}, {"end": 49, "start": 31, "tag": "CellFunction"}, {"end": 82, "start": 70, "tag": "CellFunction"}, {"end": 91, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 86, "tag": "GeneOrGenome"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 130, "start": 123, "tag": "ResearchActivity"}, {"end": 107, "start": 97, "tag": "CellFunction"}, {"end": 122, "start": 112, "tag": "CellFunction"}]}
{"id": "1319_7", "text": "In addition, PAK1/MRCK alpha, proteins downstream of Cdc42/Rac1, was positively regulated by catalpol.", "tags": [{"end": 101, "start": 93, "tag": "Chemical"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 28, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "GeneOrGenome"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 38, "start": 30, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1319_8", "text": "We also found that catalpol alleviated clinical neurological dysfunction, inhibited inflammatory infiltration, increased the proportion of Treg cells, and suppressed demyelination.", "tags": [{"end": 27, "start": 19, "tag": "Chemical"}, {"end": 72, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "Cell"}, {"end": 179, "start": 166, "tag": "PathologicFunction"}, {"end": 109, "start": 84, "tag": "PathologicFunction"}]}
{"id": "1319_9", "text": "Overall, our study is the first to reveal that catalpol can promote OL generation and myelination and contributes to the crucial regulatory process of GEF-Cdc42/Rac1 signaling expression and activation.", "tags": [{"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "Chemical"}, {"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 97, "start": 86, "tag": "CellFunction"}, {"end": 175, "start": 151, "tag": "CellFunction"}, {"end": 186, "start": 176, "tag": "CellFunction"}, {"end": 201, "start": 191, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "TemporalConcept"}]}
{"id": "1319_10", "text": "Therefore, catalpol is a promising drug candidate for the potential treatment of demyelinating diseases.", "tags": [{"end": 19, "start": 11, "tag": "Chemical"}, {"end": 103, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 68, "tag": "ResearchActivity"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}]}
{"id": "1320_0", "text": "In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and in vivo systems.", "tags": [{"end": 65, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "GeneOrGenome"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "Cell"}, {"end": 136, "start": 121, "tag": "Cell"}, {"end": 190, "start": 176, "tag": "Cell"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 204, "tag": "ResearchActivity"}, {"end": 224, "start": 217, "tag": "ResearchActivity"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 95, "start": 84, "tag": "CellFunction"}, {"end": 161, "start": 147, "tag": "CellFunction"}]}
{"id": "1320_1", "text": "Previous work also suggests that IGF-1 protects ODCs from cell death and enhances remyelination in models of toxin-induced and autoimmune demyelination.", "tags": [{"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "GeneOrGenome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 68, "start": 63, "tag": "BiologicFunction"}, {"end": 68, "start": 63, "tag": "PathologicFunction"}, {"end": 68, "start": 63, "tag": "CellFunction"}, {"end": 68, "start": 58, "tag": "CellFunction"}, {"end": 95, "start": 82, "tag": "CellFunction"}, {"end": 151, "start": 127, "tag": "PathologicFunction"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 114, "start": 109, "tag": "InjuryOrPoisoning"}, {"end": 114, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 138, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 99, "tag": "ExperimentalModelOfDisease"}, {"end": 151, "start": 127, "tag": "ExperimentalModelOfDisease"}, {"end": 108, "start": 99, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1320_2", "text": "However, since evidence remains controversial, the therapeutic potential of IGF-1 in demyelinating CNS conditions is unclear.", "tags": [{"end": 81, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 76, "tag": "GeneOrGenome"}, {"end": 81, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 72, "start": 51, "tag": "HealthCareActivity"}, {"end": 113, "start": 85, "tag": "DiseaseOrSyndrome"}]}
{"id": "1320_3", "text": "To finally shed light on the function of IGF1-signaling for ODCs, we deleted insulin-like growth factor 1 receptor (IGF1R) specifically in mature ODCs of the mouse.", "tags": [{"end": 114, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "GeneOrGenome"}, {"end": 55, "start": 41, "tag": "CellFunction"}, {"end": 145, "start": 139, "tag": "TemporalConcept"}, {"end": 21, "start": 16, "tag": "NaturalPhenomenonOrProcess"}, {"end": 163, "start": 158, "tag": "Eukaryote"}, {"end": 64, "start": 60, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "Cell"}]}
{"id": "1320_4", "text": "We found that ODC survival and myelin status were unaffected by the absence of IGF1R until 15 months of age, indicating that IGF-1 signaling does not play a major role in post-mitotic ODCs during homeostasis.", "tags": [{"end": 17, "start": 14, "tag": "Cell"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "GeneOrGenome"}, {"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 125, "tag": "GeneOrGenome"}, {"end": 100, "start": 94, "tag": "TemporalConcept"}, {"end": 183, "start": 171, "tag": "TemporalConcept"}, {"end": 37, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 125, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "OrganismAttribute"}, {"end": 26, "start": 18, "tag": "CellFunction"}, {"end": 207, "start": 196, "tag": "BiologicFunction"}, {"end": 44, "start": 38, "tag": "Finding"}, {"end": 75, "start": 68, "tag": "Finding"}, {"end": 188, "start": 184, "tag": "Cell"}]}
{"id": "1320_5", "text": "Notably, the absence of IGF1R did neither affect ODC survival nor myelin status upon cuprizone intoxication or induction of experimental autoimmune encephalomyelitis (EAE), models for toxic and autoimmune demyelination, respectively.", "tags": [{"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 52, "start": 49, "tag": "Cell"}, {"end": 107, "start": 95, "tag": "Finding"}, {"end": 120, "start": 111, "tag": "HealthCareActivity"}, {"end": 120, "start": 111, "tag": "HealthCareRelatedOrganization"}, {"end": 179, "start": 173, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 124, "tag": "ExperimentalModelOfDisease"}, {"end": 170, "start": 167, "tag": "ExperimentalModelOfDisease"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 85, "tag": "Chemical"}, {"end": 189, "start": 184, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 53, "tag": "CellFunction"}, {"end": 79, "start": 73, "tag": "Finding"}, {"end": 218, "start": 194, "tag": "PathologicFunction"}, {"end": 20, "start": 13, "tag": "Finding"}]}
{"id": "1320_6", "text": "Surprisingly, however, the absence of IGF1R from ODCs protected against clinical neuroinflammation in the EAE model.", "tags": [{"end": 43, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 106, "tag": "ExperimentalModelOfDisease"}, {"end": 98, "start": 81, "tag": "PathologicFunction"}, {"end": 34, "start": 27, "tag": "Finding"}, {"end": 53, "start": 49, "tag": "Cell"}]}
{"id": "1320_7", "text": "Together, our data indicate that IGF-1 signaling is not required for the function and survival of mature ODCs in steady-state and disease.", "tags": [{"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "GeneOrGenome"}, {"end": 125, "start": 113, "tag": "NaturalPhenomenonOrProcess"}, {"end": 48, "start": 33, "tag": "CellFunction"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 94, "start": 86, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 109, "start": 105, "tag": "Cell"}]}
{"id": "1321_0", "text": "Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) triggered by autoimmune mechanisms.", "tags": [{"end": 159, "start": 138, "tag": "PathologicFunction"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 44, "tag": "PathologicFunction"}, {"end": 88, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}]}
{"id": "1321_1", "text": "Microglia are critical for the clearance of myelin debris in areas of demyelination, a key step to allow remyelination.", "tags": [{"end": 40, "start": 31, "tag": "NaturalPhenomenonOrProcess"}, {"end": 118, "start": 105, "tag": "CellFunction"}, {"end": 57, "start": 51, "tag": "Substance"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 83, "start": 70, "tag": "PathologicFunction"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1321_2", "text": "TREM2 is expressed by microglia and promotes microglial survival, proliferation, and phagocytic activity.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 64, "start": 56, "tag": "CellFunction"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 55, "start": 45, "tag": "Cell"}, {"end": 18, "start": 9, "tag": "CellFunction"}, {"end": 31, "start": 22, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 85, "tag": "CellFunction"}]}
{"id": "1321_3", "text": "Herein we demonstrate that TREM2 was highly expressed on myelin-laden phagocytes in active demyelinating lesions in the CNS of subjects with MS.", "tags": [{"end": 32, "start": 27, "tag": "GeneOrGenome"}, {"end": 80, "start": 57, "tag": "Cell"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "CellFunction"}, {"end": 112, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 32, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1321_4", "text": "In gene expression studies, macrophages from subjects with TREM2 genetic deficiency displayed a defect in phagocytic pathways.", "tags": [{"end": 64, "start": 59, "tag": "GeneOrGenome"}, {"end": 18, "start": 3, "tag": "CellFunction"}, {"end": 39, "start": 28, "tag": "Cell"}, {"end": 83, "start": 59, "tag": "CellOrMolecularDysfunction"}, {"end": 26, "start": 19, "tag": "ResearchActivity"}, {"end": 53, "start": 45, "tag": "PopulationGroup"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 96, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1321_5", "text": "Treatment with a new TREM2 agonistic antibody promoted the clearance of myelin debris in the cuprizone model of CNS demyelination.", "tags": [{"end": 26, "start": 21, "tag": "GeneOrGenome"}, {"end": 115, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 59, "tag": "NaturalPhenomenonOrProcess"}, {"end": 85, "start": 79, "tag": "Substance"}, {"end": 102, "start": 93, "tag": "Chemical"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 93, "tag": "ExperimentalModelOfDisease"}, {"end": 45, "start": 27, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1321_6", "text": "Effects included enhancement of myelin uptake and degradation, resulting in accelerated myelin debris removal by microglia.", "tags": [{"end": 28, "start": 17, "tag": "Finding"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 61, "start": 50, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "CellFunction"}, {"end": 101, "start": 95, "tag": "Substance"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 113, "tag": "Cell"}, {"end": 109, "start": 88, "tag": "CellFunction"}]}
{"id": "1321_7", "text": "Most importantly, antibody-dependent TREM2 activation on microglia increased density of oligodendrocyte precursors in areas of demyelination, as well as the formation of mature oligodendrocytes thus enhancing remyelination and axonal integrity.", "tags": [{"end": 53, "start": 18, "tag": "CellFunction"}, {"end": 42, "start": 37, "tag": "GeneOrGenome"}, {"end": 193, "start": 157, "tag": "CellFunction"}, {"end": 222, "start": 209, "tag": "CellFunction"}, {"end": 193, "start": 170, "tag": "Cell"}, {"end": 84, "start": 67, "tag": "Finding"}, {"end": 114, "start": 88, "tag": "Cell"}, {"end": 140, "start": 127, "tag": "PathologicFunction"}, {"end": 66, "start": 57, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 243, "start": 227, "tag": "CellFunction"}]}
{"id": "1321_8", "text": "These results are relevant as they propose TREM2 on microglia as a potential new target to promote remyelination.", "tags": [{"end": 48, "start": 43, "tag": "GeneOrGenome"}, {"end": 112, "start": 99, "tag": "CellFunction"}, {"end": 61, "start": 52, "tag": "Cell"}, {"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1322_0", "text": "Fetal alcohol spectrum disorders (FASD) are alarmingly common, result in significant personal and so-cietal loss, and there are no effective treatments for these disorders.", "tags": [{"end": 38, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 34, "tag": "AnatomicalAbnormality"}, {"end": 93, "start": 85, "tag": "OrganismAttribute"}, {"end": 151, "start": 141, "tag": "HealthCareActivity"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 32, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 0, "tag": "AnatomicalAbnormality"}]}
{"id": "1322_1", "text": "Cerebellar neuropathology common in FASD and can cause impaired cognitive and motor function.", "tags": [{"end": 10, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 36, "tag": "AnatomicalAbnormality"}, {"end": 92, "start": 78, "tag": "BiologicFunction"}, {"end": 25, "start": 11, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 11, "tag": "PathologicFunction"}]}
{"id": "1322_2", "text": "The current study evaluates the effects of ethanol on oligodendrocyte-lineage cells, as well as molecules that modulate oligodendrocyte differentiation and function in the cerebellum in a postnatal mouse model of FASD.", "tags": [{"end": 42, "start": 32, "tag": "PathologicFunction"}, {"end": 50, "start": 43, "tag": "Chemical"}, {"end": 50, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 182, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 188, "tag": "TemporalConcept"}, {"end": 217, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 213, "tag": "AnatomicalAbnormality"}, {"end": 105, "start": 96, "tag": "Substance"}, {"end": 135, "start": 120, "tag": "Cell"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 83, "start": 54, "tag": "Cell"}, {"end": 203, "start": 198, "tag": "Eukaryote"}, {"end": 209, "start": 204, "tag": "ResearchActivity"}, {"end": 151, "start": 136, "tag": "CellFunction"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}]}
{"id": "1322_3", "text": "Neonatal mice were treated with ethanol from P4-P9 (postnatal day), the cerebellum was isolated at P10, and mRNAs encoding oligodendrocyte-associated molecules were quantitated by qRT-PCR.", "tags": [{"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 39, "start": 32, "tag": "Chemical"}, {"end": 39, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 65, "start": 52, "tag": "TemporalConcept"}, {"end": 82, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 99, "tag": "TemporalConcept"}, {"end": 159, "start": 150, "tag": "Substance"}, {"end": 113, "start": 108, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 138, "start": 123, "tag": "Cell"}, {"end": 187, "start": 180, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "Eukaryote"}, {"end": 50, "start": 45, "tag": "TemporalConcept"}]}
{"id": "1322_4", "text": "Our studies demonstrated that ethanol significantly reduced the expression of markers for multiple stages of oligodendrocyte maturation, including oligodendrocyte precursor cells, pre-myelinating oligodendrocytes, and mature myelinating oligodendrocytes.", "tags": [{"end": 37, "start": 30, "tag": "Chemical"}, {"end": 37, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 99, "tag": "TemporalConcept"}, {"end": 212, "start": 196, "tag": "Cell"}, {"end": 253, "start": 218, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 135, "start": 125, "tag": "BiologicFunction"}, {"end": 178, "start": 147, "tag": "Cell"}, {"end": 212, "start": 180, "tag": "Cell"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1322_5", "text": "Additionally, we determined that ethanol significantly decreased the expression of molecules that play critical roles in oligodendrocyte differentiation.", "tags": [{"end": 40, "start": 33, "tag": "Chemical"}, {"end": 40, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 83, "tag": "Substance"}, {"end": 136, "start": 121, "tag": "Cell"}, {"end": 152, "start": 137, "tag": "CellFunction"}]}
{"id": "1322_6", "text": "Interestingly, we also observed that ethanol significantly reduced the expression of myelin-associated inhibitors, which may act as a compensatory mechanism to ethanol toxicity.", "tags": [{"end": 44, "start": 37, "tag": "Chemical"}, {"end": 44, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 160, "tag": "Chemical"}, {"end": 167, "start": 160, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 168, "tag": "InjuryOrPoisoning"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "Chemical"}]}
{"id": "1322_7", "text": "Furthermore, we demonstrate that ethanol alters the expression of a variety of molecules important in oligodendrocyte function and myelination.", "tags": [{"end": 40, "start": 33, "tag": "Chemical"}, {"end": 40, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 79, "tag": "Substance"}, {"end": 142, "start": 131, "tag": "CellFunction"}, {"end": 126, "start": 102, "tag": "CellFunction"}]}
{"id": "1322_8", "text": "Collectively, our studies increase our understanding of specific mechanisms by which ethanol modulates myelination in the developing cerebellum, and potentially identify novel targets for FASD therapy.", "tags": [{"end": 92, "start": 85, "tag": "Chemical"}, {"end": 92, "start": 85, "tag": "PharmacologicSubstance"}, {"end": 143, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 39, "tag": "BiologicFunction"}, {"end": 114, "start": 103, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 200, "start": 193, "tag": "HealthCareActivity"}, {"end": 192, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 188, "tag": "AnatomicalAbnormality"}]}
{"id": "1323_0", "text": "Background and purpose Research on demyelinating disorders aims to find novel molecules that are able to induce oligodendrocyte precursor cell differentiation to promote central nervous system remyelination and functional recovery.", "tags": [{"end": 230, "start": 211, "tag": "SignOrSymptom"}, {"end": 142, "start": 112, "tag": "Cell"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 58, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 78, "tag": "Substance"}, {"end": 230, "start": 222, "tag": "BiologicFunction"}, {"end": 230, "start": 222, "tag": "HealthCareActivity"}, {"end": 230, "start": 222, "tag": "TemporalConcept"}, {"end": 206, "start": 193, "tag": "CellFunction"}, {"end": 158, "start": 138, "tag": "CellFunction"}]}
{"id": "1323_1", "text": "Delta(9)-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination.", "tags": [{"end": 29, "start": 0, "tag": "Chemical"}, {"end": 34, "start": 31, "tag": "Chemical"}, {"end": 86, "start": 82, "tag": "Chemical"}, {"end": 108, "start": 93, "tag": "Organism"}, {"end": 133, "start": 118, "tag": "CellFunction"}, {"end": 167, "start": 154, "tag": "PathologicFunction"}, {"end": 150, "start": 137, "tag": "ResearchActivity"}, {"end": 92, "start": 87, "tag": "Organism"}]}
{"id": "1323_2", "text": "However, the possible effect of THC on myelin repair has never been studied.", "tags": [{"end": 35, "start": 32, "tag": "Chemical"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 39, "tag": "CellFunction"}, {"end": 28, "start": 22, "tag": "Finding"}, {"end": 52, "start": 46, "tag": "BiologicFunction"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}]}
{"id": "1323_3", "text": "Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with two models of toxin-induced demyelination, we analysed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination.", "tags": [{"end": 169, "start": 166, "tag": "Chemical"}, {"end": 218, "start": 206, "tag": "BiologicFunction"}, {"end": 46, "start": 31, "tag": "Cell"}, {"end": 218, "start": 206, "tag": "HealthCareActivity"}, {"end": 107, "start": 101, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "Finding"}, {"end": 70, "start": 65, "tag": "Eukaryote"}, {"end": 205, "start": 190, "tag": "Cell"}, {"end": 247, "start": 234, "tag": "CellFunction"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 76, "start": 31, "tag": "ResearchActivity"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 101, "tag": "ExperimentalModelOfDisease"}, {"end": 116, "start": 111, "tag": "InjuryOrPoisoning"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1323_4", "text": "Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination and motor function recovery.", "tags": [{"end": 28, "start": 25, "tag": "Chemical"}, {"end": 81, "start": 69, "tag": "BiologicFunction"}, {"end": 95, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 114, "tag": "BiologicFunction"}, {"end": 81, "start": 69, "tag": "HealthCareActivity"}, {"end": 68, "start": 53, "tag": "Cell"}, {"end": 137, "start": 129, "tag": "BiologicFunction"}, {"end": 137, "start": 129, "tag": "HealthCareActivity"}, {"end": 137, "start": 129, "tag": "TemporalConcept"}, {"end": 109, "start": 96, "tag": "CellFunction"}]}
{"id": "1323_5", "text": "THC also promoted axonal remyelination in organotypic cerebellar cultures.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 73, "start": 65, "tag": "ResearchActivity"}, {"end": 53, "start": 42, "tag": "ResearchActivity"}, {"end": 64, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 18, "tag": "CellComponent"}, {"end": 38, "start": 25, "tag": "CellFunction"}]}
{"id": "1323_6", "text": "THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 48, "start": 39, "tag": "HealthCareActivity"}, {"end": 147, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 77, "start": 52, "tag": "Cell"}, {"end": 147, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 114, "start": 99, "tag": "CellFunction"}, {"end": 158, "start": 148, "tag": "CellFunction"}]}
{"id": "1323_7", "text": "Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.", "tags": [{"end": 62, "start": 59, "tag": "Chemical"}, {"end": 190, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 42, "tag": "ResearchActivity"}, {"end": 149, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 150, "tag": "CellFunction"}, {"end": 117, "start": 93, "tag": "HealthCareActivity"}]}
{"id": "1324_0", "text": "Demyelinating disorders of the central nervous system (CNS) occur when myelin and oligodendrocytes are damaged or lost.", "tags": [{"end": 98, "start": 82, "tag": "Cell"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1324_1", "text": "Remyelina-tion and regeneration of oligodendrocytes can be achieved from endogenous oligodendrocyte precursor cells (OPCs) that reside in the adult CNS tissue.", "tags": [{"end": 51, "start": 35, "tag": "Cell"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 115, "start": 84, "tag": "Cell"}, {"end": 31, "start": 19, "tag": "BiologicFunction"}, {"end": 115, "start": 100, "tag": "Cell"}, {"end": 109, "start": 84, "tag": "Cell"}, {"end": 31, "start": 19, "tag": "HealthCareActivity"}, {"end": 151, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 142, "tag": "PopulationGroup"}]}
{"id": "1324_2", "text": "Using a cuprizone mouse model of demyelination, we show that infusion of fractalkine (CX3CL1) into the demyeli-nated murine brain increases de novo oligodendrocyte formation and enhances remyelination in the corpus callosum and cortical gray matter.", "tags": [{"end": 69, "start": 61, "tag": "HealthCareActivity"}, {"end": 69, "start": 61, "tag": "TemporalConcept"}, {"end": 84, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 86, "tag": "GeneOrGenome"}, {"end": 92, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 237, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 208, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 8, "tag": "Chemical"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "Eukaryote"}, {"end": 236, "start": 228, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 148, "tag": "Cell"}, {"end": 200, "start": 187, "tag": "CellFunction"}, {"end": 46, "start": 33, "tag": "PathologicFunction"}, {"end": 29, "start": 18, "tag": "ResearchActivity"}, {"end": 173, "start": 140, "tag": "CellFunction"}, {"end": 123, "start": 117, "tag": "Eukaryote"}]}
{"id": "1324_3", "text": "This is achieved by increased OPC proliferation in the cortical gray matter as well as OPC differentiation and attenuation of microglia/macrophage activation both in corpus callosum and cortical gray matter.", "tags": [{"end": 75, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 30, "tag": "Cell"}, {"end": 90, "start": 87, "tag": "Cell"}, {"end": 106, "start": 91, "tag": "CellFunction"}, {"end": 106, "start": 87, "tag": "CellFunction"}, {"end": 47, "start": 34, "tag": "CellFunction"}, {"end": 181, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 126, "tag": "Cell"}, {"end": 63, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 136, "tag": "CellFunction"}]}
{"id": "1324_4", "text": "Finally, we show that activated OPCs and micro-glia/macrophages express fractalkine receptor CX3CR1 in vivo, and that in OPC-microglia co-cultures fractalkine increases in vitro oligo-dendrocyte differentiation by modulating both OPC and microglia biology.", "tags": [{"end": 92, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 64, "tag": "CellFunction"}, {"end": 146, "start": 135, "tag": "ResearchActivity"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}, {"end": 36, "start": 22, "tag": "Cell"}, {"end": 124, "start": 121, "tag": "Cell"}, {"end": 233, "start": 230, "tag": "Cell"}, {"end": 210, "start": 178, "tag": "CellFunction"}, {"end": 63, "start": 52, "tag": "Cell"}, {"end": 134, "start": 125, "tag": "Cell"}, {"end": 247, "start": 238, "tag": "Cell"}, {"end": 177, "start": 169, "tag": "ResearchActivity"}, {"end": 51, "start": 41, "tag": "Cell"}, {"end": 255, "start": 248, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 107, "start": 100, "tag": "ResearchActivity"}, {"end": 255, "start": 248, "tag": "BiologicFunction"}, {"end": 92, "start": 72, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1324_5", "text": "Our results demonstrate a novel pro-regenerative role of frac-talkine in a demyelinating mouse model.", "tags": [{"end": 88, "start": 75, "tag": "PathologicFunction"}, {"end": 100, "start": 89, "tag": "ResearchActivity"}, {"end": 69, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 75, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1325_0", "text": "It is widely thought that brain repair does not occur, but myelin regeneration provides clear evidence to the contrary.", "tags": [{"end": 38, "start": 26, "tag": "HealthCareActivity"}, {"end": 65, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 66, "tag": "BiologicFunction"}, {"end": 78, "start": 66, "tag": "HealthCareActivity"}, {"end": 78, "start": 59, "tag": "CellFunction"}, {"end": 102, "start": 94, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "BiologicFunction"}]}
{"id": "1325_1", "text": "Spontaneous remyelination may occur after injury or in multiple sclerosis (MS).", "tags": [{"end": 73, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 42, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 0, "tag": "CellFunction"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}]}
{"id": "1325_2", "text": "However, the efficiency of remyelination varies considerably between MS patients and between the lesions of each patient.", "tags": [{"end": 104, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 13, "tag": "Finding"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 120, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}]}
{"id": "1325_3", "text": "Myelin repair is essential for optimal functional recovery, so a profound understanding of the cells and mechanisms involved in this process is required for the development of new therapeutic strategies.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 161, "tag": "BiologicFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 100, "start": 95, "tag": "Cell"}, {"end": 202, "start": 192, "tag": "ResearchActivity"}, {"end": 202, "start": 192, "tag": "BiologicFunction"}, {"end": 87, "start": 74, "tag": "BiologicFunction"}, {"end": 58, "start": 50, "tag": "BiologicFunction"}, {"end": 58, "start": 50, "tag": "HealthCareActivity"}, {"end": 58, "start": 50, "tag": "TemporalConcept"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}, {"end": 202, "start": 180, "tag": "HealthCareActivity"}]}
{"id": "1325_4", "text": "In this review, we describe how animal models and modern cell tracing and imaging methods have helped to identify the cell types involved in myelin regeneration.", "tags": [{"end": 147, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 148, "tag": "BiologicFunction"}, {"end": 81, "start": 74, "tag": "HealthCareActivity"}, {"end": 160, "start": 148, "tag": "HealthCareActivity"}, {"end": 160, "start": 141, "tag": "CellFunction"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 45, "start": 32, "tag": "ResearchActivity"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 89, "start": 82, "tag": "ResearchActivity"}, {"end": 69, "start": 57, "tag": "ResearchActivity"}, {"end": 89, "start": 74, "tag": "ResearchActivity"}]}
{"id": "1325_5", "text": "In addition to the oligodendrocyte progenitor cells identified in the 1990s as the principal source of remyelinating cells in the central nervous system (CNS), other cell populations, including subventricular zone-derived neural progenitors, Schwann cells, and even spared mature oligodendrocytes, have more recently emerged as potential contributors to CNS remyelination.", "tags": [{"end": 255, "start": 242, "tag": "Cell"}, {"end": 296, "start": 273, "tag": "Cell"}, {"end": 51, "start": 19, "tag": "Cell"}, {"end": 51, "start": 35, "tag": "Cell"}, {"end": 116, "start": 103, "tag": "CellFunction"}, {"end": 213, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 357, "start": 354, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 117, "tag": "Cell"}, {"end": 316, "start": 308, "tag": "TemporalConcept"}, {"end": 371, "start": 358, "tag": "CellFunction"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 240, "start": 222, "tag": "Cell"}]}
{"id": "1325_6", "text": "We will also highlight the conditions known to limit endogenous repair, such as aging, chronic inflammation, and the production of extracellular matrix proteins, and the role of astrocytes and microglia in these processes.", "tags": [{"end": 160, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 87, "tag": "PathologicFunction"}, {"end": 151, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 95, "tag": "PathologicFunction"}, {"end": 160, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 193, "tag": "Cell"}, {"end": 188, "start": 178, "tag": "Cell"}, {"end": 85, "start": 80, "tag": "BiologicFunction"}, {"end": 85, "start": 80, "tag": "CellFunction"}, {"end": 70, "start": 64, "tag": "BiologicFunction"}, {"end": 70, "start": 64, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "TemporalConcept"}]}
{"id": "1325_7", "text": "Finally, we will present the discrepancies between observations in humans and in rodents, discussing the relationship of findings in experimental models to myelin repair in humans.", "tags": [{"end": 42, "start": 29, "tag": "Finding"}, {"end": 73, "start": 67, "tag": "Eukaryote"}, {"end": 179, "start": 173, "tag": "Eukaryote"}, {"end": 88, "start": 81, "tag": "Eukaryote"}, {"end": 117, "start": 105, "tag": "Finding"}, {"end": 162, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 156, "tag": "CellFunction"}, {"end": 63, "start": 51, "tag": "Finding"}, {"end": 152, "start": 133, "tag": "ResearchActivity"}, {"end": 169, "start": 163, "tag": "BiologicFunction"}, {"end": 169, "start": 163, "tag": "HealthCareActivity"}]}
{"id": "1325_8", "text": "These considerations are particularly important from a therapeutic standpoint.", "tags": [{"end": 20, "start": 6, "tag": "Finding"}]}
{"id": "1326_0", "text": "Neurotropic strains of mouse hepatitis virus (MHV), a coronavirus, cause acute and chronic demyelinating encephalomyelitis with similarities to the human disease multiple sclerosis.", "tags": [{"end": 44, "start": 23, "tag": "Virus"}, {"end": 49, "start": 46, "tag": "Virus"}, {"end": 65, "start": 54, "tag": "Virus"}, {"end": 104, "start": 91, "tag": "PathologicFunction"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 73, "tag": "TemporalConcept"}, {"end": 153, "start": 148, "tag": "Eukaryote"}, {"end": 90, "start": 83, "tag": "TemporalConcept"}, {"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 19, "start": 12, "tag": "Organism"}, {"end": 122, "start": 105, "tag": "DiseaseOrSyndrome"}]}
{"id": "1326_1", "text": "Here, using a lineage -tracking system, we show that some cells, primarily oligo- dendrocytes (OLs) and oligodendrocyte precursor cells (OPCs), survive the acute MHV infection, are associated with regions of demyelination, and persist in the central nervous system (CNS) for at least 150 d.", "tags": [{"end": 165, "start": 162, "tag": "Virus"}, {"end": 141, "start": 137, "tag": "Cell"}, {"end": 135, "start": 104, "tag": "Cell"}, {"end": 98, "start": 95, "tag": "Cell"}, {"end": 161, "start": 156, "tag": "TemporalConcept"}, {"end": 264, "start": 242, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 266, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 58, "tag": "Cell"}, {"end": 175, "start": 166, "tag": "PathologicFunction"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}, {"end": 38, "start": 14, "tag": "ResearchActivity"}, {"end": 93, "start": 75, "tag": "Cell"}]}
{"id": "1326_2", "text": "These surviving OLs express major histocompatibility complex (MHC) class I and other genes associated with an inflammatory response.", "tags": [{"end": 65, "start": 62, "tag": "GeneOrGenome"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 20, "tag": "CellFunction"}, {"end": 19, "start": 16, "tag": "Cell"}, {"end": 131, "start": 110, "tag": "PathologicFunction"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1326_3", "text": "Notably, the extent of inflammatory cell infiltration was variable, dependent on anatomic location within the CNS, and without obvious correlation with numbers of surviving cells.", "tags": [{"end": 35, "start": 23, "tag": "PathologicFunction"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "Cell"}, {"end": 40, "start": 36, "tag": "Cell"}, {"end": 98, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1326_4", "text": "We detected more demyelination in regions with larger numbers of T cells and microglia/macrophages compared to those with fewer infiltrating cells.", "tags": [{"end": 72, "start": 65, "tag": "Cell"}, {"end": 98, "start": 87, "tag": "Cell"}, {"end": 146, "start": 128, "tag": "Cell"}, {"end": 86, "start": 77, "tag": "Cell"}, {"end": 30, "start": 17, "tag": "PathologicFunction"}]}
{"id": "1326_5", "text": "Conversely, in regions with less inflammation, these previously infected OLs more rapidly extended processes, consistent with normal myelinating function.", "tags": [{"end": 72, "start": 64, "tag": "PathologicFunction"}, {"end": 144, "start": 133, "tag": "CellFunction"}, {"end": 76, "start": 73, "tag": "Cell"}, {"end": 45, "start": 33, "tag": "PathologicFunction"}, {"end": 132, "start": 126, "tag": "Finding"}]}
{"id": "1326_6", "text": "Together, these results show that OLs are inducers as well as targets of the host immune response and demonstrate how a CNS infection, even after resolution, can induce prolonged inflammatory changes with CNS region-dependent impairment in remyelination.", "tags": [{"end": 97, "start": 82, "tag": "BiologicFunction"}, {"end": 133, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 146, "tag": "PathologicFunction"}, {"end": 81, "start": 77, "tag": "Organism"}, {"end": 178, "start": 169, "tag": "TemporalConcept"}, {"end": 37, "start": 34, "tag": "Cell"}, {"end": 191, "start": 179, "tag": "PathologicFunction"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 124, "tag": "PathologicFunction"}, {"end": 253, "start": 240, "tag": "CellFunction"}, {"end": 253, "start": 226, "tag": "CellOrMolecularDysfunction"}, {"end": 199, "start": 192, "tag": "Finding"}]}
{"id": "1327_0", "text": "Myelin is an essential structure that protects axons, provides metabolic support to neurons and allows fast nerve transmission.", "tags": [{"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 52, "start": 47, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 114, "tag": "Finding"}, {"end": 91, "start": 84, "tag": "Cell"}]}
{"id": "1327_1", "text": "Several neurological diseases, such as multiple sclerosis, are characterized by myelin damage, which is responsible of severe functional impairment.", "tags": [{"end": 57, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 119, "tag": "Finding"}, {"end": 29, "start": 8, "tag": "DiseaseOrSyndrome"}]}
{"id": "1327_2", "text": "Myelin repair requires the timely recruitment of adult oligodendrocyte precursor cells (OPCs) at the lesion sites, their differentiation and maturation into myelinating oligodendrocytes.", "tags": [{"end": 168, "start": 157, "tag": "CellFunction"}, {"end": 185, "start": 169, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "Cell"}, {"end": 151, "start": 141, "tag": "BiologicFunction"}, {"end": 86, "start": 55, "tag": "Cell"}, {"end": 107, "start": 101, "tag": "InjuryOrPoisoning"}, {"end": 136, "start": 121, "tag": "CellFunction"}, {"end": 185, "start": 157, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 80, "start": 55, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}]}
{"id": "1327_3", "text": "As a consequence, OPCs undergo profound changes in their morphology, functions, and interactions with other cells and extracellular environment, thus requiring the reorganization of both their lipid metabolism and their membrane composition, which is substantially different compared to other plasma membranes.", "tags": [{"end": 67, "start": 57, "tag": "OrganismAttribute"}, {"end": 309, "start": 293, "tag": "CellComponent"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 228, "start": 220, "tag": "CellComponent"}, {"end": 309, "start": 300, "tag": "CellComponent"}, {"end": 299, "start": 293, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 108, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "CellFunction"}, {"end": 209, "start": 199, "tag": "BiologicFunction"}, {"end": 131, "start": 118, "tag": "CellComponent"}, {"end": 198, "start": 193, "tag": "Chemical"}, {"end": 96, "start": 84, "tag": "Finding"}, {"end": 209, "start": 193, "tag": "CellFunction"}, {"end": 209, "start": 193, "tag": "BiologicFunction"}, {"end": 47, "start": 40, "tag": "Finding"}, {"end": 143, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1327_4", "text": "Despite the growing knowledge in oligodendroglia biology and in the mechanisms involved in OPC-mediated regeneration, the identification of strategies to promote remyelination still remains a challenge.", "tags": [{"end": 29, "start": 12, "tag": "Finding"}, {"end": 201, "start": 192, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "Cell"}, {"end": 116, "start": 104, "tag": "BiologicFunction"}, {"end": 48, "start": 33, "tag": "Cell"}, {"end": 116, "start": 104, "tag": "HealthCareActivity"}, {"end": 29, "start": 20, "tag": "Finding"}, {"end": 150, "start": 140, "tag": "ResearchActivity"}, {"end": 150, "start": 140, "tag": "BiologicFunction"}, {"end": 56, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 175, "start": 162, "tag": "CellFunction"}, {"end": 56, "start": 49, "tag": "BiologicFunction"}]}
{"id": "1327_5", "text": "Here, we describe how altered lipid metabolism in oligodendrocytes influences the pathogenesis of demyelination, and we show that several FDA-approved drugs with a previously unknown remyelination potential do act on cholesterol and lipid biosynthetic pathways.", "tags": [{"end": 228, "start": 217, "tag": "Chemical"}, {"end": 228, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 50, "tag": "Cell"}, {"end": 94, "start": 82, "tag": "PathologicFunction"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 46, "start": 36, "tag": "BiologicFunction"}, {"end": 156, "start": 151, "tag": "PharmacologicSubstance"}, {"end": 260, "start": 233, "tag": "CellFunction"}, {"end": 35, "start": 30, "tag": "Chemical"}, {"end": 238, "start": 233, "tag": "Chemical"}, {"end": 196, "start": 183, "tag": "CellFunction"}, {"end": 111, "start": 98, "tag": "PathologicFunction"}, {"end": 46, "start": 30, "tag": "CellFunction"}, {"end": 46, "start": 30, "tag": "BiologicFunction"}, {"end": 141, "start": 138, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1327_6", "text": "Since the interplay between myelin lipids and axons is strictly coordinated by the extracellular matrix (ECM), we also discuss the role of different ECM components, and report the last findings on new ECM-modifiers able to foster endogenous remyelination.", "tags": [{"end": 51, "start": 46, "tag": "CellComponent"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 169, "tag": "HealthCareActivity"}, {"end": 175, "start": 169, "tag": "ResearchActivity"}, {"end": 41, "start": 35, "tag": "Chemical"}, {"end": 19, "start": 10, "tag": "Finding"}, {"end": 254, "start": 241, "tag": "CellFunction"}]}
{"id": "1328_0", "text": "Neural and oligodendrocyte precursor cells (NPCs and OPCs) in the subventricular zone (SVZ) of the brain contribute to oligodendrogenesis throughout life, in part due to direct regulation by chemokines.", "tags": [{"end": 137, "start": 119, "tag": "BiologicFunction"}, {"end": 90, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 42, "start": 11, "tag": "Cell"}, {"end": 48, "start": 44, "tag": "Cell"}, {"end": 42, "start": 27, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "Cell"}, {"end": 36, "start": 11, "tag": "Cell"}, {"end": 85, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 149, "tag": "TemporalConcept"}, {"end": 201, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 191, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1328_1", "text": "The role of the chemokine fractalkine is well established in microglia; however, the effect of fractalkine on SVZ precursor cells is unknown.", "tags": [{"end": 106, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 114, "tag": "Cell"}, {"end": 91, "start": 85, "tag": "Finding"}, {"end": 70, "start": 61, "tag": "Cell"}, {"end": 37, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 26, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1328_2", "text": "We show that murine SVZ NPCs and OPCs express the fractalkine receptor (CX3CR1) and bind fractalkine.", "tags": [{"end": 70, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 72, "tag": "GeneOrGenome"}, {"end": 100, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 38, "tag": "CellFunction"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "Eukaryote"}, {"end": 88, "start": 84, "tag": "CellFunction"}, {"end": 70, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 72, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1328_3", "text": "Exogenous fractalkine directly enhances OPC and oligodendrocyte genesis from SVZ NPCs in vitro.", "tags": [{"end": 21, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 85, "start": 81, "tag": "Cell"}, {"end": 94, "start": 86, "tag": "ResearchActivity"}, {"end": 63, "start": 48, "tag": "Cell"}, {"end": 71, "start": 48, "tag": "BiologicFunction"}]}
{"id": "1328_4", "text": "Infusion of fractalkine into the lateral ventricle of adult NPC lineage-tracing mice leads to increased newborn OPC and oligodendrocyte formation in vivo.", "tags": [{"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 60, "tag": "Cell"}, {"end": 115, "start": 112, "tag": "Cell"}, {"end": 111, "start": 104, "tag": "TemporalConcept"}, {"end": 84, "start": 80, "tag": "Eukaryote"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 135, "start": 120, "tag": "Cell"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}, {"end": 84, "start": 54, "tag": "ResearchActivity"}, {"end": 145, "start": 120, "tag": "BiologicFunction"}]}
{"id": "1328_5", "text": "We also show that OPCs secrete fractalkine and that inhibition of endogenous fractalkine signaling reduces oligodendrocyte formation in vitro.", "tags": [{"end": 42, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 23, "tag": "CellFunction"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 98, "start": 89, "tag": "CellFunction"}, {"end": 141, "start": 133, "tag": "ResearchActivity"}, {"end": 62, "start": 52, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "Cell"}, {"end": 132, "start": 107, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 77, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1328_6", "text": "Finally, we show that fractalkine signaling regulates oligodendrogenesis in cerebellar slices ex vivo.", "tags": [{"end": 33, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 43, "start": 34, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "ResearchActivity"}]}
{"id": "1328_7", "text": "In summary, we demonstrate a novel role for fractalkine signaling in regulating oligodendrocyte genesis from postnatal CNS precursor cells.", "tags": [{"end": 55, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 138, "start": 123, "tag": "Cell"}, {"end": 118, "start": 109, "tag": "TemporalConcept"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 80, "tag": "Cell"}, {"end": 103, "start": 80, "tag": "BiologicFunction"}]}
{"id": "1329_0", "text": "The optic nerve represents one of the simplest regions of the CNS and has been useful in developing an understanding of glial development and myelination.", "tags": [{"end": 15, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 120, "tag": "Cell"}, {"end": 137, "start": 120, "tag": "CellFunction"}, {"end": 65, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 126, "tag": "BiologicFunction"}, {"end": 137, "start": 126, "tag": "CellFunction"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 153, "start": 142, "tag": "CellFunction"}]}
{"id": "1329_1", "text": "While the visual system is frequently affected in demyelinating conditions, utilizing the optic nerve to model demyelination/remyelination studies has been difficult due to its accessibility, relatively small size, and dense nature that makes direct injections challenging.", "tags": [{"end": 23, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 203, "tag": "OrganismAttribute"}, {"end": 260, "start": 250, "tag": "HealthCareActivity"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 50, "tag": "PathologicFunction"}, {"end": 110, "start": 105, "tag": "ResearchActivity"}, {"end": 37, "start": 27, "tag": "TemporalConcept"}, {"end": 138, "start": 125, "tag": "CellFunction"}, {"end": 124, "start": 111, "tag": "PathologicFunction"}, {"end": 74, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 139, "tag": "ResearchActivity"}]}
{"id": "1329_2", "text": "Taking advantage of the lack of oligodendrocytes and myelination in the mouse retina, we have developed a model in which the induction of apoptosis in mature oligodendrocytes allows for the selective, non-invasive generation of demyelinating lesions in optic nerve.", "tags": [{"end": 84, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "Cell"}, {"end": 249, "start": 228, "tag": "InjuryOrPoisoning"}, {"end": 213, "start": 205, "tag": "Finding"}, {"end": 264, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 32, "tag": "Cell"}, {"end": 241, "start": 228, "tag": "PathologicFunction"}, {"end": 249, "start": 242, "tag": "InjuryOrPoisoning"}, {"end": 174, "start": 151, "tag": "Cell"}, {"end": 213, "start": 201, "tag": "Finding"}, {"end": 111, "start": 106, "tag": "ResearchActivity"}, {"end": 147, "start": 138, "tag": "CellFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 224, "start": 214, "tag": "TemporalConcept"}, {"end": 77, "start": 72, "tag": "Eukaryote"}, {"end": 134, "start": 125, "tag": "Finding"}]}
{"id": "1329_3", "text": "Delivery of an inducer of oligodendrocyte apoptosis by intravitreous injection minimizes trauma to the optic nerve and allows for the assessment of oligodendrocyte death in the absence of injury related factors.", "tags": [{"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "BiologicFunction"}, {"end": 22, "start": 15, "tag": "Substance"}, {"end": 95, "start": 89, "tag": "InjuryOrPoisoning"}, {"end": 144, "start": 134, "tag": "HealthCareActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 169, "start": 164, "tag": "BiologicFunction"}, {"end": 169, "start": 164, "tag": "PathologicFunction"}, {"end": 169, "start": 164, "tag": "CellFunction"}, {"end": 41, "start": 26, "tag": "Cell"}, {"end": 163, "start": 148, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 55, "tag": "HealthCareActivity"}, {"end": 184, "start": 177, "tag": "Finding"}]}
{"id": "1329_4", "text": "Here we show that following induction of apoptosis, oligodendrocytes are lost within 3 days.", "tags": [{"end": 37, "start": 28, "tag": "HealthCareActivity"}, {"end": 77, "start": 73, "tag": "Finding"}, {"end": 68, "start": 52, "tag": "Cell"}, {"end": 50, "start": 41, "tag": "CellFunction"}, {"end": 91, "start": 87, "tag": "TemporalConcept"}]}
{"id": "1329_5", "text": "The loss of oligodendrocytes is associated with limited microglial and astrocyte response, is patchy along the nerve, and results in localized myelin loss.", "tags": [{"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 12, "tag": "Cell"}, {"end": 149, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 4, "tag": "CellOrMolecularDysfunction"}, {"end": 80, "start": 71, "tag": "Cell"}, {"end": 66, "start": 56, "tag": "Cell"}, {"end": 154, "start": 143, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1329_6", "text": "Unlike in other regions of the murine CNS, where local demyelination stimulates activation of local oligodendrocyte precursors and remyelination, optic nerve demyelination induced by oligodendrocyte apoptosis fails to recover and results in persistent areas of myelin loss.", "tags": [{"end": 225, "start": 218, "tag": "BiologicFunction"}, {"end": 225, "start": 218, "tag": "HealthCareActivity"}, {"end": 157, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 267, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 100, "tag": "Cell"}, {"end": 251, "start": 241, "tag": "TemporalConcept"}, {"end": 41, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 199, "tag": "CellFunction"}, {"end": 37, "start": 31, "tag": "Eukaryote"}, {"end": 198, "start": 183, "tag": "Cell"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}, {"end": 171, "start": 158, "tag": "PathologicFunction"}, {"end": 272, "start": 261, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1329_7", "text": "Over time these chronic lesions change cellular composition and ultimately become devoid of GFAP+ astrocytes and OPCs.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 31, "start": 24, "tag": "InjuryOrPoisoning"}, {"end": 9, "start": 5, "tag": "TemporalConcept"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 108, "start": 98, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}]}
{"id": "1329_8", "text": "Why the optic nerve lesions fail to repair may reflect the lack of early immune responsiveness and provide a novel model of chronic demyelination.", "tags": [{"end": 94, "start": 73, "tag": "PathologicFunction"}, {"end": 19, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ResearchActivity"}, {"end": 145, "start": 132, "tag": "PathologicFunction"}, {"end": 42, "start": 36, "tag": "BiologicFunction"}, {"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 131, "start": 124, "tag": "TemporalConcept"}]}
{"id": "1330_0", "text": "Following central nervous system (CNS) demyelination, adult oligodendrocyte progenitor cells (OPCs) can differentiate into new myelin-forming oligodendrocytes in a regenerative process called remyelination.", "tags": [{"end": 158, "start": 142, "tag": "Cell"}, {"end": 98, "start": 94, "tag": "Cell"}, {"end": 117, "start": 104, "tag": "CellFunction"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 60, "tag": "Cell"}, {"end": 92, "start": 76, "tag": "Cell"}, {"end": 32, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 52, "start": 39, "tag": "PathologicFunction"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}]}
{"id": "1330_1", "text": "Although remyelination is very efficient in young adults, its efficiency declines progressively with ageing.", "tags": [{"end": 56, "start": 44, "tag": "PopulationGroup"}, {"end": 107, "start": 101, "tag": "BiologicFunction"}, {"end": 56, "start": 50, "tag": "PopulationGroup"}, {"end": 72, "start": 62, "tag": "Finding"}, {"end": 22, "start": 9, "tag": "CellFunction"}]}
{"id": "1330_2", "text": "Here we performed proteomic analysis of OPCs freshly isolated from the brains of neonate, young and aged female rats.", "tags": [{"end": 88, "start": 81, "tag": "PopulationGroup"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 104, "start": 100, "tag": "TemporalConcept"}, {"end": 116, "start": 112, "tag": "Eukaryote"}, {"end": 44, "start": 40, "tag": "Cell"}, {"end": 36, "start": 18, "tag": "ResearchActivity"}, {"end": 111, "start": 105, "tag": "OrganismAttribute"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1330_3", "text": "Approximately 50% of the proteins are expressed at different levels in OPCs from neonates compared with their adult counterparts.", "tags": [{"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 33, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 110, "tag": "PopulationGroup"}, {"end": 47, "start": 38, "tag": "CellFunction"}]}
{"id": "1330_4", "text": "The amount of myelin-associated proteins, and proteins associated with oxidative phosphorylation, inflammatory responses and actin cytoskeletal organization increased with age, whereas cholesterol-biosynthesis, transcription factors and cell cycle proteins decreased.", "tags": [{"end": 96, "start": 71, "tag": "CellFunction"}, {"end": 120, "start": 98, "tag": "PathologicFunction"}, {"end": 156, "start": 125, "tag": "CellFunction"}, {"end": 256, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 185, "tag": "Chemical"}, {"end": 196, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}, {"end": 143, "start": 131, "tag": "CellComponent"}, {"end": 175, "start": 172, "tag": "OrganismAttribute"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 248, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 257, "tag": "Finding"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 237, "tag": "CellFunction"}, {"end": 256, "start": 237, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 185, "tag": "CellFunction"}]}
{"id": "1330_5", "text": "Our experiments provide the first ageing OPC proteome, revealing the distinct features of OPCs at different ages.", "tags": [{"end": 40, "start": 34, "tag": "BiologicFunction"}, {"end": 112, "start": 108, "tag": "OrganismAttribute"}, {"end": 15, "start": 4, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 53, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 45, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1330_6", "text": "These studies provide new insights into why remyelination efficiency declines with ageing and potential roles for aged OPCs in other neurodegenerative diseases.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 118, "start": 114, "tag": "TemporalConcept"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "Finding"}, {"end": 159, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 57, "start": 44, "tag": "CellFunction"}]}
{"id": "1331_0", "text": "Brain regeneration and tumorigenesis are complex processes involving in changes in chromatin structure to regulate cellular states at the molecular and genomic level.", "tags": [{"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 36, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 83, "tag": "CellComponent"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 18, "start": 6, "tag": "BiologicFunction"}, {"end": 18, "start": 6, "tag": "HealthCareActivity"}]}
{"id": "1331_1", "text": "The modulation of chromatin structure dynamics is critical for maintaining progenitor cell plasticity, growth and differentiation.", "tags": [{"end": 37, "start": 18, "tag": "CellComponent"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 109, "start": 103, "tag": "BiologicFunction"}, {"end": 129, "start": 114, "tag": "CellFunction"}, {"end": 46, "start": 38, "tag": "NaturalPhenomenonOrProcess"}]}
{"id": "1331_2", "text": "Oligodendrocyte precursor cells (OPC) can be differentiated into mature oligodendrocytes, which produce myelin sheathes to permit saltatory nerve conduction.", "tags": [{"end": 88, "start": 72, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 36, "start": 33, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 88, "start": 65, "tag": "Cell"}, {"end": 156, "start": 130, "tag": "BiologicFunction"}, {"end": 71, "start": 65, "tag": "TemporalConcept"}, {"end": 156, "start": 146, "tag": "BiologicFunction"}, {"end": 156, "start": 146, "tag": "NaturalPhenomenonOrProcess"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 104, "tag": "CellComponent"}]}
{"id": "1331_3", "text": "OPCs and their primitive progenitors such as pri-OPC or pre-OPC are highly adaptive and plastic during injury repair or brain tumor formation.", "tags": [{"end": 36, "start": 15, "tag": "Cell"}, {"end": 95, "start": 88, "tag": "Substance"}, {"end": 131, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 52, "start": 45, "tag": "Cell"}, {"end": 63, "start": 56, "tag": "Cell"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 116, "start": 103, "tag": "HealthCareActivity"}, {"end": 109, "start": 103, "tag": "InjuryOrPoisoning"}]}
{"id": "1331_4", "text": "Recent studies indicate that chromatin modifications and epigenetic homeostasis through histone modifying enzymes shape genomic regulatory landscape conducive to OPC fate specification, lineage differentiation, maintenance of myelin sheaths, as well as brain tumorigenesis.", "tags": [{"end": 38, "start": 29, "tag": "CellComponent"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 120, "tag": "GeneOrGenome"}, {"end": 127, "start": 120, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 184, "start": 166, "tag": "CellFunction"}, {"end": 272, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 240, "start": 226, "tag": "CellComponent"}, {"end": 113, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 211, "tag": "BiologicFunction"}, {"end": 79, "start": 57, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 232, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 186, "tag": "CellFunction"}, {"end": 52, "start": 29, "tag": "CellFunction"}, {"end": 113, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 120, "tag": "CellFunction"}]}
{"id": "1331_5", "text": "Thus, histone modifications can be convergent mechanisms in regulating OPC plasticity and malignant transformation.", "tags": [{"end": 27, "start": 6, "tag": "CellFunction"}, {"end": 85, "start": 75, "tag": "NaturalPhenomenonOrProcess"}, {"end": 85, "start": 75, "tag": "CellFunction"}, {"end": 74, "start": 71, "tag": "Cell"}, {"end": 114, "start": 90, "tag": "DiseaseOrSyndrome"}]}
{"id": "1331_6", "text": "In this review, we will focus on the impact of histone modifying enzymes in modulating OPC plasticity during normal development, myelin regeneration and tumorigenesis.", "tags": [{"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 127, "start": 109, "tag": "Finding"}, {"end": 166, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 136, "tag": "BiologicFunction"}, {"end": 148, "start": 136, "tag": "HealthCareActivity"}, {"end": 90, "start": 87, "tag": "Cell"}, {"end": 148, "start": 129, "tag": "CellFunction"}, {"end": 72, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 116, "tag": "BiologicFunction"}, {"end": 127, "start": 116, "tag": "CellFunction"}, {"end": 72, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1332_0", "text": "Depression is a common mental illness, affecting more than 300 million people worldwide.", "tags": [{"end": 37, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 71, "tag": "PopulationGroup"}]}
{"id": "1332_1", "text": "Decades of investigation have yielded symptomatic therapies for this disabling condition but have not led to a consensus about its pathogenesis.", "tags": [{"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 143, "start": 131, "tag": "PathologicFunction"}, {"end": 59, "start": 50, "tag": "HealthCareActivity"}, {"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 49, "start": 38, "tag": "SignOrSymptom"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}]}
{"id": "1332_2", "text": "There are data to support several different theories of causation, including the monoamine hypothesis, hypothalamic-pituitary-adrenal axis changes, inflammation and immune system alterations, abnormalities of neurogenesis and a conducive environmental milieu.", "tags": [{"end": 90, "start": 81, "tag": "Chemical"}, {"end": 138, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 209, "tag": "BiologicFunction"}, {"end": 178, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "ResearchActivity"}, {"end": 160, "start": 148, "tag": "PathologicFunction"}, {"end": 190, "start": 165, "tag": "PathologicFunction"}, {"end": 221, "start": 192, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1332_3", "text": "Research in these areas and others has greatly advanced the current understanding of depression; however, there are other, less widely known theories of pathogenesis.", "tags": [{"end": 81, "start": 68, "tag": "BiologicFunction"}, {"end": 95, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 165, "start": 153, "tag": "PathologicFunction"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}]}
{"id": "1332_4", "text": "Oligodendrocyte lineage cells, including oligodendrocyte progenitor cells and mature oligodendrocytes, have numerous important functions, which include forming myelin sheaths that enwrap central nervous system axons, supporting axons metabolically, and mediating certain forms of neuroplasticity.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 295, "start": 280, "tag": "BiologicFunction"}, {"end": 215, "start": 210, "tag": "CellComponent"}, {"end": 233, "start": 228, "tag": "CellComponent"}, {"end": 101, "start": 85, "tag": "Cell"}, {"end": 73, "start": 57, "tag": "Cell"}, {"end": 101, "start": 78, "tag": "Cell"}, {"end": 174, "start": 160, "tag": "CellComponent"}, {"end": 73, "start": 41, "tag": "Cell"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 29, "start": 0, "tag": "Cell"}, {"end": 166, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1332_5", "text": "These specialized glial cells have been implicated in psychiatric disorders such as depression.", "tags": [{"end": 75, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 18, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "Cell"}]}
{"id": "1332_6", "text": "In this review, we summarize recent findings that shed light on how oligodendrocyte lineage cells might participate in the pathogenesis of depression, and we discuss new approaches for targeting these cells as a novel strategy to treat depression.", "tags": [{"end": 149, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 135, "start": 123, "tag": "PathologicFunction"}, {"end": 97, "start": 68, "tag": "Cell"}, {"end": 206, "start": 201, "tag": "Cell"}, {"end": 35, "start": 29, "tag": "TemporalConcept"}]}
{"id": "1333_0", "text": "Oligodendrocyte lineage cells (oligodendroglia) and neurons engage in bidirectional communication throughout life to support healthy brain function.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 59, "start": 52, "tag": "Cell"}, {"end": 46, "start": 31, "tag": "Cell"}, {"end": 147, "start": 133, "tag": "BiologicFunction"}, {"end": 132, "start": 125, "tag": "OrganismAttribute"}, {"end": 29, "start": 0, "tag": "Cell"}, {"end": 113, "start": 109, "tag": "TemporalConcept"}]}
{"id": "1333_1", "text": "Recent work shows that changes in neuronal activity can modulate proliferation, differentiation, and myelination to support the formation and function of neural circuits.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 42, "start": 34, "tag": "Cell"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 112, "start": 101, "tag": "CellFunction"}, {"end": 51, "start": 34, "tag": "CellFunction"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 169, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1333_2", "text": "While oligodendroglia express a diverse collection of receptors for growth factors, signaling molecules, neurotransmitters and neuromodulators, our knowledge of the intracellular signaling pathways that are regulated by neuronal activity remains largely incomplete.", "tags": [{"end": 63, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 84, "tag": "CellFunction"}, {"end": 122, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 94, "tag": "Substance"}, {"end": 228, "start": 220, "tag": "Cell"}, {"end": 74, "start": 68, "tag": "BiologicFunction"}, {"end": 157, "start": 148, "tag": "Finding"}, {"end": 197, "start": 165, "tag": "CellFunction"}, {"end": 93, "start": 84, "tag": "CellFunction"}, {"end": 237, "start": 220, "tag": "CellFunction"}, {"end": 21, "start": 6, "tag": "Cell"}, {"end": 82, "start": 68, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1333_3", "text": "Many of the pathways that modulate oligodendroglia behavior are driven by changes in intracellular calcium signaling, which may differentially affect cytoskeletal dynamics, gene expression, maturation, integration, and axonal support.", "tags": [{"end": 162, "start": 150, "tag": "CellComponent"}, {"end": 213, "start": 202, "tag": "CellFunction"}, {"end": 213, "start": 202, "tag": "MachineActivity"}, {"end": 225, "start": 219, "tag": "CellComponent"}, {"end": 59, "start": 51, "tag": "BiologicFunction"}, {"end": 59, "start": 51, "tag": "IndividualBehavior"}, {"end": 59, "start": 51, "tag": "ResearchActivity"}, {"end": 188, "start": 173, "tag": "CellFunction"}, {"end": 200, "start": 190, "tag": "BiologicFunction"}, {"end": 116, "start": 85, "tag": "CellFunction"}, {"end": 50, "start": 35, "tag": "Cell"}, {"end": 20, "start": 12, "tag": "CellFunction"}, {"end": 171, "start": 163, "tag": "NaturalPhenomenonOrProcess"}, {"end": 106, "start": 99, "tag": "Chemical"}, {"end": 106, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 99, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1333_4", "text": "Additionally, activity-dependent neuron-oligodendroglia communication plays an integral role in the recovery from demyelinating injuries.", "tags": [{"end": 39, "start": 33, "tag": "Cell"}, {"end": 127, "start": 114, "tag": "PathologicFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 108, "start": 100, "tag": "BiologicFunction"}, {"end": 108, "start": 100, "tag": "HealthCareActivity"}, {"end": 108, "start": 100, "tag": "TemporalConcept"}, {"end": 69, "start": 14, "tag": "CellFunction"}, {"end": 136, "start": 114, "tag": "InjuryOrPoisoning"}]}
{"id": "1333_5", "text": "In this review, we summarize the modalities of communication between neurons and oligodendroglia and explore possible roles of activity-dependent calcium signaling in mediating cellular behavior and myelination.", "tags": [{"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 60, "start": 47, "tag": "CellFunction"}, {"end": 194, "start": 186, "tag": "BiologicFunction"}, {"end": 194, "start": 186, "tag": "IndividualBehavior"}, {"end": 194, "start": 186, "tag": "ResearchActivity"}, {"end": 76, "start": 69, "tag": "Cell"}, {"end": 210, "start": 199, "tag": "CellFunction"}, {"end": 163, "start": 127, "tag": "CellFunction"}, {"end": 96, "start": 81, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 163, "start": 146, "tag": "CellFunction"}]}
{"id": "1334_0", "text": "Promoting the differentiation of oligodendrocyte precursor cells (OPCs) is important for fostering remyelination in multiple sclerosis.", "tags": [{"end": 70, "start": 66, "tag": "Cell"}, {"end": 64, "start": 33, "tag": "Cell"}, {"end": 134, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 14, "tag": "CellFunction"}, {"end": 64, "start": 49, "tag": "Cell"}, {"end": 58, "start": 33, "tag": "Cell"}, {"end": 112, "start": 99, "tag": "CellFunction"}]}
{"id": "1334_1", "text": "Catalpol has the potential to promote remyelination and exert neuroprotective effects, but its specific mechanism is still unclear.", "tags": [{"end": 8, "start": 0, "tag": "Chemical"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 85, "start": 78, "tag": "Finding"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 85, "start": 62, "tag": "Finding"}]}
{"id": "1334_2", "text": "Recent studies have shown that the NOTCH1 signaling pathway is involved in mediating OPC proliferation and differentiation.", "tags": [{"end": 59, "start": 35, "tag": "CellFunction"}, {"end": 88, "start": 85, "tag": "Cell"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "CellFunction"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "CellFunction"}, {"end": 59, "start": 42, "tag": "CellFunction"}]}
{"id": "1334_3", "text": "In this study, we elucidated that catalpol promoted OPC differentiation in vivo and vitro and explored the regulatory role of catalpol in specific biomolecular processes.", "tags": [{"end": 42, "start": 34, "tag": "Chemical"}, {"end": 134, "start": 126, "tag": "Chemical"}, {"end": 55, "start": 52, "tag": "Cell"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 71, "start": 52, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 122, "start": 107, "tag": "Finding"}, {"end": 169, "start": 147, "tag": "CellFunction"}]}
{"id": "1334_4", "text": "Following catalpol administration, better and faster recovery of body weight and motor balance was observed in mice with cuprizone (CPZ)-induced demyelination.", "tags": [{"end": 18, "start": 10, "tag": "Chemical"}, {"end": 76, "start": 65, "tag": "OrganismAttribute"}, {"end": 135, "start": 132, "tag": "Chemical"}, {"end": 130, "start": 121, "tag": "Chemical"}, {"end": 115, "start": 111, "tag": "Eukaryote"}, {"end": 69, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "BiologicFunction"}, {"end": 61, "start": 53, "tag": "HealthCareActivity"}, {"end": 61, "start": 53, "tag": "TemporalConcept"}, {"end": 158, "start": 145, "tag": "PathologicFunction"}, {"end": 33, "start": 19, "tag": "HealthCareActivity"}, {"end": 94, "start": 81, "tag": "BiologicFunction"}]}
{"id": "1334_5", "text": "Luxol fast blue staining (LFB) and transmission electron microscopy (TEM) showed that catalpol increased the myelinated area and improved myelin ultrastructure in the corpus callosum in demyelinated mice.", "tags": [{"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 29, "start": 26, "tag": "Chemical"}, {"end": 94, "start": 86, "tag": "Chemical"}, {"end": 119, "start": 109, "tag": "CellComponent"}, {"end": 137, "start": 129, "tag": "Finding"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 186, "tag": "PathologicFunction"}, {"end": 182, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 67, "start": 48, "tag": "ResearchActivity"}, {"end": 67, "start": 35, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "Chemical"}]}
{"id": "1334_6", "text": "In addition, catalpol enhanced the expression of CNPase and MBP, indicating that it increased OPC differentiation.", "tags": [{"end": 21, "start": 13, "tag": "Chemical"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "Cell"}, {"end": 113, "start": 98, "tag": "CellFunction"}, {"end": 113, "start": 94, "tag": "CellFunction"}, {"end": 45, "start": 35, "tag": "CellFunction"}, {"end": 55, "start": 49, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1334_7", "text": "Additionally, catalpol downregulated the expression of NOTCH1 signaling pathway-related molecules, such as JAGGED1, NOTCH1, NICD1, RBPJ, HES5, and HES1.", "tags": [{"end": 22, "start": 14, "tag": "Chemical"}, {"end": 114, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "GeneOrGenome"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 141, "start": 137, "tag": "GeneOrGenome"}, {"end": 151, "start": 147, "tag": "GeneOrGenome"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 97, "start": 88, "tag": "Substance"}, {"end": 36, "start": 23, "tag": "CellFunction"}, {"end": 79, "start": 55, "tag": "CellFunction"}, {"end": 122, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 147, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1334_8", "text": "We further demonstrated that in vitro, catalpol enhanced the differentiation of OPCs into OLs and inhibited NOTCH1 signaling pathway activity.", "tags": [{"end": 47, "start": 39, "tag": "Chemical"}, {"end": 132, "start": 108, "tag": "CellFunction"}, {"end": 84, "start": 80, "tag": "Cell"}, {"end": 124, "start": 115, "tag": "CellFunction"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 93, "start": 90, "tag": "Cell"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 132, "start": 125, "tag": "CellFunction"}, {"end": 132, "start": 115, "tag": "CellFunction"}]}
{"id": "1334_9", "text": "Our data suggested that catalpol may promote OPC differentiation and remyelination through modulation of the NOTCH1 pathway.", "tags": [{"end": 32, "start": 24, "tag": "Chemical"}, {"end": 48, "start": 45, "tag": "Cell"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 64, "start": 45, "tag": "CellFunction"}, {"end": 123, "start": 109, "tag": "CellFunction"}, {"end": 82, "start": 69, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1334_10", "text": "This study provides new insight into the mechanism of action of catalpol in the treatment of multiple sclerosis.", "tags": [{"end": 72, "start": 64, "tag": "Chemical"}, {"end": 111, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 89, "start": 80, "tag": "HealthCareActivity"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}]}
{"id": "1335_0", "text": "Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that causes severe motor, sensory, and cognitive impairments.", "tags": [{"end": 62, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 41, "tag": "PathologicFunction"}, {"end": 62, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 111, "tag": "Finding"}]}
{"id": "1335_1", "text": "Kallikrein-related peptidase (KLK)6 is the most abundant serine protease secreted in the CNS, mainly by oligodendrocytes, the myelin-producing cells of the CNS, and KLK6 is assumed to be a robust biomarker of MS, since it is highly increased in the cerebrospinal fluid (CSF) of MS patients.", "tags": [{"end": 28, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 126, "tag": "Cell"}, {"end": 120, "start": 104, "tag": "Cell"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 289, "start": 281, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 273, "start": 270, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 196, "tag": "ClinicalAttribute"}, {"end": 268, "start": 249, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 165, "tag": "GeneOrGenome"}]}
{"id": "1335_2", "text": "Here, we report the design and biological evaluation of KLK6's low-molecular-weight inhibitors, para-aminobenzyl derivatives.", "tags": [{"end": 26, "start": 20, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "HealthCareActivity"}, {"end": 52, "start": 42, "tag": "HealthCareActivity"}, {"end": 52, "start": 42, "tag": "ResearchActivity"}, {"end": 94, "start": 84, "tag": "Chemical"}, {"end": 94, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "GeneOrGenome"}, {"end": 60, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 96, "tag": "Chemical"}, {"end": 124, "start": 96, "tag": "PharmacologicSubstance"}]}
{"id": "1335_3", "text": "Interestingly, selected hit compounds were selective of the KLK6 proteolytic network encompassing KLK1 and plasmin that also participate in the development of MS physiopathology.", "tags": [{"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 102, "start": 98, "tag": "GeneOrGenome"}, {"end": 114, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 162, "tag": "PathologicFunction"}, {"end": 37, "start": 28, "tag": "Chemical"}, {"end": 37, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 155, "start": 144, "tag": "BiologicFunction"}, {"end": 155, "start": 144, "tag": "CellFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 65, "tag": "CellFunction"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "PharmacologicSubstance"}]}
{"id": "1335_4", "text": "Moreover, hits were found noncytotoxic on primary cultures of murine neurons and oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 58, "start": 42, "tag": "ResearchActivity"}, {"end": 14, "start": 10, "tag": "Finding"}, {"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 118, "start": 114, "tag": "Cell"}, {"end": 112, "start": 81, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 106, "start": 81, "tag": "Cell"}, {"end": 68, "start": 62, "tag": "Eukaryote"}, {"end": 76, "start": 69, "tag": "Cell"}]}
{"id": "1335_5", "text": "Among them, two compounds (32 and 42) were shown to promote the differentiation of OPCs into mature oligodendrocytes in vitro constituting thus emerging leads for the development of regenerative therapies.", "tags": [{"end": 116, "start": 100, "tag": "Cell"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 116, "start": 93, "tag": "Cell"}, {"end": 79, "start": 64, "tag": "CellFunction"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 25, "start": 16, "tag": "Chemical"}, {"end": 25, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 178, "start": 167, "tag": "BiologicFunction"}, {"end": 178, "start": 167, "tag": "CellFunction"}, {"end": 125, "start": 117, "tag": "ResearchActivity"}, {"end": 204, "start": 182, "tag": "HealthCareActivity"}]}
{"id": "1336_0", "text": "Oligodendrocyte precursor cells (OPCs) are glial cells that differentiate into mature oligodendrocytes (OLs) to generate new myelin sheaths.", "tags": [{"end": 102, "start": 86, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 79, "tag": "Cell"}, {"end": 139, "start": 125, "tag": "CellComponent"}, {"end": 107, "start": 104, "tag": "Cell"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 48, "start": 43, "tag": "Cell"}, {"end": 54, "start": 43, "tag": "Cell"}]}
{"id": "1336_1", "text": "While OPCs are distributed uniformly throughout the gray and white matter in the developing and adult brain, those in white matter proliferate and differentiate into oligodendrocytes at a greater rate than those in gray matter.", "tags": [{"end": 226, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "Cell"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 200, "start": 196, "tag": "TemporalConcept"}, {"end": 73, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 96, "tag": "PopulationGroup"}]}
{"id": "1336_2", "text": "There is currently lack of evidence to suggest that OPCs comprise genetically and transcriptionally distinct subtypes.", "tags": [{"end": 99, "start": 82, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 18, "start": 9, "tag": "TemporalConcept"}]}
{"id": "1336_3", "text": "Rather, the emerging view is that they exist in different cell and functional states, depending on their location and age.", "tags": [{"end": 113, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "OrganismAttribute"}]}
{"id": "1336_4", "text": "Contrary to the normal brain, demyelinated lesions in the gray matter of multiple sclerosis brains contain more OPCs and OLs and are remyelinated more robustly than those in white matter.", "tags": [{"end": 69, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 91, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}, {"end": 186, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 121, "tag": "Cell"}, {"end": 50, "start": 30, "tag": "PathologicFunction"}, {"end": 145, "start": 133, "tag": "CellFunction"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 16, "tag": "Finding"}, {"end": 98, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1336_5", "text": "The differences in the dynamic behavior of OL lineage cells are likely to be influenced by their microenvironment.", "tags": [{"end": 113, "start": 97, "tag": "NaturalPhenomenonOrProcess"}, {"end": 113, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 31, "tag": "BiologicFunction"}, {"end": 39, "start": 31, "tag": "IndividualBehavior"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}, {"end": 45, "start": 43, "tag": "Cell"}, {"end": 53, "start": 43, "tag": "Cell"}, {"end": 59, "start": 43, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "Finding"}]}
{"id": "1336_6", "text": "There are regional differences in astrocytes, microglia, the vasculature, and the composition of the extracellular matrix (ECM).", "tags": [{"end": 72, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 30, "start": 19, "tag": "Finding"}, {"end": 44, "start": 34, "tag": "Cell"}]}
{"id": "1336_7", "text": "We will discuss how the regional differences in these elements surrounding OPCs might shape their phenotypic variability in normal and demyelinated states.</p>", "tags": [{"end": 120, "start": 109, "tag": "Finding"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 154, "start": 148, "tag": "TemporalConcept"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 108, "start": 98, "tag": "OrganismAttribute"}]}
{"id": "1337_0", "text": "Background Promotion of myelin repair in the context of demyelinating diseases such as multiple sclerosis (MS) still represents a clinical unmet need, given that this disease is not only characterized by autoimmune activities but also by impaired regeneration processes.", "tags": [{"end": 149, "start": 130, "tag": "Finding"}, {"end": 78, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 105, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 247, "tag": "BiologicFunction"}, {"end": 259, "start": 247, "tag": "HealthCareActivity"}, {"end": 37, "start": 24, "tag": "CellFunction"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "BiologicFunction"}, {"end": 37, "start": 31, "tag": "HealthCareActivity"}, {"end": 225, "start": 204, "tag": "PathologicFunction"}, {"end": 269, "start": 238, "tag": "PathologicFunction"}]}
{"id": "1337_1", "text": "Hence, this relates to replacement of lost oligodendrocytes and myelin sheaths-the primary targets of autoimmune attacks.", "tags": [{"end": 34, "start": 23, "tag": "HealthCareActivity"}, {"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 42, "start": 38, "tag": "Finding"}, {"end": 59, "start": 43, "tag": "Cell"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 64, "tag": "CellComponent"}, {"end": 120, "start": 102, "tag": "PathologicFunction"}]}
{"id": "1337_2", "text": "Endogenous remyelination is mainly mediated via activation and differentiation of resident oligodendroglial precursor cells (OPCs), whereas its efficiency remains limited and declines with disease progression and aging.", "tags": [{"end": 129, "start": 125, "tag": "Cell"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 123, "start": 108, "tag": "Cell"}, {"end": 154, "start": 144, "tag": "Finding"}, {"end": 90, "start": 82, "tag": "PopulationGroup"}, {"end": 123, "start": 91, "tag": "Cell"}, {"end": 107, "start": 91, "tag": "Cell"}, {"end": 208, "start": 197, "tag": "PathologicFunction"}, {"end": 208, "start": 197, "tag": "TemporalConcept"}, {"end": 208, "start": 189, "tag": "PathologicFunction"}, {"end": 24, "start": 0, "tag": "CellFunction"}, {"end": 218, "start": 213, "tag": "BiologicFunction"}, {"end": 218, "start": 213, "tag": "CellFunction"}, {"end": 58, "start": 48, "tag": "CellFunction"}]}
{"id": "1337_3", "text": "Teriflunomide has been approved as a first-line treatment for relapsing remitting MS.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 57, "start": 37, "tag": "HealthCareActivity"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 71, "start": 62, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 57, "start": 48, "tag": "HealthCareActivity"}, {"end": 57, "start": 48, "tag": "ResearchActivity"}, {"end": 84, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}]}
{"id": "1337_4", "text": "Beyond its role in acting via inhibition of de novo pyrimidine synthesis leading to a cytostatic effect on proliferating lymphocyte subsets, this study aims to uncover its potential to foster myelin repair.Methods Within the cuprizone mediated de-/remyelination model teriflunomide dependent effects on oligodendroglial homeostasis and maturation, related to cellular processes important for myelin repair were analyzed in vivo.", "tags": [{"end": 62, "start": 52, "tag": "Chemical"}, {"end": 62, "start": 52, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 281, "start": 268, "tag": "Chemical"}, {"end": 377, "start": 359, "tag": "CellFunction"}, {"end": 346, "start": 336, "tag": "BiologicFunction"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 398, "start": 392, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 234, "start": 225, "tag": "Chemical"}, {"end": 72, "start": 63, "tag": "BiologicFunction"}, {"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 405, "start": 392, "tag": "CellFunction"}, {"end": 319, "start": 303, "tag": "Cell"}, {"end": 151, "start": 146, "tag": "ResearchActivity"}, {"end": 267, "start": 262, "tag": "ResearchActivity"}, {"end": 103, "start": 86, "tag": "Finding"}, {"end": 419, "start": 411, "tag": "ResearchActivity"}, {"end": 139, "start": 107, "tag": "Cell"}, {"end": 40, "start": 30, "tag": "CellFunction"}, {"end": 331, "start": 320, "tag": "BiologicFunction"}, {"end": 427, "start": 420, "tag": "ResearchActivity"}, {"end": 367, "start": 359, "tag": "Cell"}, {"end": 261, "start": 248, "tag": "CellFunction"}, {"end": 299, "start": 292, "tag": "Finding"}, {"end": 205, "start": 199, "tag": "BiologicFunction"}, {"end": 405, "start": 399, "tag": "BiologicFunction"}, {"end": 205, "start": 199, "tag": "HealthCareActivity"}, {"end": 405, "start": 399, "tag": "HealthCareActivity"}, {"end": 281, "start": 268, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 52, "tag": "CellFunction"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 225, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1337_5", "text": "Teriflunomide administration was performed either as pulse or continuously and markers specific for oligodendroglial maturation and mitochondrial integrity were examined by means of gene expression and immunohistochemical analyses.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 127, "start": 117, "tag": "BiologicFunction"}, {"end": 155, "start": 146, "tag": "IndividualBehavior"}, {"end": 145, "start": 132, "tag": "CellComponent"}, {"end": 116, "start": 100, "tag": "Cell"}, {"end": 86, "start": 79, "tag": "ClinicalAttribute"}, {"end": 197, "start": 182, "tag": "CellFunction"}, {"end": 230, "start": 202, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 14, "tag": "HealthCareActivity"}, {"end": 230, "start": 222, "tag": "ResearchActivity"}, {"end": 197, "start": 182, "tag": "ResearchActivity"}]}
{"id": "1337_6", "text": "In addition, axon myelination was determined using electron microscopy.Results Both pulse and constant teriflunomide treatment efficiently boosted myelin repair activities in this model, leading to accelerated generation of oligodendrocytes and restoration of myelin sheaths.", "tags": [{"end": 116, "start": 103, "tag": "Chemical"}, {"end": 240, "start": 224, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 266, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 274, "start": 260, "tag": "CellComponent"}, {"end": 17, "start": 13, "tag": "CellComponent"}, {"end": 102, "start": 94, "tag": "TemporalConcept"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 78, "start": 71, "tag": "ResearchActivity"}, {"end": 185, "start": 180, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 126, "start": 117, "tag": "ResearchActivity"}, {"end": 70, "start": 51, "tag": "ResearchActivity"}, {"end": 29, "start": 18, "tag": "CellFunction"}, {"end": 220, "start": 210, "tag": "TemporalConcept"}, {"end": 160, "start": 154, "tag": "BiologicFunction"}, {"end": 160, "start": 154, "tag": "HealthCareActivity"}, {"end": 116, "start": 103, "tag": "PharmacologicSubstance"}]}
{"id": "1337_7", "text": "Moreover, teriflunomide restored mitochondrial integrity within oligodendroglial cells.Conclusions The link between de novo pyrimidine synthesis inhibition, oligodendroglial rescue, and maintenance of mitochondrial homeostasis appears as a key for successful myelin repair and hence for protection of axons from degeneration.", "tags": [{"end": 23, "start": 10, "tag": "Chemical"}, {"end": 134, "start": 124, "tag": "Chemical"}, {"end": 134, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 306, "start": 301, "tag": "CellComponent"}, {"end": 265, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 324, "start": 312, "tag": "PathologicFunction"}, {"end": 144, "start": 135, "tag": "BiologicFunction"}, {"end": 272, "start": 259, "tag": "CellFunction"}, {"end": 86, "start": 64, "tag": "Cell"}, {"end": 173, "start": 157, "tag": "Cell"}, {"end": 155, "start": 145, "tag": "CellFunction"}, {"end": 197, "start": 186, "tag": "BiologicFunction"}, {"end": 272, "start": 266, "tag": "BiologicFunction"}, {"end": 272, "start": 266, "tag": "HealthCareActivity"}, {"end": 23, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 33, "tag": "CellFunction"}, {"end": 134, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 124, "tag": "CellFunction"}, {"end": 226, "start": 201, "tag": "CellFunction"}]}
{"id": "1338_0", "text": "Conflicting results on melatonin synthesis in multiple sclerosis (MS) have been reported due to variabilities in patient lifestyles, which are not considered when supplementing melatonin.", "tags": [{"end": 42, "start": 33, "tag": "BiologicFunction"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 186, "start": 177, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 23, "tag": "Chemical"}, {"end": 186, "start": 177, "tag": "Chemical"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 121, "tag": "IndividualBehavior"}]}
{"id": "1338_1", "text": "Since melatonin acts through its receptors, we identified melatonin receptors in oligodendrocytes (OLs) in the corpus callosum, where demyelination occurs; the subventricular zone, where neural stem/progenitor cells (NSPCs) are located; and the choroid plexus, which functions as a blood-cerebrospinal fluid barrier.", "tags": [{"end": 42, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 245, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 315, "start": 282, "tag": "BiologicFunction"}, {"end": 97, "start": 81, "tag": "Cell"}, {"end": 215, "start": 199, "tag": "Cell"}, {"end": 15, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 6, "tag": "Chemical"}, {"end": 67, "start": 58, "tag": "Chemical"}, {"end": 102, "start": 99, "tag": "Cell"}, {"end": 126, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 134, "tag": "PathologicFunction"}, {"end": 307, "start": 302, "tag": "Substance"}, {"end": 307, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 210, "tag": "Cell"}, {"end": 198, "start": 187, "tag": "Cell"}, {"end": 222, "start": 217, "tag": "Cell"}]}
{"id": "1338_2", "text": "Moreover, using chimeric mice, resident macrophages were found to express melatonin receptors, whereas bone marrow-derived macrophages lost this expression in the demyelinated brain.", "tags": [{"end": 29, "start": 16, "tag": "Organism"}, {"end": 39, "start": 31, "tag": "PopulationGroup"}, {"end": 175, "start": 163, "tag": "PathologicFunction"}, {"end": 107, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 74, "tag": "Chemical"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 31, "tag": "Cell"}, {"end": 134, "start": 103, "tag": "Cell"}, {"end": 181, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 25, "tag": "Eukaryote"}, {"end": 93, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 74, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1338_3", "text": "Next, we showed that cuprizone-fed mice, which is an MS model, tended to have increased melatonin levels.", "tags": [{"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 104, "start": 88, "tag": "ResearchActivity"}, {"end": 30, "start": 21, "tag": "Chemical"}, {"end": 39, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 39, "start": 35, "tag": "Eukaryote"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1338_4", "text": "While we used different approaches to alter the circadian rhythm of melatonin and cortisol, only the constant light approach increased NSPC proliferation and differentiation to oligodendrocyte precursor cells (OPCs), OPCs maturation to OLs and recruitment to the site of demyelination, the number of patrolling monocytes, and phagocytosis.", "tags": [{"end": 64, "start": 48, "tag": "BiologicFunction"}, {"end": 90, "start": 82, "tag": "Chemical"}, {"end": 320, "start": 311, "tag": "Cell"}, {"end": 77, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 68, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "TemporalConcept"}, {"end": 239, "start": 236, "tag": "Cell"}, {"end": 208, "start": 193, "tag": "Cell"}, {"end": 214, "start": 210, "tag": "Cell"}, {"end": 221, "start": 217, "tag": "Cell"}, {"end": 153, "start": 140, "tag": "CellFunction"}, {"end": 338, "start": 326, "tag": "CellFunction"}, {"end": 202, "start": 177, "tag": "Cell"}, {"end": 232, "start": 222, "tag": "BiologicFunction"}, {"end": 208, "start": 177, "tag": "Cell"}, {"end": 284, "start": 271, "tag": "PathologicFunction"}, {"end": 173, "start": 158, "tag": "CellFunction"}, {"end": 90, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 115, "start": 110, "tag": "NaturalPhenomenonOrProcess"}]}
{"id": "1338_5", "text": "In contrast, constant darkness and exogenous melatonin exacerbated these events and amplified monocyte infiltration.", "tags": [{"end": 30, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 54, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 54, "start": 45, "tag": "Chemical"}, {"end": 21, "start": 13, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "Cell"}, {"end": 115, "start": 94, "tag": "CellFunction"}]}
{"id": "1338_6", "text": "Therefore, melatonin should not be considered a universal remedy, as is currently claimed.", "tags": [{"end": 20, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 11, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 11, "tag": "Chemical"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 64, "start": 58, "tag": "HealthCareActivity"}]}
{"id": "1338_7", "text": "Our data emphasize the importance of monitoring melatonin/cortisol oscillations in each MS patient by considering diet and lifestyle to avoid melatonin overdose.", "tags": [{"end": 118, "start": 114, "tag": "HealthCareActivity"}, {"end": 160, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 152, "tag": "Finding"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 151, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 48, "tag": "Chemical"}, {"end": 151, "start": 142, "tag": "Chemical"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 37, "tag": "HealthCareActivity"}, {"end": 98, "start": 91, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 58, "tag": "Chemical"}, {"end": 66, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 123, "tag": "IndividualBehavior"}, {"end": 79, "start": 67, "tag": "Finding"}]}
{"id": "1339_0", "text": "The unmet medical need of patients with multiple sclerosis (MS) is the inexorable loss of CNS myelin and latterly neurons leading to permanent neurologic disability.", "tags": [{"end": 142, "start": 133, "tag": "TemporalConcept"}, {"end": 164, "start": 143, "tag": "SignOrSymptom"}, {"end": 58, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 114, "tag": "Cell"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 154, "tag": "Finding"}, {"end": 22, "start": 4, "tag": "Finding"}]}
{"id": "1339_1", "text": "Solicitation of endogenous oligodendrocytes progenitor cells, the precursor of oligodendrocytes, to remyelinate axons may abort the onset of disability.", "tags": [{"end": 75, "start": 66, "tag": "Cell"}, {"end": 117, "start": 112, "tag": "CellComponent"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 95, "start": 79, "tag": "Cell"}, {"end": 111, "start": 100, "tag": "CellFunction"}, {"end": 60, "start": 44, "tag": "Cell"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 151, "start": 141, "tag": "Finding"}]}
{"id": "1339_2", "text": "In female mice with experimental autoimmune encephalomyelitis (EAE), a murine model of MS, adoptive transfer of IL-10(+) regulatory B cells (B-regs) has been shown to reverse EAE by promoting the expansion of peripheral and CNS-infiltrating IL-10(+) T cells.", "tags": [{"end": 108, "start": 91, "tag": "HealthCareActivity"}, {"end": 61, "start": 20, "tag": "ExperimentalModelOfDisease"}, {"end": 66, "start": 63, "tag": "ExperimentalModelOfDisease"}, {"end": 178, "start": 175, "tag": "ExperimentalModelOfDisease"}, {"end": 227, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 121, "tag": "Cell"}, {"end": 257, "start": 250, "tag": "Cell"}, {"end": 240, "start": 228, "tag": "Cell"}, {"end": 219, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "Eukaryote"}, {"end": 83, "start": 78, "tag": "ResearchActivity"}, {"end": 77, "start": 71, "tag": "Eukaryote"}, {"end": 9, "start": 3, "tag": "OrganismAttribute"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 246, "start": 241, "tag": "GeneOrGenome"}, {"end": 89, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 147, "start": 141, "tag": "Cell"}]}
{"id": "1339_3", "text": "Here, we examined whether Bre g s treatment and its bystander effect on regulatory T cells are associated with CNS repair as reflected by oligodendrogenesis and remyelination.", "tags": [{"end": 90, "start": 72, "tag": "Cell"}, {"end": 156, "start": 138, "tag": "BiologicFunction"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 52, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}, {"end": 174, "start": 161, "tag": "CellFunction"}, {"end": 121, "start": 115, "tag": "BiologicFunction"}, {"end": 121, "start": 115, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "Cell"}]}
{"id": "1339_4", "text": "We have found that transfusion of B-regs reverses established clinical EAE and that clinical improvement is associated with a significant increase in spinal cord remyelination as reflected by g-ratio analysis within the thoracic and lumbar spine.", "tags": [{"end": 30, "start": 19, "tag": "HealthCareActivity"}, {"end": 245, "start": 240, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 161, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 192, "tag": "ResearchActivity"}, {"end": 175, "start": 162, "tag": "CellFunction"}, {"end": 146, "start": 126, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "Cell"}, {"end": 104, "start": 84, "tag": "Finding"}]}
{"id": "1339_5", "text": "We further observed in the spinal cords of EAE B-regs-treated mice that CNS resident CD11b/CD45(int)Ly6C microglia, and infiltrating CD11b(+)/CD45(high) monocytes/macrophages content reverts to normal and polarize to a M2-like CD206(+) phenotype.", "tags": [{"end": 182, "start": 175, "tag": "BiologicFunction"}, {"end": 46, "start": 43, "tag": "ExperimentalModelOfDisease"}, {"end": 39, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 163, "tag": "Cell"}, {"end": 84, "start": 76, "tag": "PopulationGroup"}, {"end": 162, "start": 153, "tag": "Cell"}, {"end": 132, "start": 120, "tag": "Cell"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 62, "tag": "Eukaryote"}, {"end": 245, "start": 236, "tag": "CellFunction"}, {"end": 226, "start": 219, "tag": "CellFunction"}, {"end": 114, "start": 105, "tag": "Cell"}, {"end": 200, "start": 194, "tag": "Finding"}, {"end": 53, "start": 47, "tag": "Cell"}, {"end": 90, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 227, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1339_6", "text": "Concurrently, there was a substantial increase in neo-oligodendrogenesis as manifest by an increase in CD45(-/low) CNS cells expressing A2B5, an early marker in oligodendrocytes progenitor cell differentiation as well as GalC(+)/01(+) premyelinating and myelin basic protein(+)/myelin oligodendrocyte glycoprotein(+) mature oligodendrocytes with reciprocal downregulation of paired related homeobox protein 1.", "tags": [{"end": 140, "start": 136, "tag": "Chemical"}, {"end": 408, "start": 390, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 125, "tag": "CellFunction"}, {"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 398, "start": 390, "tag": "GeneOrGenome"}, {"end": 398, "start": 390, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 161, "tag": "Cell"}, {"end": 340, "start": 317, "tag": "Cell"}, {"end": 209, "start": 194, "tag": "CellFunction"}, {"end": 274, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 274, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 145, "tag": "TemporalConcept"}, {"end": 193, "start": 178, "tag": "Cell"}, {"end": 371, "start": 357, "tag": "CellFunction"}, {"end": 157, "start": 151, "tag": "ClinicalAttribute"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 119, "tag": "Cell"}, {"end": 209, "start": 189, "tag": "CellFunction"}, {"end": 406, "start": 399, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 221, "tag": "GeneOrGenome"}, {"end": 225, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 313, "start": 278, "tag": "AminoAcidPeptideOrProtein"}, {"end": 313, "start": 278, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1339_7", "text": "These results demonstrate that the clinical benefit of B-regs is associated with normalization of CNS immune milieu and concurrent activation of oligodendrocyte progenitor cells with subsequent remyelination.", "tags": [{"end": 51, "start": 35, "tag": "Finding"}, {"end": 130, "start": 120, "tag": "TemporalConcept"}, {"end": 177, "start": 145, "tag": "Cell"}, {"end": 115, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 81, "tag": "ResearchActivity"}, {"end": 207, "start": 194, "tag": "CellFunction"}, {"end": 61, "start": 55, "tag": "Cell"}, {"end": 141, "start": 131, "tag": "CellFunction"}]}
{"id": "1340_0", "text": "PRC2 creates the repressivemark histone H3 Lys27 trimethylation.", "tags": [{"end": 63, "start": 32, "tag": "CellFunction"}, {"end": 48, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1340_1", "text": "Although PRC2 is involved in various biological processes, its role in glial development remains ambiguous.", "tags": [{"end": 88, "start": 71, "tag": "CellFunction"}, {"end": 57, "start": 37, "tag": "BiologicFunction"}, {"end": 76, "start": 71, "tag": "Cell"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 13, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1340_2", "text": "Here, we show that PRC2 is required for oligodendrocyte (OL) differentiation and myelination, but not for OL precursor formation.", "tags": [{"end": 59, "start": 57, "tag": "Cell"}, {"end": 118, "start": 106, "tag": "Cell"}, {"end": 92, "start": 81, "tag": "CellFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 23, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1340_3", "text": "PRC2-deficient OL lineage cells differentiate into OL precursors, but they fail to trigger the molecular program for myelination, highlighting that PRC2 is essential for directing the differentiation timing of OL precursors.", "tags": [{"end": 206, "start": 200, "tag": "TemporalConcept"}, {"end": 17, "start": 15, "tag": "Cell"}, {"end": 64, "start": 51, "tag": "Cell"}, {"end": 223, "start": 210, "tag": "Cell"}, {"end": 128, "start": 117, "tag": "CellFunction"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 199, "start": 184, "tag": "CellFunction"}, {"end": 112, "start": 95, "tag": "CellFunction"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 0, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1340_4", "text": "PRC2 null OL lineage cells aberrantly induce Notch pathway genes and acquire astrocytic features.", "tags": [{"end": 87, "start": 77, "tag": "Cell"}, {"end": 12, "start": 10, "tag": "Cell"}, {"end": 58, "start": 45, "tag": "CellFunction"}, {"end": 26, "start": 10, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 64, "start": 45, "tag": "GeneOrGenome"}]}
{"id": "1340_5", "text": "The repression of the Notch pathway restores the myelination program and inhibits abnormal astrocytic differentiation in the PRC2-deficient OL lineage, indicating that Notch is a major target of PRC2.", "tags": [{"end": 14, "start": 4, "tag": "BiologicFunction"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 117, "start": 91, "tag": "CellFunction"}, {"end": 173, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 140, "tag": "Cell"}, {"end": 68, "start": 49, "tag": "CellFunction"}, {"end": 35, "start": 22, "tag": "CellFunction"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 117, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 125, "tag": "CellOrMolecularDysfunction"}, {"end": 199, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1340_6", "text": "Altogether, our studies propose a specific action of PRC2 as a novel gatekeeper that determines the glial fate choice and the timing of OL lineage progression and myelination by impinging on the Notch pathway.", "tags": [{"end": 132, "start": 126, "tag": "TemporalConcept"}, {"end": 146, "start": 136, "tag": "Cell"}, {"end": 174, "start": 163, "tag": "CellFunction"}, {"end": 105, "start": 100, "tag": "Cell"}, {"end": 158, "start": 147, "tag": "PathologicFunction"}, {"end": 158, "start": 147, "tag": "TemporalConcept"}, {"end": 208, "start": 195, "tag": "CellFunction"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 100, "tag": "CellFunction"}]}
{"id": "1341_0", "text": "Background: Abnormalities of myelin, which increases the efficiency of action potential conduction, are found in neurological disorders.", "tags": [{"end": 135, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 71, "tag": "CellFunction"}, {"end": 98, "start": 88, "tag": "BiologicFunction"}, {"end": 98, "start": 88, "tag": "NaturalPhenomenonOrProcess"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 12, "tag": "PathologicFunction"}]}
{"id": "1341_1", "text": "Korean Red Ginseng (KRG) demonstrates therapeutic efficacy against some of these conditions, however effects on oligodendrocyte (OL)s are not well known.", "tags": [{"end": 18, "start": 0, "tag": "Organism"}, {"end": 23, "start": 20, "tag": "Organism"}, {"end": 131, "start": 129, "tag": "Cell"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 58, "start": 38, "tag": "Finding"}]}
{"id": "1341_2", "text": "Here, we examined the effects of KRG-derived components on development and protection of OL-lineage cells.", "tags": [{"end": 32, "start": 22, "tag": "PathologicFunction"}, {"end": 91, "start": 89, "tag": "Cell"}, {"end": 105, "start": 89, "tag": "Cell"}, {"end": 70, "start": 59, "tag": "BiologicFunction"}, {"end": 70, "start": 59, "tag": "CellFunction"}, {"end": 36, "start": 33, "tag": "Organism"}]}
{"id": "1341_3", "text": "Methods: Primary OL precursor cell (OPC) cultures were prepared from neonatal mouse cortex.", "tags": [{"end": 49, "start": 41, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "Cell"}, {"end": 19, "start": 17, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 77, "start": 69, "tag": "TemporalConcept"}, {"end": 83, "start": 78, "tag": "Eukaryote"}, {"end": 34, "start": 9, "tag": "Cell"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1341_4", "text": "The protective efficacies of the KRG components were examined against inhibitors of mitochondrial respiratory chain activity.", "tags": [{"end": 36, "start": 33, "tag": "Organism"}, {"end": 80, "start": 70, "tag": "Chemical"}, {"end": 80, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 84, "tag": "CellComponent"}, {"end": 124, "start": 84, "tag": "CellFunction"}]}
{"id": "1341_5", "text": "For in vivo function of Rb1 on myelination, after 10 days of oral gavage into adult male mice, forebrains were collected.", "tags": [{"end": 27, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "GeneOrGenome"}, {"end": 72, "start": 61, "tag": "HealthCareActivity"}, {"end": 83, "start": 78, "tag": "PopulationGroup"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 105, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 84, "tag": "OrganismAttribute"}, {"end": 93, "start": 89, "tag": "Eukaryote"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "TemporalConcept"}, {"end": 72, "start": 61, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "Chemical"}]}
{"id": "1341_6", "text": "OPC proliferation were assessed by BrdU incorporation, and differentiation and myelination were examined by qPCR, western blot and immunocytochemistry.", "tags": [{"end": 112, "start": 108, "tag": "ResearchActivity"}, {"end": 126, "start": 114, "tag": "ResearchActivity"}, {"end": 150, "start": 131, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "CellFunction"}, {"end": 39, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 59, "tag": "CellFunction"}]}
{"id": "1341_7", "text": "Results: The non-saponin promoted OPC proliferation, while the saponin promoted differentiation.", "tags": [{"end": 70, "start": 63, "tag": "Chemical"}, {"end": 37, "start": 34, "tag": "Cell"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 24, "start": 13, "tag": "Chemical"}]}
{"id": "1341_8", "text": "Both processes were mediated by AKT and extracellular regulated kinase (ERK) signaling.", "tags": [{"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 77, "tag": "CellFunction"}, {"end": 70, "start": 40, "tag": "CellFunction"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 40, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1341_9", "text": "KRG extract, the saponin and non-saponin protected OPCs against oxidative stress, and both KRG extract and the saponin significantly increased the expression of the antioxidant enzyme.", "tags": [{"end": 3, "start": 0, "tag": "Organism"}, {"end": 11, "start": 4, "tag": "Substance"}, {"end": 24, "start": 17, "tag": "Chemical"}, {"end": 94, "start": 91, "tag": "Organism"}, {"end": 102, "start": 95, "tag": "Substance"}, {"end": 118, "start": 111, "tag": "Chemical"}, {"end": 80, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 51, "tag": "Cell"}, {"end": 176, "start": 165, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 165, "tag": "CellFunction"}, {"end": 142, "start": 119, "tag": "Finding"}, {"end": 40, "start": 29, "tag": "Chemical"}, {"end": 183, "start": 177, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1341_10", "text": "Among 11 major ginsenosides tested, Rb1 significantly increased OL membrane size in vitro.", "tags": [{"end": 27, "start": 15, "tag": "Chemical"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 66, "start": 64, "tag": "Cell"}, {"end": 75, "start": 67, "tag": "CellComponent"}, {"end": 63, "start": 40, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "OrganismAttribute"}, {"end": 39, "start": 36, "tag": "Chemical"}]}
{"id": "1341_11", "text": "Moreover, Rb1 significantly increased myelin formation in adult mouse brain.", "tags": [{"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 10, "tag": "GeneOrGenome"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 54, "start": 38, "tag": "CellFunction"}, {"end": 37, "start": 14, "tag": "Finding"}, {"end": 75, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 64, "tag": "Eukaryote"}, {"end": 13, "start": 10, "tag": "Chemical"}]}
{"id": "1341_12", "text": "Conclusion: All KRG components prevented OPC deaths under oxidative stress.", "tags": [{"end": 19, "start": 16, "tag": "Organism"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "Finding"}, {"end": 74, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 41, "tag": "Cell"}]}
{"id": "1341_13", "text": "While non-saponin promoted proliferation, saponin fraction increased differentiation and OL membrane size.", "tags": [{"end": 49, "start": 42, "tag": "Chemical"}, {"end": 91, "start": 89, "tag": "Cell"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 100, "start": 92, "tag": "CellComponent"}, {"end": 84, "start": 69, "tag": "CellFunction"}, {"end": 105, "start": 101, "tag": "OrganismAttribute"}]}
{"id": "1341_14", "text": "Furthermore, among all the tested ginsenosides, Rb1 showed the biggest increase in the membrane size and significantly enhanced myelination in vivo.", "tags": [{"end": 46, "start": 34, "tag": "Chemical"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "GeneOrGenome"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 100, "start": 96, "tag": "OrganismAttribute"}, {"end": 51, "start": 48, "tag": "Chemical"}]}
{"id": "1341_15", "text": "These results imply therapeutic potentials of KRG and Rb1 for myelin-related disorders.", "tags": [{"end": 49, "start": 46, "tag": "Organism"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "GeneOrGenome"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 54, "tag": "Chemical"}, {"end": 86, "start": 62, "tag": "DiseaseOrSyndrome"}]}
{"id": "1341_16", "text": "(C) 2021 The Korean Society of Ginseng.", "tags": []}
{"id": "1341_17", "text": "Publishing services by Elsevier B.V.", "tags": []}
{"id": "1342_0", "text": "Multiple sclerosis (MS) is the most frequent demyelinating disease and a leading cause for disability in young adults.", "tags": [{"end": 117, "start": 105, "tag": "PopulationGroup"}, {"end": 44, "start": 36, "tag": "TemporalConcept"}, {"end": 117, "start": 111, "tag": "PopulationGroup"}, {"end": 58, "start": 45, "tag": "PathologicFunction"}, {"end": 66, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "Finding"}]}
{"id": "1342_1", "text": "Despite significant advances in immunotherapies in recent years, disease progression still cannot be prevented.", "tags": [{"end": 47, "start": 32, "tag": "HealthCareActivity"}, {"end": 84, "start": 73, "tag": "PathologicFunction"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}, {"end": 63, "start": 58, "tag": "TemporalConcept"}, {"end": 63, "start": 51, "tag": "TemporalConcept"}, {"end": 84, "start": 65, "tag": "PathologicFunction"}, {"end": 28, "start": 20, "tag": "Finding"}]}
{"id": "1342_2", "text": "Remyelination, meaning the formation of new myelin sheaths after a demyelinating event, can fail in MS lesions.", "tags": [{"end": 80, "start": 67, "tag": "PathologicFunction"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 103, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 58, "start": 44, "tag": "CellComponent"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}]}
{"id": "1342_3", "text": "Impaired differentiation of progenitor cells into myelinating oligodendrocytes may contribute to remyelination failure and, therefore, the development of pharmacological approaches which promote oligodendroglial differentiation and by that remyelination, represents a promising new treatment approach.", "tags": [{"end": 61, "start": 50, "tag": "CellFunction"}, {"end": 169, "start": 154, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 78, "start": 62, "tag": "Cell"}, {"end": 118, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 24, "start": 9, "tag": "CellFunction"}, {"end": 227, "start": 212, "tag": "CellFunction"}, {"end": 78, "start": 50, "tag": "Cell"}, {"end": 44, "start": 28, "tag": "Cell"}, {"end": 118, "start": 111, "tag": "IndividualBehavior"}, {"end": 211, "start": 195, "tag": "Cell"}, {"end": 150, "start": 139, "tag": "BiologicFunction"}, {"end": 150, "start": 139, "tag": "CellFunction"}, {"end": 291, "start": 282, "tag": "HealthCareActivity"}, {"end": 291, "start": 282, "tag": "ResearchActivity"}, {"end": 180, "start": 154, "tag": "HealthCareActivity"}, {"end": 110, "start": 97, "tag": "CellFunction"}, {"end": 253, "start": 240, "tag": "CellFunction"}]}
{"id": "1342_4", "text": "However, this generally accepted concept has been challenged recently.", "tags": [{"end": 69, "start": 61, "tag": "TemporalConcept"}]}
{"id": "1342_5", "text": "To further understand mechanisms contributing to remyelination failure in MS, we combined detailed histological analyses assessing oligodendroglial cell numbers, presence of remyelination as well as the inflammatory environment in different MS lesion types in white matter with in vitro experiments using induced-pluripotent stem cell (iPSC)-derived oligodendrocytes (hiOL) and supernatants from polarized human microglia.", "tags": [{"end": 390, "start": 378, "tag": "CellComponent"}, {"end": 298, "start": 287, "tag": "ResearchActivity"}, {"end": 340, "start": 336, "tag": "Cell"}, {"end": 366, "start": 350, "tag": "Cell"}, {"end": 250, "start": 244, "tag": "InjuryOrPoisoning"}, {"end": 70, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 272, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 63, "tag": "IndividualBehavior"}, {"end": 215, "start": 203, "tag": "PathologicFunction"}, {"end": 147, "start": 131, "tag": "Cell"}, {"end": 152, "start": 131, "tag": "Cell"}, {"end": 411, "start": 406, "tag": "Eukaryote"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 334, "start": 330, "tag": "Cell"}, {"end": 421, "start": 412, "tag": "Cell"}, {"end": 405, "start": 396, "tag": "Cell"}, {"end": 286, "start": 278, "tag": "ResearchActivity"}, {"end": 120, "start": 99, "tag": "ResearchActivity"}, {"end": 62, "start": 49, "tag": "CellFunction"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 334, "start": 305, "tag": "Cell"}]}
{"id": "1342_6", "text": "Our findings suggest that there are multiple reasons for remyelination failure in MS which are dependent on lesion stage.", "tags": [{"end": 114, "start": 108, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 71, "tag": "IndividualBehavior"}, {"end": 70, "start": 57, "tag": "CellFunction"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}]}
{"id": "1342_7", "text": "These include lack of myelin sheath formation despite the presence of mature oligodendrocytes in a subset of active lesions as well as oligodendroglial loss and a hostile tissue environment in mixed active/inactive lesions.", "tags": [{"end": 156, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 93, "start": 77, "tag": "Cell"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 116, "tag": "InjuryOrPoisoning"}, {"end": 222, "start": 215, "tag": "InjuryOrPoisoning"}, {"end": 93, "start": 70, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 151, "start": 135, "tag": "Cell"}, {"end": 177, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 22, "tag": "CellComponent"}, {"end": 66, "start": 58, "tag": "Finding"}, {"end": 45, "start": 14, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1342_8", "text": "Therefore, we conclude that better in vivo and in vitro models which mimic the pathological hallmarks of the different MS lesion types are required for the successful development of remyelination promoting drugs.", "tags": [{"end": 101, "start": 79, "tag": "Finding"}, {"end": 128, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 178, "start": 167, "tag": "BiologicFunction"}, {"end": 178, "start": 167, "tag": "CellFunction"}, {"end": 62, "start": 56, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 211, "start": 206, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 35, "tag": "ResearchActivity"}, {"end": 195, "start": 182, "tag": "CellFunction"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}]}
{"id": "1343_0", "text": "The high-mobility-group domain-containing transcription factor Sox9 confers glial competence to neuroepithelial precursors in the developing central nervous system and is an important determinant of astroglial and oligodendroglial specification.", "tags": [{"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 199, "tag": "Cell"}, {"end": 62, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 76, "tag": "Cell"}, {"end": 230, "start": 214, "tag": "Cell"}, {"end": 163, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 96, "tag": "Cell"}, {"end": 30, "start": 4, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1343_1", "text": "In oligodendroglial cells, it remains expressed in oligodendrocyte progenitor cells (OPCs) of the developing nervous system, but is shut off in differentiating oligodendrocytes as well as in OPCs that persist in the adult nervous system.", "tags": [{"end": 176, "start": 144, "tag": "Cell"}, {"end": 89, "start": 85, "tag": "Cell"}, {"end": 195, "start": 191, "tag": "Cell"}, {"end": 83, "start": 51, "tag": "Cell"}, {"end": 25, "start": 3, "tag": "Cell"}, {"end": 221, "start": 216, "tag": "PopulationGroup"}, {"end": 47, "start": 38, "tag": "CellFunction"}, {"end": 123, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1343_2", "text": "To better understand the role of Sox9 in OPCs, we generated mouse models that allowed oligodendroglial expression of a Sox9 transgene during development or in the adult.", "tags": [{"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "GeneOrGenome"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "GeneOrGenome"}, {"end": 72, "start": 60, "tag": "ResearchActivity"}, {"end": 45, "start": 41, "tag": "Cell"}, {"end": 102, "start": 86, "tag": "Cell"}, {"end": 152, "start": 141, "tag": "BiologicFunction"}, {"end": 152, "start": 141, "tag": "CellFunction"}, {"end": 113, "start": 103, "tag": "CellFunction"}, {"end": 168, "start": 163, "tag": "PopulationGroup"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1343_3", "text": "With transgene expression beginning in the last trimester of pregnancy, the number of OPCs increased dramatically, followed by comparable gains in the number of pre-myelinating and myelinating oligodendrocytes as assessed by marker gene expression.", "tags": [{"end": 14, "start": 5, "tag": "GeneOrGenome"}, {"end": 57, "start": 48, "tag": "TemporalConcept"}, {"end": 209, "start": 193, "tag": "Cell"}, {"end": 176, "start": 161, "tag": "Cell"}, {"end": 90, "start": 86, "tag": "Cell"}, {"end": 209, "start": 181, "tag": "Cell"}, {"end": 231, "start": 225, "tag": "ClinicalAttribute"}, {"end": 247, "start": 232, "tag": "CellFunction"}, {"end": 25, "start": 15, "tag": "CellFunction"}, {"end": 70, "start": 61, "tag": "BiologicFunction"}]}
{"id": "1343_4", "text": "This argues that Sox9 boosts oligodendrogenesis during ontogenetic development at all stages, including terminal oligodendrocyte differentiation.", "tags": [{"end": 21, "start": 17, "tag": "GeneOrGenome"}, {"end": 21, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 29, "tag": "BiologicFunction"}, {"end": 144, "start": 104, "tag": "CellFunction"}, {"end": 78, "start": 55, "tag": "BiologicFunction"}, {"end": 128, "start": 113, "tag": "Cell"}, {"end": 92, "start": 86, "tag": "TemporalConcept"}, {"end": 21, "start": 17, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1343_5", "text": "When Sox9 transgene expression started in the adult, many transgene-expressing OPCs failed to maintain their progenitor cell identity and instead converted into myelinating oligodendrocytes.", "tags": [{"end": 9, "start": 5, "tag": "GeneOrGenome"}, {"end": 9, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 10, "tag": "GeneOrGenome"}, {"end": 133, "start": 125, "tag": "BiologicFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 78, "start": 68, "tag": "CellFunction"}, {"end": 189, "start": 173, "tag": "Cell"}, {"end": 83, "start": 79, "tag": "Cell"}, {"end": 189, "start": 161, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 30, "start": 20, "tag": "CellFunction"}, {"end": 51, "start": 46, "tag": "PopulationGroup"}, {"end": 9, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "GeneOrGenome"}]}
{"id": "1343_6", "text": "As infrequent and inefficient differentiation of adult OPCs is one of the main obstacles to effective remyelination in demyelinating diseases such as Multiple Sclerosis, increased Sox9 levels in adult OPCs may substantially increase their remyelination capacity.", "tags": [{"end": 184, "start": 180, "tag": "GeneOrGenome"}, {"end": 184, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 3, "tag": "TemporalConcept"}, {"end": 59, "start": 55, "tag": "Cell"}, {"end": 205, "start": 201, "tag": "Cell"}, {"end": 141, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 119, "tag": "PathologicFunction"}, {"end": 45, "start": 30, "tag": "CellFunction"}, {"end": 168, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 253, "tag": "Finding"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 252, "start": 239, "tag": "CellFunction"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 200, "start": 195, "tag": "PopulationGroup"}, {"end": 184, "start": 180, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1344_0", "text": "Multiple sclerosis (MS) is an autoimmune inflammatory disease characterized by demyelination, axonal loss, and synaptic impairment in the central nervous system (CNS).", "tags": [{"end": 105, "start": 94, "tag": "PathologicFunction"}, {"end": 100, "start": 94, "tag": "CellComponent"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 119, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 79, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "PathologicFunction"}, {"end": 61, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 111, "tag": "PathologicFunction"}]}
{"id": "1344_1", "text": "The available therapies aim to reduce the severity of the pathology during the early inflammatory stages, but they are not effective in the chronic stage of the disease.", "tags": [{"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 67, "start": 58, "tag": "PathologicFunction"}, {"end": 67, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 42, "tag": "ClinicalAttribute"}, {"end": 50, "start": 42, "tag": "Finding"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 147, "start": 140, "tag": "TemporalConcept"}]}
{"id": "1344_2", "text": "In this phase, failure in endogenous remyelination is associated with the impairment of oligodendrocytes progenitor cells (OPCs) to migrate and differentiate into mature myelinating oligodendrocytes.", "tags": [{"end": 84, "start": 74, "tag": "Finding"}, {"end": 181, "start": 170, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "TemporalConcept"}, {"end": 104, "start": 88, "tag": "Cell"}, {"end": 198, "start": 182, "tag": "Cell"}, {"end": 127, "start": 123, "tag": "Cell"}, {"end": 157, "start": 144, "tag": "CellFunction"}, {"end": 198, "start": 170, "tag": "Cell"}, {"end": 121, "start": 105, "tag": "Cell"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 22, "start": 15, "tag": "IndividualBehavior"}, {"end": 198, "start": 163, "tag": "Cell"}, {"end": 50, "start": 37, "tag": "CellFunction"}]}
{"id": "1344_3", "text": "Therefore, stimulating differentiation of OPCs into myelinating oligodendrocytes has become one of the main goals of new therapeutic approaches for MS.", "tags": [{"end": 22, "start": 11, "tag": "NaturalPhenomenonOrProcess"}, {"end": 63, "start": 52, "tag": "CellFunction"}, {"end": 80, "start": 64, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "Cell"}, {"end": 38, "start": 23, "tag": "CellFunction"}, {"end": 80, "start": 52, "tag": "Cell"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 121, "tag": "HealthCareActivity"}]}
{"id": "1344_4", "text": "Different disease-modifying therapies targeting sphingosine-1-phosphate receptors (S1PRs) have been approved or are being developed to treat MS.", "tags": [{"end": 81, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 10, "tag": "HealthCareActivity"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 48, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1344_5", "text": "Besides their immunomodulatory effects, growing evidence suggests that targeting S1PRs modulates mechanisms beyond immunomodulation, such as remyelination.", "tags": [{"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 115, "tag": "BiologicFunction"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}, {"end": 131, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 40, "tag": "Finding"}, {"end": 56, "start": 48, "tag": "Finding"}, {"end": 154, "start": 141, "tag": "CellFunction"}, {"end": 38, "start": 31, "tag": "Finding"}, {"end": 38, "start": 14, "tag": "Finding"}, {"end": 30, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 14, "tag": "BiologicFunction"}, {"end": 30, "start": 14, "tag": "HealthCareActivity"}]}
{"id": "1344_6", "text": "In this context, this review focuses on the current understanding of S1PR modulators and their direct effect on OPCs and oligodendrocytes.", "tags": [{"end": 137, "start": 121, "tag": "Cell"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 108, "start": 102, "tag": "Finding"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 51, "start": 44, "tag": "TemporalConcept"}, {"end": 65, "start": 52, "tag": "BiologicFunction"}, {"end": 84, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_0", "text": "Introduction: Semaphorin 3A (Sema 3A) is a secreted protein, which plays an integral part in developing the nervous syslem.", "tags": [{"end": 27, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 14, "tag": "GeneOrGenome"}, {"end": 36, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "GeneOrGenome"}, {"end": 27, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_1", "text": "It has collapse activity on the growth cone of dorsal root ganglia After the development of the nervous sysclem, Sema 3A expression decreases.", "tags": [{"end": 43, "start": 32, "tag": "CellComponent"}, {"end": 66, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 113, "tag": "GeneOrGenome"}, {"end": 38, "start": 32, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 24, "start": 7, "tag": "CellFunction"}, {"end": 120, "start": 113, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_2", "text": "Neuropilin 1 is a membrane receptor of Sema 3A.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 35, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 26, "start": 18, "tag": "CellComponent"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_3", "text": "When semaphorin binds to neuropilin 1, the recruitment of oligodendrocyte precursor cells to the demyelinated site decreases.", "tags": [{"end": 15, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 5, "tag": "GeneOrGenome"}, {"end": 37, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 25, "tag": "GeneOrGenome"}, {"end": 109, "start": 97, "tag": "PathologicFunction"}, {"end": 89, "start": 74, "tag": "Cell"}, {"end": 83, "start": 58, "tag": "Cell"}, {"end": 89, "start": 58, "tag": "Cell"}, {"end": 15, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 25, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_4", "text": "In Multiple Sclerosis (MS), Sema 3A expression increases and inhibits oligodendrocyte precursor cell differentiation.", "tags": [{"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 28, "tag": "GeneOrGenome"}, {"end": 100, "start": 70, "tag": "Cell"}, {"end": 95, "start": 70, "tag": "Cell"}, {"end": 116, "start": 70, "tag": "CellFunction"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "CellFunction"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_5", "text": "Therefore, the remyelination of axons gets impaired.", "tags": [{"end": 37, "start": 32, "tag": "CellComponent"}, {"end": 28, "start": 15, "tag": "CellFunction"}]}
{"id": "1345_6", "text": "We hypothesized that the function of Sema 3A could be inhibited by neutralizing its binding to membrane NRP1.", "tags": [{"end": 44, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 37, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 95, "tag": "CellComponent"}, {"end": 91, "start": 84, "tag": "CellFunction"}, {"end": 44, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 104, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_7", "text": "Methods: we cloned a soluble form of mouse Neuropilin 1 (msNRP1) in a lentiviral vector and expressed the recombinant protein in HEK293T cells.", "tags": [{"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 28, "start": 21, "tag": "CellComponent"}, {"end": 125, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 129, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "Eukaryote"}, {"end": 101, "start": 92, "tag": "CellFunction"}, {"end": 55, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 57, "tag": "GeneOrGenome"}, {"end": 87, "start": 70, "tag": "Virus"}, {"end": 87, "start": 70, "tag": "ResearchActivity"}]}
{"id": "1345_8", "text": "Then, the conditioned medium of the transduced cells was used to evaluate the effects of the msNRP1 on the inhibition of Sema 3A-induced growth cone collapse activity.", "tags": [{"end": 28, "start": 10, "tag": "Chemical"}, {"end": 128, "start": 121, "tag": "GeneOrGenome"}, {"end": 128, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 137, "tag": "BiologicFunction"}, {"end": 117, "start": 107, "tag": "CellFunction"}, {"end": 52, "start": 36, "tag": "Cell"}, {"end": 52, "start": 36, "tag": "ResearchActivity"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 128, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 137, "tag": "CellFunction"}, {"end": 148, "start": 137, "tag": "CellComponent"}]}
{"id": "1345_9", "text": "Dorsal root ganglion explants of timed pregnant (E13) mice were prepared.", "tags": [{"end": 20, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "TemporalConcept"}, {"end": 58, "start": 54, "tag": "Eukaryote"}, {"end": 47, "start": 33, "tag": "Eukaryote"}]}
{"id": "1345_10", "text": "Then, the growth cone collapse activity of Sema 3A was assessed in the presence and absence of msNRP1-containing conditioned media of transduced and non-transduced HEK293T cells.", "tags": [{"end": 39, "start": 10, "tag": "CellFunction"}, {"end": 50, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 43, "tag": "GeneOrGenome"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 130, "start": 113, "tag": "Chemical"}, {"end": 16, "start": 10, "tag": "BiologicFunction"}, {"end": 177, "start": 164, "tag": "Cell"}, {"end": 21, "start": 10, "tag": "CellComponent"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 95, "tag": "GeneOrGenome"}, {"end": 177, "start": 172, "tag": "ResearchActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 177, "start": 172, "tag": "ResearchActivity"}, {"end": 163, "start": 149, "tag": "ResearchActivity"}]}
{"id": "1345_11", "text": "Comparisons between groups were performed by 1-way ANOVA and post hoc Tukey teas.", "tags": [{"end": 75, "start": 61, "tag": "ResearchActivity"}, {"end": 56, "start": 45, "tag": "ResearchActivity"}]}
{"id": "1345_12", "text": "Results: msNRP1 was successfully cloned and transduced in HEK293T cells.", "tags": [{"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 54, "start": 44, "tag": "ResearchActivity"}, {"end": 71, "start": 58, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "GeneOrGenome"}]}
{"id": "1345_13", "text": "The supematant of transduced cells was concentrated and evaluated for the production of msNRP1.", "tags": [{"end": 34, "start": 18, "tag": "Cell"}, {"end": 14, "start": 4, "tag": "Chemical"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "GeneOrGenome"}]}
{"id": "1345_14", "text": "ELISA results indicated that transduced cells secreted msNRP1.", "tags": [{"end": 45, "start": 29, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "GeneOrGenome"}]}
{"id": "1345_15", "text": "Growth cone collapse assay showed that Sema 3A activity was significantly reduced in the presence of the conditioned medium of msNRP1-transduced HEK293T cells.", "tags": [{"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 97, "start": 89, "tag": "Finding"}, {"end": 123, "start": 105, "tag": "Chemical"}, {"end": 158, "start": 134, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellComponent"}, {"end": 26, "start": 0, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "CellFunction"}, {"end": 133, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 127, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "CellFunction"}]}
{"id": "1345_16", "text": "Conversely, a conditioned medium of non-transduced HEK293T cells could not effectively prevent Sema 3A growth cone collapse activity.", "tags": [{"end": 32, "start": 14, "tag": "Chemical"}, {"end": 102, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 95, "tag": "GeneOrGenome"}, {"end": 132, "start": 103, "tag": "CellFunction"}, {"end": 64, "start": 36, "tag": "Cell"}, {"end": 102, "start": 95, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_17", "text": "Conclusion: Our results indicated that msNRP1 was successfully produced in HEK293T cells.", "tags": [{"end": 88, "start": 75, "tag": "Cell"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 39, "tag": "GeneOrGenome"}]}
{"id": "1345_18", "text": "The secreted msNRP1 effectively prevented Sema 3A collapse activity.", "tags": [{"end": 49, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 42, "tag": "GeneOrGenome"}, {"end": 19, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "GeneOrGenome"}, {"end": 67, "start": 50, "tag": "CellFunction"}, {"end": 49, "start": 42, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1345_19", "text": "Therefore, msNRP1 can increase remyelination in MS lesions, although more studies using animal models are required.", "tags": [{"end": 44, "start": 31, "tag": "CellFunction"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 51, "tag": "InjuryOrPoisoning"}, {"end": 101, "start": 88, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "GeneOrGenome"}]}
{"id": "1346_0", "text": "Remyelination, namely, the formation of new myelin sheaths around denuded axons, counteracts axonal degeneration and restores neuronal function.", "tags": [{"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 143, "start": 126, "tag": "CellFunction"}, {"end": 79, "start": 74, "tag": "CellComponent"}, {"end": 58, "start": 44, "tag": "CellComponent"}, {"end": 112, "start": 93, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1346_1", "text": "Considerable advances have been made in understanding this regenerative process that often fails in diseases like multiple sclerosis, leaving axons demyelinated and vulnerable to damage, thus contributing to disease progression.", "tags": [{"end": 160, "start": 148, "tag": "PathologicFunction"}, {"end": 147, "start": 142, "tag": "CellComponent"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 53, "start": 40, "tag": "BiologicFunction"}, {"end": 227, "start": 216, "tag": "PathologicFunction"}, {"end": 227, "start": 216, "tag": "TemporalConcept"}, {"end": 132, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 208, "tag": "PathologicFunction"}]}
{"id": "1346_2", "text": "The identification of the membrane receptor GPR17 on a subset of oligodendrocyte precursor cells (OPCs), which mediate remyelination in the adult central nervous system (CNS), has led to a huge amount of evidence that validated this receptor as a new attractive target for remyelinating therapies.", "tags": [{"end": 43, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 44, "tag": "GeneOrGenome"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 173, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 119, "tag": "CellFunction"}, {"end": 102, "start": 98, "tag": "Cell"}, {"end": 296, "start": 273, "tag": "HealthCareActivity"}, {"end": 96, "start": 65, "tag": "Cell"}, {"end": 241, "start": 233, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 204, "tag": "Finding"}, {"end": 168, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 268, "start": 247, "tag": "Finding"}]}
{"id": "1346_3", "text": "Here, we summarize the role of GPR17 in OPC function, myelination and remyelination, describing its atypical pharmacology, its downstream signaling, and the genetic and epigenetic factors modulating its activity.", "tags": [{"end": 36, "start": 31, "tag": "GeneOrGenome"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 100, "tag": "Finding"}, {"end": 121, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 157, "tag": "HealthCareActivity"}, {"end": 83, "start": 70, "tag": "CellFunction"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 65, "start": 54, "tag": "CellFunction"}, {"end": 147, "start": 127, "tag": "CellFunction"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 169, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1346_4", "text": "We also highlight crucial insights into GPR17 pathophysiology coming from the demonstration that oligodendrocyte injury, associated with inflammation in chronic neurodegenerative conditions, is invariably characterized by abnormal and persistent GPR17 upregulation, which, in turn, is accompanied by a block of OPCs at immature premyelinating stages.", "tags": [{"end": 45, "start": 40, "tag": "GeneOrGenome"}, {"end": 45, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 222, "tag": "Finding"}, {"end": 245, "start": 235, "tag": "TemporalConcept"}, {"end": 251, "start": 246, "tag": "GeneOrGenome"}, {"end": 251, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 264, "start": 252, "tag": "CellFunction"}, {"end": 307, "start": 302, "tag": "Finding"}, {"end": 327, "start": 319, "tag": "BiologicFunction"}, {"end": 349, "start": 343, "tag": "TemporalConcept"}, {"end": 315, "start": 311, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 189, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 153, "tag": "TemporalConcept"}, {"end": 119, "start": 113, "tag": "InjuryOrPoisoning"}, {"end": 149, "start": 137, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 45, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 251, "start": 246, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1346_5", "text": "Finally, we discuss the current literature in light of the potential exploitment of GPR17 as a therapeutic target to promote remyelination.", "tags": [{"end": 89, "start": 84, "tag": "GeneOrGenome"}, {"end": 89, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 32, "tag": "ResearchActivity"}, {"end": 138, "start": 125, "tag": "CellFunction"}, {"end": 31, "start": 24, "tag": "TemporalConcept"}, {"end": 89, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 95, "tag": "Finding"}]}
{"id": "1347_0", "text": "Biological inflammation induced during penetrating cortical injury can disrupt functional neuronal and glial activity within the cortex, resulting in potential recording failure of chronically implanted neural interfaces.", "tags": [{"end": 220, "start": 193, "tag": "ManufacturedObject"}, {"end": 177, "start": 170, "tag": "IndividualBehavior"}, {"end": 108, "start": 103, "tag": "Cell"}, {"end": 98, "start": 90, "tag": "Cell"}, {"end": 23, "start": 11, "tag": "PathologicFunction"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 117, "start": 103, "tag": "CellFunction"}]}
{"id": "1347_1", "text": "Oligodendrocytes provide critical support for neuronal health and function through direct contact with neuronal soma and axons within the cortex.", "tags": [{"end": 116, "start": 103, "tag": "CellComponent"}, {"end": 126, "start": 121, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 54, "start": 46, "tag": "Cell"}, {"end": 111, "start": 103, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}]}
{"id": "1347_2", "text": "Given their fundamental role to regulate neuronal activity via myelin, coupled with their heightened vulnerability to metabolic brain injury due to high energetic demands, oligodendrocytes are hypothesized as a possible source of biological failure in declining recording performances of intracortical microelectrode devices.", "tags": [{"end": 114, "start": 101, "tag": "ClinicalAttribute"}, {"end": 248, "start": 230, "tag": "Finding"}, {"end": 188, "start": 172, "tag": "Cell"}, {"end": 69, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 248, "start": 241, "tag": "IndividualBehavior"}, {"end": 58, "start": 41, "tag": "CellFunction"}, {"end": 133, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "Cell"}, {"end": 152, "start": 148, "tag": "Finding"}, {"end": 140, "start": 134, "tag": "InjuryOrPoisoning"}, {"end": 127, "start": 118, "tag": "InjuryOrPoisoning"}, {"end": 301, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 324, "start": 302, "tag": "ManufacturedObject"}, {"end": 284, "start": 262, "tag": "Finding"}]}
{"id": "1347_3", "text": "To determine the extent of their contribution to neuronal activity and function, a cuprizone-inducible model of oligodendrocyte depletion and demyelination in mice was performed prior to microelectrode implantation.", "tags": [{"end": 92, "start": 83, "tag": "Chemical"}, {"end": 66, "start": 49, "tag": "CellFunction"}, {"end": 163, "start": 159, "tag": "Eukaryote"}, {"end": 57, "start": 49, "tag": "Cell"}, {"end": 108, "start": 103, "tag": "ResearchActivity"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 155, "start": 142, "tag": "PathologicFunction"}, {"end": 201, "start": 187, "tag": "ManufacturedObject"}, {"end": 214, "start": 202, "tag": "ResearchActivity"}, {"end": 214, "start": 202, "tag": "HealthCareActivity"}]}
{"id": "1347_4", "text": "At 5 weeks of cuprizone exposure, mice demonstrated significantly reduced cortical oligodendrocyte density and myelin expression.", "tags": [{"end": 32, "start": 14, "tag": "InjuryOrPoisoning"}, {"end": 117, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 14, "tag": "Chemical"}, {"end": 10, "start": 5, "tag": "TemporalConcept"}, {"end": 128, "start": 111, "tag": "CellFunction"}, {"end": 38, "start": 34, "tag": "Eukaryote"}, {"end": 128, "start": 118, "tag": "CellFunction"}, {"end": 82, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 83, "tag": "Cell"}, {"end": 106, "start": 83, "tag": "ClinicalAttribute"}]}
{"id": "1347_5", "text": "Mice were then implanted with functional recording microelectrodes in the visual cortex and neuronal activity was evaluated up to 7 weeks alongside continued cuprizone administration.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 87, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 158, "tag": "Chemical"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 109, "start": 92, "tag": "CellFunction"}, {"end": 182, "start": 168, "tag": "HealthCareActivity"}, {"end": 66, "start": 51, "tag": "ManufacturedObject"}]}
{"id": "1347_6", "text": "Cuprizone-induced oligodendrocyte loss and demyelination was associated with significantly reduced recording performances at the onset of implantation, which remained relatively stable over time.", "tags": [{"end": 150, "start": 138, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 38, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 134, "start": 129, "tag": "TemporalConcept"}, {"end": 194, "start": 190, "tag": "TemporalConcept"}, {"end": 56, "start": 43, "tag": "PathologicFunction"}, {"end": 150, "start": 138, "tag": "ResearchActivity"}, {"end": 121, "start": 99, "tag": "Finding"}]}
{"id": "1347_7", "text": "In contast, recording performances for mice on a normal diet were intially elevated before decreasing over time to the recording level of tcuprizone-treated mice.", "tags": [{"end": 101, "start": 91, "tag": "Finding"}, {"end": 60, "start": 49, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "HealthCareActivity"}, {"end": 43, "start": 39, "tag": "Eukaryote"}, {"end": 161, "start": 157, "tag": "Eukaryote"}, {"end": 111, "start": 107, "tag": "TemporalConcept"}, {"end": 55, "start": 49, "tag": "Finding"}, {"end": 34, "start": 12, "tag": "Finding"}]}
{"id": "1347_8", "text": "Further electro-physiological analysis revealed deficits in multi-unit firing rates, frequency-dependent disruptions in neuronal oscillations, and altered laminar communication within the cortex of cuprizone-treated mice.", "tags": [{"end": 94, "start": 85, "tag": "TemporalConcept"}, {"end": 207, "start": 198, "tag": "Chemical"}, {"end": 56, "start": 48, "tag": "Finding"}, {"end": 38, "start": 8, "tag": "ResearchActivity"}, {"end": 220, "start": 216, "tag": "Eukaryote"}, {"end": 128, "start": 120, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 60, "tag": "ResearchActivity"}, {"end": 176, "start": 155, "tag": "BiologicFunction"}, {"end": 141, "start": 120, "tag": "CellFunction"}]}
{"id": "1347_9", "text": "Post-mortem immunohistochemistry revealed robust depletion of oligodendrocytes around implanted microelectrode arrays alongside comparable neuronal densities to control mice, suggesting that oligodendrocyte loss was a possible contributor to chronically impaired device performances.", "tags": [{"end": 157, "start": 139, "tag": "ClinicalAttribute"}, {"end": 78, "start": 62, "tag": "Cell"}, {"end": 211, "start": 191, "tag": "CellOrMolecularDysfunction"}, {"end": 173, "start": 169, "tag": "Eukaryote"}, {"end": 32, "start": 12, "tag": "ResearchActivity"}, {"end": 117, "start": 96, "tag": "ManufacturedObject"}, {"end": 11, "start": 0, "tag": "TemporalConcept"}, {"end": 269, "start": 263, "tag": "ManufacturedObject"}]}
{"id": "1347_10", "text": "This study highlights potentially significant contributions from the oligodendrocyte lineage population concerning the biological integration and long-term functional performance of neural interfacing technology.", "tags": [{"end": 178, "start": 156, "tag": "OrganismAttribute"}, {"end": 155, "start": 146, "tag": "TemporalConcept"}, {"end": 92, "start": 69, "tag": "Cell"}, {"end": 141, "start": 130, "tag": "CellFunction"}, {"end": 141, "start": 130, "tag": "MachineActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 103, "start": 93, "tag": "PopulationGroup"}, {"end": 178, "start": 167, "tag": "ClinicalAttribute"}, {"end": 178, "start": 167, "tag": "Finding"}, {"end": 141, "start": 119, "tag": "BiologicFunction"}, {"end": 211, "start": 182, "tag": "ResearchActivity"}]}
{"id": "1348_0", "text": "Background Multiple sclerosis is characterised by inflammation, oligodendrocyte loss and axonal demyelination and shows an additional impact on astrocytes, and their polarization.", "tags": [{"end": 109, "start": 89, "tag": "PathologicFunction"}, {"end": 178, "start": 166, "tag": "ClinicalAttribute"}, {"end": 178, "start": 166, "tag": "CellFunction"}, {"end": 95, "start": 89, "tag": "CellComponent"}, {"end": 154, "start": 144, "tag": "Cell"}, {"end": 109, "start": 96, "tag": "PathologicFunction"}, {"end": 29, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 50, "tag": "PathologicFunction"}, {"end": 84, "start": 64, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1348_1", "text": "Although a certain degree of spontaneous myelin repair can be observed, disease progression, and aging impair regeneration efforts highlighting the need to better understand glial cell dynamics to establish specific regenerative treatments.", "tags": [{"end": 184, "start": 174, "tag": "Cell"}, {"end": 122, "start": 110, "tag": "BiologicFunction"}, {"end": 122, "start": 110, "tag": "HealthCareActivity"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 179, "start": 174, "tag": "Cell"}, {"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}, {"end": 102, "start": 97, "tag": "BiologicFunction"}, {"end": 102, "start": 97, "tag": "CellFunction"}, {"end": 54, "start": 48, "tag": "BiologicFunction"}, {"end": 54, "start": 48, "tag": "HealthCareActivity"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 72, "tag": "PathologicFunction"}, {"end": 193, "start": 185, "tag": "NaturalPhenomenonOrProcess"}, {"end": 239, "start": 216, "tag": "HealthCareActivity"}, {"end": 239, "start": 216, "tag": "ResearchActivity"}]}
{"id": "1348_2", "text": "Methods Applying a chronic demyelination model, we here analysed demyelination and remyelination related effects on astrocytes and stem cell niches and studied the consequences of medrysone application on myelin repair, and astrocyte polarization.", "tags": [{"end": 140, "start": 131, "tag": "Cell"}, {"end": 189, "start": 180, "tag": "Chemical"}, {"end": 246, "start": 234, "tag": "ClinicalAttribute"}, {"end": 246, "start": 224, "tag": "CellFunction"}, {"end": 126, "start": 116, "tag": "Cell"}, {"end": 96, "start": 83, "tag": "CellFunction"}, {"end": 233, "start": 224, "tag": "Cell"}, {"end": 218, "start": 205, "tag": "CellFunction"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 40, "start": 27, "tag": "PathologicFunction"}, {"end": 78, "start": 65, "tag": "PathologicFunction"}, {"end": 26, "start": 19, "tag": "TemporalConcept"}, {"end": 218, "start": 212, "tag": "BiologicFunction"}, {"end": 218, "start": 212, "tag": "HealthCareActivity"}, {"end": 211, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 180, "tag": "PharmacologicSubstance"}]}
{"id": "1348_3", "text": "Findings Medrysone induced recovery of mature oligodendrocytes, myelin expression and node formation.", "tags": [{"end": 18, "start": 9, "tag": "Chemical"}, {"end": 62, "start": 39, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "BiologicFunction"}, {"end": 35, "start": 27, "tag": "HealthCareActivity"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 81, "start": 64, "tag": "CellFunction"}, {"end": 100, "start": 86, "tag": "CellFunction"}]}
{"id": "1348_4", "text": "In addition, C3d/S100a10 co-expression in astrocytes was enhanced.", "tags": [{"end": 52, "start": 42, "tag": "Cell"}, {"end": 24, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 17, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 25, "tag": "CellFunction"}]}
{"id": "1348_5", "text": "Moreover, Timp1 expression in C3d positive astrocytes revealed another astrocytic phenotype with a myelination promoting character.", "tags": [{"end": 15, "start": 10, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "Cell"}, {"end": 53, "start": 43, "tag": "Cell"}, {"end": 91, "start": 82, "tag": "OrganismAttribute"}, {"end": 110, "start": 99, "tag": "CellFunction"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1348_6", "text": "Interpretation Based on these findings, specific astrocyte subpopulations are suggested to act in a myelin regenerative way and manner the regulation of which can be positively modulated by this corticosteroid.", "tags": [{"end": 209, "start": 195, "tag": "Chemical"}, {"end": 209, "start": 195, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 49, "tag": "Cell"}, {"end": 106, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 195, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1348_7", "text": "Copyright (C) 2022 The Authors.", "tags": []}
{"id": "1348_8", "text": "Published by Elsevier B.V.", "tags": []}
{"id": "1349_0", "text": "Chronic cerebral hypoperfusion (CCH) may amplify the neurotoxicity of nanoscale particulate matter (nPM), resulting in white matter injury.", "tags": [{"end": 138, "start": 119, "tag": "Finding"}, {"end": 131, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 30, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 70, "tag": "Substance"}, {"end": 103, "start": 100, "tag": "Substance"}]}
{"id": "1349_1", "text": "This study characterized the joint effects of nPM (diameter <= 200 nm) and CCH secondary to bilateral carotid artery stenosis (BCAS) exposure on neuronal and white matter injury in a murine model.", "tags": [{"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 127, "tag": "PathologicFunction"}, {"end": 141, "start": 133, "tag": "InjuryOrPoisoning"}, {"end": 125, "start": 92, "tag": "InjuryOrPoisoning"}, {"end": 177, "start": 158, "tag": "Finding"}, {"end": 170, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 153, "start": 145, "tag": "Cell"}, {"end": 195, "start": 190, "tag": "ResearchActivity"}, {"end": 189, "start": 183, "tag": "Eukaryote"}, {"end": 42, "start": 35, "tag": "Finding"}, {"end": 49, "start": 46, "tag": "Substance"}, {"end": 125, "start": 92, "tag": "PathologicFunction"}, {"end": 78, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 127, "tag": "DiseaseOrSyndrome"}]}
{"id": "1349_2", "text": "nPM was collected near a highway and re-aerosolized for exposure.", "tags": [{"end": 3, "start": 0, "tag": "Substance"}]}
{"id": "1349_3", "text": "Ten-week-old C57BL/6 male mice were randomized into four groups: filtered air (FA), nPM, FA + BCAS, and nPM + BCAS.", "tags": [{"end": 46, "start": 36, "tag": "ResearchActivity"}, {"end": 98, "start": 94, "tag": "PathologicFunction"}, {"end": 114, "start": 110, "tag": "PathologicFunction"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 30, "start": 26, "tag": "Eukaryote"}, {"end": 20, "start": 13, "tag": "Eukaryote"}, {"end": 25, "start": 21, "tag": "OrganismAttribute"}, {"end": 87, "start": 84, "tag": "Substance"}, {"end": 107, "start": 104, "tag": "Substance"}, {"end": 98, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 65, "tag": "Substance"}, {"end": 81, "start": 79, "tag": "Substance"}, {"end": 91, "start": 89, "tag": "Substance"}]}
{"id": "1349_4", "text": "Mice were exposed to FA or nPM for 10 weeks.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 43, "start": 38, "tag": "TemporalConcept"}, {"end": 30, "start": 27, "tag": "Substance"}, {"end": 23, "start": 21, "tag": "Substance"}]}
{"id": "1349_5", "text": "BCAS surgeries were performed.", "tags": [{"end": 4, "start": 0, "tag": "PathologicFunction"}, {"end": 4, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 5, "tag": "HealthCareActivity"}]}
{"id": "1349_6", "text": "Markers of inflammation, oxidative stress, and apoptosis were examined.", "tags": [{"end": 23, "start": 11, "tag": "PathologicFunction"}, {"end": 41, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 56, "start": 47, "tag": "CellFunction"}]}
{"id": "1349_7", "text": "nPM + BCAS exposure increased brain hemisphere TNF alpha protein compared to FA.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Substance"}, {"end": 79, "start": 77, "tag": "Substance"}]}
{"id": "1349_8", "text": "iNOS and HNE immunofluorescence were increased in the corpus callosum and cerebral cortex of nPM + BCAS mice compared to FA.", "tags": [{"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 31, "start": 13, "tag": "ResearchActivity"}, {"end": 103, "start": 99, "tag": "PathologicFunction"}, {"end": 103, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 104, "tag": "Eukaryote"}, {"end": 89, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 93, "tag": "Substance"}, {"end": 123, "start": 121, "tag": "Substance"}]}
{"id": "1349_9", "text": "While nPM exposure alone did not decrease cortical neuronal cell count, nPM decreased corpus callosum oligodendrocyte cell count.", "tags": [{"end": 18, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 101, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 60, "tag": "Cell"}, {"end": 122, "start": 118, "tag": "Cell"}, {"end": 59, "start": 51, "tag": "Cell"}, {"end": 85, "start": 76, "tag": "Finding"}, {"end": 50, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 102, "tag": "Cell"}, {"end": 9, "start": 6, "tag": "Substance"}, {"end": 75, "start": 72, "tag": "Substance"}]}
{"id": "1349_10", "text": "nPM exposure decreased mature oligodendrocyte cell count and increased oligodendrocyte precursor cell count in the corpus callosum.", "tags": [{"end": 12, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 46, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 101, "start": 71, "tag": "Cell"}, {"end": 130, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 45, "start": 30, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Substance"}]}
{"id": "1349_11", "text": "nPM + BCAS mice exhibited a 200% increase in cortical neuronal TUNEL staining and a 700% increase in corpus callosum oligodendrocyte TUNEL staining compared to FA.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 11, "tag": "Eukaryote"}, {"end": 62, "start": 54, "tag": "Cell"}, {"end": 53, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 117, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Substance"}, {"end": 77, "start": 63, "tag": "ResearchActivity"}, {"end": 147, "start": 133, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "Substance"}]}
{"id": "1349_12", "text": "There was a supra-additive interaction between nPM and BCAS on cortical neuronal TUNEL staining (2.6x the additive effects of nPM + BCAS).", "tags": [{"end": 59, "start": 55, "tag": "PathologicFunction"}, {"end": 59, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 132, "tag": "PathologicFunction"}, {"end": 136, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "Cell"}, {"end": 71, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 115, "tag": "Finding"}, {"end": 50, "start": 47, "tag": "Substance"}, {"end": 129, "start": 126, "tag": "Substance"}, {"end": 95, "start": 81, "tag": "ResearchActivity"}]}
{"id": "1349_13", "text": "nPM + BCAS exposure increased apoptosis, neuroinflammation, and oxidative stress in the cerebral cortex and corpus callosum.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 30, "tag": "CellFunction"}, {"end": 103, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 41, "tag": "PathologicFunction"}, {"end": 3, "start": 0, "tag": "Substance"}]}
{"id": "1349_14", "text": "nPM + BCAS exposure increased neuronal apoptosis above the separate responses to each exposure.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 38, "start": 30, "tag": "Cell"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "Substance"}]}
{"id": "1349_15", "text": "However, oligodendrocytes in the corpus callosum demonstrated a greater susceptibility to the combined neurotoxic effects of nPM + BCAS exposure.", "tags": [{"end": 86, "start": 72, "tag": "ClinicalAttribute"}, {"end": 135, "start": 131, "tag": "PathologicFunction"}, {"end": 135, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 131, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 9, "tag": "Cell"}, {"end": 48, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 114, "tag": "Finding"}, {"end": 121, "start": 103, "tag": "InjuryOrPoisoning"}, {"end": 128, "start": 125, "tag": "Substance"}]}
{"id": "1350_0", "text": "Pelizaeus-Merzbacher disease is a fatal X-linked leukodystrophy caused by mutations in the PLP1 gene, which is expressed in the CNS by oligodendrocytes.", "tags": [{"end": 28, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "GeneOrGenome"}, {"end": 131, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "CellFunction"}, {"end": 83, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 151, "start": 135, "tag": "Cell"}, {"end": 120, "start": 111, "tag": "CellFunction"}]}
{"id": "1350_1", "text": "Disease onset, symptoms and mortality span a broad spectrum depending on the nature of the mutation and thus the degree of CNS hypomyelination.", "tags": [{"end": 13, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 127, "tag": "Finding"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 23, "start": 15, "tag": "SignOrSymptom"}, {"end": 99, "start": 91, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1350_2", "text": "In the absence of an effective treatment, direct cell transplantation into the CNS to restore myelin has been tested in animal models of severe forms of the disease with failure of developmental myelination, and more recently, in severely affected patients with early disease onset due to point mutations in the PLP1 gene, and absence of myelin by MRI.", "tags": [{"end": 69, "start": 49, "tag": "HealthCareActivity"}, {"end": 177, "start": 170, "tag": "IndividualBehavior"}, {"end": 267, "start": 262, "tag": "TemporalConcept"}, {"end": 321, "start": 312, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 281, "start": 268, "tag": "TemporalConcept"}, {"end": 304, "start": 289, "tag": "CellOrMolecularDysfunction"}, {"end": 206, "start": 195, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "BiologicFunction"}, {"end": 194, "start": 181, "tag": "TemporalConcept"}, {"end": 225, "start": 217, "tag": "TemporalConcept"}, {"end": 256, "start": 248, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 31, "tag": "HealthCareActivity"}, {"end": 40, "start": 31, "tag": "ResearchActivity"}, {"end": 351, "start": 348, "tag": "HealthCareActivity"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 344, "start": 338, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 120, "tag": "ResearchActivity"}]}
{"id": "1350_3", "text": "In patients with a PLP1 duplication mutation, the most common cause of Pelizaeus-Merzbacher disease, the pathology is poorly defined because of a paucity of autopsy material.", "tags": [{"end": 23, "start": 19, "tag": "GeneOrGenome"}, {"end": 35, "start": 24, "tag": "CellFunction"}, {"end": 99, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 157, "tag": "HealthCareActivity"}, {"end": 173, "start": 165, "tag": "Substance"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 105, "tag": "PathologicFunction"}, {"end": 114, "start": 105, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 44, "start": 19, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1350_4", "text": "To address this, we examined two elderly patients with duplication of PLP1 in whom the overall syndrome, including end-stage pathology, indicated a complex disease involving dysmyelination, demyelination and axonal degeneration.", "tags": [{"end": 74, "start": 55, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 188, "start": 174, "tag": "PathologicFunction"}, {"end": 214, "start": 208, "tag": "CellComponent"}, {"end": 227, "start": 208, "tag": "CellOrMolecularDysfunction"}, {"end": 227, "start": 215, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 125, "tag": "PathologicFunction"}, {"end": 134, "start": 125, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 203, "start": 190, "tag": "PathologicFunction"}, {"end": 40, "start": 33, "tag": "PopulationGroup"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}]}
{"id": "1350_5", "text": "Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of transplanted neural stem cells to restore myelin in the context of PLP overexpression.", "tags": [{"end": 28, "start": 24, "tag": "GeneOrGenome"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 169, "start": 151, "tag": "CellFunction"}, {"end": 96, "start": 84, "tag": "HealthCareActivity"}, {"end": 114, "start": 97, "tag": "Cell"}, {"end": 51, "start": 24, "tag": "ExperimentalModelOfDisease"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1350_6", "text": "Although developmental myelination and axonal coverage by endogenous oligodendrocytes was extensive, as assessed using electron microscopy (n = 3 at each of four end points) and immunostaining (n = 3 at each of four end points), wild-type neural precursors, transplanted into the brains of the newborn mutants, were able to effectively compete and replace the defective myelin (n = 2 at each of four end points).", "tags": [{"end": 238, "start": 229, "tag": "ResearchActivity"}, {"end": 301, "start": 294, "tag": "TemporalConcept"}, {"end": 309, "start": 302, "tag": "CellOrMolecularDysfunction"}, {"end": 45, "start": 39, "tag": "CellComponent"}, {"end": 85, "start": 69, "tag": "Cell"}, {"end": 138, "start": 119, "tag": "ResearchActivity"}, {"end": 270, "start": 258, "tag": "HealthCareActivity"}, {"end": 34, "start": 23, "tag": "CellFunction"}, {"end": 192, "start": 178, "tag": "ResearchActivity"}, {"end": 22, "start": 9, "tag": "BiologicFunction"}, {"end": 22, "start": 9, "tag": "TemporalConcept"}, {"end": 376, "start": 370, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 280, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 239, "tag": "Cell"}]}
{"id": "1350_7", "text": "These data demonstrate the potential of neural stem cell therapies to restore normal myelination and protect axons in patients with PLP1 gene duplication mutation and further, provide proof of principle for the benefits of stem cell transplantation for other fatal leukodystrophies with 'normal' developmental myelination.", "tags": [{"end": 136, "start": 132, "tag": "GeneOrGenome"}, {"end": 162, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 248, "start": 223, "tag": "HealthCareActivity"}, {"end": 281, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 52, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "CellComponent"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 321, "start": 310, "tag": "CellFunction"}, {"end": 84, "start": 78, "tag": "Finding"}, {"end": 294, "start": 288, "tag": "Finding"}, {"end": 309, "start": 296, "tag": "BiologicFunction"}, {"end": 309, "start": 296, "tag": "TemporalConcept"}, {"end": 126, "start": 118, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 40, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}
{"id": "1351_0", "text": "Oligodendrocyte-formed myelin sheaths allow fast synaptic transmission in the brain.", "tags": [{"end": 29, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 23, "tag": "CellComponent"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 83, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 49, "tag": "BiologicFunction"}]}
{"id": "1351_1", "text": "Impairments in the process of myelination, or demyelinating insults, might cause chronic diseases such as multiple sclerosis (MS).", "tags": [{"end": 11, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "PathologicFunction"}, {"end": 124, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 30, "tag": "CellFunction"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 81, "tag": "TemporalConcept"}, {"end": 67, "start": 60, "tag": "InjuryOrPoisoning"}]}
{"id": "1351_2", "text": "Under physiological conditions, remyelination is an ongoing process throughout adult life consisting in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes (OLs).", "tags": [{"end": 195, "start": 179, "tag": "Cell"}, {"end": 165, "start": 161, "tag": "Cell"}, {"end": 195, "start": 172, "tag": "Cell"}, {"end": 159, "start": 127, "tag": "Cell"}, {"end": 123, "start": 108, "tag": "CellFunction"}, {"end": 159, "start": 143, "tag": "Cell"}, {"end": 200, "start": 197, "tag": "Cell"}, {"end": 178, "start": 172, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "TemporalConcept"}, {"end": 89, "start": 85, "tag": "TemporalConcept"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 84, "start": 79, "tag": "PopulationGroup"}]}
{"id": "1351_3", "text": "During pathological events, this process fails due to unfavorable environment.", "tags": []}
{"id": "1351_4", "text": "Adenosine and sphingosine kinase/sphingosine 1-phosphate signaling axes (SphK/S1P) play important roles in remyelination processes.", "tags": [{"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 14, "tag": "CellFunction"}, {"end": 120, "start": 107, "tag": "CellFunction"}, {"end": 81, "start": 78, "tag": "Chemical"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 33, "tag": "Chemical"}, {"end": 32, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 14, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1351_5", "text": "Remarkably, fingolimod (FTY720), a sphingosine analog recently approved for MS treatment, plays important roles in OPC maturation.", "tags": [{"end": 30, "start": 24, "tag": "Chemical"}, {"end": 118, "start": 115, "tag": "Cell"}, {"end": 129, "start": 119, "tag": "BiologicFunction"}, {"end": 22, "start": 12, "tag": "Chemical"}, {"end": 22, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 79, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "TemporalConcept"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "Chemical"}]}
{"id": "1351_6", "text": "We recently demonstrated that the selective stimulation of A(2)(B) adenosine receptors (A(2)(B)Rs) inhibit OPC differentiation in vitro and reduce voltage-dependent outward K+ currents (I-K) necessary to OPC maturation, whereas specific SphK1 or SphK2 inhibition exerts the opposite effect.", "tags": [{"end": 242, "start": 237, "tag": "GeneOrGenome"}, {"end": 251, "start": 246, "tag": "GeneOrGenome"}, {"end": 110, "start": 107, "tag": "Cell"}, {"end": 207, "start": 204, "tag": "Cell"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 126, "start": 111, "tag": "CellFunction"}, {"end": 126, "start": 107, "tag": "CellFunction"}, {"end": 289, "start": 283, "tag": "Finding"}, {"end": 135, "start": 127, "tag": "ResearchActivity"}, {"end": 262, "start": 252, "tag": "CellFunction"}, {"end": 55, "start": 44, "tag": "HealthCareActivity"}, {"end": 55, "start": 44, "tag": "NaturalPhenomenonOrProcess"}, {"end": 11, "start": 3, "tag": "TemporalConcept"}, {"end": 86, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 147, "tag": "CellFunction"}, {"end": 242, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 237, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1351_7", "text": "During OPC differentiation A(2)(B)R expression increases, this effect being prevented by SphK1/2 blockade.", "tags": [{"end": 10, "start": 7, "tag": "Cell"}, {"end": 26, "start": 11, "tag": "CellFunction"}, {"end": 26, "start": 7, "tag": "CellFunction"}, {"end": 105, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 97, "tag": "HealthCareActivity"}, {"end": 69, "start": 63, "tag": "Finding"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 89, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1351_8", "text": "Furthermore, selective silencing of A(2)(B)R in OPC cultures prompts maturation and, intriguingly, enhances the expression of S1P lyase, the enzyme responsible for irreversible S1P catabolism.", "tags": [{"end": 32, "start": 23, "tag": "CellFunction"}, {"end": 180, "start": 177, "tag": "Chemical"}, {"end": 191, "start": 181, "tag": "BiologicFunction"}, {"end": 191, "start": 181, "tag": "CellFunction"}, {"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "Cell"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 122, "start": 112, "tag": "CellFunction"}, {"end": 44, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1351_9", "text": "Finally, the existence of an interplay between SphK1/S1P pathway and A(2)(B)Rs in OPCs was confirmed since acute stimulation of A(2)(B)Rs activates SphK1 by increasing its phosphorylation.", "tags": [{"end": 153, "start": 148, "tag": "GeneOrGenome"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 124, "start": 113, "tag": "HealthCareActivity"}, {"end": 124, "start": 113, "tag": "NaturalPhenomenonOrProcess"}, {"end": 38, "start": 29, "tag": "Finding"}, {"end": 64, "start": 57, "tag": "CellFunction"}, {"end": 187, "start": 172, "tag": "CellFunction"}, {"end": 167, "start": 157, "tag": "Finding"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "Chemical"}, {"end": 137, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1351_10", "text": "Here the role of A(2)(B)R and SphK/S1P signaling during oligodendrogenesis is reviewed in detail, with the purpose to shed new light on the interaction between A(2)(B)Rs and S1P signaling, as eventual innovative targets for the treatment of demyelinating disorders.", "tags": [{"end": 177, "start": 174, "tag": "Chemical"}, {"end": 86, "start": 78, "tag": "HealthCareActivity"}, {"end": 86, "start": 78, "tag": "ResearchActivity"}, {"end": 74, "start": 56, "tag": "BiologicFunction"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 187, "start": 178, "tag": "CellFunction"}, {"end": 132, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 264, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 228, "tag": "HealthCareActivity"}, {"end": 237, "start": 228, "tag": "ResearchActivity"}, {"end": 25, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "Chemical"}, {"end": 34, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 160, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1352_0", "text": "Progesterone and testosterone, beyond their roles as sex hormones, are neuroactive steroids, playing crucial regulatory functions within the nervous system.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 17, "tag": "Chemical"}, {"end": 29, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 71, "tag": "Chemical"}, {"end": 65, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 155, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 71, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1352_1", "text": "Among these, neuroprotection and myelin regeneration are important ones.", "tags": [{"end": 28, "start": 13, "tag": "CellFunction"}, {"end": 39, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 40, "tag": "BiologicFunction"}, {"end": 52, "start": 40, "tag": "HealthCareActivity"}, {"end": 52, "start": 33, "tag": "CellFunction"}]}
{"id": "1352_2", "text": "The present review aims to discuss the stimulatory effects of progesterone and testosterone on the process of myelination and remyelination.", "tags": [{"end": 74, "start": 62, "tag": "Chemical"}, {"end": 74, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 79, "tag": "Chemical"}, {"end": 91, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 58, "start": 51, "tag": "Finding"}, {"end": 91, "start": 79, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1352_3", "text": "These effects have been demonstrated in vitro (i.e., organotypic cultures) and in vivo (cuprizone- or lysolecithin-induced demyelination and experimental autoimmune encephalomyelitis (EAE)).", "tags": [{"end": 73, "start": 53, "tag": "ResearchActivity"}, {"end": 182, "start": 141, "tag": "ExperimentalModelOfDisease"}, {"end": 187, "start": 184, "tag": "ExperimentalModelOfDisease"}, {"end": 73, "start": 65, "tag": "ResearchActivity"}, {"end": 114, "start": 102, "tag": "Chemical"}, {"end": 114, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 13, "start": 6, "tag": "Finding"}]}
{"id": "1352_4", "text": "Both steroids stimulate myelin formation and regeneration by acting through their respective intracellular receptors: progesterone receptors (PR) and androgen receptors (AR).", "tags": [{"end": 13, "start": 5, "tag": "Chemical"}, {"end": 106, "start": 93, "tag": "CellComponent"}, {"end": 140, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "HealthCareActivity"}, {"end": 40, "start": 24, "tag": "CellFunction"}, {"end": 116, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 107, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1352_5", "text": "Activation of these receptors results in multiple events involving direct transcription and translation, regulating general homeostasis, cell proliferation, differentiation, growth and myelination.", "tags": [{"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 155, "start": 137, "tag": "CellFunction"}, {"end": 180, "start": 174, "tag": "BiologicFunction"}, {"end": 172, "start": 157, "tag": "CellFunction"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 135, "start": 124, "tag": "BiologicFunction"}, {"end": 196, "start": 185, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "CellFunction"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1352_6", "text": "It also ameliorates immune response as seen in the EAE model, resulting in a significant decrease in inflammation leading to a fast recovery.", "tags": [{"end": 35, "start": 20, "tag": "BiologicFunction"}, {"end": 113, "start": 101, "tag": "PathologicFunction"}, {"end": 140, "start": 132, "tag": "BiologicFunction"}, {"end": 140, "start": 132, "tag": "HealthCareActivity"}, {"end": 140, "start": 132, "tag": "TemporalConcept"}, {"end": 97, "start": 77, "tag": "Finding"}, {"end": 60, "start": 51, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1352_7", "text": "Although natural progesterone and testosterone have a therapeutic potential, their synthetic derivatives-the 19-norprogesterone (nestorone) and 7 alpha-methyl-nortestosterone (MENT), already used as hormonal contraception or in postmenopausal hormone replacement therapies, may offer enhanced benefits for myelin repair.", "tags": [{"end": 29, "start": 17, "tag": "Chemical"}, {"end": 29, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 34, "tag": "Chemical"}, {"end": 46, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 221, "start": 199, "tag": "HealthCareActivity"}, {"end": 312, "start": 306, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 319, "start": 306, "tag": "CellFunction"}, {"end": 75, "start": 54, "tag": "HealthCareActivity"}, {"end": 272, "start": 228, "tag": "HealthCareActivity"}, {"end": 319, "start": 313, "tag": "BiologicFunction"}, {"end": 319, "start": 313, "tag": "HealthCareActivity"}, {"end": 46, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 109, "tag": "Chemical"}, {"end": 127, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 129, "tag": "Chemical"}, {"end": 138, "start": 129, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 144, "tag": "Chemical"}, {"end": 104, "start": 83, "tag": "Chemical"}]}
{"id": "1352_8", "text": "We summarize here a recent advancement in the field of myelin biology, to treat demyelinating disorders using the natural as well as synthetic analogs of progesterone and testosterone.", "tags": [{"end": 150, "start": 133, "tag": "Chemical"}, {"end": 166, "start": 154, "tag": "Chemical"}, {"end": 166, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 171, "tag": "Chemical"}, {"end": 183, "start": 171, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 80, "tag": "PathologicFunction"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 26, "start": 20, "tag": "TemporalConcept"}, {"end": 69, "start": 62, "tag": "BiologicFunction"}, {"end": 183, "start": 171, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_0", "text": "Ethnopharmacology relevance: Wuzi Yanzong Pill (WYP), a well-known prescription for invigorating the kidney and essence, which is widely used to treat infertility such as oligoasthenospermia.", "tags": [{"end": 17, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 79, "start": 67, "tag": "HealthCareActivity"}, {"end": 119, "start": 112, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 162, "start": 151, "tag": "PathologicFunction"}, {"end": 190, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "DiseaseOrSyndrome"}]}
{"id": "1353_1", "text": "Studies have shown that WYP can be used to treat neurological diseases, but its therapeutic effects and mechanisms for multiple sclerosis (MS) remain unclear.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 137, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 80, "tag": "Finding"}, {"end": 70, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "PharmacologicSubstance"}]}
{"id": "1353_2", "text": "Aim of the study: Based on the establishment of Cuprizone (CPZ)-induced demyelination model, this study determined the effect of WYP on remyelination by detecting changes in the microenvironment of the central nervous system.", "tags": [{"end": 194, "start": 178, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 59, "tag": "Chemical"}, {"end": 57, "start": 48, "tag": "Chemical"}, {"end": 224, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 125, "start": 119, "tag": "Finding"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 85, "start": 72, "tag": "PathologicFunction"}, {"end": 91, "start": 48, "tag": "ExperimentalModelOfDisease"}, {"end": 132, "start": 129, "tag": "PharmacologicSubstance"}]}
{"id": "1353_3", "text": "Materials and methods: C57BL/6 mice were divided into three groups.", "tags": [{"end": 35, "start": 23, "tag": "Eukaryote"}]}
{"id": "1353_4", "text": "The CPZ group and CPZ thorn WYP group were fed with 0.2% CPZ feed, and the control group was fed normal feed, for 6 weeks.", "tags": [{"end": 7, "start": 4, "tag": "Chemical"}, {"end": 21, "start": 18, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 88, "start": 75, "tag": "PopulationGroup"}, {"end": 121, "start": 116, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "PopulationGroup"}, {"end": 37, "start": 32, "tag": "PopulationGroup"}, {"end": 88, "start": 83, "tag": "PopulationGroup"}, {"end": 103, "start": 97, "tag": "Finding"}, {"end": 31, "start": 28, "tag": "PharmacologicSubstance"}]}
{"id": "1353_5", "text": "At the end of the second week, the CPZ thorn WYP group was gavaged with WYP solution (16 g/kg/d), and the other two groups were gavaged with normal saline twice a day with an interval of 12 h each time, for 4 weeks.", "tags": [{"end": 84, "start": 76, "tag": "Substance"}, {"end": 154, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 163, "tag": "TemporalConcept"}, {"end": 183, "start": 175, "tag": "TemporalConcept"}, {"end": 38, "start": 35, "tag": "Chemical"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 214, "start": 209, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 201, "start": 197, "tag": "TemporalConcept"}, {"end": 48, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 72, "tag": "PharmacologicSubstance"}]}
{"id": "1353_6", "text": "Forced swimming and elevated plus maze were used to detect changes in anxiety and depression before and after treatment.", "tags": [{"end": 92, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 20, "tag": "ResearchActivity"}, {"end": 38, "start": 20, "tag": "ManufacturedObject"}, {"end": 15, "start": 0, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "Finding"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 109, "start": 104, "tag": "TemporalConcept"}]}
{"id": "1353_7", "text": "Luxol fast blue staining and the expression of MBP were used to evaluate the demyelination of the brain.", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 47, "tag": "GeneOrGenome"}, {"end": 103, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 90, "start": 77, "tag": "PathologicFunction"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1353_8", "text": "Western blot was used to detect the expression of microglia and their subtype markers Iba-1, Arg-1, iNOS, the expression of neurotrophic factors BDNF, GDNF, CNTF, and the expression of oligodendrocyte precursor cells NG2.", "tags": [{"end": 155, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 93, "tag": "GeneOrGenome"}, {"end": 220, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 217, "tag": "GeneOrGenome"}, {"end": 216, "start": 185, "tag": "Cell"}, {"end": 216, "start": 201, "tag": "Cell"}, {"end": 210, "start": 185, "tag": "Cell"}, {"end": 85, "start": 78, "tag": "ClinicalAttribute"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 120, "start": 110, "tag": "CellFunction"}, {"end": 181, "start": 171, "tag": "CellFunction"}, {"end": 59, "start": 50, "tag": "Cell"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "GeneOrGenome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 144, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 151, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_9", "text": "ELISA detected the content of IL6, IL-1 ss, IL-10, TGF-ss, BDNF, GDNF, CNTF in the brain.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 75, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 71, "tag": "GeneOrGenome"}, {"end": 75, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 44, "tag": "GeneOrGenome"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_10", "text": "The distribution of Iba-1 in the corpus callosum was observed by immunofluorescence.", "tags": [{"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 48, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_11", "text": "Results: The results showed that on the basis of improving mood abnormalities and demyelination, WYP reduced the protein content of Iba-1 and iNOS, increased the protein content of Arg-1, and reduce accumulation of microglia in the corpus callosum.", "tags": [{"end": 186, "start": 181, "tag": "GeneOrGenome"}, {"end": 247, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 211, "start": 199, "tag": "Finding"}, {"end": 224, "start": 215, "tag": "Cell"}, {"end": 95, "start": 82, "tag": "PathologicFunction"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 59, "tag": "PathologicFunction"}, {"end": 100, "start": 97, "tag": "PharmacologicSubstance"}]}
{"id": "1353_12", "text": "In addition, WYP reduced the secretion of IL-6 and IL-1 ss while promoting the secretion of IL-10 and TGF-ss.", "tags": [{"end": 55, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 51, "tag": "GeneOrGenome"}, {"end": 38, "start": 29, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "CellFunction"}, {"end": 38, "start": 29, "tag": "BiologicFunction"}, {"end": 88, "start": 79, "tag": "BiologicFunction"}, {"end": 46, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 42, "tag": "GeneOrGenome"}, {"end": 97, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_13", "text": "After WYP intervention treatment, the levels of neurotrophic factors BDNF, GDNF, CNTF increased.", "tags": [{"end": 79, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 75, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 81, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 23, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "GeneOrGenome"}, {"end": 68, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 75, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1353_14", "text": "Due to the improvement of inflammatory and nutritional environment in the CNS, promoting the proliferation of NG2 oligodendrocyte, increased the expression of MBP, and repairing myelin sheath.", "tags": [{"end": 177, "start": 168, "tag": "BiologicFunction"}, {"end": 177, "start": 168, "tag": "HealthCareActivity"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "GeneOrGenome"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 159, "tag": "GeneOrGenome"}, {"end": 184, "start": 178, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 38, "start": 26, "tag": "PathologicFunction"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 145, "tag": "CellFunction"}, {"end": 129, "start": 114, "tag": "Cell"}, {"end": 191, "start": 178, "tag": "CellComponent"}, {"end": 66, "start": 43, "tag": "Finding"}]}
{"id": "1353_15", "text": "Conclusion: Our results indicated that WYP promoted the proliferation and development of oligodendrocytes by improving the CNS microenvironment, effectively alleviating demyelination.", "tags": [{"end": 143, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 105, "start": 89, "tag": "Cell"}, {"end": 69, "start": 56, "tag": "CellFunction"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}, {"end": 42, "start": 39, "tag": "PharmacologicSubstance"}]}
{"id": "1354_0", "text": "Glial gap junction proteins, called connexins (Cxs), form gap junctions in the central nervous system (CNS) to allow the bidirectional cytosolic exchange of molecules between adjacent cells.", "tags": [{"end": 5, "start": 0, "tag": "Cell"}, {"end": 45, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 157, "tag": "Substance"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 184, "tag": "Cell"}, {"end": 101, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 121, "tag": "CellFunction"}]}
{"id": "1354_1", "text": "Their involvement in inheritable diseases and the use of experimental animal models that closely mimic such diseases revealed the critical role of glial GJs in myelination and homeostasis.", "tags": [{"end": 171, "start": 160, "tag": "CellFunction"}, {"end": 83, "start": 57, "tag": "ResearchActivity"}, {"end": 156, "start": 153, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 147, "tag": "Cell"}, {"end": 17, "start": 6, "tag": "Finding"}, {"end": 187, "start": 176, "tag": "BiologicFunction"}]}
{"id": "1354_2", "text": "Cxs are also implicated in acquired demyelinating disorders, such as Multiple Sclerosis (MS) and Alzheimer's disease (AD).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}]}
{"id": "1354_3", "text": "Animal and human studies have revealed a role of the astrocytic Cx43 in the progression of AD but the role of Cx47, which is the main partner of Cx43 in the astrocyte-oligodendrocyte GJs is still unknown.", "tags": [{"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 63, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 157, "tag": "Cell"}, {"end": 182, "start": 167, "tag": "Cell"}, {"end": 186, "start": 183, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 76, "tag": "PathologicFunction"}, {"end": 87, "start": 76, "tag": "TemporalConcept"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}]}
{"id": "1354_4", "text": "The aim of this study was to investigate the astrocytic connexins, Cx43 and Cx30 in relation to oligodendrocytic Cx47 in the cortex and thalamus of the 5XFAD mouse model of AD.", "tags": [{"end": 112, "start": 96, "tag": "Cell"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 55, "start": 45, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 152, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1354_5", "text": "The model was characterized by increased A beta deposition, gliosis, neuronal loss, and memory impairment.", "tags": [{"end": 67, "start": 60, "tag": "PathologicFunction"}, {"end": 82, "start": 69, "tag": "Finding"}, {"end": 105, "start": 88, "tag": "SignOrSymptom"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 47, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 41, "tag": "PathologicFunction"}]}
{"id": "1354_6", "text": "Compared to wild-type mice, Cx43 and Cx30 showed increased immunoreactivity in older 5XFAD mice, reflecting astrogliosis, while Cx47 immunoreactivity was reduced.", "tags": [{"end": 95, "start": 85, "tag": "ExperimentalModelOfDisease"}, {"end": 26, "start": 12, "tag": "Eukaryote"}, {"end": 75, "start": 59, "tag": "CellFunction"}, {"end": 149, "start": 133, "tag": "CellFunction"}, {"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 108, "tag": "PathologicFunction"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}]}
{"id": "1354_7", "text": "Moreover, Cx47 GJ plaques showed reduced colocalization with Cx43 plaques.", "tags": [{"end": 25, "start": 18, "tag": "AnatomicalAbnormality"}, {"end": 55, "start": 41, "tag": "BiologicFunction"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 66, "tag": "AnatomicalAbnormality"}]}
{"id": "1354_8", "text": "Oligodendrocyte precursor cells (OPCs) and mature oligodendrocyte populations were also depleted, and myelin deficits were observed.", "tags": [{"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 77, "start": 43, "tag": "Cell"}, {"end": 117, "start": 102, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1354_9", "text": "Our findings indicate reduced astrocyte-oligodendrocyte gap junction connectivity and possibly a shift in Cx43 expression toward astrocyte-astrocyte gap junctions and/or hemichannels, that could impair oligodendrocyte homeostasis and myelination.", "tags": [{"end": 102, "start": 97, "tag": "Finding"}, {"end": 148, "start": 129, "tag": "Cell"}, {"end": 162, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 138, "start": 129, "tag": "Cell"}, {"end": 148, "start": 139, "tag": "Cell"}, {"end": 245, "start": 234, "tag": "CellFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 217, "start": 202, "tag": "Cell"}, {"end": 110, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 218, "tag": "BiologicFunction"}, {"end": 68, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 69, "tag": "BiologicFunction"}]}
{"id": "1354_10", "text": "However, other factors, such as A beta toxicity, could directly affect oligodendrocyte survival in AD.", "tags": [{"end": 95, "start": 87, "tag": "CellFunction"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 47, "start": 39, "tag": "InjuryOrPoisoning"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1354_11", "text": "Our study provides evidence that Cxs might have implications in the progression of AD, although the role of oligodendrocyte Cxs in AD requires further investigation.", "tags": [{"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 108, "tag": "Cell"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 79, "start": 68, "tag": "PathologicFunction"}, {"end": 79, "start": 68, "tag": "TemporalConcept"}, {"end": 27, "start": 19, "tag": "Finding"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 151, "tag": "ResearchActivity"}, {"end": 36, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1355_0", "text": "While much of the research on neurodegenerative diseases has focused on neurons, non-neuronal cells are also affected.", "tags": [{"end": 99, "start": 81, "tag": "Cell"}, {"end": 79, "start": 72, "tag": "Cell"}, {"end": 93, "start": 85, "tag": "Cell"}, {"end": 99, "start": 85, "tag": "Cell"}, {"end": 56, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "ResearchActivity"}]}
{"id": "1355_1", "text": "The extent to which glia and other non-neuronal cells are causally involved in disease pathogenesis versus more passively responding to disease is an area of active research.", "tags": [{"end": 53, "start": 35, "tag": "Cell"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 53, "start": 39, "tag": "Cell"}, {"end": 173, "start": 165, "tag": "ResearchActivity"}, {"end": 99, "start": 87, "tag": "PathologicFunction"}]}
{"id": "1355_2", "text": "This is complicated by the fact that there is rarely one known cause of neurodegenerative diseases; rather, these disorders likely involve feedback loops that perpetuate dysfunction.", "tags": [{"end": 181, "start": 170, "tag": "PathologicFunction"}, {"end": 98, "start": 72, "tag": "DiseaseOrSyndrome"}]}
{"id": "1355_3", "text": "Here, we will review genetic as well as experimental evidence that suggest that non-neuronal cells are at least partially driving disease pathogenesis in numerous neurodegenerative disorders, including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and Parkinson's disease.", "tags": [{"end": 98, "start": 80, "tag": "Cell"}, {"end": 190, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "Finding"}, {"end": 28, "start": 21, "tag": "Finding"}, {"end": 92, "start": 84, "tag": "Cell"}, {"end": 246, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 84, "tag": "Cell"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 61, "start": 40, "tag": "Finding"}, {"end": 299, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 344, "start": 325, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 138, "tag": "PathologicFunction"}, {"end": 246, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 319, "start": 301, "tag": "DiseaseOrSyndrome"}]}
{"id": "1356_0", "text": "Receptor interacting serine/threonine protein kinase 1 (RIPK1) activation and necroptosis have been genetically and mechanistically linked with human multiple sclerosis and neurodegenerative diseases for which demyelination is a common key pathology.", "tags": [{"end": 54, "start": 0, "tag": "GeneOrGenome"}, {"end": 54, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "CellFunction"}, {"end": 89, "start": 78, "tag": "CellFunction"}, {"end": 168, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 240, "tag": "PathologicFunction"}, {"end": 249, "start": 240, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 149, "start": 144, "tag": "Eukaryote"}, {"end": 199, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 210, "tag": "PathologicFunction"}, {"end": 73, "start": 63, "tag": "CellFunction"}]}
{"id": "1356_1", "text": "Demyelination can be healed through remyelination which is mediated by new oligodendrocytes derived from the adult oligodendrocyte progenitor cells (OPCs).", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 91, "start": 75, "tag": "Cell"}, {"end": 153, "start": 149, "tag": "Cell"}, {"end": 147, "start": 115, "tag": "Cell"}, {"end": 147, "start": 131, "tag": "Cell"}, {"end": 49, "start": 36, "tag": "CellFunction"}, {"end": 114, "start": 109, "tag": "PopulationGroup"}]}
{"id": "1356_2", "text": "Unfortunately, the efficiency of remyelination declines with progressive aging partially due to the depletion of OPCs following chronic or repeated demyelination.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 29, "start": 19, "tag": "Finding"}, {"end": 72, "start": 61, "tag": "TemporalConcept"}, {"end": 46, "start": 33, "tag": "CellFunction"}, {"end": 161, "start": 148, "tag": "PathologicFunction"}, {"end": 78, "start": 73, "tag": "BiologicFunction"}, {"end": 78, "start": 73, "tag": "CellFunction"}, {"end": 135, "start": 128, "tag": "TemporalConcept"}]}
{"id": "1356_3", "text": "However, to our knowledge, so far there is no drug which enhances proliferation of OPCs, and it is unknown whether inhibiting RIPK1 activity directly affect OPCs, the central player of remyelination.", "tags": [{"end": 131, "start": 126, "tag": "GeneOrGenome"}, {"end": 131, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 161, "start": 157, "tag": "Cell"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 25, "start": 16, "tag": "Finding"}, {"end": 125, "start": 115, "tag": "BiologicFunction"}, {"end": 198, "start": 185, "tag": "CellFunction"}, {"end": 50, "start": 46, "tag": "PharmacologicSubstance"}]}
{"id": "1356_4", "text": "Using TNF alpha induced RIPK1-dependent necroptosis in Jurkat FADD(-/-) cells as a cell death assay, we screened from 2112 FDA-approved drugs and the drug candidates of new RIPK1 inhibitors selected by ourselves, and identified ZJU-37, a small molecule modified by introducing an amide bond to Nec-1s, is a new RIPK1 kinase inhibitor with higher potency than Nec-1s which has the best reported potency.", "tags": [{"end": 15, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "GeneOrGenome"}, {"end": 178, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 238, "tag": "Chemical"}, {"end": 333, "start": 324, "tag": "BiologicallyActiveSubstance"}, {"end": 333, "start": 324, "tag": "PharmacologicSubstance"}, {"end": 333, "start": 324, "tag": "Chemical"}, {"end": 112, "start": 104, "tag": "HealthCareActivity"}, {"end": 112, "start": 104, "tag": "ResearchActivity"}, {"end": 189, "start": 179, "tag": "Chemical"}, {"end": 189, "start": 179, "tag": "PharmacologicSubstance"}, {"end": 189, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 244, "tag": "Substance"}, {"end": 99, "start": 83, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "Cell"}, {"end": 93, "start": 88, "tag": "BiologicFunction"}, {"end": 93, "start": 88, "tag": "PathologicFunction"}, {"end": 93, "start": 88, "tag": "CellFunction"}, {"end": 141, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 83, "tag": "CellFunction"}, {"end": 154, "start": 150, "tag": "PharmacologicSubstance"}, {"end": 126, "start": 123, "tag": "HealthCareRelatedOrganization"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 55, "tag": "ExperimentalModelOfDisease"}, {"end": 234, "start": 228, "tag": "Chemical"}, {"end": 290, "start": 280, "tag": "Chemical"}, {"end": 323, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 323, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 365, "start": 359, "tag": "Chemical"}, {"end": 401, "start": 394, "tag": "Finding"}]}
{"id": "1356_5", "text": "We unveil in addition to protecting myelin from demyelination and axons from degeneration, ZJU-37 exhibits a new role on promoting proliferation of OPCs and enhancing remyelination by inhibiting RIPK1 kinase activity with higher potency than Nec-1s.", "tags": [{"end": 207, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "CellComponent"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 89, "start": 77, "tag": "PathologicFunction"}, {"end": 194, "start": 184, "tag": "BiologicFunction"}, {"end": 180, "start": 167, "tag": "CellFunction"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 97, "start": 91, "tag": "Chemical"}]}
{"id": "1356_6", "text": "Mechanistically, ZJU-37 promotes proliferation of OPCs by enhancing the transcription of platelet derived growth factor receptor alpha via NF-kappa B pathway.", "tags": [{"end": 85, "start": 72, "tag": "CellFunction"}, {"end": 149, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 139, "tag": "GeneOrGenome"}, {"end": 149, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 46, "start": 33, "tag": "CellFunction"}, {"end": 157, "start": 150, "tag": "CellFunction"}, {"end": 134, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "Chemical"}, {"end": 134, "start": 89, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1356_7", "text": "This work identifies ZJU-37 as a new drug candidate which enhances remyelination by promoting proliferation of OPCs, paving the way for a potential drug to enhance myelin repair.", "tags": [{"end": 115, "start": 111, "tag": "Cell"}, {"end": 170, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 94, "tag": "CellFunction"}, {"end": 177, "start": 164, "tag": "CellFunction"}, {"end": 80, "start": 67, "tag": "CellFunction"}, {"end": 41, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 148, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 171, "tag": "BiologicFunction"}, {"end": 177, "start": 171, "tag": "HealthCareActivity"}, {"end": 27, "start": 21, "tag": "Chemical"}]}
{"id": "1357_0", "text": "Multiple sclerosis is an autoimmune disease in which the immune system attacks the myelin sheath in the central nervous system.", "tags": [{"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 83, "tag": "CellComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}
{"id": "1357_1", "text": "It is characterized by blood-brain barrier dysfunction throughout the course of multiple sclerosis, followed by the entry of immune cells and activation of local microglia and astrocytes.", "tags": [{"end": 137, "start": 125, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 98, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 162, "tag": "Cell"}, {"end": 42, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 176, "tag": "Cell"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}]}
{"id": "1357_2", "text": "Glial cells (microglia, astrocytes, and oligodendrocyte lineage cells) are known as the important mediators of neuroinflammation, all of which play major roles in the pathogenesis of multiple sclerosis.", "tags": [{"end": 11, "start": 0, "tag": "Cell"}, {"end": 201, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 40, "tag": "Cell"}, {"end": 107, "start": 98, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Cell"}, {"end": 179, "start": 167, "tag": "PathologicFunction"}, {"end": 34, "start": 24, "tag": "Cell"}, {"end": 128, "start": 111, "tag": "PathologicFunction"}]}
{"id": "1357_3", "text": "Network communications between glial cells affect the activities of oligodendrocyte lineage cells and influence the demyelination-remyelination process.", "tags": [{"end": 151, "start": 116, "tag": "CellFunction"}, {"end": 97, "start": 68, "tag": "Cell"}, {"end": 91, "start": 68, "tag": "Cell"}, {"end": 42, "start": 31, "tag": "Cell"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}]}
{"id": "1357_4", "text": "A finely balanced glial response may create a favorable lesion environment for efficient remyelination and neuroregeneration.", "tags": [{"end": 62, "start": 56, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 18, "tag": "Cell"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 124, "start": 107, "tag": "BiologicFunction"}, {"end": 74, "start": 63, "tag": "Finding"}]}
{"id": "1357_5", "text": "This review focuses on glial response and neurodegeneration based on the findings from multiple sclerosis and major rodent demyelination models.", "tags": [{"end": 122, "start": 116, "tag": "Eukaryote"}, {"end": 105, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "Cell"}, {"end": 143, "start": 137, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 59, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 143, "start": 116, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1357_6", "text": "In particular, glial interaction and molecular crosstalk are discussed to provide insights into the potential cell- and molecule-specific therapeutic targets to improve remyelination and neuroregeneration.", "tags": [{"end": 128, "start": 120, "tag": "Substance"}, {"end": 20, "start": 15, "tag": "Cell"}, {"end": 114, "start": 110, "tag": "Cell"}, {"end": 157, "start": 138, "tag": "ResearchActivity"}, {"end": 56, "start": 37, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 204, "start": 187, "tag": "BiologicFunction"}]}
{"id": "1358_0", "text": "Multiple sclerosis (MS) is a complex disease, and its pathophysiology impacts the function of immune and central nervous system cell types.", "tags": [{"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 128, "tag": "Cell"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 54, "tag": "PathologicFunction"}, {"end": 69, "start": 54, "tag": "BiomedicalOccupationOrDiscipline"}]}
{"id": "1358_1", "text": "Despite extensive investigation into the aetiology of MS, the underlying cause/s remain elusive and consequently, faithful in vitro or in vivo preclinical models of MS do not exist.", "tags": [{"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 18, "tag": "ResearchActivity"}, {"end": 142, "start": 135, "tag": "ResearchActivity"}, {"end": 161, "start": 143, "tag": "ResearchActivity"}, {"end": 50, "start": 41, "tag": "Finding"}]}
{"id": "1358_2", "text": "Advances human stem cell technologies have enabled the generation of induced pluripotent stem cells (iPSCs) from people with MS.", "tags": [{"end": 37, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 65, "start": 55, "tag": "TemporalConcept"}, {"end": 99, "start": 69, "tag": "Cell"}, {"end": 106, "start": 101, "tag": "Cell"}, {"end": 14, "start": 9, "tag": "Eukaryote"}, {"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 113, "tag": "PopulationGroup"}, {"end": 24, "start": 15, "tag": "Cell"}]}
{"id": "1358_3", "text": "This review summarises the discoveries made using iPSCs derived from people with MS and explores their current and potential application/s in MS research.", "tags": [{"end": 55, "start": 50, "tag": "Cell"}, {"end": 38, "start": 27, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 153, "start": 145, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 69, "tag": "PopulationGroup"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}]}
{"id": "1359_0", "text": "Oligodendrocytes form myelin membranes and thereby secure the insulation of axons and the rapid conduction of action potentials.", "tags": [{"end": 127, "start": 110, "tag": "CellFunction"}, {"end": 81, "start": 76, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 38, "start": 29, "tag": "CellComponent"}, {"end": 38, "start": 22, "tag": "CellComponent"}, {"end": 106, "start": 96, "tag": "BiologicFunction"}, {"end": 106, "start": 96, "tag": "NaturalPhenomenonOrProcess"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1359_1", "text": "Diseases such as multiple sclerosis highlight the importance of this glial cell population for brain function.", "tags": [{"end": 8, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "PopulationGroup"}, {"end": 74, "start": 69, "tag": "Cell"}, {"end": 109, "start": 95, "tag": "BiologicFunction"}, {"end": 35, "start": 17, "tag": "DiseaseOrSyndrome"}]}
{"id": "1359_2", "text": "In the adult brain, efficient remyelination following the damage to oligodendrocytes is compromised.", "tags": [{"end": 12, "start": 7, "tag": "PopulationGroup"}, {"end": 84, "start": 68, "tag": "Cell"}, {"end": 43, "start": 30, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1359_3", "text": "Myelination is characterized by proliferation, migration, and proper integration of oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 80, "start": 69, "tag": "CellFunction"}, {"end": 80, "start": 69, "tag": "MachineActivity"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 56, "start": 47, "tag": "CellFunction"}, {"end": 115, "start": 84, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}]}
{"id": "1359_4", "text": "These processes are among others controlled by proteins of the extracellular matrix (ECM).", "tags": [{"end": 83, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1359_5", "text": "As a prominent representative ECM molecule, tenascin-C (Tnc) exerts an inhibitory effect on the migration and differentiation of OPCs.", "tags": [{"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 129, "tag": "Cell"}, {"end": 105, "start": 96, "tag": "CellFunction"}, {"end": 125, "start": 110, "tag": "CellFunction"}, {"end": 42, "start": 34, "tag": "Substance"}, {"end": 88, "start": 71, "tag": "Finding"}]}
{"id": "1359_6", "text": "The structurally similar paralogue tenascin-R (Tnr) is known to promote the differentiation of oligodendrocytes.", "tags": [{"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "CellComponent"}, {"end": 111, "start": 95, "tag": "Cell"}, {"end": 91, "start": 76, "tag": "CellFunction"}, {"end": 45, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 35, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1359_7", "text": "The model of lysolecithin-induced demyelination of cerebellar slice cultures represents an important tool for the analysis of the remyelination process.", "tags": [{"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 122, "start": 114, "tag": "ResearchActivity"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 47, "start": 34, "tag": "PathologicFunction"}, {"end": 25, "start": 13, "tag": "Chemical"}, {"end": 25, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 51, "tag": "ResearchActivity"}]}
{"id": "1359_8", "text": "Ex vivo cerebellar explant cultures of Tnc(-/-) and Tnr(-/-) mouse lines displayed enhanced remyelination by forming thicker myelin membranes upon exposure to lysolecithin.", "tags": [{"end": 35, "start": 8, "tag": "ResearchActivity"}, {"end": 171, "start": 159, "tag": "Chemical"}, {"end": 105, "start": 92, "tag": "CellFunction"}, {"end": 141, "start": 132, "tag": "CellComponent"}, {"end": 141, "start": 125, "tag": "CellComponent"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 159, "tag": "PharmacologicSubstance"}, {"end": 171, "start": 147, "tag": "ResearchActivity"}, {"end": 105, "start": 83, "tag": "Finding"}, {"end": 141, "start": 117, "tag": "Finding"}]}
{"id": "1359_9", "text": "The inhibitory effect of tenascins on remyelination could be confirmed when demyelinated wildtype control cultures were exposed to purified Tnc or Tnr protein.", "tags": [{"end": 34, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "PathologicFunction"}, {"end": 143, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 114, "start": 89, "tag": "ResearchActivity"}, {"end": 158, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 4, "tag": "Finding"}]}
{"id": "1359_10", "text": "In that approach, the remyelination efficiency decreased in a dose-dependent manner with increasing concentrations of ECM molecules added.", "tags": [{"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 122, "tag": "Substance"}, {"end": 35, "start": 22, "tag": "CellFunction"}, {"end": 46, "start": 36, "tag": "Finding"}]}
{"id": "1359_11", "text": "In order to examine potential roles in a complex in vivo environment, we successfully established cuprizone-based acute demyelination to analyze the remyelination behavior after cuprizone withdrawal in SV129, Tnc(-/-), and Tnr(-/-) mice.", "tags": [{"end": 171, "start": 163, "tag": "BiologicFunction"}, {"end": 171, "start": 163, "tag": "IndividualBehavior"}, {"end": 171, "start": 163, "tag": "ResearchActivity"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 162, "start": 149, "tag": "CellFunction"}, {"end": 107, "start": 98, "tag": "Chemical"}, {"end": 187, "start": 178, "tag": "Chemical"}, {"end": 198, "start": 178, "tag": "ResearchActivity"}, {"end": 198, "start": 178, "tag": "HealthCareActivity"}, {"end": 236, "start": 232, "tag": "Eukaryote"}, {"end": 133, "start": 120, "tag": "PathologicFunction"}, {"end": 56, "start": 49, "tag": "ResearchActivity"}, {"end": 236, "start": 232, "tag": "Eukaryote"}, {"end": 207, "start": 202, "tag": "Eukaryote"}, {"end": 212, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1359_12", "text": "In addition, we documented by immunohistochemistry in the cuprizone model the expression of chondroitin sulfate proteoglycans that are inhibitory for the differentiation of OPCs.", "tags": [{"end": 125, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 30, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "Cell"}, {"end": 67, "start": 58, "tag": "Chemical"}, {"end": 73, "start": 58, "tag": "ResearchActivity"}, {"end": 169, "start": 154, "tag": "CellFunction"}]}
{"id": "1359_13", "text": "In conclusion, inhibitory properties of Tnc and Tnr for myelin membrane formation could be demonstrated by using an ex vivo approach.", "tags": [{"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 63, "tag": "CellComponent"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 116, "tag": "ResearchActivity"}, {"end": 81, "start": 56, "tag": "CellFunction"}, {"end": 36, "start": 15, "tag": "Finding"}]}
{"id": "1360_0", "text": "The crosstalk between glial cells and neurons represents an exceptional feature for maintaining the normal function of the central nervous system (CNS).", "tags": [{"end": 145, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 22, "tag": "Cell"}, {"end": 13, "start": 4, "tag": "CellFunction"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 106, "start": 100, "tag": "Finding"}]}
{"id": "1360_1", "text": "Increasing evidence has revealed the importance of glial progenitor cells in adult neurogenesis, reestablishment of cellular pools, neuroregeneration, and axonal (re)myelination.", "tags": [{"end": 73, "start": 51, "tag": "Cell"}, {"end": 161, "start": 155, "tag": "CellComponent"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 130, "start": 116, "tag": "Cell"}, {"end": 95, "start": 83, "tag": "BiologicFunction"}, {"end": 177, "start": 166, "tag": "CellFunction"}, {"end": 82, "start": 77, "tag": "PopulationGroup"}, {"end": 149, "start": 132, "tag": "BiologicFunction"}]}
{"id": "1360_2", "text": "Several types of glial progenitors have been described, as well as their potentialities for recovering the CNS from certain traumas or pathologies.", "tags": [{"end": 131, "start": 124, "tag": "InjuryOrPoisoning"}, {"end": 34, "start": 17, "tag": "Cell"}, {"end": 110, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "DiseaseOrSyndrome"}]}
{"id": "1360_3", "text": "Among these precursors, glial-restricted precursor cells (GRPs) are considered the earliest glial progenitors and exhibit tripotency for both Type I/II astrocytes and oligodendrocytes.", "tags": [{"end": 91, "start": 83, "tag": "TemporalConcept"}, {"end": 183, "start": 167, "tag": "Cell"}, {"end": 56, "start": 24, "tag": "Cell"}, {"end": 109, "start": 92, "tag": "Cell"}, {"end": 162, "start": 142, "tag": "Cell"}, {"end": 62, "start": 58, "tag": "Cell"}]}
{"id": "1360_4", "text": "GRPs have been derived from embryos and embryonic stem cells in animal models and have maintained their capacity for self-renewal.", "tags": [{"end": 35, "start": 28, "tag": "EmbryonicStructure"}, {"end": 129, "start": 117, "tag": "CellFunction"}, {"end": 60, "start": 40, "tag": "Cell"}, {"end": 112, "start": 104, "tag": "Finding"}, {"end": 77, "start": 64, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "Cell"}]}
{"id": "1360_5", "text": "Despite the relatively limited knowledge regarding the isolation, characterization, and function of these progenitors, GRPs are promising candidates for transplantation therapy and reestablishment/repair of CNS functions in neurodegenerative and neuropsychiatric disorders, as well as in traumatic injuries.", "tags": [{"end": 306, "start": 288, "tag": "InjuryOrPoisoning"}, {"end": 210, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}, {"end": 241, "start": 224, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 31, "tag": "Finding"}, {"end": 176, "start": 169, "tag": "HealthCareActivity"}, {"end": 82, "start": 66, "tag": "ResearchActivity"}, {"end": 168, "start": 153, "tag": "HealthCareActivity"}, {"end": 203, "start": 197, "tag": "BiologicFunction"}, {"end": 203, "start": 197, "tag": "HealthCareActivity"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 272, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "Cell"}, {"end": 64, "start": 55, "tag": "ResearchActivity"}]}
{"id": "1360_6", "text": "Herein, we review the definition, isolation, characterization and potentialities of GRPs as cell-based therapies in different neurological conditions.", "tags": [{"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 149, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 92, "tag": "HealthCareActivity"}, {"end": 61, "start": 45, "tag": "ResearchActivity"}, {"end": 88, "start": 84, "tag": "Cell"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}]}
{"id": "1360_7", "text": "We briefly discuss the implications of using GRPs in CNS regenerative medicine and their possible application in a clinical setting.", "tags": [{"end": 78, "start": 57, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 3, "tag": "TemporalConcept"}, {"end": 49, "start": 45, "tag": "Cell"}]}
{"id": "1360_8", "text": "Main Points GRPs are progenitors present in the CNS with differentiation potential restricted to the glial lineage.", "tags": [{"end": 32, "start": 21, "tag": "Cell"}, {"end": 72, "start": 57, "tag": "CellFunction"}, {"end": 114, "start": 101, "tag": "Cell"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 12, "tag": "Cell"}]}
{"id": "1360_9", "text": "These cells have been employed in the treatment of a myriad of neurodegenerative and traumatic pathologies, accompanied by promising results, herein reviewed.", "tags": [{"end": 157, "start": 149, "tag": "HealthCareActivity"}, {"end": 157, "start": 149, "tag": "ResearchActivity"}, {"end": 11, "start": 6, "tag": "Cell"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "ResearchActivity"}, {"end": 106, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 85, "tag": "DiseaseOrSyndrome"}]}
{"id": "1361_0", "text": "BackgroundThe evidence associating consumption of dairy products and risk of MS is contradictory and inconclusive.", "tags": [{"end": 46, "start": 35, "tag": "BiologicFunction"}, {"end": 22, "start": 14, "tag": "Finding"}, {"end": 73, "start": 69, "tag": "Finding"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 50, "tag": "Substance"}]}
{"id": "1361_1", "text": "ObjectiveTo test associations between dairy consumption and the likelihood of a first clinical diagnosis of central nervous system demyelination (FCD), a common precursor to MS.", "tags": [{"end": 16, "start": 12, "tag": "ResearchActivity"}, {"end": 16, "start": 12, "tag": "HealthCareActivity"}, {"end": 144, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 108, "tag": "CellFunction"}, {"end": 130, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 86, "tag": "HealthCareActivity"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 131, "tag": "PathologicFunction"}, {"end": 55, "start": 44, "tag": "BiologicFunction"}, {"end": 74, "start": 64, "tag": "Finding"}, {"end": 43, "start": 38, "tag": "Substance"}]}
{"id": "1361_2", "text": "MethodsWe used data from the 2003-2006 Ausimmune Study, a population-based Australian, multicentre, matched case-control study (272 cases, 519 controls).", "tags": [{"end": 54, "start": 29, "tag": "ResearchActivity"}, {"end": 126, "start": 100, "tag": "ResearchActivity"}, {"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 68, "start": 58, "tag": "PopulationGroup"}, {"end": 19, "start": 15, "tag": "ResearchActivity"}, {"end": 85, "start": 75, "tag": "PopulationGroup"}]}
{"id": "1361_3", "text": "Total dairy consumption (servings/day) was calculated by summing consumption of milk, cheese and yogurt.", "tags": [{"end": 76, "start": 65, "tag": "BiologicFunction"}, {"end": 84, "start": 80, "tag": "Substance"}, {"end": 11, "start": 6, "tag": "Substance"}, {"end": 92, "start": 86, "tag": "Substance"}, {"end": 103, "start": 97, "tag": "Substance"}, {"end": 23, "start": 12, "tag": "BiologicFunction"}]}
{"id": "1361_4", "text": "Covariate-adjusted treatment effects using augmented inverse probability weighting was used to test for associations with FCD.", "tags": [{"end": 99, "start": 95, "tag": "ResearchActivity"}, {"end": 99, "start": 95, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "ResearchActivity"}, {"end": 72, "start": 61, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "Finding"}]}
{"id": "1361_5", "text": "We conducted sensitivity analyses in the subset of participants who had had a classic first demyelinating event (FDE), defined as a single, first episode of symptoms suggestive of CNS demyelination.", "tags": [{"end": 153, "start": 146, "tag": "TemporalConcept"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 63, "start": 51, "tag": "PopulationGroup"}, {"end": 183, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "TemporalConcept"}, {"end": 145, "start": 140, "tag": "TemporalConcept"}, {"end": 165, "start": 157, "tag": "SignOrSymptom"}, {"end": 33, "start": 25, "tag": "ResearchActivity"}, {"end": 24, "start": 13, "tag": "Finding"}, {"end": 197, "start": 184, "tag": "PathologicFunction"}, {"end": 197, "start": 180, "tag": "DiseaseOrSyndrome"}]}
{"id": "1361_6", "text": "ResultsThere were no statistically significant associations between total dairy consumption (per one serving/day) and FCD (adjusted OR 1.00; 95% CI 0.93, 1.07; p = 0.979).", "tags": [{"end": 147, "start": 145, "tag": "ResearchActivity"}, {"end": 79, "start": 74, "tag": "Substance"}, {"end": 91, "start": 80, "tag": "BiologicFunction"}]}
{"id": "1361_7", "text": "However, yogurt consumption (vs.", "tags": [{"end": 27, "start": 16, "tag": "BiologicFunction"}, {"end": 15, "start": 9, "tag": "Substance"}]}
{"id": "1361_8", "text": "no yogurt consumption) was associated with an 11% decreased likelihood of FDE (adjusted OR 0.89; 95% CI 0.89, 0.79; p = 0.046).", "tags": [{"end": 21, "start": 10, "tag": "BiologicFunction"}, {"end": 103, "start": 101, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "Finding"}]}
{"id": "1361_9", "text": "ConclusionWhile total dairy consumption was not associated with FCD in this Australian case-control study, yogurt consumption was associated with reduced likelihood of FDE.", "tags": [{"end": 86, "start": 76, "tag": "PopulationGroup"}, {"end": 105, "start": 87, "tag": "ResearchActivity"}, {"end": 125, "start": 114, "tag": "BiologicFunction"}, {"end": 27, "start": 22, "tag": "Substance"}, {"end": 39, "start": 28, "tag": "BiologicFunction"}, {"end": 113, "start": 107, "tag": "Substance"}, {"end": 164, "start": 154, "tag": "Finding"}]}
{"id": "1362_0", "text": "Myelin sheaths, by supporting axonal integrity and allowing rapid saltatory impulse conduction, are of fundamental importance for neuronal function.", "tags": [{"end": 94, "start": 66, "tag": "CellFunction"}, {"end": 94, "start": 84, "tag": "NaturalPhenomenonOrProcess"}, {"end": 46, "start": 30, "tag": "CellFunction"}, {"end": 94, "start": 84, "tag": "BiologicFunction"}, {"end": 147, "start": 130, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "CellComponent"}]}
{"id": "1362_1", "text": "In response to demyelinating injuries in the central nervous system (CNS), oligodendrocyte progenitor cells (OPCs) migrate to the lesion area, proliferate and differentiate into new oligodendrocytes that make new myelin sheaths.", "tags": [{"end": 198, "start": 182, "tag": "Cell"}, {"end": 113, "start": 109, "tag": "Cell"}, {"end": 172, "start": 159, "tag": "CellFunction"}, {"end": 28, "start": 15, "tag": "PathologicFunction"}, {"end": 136, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 75, "tag": "Cell"}, {"end": 227, "start": 213, "tag": "CellComponent"}, {"end": 107, "start": 91, "tag": "Cell"}, {"end": 37, "start": 15, "tag": "InjuryOrPoisoning"}, {"end": 67, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1362_2", "text": "This process is termed remyelination.", "tags": [{"end": 36, "start": 23, "tag": "CellFunction"}]}
{"id": "1362_3", "text": "Under specific conditions, demyelinated axons in the CNS can also be remyelinated by Schwann cells (SCs), the myelinating cell of the peripheral nervous system.", "tags": [{"end": 159, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 85, "tag": "Cell"}, {"end": 103, "start": 100, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "CellComponent"}, {"end": 39, "start": 27, "tag": "PathologicFunction"}, {"end": 81, "start": 69, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 122, "tag": "Cell"}]}
{"id": "1362_4", "text": "OPCs can be a major source of these CNS-resident SCs-a surprising finding given the distinct embryonic origins, and physiological compartmentalization of the peripheral and central nervous system.", "tags": [{"end": 52, "start": 49, "tag": "Cell"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 48, "start": 40, "tag": "PopulationGroup"}, {"end": 195, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 93, "tag": "EmbryonicStructure"}]}
{"id": "1362_5", "text": "Although the mechanisms and cues governing OPC-to-SC differentiation remain largely undiscovered, it might nevertheless be an attractive target for promoting endogenous remyelination.", "tags": [{"end": 46, "start": 43, "tag": "Cell"}, {"end": 68, "start": 53, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 52, "start": 50, "tag": "Cell"}]}
{"id": "1362_6", "text": "This article will (i) review current knowledge on the origins of SCs in the CNS, with a particular focus on OPC to SC differentiation, (ii) discuss the necessary criteria for SC myelination in the CNS and (iii) highlight the potential of using SCs for myelin regeneration in the CNS.", "tags": [{"end": 61, "start": 54, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 68, "start": 65, "tag": "Cell"}, {"end": 247, "start": 244, "tag": "Cell"}, {"end": 111, "start": 108, "tag": "Cell"}, {"end": 258, "start": 252, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 118, "tag": "CellFunction"}, {"end": 271, "start": 259, "tag": "BiologicFunction"}, {"end": 271, "start": 259, "tag": "HealthCareActivity"}, {"end": 271, "start": 252, "tag": "CellFunction"}, {"end": 79, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 197, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 282, "start": 279, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 46, "start": 37, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 189, "start": 178, "tag": "CellFunction"}]}
{"id": "1363_0", "text": "Disruption or loss of oligodendrocytes (OLs) and myelin has devastating effects on CNS function and integrity, which occur in diverse neurological disorders, including Multiple Sclerosis (MS), Alzheimer's disease and neuropsychiatric disorders.", "tags": [{"end": 38, "start": 22, "tag": "Cell"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 109, "start": 100, "tag": "IndividualBehavior"}, {"end": 186, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 212, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 72, "tag": "Finding"}, {"end": 95, "start": 83, "tag": "BiologicFunction"}, {"end": 86, "start": 83, "tag": "BiologicFunction"}, {"end": 109, "start": 100, "tag": "BiologicFunction"}, {"end": 243, "start": 217, "tag": "DiseaseOrSyndrome"}]}
{"id": "1363_1", "text": "Hence, there is a need to develop new therapies that promote oligodendrocyte regeneration and myelin repair.", "tags": [{"end": 89, "start": 77, "tag": "BiologicFunction"}, {"end": 89, "start": 77, "tag": "HealthCareActivity"}, {"end": 107, "start": 94, "tag": "CellFunction"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}]}
{"id": "1363_2", "text": "A promising approach is drug repurposing, but most agents have potentially contrasting biological actions depending on the cellular context and their dose-dependent effects on intracellular pathways.", "tags": [{"end": 40, "start": 24, "tag": "HealthCareActivity"}, {"end": 189, "start": 176, "tag": "CellComponent"}, {"end": 131, "start": 123, "tag": "Cell"}, {"end": 198, "start": 190, "tag": "CellFunction"}, {"end": 172, "start": 165, "tag": "Finding"}, {"end": 28, "start": 24, "tag": "PharmacologicSubstance"}]}
{"id": "1363_3", "text": "Here, we have used a combined systems biology and neurobiological approach to identify compounds that exert positive and negative effects on oligodendroglia, depending on concentration.", "tags": [{"end": 45, "start": 30, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 141, "tag": "Cell"}, {"end": 96, "start": 87, "tag": "Chemical"}, {"end": 96, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 137, "start": 130, "tag": "Finding"}, {"end": 184, "start": 171, "tag": "BiologicFunction"}]}
{"id": "1363_4", "text": "Notably, next generation pharmacogenomic analysis identified the PI3K/Akt modulator LY294002 as the most highly ranked small molecule with both pro- and anti-oligodendroglial concentration-dependent effects.", "tags": [{"end": 49, "start": 9, "tag": "ResearchActivity"}, {"end": 92, "start": 84, "tag": "Chemical"}, {"end": 133, "start": 119, "tag": "Chemical"}, {"end": 133, "start": 125, "tag": "Substance"}, {"end": 174, "start": 158, "tag": "Cell"}, {"end": 206, "start": 199, "tag": "Finding"}, {"end": 188, "start": 175, "tag": "BiologicFunction"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1363_5", "text": "We validated these in silico findings using multidisciplinary approaches to reveal a profoundly bipartite effect of LY294002 on the generation of OPCs and their differentiation into myelinating oligodendrocytes in both postnatal and adult contexts.", "tags": [{"end": 124, "start": 116, "tag": "Chemical"}, {"end": 193, "start": 182, "tag": "CellFunction"}, {"end": 210, "start": 194, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "Cell"}, {"end": 176, "start": 161, "tag": "CellFunction"}, {"end": 210, "start": 182, "tag": "Cell"}, {"end": 228, "start": 219, "tag": "TemporalConcept"}, {"end": 112, "start": 106, "tag": "Finding"}, {"end": 238, "start": 233, "tag": "PopulationGroup"}, {"end": 142, "start": 132, "tag": "TemporalConcept"}, {"end": 124, "start": 116, "tag": "PharmacologicSubstance"}]}
{"id": "1363_6", "text": "Finally, we employed transcriptional profiling and signalling pathway activity assays to determine cell-specific mechanisms of action of LY294002 on oligodendrocytes and resolve optimal in vivo conditions required to promote myelin repair.", "tags": [{"end": 145, "start": 137, "tag": "Chemical"}, {"end": 165, "start": 149, "tag": "Cell"}, {"end": 69, "start": 51, "tag": "CellFunction"}, {"end": 238, "start": 225, "tag": "CellFunction"}, {"end": 85, "start": 51, "tag": "ResearchActivity"}, {"end": 103, "start": 99, "tag": "Cell"}, {"end": 46, "start": 21, "tag": "ResearchActivity"}, {"end": 193, "start": 186, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "PharmacologicSubstance"}]}
{"id": "1363_7", "text": "These results demonstrate the power of multidisciplinary strategies in determining the therapeutic potential of small molecules in neurodegenerative disorders.", "tags": [{"end": 127, "start": 112, "tag": "Chemical"}, {"end": 67, "start": 57, "tag": "ResearchActivity"}, {"end": 67, "start": 57, "tag": "BiologicFunction"}, {"end": 127, "start": 118, "tag": "Substance"}, {"end": 108, "start": 87, "tag": "HealthCareActivity"}, {"end": 158, "start": 131, "tag": "DiseaseOrSyndrome"}]}
{"id": "1364_0", "text": "Given the known neuroreparative actions of IL-33 in experimental models of central nervous system (CNS) injury, we predicted that compounds which induce IL-33 are likely to promote remyelination.", "tags": [{"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 139, "start": 130, "tag": "Chemical"}, {"end": 139, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 180, "start": 173, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "InjuryOrPoisoning"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 71, "start": 52, "tag": "ResearchActivity"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 16, "tag": "CellFunction"}]}
{"id": "1364_1", "text": "We found anacardic acid as a candidate molecule to serve as a therapeutic agent to promote remyelination.", "tags": [{"end": 23, "start": 9, "tag": "Chemical"}, {"end": 79, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 39, "tag": "Substance"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 23, "start": 9, "tag": "PharmacologicSubstance"}]}
{"id": "1364_2", "text": "Addition of anacardic acid to cultured oligodendrocyte precursor cells (OPCs) rapidly increased expression of myelin genes and myelin proteins, suggesting a direct induction of genes involved in myelination by anacardic acid.", "tags": [{"end": 26, "start": 12, "tag": "Chemical"}, {"end": 142, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 224, "start": 210, "tag": "Chemical"}, {"end": 76, "start": 72, "tag": "Cell"}, {"end": 70, "start": 39, "tag": "Cell"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 96, "tag": "CellFunction"}, {"end": 206, "start": 195, "tag": "CellFunction"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 182, "start": 164, "tag": "CellFunction"}, {"end": 224, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 26, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 117, "tag": "GeneOrGenome"}]}
{"id": "1364_3", "text": "Also, when added to OPCs, anacardic acid resulted in the induction of IL-33.", "tags": [{"end": 40, "start": 26, "tag": "Chemical"}, {"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "HealthCareRelatedOrganization"}, {"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 70, "tag": "CellFunction"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 40, "start": 26, "tag": "PharmacologicSubstance"}]}
{"id": "1364_4", "text": "In vivo, treatment of with anacardic acid in doses which ranged from 0.025 mg/kg to 2.5 mg/kg, improved pathologic scores in experimental allergic encephalitis (EAE) and in the cuprizone model of demyelination/remyelination.", "tags": [{"end": 41, "start": 27, "tag": "Chemical"}, {"end": 159, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 161, "tag": "ExperimentalModelOfDisease"}, {"end": 186, "start": 177, "tag": "Chemical"}, {"end": 192, "start": 177, "tag": "ResearchActivity"}, {"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 18, "start": 9, "tag": "ResearchActivity"}, {"end": 223, "start": 210, "tag": "CellFunction"}, {"end": 209, "start": 196, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 41, "start": 27, "tag": "PharmacologicSubstance"}]}
{"id": "1364_5", "text": "Electron microscopic studies performed in mice fed with cuprizone and treated with anacardic acid showed lower g-ratio scores when compared to controls, suggesting increased remyelination of axons.", "tags": [{"end": 97, "start": 83, "tag": "Chemical"}, {"end": 125, "start": 111, "tag": "Finding"}, {"end": 196, "start": 191, "tag": "CellComponent"}, {"end": 65, "start": 56, "tag": "Chemical"}, {"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 46, "start": 42, "tag": "Eukaryote"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "HealthCareActivity"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 97, "start": 83, "tag": "PharmacologicSubstance"}]}
{"id": "1364_6", "text": "In EAE, improvement in paralytic scores was seen when the drug was given prior to or following the onset of paralytic signs.", "tags": [{"end": 123, "start": 108, "tag": "SignOrSymptom"}, {"end": 6, "start": 3, "tag": "ExperimentalModelOfDisease"}, {"end": 104, "start": 99, "tag": "TemporalConcept"}, {"end": 62, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 39, "start": 23, "tag": "Finding"}]}
{"id": "1364_7", "text": "In EAE and in the cuprizone model, areas of myelin loss, which are likely to remyelinate, was associated with a greater recruitment of IL-33-expressing OPCs in mice which received anacardic acid when compared to controls.", "tags": [{"end": 194, "start": 180, "tag": "Chemical"}, {"end": 151, "start": 141, "tag": "CellFunction"}, {"end": 6, "start": 3, "tag": "ExperimentalModelOfDisease"}, {"end": 156, "start": 152, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 27, "start": 18, "tag": "Chemical"}, {"end": 33, "start": 18, "tag": "ResearchActivity"}, {"end": 220, "start": 212, "tag": "PopulationGroup"}, {"end": 164, "start": 160, "tag": "Eukaryote"}, {"end": 194, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 55, "start": 44, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 135, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1365_0", "text": "Arrest of oligodendrocyte (OL) differentiation and remyelination following myelin damage in multiple sclerosis (MS) is associated with neurodegeneration and clinical worsening.", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 175, "start": 157, "tag": "Finding"}, {"end": 110, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 29, "start": 27, "tag": "Cell"}, {"end": 152, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 10, "tag": "Cell"}, {"end": 64, "start": 51, "tag": "CellFunction"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}]}
{"id": "1365_1", "text": "We show that Glutathione S-transferase 4 alpha (Gsta4) is highly expressed during adult OL differentiation and that Gsta4 loss impairs differentiation into myelinating OLs in vitro.", "tags": [{"end": 46, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "GeneOrGenome"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 156, "tag": "Cell"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 106, "start": 88, "tag": "CellFunction"}, {"end": 180, "start": 172, "tag": "ResearchActivity"}, {"end": 87, "start": 82, "tag": "PopulationGroup"}, {"end": 74, "start": 65, "tag": "CellFunction"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 116, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1365_2", "text": "In addition, we identify Gsta4 as a target of both dimethyl fumarate, an existing MS therapy, and clemastine fumarate, a candidate remyelinating agent in MS.", "tags": [{"end": 30, "start": 25, "tag": "GeneOrGenome"}, {"end": 30, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 98, "tag": "Chemical"}, {"end": 68, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 51, "tag": "Chemical"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 150, "start": 145, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 85, "tag": "HealthCareActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 98, "tag": "PharmacologicSubstance"}]}
{"id": "1365_3", "text": "Overexpression of Gsta4 reduces expression of Fas and activity of the mitochondria-associated Casp8-Bid-axis in adult oligodendrocyte precursor cells, leading to improved OL survival during differentiation.", "tags": [{"end": 23, "start": 18, "tag": "GeneOrGenome"}, {"end": 23, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 46, "tag": "GeneOrGenome"}, {"end": 149, "start": 118, "tag": "Cell"}, {"end": 205, "start": 190, "tag": "CellFunction"}, {"end": 173, "start": 171, "tag": "Cell"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 182, "start": 174, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 117, "start": 112, "tag": "PopulationGroup"}, {"end": 82, "start": 70, "tag": "CellComponent"}, {"end": 23, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1365_4", "text": "The Gsta4 effect on apoptosis during adult OL differentiation was corroborated in vivo in both lysolecithin-induced demyelination and experimental autoimmune encephalomyelitis models, where Casp8 activity was reduced in Gsta4-overexpressing OLs.", "tags": [{"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 134, "tag": "ExperimentalModelOfDisease"}, {"end": 107, "start": 95, "tag": "Chemical"}, {"end": 107, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 244, "start": 241, "tag": "Cell"}, {"end": 61, "start": 43, "tag": "CellFunction"}, {"end": 16, "start": 10, "tag": "Finding"}, {"end": 29, "start": 20, "tag": "CellFunction"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 42, "start": 37, "tag": "PopulationGroup"}, {"end": 225, "start": 220, "tag": "GeneOrGenome"}, {"end": 225, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "GeneOrGenome"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 190, "tag": "CellFunction"}]}
{"id": "1365_5", "text": "Our results identify Gsta4 as an intrinsic regulator of OL differentiation, survival and remyelination, as well as a potential target for future reparative MS therapies.", "tags": [{"end": 26, "start": 21, "tag": "GeneOrGenome"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 56, "tag": "CellFunction"}, {"end": 84, "start": 76, "tag": "CellFunction"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 155, "start": 145, "tag": "HealthCareActivity"}, {"end": 158, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 117, "tag": "Finding"}]}
{"id": "1366_0", "text": "A puzzling feature of schizophrenia, is the long latency between the beginning of neuropathological changes and the clinical presentation that may be two decades later.", "tags": [{"end": 161, "start": 154, "tag": "TemporalConcept"}, {"end": 137, "start": 125, "tag": "Finding"}, {"end": 35, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 49, "tag": "TemporalConcept"}]}
{"id": "1366_1", "text": "Abnormalities in oligodendrocyte function may explain this latency, because mature oligodendrocytes produce myelination, and if myelination were abnormal from the outset, it would cause the synaptic dysfunction and abnormal neural tracts that are underpinning features of schizophrenia.", "tags": [{"end": 13, "start": 0, "tag": "Finding"}, {"end": 153, "start": 145, "tag": "Finding"}, {"end": 223, "start": 215, "tag": "Finding"}, {"end": 210, "start": 190, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 76, "tag": "Cell"}, {"end": 119, "start": 108, "tag": "CellFunction"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 285, "start": 272, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 41, "start": 17, "tag": "CellFunction"}, {"end": 237, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1366_2", "text": "The hypothesis is that latency is caused by events that occur in some patients as early as in-utero or infancy, because clones of abnormal, myelinating oligodendrocytes may arise at that time; their number doubles every similar to 2 years, so their geometric increase between birth and age twenty, when clinical presentation occurs, is about 1000-fold plus the effect of compounding.", "tags": [{"end": 126, "start": 120, "tag": "Cell"}, {"end": 138, "start": 130, "tag": "Finding"}, {"end": 281, "start": 276, "tag": "BiologicFunction"}, {"end": 168, "start": 140, "tag": "Cell"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "PopulationGroup"}, {"end": 324, "start": 312, "tag": "Finding"}, {"end": 289, "start": 286, "tag": "OrganismAttribute"}, {"end": 238, "start": 233, "tag": "TemporalConcept"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 191, "start": 187, "tag": "TemporalConcept"}, {"end": 30, "start": 23, "tag": "TemporalConcept"}, {"end": 99, "start": 91, "tag": "TemporalConcept"}]}
{"id": "1366_3", "text": "For those patients in particular, the long latency is because of a small but ongoing increase in volume of the resulting, abnormally myelinated neural tracts until, after a long latent interval, a critical mass is reached that allows the full clinical features of schizophrenia.", "tags": [{"end": 260, "start": 243, "tag": "ClinicalAttribute"}, {"end": 277, "start": 264, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 84, "start": 77, "tag": "TemporalConcept"}, {"end": 50, "start": 43, "tag": "TemporalConcept"}, {"end": 157, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 122, "tag": "PathologicFunction"}]}
{"id": "1366_4", "text": "During latency, there may be behavioral aberrancies because of abnormally myelinated neural tracts but they are insufficiently numerous for the clinical syndrome.", "tags": [{"end": 161, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 51, "start": 29, "tag": "PathologicFunction"}, {"end": 84, "start": 63, "tag": "PathologicFunction"}, {"end": 98, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1366_5", "text": "The occurrence of behavioral symptoms during the long latent period, substantiates the hypothesis that abnormal oligodendrocytes explain the latency in some patients.", "tags": [{"end": 37, "start": 18, "tag": "SignOrSymptom"}, {"end": 128, "start": 112, "tag": "Cell"}, {"end": 67, "start": 61, "tag": "TemporalConcept"}, {"end": 14, "start": 4, "tag": "TemporalConcept"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 141, "tag": "TemporalConcept"}, {"end": 128, "start": 103, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1366_6", "text": "Treatment with fingolimod or siponimod benefits both oligodendrocytes and neural tracts.", "tags": [{"end": 38, "start": 29, "tag": "Chemical"}, {"end": 69, "start": 53, "tag": "Cell"}, {"end": 25, "start": 15, "tag": "Chemical"}, {"end": 25, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1366_7", "text": "Clinical trial would validate their potential benefit in appropriate patients with schizophrenia and, concurrently, would validate the hypothesis.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 96, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}]}
{"id": "1367_0", "text": "Myelin repair in the adult central nervous system (CNS) is driven by successful differentiation of resident oligodendroglial precursor cells (OPCs) and thus constitutes a neurodegenerative process capable to compensate for functional deficits upon loss of oligodendrocytes and myelin sheaths as it is observed in multiple sclerosis (MS).", "tags": [{"end": 107, "start": 99, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "PopulationGroup"}, {"end": 54, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 256, "tag": "Cell"}, {"end": 196, "start": 171, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 108, "tag": "Cell"}, {"end": 146, "start": 142, "tag": "Cell"}, {"end": 291, "start": 277, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 234, "tag": "Finding"}, {"end": 335, "start": 333, "tag": "DiseaseOrSyndrome"}, {"end": 331, "start": 313, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 49, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 248, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1367_1", "text": "The human endogenous retrovirus type W (HERV-W) represents an MS-specific pathogenic entity, and its envelope (ENV) protein was previously identified as a negative regulator of OPC maturation-hence, it is of relevance in the context of diminished myelin repair.", "tags": [{"end": 46, "start": 40, "tag": "Virus"}, {"end": 109, "start": 101, "tag": "CellComponent"}, {"end": 84, "start": 74, "tag": "PathologicFunction"}, {"end": 180, "start": 177, "tag": "Cell"}, {"end": 191, "start": 181, "tag": "BiologicFunction"}, {"end": 260, "start": 247, "tag": "CellFunction"}, {"end": 9, "start": 4, "tag": "Eukaryote"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 4, "tag": "Virus"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1367_2", "text": "We here focused on the activity of the ENV protein and investigated how it can be neutralized for improved remyelination.", "tags": [{"end": 50, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 107, "tag": "CellFunction"}, {"end": 50, "start": 39, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1367_3", "text": "ENV-mediated activation of toll like receptor 4 (TLR4) increases inducible nitric oxide synthase (iNOS) expression, prompts nitrosative stress, and results in myelin-associated deficits, such as decreased levels of oligodendroglial maturation marker expression and morphological alterations.", "tags": [{"end": 47, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 27, "tag": "GeneOrGenome"}, {"end": 142, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 204, "start": 195, "tag": "Finding"}, {"end": 242, "start": 232, "tag": "BiologicFunction"}, {"end": 231, "start": 215, "tag": "Cell"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "GeneOrGenome"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 177, "tag": "Finding"}, {"end": 47, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 243, "tag": "ClinicalAttribute"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 290, "start": 265, "tag": "PathologicFunction"}]}
{"id": "1367_4", "text": "The intervention of TLR4 surface expression represents a potential means to rescue such ENV-dependent deficits.", "tags": [{"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "GeneOrGenome"}, {"end": 24, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 25, "tag": "CellFunction"}]}
{"id": "1367_5", "text": "To this end, the rescue capacity of specific substances, either modulating V-ATPase activity or myeloid differentiation 2 (MD2)-mediated TLR4 glycosylation status, such as compound 20 (C20), L48H437, or folimycin, was analyzed, as these processes were demonstrated to be relevant for TLR4 surface expression.", "tags": [{"end": 55, "start": 45, "tag": "Substance"}, {"end": 121, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 156, "tag": "Finding"}, {"end": 183, "start": 172, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 203, "tag": "Chemical"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 284, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "GeneOrGenome"}, {"end": 288, "start": 284, "tag": "GeneOrGenome"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 284, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 75, "tag": "CellFunction"}, {"end": 83, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 191, "tag": "Chemical"}, {"end": 198, "start": 191, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 203, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 172, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 185, "tag": "PharmacologicSubstance"}, {"end": 307, "start": 289, "tag": "CellFunction"}]}
{"id": "1367_6", "text": "We found that pharmacological treatment can rescue the maturation arrest of oligodendroglial cells and their myelination capacity and can prevent iNOS induction in the presence of the ENV protein.", "tags": [{"end": 72, "start": 66, "tag": "TemporalConcept"}, {"end": 98, "start": 76, "tag": "Cell"}, {"end": 176, "start": 168, "tag": "Finding"}, {"end": 195, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 109, "tag": "CellFunction"}, {"end": 65, "start": 55, "tag": "BiologicFunction"}, {"end": 150, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 14, "tag": "HealthCareActivity"}, {"end": 160, "start": 146, "tag": "CellFunction"}]}
{"id": "1367_7", "text": "In addition, downregulation of TLR4 surface expression was observed.", "tags": [{"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 13, "tag": "CellFunction"}, {"end": 54, "start": 36, "tag": "CellFunction"}]}
{"id": "1367_8", "text": "Furthermore, mitochondrial integrity crucial for oligodendroglial cell differentiation was affected in the presence of ENV and ameliorated upon pharmacological treatment.", "tags": [{"end": 36, "start": 27, "tag": "IndividualBehavior"}, {"end": 115, "start": 107, "tag": "Finding"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 144, "tag": "HealthCareActivity"}, {"end": 26, "start": 13, "tag": "CellComponent"}, {"end": 70, "start": 49, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}]}
{"id": "1367_9", "text": "Our study, therefore, provides novel insights into possible means to overcome myelination deficits associated with HERV-W ENV-mediated myelin deficits.", "tags": [{"end": 121, "start": 115, "tag": "Virus"}, {"end": 89, "start": 78, "tag": "CellFunction"}, {"end": 150, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 98, "start": 90, "tag": "Finding"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 125, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 122, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1368_0", "text": "Oligodendrocytes, the myelinating cells in the vertebrate central nervous system, produce myelin sheaths to enable saltatory propagation of action potentials.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 104, "start": 90, "tag": "CellComponent"}, {"end": 157, "start": 140, "tag": "CellFunction"}, {"end": 80, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 22, "tag": "Cell"}, {"end": 57, "start": 47, "tag": "Eukaryote"}, {"end": 136, "start": 115, "tag": "CellFunction"}]}
{"id": "1368_1", "text": "The process of oligodendrocyte myelination entails a stepwise progression from precursor specification to differentiation, which is coordinated by a series of transcriptional and chromatin remodeling events.", "tags": [{"end": 143, "start": 132, "tag": "Finding"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 121, "start": 106, "tag": "CellFunction"}, {"end": 199, "start": 189, "tag": "BiologicFunction"}, {"end": 188, "start": 179, "tag": "CellComponent"}, {"end": 73, "start": 62, "tag": "PathologicFunction"}, {"end": 73, "start": 62, "tag": "TemporalConcept"}, {"end": 30, "start": 15, "tag": "Cell"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 102, "start": 79, "tag": "CellFunction"}]}
{"id": "1368_2", "text": "ATP-dependent chromatin remodeling enzymes, which utilize ATP as an energy source to control chromatin dynamics and regulate the accessibility of chromatin to transcriptional regulators, are critical for oligodendrocyte lineage development and regeneration.", "tags": [{"end": 61, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 185, "start": 159, "tag": "CellFunction"}, {"end": 42, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 244, "tag": "BiologicFunction"}, {"end": 102, "start": 93, "tag": "CellComponent"}, {"end": 155, "start": 146, "tag": "CellComponent"}, {"end": 74, "start": 68, "tag": "NaturalPhenomenonOrProcess"}, {"end": 227, "start": 204, "tag": "Cell"}, {"end": 256, "start": 244, "tag": "HealthCareActivity"}, {"end": 239, "start": 228, "tag": "BiologicFunction"}, {"end": 239, "start": 228, "tag": "CellFunction"}, {"end": 111, "start": 103, "tag": "NaturalPhenomenonOrProcess"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 75, "tag": "Finding"}, {"end": 34, "start": 0, "tag": "CellFunction"}]}
{"id": "1368_3", "text": "In this review, we focus on the latest insights into the spatial and temporal specificity of chromatin remodelers during oligodendrocyte development, myelinogenesis, and regeneration.", "tags": [{"end": 164, "start": 150, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "TemporalConcept"}, {"end": 148, "start": 121, "tag": "CellFunction"}, {"end": 182, "start": 170, "tag": "BiologicFunction"}, {"end": 182, "start": 170, "tag": "HealthCareActivity"}, {"end": 89, "start": 78, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 113, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 93, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1368_4", "text": "We will also bring together various plausible mechanisms by which lineage specific transcriptional regulators coordinate with chromatin remodeling factors for programming genomic landscapes to specifically modulate these different processes during developmental myelination and remyelination upon injury.", "tags": [{"end": 109, "start": 83, "tag": "CellFunction"}, {"end": 154, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 261, "start": 248, "tag": "BiologicFunction"}, {"end": 261, "start": 248, "tag": "TemporalConcept"}, {"end": 189, "start": 171, "tag": "GeneOrGenome"}, {"end": 303, "start": 297, "tag": "InjuryOrPoisoning"}, {"end": 291, "start": 278, "tag": "CellFunction"}, {"end": 273, "start": 262, "tag": "CellFunction"}, {"end": 154, "start": 126, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1369_0", "text": "Myelination facilitates rapid axonal conduction, enabling efficient communication across different parts of the nervous system.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 81, "start": 68, "tag": "HealthCareActivity"}, {"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 126, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 30, "tag": "CellFunction"}]}
{"id": "1369_1", "text": "Here we examined mechanisms controlling myelination after injury and during axon regeneration in the central nervous system (CNS).", "tags": [{"end": 93, "start": 76, "tag": "BiologicFunction"}, {"end": 123, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "InjuryOrPoisoning"}, {"end": 51, "start": 40, "tag": "CellFunction"}]}
{"id": "1369_2", "text": "Previously, we discovered multiple molecular pathways and strategies that could promote robust axon regrowth after optic nerve injury.", "tags": [{"end": 133, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 95, "tag": "CellComponent"}, {"end": 68, "start": 58, "tag": "ResearchActivity"}, {"end": 68, "start": 58, "tag": "BiologicFunction"}, {"end": 53, "start": 35, "tag": "CellFunction"}, {"end": 108, "start": 95, "tag": "BiologicFunction"}]}
{"id": "1369_3", "text": "However, regenerated axons remain unmyelinated, and the underlying mechanisms are elusive.", "tags": [{"end": 26, "start": 21, "tag": "CellComponent"}]}
{"id": "1369_4", "text": "In this study, we found that, in injured optic nerves, oligodendrocyte precursor cells (OPCs) undergo transient proliferation but fail to differentiate into mature myelination-competent oligodendrocytes, reminiscent of what is observed in human progressive multiple sclerosis.", "tags": [{"end": 53, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 186, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "Cell"}, {"end": 86, "start": 55, "tag": "Cell"}, {"end": 151, "start": 138, "tag": "CellFunction"}, {"end": 275, "start": 257, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "TemporalConcept"}, {"end": 125, "start": 112, "tag": "CellFunction"}, {"end": 163, "start": 157, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 244, "start": 239, "tag": "Eukaryote"}, {"end": 256, "start": 245, "tag": "TemporalConcept"}, {"end": 175, "start": 164, "tag": "CellFunction"}, {"end": 40, "start": 33, "tag": "InjuryOrPoisoning"}]}
{"id": "1369_5", "text": "Mechanistically, we showed that OPC-intrinsic GPR17 signaling and sustained activation of microglia inhibit different stages of OPC differentiation.", "tags": [{"end": 35, "start": 32, "tag": "Cell"}, {"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 147, "start": 128, "tag": "CellFunction"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "Cell"}, {"end": 124, "start": 118, "tag": "TemporalConcept"}, {"end": 86, "start": 76, "tag": "CellFunction"}]}
{"id": "1369_6", "text": "Importantly, co-manipulation of GPR1 7 and microglia led to extensive myelination of regenerated axons.", "tags": [{"end": 38, "start": 32, "tag": "GeneOrGenome"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 52, "start": 43, "tag": "Cell"}, {"end": 81, "start": 70, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1369_7", "text": "The regulatory mechanisms of stage-dependent OPC differentiation uncovered here suggest a translatable strategy for efficient de novo myelination after CNS injury.", "tags": [{"end": 162, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 64, "start": 45, "tag": "CellFunction"}, {"end": 155, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 126, "tag": "CellFunction"}]}
{"id": "1370_0", "text": "Background and Objectives To test whether low concentrations of teriflunomide (TF) could promote remyelination, we investigate the effect of TF on oligodendrocyte in culture and on remyelination in vivo in 2 demyelinating models.", "tags": [{"end": 10, "start": 0, "tag": "NaturalPhenomenonOrProcess"}, {"end": 77, "start": 64, "tag": "Chemical"}, {"end": 81, "start": 79, "tag": "Chemical"}, {"end": 143, "start": 141, "tag": "Chemical"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}, {"end": 173, "start": 166, "tag": "ResearchActivity"}, {"end": 228, "start": 222, "tag": "ResearchActivity"}, {"end": 137, "start": 131, "tag": "Finding"}, {"end": 202, "start": 195, "tag": "ResearchActivity"}, {"end": 162, "start": 147, "tag": "Cell"}, {"end": 45, "start": 42, "tag": "Finding"}, {"end": 60, "start": 46, "tag": "BiologicFunction"}, {"end": 110, "start": 97, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 77, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 81, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 143, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 228, "start": 208, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1370_1", "text": "Methods The effect of TF on oligodendrocyte precursor cell (OPC) proliferation and differentiation was assessed in vitro in glial cultures derived from neonatal mice and confirmed on fluorescence-activated cell sorting-sorted adult OPCs.", "tags": [{"end": 24, "start": 22, "tag": "Chemical"}, {"end": 138, "start": 130, "tag": "ResearchActivity"}, {"end": 236, "start": 232, "tag": "Cell"}, {"end": 63, "start": 60, "tag": "Cell"}, {"end": 98, "start": 83, "tag": "CellFunction"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 58, "start": 28, "tag": "Cell"}, {"end": 129, "start": 124, "tag": "Cell"}, {"end": 160, "start": 152, "tag": "PopulationGroup"}, {"end": 160, "start": 152, "tag": "TemporalConcept"}, {"end": 165, "start": 161, "tag": "Eukaryote"}, {"end": 58, "start": 54, "tag": "Cell"}, {"end": 210, "start": 206, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "Finding"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 195, "start": 183, "tag": "NaturalPhenomenonOrProcess"}, {"end": 231, "start": 226, "tag": "PopulationGroup"}, {"end": 24, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 218, "start": 183, "tag": "ResearchActivity"}]}
{"id": "1370_2", "text": "The levels of the 8,9-unsaturated sterols lanosterol and zymosterol were quantified in TF- and sham-treated cultures.", "tags": [{"end": 67, "start": 57, "tag": "Chemical"}, {"end": 116, "start": 108, "tag": "ResearchActivity"}, {"end": 41, "start": 18, "tag": "Chemical"}, {"end": 52, "start": 42, "tag": "Chemical"}, {"end": 52, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 87, "tag": "Chemical"}]}
{"id": "1370_3", "text": "In vivo, TF was administered orally, and remyelination was assessed both in myelin basic protein-GFP-nitroreductase (Mbp:GFP-NTR) transgenic Xenopus laevis demyelinated by metronidazole and in adult mice demyelinated by lysolecithin.", "tags": [{"end": 11, "start": 9, "tag": "Chemical"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 172, "tag": "Chemical"}, {"end": 168, "start": 156, "tag": "PathologicFunction"}, {"end": 216, "start": 204, "tag": "PathologicFunction"}, {"end": 232, "start": 220, "tag": "Chemical"}, {"end": 232, "start": 220, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 198, "start": 193, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 11, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 97, "tag": "Chemical"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 141, "tag": "Eukaryote"}, {"end": 155, "start": 116, "tag": "ResearchActivity"}, {"end": 185, "start": 172, "tag": "PharmacologicSubstance"}]}
{"id": "1370_4", "text": "Results In cultures, low concentrations of TF down to 10 nM decreased OPC proliferation and increased their differentiation, an effect that was also detected on adult OPCs.", "tags": [{"end": 45, "start": 43, "tag": "Chemical"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 171, "start": 167, "tag": "Cell"}, {"end": 73, "start": 70, "tag": "Cell"}, {"end": 123, "start": 108, "tag": "CellFunction"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 134, "start": 128, "tag": "Finding"}, {"end": 24, "start": 21, "tag": "Finding"}, {"end": 39, "start": 25, "tag": "BiologicFunction"}, {"end": 166, "start": 161, "tag": "PopulationGroup"}, {"end": 45, "start": 43, "tag": "PharmacologicSubstance"}]}
{"id": "1370_5", "text": "Oligodendrocyte differentiation induced by TF was abrogated by the oxidosqualene cyclase inhibitor Ro 48-8071 and was mediated by the accumulation of zymosterol.", "tags": [{"end": 45, "start": 43, "tag": "Chemical"}, {"end": 160, "start": 150, "tag": "Chemical"}, {"end": 98, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 89, "tag": "Chemical"}, {"end": 31, "start": 16, "tag": "CellFunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 146, "start": 134, "tag": "Finding"}, {"end": 45, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "PharmacologicSubstance"}]}
{"id": "1370_6", "text": "In the demyelinated tadpole, TF enhanced the regeneration of mature oligodendrocytes up to 2.5-fold.", "tags": [{"end": 31, "start": 29, "tag": "Chemical"}, {"end": 19, "start": 7, "tag": "PathologicFunction"}, {"end": 84, "start": 61, "tag": "Cell"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "HealthCareActivity"}, {"end": 31, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 27, "start": 20, "tag": "Eukaryote"}]}
{"id": "1370_7", "text": "In the mouse demyelinated spinal cord, TF promoted the differentiation of newly generated oligodendrocytes by a factor of 1.7-fold and significantly increased remyelination.", "tags": [{"end": 41, "start": 39, "tag": "Chemical"}, {"end": 106, "start": 90, "tag": "Cell"}, {"end": 25, "start": 13, "tag": "PathologicFunction"}, {"end": 37, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 55, "tag": "CellFunction"}, {"end": 12, "start": 7, "tag": "Eukaryote"}, {"end": 158, "start": 135, "tag": "Finding"}, {"end": 172, "start": 159, "tag": "CellFunction"}, {"end": 41, "start": 39, "tag": "PharmacologicSubstance"}]}
{"id": "1370_8", "text": "Discussion TF enhances zymosterol accumulation in oligodendrocytes and CNS myelin repair, a beneficial off-target effect that should be investigated in patients with multiple sclerosis.", "tags": [{"end": 33, "start": 23, "tag": "Chemical"}, {"end": 66, "start": 50, "tag": "Cell"}, {"end": 184, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 160, "start": 152, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 34, "tag": "Finding"}, {"end": 120, "start": 92, "tag": "Finding"}, {"end": 13, "start": 11, "tag": "Chemical"}, {"end": 13, "start": 11, "tag": "PharmacologicSubstance"}]}
{"id": "1371_0", "text": "Astrocyte-derived cholesterol supports brain cells under physiological conditions.", "tags": [{"end": 29, "start": 18, "tag": "Chemical"}, {"end": 29, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 39, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}]}
{"id": "1371_1", "text": "However, in demyelinating lesions, astrocytes downregulate cholesterol synthesis, and the cholesterol that is essential for remyelination has to originate from other cellular sources.", "tags": [{"end": 33, "start": 12, "tag": "InjuryOrPoisoning"}, {"end": 58, "start": 46, "tag": "CellFunction"}, {"end": 80, "start": 59, "tag": "CellFunction"}, {"end": 137, "start": 124, "tag": "CellFunction"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 70, "start": 59, "tag": "Chemical"}, {"end": 101, "start": 90, "tag": "Chemical"}, {"end": 70, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 35, "tag": "Cell"}]}
{"id": "1371_2", "text": "Here, we show that repair following acute versus chronic demyelination involves distinct processes.", "tags": [{"end": 25, "start": 19, "tag": "BiologicFunction"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}, {"end": 56, "start": 49, "tag": "TemporalConcept"}, {"end": 41, "start": 36, "tag": "TemporalConcept"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}]}
{"id": "1371_3", "text": "In particular, in chronic myelin disease, when recycling of lipids is often defective, de novo neuronal cholesterol synthesis is critical for regeneration.", "tags": [{"end": 66, "start": 60, "tag": "Chemical"}, {"end": 66, "start": 60, "tag": "ResearchActivity"}, {"end": 154, "start": 142, "tag": "BiologicFunction"}, {"end": 154, "start": 142, "tag": "HealthCareActivity"}, {"end": 154, "start": 142, "tag": "Finding"}, {"end": 115, "start": 95, "tag": "Chemical"}, {"end": 115, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 87, "tag": "CellFunction"}]}
{"id": "1371_4", "text": "By gene expression profiling, genetic loss-of-function experiments, and comprehensive phenotyping, we provide evidence that neurons increase cholesterol synthesis in chronic myelin disease models and in patients with multiple sclerosis (MS).", "tags": [{"end": 28, "start": 3, "tag": "ResearchActivity"}, {"end": 97, "start": 72, "tag": "ResearchActivity"}, {"end": 162, "start": 141, "tag": "CellFunction"}, {"end": 152, "start": 141, "tag": "Chemical"}, {"end": 152, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 239, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 3, "tag": "CellFunction"}, {"end": 211, "start": 203, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 124, "tag": "Cell"}, {"end": 235, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 30, "tag": "ResearchActivity"}, {"end": 195, "start": 166, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1371_5", "text": "In mouse models, neuronal cholesterol facilitates remyelination specifically by triggering oligodendrocyte precursor cell proliferation.", "tags": [{"end": 63, "start": 50, "tag": "CellFunction"}, {"end": 121, "start": 91, "tag": "Cell"}, {"end": 37, "start": 17, "tag": "Chemical"}, {"end": 37, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 3, "tag": "ManufacturedObject"}, {"end": 135, "start": 91, "tag": "CellFunction"}]}
{"id": "1371_6", "text": "Our data contribute to the understanding of disease progression and have implications for therapeutic strategies in patients with MS.", "tags": [{"end": 63, "start": 52, "tag": "PathologicFunction"}, {"end": 63, "start": 52, "tag": "TemporalConcept"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 44, "tag": "PathologicFunction"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 90, "tag": "HealthCareActivity"}]}
{"id": "1372_0", "text": "Carbon monoxide (CO) poisoning usually causes brain lesions and delayed encephalopathy, also known as delayed neurological sequelae (DNS).", "tags": [{"end": 15, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 15, "start": 0, "tag": "Chemical"}, {"end": 19, "start": 17, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 17, "tag": "Chemical"}, {"end": 30, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 46, "tag": "Finding"}, {"end": 131, "start": 102, "tag": "PathologicFunction"}, {"end": 86, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 133, "tag": "PathologicFunction"}]}
{"id": "1372_1", "text": "Demyelination of white matter (WM) is one of the most common sites of abnormalities in patients with DNS, but its mechanisms remain unclear.", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 33, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 101, "tag": "PathologicFunction"}]}
{"id": "1372_2", "text": "Oligodendrocytes (OLs) are myelinated cells that ensure the rapid conduction of neuronal axon signals and provide the nutritional factors necessary for maintaining nerve integrity in the central nervous system (CNS).", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 21, "start": 18, "tag": "Cell"}, {"end": 179, "start": 164, "tag": "BiologicFunction"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 214, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 80, "tag": "CellFunction"}, {"end": 101, "start": 60, "tag": "Finding"}]}
{"id": "1372_3", "text": "OLs readily regenerate and replace damaged myelin membranes around axons in the adult mammalian CNS following demyelination.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 72, "start": 67, "tag": "CellComponent"}, {"end": 85, "start": 80, "tag": "PopulationGroup"}, {"end": 99, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Eukaryote"}, {"end": 123, "start": 110, "tag": "PathologicFunction"}, {"end": 59, "start": 35, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1372_4", "text": "The ability to regenerate OLs depends on the availability of precursor cells (OPCs) in the CNS of adults.", "tags": [{"end": 29, "start": 26, "tag": "Cell"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 82, "start": 78, "tag": "Cell"}, {"end": 104, "start": 98, "tag": "PopulationGroup"}, {"end": 94, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1372_5", "text": "Multiple injury-related signals can induce OPC expansion followed by OL differentiation, axonal contact and myelin regeneration (remyelination).", "tags": [{"end": 46, "start": 43, "tag": "Cell"}, {"end": 142, "start": 129, "tag": "CellFunction"}, {"end": 103, "start": 89, "tag": "CellFunction"}, {"end": 87, "start": 69, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 43, "tag": "CellFunction"}, {"end": 71, "start": 69, "tag": "Cell"}, {"end": 127, "start": 108, "tag": "CellFunction"}, {"end": 31, "start": 9, "tag": "CellFunction"}]}
{"id": "1372_6", "text": "Therefore, OL dysfunction and regeneration failure in the deep WM of the brain are the key pathophysiological mechanisms leading to delayed brain injury after CO poisoning.", "tags": [{"end": 161, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 159, "tag": "ResearchActivity"}, {"end": 171, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 91, "tag": "PathologicFunction"}, {"end": 25, "start": 11, "tag": "CellOrMolecularDysfunction"}, {"end": 50, "start": 30, "tag": "PathologicFunction"}, {"end": 65, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 132, "tag": "PathologicFunction"}]}
{"id": "1372_7", "text": "CO-induced toxicity may interfere with OL function and render OPCs unable to regenerate OLs through some unclear mechanisms, leading to progressive demyelinating damage and resulting in DNS.", "tags": [{"end": 66, "start": 62, "tag": "Cell"}, {"end": 91, "start": 88, "tag": "Cell"}, {"end": 19, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 39, "tag": "Cell"}, {"end": 168, "start": 136, "tag": "PathologicFunction"}, {"end": 189, "start": 186, "tag": "PathologicFunction"}]}
{"id": "1372_8", "text": "In the future, combination therapies to reduce OL damage and promote OPC differentiation and remyelination may be important for the prevention and treatment of DNS after CO poisoning.", "tags": [{"end": 36, "start": 15, "tag": "HealthCareActivity"}, {"end": 72, "start": 69, "tag": "Cell"}, {"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 172, "start": 170, "tag": "InjuryOrPoisoning"}, {"end": 172, "start": 170, "tag": "ResearchActivity"}, {"end": 182, "start": 170, "tag": "InjuryOrPoisoning"}, {"end": 156, "start": 147, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}, {"end": 88, "start": 69, "tag": "CellFunction"}, {"end": 142, "start": 132, "tag": "HealthCareActivity"}, {"end": 56, "start": 47, "tag": "CellOrMolecularDysfunction"}, {"end": 163, "start": 160, "tag": "PathologicFunction"}]}
{"id": "1373_0", "text": "Oligodendrocyte precursor cells (OPCs) are present in demyelinated lesions of multiple sclerosis (MS) patients.", "tags": [{"end": 31, "start": 0, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 74, "start": 54, "tag": "PathologicFunction"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 78, "tag": "DiseaseOrSyndrome"}]}
{"id": "1373_1", "text": "However, their differentiation into functional oligodendrocytes is insufficient, and most lesions evolve into nonfunctional astroglial scars.", "tags": [{"end": 63, "start": 47, "tag": "Cell"}, {"end": 97, "start": 90, "tag": "InjuryOrPoisoning"}, {"end": 140, "start": 110, "tag": "PathologicFunction"}, {"end": 30, "start": 15, "tag": "CellFunction"}]}
{"id": "1373_2", "text": "Blockade of bone morphogenetic protein (BMP) signaling induces differentiation of OPCs into myelin-producing oligodendrocytes.", "tags": [{"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 125, "start": 92, "tag": "Cell"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "CellFunction"}, {"end": 38, "start": 12, "tag": "CellFunction"}]}
{"id": "1373_3", "text": "We studied the effect of specific blockade of BMP-2/4 signaling, by intravenous (IV) treatment with anti-BMP-2/4 neutralizing mAb in both the inflammatory model of relapsing experimental autoimmune encephalomyelitis (R-EAE) and the cuprizone-toxic model of demyelination in mice.", "tags": [{"end": 42, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 34, "tag": "HealthCareActivity"}, {"end": 63, "start": 46, "tag": "CellFunction"}, {"end": 79, "start": 68, "tag": "HealthCareActivity"}, {"end": 222, "start": 217, "tag": "ExperimentalModelOfDisease"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 270, "start": 232, "tag": "ExperimentalModelOfDisease"}, {"end": 278, "start": 274, "tag": "Eukaryote"}, {"end": 129, "start": 100, "tag": "PharmacologicSubstance"}]}
{"id": "1373_4", "text": "Administration of anti-BMP-2/4 to R-EAE-induced mice, on day 9 post-immunization (p.i.), ameliorated R-EAE signs, diminished the expression of phospho-SMAD1/5/8, primarily within the astrocytic lineage, increased the numbers of de novo immature and mature oligodendrocytes, and reduced the numbers of newly generated astrocytes within the spinal cord as early as day 18 p.i.", "tags": [{"end": 14, "start": 0, "tag": "HealthCareActivity"}, {"end": 80, "start": 57, "tag": "TemporalConcept"}, {"end": 106, "start": 101, "tag": "ExperimentalModelOfDisease"}, {"end": 201, "start": 183, "tag": "Cell"}, {"end": 272, "start": 249, "tag": "Cell"}, {"end": 350, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 373, "start": 363, "tag": "TemporalConcept"}, {"end": 112, "start": 107, "tag": "SignOrSymptom"}, {"end": 327, "start": 317, "tag": "Cell"}, {"end": 30, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 34, "tag": "ExperimentalModelOfDisease"}, {"end": 80, "start": 68, "tag": "HealthCareActivity"}, {"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 160, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 235, "start": 203, "tag": "Finding"}, {"end": 316, "start": 278, "tag": "Finding"}, {"end": 272, "start": 256, "tag": "Cell"}, {"end": 244, "start": 236, "tag": "Cell"}]}
{"id": "1373_5", "text": "This effect was accompanied with elevated remyelination, manifested by increased density of remyelinating axons (0.8 < g-ratios < 1), and reduced fully demyelinated and demyelinating axons, in the anti-BMP-2/4-treated R-EAE mice, studied by electron microscopy.", "tags": [{"end": 55, "start": 33, "tag": "Finding"}, {"end": 55, "start": 42, "tag": "CellFunction"}, {"end": 88, "start": 71, "tag": "Finding"}, {"end": 111, "start": 92, "tag": "Finding"}, {"end": 111, "start": 106, "tag": "CellComponent"}, {"end": 228, "start": 218, "tag": "ExperimentalModelOfDisease"}, {"end": 260, "start": 241, "tag": "ResearchActivity"}, {"end": 188, "start": 138, "tag": "Finding"}, {"end": 188, "start": 169, "tag": "PathologicFunction"}, {"end": 209, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 197, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 183, "tag": "PathologicFunction"}, {"end": 164, "start": 152, "tag": "PathologicFunction"}]}
{"id": "1373_6", "text": "No significant immunosuppressive effect was observed in the CNS and in the periphery, during the peak of the first attack, or at the end of the experiment.", "tags": [{"end": 39, "start": 15, "tag": "BiologicFunction"}, {"end": 121, "start": 115, "tag": "Finding"}, {"end": 154, "start": 144, "tag": "ResearchActivity"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 109, "tag": "TemporalConcept"}, {"end": 136, "start": 126, "tag": "TemporalConcept"}]}
{"id": "1373_7", "text": "Moreover, IV treatment with anti-BMP-2/4 mAb in the cuprizone-challenged mice augmented the numbers of mature oligodendrocytes and remyelination in the corpus callosum during the recovery phase of the disease.", "tags": [{"end": 44, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 126, "start": 103, "tag": "Cell"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 167, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 10, "tag": "HealthCareActivity"}, {"end": 22, "start": 10, "tag": "ResearchActivity"}, {"end": 44, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 193, "start": 179, "tag": "TemporalConcept"}]}
{"id": "1373_8", "text": "Based on our findings, the specific blockade of BMP-2/4 has a therapeutic potential in demyelinating disorders such as MS, by inducing early oligodendrogenesis-mediated remyelination in the affected tissue.", "tags": [{"end": 44, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 36, "tag": "HealthCareActivity"}, {"end": 110, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 205, "start": 199, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 62, "tag": "HealthCareActivity"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 141, "tag": "BiologicFunction"}]}
{"id": "1374_0", "text": "Neural stem and precursor cells (NPCs) build and regenerate the central nervous system (CNS) by maintaining their pool (self-renewal) and differentiating into neurons, astrocytes, and oligodendrocytes (multipotency) throughout life.", "tags": [{"end": 31, "start": 0, "tag": "Cell"}, {"end": 132, "start": 120, "tag": "CellFunction"}, {"end": 200, "start": 184, "tag": "Cell"}, {"end": 231, "start": 227, "tag": "TemporalConcept"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 159, "tag": "Cell"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 214, "start": 202, "tag": "CellFunction"}]}
{"id": "1374_1", "text": "This has inspired research into pro-regenerative therapies that utilize transplantation of exogenous NPCs or recruitment of endogenous adult NPCs for CNS regeneration and repair.", "tags": [{"end": 105, "start": 72, "tag": "HealthCareActivity"}, {"end": 58, "start": 32, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 18, "tag": "ResearchActivity"}, {"end": 105, "start": 101, "tag": "Cell"}, {"end": 145, "start": 135, "tag": "Cell"}, {"end": 145, "start": 109, "tag": "HealthCareActivity"}, {"end": 177, "start": 150, "tag": "BiologicFunction"}]}
{"id": "1374_2", "text": "Recent advances in single-cell RNA sequencing and other omics have revealed that NPCs express not just traditional progenitor-related genes, but also genes involved in immune function.", "tags": [{"end": 183, "start": 168, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 45, "start": 19, "tag": "ResearchActivity"}, {"end": 61, "start": 56, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "Cell"}]}
{"id": "1374_3", "text": "Here, we review how NPCs exert immunomodulatory function by regulating the biology of microglia, immune cells that are present in NPC niches and throughout the CNS.", "tags": [{"end": 82, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 140, "start": 130, "tag": "Cell"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 163, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 109, "start": 97, "tag": "Cell"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 56, "start": 31, "tag": "BiologicFunction"}]}
{"id": "1374_4", "text": "We discuss the role of transplanted and endogenous NPCs in regulating microglia fates, such as survival, proliferation, migration, phagocytosis and activation, in the developing, injured and degenerating CNS.", "tags": [{"end": 35, "start": 23, "tag": "HealthCareActivity"}, {"end": 35, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "CellFunction"}, {"end": 118, "start": 105, "tag": "CellFunction"}, {"end": 129, "start": 120, "tag": "CellFunction"}, {"end": 143, "start": 131, "tag": "CellFunction"}, {"end": 207, "start": 191, "tag": "PathologicFunction"}, {"end": 207, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 70, "tag": "CellFunction"}, {"end": 207, "start": 204, "tag": "BiologicFunction"}, {"end": 177, "start": 167, "tag": "BiologicFunction"}, {"end": 207, "start": 204, "tag": "PathologicFunction"}, {"end": 186, "start": 179, "tag": "PathologicFunction"}]}
{"id": "1374_5", "text": "We also provide a literature review on NPC-specific mediators that are responsible for modulating microglia biology.", "tags": [{"end": 115, "start": 108, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 29, "tag": "ResearchActivity"}, {"end": 35, "start": 29, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 28, "start": 18, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "Cell"}]}
{"id": "1374_6", "text": "Our review highlights the immunomodulatory properties of NPCs and the significance of these findings in the context of designing pro-regenerative therapies for degenerating and diseased CNS.", "tags": [{"end": 53, "start": 26, "tag": "ClinicalAttribute"}, {"end": 189, "start": 160, "tag": "PathologicFunction"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 155, "start": 129, "tag": "HealthCareActivity"}, {"end": 189, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 57, "tag": "Cell"}]}
{"id": "1375_0", "text": "Astrocytes are a group of glial cells that exhibit great morphological, transcriptional and functional diversity both in the resting brain and in response to injury.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 87, "start": 72, "tag": "CellFunction"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "Cell"}, {"end": 164, "start": 158, "tag": "InjuryOrPoisoning"}]}
{"id": "1375_1", "text": "In recent years, astrocytes have attracted increasing interest as therapeutic targets for demyelinating diseases.", "tags": [{"end": 112, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 43, "tag": "Finding"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 85, "start": 66, "tag": "ResearchActivity"}, {"end": 27, "start": 17, "tag": "Cell"}]}
{"id": "1375_2", "text": "Following a demyelinating insult, astrocytes can adopt a wide spectrum of reactive states, which can exacerbate damage, but may also facilitate oligo-dendrocyte progenitor cell differentiation and myelin regener-ation.", "tags": [{"end": 176, "start": 144, "tag": "Cell"}, {"end": 192, "start": 144, "tag": "CellFunction"}, {"end": 217, "start": 197, "tag": "CellFunction"}, {"end": 44, "start": 34, "tag": "Cell"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 32, "start": 12, "tag": "InjuryOrPoisoning"}, {"end": 118, "start": 101, "tag": "Finding"}]}
{"id": "1375_3", "text": "In this review, we provide an overview of recent literature on astrocyte-oligodendrocyte interactions in the context of demyelinating diseases.", "tags": [{"end": 142, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 48, "start": 42, "tag": "TemporalConcept"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 59, "start": 49, "tag": "ResearchActivity"}, {"end": 101, "start": 63, "tag": "CellFunction"}]}
{"id": "1375_4", "text": "We highlight novel key roles for as-trocytes both during demyelination and remyelination with a focus on potential therapeutic strategies to favor a pro -regenerative astrocyte response in (progressive) multiple sclerosis.", "tags": [{"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 176, "start": 167, "tag": "Cell"}, {"end": 221, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 105, "tag": "HealthCareActivity"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}, {"end": 185, "start": 149, "tag": "Finding"}]}
{"id": "1376_0", "text": "This review describes the role of CXCL1, a chemokine crucial in inflammation as a chemoattractant for neutrophils, in physiology and in selected major non-cancer diseases.", "tags": [{"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "GeneOrGenome"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 64, "tag": "PathologicFunction"}, {"end": 97, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 102, "tag": "Cell"}, {"end": 128, "start": 118, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 170, "start": 151, "tag": "DiseaseOrSyndrome"}]}
{"id": "1376_1", "text": "Due to the vast amount of available information, we focus on the role CXCL1 plays in the physiology of bones, bone marrow, muscle and the nervous system.", "tags": [{"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 70, "tag": "GeneOrGenome"}, {"end": 75, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 99, "start": 89, "tag": "BiologicFunction"}, {"end": 108, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1376_2", "text": "For this reason, we describe its effects on hematopoietic stem cells, myoblasts, oligodendrocyte progenitors and osteoclast precursors.", "tags": [{"end": 68, "start": 44, "tag": "Cell"}, {"end": 79, "start": 70, "tag": "Cell"}, {"end": 108, "start": 81, "tag": "Cell"}, {"end": 134, "start": 113, "tag": "Cell"}]}
{"id": "1376_3", "text": "We also present the involvement of CXCL1 in diseases of selected tissues and organs including Alzheimer's disease, epilepsy, herpes simplex virus type 1 (HSV-1) encephalitis, ischemic stroke, major depression, multiple sclerosis, neuromyelitis optica, neuropathic pain, osteoporosis, prion diseases, rheumatoid arthritis, tick-borne encephalitis (TBE), traumatic spinal cord injury and West Nile fever.", "tags": [{"end": 40, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 35, "tag": "GeneOrGenome"}, {"end": 40, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 125, "tag": "Virus"}, {"end": 159, "start": 154, "tag": "Virus"}, {"end": 173, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 252, "tag": "SignOrSymptom"}, {"end": 282, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 320, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 345, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 350, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 401, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "PathologicFunction"}, {"end": 298, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 20, "tag": "Finding"}, {"end": 381, "start": 353, "tag": "InjuryOrPoisoning"}, {"end": 289, "start": 284, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1377_0", "text": "Successful neuroprotection is only possible with contemporary microvascular protection.", "tags": [{"end": 26, "start": 11, "tag": "CellFunction"}, {"end": 61, "start": 49, "tag": "TemporalConcept"}, {"end": 86, "start": 62, "tag": "BiologicFunction"}]}
{"id": "1377_1", "text": "The prevention of disease-induced vascular modifications that accelerate brain damage remains largely elusive.", "tags": [{"end": 42, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 85, "start": 73, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 18, "tag": "PathologicFunction"}]}
{"id": "1377_2", "text": "An improved understanding of pericyte (PC) signalling could provide important insight into the function of the neurovascular unit (NVU), and into the injury-provoked responses that modify cell-cell interactions and crosstalk.", "tags": [{"end": 37, "start": 29, "tag": "Cell"}, {"end": 210, "start": 188, "tag": "CellFunction"}, {"end": 156, "start": 150, "tag": "InjuryOrPoisoning"}, {"end": 129, "start": 111, "tag": "Cell"}, {"end": 134, "start": 131, "tag": "Cell"}, {"end": 41, "start": 39, "tag": "Cell"}, {"end": 224, "start": 215, "tag": "CellFunction"}, {"end": 197, "start": 188, "tag": "CellFunction"}]}
{"id": "1377_3", "text": "Due to sharing the same basement membrane with endothelial cells, PCs have a crucial role in the control of endothelial, astrocyte, and oligodendrocyte precursor functions and hence blood-brain barrier stability.", "tags": [{"end": 41, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "Cell"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 119, "start": 108, "tag": "Cell"}, {"end": 130, "start": 121, "tag": "Cell"}, {"end": 161, "start": 136, "tag": "Cell"}, {"end": 201, "start": 182, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 182, "tag": "CellFunction"}]}
{"id": "1377_4", "text": "Both cerebrovascular and neurodegenerative diseases impair oxygen delivery and functionally impair the NVU.", "tags": [{"end": 74, "start": 59, "tag": "ClinicalAttribute"}, {"end": 51, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 103, "tag": "Cell"}, {"end": 51, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 5, "tag": "DiseaseOrSyndrome"}]}
{"id": "1377_5", "text": "In this review, the role of PCs in central nervous system health and disease is discussed, considering their origin, multipotency, functions and also dysfunction, focusing on new possible avenues to modulate neuroprotection.", "tags": [{"end": 31, "start": 28, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 57, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 109, "tag": "TemporalConcept"}, {"end": 161, "start": 150, "tag": "PathologicFunction"}, {"end": 64, "start": 58, "tag": "HealthCareActivity"}, {"end": 223, "start": 208, "tag": "CellFunction"}, {"end": 129, "start": 117, "tag": "CellFunction"}]}
{"id": "1377_6", "text": "Dysfunctional PC signalling could also be considered as a potential biomarker of NVU pathology, allowing us to individualize therapeutic interventions, monitor responses, or predict outcomes.", "tags": [{"end": 77, "start": 58, "tag": "ClinicalAttribute"}, {"end": 150, "start": 125, "tag": "HealthCareActivity"}, {"end": 27, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 152, "tag": "HealthCareActivity"}, {"end": 190, "start": 174, "tag": "HealthCareActivity"}]}
{"id": "1378_0", "text": "Oligodendrocyte loss in neurological disease leaves axons vulnerable to damage and degeneration, and activity-dependent myelination may represent an endogenous mechanism to improve remyelination following injury.", "tags": [{"end": 44, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 52, "tag": "CellComponent"}, {"end": 131, "start": 120, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 211, "start": 205, "tag": "InjuryOrPoisoning"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1378_1", "text": "Here we report that, while learning a forelimb reach task transiently suppresses oligodendrogenesis, it subsequently increases oligodendrocyte precursor cell differentiation, oligodendrocyte generation and myelin sheath remodeling in the forelimb motor cortex.", "tags": [{"end": 157, "start": 127, "tag": "Cell"}, {"end": 201, "start": 175, "tag": "BiologicFunction"}, {"end": 219, "start": 206, "tag": "CellComponent"}, {"end": 246, "start": 238, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 127, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "BiologicFunction"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 99, "start": 81, "tag": "BiologicFunction"}, {"end": 57, "start": 38, "tag": "ResearchActivity"}, {"end": 230, "start": 206, "tag": "CellFunction"}]}
{"id": "1378_2", "text": "Immediately following demyelination, neurons exhibit hyperexcitability, learning is impaired and behavioral intervention provides no benefit to remyelination.", "tags": [{"end": 70, "start": 53, "tag": "BiologicFunction"}, {"end": 120, "start": 97, "tag": "HealthCareActivity"}, {"end": 157, "start": 144, "tag": "CellFunction"}, {"end": 44, "start": 37, "tag": "Cell"}, {"end": 80, "start": 72, "tag": "BiologicFunction"}, {"end": 35, "start": 22, "tag": "PathologicFunction"}]}
{"id": "1378_3", "text": "However, partial remyelination restores neuronal and behavioral function, allowing learning to enhance oligodendrogenesis, remyelination of denuded axons and the ability of surviving oligodendrocytes to generate new myelin sheaths.", "tags": [{"end": 30, "start": 17, "tag": "CellFunction"}, {"end": 136, "start": 123, "tag": "CellFunction"}, {"end": 153, "start": 148, "tag": "CellComponent"}, {"end": 199, "start": 183, "tag": "Cell"}, {"end": 230, "start": 216, "tag": "CellComponent"}, {"end": 91, "start": 83, "tag": "BiologicFunction"}, {"end": 121, "start": 103, "tag": "BiologicFunction"}, {"end": 72, "start": 64, "tag": "CellFunction"}, {"end": 48, "start": 40, "tag": "CellFunction"}]}
{"id": "1378_4", "text": "Previously considered controversial, we show that sheath generation by mature oligodendrocytes is not only possible but also increases myelin pattern preservation following demyelination, thus presenting a new target for therapeutic interventions.", "tags": [{"end": 94, "start": 71, "tag": "Cell"}, {"end": 186, "start": 173, "tag": "PathologicFunction"}, {"end": 246, "start": 221, "tag": "HealthCareActivity"}, {"end": 162, "start": 135, "tag": "CellFunction"}, {"end": 67, "start": 50, "tag": "CellFunction"}]}
{"id": "1378_5", "text": "Together, our findings demonstrate that precisely timed motor learning improves recovery from demyelinating injury via enhanced remyelination from new and surviving oligodendrocytes.", "tags": [{"end": 55, "start": 50, "tag": "TemporalConcept"}, {"end": 70, "start": 56, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "HealthCareActivity"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 181, "start": 165, "tag": "Cell"}, {"end": 114, "start": 94, "tag": "InjuryOrPoisoning"}]}
{"id": "1378_6", "text": "Precisely timed motor learning promotes remyelination in the motor cortex by enhancing oligodendrogenesis and stimulating mature oligodendrocytes to generate new myelin, presenting mature oligodendrocytes as new targets in remyelinating therapies.", "tags": [{"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 30, "start": 16, "tag": "BiologicFunction"}, {"end": 53, "start": 40, "tag": "CellFunction"}, {"end": 73, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 122, "tag": "Cell"}, {"end": 168, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 162, "tag": "CellComponent"}, {"end": 204, "start": 181, "tag": "Cell"}, {"end": 246, "start": 223, "tag": "HealthCareActivity"}, {"end": 105, "start": 87, "tag": "BiologicFunction"}]}
{"id": "1379_0", "text": "Multiple sclerosis (MS) is the most common demyelinating autoimmune disease of the central nervous system (CNS).", "tags": [{"end": 75, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1379_1", "text": "Immune-mediated myelin and axonal damage that is accompanied by chronic axonal loss causing destruction of the myelin sheaths are hallmarks of MS.", "tags": [{"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 64, "tag": "TemporalConcept"}, {"end": 139, "start": 130, "tag": "Finding"}, {"end": 40, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 83, "start": 72, "tag": "PathologicFunction"}, {"end": 125, "start": 92, "tag": "PathologicFunction"}]}
{"id": "1379_2", "text": "While great strides have been made in understanding the molecular underpinnings of re-/myelination, currently no remyelination therapy is available for MS.", "tags": [{"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 134, "start": 113, "tag": "HealthCareActivity"}, {"end": 98, "start": 83, "tag": "CellFunction"}]}
{"id": "1379_3", "text": "As myelination is a complex process that is not fully understood, we sought to develop a systematic, reliable, automated and quantitative higher throughput screening method.", "tags": [{"end": 14, "start": 3, "tag": "CellFunction"}, {"end": 172, "start": 111, "tag": "ResearchActivity"}]}
{"id": "1379_4", "text": "We aimed to quantitate myelin sheaths in vitro with high sensitivity at the single cell level suitable for testing small compound libraries.", "tags": [{"end": 37, "start": 23, "tag": "CellComponent"}, {"end": 68, "start": 52, "tag": "Finding"}, {"end": 139, "start": 107, "tag": "ResearchActivity"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}]}
{"id": "1379_5", "text": "To this end, we miniaturised in vitro retinal ganglion cell-oligodendrocyte precursor cell (RGC-OPC) co-cultures into a multi-well plate format.", "tags": [{"end": 112, "start": 101, "tag": "ResearchActivity"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 59, "start": 38, "tag": "Cell"}, {"end": 90, "start": 60, "tag": "Cell"}, {"end": 95, "start": 92, "tag": "Cell"}, {"end": 99, "start": 96, "tag": "Cell"}, {"end": 136, "start": 120, "tag": "ManufacturedObject"}]}
{"id": "1379_6", "text": "This allowed us to maintain the reciprocal interaction of live axons and oligodendrocytes (OLs) to ensure compact myelin formation.", "tags": [{"end": 68, "start": 63, "tag": "CellComponent"}, {"end": 89, "start": 73, "tag": "Cell"}, {"end": 94, "start": 91, "tag": "Cell"}, {"end": 130, "start": 114, "tag": "CellFunction"}]}
{"id": "1379_7", "text": "To quantify our co-cultures, we developed a novel computer vision algorithm to precisely measure myelination.", "tags": [{"end": 27, "start": 16, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "CellFunction"}, {"end": 75, "start": 50, "tag": "ResearchActivity"}]}
{"id": "1379_8", "text": "We demonstrated efficacy of our system with known pro-differentiating compounds BQ3020 and XAV939 which exhibited robust, efficient, and dose dependent effects on myelination.", "tags": [{"end": 97, "start": 91, "tag": "Chemical"}, {"end": 174, "start": 163, "tag": "CellFunction"}, {"end": 86, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 91, "tag": "PharmacologicSubstance"}]}
{"id": "1379_9", "text": "Through this combination of experimental and technical advances, we have developed a method allowing systematic and reliable testing of remyelinating compound efficacy.", "tags": [{"end": 91, "start": 85, "tag": "ResearchActivity"}, {"end": 63, "start": 28, "tag": "Finding"}, {"end": 158, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 101, "tag": "ResearchActivity"}]}
{"id": "1380_0", "text": "Myelin is the lipidic insulating structure enwrapping axons and allowing fast saltatory nerve conduction.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 54, "tag": "CellComponent"}, {"end": 104, "start": 78, "tag": "BiologicFunction"}]}
{"id": "1380_1", "text": "In the central nervous system, myelin sheath is the result of the complex packaging of multilamellar extensions of oligodendrocyte (OL) membranes.", "tags": [{"end": 44, "start": 31, "tag": "CellComponent"}, {"end": 111, "start": 74, "tag": "Finding"}, {"end": 130, "start": 115, "tag": "Cell"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 132, "tag": "Cell"}, {"end": 145, "start": 136, "tag": "CellComponent"}]}
{"id": "1380_2", "text": "Before reaching myelinating capabilities, OLs undergo a very precise program of differentiation and maturation that starts from OL precursor cells (OPCs).", "tags": [{"end": 40, "start": 16, "tag": "CellFunction"}, {"end": 110, "start": 100, "tag": "BiologicFunction"}, {"end": 146, "start": 128, "tag": "Cell"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 45, "start": 42, "tag": "Cell"}]}
{"id": "1380_3", "text": "In the last 20 years, the biology of OPCs and their behavior under pathological conditions have been studied through several experimental models.", "tags": [{"end": 33, "start": 26, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 41, "start": 37, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "BiologicFunction"}, {"end": 60, "start": 52, "tag": "IndividualBehavior"}, {"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 144, "start": 125, "tag": "ExperimentalModelOfDisease"}, {"end": 20, "start": 7, "tag": "TemporalConcept"}, {"end": 90, "start": 67, "tag": "PathologicFunction"}]}
{"id": "1380_4", "text": "When co-cultured with neurons, OPCs undergo terminal maturation and produce myelin tracts around axons, allowing to investigate myelination in response to exogenous stimuli in a very simple in vitro system.", "tags": [{"end": 16, "start": 5, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "Cell"}, {"end": 63, "start": 53, "tag": "BiologicFunction"}, {"end": 89, "start": 76, "tag": "CellComponent"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 29, "start": 22, "tag": "Cell"}, {"end": 205, "start": 190, "tag": "ResearchActivity"}]}
{"id": "1380_5", "text": "On the other hand, in vivo models more closely reproducing some of the features of human pathophysiology enabled to assess the consequences of demyelination and the molecular mechanisms of remyelination, and they are often used to validate the effect of pharmacological agents.", "tags": [{"end": 202, "start": 189, "tag": "CellFunction"}, {"end": 276, "start": 254, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 83, "tag": "Eukaryote"}, {"end": 33, "start": 19, "tag": "ManufacturedObject"}, {"end": 104, "start": 89, "tag": "PathologicFunction"}, {"end": 185, "start": 165, "tag": "CellFunction"}, {"end": 104, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 143, "tag": "PathologicFunction"}]}
{"id": "1380_6", "text": "However, they are very complex, and not suitable for large scale drug discovery screening.", "tags": [{"end": 79, "start": 65, "tag": "ResearchActivity"}, {"end": 69, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}, {"end": 64, "start": 53, "tag": "ResearchActivity"}]}
{"id": "1380_7", "text": "Recent advances in cell reprogramming, biophysics and bioengineering have allowed impressive improvements in the methodological approaches to study brain physiology and myelination.", "tags": [{"end": 37, "start": 19, "tag": "CellFunction"}, {"end": 49, "start": 39, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 68, "start": 54, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 148, "tag": "BiologicFunction"}, {"end": 180, "start": 169, "tag": "CellFunction"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 7, "tag": "Finding"}]}
{"id": "1380_8", "text": "Rat and mouse OPCs can be replaced by human OPCs obtained by induced pluripotent stem cells (iPSCs) derived from healthy or diseased individuals, thus offering unprecedented possibilities for personalized disease modeling and treatment.", "tags": [{"end": 3, "start": 0, "tag": "Eukaryote"}, {"end": 18, "start": 14, "tag": "Cell"}, {"end": 48, "start": 44, "tag": "Cell"}, {"end": 235, "start": 226, "tag": "HealthCareActivity"}, {"end": 235, "start": 226, "tag": "ResearchActivity"}, {"end": 91, "start": 61, "tag": "Cell"}, {"end": 43, "start": 38, "tag": "Eukaryote"}, {"end": 98, "start": 93, "tag": "Cell"}, {"end": 144, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "Eukaryote"}, {"end": 221, "start": 192, "tag": "ExperimentalModelOfDisease"}, {"end": 144, "start": 133, "tag": "PopulationGroup"}, {"end": 120, "start": 113, "tag": "PopulationGroup"}]}
{"id": "1380_9", "text": "OPCs and neural cells can be also artificially assembled, using 3D-printed culture chambers and biomaterial scaffolds, which allow modeling cell-to-cell interactions in a highly controlled manner.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 21, "start": 9, "tag": "Cell"}, {"end": 91, "start": 64, "tag": "ManufacturedObject"}, {"end": 117, "start": 96, "tag": "ManufacturedObject"}, {"end": 165, "start": 140, "tag": "CellFunction"}]}
{"id": "1380_10", "text": "Interestingly, scaffold stiffness can be adopted to reproduce the mechanosensory properties assumed by tissues in physiological or pathological conditions.", "tags": [{"end": 110, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 131, "tag": "PathologicFunction"}, {"end": 33, "start": 15, "tag": "ResearchActivity"}, {"end": 91, "start": 66, "tag": "BiologicFunction"}]}
{"id": "1380_11", "text": "Moreover, the recent development of iPSC-derived 3D brain cultures, called organoids, has made it possible to study key aspects of embryonic brain development, such as neuronal differentiation, maturation and network formation in temporal dynamics that are inaccessible to traditional in vitro cultures.", "tags": [{"end": 84, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 131, "tag": "BiologicFunction"}, {"end": 192, "start": 168, "tag": "CellFunction"}, {"end": 204, "start": 194, "tag": "BiologicFunction"}, {"end": 146, "start": 131, "tag": "EmbryonicStructure"}, {"end": 115, "start": 110, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "TemporalConcept"}, {"end": 302, "start": 285, "tag": "ResearchActivity"}, {"end": 66, "start": 36, "tag": "ManufacturedObject"}, {"end": 66, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1380_12", "text": "Despite the huge potential of organoids, their application to myelination studies is still in its infancy.", "tags": [{"end": 39, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 105, "start": 98, "tag": "TemporalConcept"}, {"end": 105, "start": 98, "tag": "PopulationGroup"}, {"end": 73, "start": 62, "tag": "CellFunction"}]}
{"id": "1380_13", "text": "In this review, we shall summarize the novel most relevant experimental approaches and their implications for the identification of remyelinating agents for human diseases such as multiple sclerosis.</p>", "tags": [{"end": 82, "start": 59, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 198, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 132, "tag": "PharmacologicSubstance"}]}
{"id": "1381_0", "text": "The repair of inflamed, demyelinated lesions as in multiple sclerosis (MS) necessitates the clearance of cholesterol-rich myelin debris by microglia/macrophages and the switch from a pro-inflammatory to an anti-inflammatory lesion environment.", "tags": [{"end": 10, "start": 4, "tag": "BiologicFunction"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 44, "start": 14, "tag": "PathologicFunction"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 122, "tag": "CellComponent"}, {"end": 135, "start": 129, "tag": "Substance"}, {"end": 116, "start": 105, "tag": "Chemical"}, {"end": 116, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "NaturalPhenomenonOrProcess"}, {"end": 69, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 206, "tag": "BiologicFunction"}, {"end": 223, "start": 206, "tag": "PharmacologicSubstance"}, {"end": 148, "start": 139, "tag": "Cell"}, {"end": 160, "start": 149, "tag": "Cell"}, {"end": 199, "start": 183, "tag": "PathologicFunction"}, {"end": 230, "start": 224, "tag": "InjuryOrPoisoning"}]}
{"id": "1381_1", "text": "Subsequently, oligodendrocytes increase cholesterol levels as a prerequisite for synthesizing new myelin membranes.", "tags": [{"end": 30, "start": 14, "tag": "Cell"}, {"end": 51, "start": 40, "tag": "Chemical"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 98, "tag": "CellComponent"}]}
{"id": "1381_2", "text": "We hypothesized that lesion resolution is regulated by the fate of cholesterol from damaged myelin and oligodendroglial sterol synthesis.", "tags": [{"end": 119, "start": 103, "tag": "Cell"}, {"end": 119, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 120, "tag": "CellFunction"}, {"end": 78, "start": 67, "tag": "Chemical"}, {"end": 78, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 21, "tag": "InjuryOrPoisoning"}, {"end": 98, "start": 84, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1381_3", "text": "By integrating gene expression profiling, genetics and comprehensive phenotyping, we found that, paradoxically, sterol synthesis in myelin-phagocytosing microglia/macrophages determines the repair of acutely demyelinated lesions.", "tags": [{"end": 40, "start": 15, "tag": "ResearchActivity"}, {"end": 128, "start": 112, "tag": "CellFunction"}, {"end": 196, "start": 190, "tag": "BiologicFunction"}, {"end": 196, "start": 190, "tag": "HealthCareActivity"}, {"end": 228, "start": 208, "tag": "PathologicFunction"}, {"end": 50, "start": 42, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 162, "start": 153, "tag": "Cell"}, {"end": 80, "start": 55, "tag": "ResearchActivity"}, {"end": 174, "start": 163, "tag": "Cell"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "CellComponent"}]}
{"id": "1381_4", "text": "Rather than producing cholesterol, microglia/macrophages synthesized desmosterol, the immediate cholesterol precursor.", "tags": [{"end": 80, "start": 69, "tag": "Chemical"}, {"end": 95, "start": 86, "tag": "TemporalConcept"}, {"end": 33, "start": 22, "tag": "Chemical"}, {"end": 107, "start": 96, "tag": "Chemical"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 35, "tag": "Cell"}, {"end": 56, "start": 45, "tag": "Cell"}, {"end": 80, "start": 69, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1381_5", "text": "Desmosterol activated liver X receptor (LXR) signaling to resolve inflammation, creating a permissive environment for oligodendrocyte differentiation.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 45, "tag": "CellFunction"}, {"end": 78, "start": 66, "tag": "PathologicFunction"}, {"end": 133, "start": 118, "tag": "Cell"}, {"end": 149, "start": 134, "tag": "CellFunction"}, {"end": 38, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1381_6", "text": "Moreover, LXR target gene products facilitated the efflux of lipid and cholesterol from lipid-laden microglia/macrophages to support remyelination by oligodendrocytes.", "tags": [{"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 51, "tag": "CellFunction"}, {"end": 66, "start": 61, "tag": "Chemical"}, {"end": 146, "start": 133, "tag": "CellFunction"}, {"end": 166, "start": 150, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "Chemical"}, {"end": 82, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 88, "tag": "Cell"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1381_7", "text": "Consequently, pharmacological stimulation of sterol synthesis boosted the repair of demyelinated lesions, suggesting novel therapeutic strategies for myelin repair in MS.", "tags": [{"end": 41, "start": 14, "tag": "HealthCareActivity"}, {"end": 61, "start": 45, "tag": "CellFunction"}, {"end": 80, "start": 74, "tag": "BiologicFunction"}, {"end": 80, "start": 74, "tag": "HealthCareActivity"}, {"end": 104, "start": 84, "tag": "PathologicFunction"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 123, "tag": "HealthCareActivity"}, {"end": 163, "start": 150, "tag": "CellFunction"}]}
{"id": "1381_8", "text": "Efficient repair of demyelinated CNS lesions involves the resolution of inflammation and induction of remyelination.", "tags": [{"end": 16, "start": 10, "tag": "BiologicFunction"}, {"end": 16, "start": 10, "tag": "HealthCareActivity"}, {"end": 44, "start": 20, "tag": "PathologicFunction"}, {"end": 84, "start": 72, "tag": "PathologicFunction"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1381_9", "text": "Berghoff et al.", "tags": []}
{"id": "1381_10", "text": "show that sterol synthesis in microglia is key to both processes, which can be supported by squalene therapy.", "tags": [{"end": 26, "start": 10, "tag": "CellFunction"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 108, "start": 101, "tag": "HealthCareActivity"}, {"end": 100, "start": 92, "tag": "Chemical"}, {"end": 100, "start": 92, "tag": "PharmacologicSubstance"}]}
{"id": "1382_0", "text": "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease in which motor neurons throughout the brain and spinal cord progressively degenerate resulting in muscle atrophy, paralysis and death.", "tags": [{"end": 89, "start": 76, "tag": "Cell"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 165, "tag": "PathologicFunction"}, {"end": 190, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 195, "tag": "BiologicFunction"}, {"end": 200, "start": 195, "tag": "PathologicFunction"}, {"end": 200, "start": 195, "tag": "CellFunction"}]}
{"id": "1382_1", "text": "Recent studies using animal models of ALS implicate multiple cell-types (e.g., astrocytes and microglia) in ALS pathogenesis in the spinal motor systems.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 41, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 112, "tag": "PathologicFunction"}, {"end": 34, "start": 21, "tag": "ManufacturedObject"}, {"end": 103, "start": 94, "tag": "Cell"}, {"end": 89, "start": 79, "tag": "Cell"}, {"end": 41, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 71, "start": 61, "tag": "Cell"}, {"end": 152, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1382_2", "text": "To ascertain cellular vulnerability and cell-type specific mechanisms of ALS in the brainstem that orchestrates oral-motor functions, we conducted parallel single cell RNA sequencing (scRNA-seq) analysis using the high-throughput Drop-seq method.", "tags": [{"end": 93, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 195, "tag": "ResearchActivity"}, {"end": 182, "start": 156, "tag": "ResearchActivity"}, {"end": 193, "start": 184, "tag": "ResearchActivity"}, {"end": 245, "start": 214, "tag": "ResearchActivity"}]}
{"id": "1382_3", "text": "We isolated 1894 and 3199 cells from the brainstem of wildtype and mutant SOD1 symptomatic mice respectively, at postnatal day 100.", "tags": [{"end": 50, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 113, "tag": "TemporalConcept"}, {"end": 78, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 95, "start": 91, "tag": "Eukaryote"}, {"end": 78, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 67, "tag": "ExperimentalModelOfDisease"}, {"end": 78, "start": 74, "tag": "GeneOrGenome"}, {"end": 78, "start": 74, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1382_4", "text": "We recovered major known cell types and neuronal subpopulations, such as interneurons and motor neurons, and trigeminal ganglion (TG) peripheral sensory neurons, as well as, previously uncharacterized interneuron subtypes.", "tags": [{"end": 85, "start": 73, "tag": "Cell"}, {"end": 103, "start": 90, "tag": "Cell"}, {"end": 130, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 201, "tag": "Cell"}, {"end": 35, "start": 25, "tag": "Cell"}, {"end": 160, "start": 109, "tag": "Cell"}, {"end": 63, "start": 40, "tag": "Cell"}]}
{"id": "1382_5", "text": "We found that the majority of the cell types displayed transcriptomic alterations in ALS mice.", "tags": [{"end": 44, "start": 34, "tag": "Cell"}, {"end": 88, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "ExperimentalModelOfDisease"}, {"end": 81, "start": 55, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1382_6", "text": "Differentially expressed genes (DEGs) of individual cell populations revealed cell-type specific alterations in numerous pathways, including previously known ALS pathways such as inflammation (in microglia), stress response (ependymal and an uncharacterized cell population), neurogenesis (astrocytes, oligodendrocytes, neurons), synapse organization and transmission (microglia, oligodendrocyte precursor cells, and neuronal subtypes), and mitochondrial function (uncharacterized cell populations).", "tags": [{"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 68, "start": 41, "tag": "Cell"}, {"end": 191, "start": 179, "tag": "PathologicFunction"}, {"end": 223, "start": 208, "tag": "BiologicFunction"}, {"end": 223, "start": 208, "tag": "CellFunction"}, {"end": 234, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 318, "start": 302, "tag": "Cell"}, {"end": 367, "start": 330, "tag": "CellFunction"}, {"end": 411, "start": 380, "tag": "Cell"}, {"end": 161, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 288, "start": 276, "tag": "BiologicFunction"}, {"end": 327, "start": 320, "tag": "Cell"}, {"end": 129, "start": 121, "tag": "CellFunction"}, {"end": 170, "start": 162, "tag": "CellFunction"}, {"end": 463, "start": 441, "tag": "CellFunction"}, {"end": 273, "start": 258, "tag": "Cell"}, {"end": 205, "start": 196, "tag": "Cell"}, {"end": 378, "start": 369, "tag": "Cell"}, {"end": 300, "start": 290, "tag": "Cell"}, {"end": 434, "start": 417, "tag": "Cell"}, {"end": 30, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "Cell"}, {"end": 273, "start": 258, "tag": "Cell"}, {"end": 234, "start": 225, "tag": "Cell"}]}
{"id": "1382_7", "text": "Other cell-type specific processes altered in SOD1 mutant brainstem include those from motor neurons (axon regeneration, voltage-gated sodium and potassium channels underlying excitability, potassium ion transport), trigeminal sensory neurons (detection of temperature stimulus involved in sensory perception), and cellular response to toxic substances (uncharacterized cell populations).", "tags": [{"end": 67, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 87, "tag": "Cell"}, {"end": 119, "start": 102, "tag": "BiologicFunction"}, {"end": 164, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 176, "tag": "SignOrSymptom"}, {"end": 213, "start": 190, "tag": "CellFunction"}, {"end": 268, "start": 257, "tag": "OrganismAttribute"}, {"end": 268, "start": 257, "tag": "NaturalPhenomenonOrProcess"}, {"end": 308, "start": 290, "tag": "BiologicFunction"}, {"end": 352, "start": 336, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 46, "tag": "CellOrMolecularDysfunction"}, {"end": 242, "start": 216, "tag": "Cell"}, {"end": 332, "start": 315, "tag": "CellFunction"}, {"end": 15, "start": 6, "tag": "Cell"}, {"end": 386, "start": 370, "tag": "Cell"}]}
{"id": "1382_8", "text": "DEGs consistently altered across cell types (e.g., Malat1), as well as cell-type specific DEGs, were identified.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 57, "start": 51, "tag": "GeneOrGenome"}, {"end": 43, "start": 33, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "GeneOrGenome"}, {"end": 80, "start": 71, "tag": "Cell"}]}
{"id": "1382_9", "text": "Importantly, DEGs from various cell types overlapped with known ALS genes from the literature and with top hits from an existing human ALS genome-wide association study (GWAS), implicating the potential cell types in which the ALS genes function with ALS pathogenesis.", "tags": [{"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 52, "start": 42, "tag": "HealthCareActivity"}, {"end": 111, "start": 107, "tag": "Finding"}, {"end": 168, "start": 139, "tag": "ResearchActivity"}, {"end": 174, "start": 170, "tag": "ResearchActivity"}, {"end": 245, "start": 231, "tag": "CellFunction"}, {"end": 41, "start": 31, "tag": "Cell"}, {"end": 213, "start": 203, "tag": "Cell"}, {"end": 67, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 129, "tag": "Eukaryote"}, {"end": 267, "start": 255, "tag": "PathologicFunction"}, {"end": 93, "start": 83, "tag": "ResearchActivity"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}]}
{"id": "1382_10", "text": "Our molecular investigation at single cell resolution provides comprehensive insights into the cell types, genes and pathways altered in the brainstem in a widely used ALS mouse model.", "tags": [{"end": 150, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 95, "tag": "Cell"}, {"end": 183, "start": 168, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 14, "tag": "ResearchActivity"}, {"end": 125, "start": 117, "tag": "CellFunction"}, {"end": 53, "start": 31, "tag": "ResearchActivity"}, {"end": 85, "start": 63, "tag": "Finding"}]}
{"id": "1383_0", "text": "Dysfunctions in the endocannabinoid system have been associated with experimental animal models and multiple sclerosis patients.", "tags": [{"end": 42, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 127, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 69, "tag": "ResearchActivity"}, {"end": 118, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 20, "tag": "Chemical"}, {"end": 42, "start": 20, "tag": "CellFunction"}, {"end": 35, "start": 20, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1383_1", "text": "Interestingly, the endocannabinoid system has been reported to confer neuroprotection against demyelination.", "tags": [{"end": 34, "start": 19, "tag": "Chemical"}, {"end": 41, "start": 19, "tag": "CellFunction"}, {"end": 34, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 94, "tag": "PathologicFunction"}, {"end": 85, "start": 70, "tag": "CellFunction"}]}
{"id": "1383_2", "text": "The present study aims to assess the effects of the cannabinoid agonist WIN-55,212-2 in cuprizone fed animals on myelin repair capacity.", "tags": [{"end": 71, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 84, "start": 72, "tag": "Chemical"}, {"end": 84, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 135, "start": 113, "tag": "CellFunction"}, {"end": 109, "start": 88, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1383_3", "text": "Animals exposed to cuprizone were simultaneously treated withWIN-55,212-2, behaviorally tested and finally the corpus callosum was exhaustively studied by Western blotting, qRT-PCR and a myelin staining procedure.", "tags": [{"end": 7, "start": 0, "tag": "Eukaryote"}, {"end": 28, "start": 19, "tag": "Chemical"}, {"end": 171, "start": 155, "tag": "ResearchActivity"}, {"end": 180, "start": 173, "tag": "ResearchActivity"}, {"end": 126, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 61, "tag": "Chemical"}, {"end": 73, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 187, "tag": "ResearchActivity"}, {"end": 94, "start": 75, "tag": "ResearchActivity"}]}
{"id": "1383_4", "text": "We report that the long-term administration of WIN-55,212-2 reduced the global amount of CB1 protein.", "tags": [{"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 59, "start": 47, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 47, "tag": "Chemical"}, {"end": 100, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1383_5", "text": "Histological analysis revealed clear demyelination after being fed cuprizone for three weeks.", "tags": [{"end": 76, "start": 67, "tag": "Chemical"}, {"end": 92, "start": 81, "tag": "TemporalConcept"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 37, "tag": "PathologicFunction"}]}
{"id": "1383_6", "text": "However, cuprizone-fed mice subjected to 0.5 mg/Kg of WIN-55,212-2 displayed no differences when compared to controls during demyelination, although there was a robust increase in the myelinated axons during the remyelination phase.", "tags": [{"end": 200, "start": 184, "tag": "CellComponent"}, {"end": 225, "start": 212, "tag": "CellFunction"}, {"end": 231, "start": 226, "tag": "TemporalConcept"}, {"end": 117, "start": 109, "tag": "PopulationGroup"}, {"end": 91, "start": 77, "tag": "Finding"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 27, "start": 9, "tag": "ExperimentalModelOfDisease"}, {"end": 66, "start": 54, "tag": "Chemical"}, {"end": 66, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 161, "tag": "Finding"}]}
{"id": "1383_7", "text": "These animals displayed better performance on contextual fear conditioning which was in turn non-attributable to an antinociceptive effect.", "tags": [{"end": 13, "start": 6, "tag": "Eukaryote"}, {"end": 42, "start": 24, "tag": "Finding"}, {"end": 74, "start": 46, "tag": "ResearchActivity"}, {"end": 138, "start": 116, "tag": "Finding"}]}
{"id": "1383_8", "text": "In contrast, a 1 mg/Kg dosage caused a remarkable demyelination accompanied by limited potential for myelin repair.", "tags": [{"end": 63, "start": 50, "tag": "PathologicFunction"}, {"end": 114, "start": 101, "tag": "CellFunction"}]}
{"id": "1383_9", "text": "Upon drug administration while mice ongoing demyeliniation, the expression of Aif1 (microglia) and Gfap (astrocytes) followed a dose-dependent manner whereas the expression of both markers was apparently attenuated during remyelination.", "tags": [{"end": 24, "start": 5, "tag": "ResearchActivity"}, {"end": 24, "start": 5, "tag": "HealthCareActivity"}, {"end": 82, "start": 78, "tag": "GeneOrGenome"}, {"end": 103, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 99, "tag": "GeneOrGenome"}, {"end": 235, "start": 222, "tag": "CellFunction"}, {"end": 35, "start": 31, "tag": "Eukaryote"}, {"end": 93, "start": 84, "tag": "Cell"}, {"end": 115, "start": 105, "tag": "Cell"}, {"end": 82, "start": 64, "tag": "CellFunction"}, {"end": 58, "start": 44, "tag": "PathologicFunction"}, {"end": 82, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 99, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1383_10", "text": "Treatment with vehicle or 0.5 mg/Kg of the drug during demyelination increased the expression of Pdgfra (oligodendrocyte precursor cells) but this did not occur when 1 mg/Kg was administered.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "GeneOrGenome"}, {"end": 103, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 105, "tag": "Cell"}, {"end": 47, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}]}
{"id": "1383_11", "text": "In conclusion, the drug at 0.5 mg/Kg did not alter myelin architecture while 1 mg/Kg had a deleterious effect in this model.", "tags": [{"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 51, "tag": "CellComponent"}, {"end": 123, "start": 118, "tag": "ResearchActivity"}, {"end": 23, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 91, "tag": "Finding"}, {"end": 70, "start": 51, "tag": "CellFunction"}]}
{"id": "1384_0", "text": "In Alzheimer's disease, amyloid plaque formation is associated with the focal death of oligodendrocytes and soluble amyloid beta impairs the survival of oligodendrocytes in vitro.", "tags": [{"end": 103, "start": 87, "tag": "Cell"}, {"end": 128, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 141, "tag": "CellFunction"}, {"end": 169, "start": 153, "tag": "Cell"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 78, "tag": "BiologicFunction"}, {"end": 83, "start": 78, "tag": "PathologicFunction"}, {"end": 178, "start": 170, "tag": "ResearchActivity"}, {"end": 83, "start": 78, "tag": "CellFunction"}, {"end": 48, "start": 24, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1384_1", "text": "However, the response of oligodendrocyte progenitor cells (OPCs) to early amyloid pathology remains unclear.", "tags": [{"end": 57, "start": 25, "tag": "Cell"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}]}
{"id": "1384_2", "text": "To explore this, we performed a histological, electrophysiological, and behavioral characterization of transgenic mice expressing a pathological form of humanamyloid precursor protein(APP), containing three single point mutations associated with the development of familial Alzheimer's disease (PDGFB-APP(Sw.Ind), also known as J20 mice).PDGFB-APP(Sw.Ind)transgenic mice had impaired survival from weaning, were hyperactive by 2 months of age, and developed amyloid plaques by 6 months of age, however, their spatial memory remained intact over this time course.", "tags": [{"end": 149, "start": 132, "tag": "PathologicFunction"}, {"end": 392, "start": 384, "tag": "CellFunction"}, {"end": 405, "start": 398, "tag": "Finding"}, {"end": 423, "start": 412, "tag": "DiseaseOrSyndrome"}, {"end": 473, "start": 458, "tag": "AminoAcidPeptideOrProtein"}, {"end": 523, "start": 509, "tag": "BiologicFunction"}, {"end": 539, "start": 533, "tag": "Finding"}, {"end": 561, "start": 550, "tag": "TemporalConcept"}, {"end": 442, "start": 439, "tag": "OrganismAttribute"}, {"end": 492, "start": 489, "tag": "OrganismAttribute"}, {"end": 293, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 103, "tag": "Eukaryote"}, {"end": 99, "start": 32, "tag": "ResearchActivity"}, {"end": 129, "start": 119, "tag": "CellFunction"}, {"end": 554, "start": 550, "tag": "TemporalConcept"}, {"end": 561, "start": 555, "tag": "TemporalConcept"}, {"end": 229, "start": 207, "tag": "CellOrMolecularDysfunction"}, {"end": 561, "start": 555, "tag": "PathologicFunction"}, {"end": 435, "start": 427, "tag": "TemporalConcept"}, {"end": 485, "start": 479, "tag": "TemporalConcept"}, {"end": 187, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 301, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 184, "tag": "GeneOrGenome"}, {"end": 304, "start": 301, "tag": "GeneOrGenome"}, {"end": 187, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 301, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 295, "tag": "GeneOrGenome"}, {"end": 300, "start": 295, "tag": "BiologicallyActiveSubstance"}, {"end": 336, "start": 328, "tag": "ExperimentalModelOfDisease"}, {"end": 370, "start": 338, "tag": "ExperimentalModelOfDisease"}, {"end": 336, "start": 332, "tag": "ExperimentalModelOfDisease"}, {"end": 311, "start": 295, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1384_3", "text": "Hippocampal OPC density was normal in P60-P180PDGFB-APP(Sw.Ind)transgenic mice and, by performing whole-cell patch-clamp electrophysiology, we found that their membrane properties, including their response to kainate (100 mu M), were largely normal.", "tags": [{"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 160, "tag": "CellComponent"}, {"end": 216, "start": 209, "tag": "Chemical"}, {"end": 248, "start": 242, "tag": "Finding"}, {"end": 78, "start": 74, "tag": "Eukaryote"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "GeneOrGenome"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 38, "tag": "ExperimentalModelOfDisease"}, {"end": 15, "start": 12, "tag": "Cell"}]}
{"id": "1384_4", "text": "However, by P100, the response of hippocampal OPCs to GABA was elevated inPDGFB-APP(Sw.Ind)transgenic mice.", "tags": [{"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 50, "start": 46, "tag": "Cell"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 45, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 102, "tag": "Eukaryote"}, {"end": 45, "start": 34, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 80, "tag": "GeneOrGenome"}, {"end": 83, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 74, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1384_5", "text": "We also found that the nodes of Ranvier were shorter, the paranodes longer, and the myelin thicker for hippocampal axons in young adultPDGFB-APP(Sw.Ind)transgenic mice compared with wildtype littermates.", "tags": [{"end": 67, "start": 58, "tag": "CellComponent"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 84, "tag": "CellComponent"}, {"end": 120, "start": 103, "tag": "CellComponent"}, {"end": 135, "start": 124, "tag": "PopulationGroup"}, {"end": 39, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 135, "tag": "ExperimentalModelOfDisease"}, {"end": 202, "start": 182, "tag": "Eukaryote"}]}
{"id": "1384_6", "text": "Additionally, oligodendrogenesis was normal in young adulthood, but increased in the hippocampus, entorhinal cortex, and fimbria ofPDGFB-APP(Sw.Ind)transgenic mice as pathology developed.", "tags": [{"end": 62, "start": 47, "tag": "PopulationGroup"}, {"end": 96, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 167, "tag": "PathologicFunction"}, {"end": 176, "start": 167, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 163, "start": 159, "tag": "Eukaryote"}, {"end": 32, "start": 14, "tag": "BiologicFunction"}, {"end": 163, "start": 131, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1384_7", "text": "As the new oligodendrocytes were not associated with a change in total oligodendrocyte number, these cells are likely required for cell replacement.", "tags": [{"end": 27, "start": 11, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 147, "start": 131, "tag": "HealthCareActivity"}, {"end": 147, "start": 131, "tag": "ResearchActivity"}, {"end": 106, "start": 101, "tag": "Cell"}]}
{"id": "1385_0", "text": "The exacerbation of progressive multiple sclerosis (MS) is closely associated with obstruction of the differentiation of oligodendrocyte progenitor cells (OPCs).", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 94, "start": 83, "tag": "Finding"}, {"end": 153, "start": 121, "tag": "Cell"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 50, "start": 32, "tag": "DiseaseOrSyndrome"}]}
{"id": "1385_1", "text": "To discover novel therapeutic compounds for enhancing remyelination by endogenous OPCs, we screened for myelin basic protein expression using cultured rat OPCs and a library of small-molecule compounds.", "tags": [{"end": 67, "start": 54, "tag": "CellFunction"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "CellComponent"}, {"end": 135, "start": 117, "tag": "CellFunction"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 173, "start": 166, "tag": "GeneOrGenome"}, {"end": 39, "start": 12, "tag": "Substance"}, {"end": 159, "start": 142, "tag": "ResearchActivity"}, {"end": 201, "start": 177, "tag": "Substance"}]}
{"id": "1385_2", "text": "One of the most effective drugs was pinocembrin, which remarkably promoted OPC differentiation and maturation without affecting cell proliferation and survival.", "tags": [{"end": 47, "start": 36, "tag": "Chemical"}, {"end": 159, "start": 151, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 75, "tag": "CellFunction"}, {"end": 146, "start": 128, "tag": "CellFunction"}, {"end": 109, "start": 99, "tag": "CellFunction"}, {"end": 78, "start": 75, "tag": "CellFunction"}]}
{"id": "1385_3", "text": "Based on these in vitro effects, we further assessed the therapeutic effects of pinocembrin in animal models of demyelinating diseases.", "tags": [{"end": 91, "start": 80, "tag": "Chemical"}, {"end": 134, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 95, "tag": "ResearchActivity"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 76, "start": 57, "tag": "Finding"}]}
{"id": "1385_4", "text": "We demonstrated that pinocembrin significantly ameliorated the progression of experimental autoimmune encephalomyelitis (EAE) and enhanced the repair of demyelination in lysolectin-induced lesions.", "tags": [{"end": 32, "start": 21, "tag": "Chemical"}, {"end": 119, "start": 78, "tag": "ExperimentalModelOfDisease"}, {"end": 124, "start": 121, "tag": "ExperimentalModelOfDisease"}, {"end": 149, "start": 143, "tag": "BiologicFunction"}, {"end": 149, "start": 143, "tag": "HealthCareActivity"}, {"end": 74, "start": 63, "tag": "PathologicFunction"}, {"end": 74, "start": 63, "tag": "TemporalConcept"}, {"end": 166, "start": 153, "tag": "PathologicFunction"}, {"end": 180, "start": 170, "tag": "Chemical"}, {"end": 196, "start": 170, "tag": "InjuryOrPoisoning"}]}
{"id": "1385_5", "text": "Further studies indicated that pinocembrin increased the phosphorylation level of mammalian target of rapamycin (mTOR).", "tags": [{"end": 42, "start": 31, "tag": "Chemical"}, {"end": 111, "start": 102, "tag": "Chemical"}, {"end": 117, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "GeneOrGenome"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 91, "start": 82, "tag": "Eukaryote"}, {"end": 72, "start": 57, "tag": "CellFunction"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 82, "tag": "GeneOrGenome"}, {"end": 111, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 82, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1385_6", "text": "Taken together, our results demonstrated that pinocembrin promotes OPC differentiation and remyelination through the phosphorylated mTOR pathway, and suggest a novel therapeutic prospect for this natural flavonoid product in treating demyelinating diseases.", "tags": [{"end": 57, "start": 46, "tag": "Chemical"}, {"end": 70, "start": 67, "tag": "Cell"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 256, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 144, "start": 117, "tag": "CellFunction"}, {"end": 221, "start": 196, "tag": "Chemical"}]}
{"id": "1386_0", "text": "Ceruloplasmin (Cp) is a multicopper oxidase with ferroxidase properties being of importance to the mobilisation and export of iron from cells and its ability to bind copper.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 0, "tag": "GeneOrGenome"}, {"end": 17, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 15, "tag": "GeneOrGenome"}, {"end": 60, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 99, "tag": "CellFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 141, "start": 136, "tag": "Cell"}, {"end": 172, "start": 166, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 166, "tag": "Chemical"}, {"end": 130, "start": 126, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 126, "tag": "Chemical"}, {"end": 172, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 24, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1386_1", "text": "In ageing humans, Cp deficiency is known to result in aceruloplasminemia, which among other is characterised by neurological symptoms.", "tags": [{"end": 72, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 112, "tag": "SignOrSymptom"}, {"end": 16, "start": 10, "tag": "Eukaryote"}, {"end": 31, "start": 18, "tag": "DiseaseOrSyndrome"}]}
{"id": "1386_2", "text": "To obtain novel information about the functions of Cp in the central nervous system (CNS) we compared the brain proteome in forebrains from asymptomatic 4-6-month-old Cp-deficient (B6N(Cg)-Cp-tm1b(KOMP)Wtsi/J) and wild-type mice.", "tags": [{"end": 53, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 51, "tag": "GeneOrGenome"}, {"end": 120, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 214, "tag": "Eukaryote"}, {"end": 111, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 224, "tag": "ExperimentalModelOfDisease"}, {"end": 209, "start": 140, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1386_3", "text": "Of more than 5600 quantified proteins, 23 proteins, were regulated, whereas more than 1200 proteins had regulated post-translational modifications (PTMs).", "tags": [{"end": 146, "start": 114, "tag": "CellFunction"}, {"end": 152, "start": 148, "tag": "CellFunction"}]}
{"id": "1386_4", "text": "The genes of the regulated proteins, glycoproteins and phosphoproteins appeared mostly to be located to neurons and oligodendrocyte precursor cells.", "tags": [{"end": 50, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 116, "tag": "Cell"}, {"end": 111, "start": 104, "tag": "Cell"}, {"end": 70, "start": 55, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1386_5", "text": "Cp deficiency especially affected the function of proteins involved in the extension of neuronal projections, synaptic signalling and cellular mRNA processing and affected the expression of proteins involved in neurodegenerative disease and diabetes.", "tags": [{"end": 129, "start": 110, "tag": "CellFunction"}, {"end": 158, "start": 134, "tag": "CellFunction"}, {"end": 249, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 88, "tag": "CellComponent"}, {"end": 13, "start": 0, "tag": "DiseaseOrSyndrome"}]}
{"id": "1386_6", "text": "Iron concentration and transferrin saturation were reduced in the blood of even younger, 3- to 5-month-old, Cp-deficient mice.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 108, "tag": "ExperimentalModelOfDisease"}, {"end": 106, "start": 89, "tag": "PopulationGroup"}, {"end": 87, "start": 80, "tag": "TemporalConcept"}, {"end": 45, "start": 23, "tag": "ResearchActivity"}]}
{"id": "1386_7", "text": "Iron act as cofactor in many enzymatic processes and reactions.", "tags": [{"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 20, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1386_8", "text": "Changes in iron availability and oxidation as consequence of Cp deficiency could therefore affect the synthesis of proteins and lipids.", "tags": [{"end": 123, "start": 102, "tag": "CellFunction"}, {"end": 134, "start": 128, "tag": "Chemical"}, {"end": 15, "start": 11, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 11, "tag": "Chemical"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 0, "tag": "Finding"}, {"end": 42, "start": 33, "tag": "CellFunction"}]}
{"id": "1386_9", "text": "This proteomic characterisation is to our knowledge the first to document the changes taking place in the CNS-proteome and its phosphorylation and glycosylation state in Cp-deficient mice.", "tags": [{"end": 31, "start": 5, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 42, "tag": "Finding"}, {"end": 187, "start": 170, "tag": "ExperimentalModelOfDisease"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 142, "start": 127, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 110, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1387_0", "text": "The role of RNA binding proteins in regulating the phagocytic and cytokine-releasing functions of microglia is unknown.", "tags": [{"end": 32, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 94, "start": 66, "tag": "CellFunction"}, {"end": 32, "start": 12, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1387_1", "text": "Here, we show that microglia deficient for the QUAKING (QKI) RNA binding protein have increased proinflammatory cytokine release and defects in processing phagocytosed cargo.", "tags": [{"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 155, "tag": "CellComponent"}, {"end": 28, "start": 19, "tag": "Cell"}, {"end": 128, "start": 86, "tag": "Finding"}, {"end": 173, "start": 133, "tag": "Finding"}, {"end": 128, "start": 112, "tag": "CellFunction"}, {"end": 54, "start": 19, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1387_2", "text": "Splicing analysis reveals a role for QKI in regulating microexon networks of the Rho GTPase pathway.", "tags": [{"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 99, "start": 81, "tag": "CellFunction"}, {"end": 64, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 55, "tag": "CellFunction"}]}
{"id": "1387_3", "text": "We show an increase in RhoA activation and proinflammatory cytokines in QKI-deficient microglia that are repressed by treating with a Rock kinase inhibitor.", "tags": [{"end": 27, "start": 23, "tag": "GeneOrGenome"}, {"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 155, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 134, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 23, "tag": "CellFunction"}]}
{"id": "1387_4", "text": "During the cuprizone diet, mice with QKI-deficient microglia are inefficient at supporting central nervous system (CNS) remyelination and cause the recruited oligodendrocyte precursor cells to undergo apoptosis.", "tags": [{"end": 25, "start": 11, "tag": "HealthCareActivity"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 189, "start": 158, "tag": "Cell"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 27, "tag": "ExperimentalModelOfDisease"}, {"end": 113, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 201, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "Cell"}]}
{"id": "1387_5", "text": "Furthermore, the expression of QKI in microglia is downregulated in preactive, chronic active, and remyelinating white matter lesions of multiple sclerosis (MS) patients.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 51, "tag": "CellFunction"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 161, "tag": "PatientOrDisabledGroup"}, {"end": 155, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 38, "tag": "Cell"}, {"end": 34, "start": 17, "tag": "CellFunction"}, {"end": 133, "start": 68, "tag": "Finding"}]}
{"id": "1387_6", "text": "Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 95, "tag": "GeneOrGenome"}, {"end": 156, "start": 143, "tag": "CellFunction"}, {"end": 142, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 164, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 106, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 116, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 41, "tag": "CellFunction"}, {"end": 105, "start": 95, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1388_0", "text": "Multiple sclerosis (MS) is an inflammatory demyelinating disorder in the central nervous system (CNS), in which remyelination failure results in persistent neurologic impairment.", "tags": [{"end": 125, "start": 112, "tag": "CellFunction"}, {"end": 133, "start": 112, "tag": "CellOrMolecularDysfunction"}, {"end": 177, "start": 145, "tag": "Finding"}, {"end": 100, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 30, "tag": "DiseaseOrSyndrome"}]}
{"id": "1388_1", "text": "Ginkgolide B (GB), a major terpene lactone and active component of Ginkgo biloba, has neuroprotective effects in several models of neurological diseases.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 16, "start": 14, "tag": "Chemical"}, {"end": 80, "start": 67, "tag": "Organism"}, {"end": 127, "start": 121, "tag": "ResearchActivity"}, {"end": 109, "start": 86, "tag": "Finding"}, {"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 27, "tag": "Chemical"}, {"end": 42, "start": 27, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1388_2", "text": "Here, our results show, by using an in vivo cuprizone (CPZ)-induced demyelinating model, administration of GB improved behavior abnormalities, promoted myelin generation, and significantly regulated the dynamic balance of microglia and astrocytes by inhibiting the expression of TLR4, NF-kappa B and iNOS as well as IL-1 beta and TNF-alpha, and up-regulating the expression of Arg-1 and neurotrophic factors.", "tags": [{"end": 53, "start": 44, "tag": "Chemical"}, {"end": 109, "start": 107, "tag": "Chemical"}, {"end": 141, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "CellComponent"}, {"end": 218, "start": 203, "tag": "Finding"}, {"end": 283, "start": 279, "tag": "AminoAcidPeptideOrProtein"}, {"end": 283, "start": 279, "tag": "GeneOrGenome"}, {"end": 283, "start": 279, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 300, "tag": "AminoAcidPeptideOrProtein"}, {"end": 325, "start": 316, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "ResearchActivity"}, {"end": 373, "start": 345, "tag": "CellFunction"}, {"end": 295, "start": 285, "tag": "AminoAcidPeptideOrProtein"}, {"end": 295, "start": 285, "tag": "GeneOrGenome"}, {"end": 295, "start": 285, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 222, "tag": "Cell"}, {"end": 246, "start": 236, "tag": "Cell"}, {"end": 275, "start": 250, "tag": "CellFunction"}, {"end": 407, "start": 387, "tag": "AminoAcidPeptideOrProtein"}, {"end": 407, "start": 387, "tag": "BiologicallyActiveSubstance"}, {"end": 339, "start": 330, "tag": "BiologicallyActiveSubstance"}, {"end": 339, "start": 330, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "Chemical"}, {"end": 87, "start": 54, "tag": "ExperimentalModelOfDisease"}, {"end": 169, "start": 152, "tag": "CellFunction"}, {"end": 304, "start": 300, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 316, "tag": "PharmacologicSubstance"}, {"end": 382, "start": 377, "tag": "GeneOrGenome"}]}
{"id": "1388_3", "text": "GB treatment also induced the generation of oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 2, "start": 0, "tag": "Chemical"}, {"end": 75, "start": 30, "tag": "CellFunction"}, {"end": 75, "start": 44, "tag": "Cell"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 12, "start": 3, "tag": "HealthCareActivity"}, {"end": 12, "start": 3, "tag": "ResearchActivity"}]}
{"id": "1388_4", "text": "In vitro cell experiments yielded the results similar to those of the in vivo model.", "tags": [{"end": 25, "start": 9, "tag": "ResearchActivity"}, {"end": 83, "start": 70, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1388_5", "text": "The dynamic balance by decreasing microglia-mediated neuroinflammation and promoting astrocyte-derived neurotrophic factors should contribute to endogenous remyelination.", "tags": [{"end": 19, "start": 4, "tag": "Finding"}, {"end": 33, "start": 23, "tag": "Finding"}, {"end": 169, "start": 156, "tag": "CellFunction"}, {"end": 70, "start": 53, "tag": "PathologicFunction"}, {"end": 43, "start": 34, "tag": "Cell"}, {"end": 123, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 85, "tag": "Cell"}]}
{"id": "1388_6", "text": "Despite GB treatment may represent a novel strategy for promoting myelin recovery, the precise mechanism of GB targeting microglia and astrocytes remains to be further explored.", "tags": [{"end": 10, "start": 8, "tag": "Chemical"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 66, "tag": "CellComponent"}, {"end": 81, "start": 73, "tag": "BiologicFunction"}, {"end": 81, "start": 73, "tag": "HealthCareActivity"}, {"end": 110, "start": 108, "tag": "Chemical"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 130, "start": 121, "tag": "Cell"}, {"end": 145, "start": 135, "tag": "Cell"}]}
{"id": "1389_0", "text": "Recent studies have indicated oligodendroglial-vascular crosstalk during brain development, but the underlying mechanisms are incompletely understood.", "tags": [{"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 90, "start": 73, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 30, "tag": "Cell"}]}
{"id": "1389_1", "text": "We report that oligodendrocyte precursor cells (OPCs) contact sprouting endothelial tip cells in mouse, ferret, and human neonatal white matter.", "tags": [{"end": 46, "start": 15, "tag": "Cell"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 93, "start": 72, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "Eukaryote"}, {"end": 130, "start": 122, "tag": "PopulationGroup"}, {"end": 130, "start": 122, "tag": "TemporalConcept"}, {"end": 121, "start": 116, "tag": "Eukaryote"}, {"end": 143, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 102, "start": 97, "tag": "Eukaryote"}]}
{"id": "1389_2", "text": "Using transgenic mice, we show that increased or decreased OPC density results in cognate changes in white matter vascular investment.", "tags": [{"end": 70, "start": 36, "tag": "Finding"}, {"end": 62, "start": 59, "tag": "Cell"}, {"end": 122, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 6, "tag": "ResearchActivity"}, {"end": 113, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1389_3", "text": "Hypoxia induced increases in OPC numbers, vessel density and endothelial cell expression of the Wnt pathway targets Apcdd1 and Axin2 in white matter, suggesting paracrine OPC-endothelial signaling.", "tags": [{"end": 7, "start": 0, "tag": "PathologicFunction"}, {"end": 32, "start": 29, "tag": "Cell"}, {"end": 77, "start": 61, "tag": "Cell"}, {"end": 107, "start": 96, "tag": "CellFunction"}, {"end": 122, "start": 116, "tag": "GeneOrGenome"}, {"end": 132, "start": 127, "tag": "GeneOrGenome"}, {"end": 132, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 16, "tag": "Finding"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 161, "tag": "CellFunction"}]}
{"id": "1389_4", "text": "Conditional knockout of OPC Wntless resulted in diminished white matter vascular growth in normoxia, whereas loss of Wnt7a/b function blunted the angiogenic response to hypoxia, resulting in severe white matter damage.", "tags": [{"end": 35, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 146, "tag": "BiologicFunction"}, {"end": 176, "start": 169, "tag": "PathologicFunction"}, {"end": 80, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 217, "start": 191, "tag": "Finding"}, {"end": 71, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 81, "tag": "BiologicFunction"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 133, "start": 109, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1389_5", "text": "These findings indicate that OPC-endothelial cell interactions regulate neonatal white matter vascular development in a Wnt-dependent manner and further suggest this mechanism is important in attenuating hypoxic injury.", "tags": [{"end": 80, "start": 72, "tag": "PopulationGroup"}, {"end": 80, "start": 72, "tag": "TemporalConcept"}, {"end": 114, "start": 94, "tag": "BiologicFunction"}, {"end": 218, "start": 204, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 29, "tag": "CellFunction"}, {"end": 93, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 120, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1390_0", "text": "NOD mice represent a unique strain that recapitulates some aspects of progressive MS when subjected to experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 144, "start": 103, "tag": "ExperimentalModelOfDisease"}, {"end": 149, "start": 146, "tag": "ExperimentalModelOfDisease"}, {"end": 84, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1390_1", "text": "It is unknown, however, whether a proneness to demyelination and/or defect in remyelination contribute to disease progression in NOD mice.", "tags": [{"end": 91, "start": 68, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 106, "tag": "PathologicFunction"}, {"end": 60, "start": 47, "tag": "PathologicFunction"}, {"end": 137, "start": 129, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1390_2", "text": "Answering to this question might help deciphering the molecular and cellular events underpinning disease evolution in progressive MS.", "tags": [{"end": 114, "start": 97, "tag": "PathologicFunction"}, {"end": 132, "start": 118, "tag": "DiseaseOrSyndrome"}]}
{"id": "1390_3", "text": "Here, we compared the cuprizone-dependent demyelination and remyelination responses, as well as their functional correlates, in NOD, C57BL/6, and SJL mice typically adopted to model progressive, chronic or relapsing EAE.", "tags": [{"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 215, "start": 206, "tag": "TemporalConcept"}, {"end": 219, "start": 216, "tag": "ExperimentalModelOfDisease"}, {"end": 55, "start": 42, "tag": "PathologicFunction"}, {"end": 202, "start": 195, "tag": "TemporalConcept"}, {"end": 193, "start": 182, "tag": "TemporalConcept"}, {"end": 31, "start": 22, "tag": "Chemical"}, {"end": 154, "start": 146, "tag": "Eukaryote"}, {"end": 154, "start": 150, "tag": "ExperimentalModelOfDisease"}, {"end": 131, "start": 128, "tag": "ExperimentalModelOfDisease"}, {"end": 154, "start": 150, "tag": "Eukaryote"}, {"end": 140, "start": 133, "tag": "Eukaryote"}]}
{"id": "1390_4", "text": "We report that demyelination occurred to a similar extent in the three mice strains, and that in none of them there was evidence of axonal degeneration during prolonged demyelination.", "tags": [{"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 128, "start": 120, "tag": "Finding"}, {"end": 83, "start": 71, "tag": "Eukaryote"}, {"end": 151, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 28, "start": 15, "tag": "PathologicFunction"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}]}
{"id": "1390_5", "text": "Moreover, immunostaining for GFAP(+) astrocytes, Iba1(+) microglia, and NG2(+) oligodendrocyte precursor cells similarly increased in the 3 mouse strains after cuprizone exposure.", "tags": [{"end": 110, "start": 79, "tag": "Cell"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 66, "start": 57, "tag": "Cell"}, {"end": 47, "start": 37, "tag": "Cell"}, {"end": 24, "start": 10, "tag": "ResearchActivity"}, {"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "GeneOrGenome"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 160, "tag": "HealthCareActivity"}, {"end": 178, "start": 160, "tag": "ResearchActivity"}]}
{"id": "1390_6", "text": "The mice underwent concomitant and complete remyelination 2 weeks after cuprizone withdrawal.", "tags": [{"end": 30, "start": 19, "tag": "TemporalConcept"}, {"end": 57, "start": 44, "tag": "CellFunction"}, {"end": 71, "start": 58, "tag": "TemporalConcept"}, {"end": 81, "start": 72, "tag": "Chemical"}, {"end": 92, "start": 72, "tag": "ResearchActivity"}, {"end": 8, "start": 4, "tag": "Eukaryote"}, {"end": 92, "start": 72, "tag": "HealthCareActivity"}]}
{"id": "1390_7", "text": "On a functional level, NOD mice showed the earliest reduction of spontaneous motility and full recovery, but no impairment of motor skill.", "tags": [{"end": 103, "start": 95, "tag": "BiologicFunction"}, {"end": 103, "start": 95, "tag": "HealthCareActivity"}, {"end": 137, "start": 109, "tag": "Finding"}, {"end": 137, "start": 126, "tag": "BiologicFunction"}, {"end": 51, "start": 43, "tag": "TemporalConcept"}, {"end": 31, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 85, "start": 52, "tag": "Finding"}]}
{"id": "1390_8", "text": "Conversely, C57BL/6 animals showed phasic reduction of both spontaneous motility and motor skill.", "tags": [{"end": 80, "start": 72, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 51, "start": 35, "tag": "Finding"}, {"end": 27, "start": 12, "tag": "Eukaryote"}, {"end": 80, "start": 72, "tag": "CellFunction"}]}
{"id": "1390_9", "text": "Lastly, SJL mice presented the most severe neurological impairment with long-lasting reduction of spontaneous motility and motor skill.", "tags": [{"end": 66, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 110, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "BiologicFunction"}, {"end": 134, "start": 123, "tag": "BiologicFunction"}, {"end": 16, "start": 8, "tag": "Eukaryote"}, {"end": 94, "start": 85, "tag": "Finding"}, {"end": 94, "start": 85, "tag": "NaturalPhenomenonOrProcess"}, {"end": 66, "start": 36, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 84, "start": 72, "tag": "TemporalConcept"}]}
{"id": "1390_10", "text": "Overall, data suggest that the unique feature of EAE progression in NOD mice is not due to proneness to demyelination or intrinsic defects in myelin formation.", "tags": [{"end": 52, "start": 49, "tag": "ExperimentalModelOfDisease"}, {"end": 148, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 142, "tag": "CellComponent"}, {"end": 64, "start": 53, "tag": "PathologicFunction"}, {"end": 64, "start": 53, "tag": "TemporalConcept"}, {"end": 13, "start": 9, "tag": "ResearchActivity"}, {"end": 117, "start": 104, "tag": "PathologicFunction"}, {"end": 76, "start": 68, "tag": "ExperimentalModelOfDisease"}, {"end": 158, "start": 121, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1390_11", "text": "Findings also unravel important functional differences in the response of the three mouse stains to cuprizone that can be harnessed to design and interpret future experiments.", "tags": [{"end": 109, "start": 100, "tag": "Chemical"}, {"end": 174, "start": 163, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "TemporalConcept"}, {"end": 54, "start": 43, "tag": "Finding"}, {"end": 96, "start": 84, "tag": "Eukaryote"}]}
{"id": "1391_0", "text": "Demyelination occurs in response to brain injury and is observed in many neurodegenerative diseases.", "tags": [{"end": 48, "start": 36, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 99, "start": 73, "tag": "DiseaseOrSyndrome"}]}
{"id": "1391_1", "text": "Myelin is synthesized from oligodendrocytes in the central nervous system, and oligodendrocyte death-induced demyelination is one of the mechanisms involved in white matter damage after stroke and neurodegeneration.", "tags": [{"end": 192, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 172, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 95, "tag": "BiologicFunction"}, {"end": 100, "start": 95, "tag": "PathologicFunction"}, {"end": 100, "start": 95, "tag": "CellFunction"}, {"end": 214, "start": 197, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 79, "tag": "Cell"}, {"end": 122, "start": 109, "tag": "PathologicFunction"}]}
{"id": "1391_2", "text": "Oligodendrocyte precursor cells (OPCs) exist in the brain of normal adults, and their differentiation into mature oligodendrocytes play a central role in remyelination.", "tags": [{"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 130, "start": 114, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 130, "start": 107, "tag": "Cell"}, {"end": 101, "start": 86, "tag": "CellFunction"}, {"end": 113, "start": 107, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "Finding"}, {"end": 167, "start": 154, "tag": "CellFunction"}]}
{"id": "1391_3", "text": "Although the differentiation and maturity of OPCs drive endogenous efforts for remyelination, the failure of axons to remyelinate is still the biggest obstacle to brain repair after injury or diseases.", "tags": [{"end": 41, "start": 33, "tag": "TemporalConcept"}, {"end": 175, "start": 163, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "CellComponent"}, {"end": 49, "start": 45, "tag": "Cell"}, {"end": 129, "start": 118, "tag": "CellFunction"}, {"end": 28, "start": 13, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "IndividualBehavior"}, {"end": 188, "start": 182, "tag": "InjuryOrPoisoning"}, {"end": 92, "start": 79, "tag": "CellFunction"}, {"end": 175, "start": 169, "tag": "BiologicFunction"}, {"end": 175, "start": 169, "tag": "HealthCareActivity"}]}
{"id": "1391_4", "text": "In recent years, studies have made attempts to promote remyelination after brain injury and disease, but its cellular or molecular mechanism is not yet fully understood.", "tags": [{"end": 87, "start": 75, "tag": "InjuryOrPoisoning"}, {"end": 140, "start": 121, "tag": "CellFunction"}, {"end": 54, "start": 47, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 17, "tag": "ResearchActivity"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 117, "start": 109, "tag": "Cell"}, {"end": 68, "start": 55, "tag": "CellFunction"}]}
{"id": "1391_5", "text": "In this review, we discuss recent studies examining the demyelination process and potential therapeutic strategies for remyelination in aging and stroke.", "tags": [{"end": 114, "start": 82, "tag": "HealthCareActivity"}, {"end": 152, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 41, "start": 34, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "BiologicFunction"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}, {"end": 132, "start": 119, "tag": "CellFunction"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 141, "start": 136, "tag": "BiologicFunction"}, {"end": 141, "start": 136, "tag": "CellFunction"}, {"end": 114, "start": 92, "tag": "HealthCareActivity"}]}
{"id": "1391_6", "text": "Based on our current understanding of the cellular and molecular mechanisms underlying remyelination, we hypothesize that myelin and oligodendrocytes are viable therapeutic targets to mitigate brain injury and to treat demyelinating-related neurodegeneration diseases.", "tags": [{"end": 205, "start": 193, "tag": "InjuryOrPoisoning"}, {"end": 149, "start": 133, "tag": "Cell"}, {"end": 232, "start": 219, "tag": "PathologicFunction"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 161, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}, {"end": 258, "start": 241, "tag": "CellOrMolecularDysfunction"}, {"end": 34, "start": 21, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "Cell"}, {"end": 100, "start": 87, "tag": "CellFunction"}, {"end": 75, "start": 55, "tag": "CellFunction"}]}
{"id": "1392_0", "text": "Sphingosine-1-phosphate receptor 1 (S1PR1) is ubiquitously expressed among all tissues and plays key roles in many physiological and cellular processes.", "tags": [{"end": 34, "start": 0, "tag": "GeneOrGenome"}, {"end": 34, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 133, "tag": "CellFunction"}, {"end": 68, "start": 46, "tag": "CellFunction"}]}
{"id": "1392_1", "text": "In the central nervous system (CNS), S1PR1 is expressed in different types of cells including neurons, astrocytes, and oligodendrocyte precursor cells.", "tags": [{"end": 42, "start": 37, "tag": "GeneOrGenome"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 119, "tag": "Cell"}, {"end": 83, "start": 78, "tag": "Cell"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "Cell"}, {"end": 113, "start": 103, "tag": "Cell"}]}
{"id": "1392_2", "text": "S1PR1 has been recognized as a novel therapeutic target in multiple sclerosis and other diseases.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 31, "tag": "Finding"}]}
{"id": "1392_3", "text": "We previously reported a promising S1PR1-specific radioligand, [C-11]CS1P1 (previously named [C-11]TZ3321), which is under clinical investigation for human use.", "tags": [{"end": 155, "start": 150, "tag": "Eukaryote"}, {"end": 145, "start": 123, "tag": "ResearchActivity"}, {"end": 61, "start": 35, "tag": "Chemical"}, {"end": 74, "start": 63, "tag": "Chemical"}, {"end": 105, "start": 93, "tag": "Chemical"}]}
{"id": "1392_4", "text": "In the current study, we performed a detailed characterization of [H-3]CS1P1 for its binding specificity to S1PR1 in CNS using autoradiography and immunohistochemistry in human and rat CNS tissues.", "tags": [{"end": 113, "start": 108, "tag": "GeneOrGenome"}, {"end": 113, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 127, "tag": "ResearchActivity"}, {"end": 184, "start": 181, "tag": "Eukaryote"}, {"end": 196, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 62, "start": 46, "tag": "ResearchActivity"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 176, "start": 171, "tag": "Eukaryote"}, {"end": 167, "start": 147, "tag": "ResearchActivity"}, {"end": 76, "start": 66, "tag": "Chemical"}, {"end": 104, "start": 85, "tag": "ResearchActivity"}]}
{"id": "1392_5", "text": "Our data indicate that [H-3]CS1P1 binds to S1PR1 in human frontal cortex tissue with a K-d of 3.98 nM and a B-max of 172.5 nM.", "tags": [{"end": 39, "start": 34, "tag": "CellFunction"}, {"end": 48, "start": 43, "tag": "GeneOrGenome"}, {"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "Eukaryote"}, {"end": 33, "start": 23, "tag": "Chemical"}]}
{"id": "1392_6", "text": "The distribution of [H-3]CS1P1 in human and rat CNS tissues is consistent with the distribution of S1PR1 detected by immunohistochemistry studies.", "tags": [{"end": 47, "start": 44, "tag": "Eukaryote"}, {"end": 59, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 99, "tag": "GeneOrGenome"}, {"end": 104, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 138, "tag": "ResearchActivity"}, {"end": 39, "start": 34, "tag": "Eukaryote"}, {"end": 137, "start": 117, "tag": "ResearchActivity"}, {"end": 30, "start": 20, "tag": "Chemical"}]}
{"id": "1392_7", "text": "Our microPET studies of [C-11]CS1P1 in a nonhuman primate (NHP) show a standardized uptake value of 2.4 in the NHP brain, with test-retest variability of 0.23% among six different NHPs.", "tags": [{"end": 150, "start": 127, "tag": "ResearchActivity"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 57, "start": 41, "tag": "Eukaryote"}, {"end": 62, "start": 59, "tag": "Eukaryote"}, {"end": 114, "start": 111, "tag": "Eukaryote"}, {"end": 184, "start": 180, "tag": "Eukaryote"}, {"end": 12, "start": 4, "tag": "ManufacturedObject"}, {"end": 35, "start": 24, "tag": "Chemical"}]}
{"id": "1392_8", "text": "Radiometabolite analysis in the plasma samples of NHP and rat, as well as in rat brain samples, showed that [C-11]CS1P1 was stable in vivo.", "tags": [{"end": 61, "start": 58, "tag": "Eukaryote"}, {"end": 80, "start": 77, "tag": "Eukaryote"}, {"end": 86, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 138, "start": 131, "tag": "ResearchActivity"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 50, "tag": "Eukaryote"}, {"end": 119, "start": 108, "tag": "Chemical"}, {"end": 15, "start": 0, "tag": "Chemical"}]}
{"id": "1392_9", "text": "Kinetic modeling studies using a two-compartment tissue model showed that the positron emission tomography (PET) data fit the model well.", "tags": [{"end": 106, "start": 78, "tag": "HealthCareActivity"}, {"end": 106, "start": 78, "tag": "ManufacturedObject"}, {"end": 111, "start": 108, "tag": "HealthCareActivity"}, {"end": 117, "start": 113, "tag": "ResearchActivity"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 33, "tag": "ResearchActivity"}]}
{"id": "1392_10", "text": "Overall, our study provides a detailed characterization of [H-3]CS1P1 binding to S1PR1 in the CNS.", "tags": [{"end": 77, "start": 70, "tag": "CellFunction"}, {"end": 86, "start": 81, "tag": "GeneOrGenome"}, {"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 81, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "ResearchActivity"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 59, "tag": "Chemical"}]}
{"id": "1392_11", "text": "Combined with our microPET studies in the NHP brain, our data suggest that [C-11]CS1P1 is a promising radioligand for PET imaging of S1PR1 in the CNS.", "tags": [{"end": 113, "start": 102, "tag": "Chemical"}, {"end": 129, "start": 118, "tag": "HealthCareActivity"}, {"end": 138, "start": 133, "tag": "GeneOrGenome"}, {"end": 138, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 57, "tag": "ResearchActivity"}, {"end": 34, "start": 27, "tag": "ResearchActivity"}, {"end": 26, "start": 18, "tag": "ManufacturedObject"}, {"end": 45, "start": 42, "tag": "Eukaryote"}, {"end": 86, "start": 75, "tag": "Chemical"}]}
{"id": "1393_0", "text": "The subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus are known as neurogenic niches.", "tags": [{"end": 23, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 140, "tag": "Finding"}]}
{"id": "1393_1", "text": "We show that the median eminence (ME) of the hypothalamus comprises BrdU(+) newly proliferating cells co-expressing NG2 (oligodendrocyte progenitors) and RIP (pre-myelinating oligodendrocytes), suggesting their differentiation toward mature oligodendrocytes (OLs).", "tags": [{"end": 32, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "GeneOrGenome"}, {"end": 148, "start": 121, "tag": "Cell"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 154, "tag": "GeneOrGenome"}, {"end": 191, "start": 159, "tag": "Cell"}, {"end": 257, "start": 234, "tag": "Cell"}, {"end": 262, "start": 259, "tag": "Cell"}, {"end": 101, "start": 76, "tag": "Cell"}, {"end": 226, "start": 211, "tag": "CellFunction"}, {"end": 72, "start": 68, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 72, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1393_2", "text": "ME cells can generate neurospheres (NS) in vitro, which differentiate mostly to OLs compared with SVZ-NS that typically generate neurons.", "tags": [{"end": 8, "start": 0, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "Cell"}, {"end": 136, "start": 129, "tag": "Cell"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 34, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1393_3", "text": "Interestingly, this population of oligodendrocyte progenitors is increased in the ME from experimental autoimmune encephalomyelitis (EAE)-affected mice.", "tags": [{"end": 61, "start": 34, "tag": "Cell"}, {"end": 84, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 30, "start": 20, "tag": "PopulationGroup"}, {"end": 151, "start": 132, "tag": "ExperimentalModelOfDisease"}, {"end": 136, "start": 133, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1393_4", "text": "Notably, the thrombospondin 1 (TSP1) expressed by astrocytes, acts as negative regulator of oligodendrogenesis in vitro and is downregulated in the ME of EAE mice.", "tags": [{"end": 29, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 13, "tag": "GeneOrGenome"}, {"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 110, "start": 70, "tag": "CellFunction"}, {"end": 150, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 154, "tag": "ExperimentalModelOfDisease"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 60, "start": 50, "tag": "Cell"}, {"end": 110, "start": 92, "tag": "BiologicFunction"}, {"end": 29, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1393_5", "text": "Importantly, transplanted ME-NS preferentially differentiate to MBP+ OLs compared with SVZ-NS in Shiverer mice.", "tags": [{"end": 72, "start": 69, "tag": "Cell"}, {"end": 28, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 13, "tag": "HealthCareActivity"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 97, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1393_6", "text": "Hence, discovering the ME as a new site for myelin-producing cells has a great importance for advising future therapy for demyelinating diseases and spinal cord injury.", "tags": [{"end": 25, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 44, "tag": "Cell"}, {"end": 109, "start": 103, "tag": "TemporalConcept"}, {"end": 117, "start": 110, "tag": "HealthCareActivity"}, {"end": 167, "start": 149, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1394_0", "text": "Gap junctions (GJs) are specialized transmembrane channels assembled by two hemichannels of six connexin (Cx) proteins that facilitate neuroglial crosstalk in the central nervous system (CNS).", "tags": [{"end": 13, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 135, "tag": "Cell"}, {"end": 155, "start": 135, "tag": "CellFunction"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1394_1", "text": "Previous studies confirmed the crucial role of glial GJs in neurodegenerative disorders with dementia or motor dysfunction including Alzheimer's disease (AD).", "tags": [{"end": 52, "start": 47, "tag": "Cell"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 105, "tag": "DiseaseOrSyndrome"}]}
{"id": "1394_2", "text": "The aim of this study was to examine the alterations in astrocyte and related oligodendrocyte GJs in association with A beta plaques in the spinal cord of the 5xFAD mouse model of AD.", "tags": [{"end": 65, "start": 56, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "Cell"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 118, "tag": "PathologicFunction"}, {"end": 182, "start": 159, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1394_3", "text": "Our analysis revealed abundant A beta plaque deposition, activated microglia, and astrogliosis in 12-month-old (12M) 5xFAD mice, with significant impairment of motor performance starting from 3-months (3M) of age.", "tags": [{"end": 212, "start": 209, "tag": "OrganismAttribute"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 177, "start": 160, "tag": "ClinicalAttribute"}, {"end": 76, "start": 67, "tag": "Cell"}, {"end": 94, "start": 82, "tag": "PathologicFunction"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 44, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 31, "tag": "PathologicFunction"}, {"end": 110, "start": 98, "tag": "PopulationGroup"}, {"end": 127, "start": 117, "tag": "ExperimentalModelOfDisease"}, {"end": 156, "start": 134, "tag": "Finding"}]}
{"id": "1394_4", "text": "Additionally, 12M 5xFAD mice displayed increased immunoreactivity of astroglial Cx43 and Cx30 surrounding A beta plaques and higher protein levels, indicating upregulated astrocyte-to-astrocyte GJ connectivity.", "tags": [{"end": 65, "start": 49, "tag": "CellFunction"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 84, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 106, "tag": "PathologicFunction"}, {"end": 28, "start": 18, "tag": "ExperimentalModelOfDisease"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 171, "tag": "Cell"}, {"end": 193, "start": 184, "tag": "Cell"}]}
{"id": "1394_5", "text": "In addition, they demonstrated increased numbers of mature CC1-positive and precursor oligodendrocytes (OPCs) with higher immunoreactivity of Cx47-positive GJs in individual cells.", "tags": [{"end": 58, "start": 52, "tag": "TemporalConcept"}, {"end": 102, "start": 76, "tag": "Cell"}, {"end": 138, "start": 122, "tag": "CellFunction"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 174, "tag": "Cell"}, {"end": 108, "start": 104, "tag": "Cell"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1394_6", "text": "Moreover, total Cx47 protein levels were significantly elevated in 12M 5xFAD, reflecting increased oligodendrocyte-tooligodendrocyte Cx47-Cx47 GJ connectivity.", "tags": [{"end": 28, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 132, "start": 117, "tag": "Cell"}, {"end": 158, "start": 143, "tag": "CellFunction"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 138, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1394_7", "text": "In contrast, we observed a marked reduction in Cx32 protein levels in 12M 5xFAD spinal cords compared with controls, while qRT-PCR analysis revealed a significant upregulation in Cx32 mRNA levels.", "tags": [{"end": 92, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 123, "tag": "ResearchActivity"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 43, "start": 27, "tag": "Finding"}, {"end": 59, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 179, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 188, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 74, "tag": "ExperimentalModelOfDisease"}, {"end": 175, "start": 151, "tag": "Finding"}]}
{"id": "1394_8", "text": "Finally, myelin deficits were found focally in the areas occupied by A beta plaques, whereas axons themselves remained preserved.", "tags": [{"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 9, "tag": "CellComponent"}, {"end": 98, "start": 93, "tag": "CellComponent"}, {"end": 83, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 69, "tag": "PathologicFunction"}, {"end": 24, "start": 9, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1394_9", "text": "Overall, our data provide novel insights into the altered glial GJ expression in the spinal cord of the 5xFAD model of AD and the implicated role of GJ pathology in neurodegeneration.", "tags": [{"end": 63, "start": 58, "tag": "Cell"}, {"end": 96, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 149, "tag": "PathologicFunction"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 182, "start": 165, "tag": "CellOrMolecularDysfunction"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 64, "tag": "CellFunction"}, {"end": 66, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 104, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1394_10", "text": "Further investigation to understand the functional consequences of these extensive alterations in oligodendrocyte-astrocyte (O/A) GJ connectivity is warranted.", "tags": [{"end": 94, "start": 73, "tag": "Finding"}, {"end": 21, "start": 8, "tag": "ResearchActivity"}, {"end": 145, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 98, "tag": "Cell"}, {"end": 123, "start": 114, "tag": "Cell"}]}
{"id": "1395_0", "text": "Myelin is essential to nervous system function, playing roles in saltatory conduction and trophic support.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 23, "tag": "BiologicFunction"}, {"end": 85, "start": 65, "tag": "BiologicFunction"}, {"end": 105, "start": 90, "tag": "CellFunction"}]}
{"id": "1395_1", "text": "Oligodendrocytes (OLs) and Schwann cells (SCs) form myelin in the central and peripheral nervous systems respectively and follow different developmental paths.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 21, "start": 18, "tag": "Cell"}, {"end": 40, "start": 27, "tag": "Cell"}, {"end": 45, "start": 42, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 52, "tag": "CellComponent"}, {"end": 104, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 139, "tag": "BiologicFunction"}, {"end": 152, "start": 139, "tag": "TemporalConcept"}]}
{"id": "1395_2", "text": "OLs are neural stem-cell derived and follow an intrinsic developmental program resulting in a largely irreversible differentiation state.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 78, "start": 57, "tag": "BiologicFunction"}, {"end": 136, "start": 115, "tag": "CellFunction"}, {"end": 24, "start": 8, "tag": "Cell"}]}
{"id": "1395_3", "text": "During embryonic development, OL precursor cells (OPCs) are produced in distinct waves originating from different locations in the central nervous system, with a subset developing into myelinating OLs.", "tags": [{"end": 48, "start": 30, "tag": "Cell"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 86, "start": 81, "tag": "NaturalPhenomenonOrProcess"}, {"end": 200, "start": 185, "tag": "Cell"}, {"end": 153, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 7, "tag": "BiologicFunction"}]}
{"id": "1395_4", "text": "OPCs remain evenly distributed throughout life, providing a population of responsive, multifunctional cells with the capacity to remyelinate after injury.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}, {"end": 140, "start": 129, "tag": "CellFunction"}, {"end": 107, "start": 102, "tag": "Cell"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 153, "start": 147, "tag": "InjuryOrPoisoning"}]}
{"id": "1395_5", "text": "SCs derive from the neural crest, are highly dependent on extrinsic signals, and have plastic differentiation states.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 32, "start": 20, "tag": "EmbryonicStructure"}, {"end": 116, "start": 94, "tag": "CellFunction"}, {"end": 75, "start": 38, "tag": "Finding"}]}
{"id": "1395_6", "text": "SC precursors (SCPs) are produced in early embryonic nerve structures and differentiate into multipotent immature SCs (iSCs), which initiate radial sorting and differentiate into myelinating and non-myelinating SCs.", "tags": [{"end": 13, "start": 0, "tag": "Cell"}, {"end": 69, "start": 43, "tag": "EmbryonicStructure"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 117, "start": 93, "tag": "Cell"}, {"end": 173, "start": 160, "tag": "CellFunction"}, {"end": 19, "start": 15, "tag": "Cell"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 214, "start": 195, "tag": "Cell"}, {"end": 155, "start": 141, "tag": "CellFunction"}, {"end": 190, "start": 179, "tag": "Cell"}, {"end": 214, "start": 211, "tag": "Cell"}]}
{"id": "1395_7", "text": "Differentiated SCs retain the capacity to radically change phenotypes in response to external signals, including becoming repair SCs, which drive peripheral regeneration.", "tags": [{"end": 18, "start": 0, "tag": "Cell"}, {"end": 69, "start": 59, "tag": "OrganismAttribute"}, {"end": 132, "start": 122, "tag": "Cell"}, {"end": 169, "start": 146, "tag": "BiologicFunction"}]}
{"id": "1395_8", "text": "While several transcription factors and myelin components are common between OLs and SCs, their differentiation mechanisms are highly distinct, owing to their unique lineages and their respective environments.", "tags": [{"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "CellComponent"}, {"end": 57, "start": 47, "tag": "CellComponent"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 88, "start": 85, "tag": "Cell"}, {"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 35, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 166, "tag": "CellFunction"}]}
{"id": "1395_9", "text": "In addition, both OLs and SCs respond to neuronal activity and regulate nervous system output in reciprocal manners, possibly through different pathways.", "tags": [{"end": 21, "start": 18, "tag": "Cell"}, {"end": 29, "start": 26, "tag": "Cell"}, {"end": 86, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 144, "tag": "CellFunction"}, {"end": 58, "start": 41, "tag": "CellFunction"}]}
{"id": "1395_10", "text": "Here, we outline their basic developmental programs, mechanisms regulating their differentiation, and recent advances in the field.", "tags": [{"end": 51, "start": 29, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 117, "start": 109, "tag": "Finding"}]}
{"id": "1396_0", "text": "Myelination of projection neurons by oligodendrocytes is key to optimize action potential conduction over long distances.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 33, "start": 15, "tag": "CellComponent"}, {"end": 53, "start": 37, "tag": "Cell"}, {"end": 89, "start": 73, "tag": "CellFunction"}, {"end": 100, "start": 90, "tag": "BiologicFunction"}, {"end": 100, "start": 90, "tag": "NaturalPhenomenonOrProcess"}]}
{"id": "1396_1", "text": "However, a large fraction of myelin enwraps the axons of parvalbumin-positive fast-spiking interneurons (FSI), exclusively involved in local cortical circuits.", "tags": [{"end": 35, "start": 29, "tag": "CellComponent"}, {"end": 53, "start": 48, "tag": "CellComponent"}, {"end": 158, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 78, "tag": "Cell"}, {"end": 108, "start": 105, "tag": "Cell"}, {"end": 68, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 57, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1396_2", "text": "Whether FSI myelination contributes to the fine-tuning of intracortical networks is unknown.", "tags": [{"end": 23, "start": 12, "tag": "CellFunction"}, {"end": 11, "start": 8, "tag": "Cell"}, {"end": 80, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1396_3", "text": "Here we demonstrate that FSI myelination is required for the establishment and maintenance of the powerful FSI-mediated feedforward inhibition of cortical sensory circuits.", "tags": [{"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "BiologicFunction"}, {"end": 142, "start": 107, "tag": "CellFunction"}, {"end": 171, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "Cell"}]}
{"id": "1396_4", "text": "The disruption of GABAergic synaptic signaling of oligodendrocyte precursor cells prior to myelination onset resulted in severe FSI myelination defects characterized by longer internodes and nodes, aberrant myelination of branch points and proximal axon malformation.", "tags": [{"end": 81, "start": 50, "tag": "Cell"}, {"end": 102, "start": 91, "tag": "CellFunction"}, {"end": 151, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 186, "start": 176, "tag": "CellComponent"}, {"end": 266, "start": 240, "tag": "CellOrMolecularDysfunction"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 196, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 18, "tag": "CellFunction"}, {"end": 131, "start": 128, "tag": "Cell"}, {"end": 218, "start": 198, "tag": "CellOrMolecularDysfunction"}, {"end": 235, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1396_5", "text": "Consequently, high-frequency FSI discharges as well as FSI-dependent postsynaptic latencies and strengths of excitatory neurons were reduced.", "tags": [{"end": 81, "start": 69, "tag": "CellComponent"}, {"end": 127, "start": 109, "tag": "Cell"}, {"end": 32, "start": 29, "tag": "Cell"}]}
{"id": "1396_6", "text": "These dysfunctions generated a strong excitation-inhibition imbalance that correlated with whisker-dependent texture discrimination impairments.", "tags": [{"end": 18, "start": 6, "tag": "PathologicFunction"}, {"end": 69, "start": 38, "tag": "CellOrMolecularDysfunction"}, {"end": 131, "start": 91, "tag": "ResearchActivity"}, {"end": 98, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1396_7", "text": "FSI myelination is therefore critical for the function of mature cortical inhibitory circuits.", "tags": [{"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 64, "start": 58, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 93, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1396_8", "text": "Myelination optimizes conduction speed of excitatory neurons.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 32, "start": 22, "tag": "BiologicFunction"}, {"end": 32, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 60, "start": 42, "tag": "Cell"}]}
{"id": "1396_9", "text": "However, whether myelination of interneurons (INs) refines cortical networks is unclear.", "tags": [{"end": 28, "start": 17, "tag": "CellFunction"}, {"end": 44, "start": 32, "tag": "Cell"}, {"end": 49, "start": 46, "tag": "Cell"}, {"end": 76, "start": 59, "tag": "BiologicFunction"}]}
{"id": "1396_10", "text": "Here, the authors show that INs myelination shapes feedforward inhibition of mouse cortical sensory circuits and impacts whisker-mediated behaviour.", "tags": [{"end": 31, "start": 28, "tag": "Cell"}, {"end": 43, "start": 32, "tag": "CellFunction"}, {"end": 73, "start": 63, "tag": "CellFunction"}, {"end": 108, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "Eukaryote"}, {"end": 128, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 121, "tag": "BiologicFunction"}]}
{"id": "1397_0", "text": "Cuprizone is a copper-chelating agent that induces pathology similar to that within some multiple sclerosis (MS) lesions.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 60, "start": 51, "tag": "PathologicFunction"}, {"end": 60, "start": 51, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 15, "tag": "Chemical"}, {"end": 21, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 15, "tag": "PharmacologicSubstance"}]}
{"id": "1397_1", "text": "The reliability and reproducibility of cuprizone for inducing demyelinating disease pathology depends on the animals ingesting consistent doses of cuprizone.", "tags": [{"end": 48, "start": 39, "tag": "Chemical"}, {"end": 83, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 109, "tag": "Eukaryote"}, {"end": 126, "start": 117, "tag": "BiologicFunction"}, {"end": 156, "start": 147, "tag": "Chemical"}, {"end": 93, "start": 76, "tag": "PathologicFunction"}]}
{"id": "1397_2", "text": "Cuprizone-containing pelleted feed is a convenient way of delivering cuprizone, but the efficacy of these pellets at inducing demyelination has been questioned.", "tags": [{"end": 78, "start": 69, "tag": "Chemical"}, {"end": 139, "start": 126, "tag": "PathologicFunction"}, {"end": 34, "start": 0, "tag": "Chemical"}]}
{"id": "1397_3", "text": "This study compared the degree of demyelinating disease pathology between mice fed cuprizone delivered in pellets to mice fed a powdered cuprizone formulation at an early 3 week demyelinating timepoint.", "tags": [{"end": 55, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 83, "tag": "Chemical"}, {"end": 158, "start": 147, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "TemporalConcept"}, {"end": 191, "start": 178, "tag": "PathologicFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 78, "start": 74, "tag": "Eukaryote"}, {"end": 121, "start": 117, "tag": "Eukaryote"}, {"end": 65, "start": 48, "tag": "PathologicFunction"}, {"end": 146, "start": 137, "tag": "Chemical"}, {"end": 201, "start": 192, "tag": "TemporalConcept"}]}
{"id": "1397_4", "text": "Within rostral corpus callosum, cuprizone pellets were more effective than cuprizone powder at increasing astrogliosis, microglial activation, DNA damage, and decreasing the density of mature oligodendrocytes.", "tags": [{"end": 30, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 32, "tag": "Chemical"}, {"end": 141, "start": 120, "tag": "CellFunction"}, {"end": 153, "start": 143, "tag": "CellOrMolecularDysfunction"}, {"end": 208, "start": 185, "tag": "Cell"}, {"end": 30, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 143, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 106, "tag": "PathologicFunction"}, {"end": 91, "start": 75, "tag": "Chemical"}]}
{"id": "1397_5", "text": "However, cuprizone powder demonstrated greater protein nitration relative to controls.", "tags": [{"end": 85, "start": 77, "tag": "PopulationGroup"}, {"end": 64, "start": 47, "tag": "CellFunction"}, {"end": 25, "start": 9, "tag": "Chemical"}]}
{"id": "1397_6", "text": "Furthermore, mice fed control powder had significantly fewer mature oligodendrocytes than those fed control pellets.", "tags": [{"end": 84, "start": 61, "tag": "Cell"}, {"end": 17, "start": 13, "tag": "Eukaryote"}, {"end": 36, "start": 22, "tag": "Substance"}]}
{"id": "1397_7", "text": "In caudal corpus callosum, cuprizone pellets performed better than cuprizone powder relative to controls at increasing astrogliosis, microglial activation, protein nitration, DNA damage, tissue swelling, and reducing the density of mature oligodendrocytes.", "tags": [{"end": 9, "start": 3, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 27, "tag": "Chemical"}, {"end": 83, "start": 67, "tag": "Chemical"}, {"end": 154, "start": 133, "tag": "CellFunction"}, {"end": 185, "start": 175, "tag": "CellOrMolecularDysfunction"}, {"end": 255, "start": 232, "tag": "Cell"}, {"end": 25, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 96, "tag": "PopulationGroup"}, {"end": 178, "start": 175, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 131, "start": 119, "tag": "PathologicFunction"}, {"end": 173, "start": 156, "tag": "CellFunction"}, {"end": 202, "start": 187, "tag": "PathologicFunction"}]}
{"id": "1397_8", "text": "Importantly, only cuprizone pellets induced detectable demyelination compared to controls.", "tags": [{"end": 35, "start": 18, "tag": "Chemical"}, {"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}]}
{"id": "1397_9", "text": "The two feeds had similar effects on oligodendrocyte precursor cell (OPC) dynamics.", "tags": [{"end": 13, "start": 8, "tag": "HealthCareActivity"}, {"end": 67, "start": 37, "tag": "Cell"}, {"end": 72, "start": 69, "tag": "Cell"}]}
{"id": "1397_10", "text": "Taken together, these data suggest that demyelinating disease pathology is modelled more effectively with cuprizone pellets than powder at 3 weeks.", "tags": [{"end": 61, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 106, "tag": "Chemical"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 26, "start": 22, "tag": "ResearchActivity"}, {"end": 71, "start": 54, "tag": "PathologicFunction"}, {"end": 135, "start": 129, "tag": "Chemical"}, {"end": 115, "start": 106, "tag": "Chemical"}]}
{"id": "1397_11", "text": "Combined with the added convenience, cuprizone pellets are a suitable choice for inducing early demyelinating disease pathology.", "tags": [{"end": 54, "start": 37, "tag": "Chemical"}, {"end": 117, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 110, "tag": "PathologicFunction"}]}
{"id": "1398_0", "text": "To understand the cellular composition and region-specific specialization of white matter - a disease-relevant, glia-rich tissue highly expanded in primates relative to rodents - we profiled transcriptomes of similar to 500,000 nuclei from 19 tissue types of the central nervous system of healthy common marmoset and mapped 87 subclusters spatially onto a 3D MRI atlas.", "tags": [{"end": 205, "start": 191, "tag": "MolecularSequence"}, {"end": 255, "start": 243, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 368, "start": 363, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 285, "start": 263, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 359, "tag": "HealthCareActivity"}, {"end": 296, "start": 289, "tag": "OrganismAttribute"}, {"end": 89, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 128, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 148, "tag": "Eukaryote"}, {"end": 176, "start": 169, "tag": "Eukaryote"}, {"end": 234, "start": 228, "tag": "CellComponent"}, {"end": 312, "start": 297, "tag": "Eukaryote"}, {"end": 368, "start": 356, "tag": "ResearchActivity"}]}
{"id": "1398_1", "text": "We performed cross-species comparison, explored regulatory pathways, modeled regional intercellular communication, and surveyed cellular determinants of neurological disorders.", "tags": [{"end": 175, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 13, "tag": "ResearchActivity"}, {"end": 67, "start": 59, "tag": "CellFunction"}, {"end": 26, "start": 19, "tag": "OrganismAttribute"}, {"end": 113, "start": 77, "tag": "CellFunction"}]}
{"id": "1398_2", "text": "Here, we analyze this resource and find strong spatial segregation of microglia, oligodendrocyte progenitor cells, and astrocytes.", "tags": [{"end": 113, "start": 81, "tag": "Cell"}, {"end": 79, "start": 70, "tag": "Cell"}, {"end": 129, "start": 119, "tag": "Cell"}, {"end": 66, "start": 40, "tag": "Finding"}]}
{"id": "1398_3", "text": "White matter glia are diverse, enriched with genes involved in stimulus-response and biomolecule modification, and predicted to interact with other resident cells more extensively than their gray matter counterparts.", "tags": [{"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 148, "tag": "Cell"}, {"end": 202, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 13, "tag": "Cell"}]}
{"id": "1398_4", "text": "Conversely, gray matter glia preserve the expression of neural tube patterning genes into adulthood and share six transcription factors that restrict transcriptome complexity.", "tags": [{"end": 84, "start": 56, "tag": "GeneOrGenome"}, {"end": 99, "start": 90, "tag": "TemporalConcept"}, {"end": 163, "start": 150, "tag": "MolecularSequence"}, {"end": 23, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 135, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 56, "tag": "EmbryonicStructure"}]}
{"id": "1398_5", "text": "A companion Callithrix jacchus Primate Cell Atlas (CjPCA) is available through https://cjpca.ninds.nih.gov.", "tags": [{"end": 11, "start": 2, "tag": "PopulationGroup"}, {"end": 49, "start": 12, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}]}
{"id": "1399_0", "text": "The Na+/Ca2+ exchanger NCX3 is an important regulator of sodium and calcium homeostasis in oligodendrocyte lineage.", "tags": [{"end": 22, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 23, "tag": "GeneOrGenome"}, {"end": 87, "start": 44, "tag": "CellFunction"}, {"end": 114, "start": 91, "tag": "Cell"}, {"end": 22, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1399_1", "text": "To date, no information is available on the effects resulting from prolonged exposure to NCX3 blockers and subsequent drug washout in oligodendroglia.", "tags": [{"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 149, "start": 134, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 122, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 118, "tag": "ResearchActivity"}, {"end": 102, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 89, "tag": "Chemical"}]}
{"id": "1399_2", "text": "Here, we investigated, by means of biochemical, morphological and functional analyses, the pharmacological effects of the NCX3 inhibitor, the 5-amino-N-butyl-2(4-ethoxyphenoxy)-benzamide hydrochloride (BED), on NCXs expression and activity, as well as intracellular [Na+](i) and [Ca2+](i) levels, during treatment and following drug washout both in human MO3.13 oligodendrocytes and rat primary oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 85, "start": 35, "tag": "ResearchActivity"}, {"end": 378, "start": 355, "tag": "Cell"}, {"end": 386, "start": 383, "tag": "Eukaryote"}, {"end": 426, "start": 387, "tag": "Cell"}, {"end": 432, "start": 428, "tag": "Cell"}, {"end": 313, "start": 304, "tag": "HealthCareActivity"}, {"end": 313, "start": 304, "tag": "ResearchActivity"}, {"end": 354, "start": 349, "tag": "Eukaryote"}, {"end": 332, "start": 328, "tag": "PharmacologicSubstance"}, {"end": 226, "start": 211, "tag": "CellFunction"}, {"end": 136, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 122, "tag": "Chemical"}, {"end": 114, "start": 91, "tag": "Finding"}, {"end": 200, "start": 142, "tag": "Chemical"}, {"end": 205, "start": 202, "tag": "Chemical"}, {"end": 340, "start": 328, "tag": "ResearchActivity"}, {"end": 295, "start": 252, "tag": "ResearchActivity"}]}
{"id": "1399_3", "text": "BED exposure antagonized NCX activity, induced OPCs proliferation and [Na+](i) accumulation.", "tags": [{"end": 51, "start": 47, "tag": "Cell"}, {"end": 91, "start": 70, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 37, "start": 25, "tag": "CellFunction"}, {"end": 65, "start": 47, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "1399_4", "text": "By contrast, 2 days of BED washout after 4 days of treatment significantly upregulated low molecular weight NCX3 proteins, reversed NCX activity, and increased intracellular [Ca2+](i).", "tags": [{"end": 19, "start": 15, "tag": "TemporalConcept"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 144, "start": 132, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "HealthCareActivity"}, {"end": 60, "start": 51, "tag": "ResearchActivity"}, {"end": 180, "start": 174, "tag": "Chemical"}, {"end": 121, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 34, "start": 23, "tag": "HealthCareActivity"}, {"end": 121, "start": 108, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1399_5", "text": "This BED-free effect was accompanied by an upregulation of NCX3 expression in oligodendrocyte processes and accelerated expression of myelin markers in rat primary oligodendrocytes.", "tags": [{"end": 74, "start": 43, "tag": "CellFunction"}, {"end": 93, "start": 78, "tag": "Cell"}, {"end": 140, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 152, "tag": "Eukaryote"}, {"end": 180, "start": 156, "tag": "Cell"}, {"end": 8, "start": 5, "tag": "Chemical"}, {"end": 20, "start": 14, "tag": "Finding"}, {"end": 148, "start": 141, "tag": "ClinicalAttribute"}]}
{"id": "1399_6", "text": "Collectively, our findings show that the pharmacological inhibition of the NCX3 exchanger with BED blocker maybe followed by a rebound increase in NCX3 expression and reversal activity that accelerate myelin sheet formation in oligodendrocytes.", "tags": [{"end": 56, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 223, "start": 201, "tag": "CellFunction"}, {"end": 243, "start": 227, "tag": "Cell"}, {"end": 67, "start": 57, "tag": "CellFunction"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 89, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 95, "tag": "Chemical"}]}
{"id": "1399_7", "text": "In addition, they indicate that a particular attention should be paid to the use of NCX inhibitors for possible rebound effects, and suggest that further studies will be necessary to investigate whether selective pharmacological modulation of NCX3 exchanger may be exploited to benefit demyelination and remyelination in demyelinating diseases.", "tags": [{"end": 98, "start": 84, "tag": "Chemical"}, {"end": 247, "start": 243, "tag": "GeneOrGenome"}, {"end": 257, "start": 248, "tag": "CellFunction"}, {"end": 317, "start": 304, "tag": "CellFunction"}, {"end": 343, "start": 321, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 154, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "BiologicFunction"}, {"end": 299, "start": 286, "tag": "PathologicFunction"}, {"end": 98, "start": 84, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1400_0", "text": "Background Clinicians caring for patients with Multiple Sclerosis (MS) need improved biomarkers to aid them in disease management.", "tags": [{"end": 28, "start": 22, "tag": "IndividualBehavior"}, {"end": 65, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "Finding"}, {"end": 129, "start": 111, "tag": "HealthCareActivity"}, {"end": 95, "start": 85, "tag": "ClinicalAttribute"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 119, "tag": "HealthCareActivity"}, {"end": 21, "start": 11, "tag": "HealthCareActivity"}]}
{"id": "1400_1", "text": "Objective We assessed the predictive value of the candidate biomarker CXCL13 index in comparison to oligoclonal bands (OCBs) and CSF neurofilament light (NfL) concentration, examining the ability of each biomarker to predict future disease activity in clinically and radiologically isolated syndromes, relapsing-remitting MS, and progressive MS.", "tags": [{"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "GeneOrGenome"}, {"end": 82, "start": 70, "tag": "ResearchActivity"}, {"end": 117, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "ResearchActivity"}, {"end": 132, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 324, "start": 302, "tag": "DiseaseOrSyndrome"}, {"end": 344, "start": 342, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 225, "tag": "TemporalConcept"}, {"end": 96, "start": 86, "tag": "ResearchActivity"}, {"end": 311, "start": 302, "tag": "TemporalConcept"}, {"end": 344, "start": 330, "tag": "DiseaseOrSyndrome"}, {"end": 341, "start": 330, "tag": "TemporalConcept"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 213, "start": 204, "tag": "ClinicalAttribute"}, {"end": 42, "start": 26, "tag": "Finding"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 129, "tag": "HealthCareActivity"}, {"end": 248, "start": 232, "tag": "HealthCareActivity"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1400_2", "text": "Methods Matched serum and CSF samples were obtained from 67 non-inflammatory neurologic disease patients and 67 MS patients.", "tags": [{"end": 37, "start": 8, "tag": "ResearchActivity"}, {"end": 21, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 96, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 60, "tag": "DiseaseOrSyndrome"}]}
{"id": "1400_3", "text": "CSF and serum CXCL13 and CSF NfL were analyzed by Luminex and ELISA, respectively.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "GeneOrGenome"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 50, "tag": "ResearchActivity"}]}
{"id": "1400_4", "text": "CXCL13 data were also analyzed as CSF/serum ratios and indices.", "tags": [{"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "ResearchActivity"}, {"end": 50, "start": 34, "tag": "ResearchActivity"}]}
{"id": "1400_5", "text": "Electronic medical records were accessed to determine diagnosis, CSF profiles, and disease activity after the lumbar puncture.", "tags": [{"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 110, "tag": "HealthCareActivity"}, {"end": 63, "start": 54, "tag": "HealthCareActivity"}, {"end": 77, "start": 65, "tag": "HealthCareActivity"}, {"end": 26, "start": 0, "tag": "HealthCareActivity"}, {"end": 99, "start": 83, "tag": "HealthCareActivity"}]}
{"id": "1400_6", "text": "Results Among CXCL13 measures, CXCL13 index was the best predictor of future disease activity in MS patients (AUC=0.82; CI=0.69-0.95; p=0.0002).", "tags": [{"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "GeneOrGenome"}, {"end": 29, "start": 14, "tag": "HealthCareActivity"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 31, "tag": "HealthCareActivity"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 77, "tag": "HealthCareActivity"}]}
{"id": "1400_7", "text": "CXCL13 index values were significantly elevated in activity-positive MS patients compared to activity-negative patients (p<0.0001).", "tags": [{"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 119, "start": 111, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "1400_8", "text": "As a single predictor, CXCL13 index outperformed both OCBs and CSF NfL in sensitivity, specificity, and positive and negative predictive value, for future disease activity in MS patients.", "tags": [{"end": 35, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 23, "tag": "GeneOrGenome"}, {"end": 35, "start": 23, "tag": "HealthCareActivity"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 74, "tag": "Finding"}, {"end": 98, "start": 87, "tag": "Finding"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 148, "tag": "TemporalConcept"}, {"end": 186, "start": 178, "tag": "PatientOrDisabledGroup"}, {"end": 171, "start": 155, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 5, "tag": "Finding"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1400_9", "text": "Moreover, combining CXCL13 index and CSF NfL status improved sensitivity and predictive values for disease activity in MS patients.", "tags": [{"end": 32, "start": 20, "tag": "HealthCareActivity"}, {"end": 40, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 61, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 122, "tag": "PatientOrDisabledGroup"}, {"end": 115, "start": 99, "tag": "HealthCareActivity"}, {"end": 94, "start": 77, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 37, "tag": "HealthCareActivity"}]}
{"id": "1400_10", "text": "Conclusions The CXCL13 index is an excellent candidate prognostic biomarker for disease activity in patients with MS.", "tags": [{"end": 22, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 16, "tag": "GeneOrGenome"}, {"end": 28, "start": 16, "tag": "ResearchActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 55, "tag": "ClinicalAttribute"}, {"end": 96, "start": 80, "tag": "HealthCareActivity"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1401_0", "text": "Background:To evaluate retinal vessel density (VD) in macular and in peripapillary regions in patients with recent onset of multiple sclerosis, at initial demyelinating event (IDE) and in matched relapsing-remitting multiple sclerosis (RRMS) patients.", "tags": [{"end": 234, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 108, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 250, "start": 242, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 23, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "TemporalConcept"}, {"end": 90, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "HealthCareActivity"}]}
{"id": "1401_1", "text": "Methods:We evaluated VD in superficial capillary plexus, deep capillary plexus, choriocapillaris and radial peripapillary capillary plexus in IDE, RRMS patients and in matched healthy controls (HCs) through Optical Coherence Tomography Angiography (OCT-A).", "tags": [{"end": 96, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 207, "tag": "HealthCareActivity"}, {"end": 254, "start": 249, "tag": "HealthCareActivity"}, {"end": 183, "start": 176, "tag": "OrganismAttribute"}, {"end": 160, "start": 152, "tag": "PatientOrDisabledGroup"}, {"end": 192, "start": 176, "tag": "PopulationGroup"}, {"end": 23, "start": 21, "tag": "HealthCareActivity"}, {"end": 55, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "PopulationGroup"}]}
{"id": "1401_2", "text": "Clinical history, including history of optic neuritis, Expanded Disability Status scale and disease duration of patients were collected.", "tags": [{"end": 35, "start": 28, "tag": "Finding"}, {"end": 53, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 92, "tag": "HealthCareActivity"}, {"end": 120, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 0, "tag": "Finding"}, {"end": 87, "start": 55, "tag": "HealthCareActivity"}, {"end": 108, "start": 100, "tag": "TemporalConcept"}]}
{"id": "1401_3", "text": "Results:Thirty patients (20 with IDE and 10 with RRMS) and 15 HCs were enrolled.", "tags": [{"end": 53, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 15, "tag": "PatientOrDisabledGroup"}, {"end": 36, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 62, "tag": "PopulationGroup"}]}
{"id": "1401_4", "text": "IDE patients showed a lower VD in radial peripapillary capillary plexus compared with controls (coeff.", "tags": [{"end": 94, "start": 86, "tag": "PopulationGroup"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 28, "tag": "HealthCareActivity"}, {"end": 71, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1401_5", "text": "beta = -3.578;p= 0.002).", "tags": []}
{"id": "1401_6", "text": "RRMS patients displayed a lower VD in both superficial capillary plexus and radial peripapillary capillary plexus compared with HCs (coeff.", "tags": [{"end": 4, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 5, "tag": "PatientOrDisabledGroup"}, {"end": 34, "start": 32, "tag": "HealthCareActivity"}, {"end": 71, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 128, "tag": "PopulationGroup"}]}
{"id": "1401_7", "text": "beta = -4.955;p= 0.002, and coeff.", "tags": []}
{"id": "1401_8", "text": "beta = -7.446;p< 0.001, respectively).", "tags": []}
{"id": "1401_9", "text": "Furthermore, RRMS patients showed a decreased VD in radial peripapillary capillary plexus compared with IDE patients (coeff.", "tags": [{"end": 17, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 108, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 46, "tag": "HealthCareActivity"}, {"end": 89, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}]}
{"id": "1401_10", "text": "beta = -3.868;p= 0.003).", "tags": []}
{"id": "1401_11", "text": "Conclusions:Peripapillary region vessel density reduction, revealed through OCT-A, might be considered as an early event in MS, and might be relevant as a biomarker of disease pathology.", "tags": [{"end": 81, "start": 76, "tag": "HealthCareActivity"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 48, "tag": "Finding"}, {"end": 57, "start": 48, "tag": "NaturalPhenomenonOrProcess"}, {"end": 47, "start": 33, "tag": "HealthCareActivity"}, {"end": 185, "start": 168, "tag": "PathologicFunction"}, {"end": 164, "start": 155, "tag": "ClinicalAttribute"}, {"end": 32, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1402_0", "text": "Introduction: Multiple Sclerosis (MS) is presented with motor and sensory function loss.", "tags": [{"end": 32, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 66, "tag": "PathologicFunction"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}]}
{"id": "1402_1", "text": "It is caused by demyelination and following axonal lesion.", "tags": [{"end": 29, "start": 16, "tag": "PathologicFunction"}, {"end": 57, "start": 44, "tag": "InjuryOrPoisoning"}]}
{"id": "1402_2", "text": "As Myelin Basic Protein (MBP) is one of the key elements of the myelin cover, we examined the level of MBP in serum, Stimulated, and unstimulated saliva as a suitable biomarker for detecting MS.", "tags": [{"end": 23, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 3, "tag": "GeneOrGenome"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 64, "tag": "CellComponent"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 25, "tag": "GeneOrGenome"}, {"end": 106, "start": 103, "tag": "GeneOrGenome"}, {"end": 176, "start": 167, "tag": "ClinicalAttribute"}, {"end": 23, "start": 3, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1402_3", "text": "Methods: A case-control Study was performed in 29 healthy women and 32 definitive relapsing-remitting MS patients hospitalized in Imam Reza hospital, Tehran, Iran.", "tags": [{"end": 29, "start": 11, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 57, "start": 50, "tag": "OrganismAttribute"}, {"end": 104, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 11, "tag": "ManufacturedObject"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 130, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1402_4", "text": "MBP level was assayed in serum and Stimulated and unstimulated whole saliva.", "tags": [{"end": 30, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "1402_5", "text": "Results: MBP was expressed at a lower level in serum and Stimulated saliva of MS patients compared to the control group.", "tags": [{"end": 52, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 17, "tag": "CellFunction"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 119, "start": 106, "tag": "PopulationGroup"}]}
{"id": "1402_6", "text": "The serum MBP level had a considerable correlation with its Stimulated saliva level.", "tags": [{"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 10, "tag": "GeneOrGenome"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}]}
{"id": "1402_7", "text": "The receiver operating characteristic analysis showed significant diagnostic ability for MBP to discriminate MS patients with serum and Stimulated saliva from controls.", "tags": [{"end": 131, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 159, "tag": "PopulationGroup"}, {"end": 120, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 153, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 89, "tag": "GeneOrGenome"}]}
{"id": "1402_8", "text": "Conclusion: Serum and saliva level of MBP is lower in MS, so it may be considered a potential biomarker in MS.", "tags": [{"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 84, "tag": "ClinicalAttribute"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "GeneOrGenome"}, {"end": 103, "start": 94, "tag": "ClinicalAttribute"}, {"end": 41, "start": 29, "tag": "HealthCareActivity"}]}
{"id": "1403_0", "text": "Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients.", "tags": [{"end": 71, "start": 62, "tag": "HealthCareActivity"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 75, "tag": "InjuryOrPoisoning"}]}
{"id": "1403_1", "text": "Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis.", "tags": [{"end": 63, "start": 54, "tag": "TemporalConcept"}, {"end": 89, "start": 76, "tag": "ResearchActivity"}, {"end": 159, "start": 141, "tag": "ClinicalAttribute"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 127, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "ClinicalAttribute"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 12, "tag": "ClinicalAttribute"}, {"end": 49, "start": 45, "tag": "ClinicalAttribute"}]}
{"id": "1403_2", "text": "There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g.", "tags": [{"end": 26, "start": 18, "tag": "Finding"}, {"end": 43, "start": 32, "tag": "ClinicalAttribute"}, {"end": 59, "start": 52, "tag": "TemporalConcept"}, {"end": 98, "start": 80, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 60, "tag": "PathologicFunction"}]}
{"id": "1403_3", "text": "relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years.", "tags": [{"end": 54, "start": 43, "tag": "ClinicalAttribute"}, {"end": 103, "start": 98, "tag": "TemporalConcept"}, {"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 32, "start": 16, "tag": "HealthCareActivity"}, {"end": 79, "start": 63, "tag": "HealthCareActivity"}]}
{"id": "1403_4", "text": "In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerative damage in multiple sclerosis is less clear.", "tags": [{"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 51, "start": 42, "tag": "TemporalConcept"}, {"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 110, "tag": "PathologicFunction"}, {"end": 36, "start": 32, "tag": "ClinicalAttribute"}]}
{"id": "1403_5", "text": "However, early results from real-world cohorts and clinical trials using sNfL as a marker of treatment response in multiple sclerosis are encouraging.", "tags": [{"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 83, "tag": "ClinicalAttribute"}, {"end": 66, "start": 51, "tag": "ResearchActivity"}, {"end": 46, "start": 39, "tag": "PopulationGroup"}, {"end": 111, "start": 93, "tag": "ClinicalAttribute"}, {"end": 133, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "ClinicalAttribute"}]}
{"id": "1403_6", "text": "Importantly, clinical algorithms should now be developed that incorporate the routine use of sNfL to guide individualized clinical decision-making in people with multiple sclerosis, together with additional fluid biomarkers and clinical and MRI measures.", "tags": [{"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 107, "tag": "HealthCareActivity"}, {"end": 212, "start": 207, "tag": "Substance"}, {"end": 253, "start": 245, "tag": "ClinicalAttribute"}, {"end": 236, "start": 228, "tag": "ClinicalAttribute"}, {"end": 223, "start": 213, "tag": "ClinicalAttribute"}, {"end": 156, "start": 150, "tag": "PopulationGroup"}, {"end": 244, "start": 241, "tag": "HealthCareActivity"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 131, "tag": "BiologicFunction"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 93, "tag": "ClinicalAttribute"}]}
{"id": "1403_7", "text": "Here, we propose specific clinical scenarios where implementing sNfL measures may be of utility, including, among others: initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection.", "tags": [{"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 122, "tag": "TemporalConcept"}, {"end": 177, "start": 165, "tag": "HealthCareActivity"}, {"end": 177, "start": 165, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 222, "start": 214, "tag": "ClinicalAttribute"}, {"end": 243, "start": 226, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 64, "tag": "ClinicalAttribute"}, {"end": 209, "start": 181, "tag": "HealthCareActivity"}]}
{"id": "1404_0", "text": "Background: White matter lesions (WMLs) on brain magnetic resonance imaging (MRI) in multiple sclerosis (MS) may contribute to misdiagnosis.", "tags": [{"end": 139, "start": 127, "tag": "Finding"}, {"end": 48, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 49, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 103, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 25, "tag": "InjuryOrPoisoning"}, {"end": 24, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 38, "start": 34, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 49, "tag": "ManufacturedObject"}]}
{"id": "1404_1", "text": "In chronic active lesions, peripheral iron-laden macrophages appear as paramagnetic rim lesions (PRLs).", "tags": [{"end": 10, "start": 3, "tag": "TemporalConcept"}, {"end": 42, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 38, "tag": "Chemical"}, {"end": 42, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 3, "tag": "InjuryOrPoisoning"}, {"end": 95, "start": 71, "tag": "ClinicalAttribute"}, {"end": 60, "start": 38, "tag": "Cell"}, {"end": 37, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 97, "tag": "ClinicalAttribute"}]}
{"id": "1404_2", "text": "Objective: To evaluate the sensitivity and specificity of PRLs in differentiating MS from mimics using clinical 3T MRI scanners.", "tags": [{"end": 127, "start": 103, "tag": "ManufacturedObject"}, {"end": 38, "start": 27, "tag": "Finding"}, {"end": 54, "start": 43, "tag": "Finding"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 103, "tag": "HealthCareActivity"}, {"end": 62, "start": 58, "tag": "InjuryOrPoisoning"}]}
{"id": "1404_3", "text": "Method: This retrospective international study reviewed MRI scans of patients with MS (n = 254), MS mimics (n = 91) and older healthy controls (n = 217).", "tags": [{"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 46, "start": 13, "tag": "ResearchActivity"}, {"end": 133, "start": 126, "tag": "OrganismAttribute"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 126, "tag": "PopulationGroup"}, {"end": 106, "start": 97, "tag": "Finding"}, {"end": 125, "start": 120, "tag": "TemporalConcept"}]}
{"id": "1404_4", "text": "WMLs, detected using fluid-attenuated inversion recovery MRI, were analysed with phase-sensitive imaging.", "tags": [{"end": 60, "start": 21, "tag": "HealthCareActivity"}, {"end": 56, "start": 48, "tag": "BiologicFunction"}, {"end": 56, "start": 48, "tag": "HealthCareActivity"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 104, "start": 81, "tag": "HealthCareActivity"}, {"end": 56, "start": 48, "tag": "TemporalConcept"}, {"end": 4, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 21, "tag": "ManufacturedObject"}]}
{"id": "1404_5", "text": "Sensitivity and specificity were assessed for PRLs.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}]}
{"id": "1404_6", "text": "Results: At least one PRL was found in 22.9% of MS and 26.1% of clinically isolated syndrome (CIS) patients.", "tags": [{"end": 25, "start": 22, "tag": "ClinicalAttribute"}, {"end": 92, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}]}
{"id": "1404_7", "text": "Only one PRL was found elsewhere.", "tags": [{"end": 12, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1404_8", "text": "The identification of > 1 PRL was the optimal cut-off and had high specificity (99.7%, confidence interval (CI) = 98.20%-99.99%) when distinguishing MS and CIS from mimics and healthy controls, but lower sensitivity (24.0%, CI = 18.9%-36.6%).", "tags": [{"end": 29, "start": 26, "tag": "ClinicalAttribute"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 204, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "Finding"}, {"end": 183, "start": 176, "tag": "OrganismAttribute"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 87, "tag": "ResearchActivity"}, {"end": 192, "start": 176, "tag": "PopulationGroup"}]}
{"id": "1404_9", "text": "All patients with a PRL showing a central vein sign (CVS) in the same lesion (n = 54) had MS or CIS, giving a specificity of 100% (CI = 98.8%-100.0%) but equally low sensitivity (21.3%, CI = 16.4%-26.81%) Conclusion: PRLs may reduce diagnostic uncertainty in MS by being a highly specific imaging diagnostic biomarker, especially when used in conjunction with the CVS.", "tags": [{"end": 23, "start": 20, "tag": "ClinicalAttribute"}, {"end": 99, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 166, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 317, "start": 289, "tag": "ClinicalAttribute"}, {"end": 51, "start": 34, "tag": "ClinicalAttribute"}, {"end": 367, "start": 364, "tag": "ClinicalAttribute"}, {"end": 56, "start": 53, "tag": "ClinicalAttribute"}]}
{"id": "1405_0", "text": "Objectives Neuropathological studies have shown that multiple sclerosis (MS) lesions are heterogeneous in terms of myelin/axon damage and repair as well as iron content.", "tags": [{"end": 102, "start": 89, "tag": "OrganismAttribute"}, {"end": 168, "start": 156, "tag": "BiologicFunction"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 156, "tag": "PharmacologicSubstance"}, {"end": 160, "start": 156, "tag": "Chemical"}, {"end": 160, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 138, "tag": "BiologicFunction"}, {"end": 144, "start": 138, "tag": "HealthCareActivity"}, {"end": 84, "start": 77, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 115, "tag": "CellComponent"}, {"end": 126, "start": 122, "tag": "CellComponent"}, {"end": 133, "start": 115, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1405_1", "text": "However, it remains a challenge to identify specific chronic lesion types, especially remyelinated lesions, in vivo in patients with MS.", "tags": [{"end": 98, "start": 86, "tag": "CellFunction"}, {"end": 115, "start": 108, "tag": "ResearchActivity"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 53, "tag": "TemporalConcept"}, {"end": 127, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 106, "start": 99, "tag": "InjuryOrPoisoning"}, {"end": 67, "start": 61, "tag": "InjuryOrPoisoning"}, {"end": 31, "start": 22, "tag": "HealthCareActivity"}]}
{"id": "1405_2", "text": "Methods We performed 3 studies: (1) a cross-sectional study in a prospective cohort of 115 patients with MS and 76 healthy controls, who underwent 3 T magnetic resonance imaging (MRI) for quantitative susceptibility mapping (QSM), myelin water fraction (MWF), and neurite density index (NDI) maps.", "tags": [{"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 122, "start": 115, "tag": "OrganismAttribute"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 147, "tag": "HealthCareActivity"}, {"end": 177, "start": 147, "tag": "ManufacturedObject"}, {"end": 182, "start": 179, "tag": "HealthCareActivity"}, {"end": 99, "start": 91, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 77, "tag": "PopulationGroup"}, {"end": 76, "start": 65, "tag": "BiologicFunction"}, {"end": 237, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 231, "tag": "CellComponent"}, {"end": 177, "start": 170, "tag": "HealthCareActivity"}, {"end": 59, "start": 38, "tag": "ResearchActivity"}, {"end": 131, "start": 115, "tag": "PopulationGroup"}, {"end": 223, "start": 188, "tag": "HealthCareActivity"}, {"end": 223, "start": 188, "tag": "ManufacturedObject"}, {"end": 228, "start": 225, "tag": "HealthCareActivity"}, {"end": 228, "start": 225, "tag": "ManufacturedObject"}, {"end": 252, "start": 231, "tag": "ResearchActivity"}, {"end": 296, "start": 292, "tag": "ResearchActivity"}, {"end": 285, "start": 264, "tag": "ResearchActivity"}, {"end": 243, "start": 238, "tag": "Chemical"}, {"end": 290, "start": 287, "tag": "ResearchActivity"}, {"end": 257, "start": 254, "tag": "ResearchActivity"}]}
{"id": "1405_3", "text": "White matter (WM) lesions in QSM were classified into 5 QSM lesion types (iso-intense, hypo-intense, hyperintense, lesions with hypo-intense rims, and lesions with paramagnetic rim legions [PRLs]); (2) a longitudinal study of 40 patients with MS to study the evolution of lesions over 2 years; (3) a postmortem histopathology-QSM validation study in 3 brains of patients with MS to assess the accuracy of QSM classification to identify neuropathological lesion types in 63 WM lesions.", "tags": [{"end": 222, "start": 204, "tag": "ResearchActivity"}, {"end": 268, "start": 259, "tag": "TemporalConcept"}, {"end": 310, "start": 300, "tag": "TemporalConcept"}, {"end": 346, "start": 311, "tag": "ResearchActivity"}, {"end": 254, "start": 249, "tag": "ResearchActivity"}, {"end": 292, "start": 287, "tag": "TemporalConcept"}, {"end": 245, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 378, "start": 376, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 229, "tag": "PatientOrDisabledGroup"}, {"end": 370, "start": 362, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 475, "start": 473, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "InjuryOrPoisoning"}, {"end": 122, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 158, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 279, "start": 272, "tag": "InjuryOrPoisoning"}, {"end": 483, "start": 476, "tag": "InjuryOrPoisoning"}, {"end": 66, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 460, "start": 454, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 358, "start": 352, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 29, "tag": "HealthCareActivity"}, {"end": 268, "start": 259, "tag": "BiologicFunction"}, {"end": 59, "start": 56, "tag": "HealthCareActivity"}]}
{"id": "1405_4", "text": "Results At baseline, hypo- and isointense lesions showed higher mean MWF and NDI values compared to other QSM lesion types (p < 0.0001).", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "InjuryOrPoisoning"}, {"end": 116, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 77, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "HealthCareActivity"}]}
{"id": "1405_5", "text": "Further, at 2-year follow-up, hypo-/iso-intense lesions showed an increase in MWF.", "tags": [{"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 18, "start": 14, "tag": "TemporalConcept"}, {"end": 55, "start": 48, "tag": "InjuryOrPoisoning"}, {"end": 81, "start": 78, "tag": "ResearchActivity"}]}
{"id": "1405_6", "text": "Postmortem analyses revealed that QSM highly accurately identifies (1) fully remyelinated areas as hypo-/iso-intense (sensitivity = 88.89% and specificity = 100%), (2) chronic inactive lesions as hyperintense (sensitivity = 71.43% and specificity = 92.00%), and (3) chronic active/smoldering lesions as PRLs (sensitivity = 92.86% and specificity = 86.36%).", "tags": [{"end": 19, "start": 0, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "TemporalConcept"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 221, "start": 210, "tag": "Finding"}, {"end": 320, "start": 309, "tag": "Finding"}, {"end": 154, "start": 143, "tag": "Finding"}, {"end": 246, "start": 235, "tag": "Finding"}, {"end": 345, "start": 334, "tag": "Finding"}, {"end": 175, "start": 168, "tag": "TemporalConcept"}, {"end": 273, "start": 266, "tag": "TemporalConcept"}, {"end": 192, "start": 185, "tag": "InjuryOrPoisoning"}, {"end": 299, "start": 292, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 34, "tag": "HealthCareActivity"}]}
{"id": "1405_7", "text": "Interpretation These results provide the first evidence that it is possible to distinguish chronic MS lesions in a clinical setting, hereby supporting with new biomarkers to develop and assess remyelinating treatments.", "tags": [{"end": 55, "start": 47, "tag": "Finding"}, {"end": 170, "start": 160, "tag": "ClinicalAttribute"}, {"end": 217, "start": 193, "tag": "HealthCareActivity"}, {"end": 217, "start": 193, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 91, "tag": "TemporalConcept"}, {"end": 109, "start": 102, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 41, "tag": "TemporalConcept"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}]}
{"id": "1405_8", "text": "ANN NEUROL 2022", "tags": []}
{"id": "1406_0", "text": "Objective To investigate serum neurofilament light chain (sNfL) as a potential biomarker for disease activity and treatment response in pediatric patients with multiple sclerosis (MS).", "tags": [{"end": 30, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 114, "tag": "ClinicalAttribute"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "ResearchActivity"}, {"end": 88, "start": 69, "tag": "ClinicalAttribute"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 178, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 79, "tag": "ClinicalAttribute"}, {"end": 56, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 93, "tag": "HealthCareActivity"}, {"end": 62, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 58, "tag": "ClinicalAttribute"}, {"end": 56, "start": 25, "tag": "ClinicalAttribute"}]}
{"id": "1406_1", "text": "Methods In this retrospective cohort study, sNfL levels were measured in a pediatric MS cohort (n = 55, follow-up 12-105 months) and in a non-neurologic pediatric control cohort (n = 301) using a high-sensitivity single-molecule array assay.", "tags": [{"end": 42, "start": 16, "tag": "ResearchActivity"}, {"end": 113, "start": 104, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "TemporalConcept"}, {"end": 127, "start": 121, "tag": "TemporalConcept"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 44, "tag": "ClinicalAttribute"}, {"end": 177, "start": 138, "tag": "PopulationGroup"}, {"end": 240, "start": 196, "tag": "ResearchActivity"}]}
{"id": "1406_2", "text": "Association of sNfL levels and treatment and clinical and MRI parameters were calculated.", "tags": [{"end": 40, "start": 31, "tag": "HealthCareActivity"}, {"end": 40, "start": 31, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "HealthCareActivity"}, {"end": 26, "start": 15, "tag": "ClinicalAttribute"}]}
{"id": "1406_3", "text": "Results Untreated patients had higher sNfL levels than controls (median 19.0 vs 4.6 pg/mL; CI [4.732, 6.911]),p< 0.001).", "tags": [{"end": 49, "start": 38, "tag": "ClinicalAttribute"}, {"end": 93, "start": 91, "tag": "ResearchActivity"}, {"end": 63, "start": 55, "tag": "PopulationGroup"}, {"end": 26, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 65, "tag": "ResearchActivity"}]}
{"id": "1406_4", "text": "sNfL levels were significantly associated with MRI activity (+9.1% per contrast-enhancing lesion, CI [1.045, 1.138],p< 0.001; +0.6% per T2-weighted lesion, CI [1.001, 1.010],p= 0.015).", "tags": [{"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 100, "start": 98, "tag": "ResearchActivity"}, {"end": 158, "start": 156, "tag": "ResearchActivity"}, {"end": 50, "start": 47, "tag": "HealthCareActivity"}, {"end": 96, "start": 90, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 148, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 136, "tag": "ClinicalAttribute"}]}
{"id": "1406_5", "text": "Higher values were associated with a relapse <90 days ago (+51.1%; CI [1.184, 1.929],p< 0.001) and a higher Expanded Disability Status Scale score (CI [1.001, 1.240],p= 0.048).", "tags": [{"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 69, "start": 67, "tag": "ResearchActivity"}, {"end": 150, "start": 148, "tag": "ResearchActivity"}, {"end": 53, "start": 49, "tag": "TemporalConcept"}, {"end": 146, "start": 108, "tag": "HealthCareActivity"}]}
{"id": "1406_6", "text": "In patients treated with interferon beta-1a/b (n = 27), sNfL levels declined from 14.7 to 7.9 pg/mL after 6 +/- 2 months (CI [0.339, 0.603],p< 0.001).", "tags": [{"end": 124, "start": 122, "tag": "ResearchActivity"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 120, "start": 112, "tag": "TemporalConcept"}, {"end": 45, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 56, "tag": "ClinicalAttribute"}]}
{"id": "1406_7", "text": "Patients with insufficient control of clinical or MRI disease activity under treatment with interferon beta-1a/b or glatiramer acetate who switched to fingolimod (n = 18) showed a reduction of sNfL levels from 16.5 to 10.0 pg/mL 6 +/- 2 months after switch (CI [0.481, 0.701],p< 0.001).", "tags": [{"end": 134, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 151, "tag": "Chemical"}, {"end": 204, "start": 193, "tag": "ClinicalAttribute"}, {"end": 260, "start": 258, "tag": "ResearchActivity"}, {"end": 243, "start": 237, "tag": "TemporalConcept"}, {"end": 86, "start": 77, "tag": "HealthCareActivity"}, {"end": 86, "start": 77, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "HealthCareActivity"}, {"end": 189, "start": 180, "tag": "Finding"}, {"end": 189, "start": 180, "tag": "NaturalPhenomenonOrProcess"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 243, "start": 235, "tag": "TemporalConcept"}, {"end": 70, "start": 54, "tag": "HealthCareActivity"}, {"end": 112, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 151, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 151, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1406_8", "text": "Conclusions sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS.", "tags": [{"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 75, "tag": "ClinicalAttribute"}, {"end": 84, "start": 75, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "ResearchActivity"}, {"end": 109, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 43, "tag": "HealthCareActivity"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 70, "start": 54, "tag": "HealthCareActivity"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1406_9", "text": "It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS.", "tags": [{"end": 53, "start": 37, "tag": "Finding"}, {"end": 76, "start": 67, "tag": "HealthCareActivity"}, {"end": 76, "start": 67, "tag": "ResearchActivity"}, {"end": 116, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 90, "tag": "PatientOrDisabledGroup"}]}
{"id": "1406_10", "text": "This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS.", "tags": [{"end": 29, "start": 20, "tag": "Finding"}, {"end": 55, "start": 44, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 38, "start": 30, "tag": "Finding"}, {"end": 108, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 76, "tag": "HealthCareActivity"}]}
{"id": "1407_0", "text": "Background: Inflammation in chronic active lesions occurs behind a closed blood-brain barrier and cannot be detected with MRI.", "tags": [{"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 85, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 35, "start": 28, "tag": "TemporalConcept"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 43, "tag": "InjuryOrPoisoning"}]}
{"id": "1407_1", "text": "Activated microglia are highly enriched for iron and can be visualized with quantitative susceptibility mapping (QSM), an MRI technique used to delineate iron.", "tags": [{"end": 19, "start": 10, "tag": "Cell"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 48, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 158, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 48, "start": 44, "tag": "Chemical"}, {"end": 158, "start": 154, "tag": "Chemical"}, {"end": 48, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}, {"end": 111, "start": 76, "tag": "HealthCareActivity"}, {"end": 116, "start": 113, "tag": "HealthCareActivity"}]}
{"id": "1407_2", "text": "Objective: To characterize the histopathological correlates of different QSM hyperintensity patterns in MS lesions.", "tags": [{"end": 59, "start": 31, "tag": "ClinicalAttribute"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 107, "tag": "InjuryOrPoisoning"}, {"end": 100, "start": 73, "tag": "ClinicalAttribute"}]}
{"id": "1407_3", "text": "Methods: MS brain slabs were imaged with MRI and QSM, and processed for histology.", "tags": [{"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 81, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 72, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "HealthCareActivity"}]}
{"id": "1407_4", "text": "Immunolabeled cells were quantified in the lesion rim, center, and adjacent normal-appearing white matter (NAWM).", "tags": [{"end": 105, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 105, "start": 76, "tag": "ClinicalAttribute"}, {"end": 111, "start": 107, "tag": "ClinicalAttribute"}]}
{"id": "1407_5", "text": "Iron(+) myeloid cell densities at the rims were correlated with susceptibilities.", "tags": [{"end": 20, "start": 8, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 80, "start": 64, "tag": "ClinicalAttribute"}, {"end": 80, "start": 64, "tag": "OrganismAttribute"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1407_6", "text": "Human-induced pluripotent stem cell (iPSC)-derived microglia were used to determine the effect of iron on the production of reactive oxygen species (ROS) and pro-inflammatory cytokines.", "tags": [{"end": 184, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 175, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "Cell"}, {"end": 147, "start": 140, "tag": "OrganismAttribute"}, {"end": 147, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 124, "tag": "Chemical"}, {"end": 102, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 98, "tag": "Chemical"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 158, "tag": "PathologicFunction"}, {"end": 152, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 149, "tag": "Chemical"}, {"end": 41, "start": 37, "tag": "Cell"}, {"end": 35, "start": 0, "tag": "Cell"}, {"end": 60, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1407_7", "text": "Results: QSM hyperintensity at the lesion perimeter correlated with activated iron(+) myeloid cells in the rim and NAWM.", "tags": [{"end": 99, "start": 86, "tag": "Cell"}, {"end": 82, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 78, "tag": "Chemical"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 35, "tag": "InjuryOrPoisoning"}, {"end": 119, "start": 115, "tag": "ClinicalAttribute"}, {"end": 27, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1407_8", "text": "Lesions with high punctate or homogenous QSM signal contained no or minimally activated iron(-) myeloid cells.", "tags": [{"end": 7, "start": 0, "tag": "Finding"}, {"end": 109, "start": 96, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 88, "tag": "Chemical"}, {"end": 92, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 41, "tag": "ClinicalAttribute"}]}
{"id": "1407_9", "text": "In vitro, iron accumulation was highest in Ml-polarized human iPSC-derived microglia, but it did not enhance ROS or cytokine production.", "tags": [{"end": 27, "start": 10, "tag": "Finding"}, {"end": 135, "start": 116, "tag": "BiologicFunction"}, {"end": 135, "start": 116, "tag": "CellFunction"}, {"end": 61, "start": 56, "tag": "Eukaryote"}, {"end": 84, "start": 75, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 10, "tag": "Chemical"}, {"end": 14, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "Chemical"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 84, "start": 62, "tag": "ResearchActivity"}]}
{"id": "1407_10", "text": "Conclusion: A high QSM signal outlining the lesion rim but not punctate signal in the center is a biomarker for chronic inflammation in white matter lesions.", "tags": [{"end": 119, "start": 112, "tag": "TemporalConcept"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 149, "tag": "InjuryOrPoisoning"}, {"end": 132, "start": 112, "tag": "PathologicFunction"}, {"end": 54, "start": 44, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 29, "start": 19, "tag": "ClinicalAttribute"}]}
{"id": "1408_0", "text": "This cross-sectional European study evaluates the application of optimized magnetic resonance imaging protocols at 3 Tesla (T) for detecting and distinguishing MS from other conditions that mimic MS among adults.", "tags": [{"end": 35, "start": 5, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 75, "tag": "HealthCareActivity"}, {"end": 101, "start": 75, "tag": "ManufacturedObject"}, {"end": 211, "start": 205, "tag": "PopulationGroup"}, {"end": 126, "start": 75, "tag": "HealthCareActivity"}]}
{"id": "1408_1", "text": "Importance The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.", "tags": [{"end": 27, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 225, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 176, "tag": "HealthCareActivity"}, {"end": 218, "start": 176, "tag": "ManufacturedObject"}, {"end": 223, "start": 220, "tag": "HealthCareActivity"}, {"end": 128, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "HealthCareActivity"}, {"end": 218, "start": 211, "tag": "HealthCareActivity"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}]}
{"id": "1408_2", "text": "The diagnostic value of the central vein sign in a multicenter setting with a variety of clinical 3 tesla (T) MRI protocols, however, remains unknown.", "tags": [{"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 89, "tag": "HealthCareActivity"}, {"end": 113, "start": 110, "tag": "HealthCareActivity"}, {"end": 45, "start": 28, "tag": "ClinicalAttribute"}]}
{"id": "1408_3", "text": "Objective To evaluate the sensitivity and specificity of various central vein sign lesion criteria for differentiating MS from non-MS conditions using 3T brain MRI with various commonly used pulse sequences.", "tags": [{"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "Finding"}, {"end": 53, "start": 42, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}, {"end": 89, "start": 65, "tag": "ClinicalAttribute"}, {"end": 206, "start": 191, "tag": "ResearchActivity"}]}
{"id": "1408_4", "text": "Design, Setting, and Participants This large multicenter, cross-sectional study enrolled participants (n = 648) of ongoing observational studies and patients included in neuroimaging research databases of 8 neuroimaging centers in Europe.", "tags": [{"end": 101, "start": 89, "tag": "PopulationGroup"}, {"end": 157, "start": 149, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 123, "tag": "ResearchActivity"}, {"end": 79, "start": 58, "tag": "ResearchActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 201, "start": 170, "tag": "ResearchActivity"}, {"end": 227, "start": 207, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1408_5", "text": "Patient enrollment and MRI data collection were performed between January 1, 2010, and November 30, 2016.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 42, "start": 27, "tag": "ResearchActivity"}, {"end": 31, "start": 27, "tag": "ResearchActivity"}, {"end": 26, "start": 23, "tag": "HealthCareActivity"}, {"end": 81, "start": 66, "tag": "TemporalConcept"}, {"end": 104, "start": 87, "tag": "TemporalConcept"}]}
{"id": "1408_6", "text": "Data analysis was conducted between January 1, 2016, and April 30, 2018.", "tags": [{"end": 13, "start": 5, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 36, "tag": "TemporalConcept"}, {"end": 71, "start": 57, "tag": "TemporalConcept"}]}
{"id": "1408_7", "text": "Investigators were blinded to participant diagnosis by a novel blinding procedure.", "tags": [{"end": 41, "start": 30, "tag": "PopulationGroup"}, {"end": 51, "start": 42, "tag": "HealthCareActivity"}]}
{"id": "1408_8", "text": "Main Outcomes and Measures Occurrence of central vein sign was detected on 3T T2*-weighted or susceptibility-weighted imaging.", "tags": [{"end": 37, "start": 27, "tag": "TemporalConcept"}, {"end": 37, "start": 27, "tag": "HealthCareActivity"}, {"end": 53, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 75, "tag": "HealthCareActivity"}, {"end": 125, "start": 118, "tag": "HealthCareActivity"}, {"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 58, "start": 41, "tag": "ClinicalAttribute"}]}
{"id": "1408_9", "text": "Sensitivity and specificity were assessed for these MRI sequences and for different central vein sign lesion criteria, which were defined by the proportion of lesions with central vein sign or by absolute numbers of lesions with central vein sign.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 55, "start": 52, "tag": "HealthCareActivity"}, {"end": 166, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 223, "start": 216, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 84, "tag": "ClinicalAttribute"}, {"end": 189, "start": 172, "tag": "ClinicalAttribute"}, {"end": 246, "start": 229, "tag": "ClinicalAttribute"}]}
{"id": "1408_10", "text": "Results A total of 606 participants were included in the study after exclusion of 42 participants.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 62, "start": 57, "tag": "ResearchActivity"}, {"end": 35, "start": 23, "tag": "PopulationGroup"}, {"end": 97, "start": 85, "tag": "PopulationGroup"}]}
{"id": "1408_11", "text": "Among the 606 participants, 413 (68.2%) were women.", "tags": [{"end": 50, "start": 45, "tag": "PopulationGroup"}, {"end": 26, "start": 14, "tag": "PopulationGroup"}]}
{"id": "1408_12", "text": "Patients with clinically isolated syndrome and relapsing-remitting MS (RRMS) included 235 women (66.6%) and had a median (range) age of 37 (14.7-61.4) years, a median (range) disease duration of 2 (0-33) years, and a median (range) Expanded Disability Status Scale score of 1.5 (0-6.5).", "tags": [{"end": 42, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 90, "tag": "PopulationGroup"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 209, "start": 204, "tag": "TemporalConcept"}, {"end": 69, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 175, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 270, "start": 232, "tag": "HealthCareActivity"}]}
{"id": "1408_13", "text": "Patients without MS included 178 women (70.4%) and had a median (range) age of 54 (18-83) years.", "tags": [{"end": 38, "start": 33, "tag": "PopulationGroup"}, {"end": 75, "start": 72, "tag": "OrganismAttribute"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 19, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}
{"id": "1408_14", "text": "A total of 4447 lesions were analyzed in a total of 487 patients: 690 lesions in 98 participants with clinically isolated syndrome, 2815 lesions in 225 participants with RRMS, 54 lesions in 13 participants with neuromyelitis optica spectrum disorder, 54 lesions in 14 participants with systemic lupus erythematosus, 121 lesions in 29 participants with migraine or cluster headache, 240 lesions in 20 participants with diabetes, and 473 lesions in 88 participants with other types of small-vessel disease.", "tags": [{"end": 130, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 360, "start": 352, "tag": "DiseaseOrSyndrome"}, {"end": 380, "start": 364, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 84, "tag": "PopulationGroup"}, {"end": 164, "start": 152, "tag": "PopulationGroup"}, {"end": 205, "start": 193, "tag": "PopulationGroup"}, {"end": 280, "start": 268, "tag": "PopulationGroup"}, {"end": 346, "start": 334, "tag": "PopulationGroup"}, {"end": 412, "start": 400, "tag": "PopulationGroup"}, {"end": 462, "start": 450, "tag": "PopulationGroup"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 16, "tag": "InjuryOrPoisoning"}, {"end": 77, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 144, "start": 137, "tag": "InjuryOrPoisoning"}, {"end": 186, "start": 179, "tag": "InjuryOrPoisoning"}, {"end": 261, "start": 254, "tag": "InjuryOrPoisoning"}, {"end": 327, "start": 320, "tag": "InjuryOrPoisoning"}, {"end": 393, "start": 386, "tag": "InjuryOrPoisoning"}, {"end": 443, "start": 436, "tag": "InjuryOrPoisoning"}, {"end": 231, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 418, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 174, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 503, "start": 483, "tag": "DiseaseOrSyndrome"}]}
{"id": "1408_15", "text": "The sensitivity was 68.1% and specificity was 82.9% for distinguishing MS from not MS using a 35% central vein sign proportion threshold.", "tags": [{"end": 136, "start": 127, "tag": "Finding"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 41, "start": 30, "tag": "Finding"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 98, "tag": "ClinicalAttribute"}]}
{"id": "1408_16", "text": "The 3 central vein sign lesion criteria had a sensitivity of 61.9% and specificity of 89.0%.", "tags": [{"end": 57, "start": 46, "tag": "Finding"}, {"end": 82, "start": 71, "tag": "Finding"}, {"end": 30, "start": 24, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 6, "tag": "ClinicalAttribute"}]}
{"id": "1408_17", "text": "Sensitivity was higher when an optimized T2*-weighted sequence was used.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}]}
{"id": "1408_18", "text": "Conclusions and Relevance In this study, use of the central vein sign at 3T MRI yielded a high specificity and a moderate sensitivity in differentiating MS from not MS; international, multicenter studies may be needed to ascertain whether the central vein sign-based criteria can accurately detect MS.", "tags": [{"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 203, "start": 184, "tag": "ResearchActivity"}, {"end": 39, "start": 34, "tag": "ResearchActivity"}, {"end": 133, "start": 122, "tag": "Finding"}, {"end": 106, "start": 95, "tag": "Finding"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 298, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 73, "tag": "HealthCareActivity"}, {"end": 79, "start": 73, "tag": "ManufacturedObject"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 275, "start": 243, "tag": "HealthCareActivity"}, {"end": 260, "start": 243, "tag": "ClinicalAttribute"}]}
{"id": "1408_19", "text": "Question Is the central vein sign on clinical 3T magnetic resonance imaging a useful biomarker for the diagnosis of multiple sclerosis? Findings In this multicenter cross-sectional study of 4447 lesions in 606 participants, use of a 35% central vein sign proportion threshold yielded a sensitivity of 68.1% and a specificity of 82.9% for distinguishing multiple sclerosis from non-multiple sclerosis.", "tags": [{"end": 28, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 275, "start": 266, "tag": "Finding"}, {"end": 112, "start": 103, "tag": "HealthCareActivity"}, {"end": 297, "start": 286, "tag": "Finding"}, {"end": 324, "start": 313, "tag": "Finding"}, {"end": 75, "start": 37, "tag": "HealthCareActivity"}, {"end": 75, "start": 37, "tag": "ManufacturedObject"}, {"end": 222, "start": 210, "tag": "PopulationGroup"}, {"end": 134, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 371, "start": 353, "tag": "DiseaseOrSyndrome"}, {"end": 399, "start": 381, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 195, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 186, "start": 165, "tag": "ResearchActivity"}, {"end": 94, "start": 85, "tag": "ClinicalAttribute"}, {"end": 33, "start": 16, "tag": "ClinicalAttribute"}, {"end": 254, "start": 237, "tag": "ClinicalAttribute"}]}
{"id": "1408_20", "text": "The criteria of 3 or more central vein sign lesions had a sensitivity of 61.9% and a specificity of 89.0%.", "tags": [{"end": 38, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 58, "tag": "Finding"}, {"end": 96, "start": 85, "tag": "Finding"}, {"end": 51, "start": 26, "tag": "ClinicalAttribute"}]}
{"id": "1408_21", "text": "Meaning The 3T central vein sign-based criteria showed a high specificity in the differentiation between multiple sclerosis and non-multiple sclerosis; future studies may be needed to confirm the applicability of this finding to support the diagnosis of multiple sclerosis in clinical practice.", "tags": [{"end": 191, "start": 184, "tag": "Finding"}, {"end": 225, "start": 218, "tag": "Finding"}, {"end": 250, "start": 241, "tag": "HealthCareActivity"}, {"end": 166, "start": 159, "tag": "ResearchActivity"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 158, "start": 152, "tag": "TemporalConcept"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 123, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 276, "tag": "HealthCareActivity"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}, {"end": 47, "start": 12, "tag": "HealthCareActivity"}]}
{"id": "1409_0", "text": "There is increasing interest in the development of multiple sclerosis (MS) biomarkers that reflect central nervous system tissue injury to determine prognosis.", "tags": [{"end": 47, "start": 36, "tag": "BiologicFunction"}, {"end": 47, "start": 36, "tag": "CellFunction"}, {"end": 135, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "HealthCareActivity"}, {"end": 28, "start": 9, "tag": "Finding"}]}
{"id": "1409_1", "text": "We aimed to assess the prognostic value of kinesin superfamily motor protein KIF5A in MS by measuring levels of KIF5A in cerebrospinal fluid (CSF) combined with analysis of single nucleotide polymorphisms (SNPs; rs12368653 and rs703842) located within a MS susceptibility gene locus at chromosome 12q13-14 region.", "tags": [{"end": 82, "start": 77, "tag": "GeneOrGenome"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 145, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 173, "tag": "MolecularSequence"}, {"end": 210, "start": 206, "tag": "MolecularSequence"}, {"end": 140, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 212, "tag": "MolecularSequence"}, {"end": 235, "start": 227, "tag": "MolecularSequence"}, {"end": 312, "start": 286, "tag": "CellComponent"}, {"end": 282, "start": 272, "tag": "GeneOrGenome"}, {"end": 271, "start": 257, "tag": "Finding"}]}
{"id": "1409_2", "text": "Enzyme-linked immunosorbent assay was used to measure KIF5A in CSF obtained from two independent biobanks comprising non-inflammatory neurological disease controls (NINDC), clinically isolated syndrome (CIS) and MS cases.", "tags": [{"end": 33, "start": 0, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 97, "tag": "HealthCareRelatedOrganization"}, {"end": 170, "start": 165, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 155, "tag": "PopulationGroup"}, {"end": 220, "start": 212, "tag": "PatientOrDisabledGroup"}]}
{"id": "1409_3", "text": "CSF KIF5A expression was significantly elevated in progressive MS cases compared with NINDCs, CIS and relapsing-remitting MS (RRMS).", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 86, "tag": "PatientOrDisabledGroup"}]}
{"id": "1409_4", "text": "In addition, levels of KIF5A positively correlated with change in MS disease severity scores (EDSS, MSSS and ARMSSS), in RRMS patients who had documented disease progression at 2-year clinical follow-up.", "tags": [{"end": 28, "start": 23, "tag": "GeneOrGenome"}, {"end": 202, "start": 184, "tag": "HealthCareActivity"}, {"end": 173, "start": 162, "tag": "PathologicFunction"}, {"end": 173, "start": 162, "tag": "TemporalConcept"}, {"end": 173, "start": 154, "tag": "PathologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 179, "tag": "TemporalConcept"}, {"end": 134, "start": 126, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 66, "tag": "HealthCareActivity"}, {"end": 125, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 100, "tag": "HealthCareActivity"}]}
{"id": "1409_5", "text": "Copies of adenine risk alleles (AG/AA; rs12368653 and rs703842) corresponded with a higher proportion of individuals in relapse at the time of lumbar puncture (LP), higher use of disease-modifying therapies post LP and shorter MS duration.", "tags": [{"end": 127, "start": 120, "tag": "Finding"}, {"end": 158, "start": 143, "tag": "HealthCareActivity"}, {"end": 162, "start": 160, "tag": "HealthCareActivity"}, {"end": 211, "start": 207, "tag": "TemporalConcept"}, {"end": 214, "start": 212, "tag": "HealthCareActivity"}, {"end": 238, "start": 230, "tag": "TemporalConcept"}, {"end": 206, "start": 197, "tag": "HealthCareActivity"}, {"end": 139, "start": 135, "tag": "TemporalConcept"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 105, "tag": "PopulationGroup"}, {"end": 206, "start": 179, "tag": "HealthCareActivity"}, {"end": 17, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 23, "tag": "GeneOrGenome"}, {"end": 37, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 49, "start": 39, "tag": "MolecularSequence"}, {"end": 62, "start": 54, "tag": "MolecularSequence"}]}
{"id": "1409_6", "text": "Our study suggests that CSF KIF5A has potential as a predictive biomarker in MS and further studies into the potential prognostic value of analysing MS susceptibility SNPs should be considered.", "tags": [{"end": 27, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 28, "tag": "GeneOrGenome"}, {"end": 171, "start": 167, "tag": "MolecularSequence"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 53, "tag": "ClinicalAttribute"}, {"end": 33, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 109, "tag": "Finding"}, {"end": 171, "start": 149, "tag": "ClinicalAttribute"}]}
{"id": "1410_0", "text": "Background: Clinical measures in multiple sclerosis (MS) face limitations that may be overcome by utilising smartphone keyboard interactions acquired continuously and remotely during regular typing.", "tags": [{"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 108, "tag": "ManufacturedObject"}, {"end": 118, "start": 108, "tag": "ManufacturedObject"}]}
{"id": "1410_1", "text": "Objective: The aim of this study was to determine the reliability and validity of keystroke dynamics to assess clinical aspects of MS.", "tags": [{"end": 78, "start": 70, "tag": "ResearchActivity"}, {"end": 127, "start": 111, "tag": "ClinicalAttribute"}, {"end": 32, "start": 27, "tag": "ResearchActivity"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 82, "tag": "ClinicalAttribute"}]}
{"id": "1410_2", "text": "Methods: In total, 102 MS patients and 24 controls were included in this observational study.", "tags": [{"end": 92, "start": 73, "tag": "ResearchActivity"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 42, "tag": "PopulationGroup"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}]}
{"id": "1410_3", "text": "Keyboard interactions were obtained with the Neurokeys keyboard app.", "tags": [{"end": 67, "start": 45, "tag": "HealthCareActivity"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1410_4", "text": "Eight timing-related keystroke features were assessed for reliability with intraclass correlation coefficients (ICCs); construct validity by analysing group differences (in fatigue, gadolinium-enhancing lesions on magnetic resonance imaging (MRI), and patients vs controls); and concurrent validity by correlating with disability measures.", "tags": [{"end": 137, "start": 129, "tag": "Finding"}, {"end": 156, "start": 151, "tag": "PopulationGroup"}, {"end": 180, "start": 173, "tag": "SignOrSymptom"}, {"end": 210, "start": 182, "tag": "ClinicalAttribute"}, {"end": 298, "start": 290, "tag": "Finding"}, {"end": 329, "start": 319, "tag": "Finding"}, {"end": 240, "start": 214, "tag": "HealthCareActivity"}, {"end": 240, "start": 214, "tag": "ManufacturedObject"}, {"end": 245, "start": 242, "tag": "HealthCareActivity"}, {"end": 272, "start": 264, "tag": "PopulationGroup"}, {"end": 260, "start": 252, "tag": "PatientOrDisabledGroup"}, {"end": 289, "start": 279, "tag": "TemporalConcept"}, {"end": 210, "start": 203, "tag": "InjuryOrPoisoning"}, {"end": 240, "start": 233, "tag": "HealthCareActivity"}, {"end": 110, "start": 75, "tag": "ResearchActivity"}, {"end": 116, "start": 112, "tag": "ResearchActivity"}, {"end": 338, "start": 319, "tag": "HealthCareActivity"}, {"end": 39, "start": 21, "tag": "ClinicalAttribute"}]}
{"id": "1410_5", "text": "Results: Reliability was moderate in two (ICC = 0.601 and 0.742) and good to excellent in the remaining six features (ICC = 0.760-0.965).", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 42, "tag": "ResearchActivity"}, {"end": 121, "start": 118, "tag": "ResearchActivity"}, {"end": 20, "start": 9, "tag": "Finding"}]}
{"id": "1410_6", "text": "Patients had significantly higher keystroke latencies than controls.", "tags": [{"end": 67, "start": 59, "tag": "PopulationGroup"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 34, "tag": "ClinicalAttribute"}]}
{"id": "1410_7", "text": "Latency between key presses correlated the highest with Expanded Disability Status Scale (r = 0.407) and latency between key releases with Nine-Hole Peg Test and Symbol Digit Modalities Test (rho = 0.503 and r = -0.553, respectively), ps < 0.001.", "tags": [{"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 88, "start": 56, "tag": "HealthCareActivity"}, {"end": 157, "start": 139, "tag": "HealthCareActivity"}, {"end": 190, "start": 162, "tag": "HealthCareActivity"}]}
{"id": "1410_8", "text": "Conclusion: Keystroke dynamics were reliable, distinguished patients and controls, and were associated with clinical disability measures.", "tags": [{"end": 81, "start": 73, "tag": "PopulationGroup"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1410_9", "text": "Consequently, keystroke dynamics are a promising valid surrogate marker for clinical disability in MS.", "tags": [{"end": 32, "start": 24, "tag": "NaturalPhenomenonOrProcess"}, {"end": 95, "start": 65, "tag": "ClinicalAttribute"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 14, "tag": "ClinicalAttribute"}]}
{"id": "1411_0", "text": "Multiple sclerosis (MS) features extensive connectivity changes, but how structural and functional connectivity relate, and whether this relation could be a useful biomarker for cognitive impairment in MS is unclear.", "tags": [{"end": 111, "start": 88, "tag": "BiologicFunction"}, {"end": 198, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 164, "tag": "ClinicalAttribute"}]}
{"id": "1411_1", "text": "This study included 79 MS patients and 40 healthy controls (HCs).", "tags": [{"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "OrganismAttribute"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 42, "tag": "PopulationGroup"}]}
{"id": "1411_2", "text": "Patients were classified as cognitively impaired (CI) or cognitively preserved (CP).", "tags": [{"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 78, "start": 57, "tag": "PatientOrDisabledGroup"}]}
{"id": "1411_3", "text": "Structural connectivity was determined using diffusion MRI and functional connectivity using resting-state magnetoencephalography (MEG) data (theta, alpha1, and alpha2 bands).", "tags": [{"end": 58, "start": 45, "tag": "HealthCareActivity"}, {"end": 86, "start": 63, "tag": "BiologicFunction"}, {"end": 134, "start": 131, "tag": "HealthCareActivity"}, {"end": 140, "start": 136, "tag": "ResearchActivity"}, {"end": 58, "start": 55, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "NaturalPhenomenonOrProcess"}, {"end": 23, "start": 0, "tag": "BiologicFunction"}, {"end": 129, "start": 93, "tag": "HealthCareActivity"}, {"end": 173, "start": 142, "tag": "HealthCareActivity"}]}
{"id": "1411_4", "text": "Structure-function coupling was assessed by correlating modalities, and further explored in frequency bands that significantly correlated with whole-brain structural connectivity.", "tags": [{"end": 154, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 92, "tag": "TemporalConcept"}, {"end": 107, "start": 92, "tag": "HealthCareActivity"}, {"end": 178, "start": 143, "tag": "Finding"}, {"end": 27, "start": 0, "tag": "Finding"}]}
{"id": "1411_5", "text": "Functional correlates of short- and long-range structural connections (based on tract length) were then specifically assessed.", "tags": [{"end": 10, "start": 0, "tag": "BiologicFunction"}, {"end": 92, "start": 80, "tag": "ResearchActivity"}, {"end": 69, "start": 36, "tag": "ResearchActivity"}]}
{"id": "1411_6", "text": "Receiving operating curve analyses were performed on coupling values to identify biomarker potential.", "tags": [{"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 34, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 53, "tag": "Finding"}]}
{"id": "1411_7", "text": "Only the theta band showed significant correlations between whole-brain structural and functional connectivity (rho = -0.26, p = 0.023, only in MS).", "tags": [{"end": 110, "start": 87, "tag": "BiologicFunction"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 27, "tag": "Finding"}, {"end": 51, "start": 39, "tag": "ResearchActivity"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}, {"end": 110, "start": 98, "tag": "BiologicFunction"}, {"end": 82, "start": 72, "tag": "BiologicFunction"}]}
{"id": "1411_8", "text": "Long-range structure-function coupling was stronger in CI patients compared to HCs (p = 0.005).", "tags": [{"end": 66, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1411_9", "text": "Short-range coupling showed no group differences.", "tags": [{"end": 48, "start": 31, "tag": "Finding"}, {"end": 48, "start": 37, "tag": "Finding"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1411_10", "text": "Structure-function coupling was not a significant classifier of cognitive impairment for any tract length (short-range area under the curve (AUC) = 0.498, p = 0.976, long-range AUC = 0.611, p = 0.095).", "tags": [{"end": 98, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 107, "tag": "ResearchActivity"}, {"end": 144, "start": 141, "tag": "ResearchActivity"}, {"end": 180, "start": 166, "tag": "ResearchActivity"}, {"end": 105, "start": 99, "tag": "ResearchActivity"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1411_11", "text": "Long-range structure-function coupling was stronger in CI MS compared to HCs, but more research is needed to further explore this measure as biomarkers in MS.", "tags": [{"end": 151, "start": 141, "tag": "ClinicalAttribute"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "ResearchActivity"}, {"end": 38, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1411_12", "text": "Author Summary Cognitive impairment in multiple sclerosis (MS) is common and relates to structural and functional connectivity.", "tags": [{"end": 126, "start": 103, "tag": "BiologicFunction"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 15, "tag": "DiseaseOrSyndrome"}]}
{"id": "1411_13", "text": "However, it remains unclear whether the interplay (coupling) between structural and functional connectivity could be a biomarker of MS-related cognitive impairment.", "tags": [{"end": 163, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 119, "tag": "ClinicalAttribute"}, {"end": 107, "start": 95, "tag": "BiologicFunction"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 107, "start": 84, "tag": "BiologicFunction"}, {"end": 59, "start": 51, "tag": "Finding"}, {"end": 49, "start": 40, "tag": "Finding"}]}
{"id": "1411_14", "text": "This study investigated the cognitive relevance of structure-function coupling in 79 MS patients and 40 healthy controls using diffusion MRI and magnetoencephalography.", "tags": [{"end": 140, "start": 127, "tag": "HealthCareActivity"}, {"end": 167, "start": 145, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 111, "start": 104, "tag": "OrganismAttribute"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 137, "tag": "HealthCareActivity"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 136, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 120, "start": 104, "tag": "PopulationGroup"}, {"end": 78, "start": 51, "tag": "Finding"}]}
{"id": "1411_15", "text": "Results show that coupling was stronger in cognitively impaired MS patients compared to controls, but only when considering long-distance connections.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 26, "start": 18, "tag": "Finding"}]}
{"id": "1411_16", "text": "Nonetheless, classifier analyses indicated only weak biomarker potential in terms of sensitivity and specificity.", "tags": [{"end": 96, "start": 85, "tag": "Finding"}, {"end": 112, "start": 101, "tag": "Finding"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}]}
{"id": "1411_17", "text": "Future studies should include additional operationalization of coupling as well as longitudinal and regional or network level data.", "tags": [{"end": 59, "start": 41, "tag": "ResearchActivity"}, {"end": 95, "start": 83, "tag": "ResearchActivity"}, {"end": 130, "start": 112, "tag": "ResearchActivity"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}]}
{"id": "1412_0", "text": "Background and purpose: The development of new biomarkers for multiple sclerosis (MS) is of paramount importance to improve our ability to predict disease progression and disability.", "tags": [{"end": 39, "start": 28, "tag": "BiologicFunction"}, {"end": 39, "start": 28, "tag": "CellFunction"}, {"end": 181, "start": 171, "tag": "Finding"}, {"end": 166, "start": 155, "tag": "PathologicFunction"}, {"end": 166, "start": 155, "tag": "TemporalConcept"}, {"end": 57, "start": 47, "tag": "ClinicalAttribute"}, {"end": 166, "start": 147, "tag": "PathologicFunction"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 128, "tag": "OrganismAttribute"}]}
{"id": "1412_1", "text": "The aim of this study was to evaluate the potential role of the optic nerve diameter (OND) measured by ultrasonography as a biomarker of early disability in patients with relapsing-remitting multiple sclerosis (RRMS).", "tags": [{"end": 75, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 103, "tag": "HealthCareActivity"}, {"end": 209, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 209, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 171, "tag": "TemporalConcept"}, {"end": 133, "start": 124, "tag": "ClinicalAttribute"}, {"end": 84, "start": 64, "tag": "ClinicalAttribute"}, {"end": 89, "start": 86, "tag": "ClinicalAttribute"}, {"end": 153, "start": 143, "tag": "Finding"}]}
{"id": "1412_2", "text": "Methods: Forty-nine RRMS patients, 23 with a history of optic neuritis (MS-ON) and 26 without a history of optic neuritis (MS N-ON), and 50 age- and sex-matched healthy control subjects were included in the study.", "tags": [{"end": 24, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 45, "tag": "Finding"}, {"end": 70, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 96, "tag": "Finding"}, {"end": 121, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 207, "tag": "ResearchActivity"}, {"end": 143, "start": 140, "tag": "OrganismAttribute"}, {"end": 168, "start": 161, "tag": "OrganismAttribute"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 169, "tag": "PopulationGroup"}, {"end": 33, "start": 25, "tag": "PatientOrDisabledGroup"}, {"end": 152, "start": 149, "tag": "OrganismAttribute"}]}
{"id": "1412_3", "text": "The OND and optic nerve sheath diameter (ONSD) were measured by transorbital sonography (TOS), and the retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thicknesses were measured by optical coherence tomography (OCT) using the Optovue RTVue (TM) system (Optovue, Inc., Fremont, CA, USA).", "tags": [{"end": 60, "start": 52, "tag": "HealthCareActivity"}, {"end": 193, "start": 185, "tag": "HealthCareActivity"}, {"end": 225, "start": 197, "tag": "HealthCareActivity"}, {"end": 230, "start": 227, "tag": "HealthCareActivity"}, {"end": 259, "start": 257, "tag": "CellComponent"}, {"end": 39, "start": 12, "tag": "ClinicalAttribute"}, {"end": 45, "start": 41, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 87, "start": 64, "tag": "HealthCareActivity"}, {"end": 128, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 140, "tag": "Cell"}, {"end": 267, "start": 261, "tag": "ManufacturedObject"}, {"end": 255, "start": 242, "tag": "ManufacturedObject"}, {"end": 92, "start": 89, "tag": "HealthCareActivity"}]}
{"id": "1412_4", "text": "Results: There was no significant difference between the patient (whether ON or N-ON eyes) and control groups in either the OND (p=0.979) or the ONSD (p=0.911).", "tags": [{"end": 64, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 44, "start": 19, "tag": "Finding"}, {"end": 109, "start": 95, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "ClinicalAttribute"}, {"end": 149, "start": 145, "tag": "ClinicalAttribute"}]}
{"id": "1412_5", "text": "However, patients with an expanded disability status scale (EDSS) score >2 had a significantly lower OND and RNFL thicknesses (p=0.014, p=0.010 respectively) than patients with an EDSS score <= 2.", "tags": [{"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 26, "tag": "HealthCareActivity"}, {"end": 64, "start": 60, "tag": "HealthCareActivity"}, {"end": 123, "start": 109, "tag": "ClinicalAttribute"}, {"end": 123, "start": 114, "tag": "ClinicalAttribute"}, {"end": 104, "start": 101, "tag": "ClinicalAttribute"}, {"end": 190, "start": 180, "tag": "HealthCareActivity"}]}
{"id": "1412_6", "text": "Statistical logistic regression revealed that OND was an independent predictor of EDSS>2 (p=0.044, OR =0.000, 95% CI=0.000-0.589).", "tags": [{"end": 31, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1412_7", "text": "Conclusion: The OND, as measured by ultrasonography, could be potentially used as a biomarker for the detection of early disability in RRMS patients.", "tags": [{"end": 51, "start": 36, "tag": "HealthCareActivity"}, {"end": 111, "start": 102, "tag": "HealthCareActivity"}, {"end": 139, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 140, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 131, "start": 121, "tag": "Finding"}, {"end": 19, "start": 16, "tag": "ClinicalAttribute"}]}
{"id": "1413_0", "text": "Background:Resourceful endpoints of axonal loss are needed to predict the course of multiple sclerosis (MS).", "tags": [{"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 74, "tag": "TemporalConcept"}, {"end": 47, "start": 36, "tag": "PathologicFunction"}]}
{"id": "1413_1", "text": "Corneal confocal microscopy (CCM) can detect axonal loss in patients with clinically isolated syndrome and established MS, which relates to neurological disability.", "tags": [{"end": 27, "start": 0, "tag": "HealthCareActivity"}, {"end": 32, "start": 29, "tag": "HealthCareActivity"}, {"end": 102, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 140, "tag": "SignOrSymptom"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 45, "tag": "PathologicFunction"}]}
{"id": "1413_2", "text": "Objective:To assess corneal axonal loss over time in relation to retinal atrophy, and neurological and radiological abnormalities in MS.", "tags": [{"end": 27, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 45, "tag": "TemporalConcept"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 28, "tag": "PathologicFunction"}, {"end": 129, "start": 103, "tag": "PathologicFunction"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 98, "start": 86, "tag": "PathologicFunction"}]}
{"id": "1413_3", "text": "Methods:Patients with relapsing-remitting (RRMS) (n = 68) or secondary progressive MS (SPMS) (n = 15) underwent CCM and optical coherence tomography.", "tags": [{"end": 115, "start": 112, "tag": "HealthCareActivity"}, {"end": 148, "start": 120, "tag": "HealthCareActivity"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 31, "start": 22, "tag": "TemporalConcept"}, {"end": 85, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 87, "tag": "DiseaseOrSyndrome"}]}
{"id": "1413_4", "text": "Corneal nerve fibre density (CNFD-fibres/mm(2)), corneal nerve branch density (CNBD-branches/mm(2)), corneal nerve fibre length (CNFL-mm/mm(2)) and retinal nerve fibre layer (RNFL-mu m) thickness were quantified along with neurological and radiological assessments at baseline and after 2 years of follow-up.", "tags": [{"end": 264, "start": 240, "tag": "HealthCareActivity"}, {"end": 307, "start": 298, "tag": "HealthCareActivity"}, {"end": 307, "start": 298, "tag": "TemporalConcept"}, {"end": 294, "start": 289, "tag": "TemporalConcept"}, {"end": 27, "start": 0, "tag": "ClinicalAttribute"}, {"end": 77, "start": 49, "tag": "ClinicalAttribute"}, {"end": 127, "start": 101, "tag": "ClinicalAttribute"}, {"end": 195, "start": 186, "tag": "ClinicalAttribute"}, {"end": 173, "start": 148, "tag": "ClinicalAttribute"}, {"end": 33, "start": 29, "tag": "ClinicalAttribute"}, {"end": 83, "start": 79, "tag": "ClinicalAttribute"}, {"end": 133, "start": 129, "tag": "ClinicalAttribute"}, {"end": 179, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 253, "tag": "HealthCareActivity"}, {"end": 235, "start": 223, "tag": "HealthCareActivity"}]}
{"id": "1413_5", "text": "Age-matched, healthy controls (n = 20) were also assessed.", "tags": [{"end": 20, "start": 13, "tag": "OrganismAttribute"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}, {"end": 29, "start": 13, "tag": "PopulationGroup"}]}
{"id": "1413_6", "text": "Results:In patients with RRMS compared with controls at baseline, CNFD (p = 0.004) and RNFL thickness (p < 0.001) were lower, and CNBD (p = 0.003) was higher.", "tags": [{"end": 101, "start": 87, "tag": "ClinicalAttribute"}, {"end": 52, "start": 44, "tag": "PopulationGroup"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 66, "tag": "ClinicalAttribute"}, {"end": 134, "start": 130, "tag": "ClinicalAttribute"}]}
{"id": "1413_7", "text": "In patients with SPMS compared with controls, CNFD (p < 0.001), CNFL (p = 0.04) and RNFL thickness (p < 0.001) were lower.", "tags": [{"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 21, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}, {"end": 68, "start": 64, "tag": "ClinicalAttribute"}, {"end": 98, "start": 84, "tag": "ClinicalAttribute"}]}
{"id": "1413_8", "text": "For identifying RRMS, CNBD had the highest area under the receiver operating characteristic (AUROC) curve (0.99); and for SPMS, CNFD had the highest AUROC (0.95).", "tags": [{"end": 20, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 22, "tag": "ClinicalAttribute"}, {"end": 126, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 100, "tag": "ResearchActivity"}, {"end": 91, "start": 43, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "ResearchActivity"}, {"end": 132, "start": 128, "tag": "ClinicalAttribute"}, {"end": 154, "start": 149, "tag": "ResearchActivity"}]}
{"id": "1413_9", "text": "At follow-up, there was a further significant decrease in CNFD (p = 0.04), CNBD (p = 0.001), CNFL (p = 0.008) and RNFL (p = 0.002) in RRMS; in CNFD (p = 0.04) and CNBD (p = 0.002) in SPMS; and in CNBD (p = 0.01) in SPMS compared with RRMS.", "tags": [{"end": 12, "start": 3, "tag": "HealthCareActivity"}, {"end": 12, "start": 3, "tag": "TemporalConcept"}, {"end": 54, "start": 34, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "ClinicalAttribute"}, {"end": 79, "start": 75, "tag": "ClinicalAttribute"}, {"end": 97, "start": 93, "tag": "ClinicalAttribute"}, {"end": 138, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 143, "tag": "ClinicalAttribute"}, {"end": 167, "start": 163, "tag": "ClinicalAttribute"}, {"end": 187, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 196, "tag": "ClinicalAttribute"}, {"end": 219, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1413_10", "text": "Follow-up corneal nerve loss was greater in patients with new enhancing lesions and optic neuritis history.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 72, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 10, "tag": "PathologicFunction"}, {"end": 98, "start": 84, "tag": "DiseaseOrSyndrome"}]}
{"id": "1413_11", "text": "Conclusion:Progressive corneal and retinal axonal loss was identified in patients with MS, especially those with more active disease.", "tags": [{"end": 30, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 118, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}]}
{"id": "1413_12", "text": "CCM may serve as an imaging biomarker of axonal loss in MS.", "tags": [{"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 41, "tag": "PathologicFunction"}, {"end": 27, "start": 20, "tag": "HealthCareActivity"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}]}
{"id": "1414_0", "text": "Kappa free light chain (KFLC) index, a measure for intrathecal production of free kappa chains, has been increasingly recognized for its diagnostic potential in multiple sclerosis (MS) as a quantitative alternative to IgG oligoclonal bands (OCBs).", "tags": [{"end": 22, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "ClinicalAttribute"}, {"end": 157, "start": 137, "tag": "HealthCareActivity"}, {"end": 239, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 245, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 245, "start": 241, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1414_1", "text": "Our objective was to investigate the sensitivity, specificity, and overall diagnostic accuracy of KFLC index in MS.", "tags": [{"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 37, "tag": "Finding"}, {"end": 61, "start": 50, "tag": "Finding"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "Finding"}, {"end": 108, "start": 98, "tag": "ClinicalAttribute"}]}
{"id": "1414_2", "text": "KFLC index was prospectively determined as part of the diagnostic workup in patients with suspected MS (n = 327) between May 2013 and February 2020.", "tags": [{"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 129, "start": 121, "tag": "TemporalConcept"}, {"end": 147, "start": 134, "tag": "TemporalConcept"}]}
{"id": "1414_3", "text": "Patients with clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS), and MS had markedly higher KFLC index (44.6, IQR 16-128) compared with subjects with other neuro-inflammatory disorders (ONID) and symptomatic controls (SC) (2.19, IQR 1.68-2.98, p < 0.001).", "tags": [{"end": 42, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 161, "tag": "PopulationGroup"}, {"end": 241, "start": 233, "tag": "PopulationGroup"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 232, "start": 221, "tag": "SignOrSymptom"}, {"end": 209, "start": 181, "tag": "DiseaseOrSyndrome"}]}
{"id": "1414_4", "text": "KFLC index had a sensitivity of 0.93 (95% CI 0.88-0.95) and specificity of 0.87 (95% CI 0.8-0.92) to discriminate CIS/RIS/MS from ONID and SC (AUC 0.94, 95% CI 0.91-0.97, p < 0.001).", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 44, "start": 42, "tag": "GeneOrGenome"}, {"end": 44, "start": 42, "tag": "ResearchActivity"}, {"end": 159, "start": 157, "tag": "ResearchActivity"}, {"end": 28, "start": 17, "tag": "Finding"}, {"end": 71, "start": 60, "tag": "Finding"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 143, "tag": "ResearchActivity"}, {"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 85, "tag": "ResearchActivity"}]}
{"id": "1414_5", "text": "KFLC index and intrathecal fraction (IF) KFLC had similar accuracies to detect MS.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 45, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1414_6", "text": "Treatment with disease-modifying therapy (DMT) did not influence the level of KFLC index and it was not affected by demographic factors or associated with degenerative or inflammatory biomarkers in cerebrospinal fluid (CSF).", "tags": [{"end": 88, "start": 78, "tag": "ClinicalAttribute"}, {"end": 167, "start": 155, "tag": "PathologicFunction"}, {"end": 222, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 184, "tag": "ClinicalAttribute"}, {"end": 40, "start": 33, "tag": "HealthCareActivity"}, {"end": 217, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 40, "start": 15, "tag": "HealthCareActivity"}, {"end": 135, "start": 116, "tag": "Finding"}]}
{"id": "1414_7", "text": "KFLC index in MS diagnostics has methodological advantages compared to OCB and is independent to subjective interpretation.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 28, "start": 17, "tag": "HealthCareActivity"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}]}
{"id": "1414_8", "text": "Moreover, it is an attractive diagnostic tool since the diagnostic specificity and sensitivity of KFLC index are similar with that of OCBs and KFLCIF and better than for IgG index.", "tags": [{"end": 108, "start": 98, "tag": "ClinicalAttribute"}, {"end": 138, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 83, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "Finding"}, {"end": 173, "start": 170, "tag": "PharmacologicSubstance"}, {"end": 179, "start": 170, "tag": "ClinicalAttribute"}]}
{"id": "1414_9", "text": "We show that KFLC index was influenced neither by DMT nor by demographic factors or other inflammatory or degenerative processes in MS as determined by biomarkers in CSF.", "tags": [{"end": 80, "start": 61, "tag": "Finding"}, {"end": 169, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 152, "tag": "ClinicalAttribute"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 13, "tag": "ClinicalAttribute"}]}
{"id": "1415_0", "text": "Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS).", "tags": [{"end": 23, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 88, "tag": "PathologicFunction"}, {"end": 99, "start": 88, "tag": "TemporalConcept"}, {"end": 99, "start": 80, "tag": "PathologicFunction"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}, {"end": 23, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 12, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1415_1", "text": "Objective: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients.", "tags": [{"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}, {"end": 91, "start": 72, "tag": "PathologicFunction"}, {"end": 137, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "PatientOrDisabledGroup"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}, {"end": 67, "start": 58, "tag": "ClinicalAttribute"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}, {"end": 37, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "ClinicalAttribute"}, {"end": 106, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 95, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1415_2", "text": "Methods: Eighty-nine natalizumab-treated RRMS patients with minimum follow-up of 3 years were included.", "tags": [{"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "TemporalConcept"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 21, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 41, "tag": "DiseaseOrSyndrome"}]}
{"id": "1415_3", "text": "sCNTN1 was analyzed at baseline (before natalizumab initiation), 3, 12, 24 months (M) and last follow-up (median 5.2 years) and compared to 222 healthy controls (HC) and 15 primary progressive MS patients (PPMS).", "tags": [{"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 52, "tag": "TemporalConcept"}, {"end": 84, "start": 83, "tag": "TemporalConcept"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "TemporalConcept"}, {"end": 81, "start": 75, "tag": "TemporalConcept"}, {"end": 122, "start": 117, "tag": "TemporalConcept"}, {"end": 151, "start": 144, "tag": "OrganismAttribute"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 196, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 181, "tag": "TemporalConcept"}, {"end": 160, "start": 144, "tag": "PopulationGroup"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 40, "tag": "PharmacologicSubstance"}]}
{"id": "1415_4", "text": "Results were compared between patients with progressive, stable, or improved disability according to EDSS-plus criteria.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 87, "start": 77, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 44, "tag": "TemporalConcept"}, {"end": 105, "start": 101, "tag": "HealthCareActivity"}]}
{"id": "1415_5", "text": "Results: Median sCNTN1 levels (ng/mL,) in RRMS (baseline: 10.7, 3M: 9.7, 12M: 10.4, 24M: 10.8; last follow-up: 9.7) were significantly lower compared to HC (12.5; p <= 0.001).", "tags": [{"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 29, "start": 16, "tag": "ClinicalAttribute"}, {"end": 46, "start": 42, "tag": "DiseaseOrSyndrome"}]}
{"id": "1415_6", "text": "It was observed that 48% of patients showed progression during follow-up, 11% improved, and 40% remained stable.", "tags": [{"end": 72, "start": 63, "tag": "HealthCareActivity"}, {"end": 72, "start": 63, "tag": "TemporalConcept"}, {"end": 55, "start": 44, "tag": "PathologicFunction"}, {"end": 55, "start": 44, "tag": "TemporalConcept"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}]}
{"id": "1415_7", "text": "sCNTN1 levels were significantly lower in progressors both at baseline and at 12M compared to non-progressors.", "tags": [{"end": 13, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1415_8", "text": "A 1 ng/mL decrease in baseline sCNTN1 was consistent with an odds ratio of 1.23 (95% confidence interval 1.04-1.45) (p = 0.017) for progression during follow-up.", "tags": [{"end": 160, "start": 151, "tag": "HealthCareActivity"}, {"end": 160, "start": 151, "tag": "TemporalConcept"}, {"end": 143, "start": 132, "tag": "PathologicFunction"}, {"end": 143, "start": 132, "tag": "TemporalConcept"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 104, "start": 85, "tag": "ResearchActivity"}, {"end": 37, "start": 31, "tag": "ClinicalAttribute"}]}
{"id": "1415_9", "text": "Conclusion: Lower baseline sCNTN1 concentrations were associated with long-term disability progression during natalizumab treatment, making it a possible blood-based prognostic biomarker for RRMS.", "tags": [{"end": 48, "start": 27, "tag": "ClinicalAttribute"}, {"end": 90, "start": 80, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 91, "tag": "PathologicFunction"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 131, "start": 122, "tag": "HealthCareActivity"}, {"end": 131, "start": 122, "tag": "ResearchActivity"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 70, "tag": "TemporalConcept"}, {"end": 186, "start": 166, "tag": "ClinicalAttribute"}, {"end": 121, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 191, "tag": "DiseaseOrSyndrome"}]}
{"id": "1416_0", "text": "Background and Objectives The diagnosis of secondary progressive multiple sclerosis (SPMS) is often delayed because of the lack of objective clinical tools, which increases the diagnostic uncertainty and hampers the therapeutic development in progressive multiple sclerosis (MS).", "tags": [{"end": 83, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 100, "tag": "TemporalConcept"}, {"end": 89, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 239, "start": 216, "tag": "ResearchActivity"}, {"end": 39, "start": 30, "tag": "HealthCareActivity"}, {"end": 199, "start": 177, "tag": "Finding"}]}
{"id": "1416_1", "text": "Optical coherence tomography (OCT) has been proposed as a promising biomarker of progressive neurodegeneration.", "tags": [{"end": 28, "start": 0, "tag": "HealthCareActivity"}, {"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 77, "start": 58, "tag": "ClinicalAttribute"}, {"end": 92, "start": 81, "tag": "TemporalConcept"}, {"end": 110, "start": 93, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1416_2", "text": "To explore longitudinal changes in the thicknesses of retinal layers on OCT in individuals with relapsing-remitting MS (RRMS) who converted to SPMS vs matched patients with RRMS who did not convert to SPMS.", "tags": [{"end": 118, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 68, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 159, "tag": "PatientOrDisabledGroup"}, {"end": 90, "start": 79, "tag": "PopulationGroup"}, {"end": 68, "start": 39, "tag": "ClinicalAttribute"}]}
{"id": "1416_3", "text": "Our hypothesis is that the 2 cohorts exhibit different rates of retinal thinning.", "tags": [{"end": 80, "start": 64, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "PopulationGroup"}]}
{"id": "1416_4", "text": "Methods From our prospective observational cohort of patients with MS at the American University of Beirut, we selected patients with RRMS who converted to SPMS during the observation period and patients with RRMS, matched by age, disease duration, and Expanded Disability Status Scale (EDSS) at the first visit.", "tags": [{"end": 190, "start": 172, "tag": "TemporalConcept"}, {"end": 247, "start": 231, "tag": "HealthCareActivity"}, {"end": 247, "start": 239, "tag": "TemporalConcept"}, {"end": 28, "start": 17, "tag": "BiologicFunction"}, {"end": 247, "start": 231, "tag": "TemporalConcept"}, {"end": 160, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 300, "tag": "TemporalConcept"}, {"end": 138, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 253, "tag": "HealthCareActivity"}, {"end": 291, "start": 287, "tag": "HealthCareActivity"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 120, "tag": "PatientOrDisabledGroup"}, {"end": 203, "start": 195, "tag": "PatientOrDisabledGroup"}, {"end": 311, "start": 306, "tag": "HealthCareActivity"}, {"end": 229, "start": 226, "tag": "OrganismAttribute"}, {"end": 106, "start": 77, "tag": "HealthCareRelatedOrganization"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}]}
{"id": "1416_5", "text": "Baseline retinal measurements were obtained using spectral domain OCT, and all patients underwent clinical and OCT evaluation every 6-12 months on average throughout the study period (mean = 4 years).", "tags": [{"end": 69, "start": 50, "tag": "HealthCareActivity"}, {"end": 114, "start": 111, "tag": "HealthCareActivity"}, {"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 175, "start": 170, "tag": "ResearchActivity"}, {"end": 198, "start": 193, "tag": "TemporalConcept"}, {"end": 143, "start": 137, "tag": "TemporalConcept"}, {"end": 29, "start": 17, "tag": "HealthCareActivity"}, {"end": 125, "start": 115, "tag": "HealthCareActivity"}, {"end": 125, "start": 115, "tag": "ResearchActivity"}]}
{"id": "1416_6", "text": "Mixed-effect regression models were used to assess the annualized rates of retinal changes and the differences between the 2 groups and between converters to SPMS before and after their conversion.", "tags": [{"end": 154, "start": 144, "tag": "Finding"}, {"end": 162, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 110, "start": 99, "tag": "Finding"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "PopulationGroup"}, {"end": 196, "start": 186, "tag": "Finding"}]}
{"id": "1416_7", "text": "Results A total of 61 participants were selected (21 SPMS and 40 RRMS).", "tags": [{"end": 57, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1416_8", "text": "There were no differences in baseline characteristics and retinal measurements between the 2 groups.", "tags": [{"end": 25, "start": 11, "tag": "Finding"}, {"end": 65, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 38, "tag": "OrganismAttribute"}, {"end": 99, "start": 93, "tag": "PopulationGroup"}, {"end": 78, "start": 66, "tag": "HealthCareActivity"}]}
{"id": "1416_9", "text": "The annualized rates of thinning of all retinal layers, except for macular volume, were greater in converters before conversion compared with nonconverters by 112% for peripapillary retinal nerve fiber layer (p = 0.008), 344% for tRNFL (p < 0.0001), and 82% for cell-inner plexiform layer (GCIPL) (p = 0.002).", "tags": [{"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 99, "tag": "Finding"}, {"end": 207, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 110, "tag": "TemporalConcept"}, {"end": 127, "start": 117, "tag": "Finding"}, {"end": 20, "start": 15, "tag": "TemporalConcept"}, {"end": 32, "start": 24, "tag": "Finding"}, {"end": 81, "start": 67, "tag": "ClinicalAttribute"}, {"end": 235, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 288, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 290, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1416_10", "text": "When comparing the annualized rate of thinning for the same patients with SPMS before and after conversion, no significant differences were found except for tRNFL and GCIPL with slower thinning rates postconversion (46% and 68%, respectively).", "tags": [{"end": 78, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 30, "tag": "TemporalConcept"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 123, "tag": "Finding"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 106, "start": 96, "tag": "Finding"}, {"end": 162, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 214, "start": 200, "tag": "TemporalConcept"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 199, "start": 194, "tag": "TemporalConcept"}, {"end": 193, "start": 185, "tag": "Finding"}]}
{"id": "1416_11", "text": "Discussion Patients who converted to SPMS exhibited faster retinal thinning as reflected on OCT.", "tags": [{"end": 75, "start": 59, "tag": "Finding"}, {"end": 41, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}]}
{"id": "1416_12", "text": "Longitudinal assessment of retinal thinning could confirm the transition to SPMS and help with the therapeutic decision making for patients with MS with clinical suspicion of disease progression.", "tags": [{"end": 43, "start": 27, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "Finding"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 194, "start": 175, "tag": "PathologicFunction"}, {"end": 126, "start": 111, "tag": "BiologicFunction"}, {"end": 171, "start": 153, "tag": "Finding"}]}
{"id": "1417_0", "text": "Background Multiple sclerosis (MS) has two pathophysiological processes, one inflammatory and the other degenerative.", "tags": [{"end": 71, "start": 43, "tag": "BiologicFunction"}, {"end": 116, "start": 104, "tag": "PathologicFunction"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 43, "tag": "PathologicFunction"}, {"end": 89, "start": 77, "tag": "PathologicFunction"}]}
{"id": "1417_1", "text": "We investigated the relationship between active lesions on magnetic resonance imaging showing the inflammatory phase in MS patients and serum parameters that can be used as inflammatory biomarkers.", "tags": [{"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 141, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 123, "tag": "PatientOrDisabledGroup"}, {"end": 196, "start": 173, "tag": "ClinicalAttribute"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 32, "start": 20, "tag": "Finding"}, {"end": 85, "start": 59, "tag": "HealthCareActivity"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}]}
{"id": "1417_2", "text": "Thus, we aim to detect the inflammatory period in clinical and radiological follow-up and to reveal the period in which disease-modifying treatments are effective with serum parameters.", "tags": [{"end": 148, "start": 120, "tag": "HealthCareActivity"}, {"end": 173, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "TemporalConcept"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 85, "start": 76, "tag": "HealthCareActivity"}, {"end": 85, "start": 76, "tag": "TemporalConcept"}, {"end": 39, "start": 27, "tag": "PathologicFunction"}]}
{"id": "1417_3", "text": "Methods One hundred eighty-six MS patients presented to our hospital between January 2016 and November 2021 and 94 age- and sex-matched healthy volunteers were recruited for our study.", "tags": [{"end": 68, "start": 60, "tag": "HealthCareRelatedOrganization"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 144, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "OrganismAttribute"}, {"end": 42, "start": 34, "tag": "PatientOrDisabledGroup"}, {"end": 143, "start": 136, "tag": "OrganismAttribute"}, {"end": 183, "start": 178, "tag": "ResearchActivity"}, {"end": 118, "start": 115, "tag": "OrganismAttribute"}, {"end": 89, "start": 77, "tag": "TemporalConcept"}, {"end": 107, "start": 94, "tag": "TemporalConcept"}]}
{"id": "1417_4", "text": "While 99 patients had active lesions on magnetic resonance imaging, 87 patients did not have any active lesions.", "tags": [{"end": 36, "start": 22, "tag": "InjuryOrPoisoning"}, {"end": 111, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 40, "tag": "HealthCareActivity"}]}
{"id": "1417_5", "text": "Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) were determined.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 21, "start": 11, "tag": "Cell"}, {"end": 27, "start": 0, "tag": "ClinicalAttribute"}, {"end": 60, "start": 35, "tag": "ClinicalAttribute"}, {"end": 97, "start": 72, "tag": "ClinicalAttribute"}, {"end": 43, "start": 35, "tag": "Cell"}, {"end": 54, "start": 44, "tag": "Cell"}, {"end": 80, "start": 72, "tag": "Cell"}, {"end": 91, "start": 81, "tag": "Cell"}]}
{"id": "1417_6", "text": "The SII (systemic immune inflammatory index) value was calculated according to the platelet X neutrophil/lymphocyte ratio formula.", "tags": [{"end": 91, "start": 83, "tag": "Cell"}, {"end": 43, "start": 9, "tag": "ResearchActivity"}, {"end": 104, "start": 94, "tag": "Cell"}, {"end": 115, "start": 105, "tag": "Cell"}, {"end": 50, "start": 45, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}]}
{"id": "1417_7", "text": "Results NLR, MLR, PLR and SII values were found to be statistically significantly higher in MS patients than in the control group.", "tags": [{"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 116, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 26, "tag": "ResearchActivity"}, {"end": 11, "start": 8, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "ClinicalAttribute"}, {"end": 21, "start": 18, "tag": "ClinicalAttribute"}]}
{"id": "1417_8", "text": "The NLR, MLR, PLR and SII were higher in the active group with gadolonium than in the group without active lesions.", "tags": [{"end": 114, "start": 100, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 52, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 73, "start": 63, "tag": "Chemical"}, {"end": 73, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 22, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 12, "start": 9, "tag": "ClinicalAttribute"}, {"end": 17, "start": 14, "tag": "ClinicalAttribute"}]}
{"id": "1417_9", "text": "In addition, the cutoff values that we can use to determine the presence of active lesions were 1.53, 0.18, 117.15, and 434.45 for NLR, MLR PLR and SII, respectively.", "tags": [{"end": 30, "start": 17, "tag": "ResearchActivity"}, {"end": 90, "start": 76, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 64, "tag": "Finding"}, {"end": 134, "start": 131, "tag": "ClinicalAttribute"}, {"end": 139, "start": 136, "tag": "ClinicalAttribute"}, {"end": 143, "start": 140, "tag": "ClinicalAttribute"}, {"end": 151, "start": 148, "tag": "ClinicalAttribute"}]}
{"id": "1417_10", "text": "Conclusions We found that all parameters correlated with radiological activity.", "tags": []}
{"id": "1417_11", "text": "In addition, we showed that we can detect the inflammatory period with high sensitivity and specificity with the cutoff value used for SII and PLR.", "tags": [{"end": 103, "start": 71, "tag": "Finding"}, {"end": 125, "start": 113, "tag": "ResearchActivity"}, {"end": 65, "start": 59, "tag": "TemporalConcept"}, {"end": 58, "start": 46, "tag": "PathologicFunction"}, {"end": 138, "start": 135, "tag": "ResearchActivity"}, {"end": 146, "start": 143, "tag": "ClinicalAttribute"}]}
{"id": "1417_12", "text": "Among these easily accessible and inexpensive evaluations, we concluded that SII, including the values in the PLR formula, can come to the fore.", "tags": [{"end": 57, "start": 46, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "ResearchActivity"}, {"end": 113, "start": 110, "tag": "ClinicalAttribute"}]}
{"id": "1418_0", "text": "INTRODUCTION As the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others.", "tags": [{"end": 54, "start": 49, "tag": "ResearchActivity"}, {"end": 74, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "ClinicalAttribute"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 219, "start": 210, "tag": "ClinicalAttribute"}]}
{"id": "1418_1", "text": "METHODS We used hierarchical clustering to group 19 cross-sectional biomarkers in autosomal dominant AD.", "tags": [{"end": 39, "start": 16, "tag": "ResearchActivity"}, {"end": 78, "start": 68, "tag": "ClinicalAttribute"}, {"end": 103, "start": 82, "tag": "DiseaseOrSyndrome"}]}
{"id": "1418_2", "text": "Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO).", "tags": [{"end": 93, "start": 78, "tag": "ResearchActivity"}, {"end": 93, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 86, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 132, "start": 98, "tag": "TemporalConcept"}, {"end": 74, "start": 64, "tag": "Finding"}, {"end": 137, "start": 134, "tag": "TemporalConcept"}]}
{"id": "1418_3", "text": "Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 65, "start": 53, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 118, "tag": "ClinicalAttribute"}, {"end": 86, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 132, "tag": "CellFunction"}, {"end": 167, "start": 155, "tag": "PathologicFunction"}, {"end": 51, "start": 31, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1418_4", "text": "RESULTS Three primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers.", "tags": [{"end": 65, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1418_5", "text": "Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO.", "tags": [{"end": 36, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 83, "tag": "ResearchActivity"}, {"end": 98, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 69, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "TemporalConcept"}]}
{"id": "1418_6", "text": "Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.", "tags": [{"end": 19, "start": 9, "tag": "ClinicalAttribute"}, {"end": 41, "start": 23, "tag": "CellFunction"}, {"end": 58, "start": 46, "tag": "PathologicFunction"}, {"end": 90, "start": 75, "tag": "Finding"}]}
{"id": "1418_7", "text": "DISCUSSION These results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.", "tags": [{"end": 123, "start": 116, "tag": "TemporalConcept"}, {"end": 166, "start": 155, "tag": "PathologicFunction"}, {"end": 166, "start": 155, "tag": "TemporalConcept"}, {"end": 107, "start": 97, "tag": "ClinicalAttribute"}, {"end": 137, "start": 127, "tag": "ClinicalAttribute"}, {"end": 166, "start": 147, "tag": "PathologicFunction"}]}
{"id": "1419_0", "text": "BackgroundChitinase -3-like 1-protein (CHI3L1) is a glycoside secreted by monocytes, microglia, and activated astrocytes.", "tags": [{"end": 61, "start": 52, "tag": "Chemical"}, {"end": 83, "start": 74, "tag": "Cell"}, {"end": 45, "start": 39, "tag": "GeneOrGenome"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 100, "tag": "Cell"}, {"end": 94, "start": 85, "tag": "Cell"}, {"end": 37, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1419_1", "text": "Its distribution in inflammatory lesions denotes its role in astrocytic response to modulate CNS inflammation.", "tags": [{"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 97, "tag": "PathologicFunction"}, {"end": 40, "start": 20, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 61, "tag": "CellFunction"}]}
{"id": "1419_2", "text": "In multiple sclerosis (MS), CHI3L1 levels have been found to be influenced by disease severity, activity, and progression.", "tags": [{"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 28, "tag": "GeneOrGenome"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 78, "tag": "ClinicalAttribute"}, {"end": 94, "start": 78, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 34, "start": 28, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1419_3", "text": "We aimed to measure CSF level of CHI3L1 in patients with MS and correlate its level with disability measures for a possible role as a biomarker for disease progression.MethodsFifty-two MS patients (30 relapsing-remitting MS and 22 progressive MS) and thirty-five age and sex-matched healthy controls were included.", "tags": [{"end": 223, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 89, "tag": "HealthCareActivity"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 33, "tag": "GeneOrGenome"}, {"end": 39, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 274, "start": 271, "tag": "OrganismAttribute"}, {"end": 99, "start": 89, "tag": "Finding"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 134, "tag": "ClinicalAttribute"}, {"end": 51, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 196, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 290, "start": 283, "tag": "OrganismAttribute"}, {"end": 299, "start": 291, "tag": "PopulationGroup"}, {"end": 167, "start": 156, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "TemporalConcept"}, {"end": 167, "start": 148, "tag": "PathologicFunction"}, {"end": 266, "start": 263, "tag": "OrganismAttribute"}, {"end": 39, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 20, "tag": "ClinicalAttribute"}]}
{"id": "1419_4", "text": "They all underwent full clinical assessment (including disability and cognitive scales), radiological assessment, and CSF level of CHI3L1.ResultsPatients with MS had higher CSF level of CHI3L1 than controls.", "tags": [{"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 131, "tag": "GeneOrGenome"}, {"end": 192, "start": 186, "tag": "GeneOrGenome"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 55, "tag": "Finding"}, {"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 198, "tag": "PopulationGroup"}, {"end": 43, "start": 24, "tag": "HealthCareActivity"}, {"end": 112, "start": 89, "tag": "HealthCareActivity"}, {"end": 137, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 118, "tag": "ClinicalAttribute"}, {"end": 192, "start": 173, "tag": "ClinicalAttribute"}, {"end": 192, "start": 186, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1419_5", "text": "Patients with progressive forms had higher levels than relapsing forms.", "tags": [{"end": 64, "start": 55, "tag": "TemporalConcept"}, {"end": 25, "start": 14, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}
{"id": "1419_6", "text": "There were positive correlations between disease duration, number of attacks, total EDSS, and CSF level of CHI3L1.", "tags": [{"end": 76, "start": 69, "tag": "Finding"}, {"end": 76, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "TemporalConcept"}, {"end": 113, "start": 107, "tag": "GeneOrGenome"}, {"end": 113, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 84, "tag": "HealthCareActivity"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 20, "tag": "ResearchActivity"}, {"end": 113, "start": 94, "tag": "ClinicalAttribute"}, {"end": 113, "start": 107, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1419_7", "text": "Patients who had higher level of CSF CHI3L1 showed worse performance in MMSE and BICAMS and more lesions in T2 MRI brain.", "tags": [{"end": 43, "start": 37, "tag": "GeneOrGenome"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "HealthCareActivity"}, {"end": 104, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 51, "tag": "Finding"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 57, "tag": "Finding"}, {"end": 114, "start": 108, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 43, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 81, "tag": "HealthCareActivity"}]}
{"id": "1419_8", "text": "A cut off value of 154 ng/mL was found between patients with RRMS and PMS patients.ConclusionCHI3L1 can be considered as a biomarker of disease progression.", "tags": [{"end": 73, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 123, "tag": "ClinicalAttribute"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 155, "start": 144, "tag": "PathologicFunction"}, {"end": 155, "start": 144, "tag": "TemporalConcept"}, {"end": 155, "start": 136, "tag": "PathologicFunction"}, {"end": 15, "start": 2, "tag": "ResearchActivity"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}]}
{"id": "1419_9", "text": "CHI3L1 level increases in progressive MS more than RRMS.", "tags": [{"end": 40, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1419_10", "text": "Also, high CSF level of CHI3L1 was associated with more disability including motor, cognitive, and radiological aspects.", "tags": [{"end": 30, "start": 24, "tag": "GeneOrGenome"}, {"end": 30, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 56, "tag": "Finding"}, {"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 6, "tag": "Finding"}, {"end": 30, "start": 11, "tag": "ClinicalAttribute"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1420_0", "text": "Purpose: Magnetic resonance imaging (MRI) findings in multiple sclerosis (MS) overlap with numerous MS mimics.", "tags": [{"end": 109, "start": 100, "tag": "Finding"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 35, "start": 9, "tag": "HealthCareActivity"}, {"end": 40, "start": 37, "tag": "HealthCareActivity"}]}
{"id": "1420_1", "text": "The central vein sign (CVS) can help to differentiate MS from other mimics.", "tags": [{"end": 21, "start": 4, "tag": "ClinicalAttribute"}, {"end": 26, "start": 23, "tag": "ClinicalAttribute"}, {"end": 16, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}]}
{"id": "1420_2", "text": "This study aimed to determine the value of CVS as a diagnostic biomarker for distinguishing MS from its mimics.", "tags": [{"end": 46, "start": 43, "tag": "ClinicalAttribute"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 52, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}
{"id": "1420_3", "text": "Patients and Methods: Patients were prospectively recruited into two groups: a typical clinical (TC) MS presentation with an atypical MRI for MS and an atypical clinical (ATC) MS presentation with a typical MRI for MS.", "tags": [{"end": 116, "start": 104, "tag": "Finding"}, {"end": 95, "start": 79, "tag": "Finding"}, {"end": 191, "start": 179, "tag": "Finding"}, {"end": 169, "start": 152, "tag": "Finding"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 125, "tag": "Finding"}, {"end": 75, "start": 69, "tag": "PopulationGroup"}, {"end": 137, "start": 134, "tag": "HealthCareActivity"}, {"end": 210, "start": 207, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 22, "tag": "PatientOrDisabledGroup"}]}
{"id": "1420_4", "text": "Patients underwent a 1.5T MRI brain scan with a T2*-weighted gradient-echo sequence.", "tags": [{"end": 40, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 21, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 48, "tag": "ResearchActivity"}]}
{"id": "1420_5", "text": "The presence of the central vein was assessed by a radiologist blinded to patients' clinical presentation.", "tags": [{"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 105, "start": 84, "tag": "Finding"}, {"end": 32, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 12, "start": 4, "tag": "Finding"}]}
{"id": "1420_6", "text": "The MS consultant made the final diagnosis without reviewing the T2*-weighted gradient-echo sequence or the CVS analysis results.", "tags": [{"end": 17, "start": 7, "tag": "PopulationGroup"}, {"end": 111, "start": 108, "tag": "ClinicalAttribute"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "HealthCareActivity"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 100, "start": 65, "tag": "HealthCareActivity"}]}
{"id": "1420_7", "text": "Results: Forty-two patients were included.", "tags": [{"end": 27, "start": 19, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1420_8", "text": "Ten (40%) out of 25 TC patients were diagnosed with clinically definite MS (CDMS), with a mean percentage of CV-positive lesions of 65.5% among CDMS patients.", "tags": [{"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 121, "tag": "InjuryOrPoisoning"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 157, "start": 149, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 37, "tag": "HealthCareActivity"}]}
{"id": "1420_9", "text": "Four (23.5%) out of 17 ATC patients were diagnosed with CDMS with a mean CV-positive lesions percentage of 68.25% among CDMS patients.", "tags": [{"end": 92, "start": 85, "tag": "InjuryOrPoisoning"}, {"end": 35, "start": 27, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}]}
{"id": "1420_10", "text": "TC patients who were not diagnosed as CDMS had a mean CV-positive lesions percentage of 10.13%, while ATC patients who were not diagnosed as CDMS had a mean CV-positive lesions percentage of 16.38%.", "tags": [{"end": 73, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 176, "start": 169, "tag": "InjuryOrPoisoning"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 137, "start": 128, "tag": "HealthCareActivity"}]}
{"id": "1420_11", "text": "The CVS showed 85.7% sensitivity and 100% specificity (95% confidence interval: 0.919-1.018) for diagnosis of MS at a cut off value of 45% (p < 0.001).", "tags": [{"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "ResearchActivity"}, {"end": 106, "start": 97, "tag": "HealthCareActivity"}, {"end": 32, "start": 21, "tag": "Finding"}, {"end": 53, "start": 42, "tag": "Finding"}, {"end": 131, "start": 118, "tag": "ResearchActivity"}]}
{"id": "1420_12", "text": "The percentage of CV-positive lesions was significantly higher in oligoclonal bands (OCBs) positive patients compared to OCBs negative patients (p < 0.001) and those with spinal cord lesions compared to patients with no spinal cord lesions (p = 0.017).", "tags": [{"end": 190, "start": 171, "tag": "Finding"}, {"end": 239, "start": 220, "tag": "Finding"}, {"end": 182, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 231, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 190, "start": 183, "tag": "InjuryOrPoisoning"}, {"end": 239, "start": 232, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 143, "start": 135, "tag": "PatientOrDisabledGroup"}, {"end": 211, "start": 203, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 66, "tag": "ResearchActivity"}, {"end": 125, "start": 121, "tag": "ResearchActivity"}, {"end": 89, "start": 85, "tag": "ResearchActivity"}]}
{"id": "1420_13", "text": "Conclusion: The CVS has 85.7% sensitivity and 100% specificity for the diagnosis of MS at a cutoff value of 45%.", "tags": [{"end": 19, "start": 16, "tag": "ClinicalAttribute"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 92, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "HealthCareActivity"}, {"end": 41, "start": 30, "tag": "Finding"}, {"end": 62, "start": 51, "tag": "Finding"}]}
{"id": "1421_0", "text": "Objective We aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin (Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening.", "tags": [{"end": 214, "start": 205, "tag": "Finding"}, {"end": 131, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 128, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 151, "tag": "Finding"}, {"end": 204, "start": 197, "tag": "TemporalConcept"}, {"end": 123, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 171, "tag": "Finding"}]}
{"id": "1421_1", "text": "Methods We compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neurofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS.", "tags": [{"end": 131, "start": 100, "tag": "ClinicalAttribute"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 179, "tag": "PatientOrDisabledGroup"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 171, "start": 162, "tag": "HealthCareActivity"}, {"end": 171, "start": 162, "tag": "TemporalConcept"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 89, "start": 63, "tag": "HealthCareActivity"}, {"end": 131, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "ClinicalAttribute"}]}
{"id": "1421_2", "text": "Patients were categorized by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgG(IF) and IgM(IF)).", "tags": [{"end": 66, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 45, "tag": "ResearchActivity"}, {"end": 72, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 68, "tag": "ResearchActivity"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "ResearchActivity"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 103, "tag": "PharmacologicSubstance"}, {"end": 146, "start": 143, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}
{"id": "1421_3", "text": "Relationships with the time to first relapse, sNfL concentrations, T2-weighted (T2w) lesions, MS Severity Score (MSSS), and time to initiation of high-efficacy therapy were analyzed in covariate-adjusted statistical models.", "tags": [{"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "HealthCareActivity"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 51, "tag": "BiologicFunction"}, {"end": 142, "start": 132, "tag": "TemporalConcept"}, {"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 44, "start": 37, "tag": "Finding"}, {"end": 92, "start": 67, "tag": "InjuryOrPoisoning"}, {"end": 36, "start": 31, "tag": "TemporalConcept"}, {"end": 27, "start": 23, "tag": "TemporalConcept"}, {"end": 128, "start": 124, "tag": "TemporalConcept"}, {"end": 159, "start": 151, "tag": "Finding"}, {"end": 167, "start": 160, "tag": "HealthCareActivity"}, {"end": 222, "start": 216, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "ResearchActivity"}, {"end": 150, "start": 146, "tag": "Finding"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}, {"end": 111, "start": 94, "tag": "HealthCareActivity"}]}
{"id": "1421_4", "text": "Results By categorical analysis, in patients with IgM(IF) the median time to first relapse was 28 months shorter and MSSS on average higher by 1.11 steps compared with patients without intrathecal immunoglobulin synthesis.", "tags": [{"end": 221, "start": 197, "tag": "BiologicFunction"}, {"end": 121, "start": 117, "tag": "HealthCareActivity"}, {"end": 196, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 83, "tag": "TemporalConcept"}, {"end": 90, "start": 83, "tag": "Finding"}, {"end": 82, "start": 77, "tag": "TemporalConcept"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 176, "start": 168, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 68, "start": 62, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1421_5", "text": "Moreover, patients with IgM(IF) had higher sNfL concentrations, more new/enlarging T2w lesions, and higher total T2w lesion counts (all p <= 0.01).", "tags": [{"end": 86, "start": 83, "tag": "HealthCareActivity"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 48, "tag": "BiologicFunction"}, {"end": 123, "start": 117, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 87, "tag": "InjuryOrPoisoning"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1421_6", "text": "These associations were absent or equally smaller in patients who were positive for only OCGB or OCGB/IgG(IF).", "tags": [{"end": 30, "start": 24, "tag": "Finding"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 89, "tag": "ResearchActivity"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 97, "tag": "ResearchActivity"}, {"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 97, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1421_7", "text": "Furthermore, quantitative analyses revealed that in patients with IgM(IF) >= median, the time to first relapse and to initiation of high-efficacy therapy was shorter by 32 and by 203 months, respectively (both p < 0.01), in comparison to patients with IgM(IF) < median.", "tags": [{"end": 128, "start": 118, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "Finding"}, {"end": 234, "start": 224, "tag": "ResearchActivity"}, {"end": 102, "start": 97, "tag": "TemporalConcept"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 246, "start": 238, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 89, "tag": "TemporalConcept"}, {"end": 189, "start": 183, "tag": "TemporalConcept"}, {"end": 34, "start": 26, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "Finding"}, {"end": 153, "start": 146, "tag": "HealthCareActivity"}, {"end": 83, "start": 77, "tag": "ResearchActivity"}, {"end": 268, "start": 262, "tag": "ResearchActivity"}, {"end": 136, "start": 132, "tag": "Finding"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 255, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 252, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1421_8", "text": "Dose-dependent associations were also found for IgM(IF) but not for IgG(IF) with magnetic resonance imaging-defined disease activity and sNfL.", "tags": [{"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 116, "tag": "HealthCareActivity"}, {"end": 14, "start": 5, "tag": "Finding"}, {"end": 107, "start": 81, "tag": "HealthCareActivity"}, {"end": 141, "start": 137, "tag": "ClinicalAttribute"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1421_9", "text": "Interpretation This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS.", "tags": [{"end": 65, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 111, "tag": "HealthCareActivity"}, {"end": 140, "start": 132, "tag": "ClinicalAttribute"}, {"end": 140, "start": 132, "tag": "Finding"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 31, "start": 26, "tag": "ResearchActivity"}, {"end": 69, "start": 54, "tag": "ClinicalAttribute"}]}
{"id": "1421_10", "text": "ANN NEUROL 2021", "tags": []}
{"id": "1422_0", "text": "Background Impaired gait plays an important role for quality of life in patients with Huntington's disease (HD).", "tags": [{"end": 24, "start": 11, "tag": "Finding"}, {"end": 106, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 64, "tag": "TemporalConcept"}, {"end": 68, "start": 53, "tag": "Finding"}, {"end": 24, "start": 20, "tag": "OrganismAttribute"}]}
{"id": "1422_1", "text": "Measuring objective gait parameters in HD might provide an unbiased assessment of motor deficits in order to determine potential beneficial effects of future treatments.", "tags": [{"end": 96, "start": 82, "tag": "PathologicFunction"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 158, "tag": "HealthCareActivity"}, {"end": 168, "start": 158, "tag": "ResearchActivity"}, {"end": 157, "start": 151, "tag": "TemporalConcept"}, {"end": 147, "start": 129, "tag": "Finding"}, {"end": 24, "start": 20, "tag": "OrganismAttribute"}]}
{"id": "1422_2", "text": "Objective To objectively identify characteristic features of gait in HD patients using sensor-based gait analysis.", "tags": [{"end": 113, "start": 105, "tag": "ResearchActivity"}, {"end": 80, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 65, "start": 61, "tag": "OrganismAttribute"}, {"end": 104, "start": 100, "tag": "OrganismAttribute"}]}
{"id": "1422_3", "text": "Particularly, gait parameters were correlated to the Unified Huntington's Disease Rating Scale, total motor score (TMS), and total functional capacity (TFC).", "tags": [{"end": 94, "start": 53, "tag": "HealthCareActivity"}, {"end": 18, "start": 14, "tag": "OrganismAttribute"}, {"end": 113, "start": 96, "tag": "HealthCareActivity"}, {"end": 150, "start": 125, "tag": "HealthCareActivity"}]}
{"id": "1422_4", "text": "Methods Patients with manifest HD at two German sites (n = 43) were included and clinically assessed during their annual ENROLL-HD visit.", "tags": [{"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "HealthCareActivity"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 22, "tag": "SignOrSymptom"}, {"end": 130, "start": 121, "tag": "ResearchActivity"}]}
{"id": "1422_5", "text": "In addition, patients with HD and a cohort of age- and gender-matched controls performed a defined gait test (4 x 10 m walk).", "tags": [{"end": 49, "start": 46, "tag": "OrganismAttribute"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "PopulationGroup"}, {"end": 61, "start": 55, "tag": "OrganismAttribute"}, {"end": 21, "start": 13, "tag": "PatientOrDisabledGroup"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 103, "start": 99, "tag": "OrganismAttribute"}, {"end": 108, "start": 99, "tag": "HealthCareActivity"}]}
{"id": "1422_6", "text": "Gait patterns were recorded by inertial sensors attached to both shoes.", "tags": []}
{"id": "1422_7", "text": "Machine learning algorithms were applied to calculate spatio-temporal gait parameters and gait variability expressed as coefficient of variance (CV).", "tags": [{"end": 27, "start": 0, "tag": "MachineActivity"}, {"end": 16, "start": 8, "tag": "BiologicFunction"}, {"end": 74, "start": 70, "tag": "OrganismAttribute"}, {"end": 94, "start": 90, "tag": "OrganismAttribute"}, {"end": 143, "start": 120, "tag": "ResearchActivity"}, {"end": 106, "start": 90, "tag": "ClinicalAttribute"}]}
{"id": "1422_8", "text": "Results Stride length (- 15%) and gait velocity (- 19%) were reduced, while stride (+ 7%) and stance time (+ 2%) were increased in patients with HD.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 101, "tag": "TemporalConcept"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 47, "start": 34, "tag": "OrganismAttribute"}, {"end": 21, "start": 8, "tag": "OrganismAttribute"}, {"end": 105, "start": 94, "tag": "OrganismAttribute"}, {"end": 82, "start": 76, "tag": "OrganismAttribute"}]}
{"id": "1422_9", "text": "However, parameters reflecting gait variability were substantially altered in HD patients (+ 17% stride length CV up to + 41% stride time CV with largest effect size) and showed strong correlations to TMS and TFC (0.416 <= r(Sp) <= 0.690).", "tags": [{"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 31, "tag": "OrganismAttribute"}, {"end": 197, "start": 185, "tag": "ResearchActivity"}, {"end": 165, "start": 161, "tag": "OrganismAttribute"}, {"end": 110, "start": 97, "tag": "OrganismAttribute"}, {"end": 204, "start": 201, "tag": "HealthCareActivity"}, {"end": 212, "start": 209, "tag": "HealthCareActivity"}, {"end": 47, "start": 31, "tag": "ClinicalAttribute"}]}
{"id": "1422_10", "text": "Objective gait variability parameters correlated with disease stage based upon TFC.", "tags": [{"end": 67, "start": 54, "tag": "ClinicalAttribute"}, {"end": 67, "start": 54, "tag": "TemporalConcept"}, {"end": 14, "start": 10, "tag": "OrganismAttribute"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 26, "start": 10, "tag": "ClinicalAttribute"}]}
{"id": "1422_11", "text": "Conclusions Sensor-based gait variability parameters were identified as clinically most relevant digital biomarker for gait impairment in HD.", "tags": [{"end": 134, "start": 119, "tag": "Finding"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 25, "tag": "OrganismAttribute"}, {"end": 123, "start": 119, "tag": "OrganismAttribute"}, {"end": 114, "start": 97, "tag": "ClinicalAttribute"}, {"end": 41, "start": 25, "tag": "ClinicalAttribute"}]}
{"id": "1422_12", "text": "Altered gait variability represents characteristic irregularity of gait in HD and reflects disease severity.", "tags": [{"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 91, "tag": "ClinicalAttribute"}, {"end": 12, "start": 8, "tag": "OrganismAttribute"}, {"end": 71, "start": 67, "tag": "OrganismAttribute"}, {"end": 71, "start": 51, "tag": "Finding"}, {"end": 24, "start": 8, "tag": "ClinicalAttribute"}]}
{"id": "1423_0", "text": "Background: Fatigue is the major cause of disability in MS.", "tags": [{"end": 19, "start": 12, "tag": "SignOrSymptom"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 42, "tag": "Finding"}]}
{"id": "1423_1", "text": "Fatigue has been suggested to be primary, part of the neurological disease; it can also be secondary to other diseases outside the CNS or exist as a separate comorbidity.", "tags": [{"end": 7, "start": 0, "tag": "SignOrSymptom"}, {"end": 169, "start": 158, "tag": "Finding"}, {"end": 74, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1423_2", "text": "The only forms of measurement currently available are through subjective standardized questionnaires, which are not able to identify primary MS-related fatigue.", "tags": [{"end": 100, "start": 62, "tag": "HealthCareActivity"}, {"end": 159, "start": 152, "tag": "SignOrSymptom"}, {"end": 143, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 18, "tag": "ResearchActivity"}, {"end": 29, "start": 18, "tag": "HealthCareActivity"}, {"end": 39, "start": 30, "tag": "TemporalConcept"}]}
{"id": "1423_3", "text": "Therefore, there is a need for objective biomarkers of fatigue in MS.", "tags": [{"end": 62, "start": 55, "tag": "SignOrSymptom"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "ClinicalAttribute"}]}
{"id": "1423_4", "text": "This study explored the viability of 17 possible biomarkers of primary fatigue in MS.", "tags": [{"end": 33, "start": 24, "tag": "CellFunction"}, {"end": 78, "start": 63, "tag": "SignOrSymptom"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 49, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}
{"id": "1423_5", "text": "Our chosen biomarker panel represents the function and health of different parts of the CNS.", "tags": [{"end": 50, "start": 42, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 11, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}, {"end": 26, "start": 11, "tag": "ResearchActivity"}]}
{"id": "1423_6", "text": "Methods: We evaluated 31 MS patients and 17 healthy controls using the Fatigue Severity Scale (FSS) and Insomnia Severity Index (ISI).", "tags": [{"end": 127, "start": 104, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareActivity"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 44, "tag": "OrganismAttribute"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 93, "start": 71, "tag": "HealthCareActivity"}, {"end": 98, "start": 95, "tag": "HealthCareActivity"}]}
{"id": "1423_7", "text": "We assessed clinical parameters and collected CSF from all participants to analyze 17 biomarkers, some of which in multiple targeted sequences, reflecting structural and functional changes in the brain.", "tags": [{"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 196, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 59, "tag": "PopulationGroup"}, {"end": 96, "start": 86, "tag": "ClinicalAttribute"}, {"end": 31, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1423_8", "text": "Based on FSS scores, MS was divided into MS-Fatigue (MS-F, FSS >= 4) and MS-NoFatigue (MS-NoF, FSS < 4).", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 13, "tag": "Finding"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}]}
{"id": "1423_9", "text": "Results: MS-F had significantly lower levels of amyloid precursor protein (APP) peptides than MS-NoF (p = 0.005, p = 0.011).", "tags": [{"end": 88, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "GeneOrGenome"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1423_10", "text": "The only biomarker correlating with FSS in any group was APP in MS (r = -0.47, -0.52; p = 0.007, 0.002).", "tags": [{"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 9, "tag": "ClinicalAttribute"}, {"end": 52, "start": 47, "tag": "PopulationGroup"}, {"end": 39, "start": 36, "tag": "HealthCareActivity"}]}
{"id": "1423_11", "text": "APP did not correlate with any clinical parameter in MS but correlated with multiple markers.", "tags": [{"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 85, "tag": "ClinicalAttribute"}, {"end": 49, "start": 31, "tag": "ClinicalAttribute"}]}
{"id": "1423_12", "text": "In MS, FSS correlated with the ISI and months since diagnosis.", "tags": [{"end": 34, "start": 31, "tag": "HealthCareActivity"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "HealthCareActivity"}, {"end": 45, "start": 39, "tag": "TemporalConcept"}, {"end": 10, "start": 7, "tag": "HealthCareActivity"}]}
{"id": "1423_13", "text": "Conclusion: Although the mechanisms remain unknown, altered APP metabolism in MS seems to be associated with fatigue.", "tags": [{"end": 116, "start": 109, "tag": "SignOrSymptom"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "GeneOrGenome"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "BiologicFunction"}, {"end": 74, "start": 64, "tag": "CellFunction"}]}
{"id": "1423_14", "text": "APP should be evaluated as a biomarker of the role of structural MS pathology in the development of fatigue in individual MS patients.", "tags": [{"end": 107, "start": 100, "tag": "SignOrSymptom"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 121, "start": 111, "tag": "PopulationGroup"}]}
{"id": "1424_0", "text": "Alzheimer's disease (AD) is the most common fatal neurodegenerative disease of the elderly worldwide.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 83, "tag": "PopulationGroup"}]}
{"id": "1424_1", "text": "The identification of AD biomarkers will allow for earlier diagnosis and thus earlier intervention.", "tags": [{"end": 68, "start": 59, "tag": "HealthCareActivity"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 51, "tag": "TemporalConcept"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}]}
{"id": "1424_2", "text": "The aim of this study was to find such biomarkers.", "tags": [{"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}]}
{"id": "1424_3", "text": "It was observed that the expression of Alix was significantly decreased in brain tissues and serum samples from AD patients compared to the controls.", "tags": [{"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 88, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 140, "tag": "PopulationGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 98, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1424_4", "text": "A significant correlation between Alix levels and cognitive decline was observed (r = 0.80; p < 0.001) as well as a significant negative correlation between Alix and A beta(40) in serum levels (r =-0.60, p < 0.001).", "tags": [{"end": 38, "start": 34, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "GeneOrGenome"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1424_5", "text": "The receiver operating characteristic curve (ROC) analysis showed the area under the curve (AUC) of Alix was 0.80, and the optimal cut-off point of 199.5 pg/ml was selected with the highest sum of sensitivity and specificity.", "tags": [{"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 208, "start": 197, "tag": "Finding"}, {"end": 224, "start": 213, "tag": "Finding"}, {"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 43, "start": 4, "tag": "ResearchActivity"}, {"end": 90, "start": 70, "tag": "ResearchActivity"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1424_6", "text": "The diagnostic accuracy for serum Alix was 74%, with 76% sensitivity and 71% specificity respectively, which could differentiate AD from controls.", "tags": [{"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 34, "tag": "GeneOrGenome"}, {"end": 68, "start": 57, "tag": "Finding"}, {"end": 88, "start": 77, "tag": "Finding"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 137, "tag": "PopulationGroup"}, {"end": 38, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1424_7", "text": "In addition, the expression of Alix was found to be significantly decreased in AD compared to vascular dementia (VaD).", "tags": [{"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1424_8", "text": "ROC analysis between AD and VaD showed that the AUC was 0.777, which could be indicative of the role of serum Alix as a biomarker in the differential diagnosis between AD and VaD.", "tags": [{"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 110, "tag": "GeneOrGenome"}, {"end": 159, "start": 150, "tag": "HealthCareActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "ResearchActivity"}, {"end": 159, "start": 137, "tag": "HealthCareActivity"}, {"end": 129, "start": 120, "tag": "ClinicalAttribute"}, {"end": 114, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 175, "tag": "DiseaseOrSyndrome"}]}
{"id": "1424_9", "text": "Most surprisingly, the decreased expression of Alix was attenuated after the treatment of Memantine in different AD animal models.", "tags": [{"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 99, "start": 90, "tag": "Chemical"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "HealthCareActivity"}, {"end": 86, "start": 77, "tag": "ResearchActivity"}, {"end": 129, "start": 116, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "PharmacologicSubstance"}]}
{"id": "1424_10", "text": "In conclusion, our results indicate the possibility of serum Alix as a novel and non-invasive biomarker for AD for the first time.", "tags": [{"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 61, "tag": "GeneOrGenome"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 119, "tag": "TemporalConcept"}, {"end": 103, "start": 81, "tag": "ClinicalAttribute"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 94, "tag": "ClinicalAttribute"}, {"end": 76, "start": 71, "tag": "ClinicalAttribute"}]}
{"id": "1425_0", "text": "Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinical to mild cognitive impairment until dementia is driven by interacting genetic/biological mechanisms not fully captured by current clinical/research criteria.", "tags": [{"end": 85, "start": 76, "tag": "BiologicFunction"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 224, "tag": "TemporalConcept"}, {"end": 131, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 241, "tag": "ResearchActivity"}, {"end": 39, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 39, "start": 25, "tag": "PathologicFunction"}]}
{"id": "1425_1", "text": "We characterized the heterogeneous construct of AD through a cerebrospinal fluid biomarker-guided stratification approach.", "tags": [{"end": 80, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 121, "start": 98, "tag": "ResearchActivity"}]}
{"id": "1425_2", "text": "We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (A beta(1-42), t-tau, -p-tau(181), NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 +/- 10.4, 70.4 +/- 7.7, 71.7 +/- 8.4, 76.2 +/- 3.5 years [mean +/- SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters.", "tags": [{"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 275, "start": 272, "tag": "OrganismAttribute"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "ClinicalAttribute"}, {"end": 338, "start": 333, "tag": "TemporalConcept"}, {"end": 81, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 143, "tag": "OrganismAttribute"}, {"end": 141, "start": 129, "tag": "PopulationGroup"}, {"end": 235, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 24, "tag": "PathologicFunction"}, {"end": 159, "start": 143, "tag": "PopulationGroup"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 433, "start": 374, "tag": "MachineActivity"}]}
{"id": "1425_3", "text": "We found 5 distinct clusters (sizes: N = 38, 16, 24, 14, and 21) whose composition was independent of phenotypical groups.", "tags": []}
{"id": "1425_4", "text": "Two clusters showed biomarker profiles linked to neurodegenerative processes not associated with classical AD-related pathophysiology.", "tags": [{"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 118, "tag": "PathologicFunction"}, {"end": 133, "start": 118, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}]}
{"id": "1425_5", "text": "One cluster was characterized by the neuroinflammation biomarker YKL-40.", "tags": [{"end": 71, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 37, "tag": "PathologicFunction"}, {"end": 64, "start": 55, "tag": "ClinicalAttribute"}]}
{"id": "1425_6", "text": "Combining nonlinear data aggregation with informative biomarkers can generate novel patient strata which are representative of cellular/molecular pathophysiology and may aid in predicting disease evolution and mechanistic drug response.", "tags": [{"end": 205, "start": 196, "tag": "BiologicFunction"}, {"end": 36, "start": 10, "tag": "ResearchActivity"}, {"end": 91, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 161, "start": 146, "tag": "PathologicFunction"}, {"end": 226, "start": 222, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 205, "start": 188, "tag": "Finding"}, {"end": 235, "start": 222, "tag": "BiologicFunction"}]}
{"id": "1425_7", "text": "(C) 2019 The Authors.", "tags": []}
{"id": "1425_8", "text": "Published by Elsevier Inc.", "tags": []}
{"id": "1426_0", "text": "Johansson et al.", "tags": []}
{"id": "1426_1", "text": "describe plasma biomarkers in a longitudinal Swedish cohort of patients with monogenic Alzheimer's disease.", "tags": [{"end": 106, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 63, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 53, "tag": "PopulationGroup"}]}
{"id": "1426_2", "text": "Plasma GFAP began to increase 10 years before symptom onset, prior to P-tau181 and NfL, suggesting that GFAP is mirroring Alzheimer's disease pathology upstream of tau phosphorylation and neurodegeneration.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "TemporalConcept"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "GeneOrGenome"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 167, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "TemporalConcept"}, {"end": 205, "start": 188, "tag": "CellOrMolecularDysfunction"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 134, "tag": "PathologicFunction"}, {"end": 59, "start": 46, "tag": "TemporalConcept"}, {"end": 53, "start": 46, "tag": "SignOrSymptom"}, {"end": 167, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 70, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1426_3", "text": "Emerging plasma biomarkers of Alzheimer's disease might be non-invasive tools to trace early Alzheimer's disease-related abnormalities such as the accumulation of amyloid-beta peptides, neurofibrillary tau tangles, glial activation and neurodegeneration.", "tags": [{"end": 213, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 201, "start": 186, "tag": "CellComponent"}, {"end": 231, "start": 215, "tag": "CellFunction"}, {"end": 71, "start": 59, "tag": "ClinicalAttribute"}, {"end": 220, "start": 215, "tag": "Cell"}, {"end": 71, "start": 63, "tag": "Finding"}, {"end": 184, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 236, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 147, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1426_4", "text": "It is, however, unclear which pathological processes in the CNS can be adequately detected by peripheral measurements and whether plasma biomarkers are equally applicable in both clinical and preclinical phases.", "tags": [{"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 30, "tag": "PathologicFunction"}, {"end": 147, "start": 137, "tag": "ClinicalAttribute"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1426_5", "text": "Here we aimed to explore the timing and performance of plasma biomarkers in mutation carriers compared to non-carriers in autosomal dominant Alzheimer's disease.", "tags": [{"end": 35, "start": 29, "tag": "TemporalConcept"}, {"end": 93, "start": 85, "tag": "PopulationGroup"}, {"end": 140, "start": 132, "tag": "CellFunction"}, {"end": 51, "start": 40, "tag": "Finding"}, {"end": 152, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 106, "tag": "PopulationGroup"}]}
{"id": "1426_6", "text": "Samples (n = 164) from mutation carriers (n = 33) and non-carriers (n = 42) in a Swedish cohort of autosomal dominant Alzheimer's disease (APP p.KM670/671NL, APP p.E693G and PSEN1 p.H163Y) were included in explorative longitudinal analyses.", "tags": [{"end": 40, "start": 32, "tag": "PopulationGroup"}, {"end": 88, "start": 81, "tag": "PopulationGroup"}, {"end": 117, "start": 99, "tag": "CellFunction"}, {"end": 142, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 139, "tag": "GeneOrGenome"}, {"end": 161, "start": 158, "tag": "GeneOrGenome"}, {"end": 142, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 109, "tag": "CellFunction"}, {"end": 179, "start": 174, "tag": "GeneOrGenome"}, {"end": 179, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 239, "start": 206, "tag": "ResearchActivity"}, {"end": 31, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 66, "start": 54, "tag": "PopulationGroup"}]}
{"id": "1426_7", "text": "Plasma phosphorylated tau (P-tau181), total tau (T-tau), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) concentrations were measured with a single-molecule array method as previously described.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 168, "tag": "ResearchActivity"}, {"end": 21, "start": 7, "tag": "CellFunction"}, {"end": 124, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 93, "tag": "GeneOrGenome"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "GeneOrGenome"}, {"end": 196, "start": 190, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "Cell"}, {"end": 196, "start": 190, "tag": "HealthCareActivity"}, {"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 27, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1426_8", "text": "Plasma biomarkers were additionally correlated to Alzheimer's disease core biomarkers in the CSF.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 7, "tag": "ClinicalAttribute"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1426_9", "text": "Results from the longitudinal analyses confirmed that plasma P-tau181, NfL and GFAP concentrations were higher in mutation carriers compared to non-carriers.", "tags": [{"end": 131, "start": 123, "tag": "PopulationGroup"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 60, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 38, "start": 17, "tag": "ResearchActivity"}, {"end": 122, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 69, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 144, "tag": "PopulationGroup"}]}
{"id": "1426_10", "text": "This change was observed in the presymptomatic phase and detectable first as an increase in GFAP approximately 10 years before estimated symptom onset, followed by increased levels of P-tau181 and NfL closer to expected onset.", "tags": [{"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 180, "start": 164, "tag": "Finding"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 200, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 220, "tag": "TemporalConcept"}, {"end": 52, "start": 47, "tag": "TemporalConcept"}, {"end": 150, "start": 137, "tag": "TemporalConcept"}, {"end": 144, "start": 137, "tag": "SignOrSymptom"}, {"end": 192, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 184, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1426_11", "text": "Plasma P-tau181 levels were correlated to levels of P-tau181 and T-tau in the CSF.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 52, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1426_12", "text": "Altogether, plasma P-tau181, GFAP and NfL seem to be feasible biomarkers to detect different Alzheimer's disease-related pathologies already in presymptomatic individuals.", "tags": [{"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 29, "tag": "GeneOrGenome"}, {"end": 132, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}, {"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 144, "tag": "PopulationGroup"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 19, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1426_13", "text": "Interestingly, changes in plasma GFAP concentrations were detected prior to P-tau181 and NfL.", "tags": [{"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 76, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1426_14", "text": "Our results suggest that plasma GFAP might reflect Alzheimer's disease pathology upstream to accumulation of tangles and neurodegeneration.", "tags": [{"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 116, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 70, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 63, "tag": "PathologicFunction"}]}
{"id": "1426_15", "text": "The implications of these findings need additional validation, in particular because of the limited sample size.", "tags": [{"end": 61, "start": 51, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "OrganismAttribute"}]}
{"id": "1427_0", "text": "Introduction: We developed the Alzheimer's Biomarker Survey to assess willingness to enroll in biomarker studies that disclose results and anticipated reactions to an elevated biomarker result.", "tags": [{"end": 192, "start": 186, "tag": "Finding"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "ClinicalAttribute"}, {"end": 185, "start": 176, "tag": "ClinicalAttribute"}, {"end": 59, "start": 31, "tag": "HealthCareActivity"}]}
{"id": "1427_1", "text": "Methods: Participants included cognitively unimpaired adults enrolled in longitudinal AD studies (n = 334, mean age = 64.8 +/- 7.7, 44% non-Hispanic Black or African American).", "tags": [{"end": 174, "start": 136, "tag": "PopulationGroup"}, {"end": 115, "start": 112, "tag": "OrganismAttribute"}, {"end": 96, "start": 89, "tag": "ResearchActivity"}, {"end": 85, "start": 73, "tag": "ResearchActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 54, "tag": "PopulationGroup"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}]}
{"id": "1427_2", "text": "Exploratory and confirmatory factor analyses determined the latent structure comprising anticipated reactions to learning AD biomarker results.", "tags": [{"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 125, "tag": "ClinicalAttribute"}, {"end": 121, "start": 113, "tag": "BiologicFunction"}]}
{"id": "1427_3", "text": "Measurement invariance was tested across racial groups.", "tags": [{"end": 54, "start": 41, "tag": "PopulationGroup"}]}
{"id": "1427_4", "text": "Results: Two models comprising behavior change and psychological impact fit well for the total sample and the two racial groups.", "tags": [{"end": 46, "start": 31, "tag": "Finding"}, {"end": 71, "start": 51, "tag": "Finding"}, {"end": 39, "start": 31, "tag": "BiologicFunction"}, {"end": 39, "start": 31, "tag": "IndividualBehavior"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 127, "start": 114, "tag": "PopulationGroup"}, {"end": 101, "start": 95, "tag": "Substance"}, {"end": 101, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1427_5", "text": "The 2-factor behavior change model assessed constructs of planning and dementia risk-reduction.", "tags": [{"end": 66, "start": 58, "tag": "BiologicFunction"}, {"end": 21, "start": 13, "tag": "BiologicFunction"}, {"end": 21, "start": 13, "tag": "IndividualBehavior"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 94, "start": 71, "tag": "Finding"}, {"end": 79, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1427_6", "text": "The 3-factor psychological impact model assessed constructs of distress, cognitive symptoms, and stigma.", "tags": [{"end": 71, "start": 63, "tag": "BiologicFunction"}, {"end": 103, "start": 97, "tag": "Finding"}, {"end": 91, "start": 73, "tag": "SignOrSymptom"}, {"end": 39, "start": 4, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "CellComponent"}]}
{"id": "1427_7", "text": "Both models exhibited measurement invariance across racial groups.", "tags": [{"end": 33, "start": 22, "tag": "ResearchActivity"}, {"end": 33, "start": 22, "tag": "HealthCareActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 65, "start": 52, "tag": "PopulationGroup"}]}
{"id": "1427_8", "text": "Discussion: The 28-item Anticipated Reactions to AD Biomarker Disclosure scale is a reliable and valid measure of anticipated reactions when communicating AD biomarker results to research participants.", "tags": [{"end": 61, "start": 52, "tag": "ClinicalAttribute"}, {"end": 187, "start": 179, "tag": "ResearchActivity"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 200, "start": 188, "tag": "PopulationGroup"}, {"end": 78, "start": 49, "tag": "HealthCareActivity"}]}
{"id": "1428_0", "text": "Background Alzheimer disease (AD) is the most common cause of dementia.", "tags": [{"end": 28, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "DiseaseOrSyndrome"}]}
{"id": "1428_1", "text": "Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest.", "tags": [{"end": 99, "start": 81, "tag": "SignOrSymptom"}, {"end": 28, "start": 22, "tag": "TemporalConcept"}, {"end": 14, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 51, "tag": "Finding"}]}
{"id": "1428_2", "text": "The presence of AD brain changes can be ascertained by molecular biomarkers obtained via imaging and lumbar puncture.", "tags": [{"end": 75, "start": 55, "tag": "ClinicalAttribute"}, {"end": 75, "start": 65, "tag": "ClinicalAttribute"}, {"end": 18, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "HealthCareActivity"}, {"end": 96, "start": 89, "tag": "HealthCareActivity"}, {"end": 32, "start": 19, "tag": "Finding"}]}
{"id": "1428_3", "text": "However, the use of these methods is limited by cost, acceptability, and availability.", "tags": []}
{"id": "1428_4", "text": "The preclinical stage of AD may have a subtle functional signature, which can impact complex behaviours such as driving.", "tags": [{"end": 103, "start": 93, "tag": "IndividualBehavior"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 4, "tag": "TemporalConcept"}, {"end": 119, "start": 112, "tag": "IndividualBehavior"}]}
{"id": "1428_5", "text": "The objective of the present study was to evaluate the ability of in-vehicle GPS data loggers to distinguish cognitively normal older drivers with preclinical AD from those without preclinical AD using machine learning methods.", "tags": [{"end": 141, "start": 134, "tag": "PopulationGroup"}, {"end": 127, "start": 121, "tag": "Finding"}, {"end": 218, "start": 202, "tag": "MachineActivity"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 161, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 66, "tag": "ManufacturedObject"}, {"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 62, "start": 55, "tag": "OrganismAttribute"}, {"end": 218, "start": 210, "tag": "BiologicFunction"}]}
{"id": "1428_6", "text": "Methods We followed naturalistic driving in cognitively normal older drivers for 1 year with a commercial in-vehicle GPS data logger.", "tags": [{"end": 62, "start": 56, "tag": "Finding"}, {"end": 68, "start": 63, "tag": "TemporalConcept"}, {"end": 87, "start": 83, "tag": "TemporalConcept"}, {"end": 76, "start": 69, "tag": "PopulationGroup"}, {"end": 132, "start": 106, "tag": "ManufacturedObject"}, {"end": 40, "start": 33, "tag": "IndividualBehavior"}]}
{"id": "1428_7", "text": "The cohort included n = 64 individuals with and n = 75 without preclinical AD, as determined by cerebrospinal fluid biomarkers.", "tags": [{"end": 126, "start": 116, "tag": "ClinicalAttribute"}, {"end": 77, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 115, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 27, "tag": "PopulationGroup"}]}
{"id": "1428_8", "text": "Four Random Forest (RF) models were trained to detect preclinical AD.", "tags": [{"end": 68, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 5, "tag": "ResearchActivity"}]}
{"id": "1428_9", "text": "RF Gini index was used to identify the strongest predictors of preclinical AD.", "tags": [{"end": 77, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 49, "tag": "Finding"}, {"end": 13, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1428_10", "text": "Results The F1 score of the RF models for identifying preclinical AD was 0.85 using APOE epsilon 4 status and age only, 0.82 using GPS-based driving indicators only, 0.88 using age and driving indicators, and 0.91 using age, APOE epsilon 4 status, and driving.", "tags": [{"end": 98, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 99, "tag": "Finding"}, {"end": 239, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 240, "tag": "Finding"}, {"end": 113, "start": 110, "tag": "OrganismAttribute"}, {"end": 180, "start": 177, "tag": "OrganismAttribute"}, {"end": 223, "start": 220, "tag": "OrganismAttribute"}, {"end": 68, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 37, "start": 28, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 259, "start": 252, "tag": "IndividualBehavior"}, {"end": 159, "start": 131, "tag": "ResearchActivity"}, {"end": 203, "start": 185, "tag": "ResearchActivity"}, {"end": 192, "start": 185, "tag": "IndividualBehavior"}, {"end": 148, "start": 141, "tag": "IndividualBehavior"}]}
{"id": "1428_11", "text": "The area under the receiver operating curve for the final model was 0.96.", "tags": [{"end": 63, "start": 58, "tag": "ResearchActivity"}, {"end": 43, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1428_12", "text": "Conclusion The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.", "tags": [{"end": 136, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "ClinicalAttribute"}, {"end": 148, "start": 143, "tag": "TemporalConcept"}, {"end": 155, "start": 149, "tag": "PopulationGroup"}, {"end": 105, "start": 88, "tag": "ClinicalAttribute"}, {"end": 40, "start": 37, "tag": "ManufacturedObject"}, {"end": 48, "start": 41, "tag": "IndividualBehavior"}]}
{"id": "1429_0", "text": "BackgroundCognitive decline has been reported in premanifest and manifest Huntington's disease but reliable biomarkers are lacking.", "tags": [{"end": 94, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 65, "tag": "SignOrSymptom"}, {"end": 118, "start": 108, "tag": "ClinicalAttribute"}, {"end": 27, "start": 10, "tag": "DiseaseOrSyndrome"}]}
{"id": "1429_1", "text": "Inner retinal layer thickness seems to be a good biomarker of cognition in other neurodegenerative diseases.ObjectiveTo explore the relationship between optical coherence tomography-derived metrics and global cognition in Huntington's Disease.MethodsThirty-six patients with Huntington's disease (16 premanifest and 20 manifest) and 36 controls matched by age, sex, smoking status, and hypertension status underwent macular volumetric and peripapillary optical coherence tomography scans.", "tags": [{"end": 398, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 487, "start": 453, "tag": "HealthCareActivity"}, {"end": 242, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 295, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 153, "tag": "HealthCareActivity"}, {"end": 481, "start": 453, "tag": "HealthCareActivity"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 364, "start": 361, "tag": "OrganismAttribute"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 319, "tag": "SignOrSymptom"}, {"end": 58, "start": 49, "tag": "ClinicalAttribute"}, {"end": 344, "start": 336, "tag": "PopulationGroup"}, {"end": 269, "start": 261, "tag": "PatientOrDisabledGroup"}, {"end": 487, "start": 482, "tag": "HealthCareActivity"}, {"end": 359, "start": 356, "tag": "OrganismAttribute"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 218, "start": 209, "tag": "BiologicFunction"}, {"end": 144, "start": 132, "tag": "Finding"}, {"end": 380, "start": 374, "tag": "Finding"}, {"end": 405, "start": 399, "tag": "Finding"}, {"end": 434, "start": 424, "tag": "HealthCareActivity"}, {"end": 29, "start": 0, "tag": "ClinicalAttribute"}, {"end": 373, "start": 366, "tag": "IndividualBehavior"}, {"end": 423, "start": 416, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 452, "start": 439, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1429_2", "text": "Disease duration, motor status, global cognition and CAG repeats were recorded in patients.", "tags": [{"end": 16, "start": 0, "tag": "TemporalConcept"}, {"end": 64, "start": 53, "tag": "MolecularSequence"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 39, "tag": "BiologicFunction"}, {"end": 30, "start": 24, "tag": "Finding"}]}
{"id": "1429_3", "text": "Group differences in imaging parameters and their association with clinical outcomes were analyzed using linear mixed-effect models.ResultsPremanifest and manifest Huntington's disease patients presented thinner retinal external limiting membrane-Bruch's membrane complex, and manifest patients had thinner temporal peripapillary retinal nerve fiber layer compared to controls.", "tags": [{"end": 5, "start": 0, "tag": "PopulationGroup"}, {"end": 84, "start": 67, "tag": "ClinicalAttribute"}, {"end": 184, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 355, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 246, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 376, "start": 368, "tag": "PopulationGroup"}, {"end": 193, "start": 185, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 155, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 6, "tag": "Finding"}, {"end": 131, "start": 105, "tag": "ResearchActivity"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}, {"end": 271, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 294, "start": 277, "tag": "PatientOrDisabledGroup"}]}
{"id": "1429_4", "text": "In manifest Huntington's disease, macular thickness was significantly associated with MoCA scores, inner nuclear layer showing the largest regression coefficients.", "tags": [{"end": 118, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 86, "tag": "HealthCareActivity"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 34, "tag": "ClinicalAttribute"}, {"end": 51, "start": 34, "tag": "SignOrSymptom"}, {"end": 51, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 3, "tag": "SignOrSymptom"}, {"end": 97, "start": 91, "tag": "Finding"}, {"end": 162, "start": 139, "tag": "ResearchActivity"}]}
{"id": "1429_5", "text": "This relationship was consistent after adjusting for age, sex, and education and p-value correction with False Discovery Rate.", "tags": [{"end": 125, "start": 105, "tag": "Finding"}, {"end": 61, "start": 58, "tag": "OrganismAttribute"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 17, "start": 5, "tag": "Finding"}, {"end": 76, "start": 67, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 99, "start": 81, "tag": "ResearchActivity"}]}
{"id": "1429_6", "text": "None of the retinal variables were related to Unified Huntington's Disease Rating Scale score, disease duration, or disease burden.", "tags": [{"end": 130, "start": 116, "tag": "ResearchActivity"}, {"end": 111, "start": 95, "tag": "HealthCareActivity"}, {"end": 111, "start": 95, "tag": "TemporalConcept"}, {"end": 87, "start": 46, "tag": "HealthCareActivity"}, {"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 88, "tag": "Finding"}]}
{"id": "1429_7", "text": "Premanifest patients did not show a significant association between OCT-derived parameters and clinical outcomes in corrected models.ConclusionsIn line with other neurodegenerative diseases, OCT is a potential biomarker of cognitive status in manifest HD.", "tags": [{"end": 59, "start": 36, "tag": "Finding"}, {"end": 112, "start": 95, "tag": "ClinicalAttribute"}, {"end": 71, "start": 68, "tag": "HealthCareActivity"}, {"end": 194, "start": 191, "tag": "HealthCareActivity"}, {"end": 239, "start": 223, "tag": "BiologicFunction"}, {"end": 189, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 243, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 126, "tag": "ResearchActivity"}, {"end": 219, "start": 200, "tag": "ClinicalAttribute"}]}
{"id": "1429_8", "text": "Future prospective studies are needed to evaluate OCT as a potential surrogate marker of cognitive decline in HD.", "tags": [{"end": 26, "start": 7, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "HealthCareActivity"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 89, "tag": "DiseaseOrSyndrome"}]}
{"id": "1430_0", "text": "Multiple sclerosis (MS) and glioblastoma (GBM) are two distinct diseases that affect the central nervous system (CNS).", "tags": [{"end": 40, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1430_1", "text": "However, perturbation in CNS vasculature are hallmarks of both diseases.", "tags": [{"end": 40, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 45, "tag": "Finding"}]}
{"id": "1430_2", "text": "ELTD1 (epidermal growth factor, latrophilin, and 7 transmembrane domain containing protein 1 on chromosome 1) is associated with vascular development, and has been linked with tumor angiogenesis.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 32, "tag": "GeneOrGenome"}, {"end": 71, "start": 51, "tag": "MolecularSequence"}, {"end": 194, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 129, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "CellFunction"}, {"end": 137, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 7, "tag": "PharmacologicSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 7, "tag": "GeneOrGenome"}]}
{"id": "1430_3", "text": "In glioblastomas, we detected overexpression of ELTD1, and found that an antibody targeting ELTD1 could increase animal survival and decrease tumor volumes in a xenograft GBM model.", "tags": [{"end": 16, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 30, "tag": "CellFunction"}, {"end": 44, "start": 30, "tag": "Finding"}, {"end": 44, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 81, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 92, "tag": "GeneOrGenome"}, {"end": 147, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "HealthCareActivity"}, {"end": 174, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 120, "tag": "CellFunction"}, {"end": 180, "start": 175, "tag": "ResearchActivity"}, {"end": 119, "start": 113, "tag": "Eukaryote"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 142, "tag": "ClinicalAttribute"}]}
{"id": "1430_4", "text": "RNA-seq analysis of the preclinical data in the model for GBM identified that some of the molecular pathways affected by the anti-ELTD1 antibody therapy are also found to be associated with MS.", "tags": [{"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 24, "tag": "ResearchActivity"}, {"end": 108, "start": 90, "tag": "CellFunction"}, {"end": 108, "start": 100, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 36, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 145, "tag": "HealthCareActivity"}, {"end": 144, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 125, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1430_5", "text": "In this study, we used molecular-targeted (mt) MR imaging and immunohistochemistry to assess ELTD1 levels in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.", "tags": [{"end": 98, "start": 93, "tag": "GeneOrGenome"}, {"end": 82, "start": 62, "tag": "ResearchActivity"}, {"end": 150, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 155, "start": 152, "tag": "ExperimentalModelOfDisease"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 171, "start": 166, "tag": "ResearchActivity"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 50, "tag": "HealthCareActivity"}, {"end": 177, "start": 160, "tag": "ExperimentalModelOfDisease"}, {"end": 57, "start": 23, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 93, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1430_6", "text": "Specifically, we found that ELTD1 is readily detected in the brains of mice with EAE and is predominantly found in the corpus callosum.", "tags": [{"end": 33, "start": 28, "tag": "GeneOrGenome"}, {"end": 134, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 81, "tag": "ExperimentalModelOfDisease"}, {"end": 75, "start": 71, "tag": "Eukaryote"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 71, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1430_7", "text": "In addition, we found that the blood-brain barrier (BBB) was compromised in the brains of EAE mice using contrast-enhanced MRI (CE-MRI), as well as altered relative cerebral blood flow (rCBF) in the brains and cervical spinal cords of these mice using perfusion imaging, compared to controls.", "tags": [{"end": 126, "start": 105, "tag": "HealthCareActivity"}, {"end": 134, "start": 128, "tag": "HealthCareActivity"}, {"end": 184, "start": 165, "tag": "BiologicFunction"}, {"end": 190, "start": 186, "tag": "HealthCareActivity"}, {"end": 231, "start": 210, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 252, "tag": "HealthCareActivity"}, {"end": 93, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 98, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 231, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 94, "tag": "Eukaryote"}, {"end": 245, "start": 241, "tag": "Eukaryote"}, {"end": 291, "start": 283, "tag": "PopulationGroup"}, {"end": 126, "start": 123, "tag": "HealthCareActivity"}, {"end": 134, "start": 131, "tag": "HealthCareActivity"}, {"end": 269, "start": 262, "tag": "HealthCareActivity"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 199, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 156, "tag": "HealthCareActivity"}]}
{"id": "1430_8", "text": "These findings indicate that ELTD1 may be a promising biomarker for CNS-inflammation in MS.", "tags": [{"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 54, "tag": "ClinicalAttribute"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "PathologicFunction"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1431_0", "text": "Background Juvenile-onset Huntington's disease (JOHD) is a rare and particularly devastating form of Huntington's disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking.", "tags": [{"end": 46, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 182, "tag": "Finding"}, {"end": 46, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 20, "tag": "TemporalConcept"}, {"end": 155, "start": 137, "tag": "HealthCareActivity"}, {"end": 63, "start": 59, "tag": "TemporalConcept"}]}
{"id": "1431_1", "text": "Neurofilament light protein (NfL) in plasma has emerged as a prognostic biomarker for adult-onset HD.", "tags": [{"end": 27, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 86, "tag": "Finding"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 81, "start": 61, "tag": "ClinicalAttribute"}, {"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "TemporalConcept"}]}
{"id": "1431_2", "text": "Methods We performed a retrospective analysis of samples and data collected between 2009 and 2020 from the Kids-HD and Kids-JHD studies.", "tags": [{"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 61, "tag": "ResearchActivity"}, {"end": 135, "start": 128, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "ResearchActivity"}, {"end": 45, "start": 23, "tag": "ResearchActivity"}, {"end": 56, "start": 49, "tag": "Substance"}, {"end": 56, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 119, "tag": "ResearchActivity"}]}
{"id": "1431_3", "text": "Plasma samples from children and young adults with JOHD, premanifest HD (preHD) mutation carriers, and age-matched controls were used to quantify plasma NfL concentrations using ultrasensitive immunoassay.", "tags": [{"end": 28, "start": 20, "tag": "PopulationGroup"}, {"end": 45, "start": 33, "tag": "PopulationGroup"}, {"end": 55, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 178, "tag": "ResearchActivity"}, {"end": 71, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 115, "tag": "PopulationGroup"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "OrganismAttribute"}, {"end": 97, "start": 89, "tag": "PopulationGroup"}, {"end": 14, "start": 7, "tag": "Substance"}, {"end": 14, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 146, "tag": "ClinicalAttribute"}, {"end": 78, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 80, "tag": "PopulationGroup"}]}
{"id": "1431_4", "text": "Results We report elevated plasma NfL concentrations in JOHD and premanifest HD mutation-carrying children.", "tags": [{"end": 60, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "PopulationGroup"}, {"end": 79, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 52, "start": 34, "tag": "ClinicalAttribute"}]}
{"id": "1431_5", "text": "In pediatric HD mutation carriers who were within 20 years of their predicted onset and patients with JOHD, plasma NfL level was associated with caudate and putamen volumes.", "tags": [{"end": 106, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 53, "tag": "TemporalConcept"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 33, "start": 25, "tag": "PopulationGroup"}, {"end": 33, "start": 16, "tag": "PopulationGroup"}, {"end": 124, "start": 108, "tag": "ClinicalAttribute"}, {"end": 172, "start": 157, "tag": "ClinicalAttribute"}, {"end": 172, "start": 165, "tag": "ClinicalAttribute"}, {"end": 152, "start": 145, "tag": "ClinicalAttribute"}]}
{"id": "1431_6", "text": "Conclusions Quantifying plasma NfL concentration may assist clinical diagnosis and therapeutic trial design in the pediatric population.", "tags": [{"end": 135, "start": 115, "tag": "PopulationGroup"}, {"end": 34, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 83, "tag": "ResearchActivity"}, {"end": 78, "start": 60, "tag": "HealthCareActivity"}, {"end": 48, "start": 24, "tag": "ClinicalAttribute"}]}
{"id": "1431_7", "text": "(c) 2022 The Authors.", "tags": []}
{"id": "1431_8", "text": "Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.", "tags": [{"end": 90, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 67, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1432_0", "text": "Study Objectives: To determine the effect of self-reported clinical diagnosis of obstructive sleep apnea (OSA) on longitudinal changes in brain amyloid PET and CSF biomarkers (A beta 42, T-tau, and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI), and Alzheimer's disease (AD) elderly.", "tags": [{"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 45, "tag": "ResearchActivity"}, {"end": 106, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 228, "tag": "Finding"}, {"end": 192, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 114, "tag": "Finding"}, {"end": 226, "start": 220, "tag": "Finding"}, {"end": 185, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 293, "start": 291, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 174, "start": 164, "tag": "ClinicalAttribute"}, {"end": 263, "start": 260, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 208, "tag": "Finding"}, {"end": 302, "start": 295, "tag": "PopulationGroup"}, {"end": 155, "start": 152, "tag": "HealthCareActivity"}, {"end": 258, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 59, "tag": "HealthCareActivity"}]}
{"id": "1432_1", "text": "Methods: Longitudinal study with mean follow-up time of 2.52 +/- 0.51 years.", "tags": [{"end": 27, "start": 9, "tag": "ResearchActivity"}, {"end": 52, "start": 48, "tag": "TemporalConcept"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "TemporalConcept"}, {"end": 75, "start": 70, "tag": "TemporalConcept"}]}
{"id": "1432_2", "text": "Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.", "tags": [{"end": 87, "start": 79, "tag": "ResearchActivity"}, {"end": 71, "start": 28, "tag": "ResearchActivity"}, {"end": 71, "start": 28, "tag": "HealthCareRelatedOrganization"}, {"end": 77, "start": 73, "tag": "HealthCareRelatedOrganization"}, {"end": 77, "start": 73, "tag": "ResearchActivity"}, {"end": 47, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1432_3", "text": "Participants included 516 NL, 798 MCI, and 325 AD elderly.", "tags": [{"end": 28, "start": 26, "tag": "Finding"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 57, "start": 50, "tag": "PopulationGroup"}]}
{"id": "1432_4", "text": "Main outcomes were annual rate of change in brain amyloid burden (i.e.", "tags": [{"end": 30, "start": 26, "tag": "TemporalConcept"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}]}
{"id": "1432_5", "text": "longitudinal increases in florbetapir PET uptake or decreases in CSF A beta 42 levels); and tau protein aggregation (i.e.", "tags": [{"end": 37, "start": 26, "tag": "Chemical"}, {"end": 61, "start": 52, "tag": "Finding"}, {"end": 78, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 48, "start": 42, "tag": "BiologicFunction"}, {"end": 48, "start": 42, "tag": "CellFunction"}, {"end": 85, "start": 65, "tag": "ClinicalAttribute"}, {"end": 115, "start": 92, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1432_6", "text": "longitudinal increases in CSF total tau [T-tau] and phosphorylated tau [P-tau]).", "tags": [{"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 52, "tag": "CellFunction"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 26, "tag": "ClinicalAttribute"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1432_7", "text": "Adjusted multilevel mixed effects linear regression models with randomly varying intercepts and slopes was used to test whether the rate of biomarker change differed between participants with and without OSA.", "tags": [{"end": 207, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 132, "tag": "TemporalConcept"}, {"end": 58, "start": 0, "tag": "ResearchActivity"}, {"end": 149, "start": 140, "tag": "ClinicalAttribute"}, {"end": 186, "start": 174, "tag": "PopulationGroup"}, {"end": 119, "start": 115, "tag": "ResearchActivity"}, {"end": 119, "start": 115, "tag": "HealthCareActivity"}, {"end": 156, "start": 150, "tag": "Finding"}]}
{"id": "1432_8", "text": "Results: In NL and MCI groups, OSA+ subjects experienced faster annual increase in florbetapir uptake (B =.06, 95% CI =.02,.11 and B =.08, 95% CI =.05, .12, respectively) and decrease in CSF A beta 42 levels (B = -2.71, 95% CI = -3.11, -2.35 and B = -2.62, 95% CI = -3.23, -2.03, respectively); as well as increases in CSF T-tau (B = 3.68, 95% CI = 3.31, 4.07 and B = 2.21, 95% CI = 1.58, 2.86, respectively) and P-tau (B = 1.221, 95% CI = 1.02, 1.42 and B = 1.74, 95% CI = 1.22, 2.27, respectively); compared with OSA- participants.", "tags": [{"end": 14, "start": 12, "tag": "Finding"}, {"end": 94, "start": 83, "tag": "Chemical"}, {"end": 183, "start": 175, "tag": "Finding"}, {"end": 328, "start": 323, "tag": "AminoAcidPeptideOrProtein"}, {"end": 328, "start": 323, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 418, "start": 413, "tag": "AminoAcidPeptideOrProtein"}, {"end": 418, "start": 413, "tag": "BiologicallyActiveSubstance"}, {"end": 328, "start": 325, "tag": "AminoAcidPeptideOrProtein"}, {"end": 418, "start": 415, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 322, "start": 319, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 328, "start": 325, "tag": "BiologicallyActiveSubstance"}, {"end": 418, "start": 415, "tag": "BiologicallyActiveSubstance"}, {"end": 532, "start": 520, "tag": "PopulationGroup"}, {"end": 22, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 64, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "ResearchActivity"}, {"end": 226, "start": 224, "tag": "ResearchActivity"}, {"end": 263, "start": 261, "tag": "ResearchActivity"}, {"end": 346, "start": 344, "tag": "ResearchActivity"}, {"end": 380, "start": 378, "tag": "ResearchActivity"}, {"end": 437, "start": 435, "tag": "ResearchActivity"}, {"end": 471, "start": 469, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 197, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "BiologicFunction"}, {"end": 101, "start": 95, "tag": "CellFunction"}, {"end": 207, "start": 187, "tag": "ClinicalAttribute"}, {"end": 328, "start": 319, "tag": "ClinicalAttribute"}]}
{"id": "1432_9", "text": "No significant variations in the biomarker changes over time were seen in the AD group.", "tags": [{"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}, {"end": 60, "start": 56, "tag": "TemporalConcept"}, {"end": 86, "start": 81, "tag": "PopulationGroup"}, {"end": 50, "start": 43, "tag": "Finding"}, {"end": 25, "start": 0, "tag": "Finding"}]}
{"id": "1432_10", "text": "Conclusions: In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed to test if OSA treatment may affect the progression of cognitive impairment due to AD.", "tags": [{"end": 23, "start": 21, "tag": "Finding"}, {"end": 83, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 42, "tag": "HealthCareActivity"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 135, "tag": "PathologicFunction"}, {"end": 146, "start": 135, "tag": "TemporalConcept"}, {"end": 40, "start": 33, "tag": "PopulationGroup"}, {"end": 102, "start": 98, "tag": "ResearchActivity"}, {"end": 102, "start": 98, "tag": "HealthCareActivity"}]}
{"id": "1433_0", "text": "Oxidative stress has long been implicated in the pathophysiology and progression of Huntington's disease (HD).", "tags": [{"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 104, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 49, "tag": "PathologicFunction"}, {"end": 64, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 80, "start": 69, "tag": "PathologicFunction"}, {"end": 80, "start": 69, "tag": "TemporalConcept"}]}
{"id": "1433_1", "text": "Uric acid (UA) is a naturally occurring antioxidant that is present in the brain and periphery.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 11, "tag": "Chemical"}, {"end": 13, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 40, "tag": "CellFunction"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1433_2", "text": "Growing evidence has implicated UA as a molecular biomarker for several neurodegenerative diseases, most notably Parkinson's disease (PD).", "tags": [{"end": 34, "start": 32, "tag": "Chemical"}, {"end": 34, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 40, "tag": "ClinicalAttribute"}, {"end": 98, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 0, "tag": "Finding"}]}
{"id": "1433_3", "text": "In this study, we investigated UA levels in clinical samples from HD patients and normal controls (NCs) and assessed potential relationships between UA levels and disease and clinical data.", "tags": [{"end": 33, "start": 31, "tag": "Chemical"}, {"end": 33, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 149, "tag": "Chemical"}, {"end": 151, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 82, "tag": "Finding"}, {"end": 188, "start": 175, "tag": "ResearchActivity"}, {"end": 77, "start": 66, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 82, "tag": "PopulationGroup"}, {"end": 140, "start": 127, "tag": "Finding"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 60, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 44, "tag": "Substance"}]}
{"id": "1433_4", "text": "UA levels were measured in plasma (n = 107) and saliva (n = 178) samples from premanifest (pre-HD) and manifest HD patients and control subjects.", "tags": [{"end": 2, "start": 0, "tag": "Chemical"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 128, "tag": "PopulationGroup"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 128, "tag": "PopulationGroup"}, {"end": 144, "start": 136, "tag": "PopulationGroup"}, {"end": 72, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 65, "tag": "Substance"}, {"end": 123, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 78, "tag": "PatientOrDisabledGroup"}]}
{"id": "1433_5", "text": "Gender effects of UA levels were observed in both biofluids, with male patients showing higher UA levels compared to female patients.", "tags": [{"end": 6, "start": 0, "tag": "OrganismAttribute"}, {"end": 20, "start": 18, "tag": "Chemical"}, {"end": 20, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 95, "tag": "Chemical"}, {"end": 97, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 117, "tag": "OrganismAttribute"}, {"end": 70, "start": 66, "tag": "OrganismAttribute"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 50, "tag": "Substance"}, {"end": 14, "start": 7, "tag": "Finding"}]}
{"id": "1433_6", "text": "Comparisons of UA levels across diagnostic groups, separated by gender, revealed that both plasma and salivary UA levels were significantly lower in female pre-HD and manifest HD patients compared to NCs.", "tags": [{"end": 17, "start": 15, "tag": "Chemical"}, {"end": 17, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 111, "tag": "Chemical"}, {"end": 113, "start": 111, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 149, "tag": "OrganismAttribute"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}, {"end": 70, "start": 64, "tag": "OrganismAttribute"}, {"end": 120, "start": 102, "tag": "ClinicalAttribute"}, {"end": 120, "start": 111, "tag": "ClinicalAttribute"}, {"end": 97, "start": 91, "tag": "ClinicalAttribute"}]}
{"id": "1433_7", "text": "Salivary levels of UA were also significantly lower in male manifest HD patients versus controls, but not in plasma.", "tags": [{"end": 21, "start": 19, "tag": "Chemical"}, {"end": 21, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 60, "tag": "SignOrSymptom"}, {"end": 59, "start": 55, "tag": "OrganismAttribute"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1433_8", "text": "Correlations of peripheral UA levels to clinical data also showed differences according to gender.", "tags": [{"end": 29, "start": 27, "tag": "Chemical"}, {"end": 29, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 40, "tag": "ResearchActivity"}, {"end": 77, "start": 66, "tag": "Finding"}, {"end": 97, "start": 91, "tag": "OrganismAttribute"}, {"end": 26, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 16, "tag": "ClinicalAttribute"}]}
{"id": "1433_9", "text": "In male HD patients, both plasma and salivary UA levels were significantly negatively correlated with total functional capacity (TFC), while positive correlations were observed with total motor score (TMS).", "tags": [{"end": 48, "start": 46, "tag": "Chemical"}, {"end": 48, "start": 46, "tag": "ResearchActivity"}, {"end": 127, "start": 108, "tag": "Finding"}, {"end": 199, "start": 182, "tag": "HealthCareActivity"}, {"end": 127, "start": 102, "tag": "HealthCareActivity"}, {"end": 204, "start": 201, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareActivity"}, {"end": 19, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 45, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 3, "tag": "OrganismAttribute"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 150, "tag": "ResearchActivity"}, {"end": 55, "start": 37, "tag": "ClinicalAttribute"}, {"end": 55, "start": 46, "tag": "ClinicalAttribute"}, {"end": 32, "start": 26, "tag": "ClinicalAttribute"}]}
{"id": "1433_10", "text": "Female HD patients showed a significant positive correlation between plasma UA levels and TMS, while salivary UA levels from female patients were significantly correlated to disease burden.", "tags": [{"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "OrganismAttribute"}, {"end": 78, "start": 76, "tag": "Chemical"}, {"end": 78, "start": 76, "tag": "ResearchActivity"}, {"end": 188, "start": 174, "tag": "ResearchActivity"}, {"end": 93, "start": 90, "tag": "HealthCareActivity"}, {"end": 131, "start": 125, "tag": "OrganismAttribute"}, {"end": 18, "start": 7, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 132, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 28, "tag": "ResearchActivity"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 119, "start": 101, "tag": "ClinicalAttribute"}]}
{"id": "1433_11", "text": "Finally, in a separate cohort, we show that UA levels are decreased in postmortem prefrontal cortical samples (n = 20) from HD subjects compared to matched controls.", "tags": [{"end": 46, "start": 44, "tag": "Chemical"}, {"end": 46, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "Finding"}, {"end": 101, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 164, "start": 156, "tag": "PopulationGroup"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 81, "start": 71, "tag": "TemporalConcept"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 109, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 102, "tag": "Substance"}]}
{"id": "1433_12", "text": "These findings suggest that decreased levels of UA in the brains of HD patients can be reflected in peripheral fluids, with salivary measures of UA particularly offering significant promise as a potentially relevant, non-invasive biomarker of disease symptoms and burden.", "tags": [{"end": 50, "start": 48, "tag": "Chemical"}, {"end": 50, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 145, "tag": "Chemical"}, {"end": 147, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 259, "start": 243, "tag": "SignOrSymptom"}, {"end": 239, "start": 217, "tag": "ClinicalAttribute"}, {"end": 79, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 132, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 239, "start": 230, "tag": "ClinicalAttribute"}, {"end": 270, "start": 264, "tag": "ResearchActivity"}, {"end": 110, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 111, "tag": "Substance"}]}
{"id": "1433_13", "text": "Our findings further highlight the impact of sexual dimorphism in HD pathophysiology.", "tags": [{"end": 62, "start": 45, "tag": "BiologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 69, "tag": "PathologicFunction"}]}
{"id": "1434_0", "text": "Background Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults.", "tags": [{"end": 106, "start": 95, "tag": "BiologicFunction"}, {"end": 132, "start": 124, "tag": "BiologicFunction"}, {"end": 44, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 165, "tag": "Cell"}, {"end": 79, "start": 67, "tag": "Cell"}, {"end": 160, "start": 154, "tag": "CellComponent"}, {"end": 132, "start": 111, "tag": "BiologicFunction"}, {"end": 180, "start": 174, "tag": "InjuryOrPoisoning"}]}
{"id": "1434_1", "text": "The serum level of BDNF is altered in a diversity of neurological diseases.", "tags": [{"end": 74, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 4, "tag": "ClinicalAttribute"}]}
{"id": "1434_2", "text": "The aim of this work was to investigate the serum level of BDNF in patients with relapsing-remitting multiple sclerosis and the relation between BDNF and disease activity and severity.", "tags": [{"end": 170, "start": 154, "tag": "HealthCareActivity"}, {"end": 183, "start": 175, "tag": "ClinicalAttribute"}, {"end": 183, "start": 175, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}
{"id": "1434_3", "text": "Methods A case-control study was conducted on 90 subjects: 60 patients with relapsing-remitting multiple sclerosis (30 in relapse and 30 in remission) on different lines of medical treatment and 30 healthy volunteers as a control.", "tags": [{"end": 28, "start": 10, "tag": "ResearchActivity"}, {"end": 149, "start": 140, "tag": "Finding"}, {"end": 190, "start": 173, "tag": "HealthCareActivity"}, {"end": 129, "start": 122, "tag": "TemporalConcept"}, {"end": 129, "start": 122, "tag": "Finding"}, {"end": 216, "start": 206, "tag": "PopulationGroup"}, {"end": 114, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "PatientOrDisabledGroup"}, {"end": 205, "start": 198, "tag": "OrganismAttribute"}, {"end": 14, "start": 10, "tag": "ManufacturedObject"}, {"end": 22, "start": 15, "tag": "PopulationGroup"}, {"end": 229, "start": 222, "tag": "PopulationGroup"}, {"end": 57, "start": 49, "tag": "PopulationGroup"}]}
{"id": "1434_4", "text": "Clinical, functional, and radiological evaluation was done for the patients, and all the patients and controls were subjected to assessment of the serum level of BDNF by sandwich-ELISA technique.", "tags": [{"end": 49, "start": 39, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 194, "start": 170, "tag": "ResearchActivity"}, {"end": 194, "start": 185, "tag": "ResearchActivity"}, {"end": 152, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 102, "tag": "PopulationGroup"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 89, "tag": "PatientOrDisabledGroup"}, {"end": 139, "start": 129, "tag": "HealthCareActivity"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 49, "start": 26, "tag": "HealthCareActivity"}, {"end": 166, "start": 147, "tag": "ClinicalAttribute"}]}
{"id": "1434_5", "text": "Results The BDNF level was significantly higher in MS patients in relapse than in patients in remission (P value = 0.006).", "tags": [{"end": 103, "start": 94, "tag": "Finding"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 66, "tag": "TemporalConcept"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 54, "tag": "PatientOrDisabledGroup"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1434_6", "text": "In the remission group, there was no significant linear correlation between different MS patients' characteristics and BDNF level, while in the relapse group, a positive linear correlation was found between the number of T2 infratentorial lesions and BDNF level (r = 0.402, P = 0.028).", "tags": [{"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 144, "tag": "TemporalConcept"}, {"end": 151, "start": 144, "tag": "Finding"}, {"end": 246, "start": 239, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 251, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 255, "start": 251, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 99, "tag": "OrganismAttribute"}, {"end": 97, "start": 89, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 17, "tag": "PopulationGroup"}, {"end": 157, "start": 152, "tag": "PopulationGroup"}, {"end": 16, "start": 7, "tag": "Finding"}, {"end": 67, "start": 49, "tag": "ResearchActivity"}, {"end": 188, "start": 170, "tag": "ResearchActivity"}, {"end": 246, "start": 221, "tag": "ClinicalAttribute"}, {"end": 129, "start": 119, "tag": "ClinicalAttribute"}, {"end": 261, "start": 251, "tag": "ClinicalAttribute"}]}
{"id": "1434_7", "text": "There was no statistically significant difference between the BDNF level in patients administered different drugs for MS in both remission and relapse groups (P value > 0.05).", "tags": [{"end": 138, "start": 129, "tag": "Finding"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 143, "tag": "TemporalConcept"}, {"end": 150, "start": 143, "tag": "Finding"}, {"end": 66, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 108, "tag": "PharmacologicSubstance"}, {"end": 157, "start": 151, "tag": "PopulationGroup"}, {"end": 49, "start": 10, "tag": "Finding"}, {"end": 166, "start": 159, "tag": "ResearchActivity"}, {"end": 72, "start": 62, "tag": "ClinicalAttribute"}]}
{"id": "1434_8", "text": "Conclusion BDNF was significantly higher in relapsing-remitting multiple sclerosis patients in the relapse phase.", "tags": [{"end": 106, "start": 99, "tag": "TemporalConcept"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 15, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}]}
{"id": "1434_9", "text": "Attention should be paid to the link between serum BDNF level as a neuroprotective factor and multiple sclerosis; it can be a biomarker for MS activity in the near future.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 89, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 61, "start": 45, "tag": "ClinicalAttribute"}]}
{"id": "1435_0", "text": "Huntington's disease is a dominantly inherited, fatal neurodegenerative disorder caused by a CAG expansion in the huntingtin (HTT) gene, coding for pathological mutant HTT protein (mHTT).", "tags": [{"end": 179, "start": 148, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 93, "tag": "MolecularSequence"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 124, "start": 114, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 126, "tag": "GeneOrGenome"}, {"end": 129, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 181, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1435_1", "text": "Because of its gain-of-function mechanism and monogenic aetiology, strategies to lower HTT are being actively investigated as disease-modifying therapies.", "tags": [{"end": 90, "start": 87, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 126, "tag": "HealthCareActivity"}, {"end": 65, "start": 46, "tag": "Finding"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 15, "tag": "CellFunction"}]}
{"id": "1435_2", "text": "Most approaches are currently targeted at the manifest stage, where clinical outcomes are used to evaluate the effectiveness of therapy.", "tags": [{"end": 85, "start": 68, "tag": "ClinicalAttribute"}, {"end": 124, "start": 111, "tag": "Finding"}, {"end": 29, "start": 20, "tag": "TemporalConcept"}, {"end": 135, "start": 128, "tag": "HealthCareActivity"}, {"end": 60, "start": 46, "tag": "TemporalConcept"}]}
{"id": "1435_3", "text": "However, as almost 50% of striatal volume has been lost at the time of onset of clinical manifest, it would be preferable to begin therapy in the premanifest period.", "tags": [{"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 26, "tag": "ClinicalAttribute"}, {"end": 97, "start": 80, "tag": "SignOrSymptom"}, {"end": 164, "start": 146, "tag": "TemporalConcept"}, {"end": 67, "start": 63, "tag": "TemporalConcept"}, {"end": 138, "start": 131, "tag": "HealthCareActivity"}, {"end": 76, "start": 71, "tag": "TemporalConcept"}]}
{"id": "1435_4", "text": "An unmet challenge is how to evaluate therapeutic efficacy before the presence of clinical symptoms as outcome measures.", "tags": [{"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 99, "start": 82, "tag": "SignOrSymptom"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 65, "start": 59, "tag": "TemporalConcept"}, {"end": 58, "start": 38, "tag": "Finding"}, {"end": 110, "start": 103, "tag": "Finding"}]}
{"id": "1435_5", "text": "To address this, we aim to develop non-invasive sensitive biomarkers that provide insight into therapeutic efficacy in the premanifest stage of Huntington's disease.", "tags": [{"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 58, "tag": "ClinicalAttribute"}, {"end": 47, "start": 35, "tag": "ClinicalAttribute"}, {"end": 115, "start": 95, "tag": "Finding"}, {"end": 140, "start": 123, "tag": "TemporalConcept"}]}
{"id": "1435_6", "text": "In this study, we mapped the temporal trajectories of arteriolar cerebral blood volumes (CBVa) using inflow-based vascular-space-occupancy (iVASO) MRI in the heterozygous zQ175 mice, a full-length mHTT expressing and slowly progressing model with a premanifest period as in human Huntington's disease.", "tags": [{"end": 212, "start": 202, "tag": "CellFunction"}, {"end": 300, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 261, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 150, "start": 147, "tag": "HealthCareActivity"}, {"end": 138, "start": 101, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 241, "start": 217, "tag": "ResearchActivity"}, {"end": 37, "start": 29, "tag": "TemporalConcept"}, {"end": 279, "start": 274, "tag": "Eukaryote"}, {"end": 87, "start": 54, "tag": "ClinicalAttribute"}, {"end": 87, "start": 74, "tag": "ClinicalAttribute"}, {"end": 145, "start": 140, "tag": "HealthCareActivity"}, {"end": 181, "start": 158, "tag": "ExperimentalModelOfDisease"}, {"end": 201, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 197, "tag": "CellOrMolecularDysfunction"}, {"end": 93, "start": 89, "tag": "ClinicalAttribute"}]}
{"id": "1435_7", "text": "Significantly elevated CBVa was evident in premanifest zQ175 mice prior to motor deficits and striatal atrophy, recapitulating altered CBVa in human premanifest Huntington's disease.", "tags": [{"end": 110, "start": 94, "tag": "Finding"}, {"end": 102, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 75, "tag": "PathologicFunction"}, {"end": 181, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 148, "start": 143, "tag": "Eukaryote"}, {"end": 65, "start": 43, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 23, "tag": "ClinicalAttribute"}, {"end": 139, "start": 135, "tag": "ClinicalAttribute"}]}
{"id": "1435_8", "text": "CRISPR/Cas9-mediated non-allele-specific HTT silencing in striatal neurons restored altered CBVa in premanifest zQ175 mice, delayed onset of striatal atrophy, and slowed the progression of motor phenotype and brain pathology.", "tags": [{"end": 137, "start": 124, "tag": "TemporalConcept"}, {"end": 157, "start": 141, "tag": "Finding"}, {"end": 149, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 58, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "GeneOrGenome"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 0, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 204, "start": 195, "tag": "OrganismAttribute"}, {"end": 185, "start": 174, "tag": "PathologicFunction"}, {"end": 185, "start": 174, "tag": "TemporalConcept"}, {"end": 31, "start": 25, "tag": "GeneOrGenome"}, {"end": 224, "start": 209, "tag": "PathologicFunction"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 0, "tag": "ResearchActivity"}, {"end": 122, "start": 100, "tag": "ExperimentalModelOfDisease"}, {"end": 96, "start": 92, "tag": "ClinicalAttribute"}]}
{"id": "1435_9", "text": "This study-for the first time-shows that a non-invasive functional MRI measure detects therapeutic efficacy in the premanifest stage and demonstrates long-term benefits of a non-allele-selective HTT silencing treatment introduced in the premanifest Huntington's disease.", "tags": [{"end": 269, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 150, "tag": "TemporalConcept"}, {"end": 24, "start": 19, "tag": "TemporalConcept"}, {"end": 218, "start": 174, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 107, "start": 87, "tag": "Finding"}, {"end": 70, "start": 43, "tag": "HealthCareActivity"}, {"end": 132, "start": 115, "tag": "TemporalConcept"}, {"end": 168, "start": 160, "tag": "Finding"}]}
{"id": "1436_0", "text": "The authors used PET imaging to stage individuals according to the Braak neuropathological system for Alzheimer's disease.", "tags": [{"end": 37, "start": 32, "tag": "TemporalConcept"}, {"end": 37, "start": 32, "tag": "ClinicalAttribute"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 28, "start": 17, "tag": "HealthCareActivity"}, {"end": 121, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 49, "start": 38, "tag": "PopulationGroup"}, {"end": 97, "start": 67, "tag": "HealthCareActivity"}]}
{"id": "1436_1", "text": "PET stage was associated with biomarker and cognitive changes, highlighting the potential to stage Alzheimer's disease in living people.", "tags": [{"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ClinicalAttribute"}, {"end": 61, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 93, "tag": "TemporalConcept"}, {"end": 98, "start": 93, "tag": "ClinicalAttribute"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 30, "tag": "ClinicalAttribute"}, {"end": 135, "start": 122, "tag": "PopulationGroup"}]}
{"id": "1436_2", "text": "Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems.", "tags": [{"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 46, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 62, "tag": "HealthCareActivity"}]}
{"id": "1436_3", "text": "Using the topographical information from [F-18]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals.", "tags": [{"end": 86, "start": 54, "tag": "HealthCareActivity"}, {"end": 91, "start": 88, "tag": "HealthCareActivity"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 141, "tag": "PopulationGroup"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 109, "tag": "HealthCareActivity"}]}
{"id": "1436_4", "text": "We used PET-based Braak stage to model the trajectories of amyloid-beta, phosphorylated tau (pTau) in cerebrospinal fluid (pTau(181), pTau(217), pTau(231) and pTau(235)) and plasma (pTau(181) and pTau(231)), neurodegeneration and cognitive symptoms.", "tags": [{"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 248, "start": 230, "tag": "SignOrSymptom"}, {"end": 11, "start": 8, "tag": "HealthCareActivity"}, {"end": 91, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 208, "tag": "CellOrMolecularDysfunction"}, {"end": 180, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "ResearchActivity"}, {"end": 121, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 8, "tag": "HealthCareActivity"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 196, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1436_5", "text": "We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III-IV, followed by plateaus.", "tags": [{"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 96, "start": 93, "tag": "HealthCareActivity"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 27, "tag": "ClinicalAttribute"}, {"end": 119, "start": 110, "tag": "ClinicalAttribute"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 142, "tag": "HealthCareActivity"}]}
{"id": "1436_6", "text": "Early Braak stages were associated with isolated memory impairment, whereas Braak stages V-VI were incompatible with normal cognition.", "tags": [{"end": 18, "start": 12, "tag": "TemporalConcept"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 133, "start": 117, "tag": "Finding"}, {"end": 123, "start": 117, "tag": "Finding"}, {"end": 133, "start": 124, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 66, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 6, "tag": "HealthCareActivity"}, {"end": 93, "start": 76, "tag": "HealthCareActivity"}]}
{"id": "1436_7", "text": "In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-beta positivity.", "tags": [{"end": 41, "start": 38, "tag": "HealthCareActivity"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}, {"end": 54, "start": 43, "tag": "TemporalConcept"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "TemporalConcept"}, {"end": 18, "start": 7, "tag": "PopulationGroup"}, {"end": 118, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1436_8", "text": "Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.", "tags": [{"end": 106, "start": 99, "tag": "HealthCareActivity"}, {"end": 106, "start": 99, "tag": "ManufacturedObject"}, {"end": 118, "start": 110, "tag": "ClinicalAttribute"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 135, "start": 129, "tag": "Eukaryote"}, {"end": 24, "start": 21, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "Finding"}, {"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 44, "start": 21, "tag": "HealthCareActivity"}]}
{"id": "1437_0", "text": "Introduction Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline.", "tags": [{"end": 33, "start": 13, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 22, "tag": "PathologicFunction"}, {"end": 73, "start": 65, "tag": "TemporalConcept"}, {"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 135, "tag": "DiseaseOrSyndrome"}]}
{"id": "1437_1", "text": "Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed.", "tags": [{"end": 35, "start": 25, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "PathologicFunction"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 118, "start": 97, "tag": "ClinicalAttribute"}, {"end": 82, "start": 61, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1437_2", "text": "Method Solid-phase extraction and parallel reaction monitoring mass spectrometry were used to quantify 17 synaptic proteins in CSF, in two cross-sectional studies including AD (n = 52) and controls (n = 37).", "tags": [{"end": 162, "start": 139, "tag": "ResearchActivity"}, {"end": 123, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 189, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 18, "start": 13, "tag": "TemporalConcept"}, {"end": 80, "start": 34, "tag": "HealthCareActivity"}, {"end": 29, "start": 7, "tag": "ResearchActivity"}]}
{"id": "1437_3", "text": "Results Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, phosphatidylethanolamine-binding protein 1, and 14-3-3 proteins were observed in AD patients compared to controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased.", "tags": [{"end": 32, "start": 18, "tag": "BiologicFunction"}, {"end": 50, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 82, "tag": "GeneOrGenome"}, {"end": 124, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 228, "tag": "GeneOrGenome"}, {"end": 255, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 166, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 187, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 223, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 203, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 203, "tag": "GeneOrGenome"}, {"end": 145, "start": 130, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1437_4", "text": "Discussion We have established a method with a novel panel of synaptic proteins as biomarkers of synaptic dysfunction.", "tags": [{"end": 117, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 117, "start": 106, "tag": "PathologicFunction"}, {"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 39, "start": 33, "tag": "HealthCareActivity"}, {"end": 79, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}]}
{"id": "1437_5", "text": "The results indicate that several of the proteins included in the panel may serve as synaptic biomarkers for AD.", "tags": [{"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 94, "tag": "ClinicalAttribute"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}]}
{"id": "1438_0", "text": "Introduction: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD).", "tags": [{"end": 61, "start": 50, "tag": "Finding"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 18, "tag": "Cell"}, {"end": 105, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1438_1", "text": "We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account.", "tags": [{"end": 36, "start": 20, "tag": "BiologicFunction"}, {"end": 36, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 76, "tag": "Finding"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1438_2", "text": "Methods: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects.", "tags": [{"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 96, "tag": "PopulationGroup"}, {"end": 76, "start": 60, "tag": "PopulationGroup"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 77, "tag": "Finding"}]}
{"id": "1438_3", "text": "All participants underwent ophthalmological screening to exclude interfering ocular disease.", "tags": [{"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 91, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 27, "tag": "HealthCareActivity"}]}
{"id": "1438_4", "text": "Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size.", "tags": [{"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 41, "tag": "ClinicalAttribute"}, {"end": 27, "start": 8, "tag": "ResearchActivity"}, {"end": 89, "start": 70, "tag": "ClinicalAttribute"}, {"end": 115, "start": 91, "tag": "ClinicalAttribute"}, {"end": 147, "start": 121, "tag": "ClinicalAttribute"}]}
{"id": "1438_5", "text": "Results: We found no disease effects on retinal vascular measures (all beta's, vertical bar 0.15 vertical bar, all P..2), adjusted for confounders.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 40, "tag": "ClinicalAttribute"}, {"end": 146, "start": 135, "tag": "Finding"}]}
{"id": "1438_6", "text": "Venular tortuosity was inversely associated with Fazekas score in control subjects (beta -0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (beta -0.64, P < .01).", "tags": [{"end": 18, "start": 8, "tag": "Finding"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 112, "tag": "ClinicalAttribute"}, {"end": 82, "start": 66, "tag": "PopulationGroup"}, {"end": 82, "start": 74, "tag": "PopulationGroup"}, {"end": 62, "start": 49, "tag": "HealthCareActivity"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 189, "tag": "HealthCareActivity"}]}
{"id": "1438_7", "text": "Discussion: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker.", "tags": [{"end": 46, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 250, "start": 218, "tag": "HealthCareActivity"}, {"end": 193, "start": 183, "tag": "ClinicalAttribute"}, {"end": 143, "start": 135, "tag": "ClinicalAttribute"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 266, "start": 257, "tag": "ClinicalAttribute"}, {"end": 182, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 90, "tag": "PopulationGroup"}, {"end": 34, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 98, "tag": "PopulationGroup"}, {"end": 157, "start": 145, "tag": "HealthCareActivity"}]}
{"id": "1438_8", "text": "(C) 2019 The Authors.", "tags": []}
{"id": "1438_9", "text": "Published by Elsevier Inc.", "tags": []}
{"id": "1438_10", "text": "on behalf of the Alzheimer's Association.", "tags": [{"end": 40, "start": 17, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1439_0", "text": "Background: African American/Black adults have a disproportionate incidence of Alzheimer's disease (AD) and are underrepresented in biomarker discovery efforts.", "tags": [{"end": 19, "start": 12, "tag": "PopulationGroup"}, {"end": 75, "start": 66, "tag": "Finding"}, {"end": 151, "start": 142, "tag": "ResearchActivity"}, {"end": 98, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "ClinicalAttribute"}, {"end": 41, "start": 12, "tag": "PopulationGroup"}]}
{"id": "1439_1", "text": "Objective: This study aimed to identify potential diagnostic biomarkers for AD using a combination of proteomics and machine learning approaches in a cohort that included African American/Black adults.", "tags": [{"end": 112, "start": 102, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 178, "start": 171, "tag": "PopulationGroup"}, {"end": 133, "start": 117, "tag": "MachineActivity"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 71, "start": 50, "tag": "ClinicalAttribute"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 150, "tag": "PopulationGroup"}, {"end": 200, "start": 171, "tag": "PopulationGroup"}, {"end": 133, "start": 125, "tag": "BiologicFunction"}, {"end": 112, "start": 102, "tag": "ResearchActivity"}]}
{"id": "1439_2", "text": "Methods: We conducted a discovery-based plasma proteomics study on plasma samples (N = 113) obtained from clinically diagnosed AD and cognitively normal adults that were self-reported African American/Black or non-Hispanic White.", "tags": [{"end": 152, "start": 134, "tag": "Finding"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 63, "start": 47, "tag": "ResearchActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 153, "tag": "PopulationGroup"}, {"end": 228, "start": 210, "tag": "PopulationGroup"}, {"end": 206, "start": 184, "tag": "PopulationGroup"}]}
{"id": "1439_3", "text": "Sets of differentially-expressed proteins were then classified using a support vector machine (SVM) to identify biomarker candidates.", "tags": [{"end": 41, "start": 8, "tag": "Finding"}, {"end": 41, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 112, "tag": "ClinicalAttribute"}, {"end": 93, "start": 71, "tag": "MachineActivity"}, {"end": 98, "start": 95, "tag": "MachineActivity"}]}
{"id": "1439_4", "text": "Results: In total, 740 proteins were identified of which, 25 differentially-expressed proteins in AD came from comparisons within a single racial and ethnic background group.", "tags": [{"end": 94, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 150, "tag": "PopulationGroup"}, {"end": 31, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 173, "start": 168, "tag": "PopulationGroup"}]}
{"id": "1439_5", "text": "Six proteins were differentially-expressed in AD regardless of racial and ethnic background.", "tags": [{"end": 91, "start": 74, "tag": "PopulationGroup"}, {"end": 12, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}]}
{"id": "1439_6", "text": "Supervised classification by SVM yielded an area under the curve (AUC) of 0.91 and accuracy of 86% for differentiating AD in samples from non-Hispanic White adults when trained with differentially-expressed proteins unique to that group.", "tags": [{"end": 215, "start": 182, "tag": "Finding"}, {"end": 215, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 66, "tag": "ResearchActivity"}, {"end": 206, "start": 197, "tag": "CellFunction"}, {"end": 163, "start": 138, "tag": "PopulationGroup"}, {"end": 236, "start": 231, "tag": "PopulationGroup"}, {"end": 64, "start": 44, "tag": "ResearchActivity"}, {"end": 91, "start": 83, "tag": "Finding"}]}
{"id": "1439_7", "text": "However, the same model yielded an AUC of 0.49 and accuracy of 47% for differentiating AD in samples from African American/Black adults.", "tags": [{"end": 135, "start": 106, "tag": "PopulationGroup"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 38, "start": 35, "tag": "ResearchActivity"}, {"end": 135, "start": 129, "tag": "PopulationGroup"}, {"end": 59, "start": 51, "tag": "Finding"}]}
{"id": "1439_8", "text": "Other covariates such as age, APOE4 status, sex, and years of education were found to improve the model mostly in the samples from non-Hispanic White adults for classifying AD.", "tags": [{"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "Finding"}, {"end": 71, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 28, "start": 25, "tag": "OrganismAttribute"}, {"end": 58, "start": 53, "tag": "TemporalConcept"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 156, "start": 131, "tag": "PopulationGroup"}, {"end": 47, "start": 44, "tag": "OrganismAttribute"}]}
{"id": "1439_9", "text": "Conclusion: These results demonstrate the importance of study designs in AD biomarker discovery, which must include diverse racial and ethnic groups such as African American/Black adults to develop effective biomarkers.", "tags": [{"end": 148, "start": 135, "tag": "PopulationGroup"}, {"end": 186, "start": 157, "tag": "PopulationGroup"}, {"end": 61, "start": 56, "tag": "ResearchActivity"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 218, "start": 208, "tag": "ClinicalAttribute"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 186, "start": 180, "tag": "PopulationGroup"}]}
{"id": "1440_0", "text": "Alzheimer's disease (AD) is now conceptualized as a biological entity defined by amyloid and tau deposition and neurodegeneration, with heterogeneous clinical presentations.", "tags": [{"end": 172, "start": 159, "tag": "SignOrSymptom"}, {"end": 149, "start": 136, "tag": "OrganismAttribute"}, {"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 112, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 93, "tag": "PathologicFunction"}]}
{"id": "1440_1", "text": "With the aid of in vivo biomarkers, clinicians are better poised to examine clinical syndromic variability arising from a common pathology.", "tags": [{"end": 46, "start": 36, "tag": "HealthCareActivity"}, {"end": 34, "start": 24, "tag": "ClinicalAttribute"}, {"end": 138, "start": 129, "tag": "PathologicFunction"}, {"end": 138, "start": 129, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 76, "tag": "Finding"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}]}
{"id": "1440_2", "text": "Word retrieval deficits, measured using verbal fluency and confrontation naming tests, are hallmark features of the early clinical stages of the amnestic presentations of AD, specifically in category fluency and naming with relatively spared letter fluency.", "tags": [{"end": 218, "start": 212, "tag": "BiologicFunction"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 137, "start": 122, "tag": "TemporalConcept"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 116, "tag": "TemporalConcept"}, {"end": 85, "start": 80, "tag": "ResearchActivity"}, {"end": 85, "start": 59, "tag": "HealthCareActivity"}, {"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 54, "start": 40, "tag": "OrganismAttribute"}, {"end": 85, "start": 80, "tag": "HealthCareActivity"}, {"end": 54, "start": 40, "tag": "HealthCareActivity"}]}
{"id": "1440_3", "text": "As yet, there is no consensus regarding performance on these tests in atypical clinical phenotypes of AD, including posterior cortical atrophy (PCA) and logopenic primary progressive aphasia (lvPPA), in individuals who are amyloid-positive (A beta+) but present with different clinical profiles and patterns of neurodegeneration compared to amnestic AD.", "tags": [{"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "ResearchActivity"}, {"end": 98, "start": 79, "tag": "ClinicalAttribute"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 352, "start": 341, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 203, "tag": "PopulationGroup"}, {"end": 190, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 51, "start": 40, "tag": "Finding"}, {"end": 66, "start": 61, "tag": "ResearchActivity"}, {"end": 66, "start": 61, "tag": "HealthCareActivity"}, {"end": 247, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 328, "start": 311, "tag": "CellOrMolecularDysfunction"}, {"end": 307, "start": 299, "tag": "ResearchActivity"}, {"end": 197, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 294, "start": 277, "tag": "ClinicalAttribute"}]}
{"id": "1440_4", "text": "The goal of the current study is to determine how A beta+ individuals across the syndromic spectrum of AD perform on three different word retrieval tasks.", "tags": [{"end": 105, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}, {"end": 69, "start": 58, "tag": "PopulationGroup"}, {"end": 29, "start": 24, "tag": "ResearchActivity"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 133, "tag": "HealthCareActivity"}]}
{"id": "1440_5", "text": "A secondary goal is to determine the neuroanatomical substrates underlying word retrieval performance in these A beta+ individuals.", "tags": [{"end": 130, "start": 119, "tag": "PopulationGroup"}, {"end": 101, "start": 90, "tag": "Finding"}, {"end": 117, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 37, "tag": "Finding"}, {"end": 89, "start": 75, "tag": "BiologicFunction"}]}
{"id": "1440_6", "text": "Thirty-two A beta+ participants with the amnestic presentation, 16 with A beta+ PCA, 22 with A beta+ lvPPA, and 99 amyloid-negative (A beta-) control participants were evaluated with verbal fluency and visual confrontation naming tests as well as high-resolution MRI.", "tags": [{"end": 83, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 80, "tag": "ResearchActivity"}, {"end": 31, "start": 19, "tag": "PopulationGroup"}, {"end": 162, "start": 150, "tag": "PopulationGroup"}, {"end": 122, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 142, "tag": "PopulationGroup"}, {"end": 266, "start": 247, "tag": "HealthCareActivity"}, {"end": 235, "start": 202, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 247, "tag": "Finding"}, {"end": 106, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 183, "tag": "OrganismAttribute"}]}
{"id": "1440_7", "text": "The A beta+ patient groups were rated at very mild or mild levels of severity (CDR 0.5 or 1) and had comparable levels of global cognitive impairment (average MMSE = 23.7 + 3.9).", "tags": [{"end": 149, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 159, "tag": "HealthCareActivity"}, {"end": 77, "start": 69, "tag": "ClinicalAttribute"}, {"end": 77, "start": 69, "tag": "Finding"}, {"end": 149, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 20, "tag": "PopulationGroup"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 10, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "Finding"}, {"end": 58, "start": 54, "tag": "Finding"}]}
{"id": "1440_8", "text": "Behaviorally, we found that the word retrieval profile of PCA patients is comparable to that of amnestic patients, characterized by intact letter fluency but impaired category fluency and visual confrontation naming, while lvPPA patients demonstrated impairment across all tests of word retrieval.", "tags": [{"end": 215, "start": 188, "tag": "BiologicFunction"}, {"end": 261, "start": 251, "tag": "Finding"}, {"end": 138, "start": 132, "tag": "Finding"}, {"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "ResearchActivity"}, {"end": 70, "start": 62, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 96, "tag": "PatientOrDisabledGroup"}, {"end": 237, "start": 229, "tag": "PatientOrDisabledGroup"}, {"end": 278, "start": 273, "tag": "ResearchActivity"}, {"end": 278, "start": 273, "tag": "HealthCareActivity"}, {"end": 46, "start": 32, "tag": "BiologicFunction"}, {"end": 153, "start": 139, "tag": "OrganismAttribute"}, {"end": 228, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 296, "start": 282, "tag": "BiologicFunction"}, {"end": 183, "start": 167, "tag": "OrganismAttribute"}]}
{"id": "1440_9", "text": "Across all AD variants, we observed that letter fluency was associated with cortical thickness in prefrontal, central precuneus, lateral parietal and temporal cortex, while category fluency and naming were associated with cortical thickness in left middle frontal gyrus, posterior middle temporal gyrus, and lateral parietal cortex.", "tags": [{"end": 108, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 194, "tag": "BiologicFunction"}, {"end": 269, "start": 244, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 302, "start": 271, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 331, "start": 308, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 76, "tag": "ClinicalAttribute"}, {"end": 240, "start": 222, "tag": "ClinicalAttribute"}, {"end": 13, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 41, "tag": "OrganismAttribute"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 173, "tag": "OrganismAttribute"}]}
{"id": "1440_10", "text": "Visual confrontation naming was uniquely associated with atrophy in inferior temporal and visual association cortex.", "tags": [{"end": 85, "start": 77, "tag": "TemporalConcept"}, {"end": 64, "start": 57, "tag": "PathologicFunction"}, {"end": 64, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 0, "tag": "BiologicFunction"}, {"end": 115, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1440_11", "text": "We conclude that a better understanding of the word retrieval profiles and underlying neurodegeneration across the AD syndromic spectrum will help improve interpretation of neuropsychological profiles with regard to the localization of neurodegeneration, particularly in the atypical AD variants.", "tags": [{"end": 154, "start": 147, "tag": "Finding"}, {"end": 136, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 275, "tag": "Finding"}, {"end": 39, "start": 26, "tag": "BiologicFunction"}, {"end": 103, "start": 86, "tag": "CellOrMolecularDysfunction"}, {"end": 253, "start": 236, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 173, "tag": "HealthCareActivity"}, {"end": 70, "start": 62, "tag": "ResearchActivity"}, {"end": 200, "start": 192, "tag": "ResearchActivity"}, {"end": 61, "start": 47, "tag": "BiologicFunction"}]}
{"id": "1441_0", "text": "Introduction: Biomarkers of Alzheimer's disease (AD) that can easily be measured in routine health checkups are desirable.", "tags": [{"end": 107, "start": 92, "tag": "HealthCareActivity"}, {"end": 91, "start": 84, "tag": "TemporalConcept"}, {"end": 24, "start": 14, "tag": "ClinicalAttribute"}, {"end": 47, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}]}
{"id": "1441_1", "text": "Urine is a source of biomarkers that can be collected easily and noninvasively.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 21, "tag": "ClinicalAttribute"}]}
{"id": "1441_2", "text": "We previously reported on the comprehensive profile of the urinary proteome of AD patients and identified proteins estimated to be significantly increased or decreased in AD patients by a label-free quantification method.", "tags": [{"end": 198, "start": 188, "tag": "ResearchActivity"}, {"end": 167, "start": 158, "tag": "Finding"}, {"end": 75, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 182, "start": 174, "tag": "PatientOrDisabledGroup"}, {"end": 154, "start": 131, "tag": "Finding"}, {"end": 220, "start": 214, "tag": "ResearchActivity"}, {"end": 220, "start": 214, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1441_3", "text": "The present study aimed to validate urinary levels of proteins that significantly differed between AD and control samples from our proteomics study (i.e., apolipoprotein C3 [ApoC3], insulin-like growth factor-binding protein 3 [Igfbp3], and apolipoprotein D [ApoD]).", "tags": [{"end": 172, "start": 155, "tag": "GeneOrGenome"}, {"end": 172, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 174, "tag": "GeneOrGenome"}, {"end": 179, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 228, "tag": "GeneOrGenome"}, {"end": 257, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 241, "tag": "GeneOrGenome"}, {"end": 257, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "GeneOrGenome"}, {"end": 141, "start": 131, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 147, "start": 131, "tag": "ResearchActivity"}, {"end": 141, "start": 131, "tag": "ResearchActivity"}, {"end": 43, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 106, "tag": "PopulationGroup"}, {"end": 189, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 182, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 114, "tag": "Substance"}, {"end": 121, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 259, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1441_4", "text": "Methods: Enzyme-linked immunosorbent assays (ELISAs) were performed using urine samples from the same patient and control groups analyzed in the previous proteomics study (18 AD and 18 controls, set 1) and urine samples from an independent group of AD patients and controls (13 AD, 5 mild cognitive impairment [MCI], and 32 controls) from the National Center for Geriatrics and Gerontology Biobank (set 2).", "tags": [{"end": 43, "start": 9, "tag": "ResearchActivity"}, {"end": 51, "start": 45, "tag": "ResearchActivity"}, {"end": 239, "start": 228, "tag": "Finding"}, {"end": 164, "start": 154, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 170, "start": 154, "tag": "ResearchActivity"}, {"end": 164, "start": 154, "tag": "ResearchActivity"}, {"end": 109, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 114, "tag": "PopulationGroup"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 185, "tag": "PopulationGroup"}, {"end": 273, "start": 265, "tag": "PopulationGroup"}, {"end": 332, "start": 324, "tag": "PopulationGroup"}, {"end": 260, "start": 252, "tag": "PatientOrDisabledGroup"}, {"end": 314, "start": 311, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 114, "tag": "PopulationGroup"}, {"end": 128, "start": 122, "tag": "PopulationGroup"}, {"end": 309, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 240, "tag": "PopulationGroup"}, {"end": 137, "start": 129, "tag": "ResearchActivity"}, {"end": 87, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 397, "start": 343, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1441_5", "text": "Results: In set 1, the crude urinary levels of ApoD, Igfbp3, and creatinine-adjusted ApoD were significantly higher in the AD group relative to the control group (p = 0.003, p = 0.002, and p = 0.019, respectively), consistent with our previous proteomics results.", "tags": [{"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 53, "tag": "GeneOrGenome"}, {"end": 89, "start": 85, "tag": "GeneOrGenome"}, {"end": 254, "start": 244, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 254, "start": 244, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 148, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 131, "start": 126, "tag": "PopulationGroup"}, {"end": 161, "start": 156, "tag": "PopulationGroup"}, {"end": 161, "start": 148, "tag": "PopulationGroup"}, {"end": 51, "start": 29, "tag": "ClinicalAttribute"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "Chemical"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1441_6", "text": "In set 2, however, the crude urinary levels of Igfbp3 were significantly lower in the AD+MCI group than in the control group (p = 0.028), and the levels of ApoD and ApoC3 did not differ significantly compared to the control group.", "tags": [{"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 47, "tag": "GeneOrGenome"}, {"end": 160, "start": 156, "tag": "GeneOrGenome"}, {"end": 170, "start": 165, "tag": "GeneOrGenome"}, {"end": 170, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 111, "tag": "PopulationGroup"}, {"end": 223, "start": 216, "tag": "PopulationGroup"}, {"end": 98, "start": 93, "tag": "PopulationGroup"}, {"end": 124, "start": 119, "tag": "PopulationGroup"}, {"end": 229, "start": 224, "tag": "PopulationGroup"}, {"end": 124, "start": 111, "tag": "PopulationGroup"}, {"end": 229, "start": 216, "tag": "PopulationGroup"}, {"end": 53, "start": 29, "tag": "ClinicalAttribute"}]}
{"id": "1441_7", "text": "Combined analysis of all samples revealed creatinine-adjusted ApoC3 levels to be significantly higher in the AD+MCI group ( p = 0.015) and the AD-only group (p = 0.011) relative to the control group.", "tags": [{"end": 67, "start": 62, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 185, "tag": "PopulationGroup"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 121, "start": 116, "tag": "PopulationGroup"}, {"end": 156, "start": 151, "tag": "PopulationGroup"}, {"end": 198, "start": 193, "tag": "PopulationGroup"}, {"end": 198, "start": 185, "tag": "PopulationGroup"}, {"end": 32, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 25, "tag": "Substance"}, {"end": 52, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 42, "tag": "Chemical"}]}
{"id": "1441_8", "text": "Conclusion: ApoC3 may be a potential biomarker for AD, as validated by ELISA.", "tags": [{"end": 17, "start": 12, "tag": "GeneOrGenome"}, {"end": 17, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 71, "tag": "ResearchActivity"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 27, "tag": "ClinicalAttribute"}]}
{"id": "1441_9", "text": "Further analysis of ApoC3 as a urinary biomarker for AD is warranted.", "tags": [{"end": 25, "start": 20, "tag": "GeneOrGenome"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 39, "tag": "ClinicalAttribute"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}]}
{"id": "1441_10", "text": "(c) 2020 The Author(s) Published by S.", "tags": []}
{"id": "1441_11", "text": "Karger AG, Basel", "tags": []}
{"id": "1442_0", "text": "Objective: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).", "tags": [{"end": 57, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 59, "tag": "ClinicalAttribute"}, {"end": 53, "start": 33, "tag": "ClinicalAttribute"}, {"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "TemporalConcept"}, {"end": 156, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 55, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1442_1", "text": "(1)We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity.", "tags": [{"end": 34, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 99, "tag": "BiologicFunction"}, {"end": 76, "start": 62, "tag": "CellFunction"}, {"end": 34, "start": 32, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1442_2", "text": "Background: Several non-neurological alterations have been described in sAD, mainly in skin, blood cell, and immunological capacities.", "tags": [{"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 109, "tag": "ClinicalAttribute"}, {"end": 103, "start": 93, "tag": "Cell"}]}
{"id": "1442_3", "text": "We reviewed briefly the main pathophysiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid deposits) emphasizing the most brain based hypotheses such as the updated tau-related neuron skeletal hypothesis; we also comment on the systemic theories that emphasize the fetal origin of the complex disorders that include the low inflammatory and immunity theories of sAD.", "tags": [{"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 113, "tag": "AnatomicalAbnormality"}, {"end": 222, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 379, "start": 371, "tag": "BiologicFunction"}, {"end": 395, "start": 392, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 207, "tag": "Cell"}, {"end": 11, "start": 3, "tag": "HealthCareActivity"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 307, "start": 301, "tag": "TemporalConcept"}, {"end": 19, "start": 12, "tag": "TemporalConcept"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 29, "tag": "PathologicFunction"}, {"end": 275, "start": 258, "tag": "ResearchActivity"}, {"end": 366, "start": 350, "tag": "Finding"}]}
{"id": "1442_4", "text": "New/updated hypothesis: Lf has important anti-infectious and immunomodulatory roles in health and disease.", "tags": [{"end": 26, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 41, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 87, "tag": "HealthCareActivity"}, {"end": 83, "start": 61, "tag": "Finding"}]}
{"id": "1442_5", "text": "We present the hypothesis that the reduced levels of saliva Lf could be an effect of immunological disturbances associated to sAD.", "tags": [{"end": 62, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 85, "tag": "PathologicFunction"}]}
{"id": "1442_6", "text": "Under this scenario, two alternative pathways are possible: first, whether sAD could be a systemic disorder (or disorders) related to early immunological and low inflammatory alterations; second, if systemic immunity alterations of sAD manifestations could be downstream of early sAD brain affectations.", "tags": [{"end": 78, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 175, "tag": "Finding"}, {"end": 153, "start": 140, "tag": "Finding"}, {"end": 186, "start": 158, "tag": "Finding"}, {"end": 216, "start": 208, "tag": "BiologicFunction"}, {"end": 235, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 236, "tag": "SignOrSymptom"}, {"end": 289, "start": 284, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 37, "tag": "CellFunction"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}]}
{"id": "1442_7", "text": "Major challenges for the hypothesis: The major challenge of the Lf as early sAD biomarker would be its validation in other clinical and population-based studies.", "tags": [{"end": 66, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 103, "tag": "ResearchActivity"}, {"end": 16, "start": 6, "tag": "HealthCareActivity"}, {"end": 146, "start": 136, "tag": "PopulationGroup"}, {"end": 160, "start": 153, "tag": "ResearchActivity"}, {"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 89, "start": 80, "tag": "ClinicalAttribute"}, {"end": 56, "start": 47, "tag": "HealthCareActivity"}]}
{"id": "1442_8", "text": "It is possible the decreased salivary Lf in early sAD could be related to immunological modulation actions, but other different unknown mechanisms could be the origin of such reduction.", "tags": [{"end": 40, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 160, "tag": "TemporalConcept"}, {"end": 37, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 175, "tag": "Finding"}, {"end": 184, "start": 175, "tag": "NaturalPhenomenonOrProcess"}, {"end": 106, "start": 74, "tag": "Finding"}, {"end": 40, "start": 29, "tag": "ClinicalAttribute"}]}
{"id": "1442_9", "text": "Linkage to other major theories: This hypothesis is in agreement with two physiopathological explanations of the sAD as a downstream process determined by the early lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or as a consequence of low neuroinflammation and dysimmunity since the early life aggravated in the elderly (immunosenescence).", "tags": [{"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 269, "tag": "Finding"}, {"end": 371, "start": 355, "tag": "BiologicFunction"}, {"end": 192, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 243, "start": 226, "tag": "CellOrMolecularDysfunction"}, {"end": 290, "start": 273, "tag": "PathologicFunction"}, {"end": 172, "start": 165, "tag": "InjuryOrPoisoning"}, {"end": 327, "start": 323, "tag": "TemporalConcept"}, {"end": 353, "start": 346, "tag": "PopulationGroup"}, {"end": 306, "start": 295, "tag": "PathologicFunction"}, {"end": 224, "start": 197, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1443_0", "text": "Introduction: Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration.", "tags": [{"end": 31, "start": 23, "tag": "BiologicFunction"}, {"end": 73, "start": 66, "tag": "Chemical"}, {"end": 115, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 42, "start": 32, "tag": "ClinicalAttribute"}, {"end": 94, "start": 77, "tag": "PathologicFunction"}]}
{"id": "1443_1", "text": "This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative-funded project AETIONOMY.", "tags": [{"end": 171, "start": 163, "tag": "PopulationGroup"}, {"end": 229, "start": 212, "tag": "ResearchActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 204, "start": 163, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1443_2", "text": "Methods: A total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF.", "tags": [{"end": 75, "start": 68, "tag": "NaturalPhenomenonOrProcess"}, {"end": 130, "start": 122, "tag": "BiologicFunction"}, {"end": 48, "start": 41, "tag": "ResearchActivity"}, {"end": 141, "start": 131, "tag": "ClinicalAttribute"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 75, "start": 68, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "ResearchActivity"}]}
{"id": "1443_3", "text": "Results were compared to data of an independent cohort of 399 subjects previously published.", "tags": [{"end": 29, "start": 25, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 48, "tag": "PopulationGroup"}, {"end": 70, "start": 62, "tag": "PopulationGroup"}]}
{"id": "1443_4", "text": "Results: Immunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex, APOE genotype, and center-specific factors.", "tags": [{"end": 17, "start": 9, "tag": "BiologicFunction"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 162, "tag": "OrganismAttribute"}, {"end": 113, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 145, "tag": "BiologicFunction"}, {"end": 150, "start": 145, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 136, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 9, "tag": "ClinicalAttribute"}, {"end": 143, "start": 129, "tag": "ClinicalAttribute"}, {"end": 113, "start": 78, "tag": "ClinicalAttribute"}]}
{"id": "1443_5", "text": "Discussion: Immunity biomarker levels in CSF reflect molecular and cellular pathology rather than diagnosis in neurodegenerative disorders.", "tags": [{"end": 20, "start": 12, "tag": "BiologicFunction"}, {"end": 62, "start": 53, "tag": "CellFunction"}, {"end": 85, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1443_6", "text": "Assay standardization and stratification for age and other covariates could improve the power of such markers in clinical applications or intervention studies targeting immune responses in neurodegeneration.", "tags": [{"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 6, "tag": "ResearchActivity"}, {"end": 185, "start": 169, "tag": "BiologicFunction"}, {"end": 134, "start": 113, "tag": "HealthCareActivity"}, {"end": 40, "start": 26, "tag": "ResearchActivity"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 206, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 138, "tag": "ResearchActivity"}]}
{"id": "1444_0", "text": "Background An association has been found between the presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid and a more severe clinical multiple sclerosis course.", "tags": [{"end": 70, "start": 65, "tag": "Chemical"}, {"end": 152, "start": 146, "tag": "Finding"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 129, "tag": "Substance"}, {"end": 134, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 181, "tag": "TemporalConcept"}, {"end": 101, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 103, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1444_1", "text": "Objective To investigate lipid-specific oligoclonal IgM bands as a prognostic biomarker of cognitive impairment in the early stages of multiple sclerosis.", "tags": [{"end": 131, "start": 119, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "TemporalConcept"}, {"end": 30, "start": 25, "tag": "Chemical"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}, {"end": 87, "start": 67, "tag": "ClinicalAttribute"}, {"end": 153, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 25, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1444_2", "text": "Methods Forty-four patients underwent neuropsychological assessment at baseline and 4 years.", "tags": [{"end": 67, "start": 38, "tag": "HealthCareActivity"}, {"end": 91, "start": 86, "tag": "TemporalConcept"}, {"end": 27, "start": 19, "tag": "PatientOrDisabledGroup"}]}
{"id": "1444_3", "text": "Cognitive performance at follow-up was compared adjusting by age, education, anxiety-depression, and baseline performance.", "tags": [{"end": 75, "start": 66, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}, {"end": 121, "start": 101, "tag": "ClinicalAttribute"}, {"end": 95, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 61, "tag": "OrganismAttribute"}, {"end": 84, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}]}
{"id": "1444_4", "text": "Results LS-OCMB+ patients only performed worse for Long-Term Storage in the Selective Reminding Test (p = .018).", "tags": [{"end": 60, "start": 51, "tag": "TemporalConcept"}, {"end": 60, "start": 51, "tag": "HealthCareActivity"}, {"end": 68, "start": 61, "tag": "CellComponent"}, {"end": 68, "start": 61, "tag": "BiologicFunction"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 76, "tag": "HealthCareActivity"}]}
{"id": "1444_5", "text": "Conclusion There are no remarkable cognitive differences between LS-OCMB- and LS-OCMB+ patients in the early stages of MS.", "tags": [{"end": 115, "start": 103, "tag": "TemporalConcept"}, {"end": 115, "start": 109, "tag": "TemporalConcept"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 78, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1445_0", "text": "Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal fluid (CSF) p-tau181, and AV1451 positron emission tomography (PET).", "tags": [{"end": 66, "start": 53, "tag": "Finding"}, {"end": 202, "start": 196, "tag": "Chemical"}, {"end": 126, "start": 112, "tag": "CellFunction"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 43, "tag": "ClinicalAttribute"}, {"end": 175, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 233, "tag": "HealthCareActivity"}, {"end": 175, "start": 170, "tag": "Substance"}, {"end": 231, "start": 203, "tag": "HealthCareActivity"}, {"end": 231, "start": 203, "tag": "ManufacturedObject"}, {"end": 143, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 196, "tag": "PharmacologicSubstance"}]}
{"id": "1445_1", "text": "Methods In the Alzheimer's Disease Neuroimaging Initiative, 724 non-demented participants were categorized into plasma/CSF and plasma/PET groups.", "tags": [{"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 77, "tag": "PopulationGroup"}, {"end": 137, "start": 134, "tag": "HealthCareActivity"}, {"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 138, "tag": "PopulationGroup"}, {"end": 58, "start": 15, "tag": "ResearchActivity"}, {"end": 76, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 15, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1445_2", "text": "Demographic and clinical variables, amyloid-beta (A beta) burden, flortaucipir-PET binding in Braak regions of interest (ROIs), longitudinal changes in clinical outcomes, and conversion risk were compared.", "tags": [{"end": 185, "start": 175, "tag": "CellFunction"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}, {"end": 148, "start": 128, "tag": "ResearchActivity"}, {"end": 48, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "HealthCareActivity"}, {"end": 169, "start": 161, "tag": "Finding"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "ResearchActivity"}, {"end": 190, "start": 175, "tag": "ClinicalAttribute"}, {"end": 169, "start": 152, "tag": "ClinicalAttribute"}, {"end": 78, "start": 66, "tag": "Chemical"}, {"end": 119, "start": 94, "tag": "ResearchActivity"}]}
{"id": "1445_3", "text": "Results Across different tau biomarker groups, the proportion of participants with a discordant profile varied (plasma+/CSF- 15.6%, plasma-/CSF+ 15.3%, plasma+/PET- 22.4%, and plasma-/PET+ 6.1%).", "tags": [{"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 77, "start": 65, "tag": "PopulationGroup"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}, {"end": 187, "start": 184, "tag": "HealthCareActivity"}, {"end": 45, "start": 39, "tag": "PopulationGroup"}]}
{"id": "1445_4", "text": "Within the plasma/CSF categories, we found an increase from concordant-negative to discordant to concordant-positive in the frequency of A beta pathology or cognitive impairment, rates of cognitive decline, and risk of cognitive conversion.", "tags": [{"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}, {"end": 153, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 205, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "TemporalConcept"}, {"end": 239, "start": 211, "tag": "Finding"}]}
{"id": "1445_5", "text": "However, the two discordant categories (plasma+/CSF- and plasma-/CSF+) showed comparable performances, resulting in similarly reduced cognitive capacities.", "tags": [{"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 89, "tag": "IndividualBehavior"}, {"end": 154, "start": 126, "tag": "Finding"}]}
{"id": "1445_6", "text": "Regarding plasma/PET categories, as expected, PET-positive individuals had increased A beta burden, elevated flortaucipir retention in Braak ROIs, and accelerated cognitive deterioration than concordant-negative persons.", "tags": [{"end": 131, "start": 122, "tag": "BiologicFunction"}, {"end": 131, "start": 122, "tag": "ClinicalAttribute"}, {"end": 131, "start": 122, "tag": "CellFunction"}, {"end": 186, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 212, "tag": "PopulationGroup"}, {"end": 98, "start": 92, "tag": "ResearchActivity"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 59, "tag": "PopulationGroup"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 49, "start": 46, "tag": "HealthCareActivity"}, {"end": 91, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 135, "tag": "ResearchActivity"}, {"end": 121, "start": 109, "tag": "Chemical"}]}
{"id": "1445_7", "text": "Noteworthy, discordant participants with normal PET exhibited reduced flortaucipir uptake in Braak stage ROIs and slower rates of cognitive decline, relative to those PET-positive.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 89, "start": 83, "tag": "CellFunction"}, {"end": 35, "start": 23, "tag": "PopulationGroup"}, {"end": 47, "start": 41, "tag": "Finding"}, {"end": 51, "start": 48, "tag": "HealthCareActivity"}, {"end": 170, "start": 167, "tag": "HealthCareActivity"}, {"end": 147, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 93, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "Chemical"}]}
{"id": "1445_8", "text": "Therefore, individuals with PET abnormality appeared to have advanced tau pathological changes and poorer cognitive function, regardless of the plasma status.", "tags": [{"end": 124, "start": 106, "tag": "BiologicFunction"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 151, "tag": "Finding"}, {"end": 22, "start": 11, "tag": "PopulationGroup"}, {"end": 31, "start": 28, "tag": "HealthCareActivity"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}, {"end": 94, "start": 61, "tag": "Finding"}]}
{"id": "1445_9", "text": "Furthermore, these results were found only in individuals with A beta pathology.", "tags": [{"end": 79, "start": 70, "tag": "PathologicFunction"}, {"end": 79, "start": 70, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 57, "start": 46, "tag": "PopulationGroup"}, {"end": 69, "start": 63, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1445_10", "text": "Conclusions Our results indicate that plasma and CSF p-tau181 abnormalities associated with amyloidosis occur simultaneously in the progression of AD pathogenesis and related cognitive decline, before tau-PET turns positive.", "tags": [{"end": 103, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 150, "tag": "PathologicFunction"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 204, "start": 201, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 201, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 205, "tag": "HealthCareActivity"}, {"end": 143, "start": 132, "tag": "PathologicFunction"}, {"end": 143, "start": 132, "tag": "TemporalConcept"}, {"end": 192, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 110, "tag": "TemporalConcept"}, {"end": 61, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 53, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1446_0", "text": "Vascular dementia (VD) and Alzheimer's disease (AD) are common types of dementia for which no curative therapies are known.", "tags": [{"end": 17, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 103, "tag": "HealthCareActivity"}, {"end": 46, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "DiseaseOrSyndrome"}]}
{"id": "1446_1", "text": "In this study, we identified hub genes associated with AD and VD in order to explore new potential therapeutic targets.", "tags": [{"end": 118, "start": 89, "tag": "ResearchActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 29, "tag": "GeneOrGenome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}
{"id": "1446_2", "text": "Genes differentially expressed in VD and AD in all three datasets (GSE122063, GSE132903, and GSE5281) were identified and used to construct a protein-protein interaction network.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 177, "start": 142, "tag": "CellFunction"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "CellFunction"}, {"end": 117, "start": 107, "tag": "Finding"}, {"end": 30, "start": 6, "tag": "Finding"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 76, "start": 67, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "ResearchActivity"}, {"end": 100, "start": 93, "tag": "ResearchActivity"}]}
{"id": "1446_3", "text": "We identified 10 modules containing 427 module genes in AD and VD.", "tags": [{"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 40, "tag": "GeneOrGenome"}]}
{"id": "1446_4", "text": "Module genes showing an area under the diagnostic curve > 0.60 for AD or VD were used to construct a least absolute shrinkage and selection operator model and were entered into a support vector machine-recursive feature elimination algorithm, which identified REPS1 as a hub gene in AD and VD.", "tags": [{"end": 265, "start": 260, "tag": "GeneOrGenome"}, {"end": 125, "start": 116, "tag": "Finding"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 292, "start": 290, "tag": "HealthCareActivity"}, {"end": 241, "start": 202, "tag": "MachineActivity"}, {"end": 201, "start": 179, "tag": "MachineActivity"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 154, "start": 149, "tag": "ResearchActivity"}, {"end": 55, "start": 24, "tag": "ResearchActivity"}, {"end": 279, "start": 271, "tag": "GeneOrGenome"}, {"end": 265, "start": 260, "tag": "AminoAcidPeptideOrProtein"}, {"end": 265, "start": 260, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1446_5", "text": "Furthermore, REPS1 was associated with activation of pyruvate metabolism and inhibition of Ras signaling pathway.", "tags": [{"end": 18, "start": 13, "tag": "GeneOrGenome"}, {"end": 72, "start": 53, "tag": "CellFunction"}, {"end": 112, "start": 91, "tag": "CellFunction"}, {"end": 87, "start": 77, "tag": "CellFunction"}, {"end": 72, "start": 62, "tag": "BiologicFunction"}, {"end": 72, "start": 62, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 13, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1446_6", "text": "Module genes, together with differentially expressed microRNAs from the dataset GSE46579, were used to construct a regulatory network.", "tags": [{"end": 133, "start": 115, "tag": "CellFunction"}, {"end": 62, "start": 53, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 80, "tag": "ResearchActivity"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 52, "start": 28, "tag": "Finding"}]}
{"id": "1446_7", "text": "REPS1 was predicted to bind to the microRNA hsa_miR_5701.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 27, "start": 23, "tag": "CellFunction"}, {"end": 56, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1446_8", "text": "Single-sample gene set enrichment analysis was used to explore immune cell infiltration, which suggested a negative correlation between REPS1 expression and infiltration by plasmacytoid dendritic cells in AD and VD.", "tags": [{"end": 74, "start": 63, "tag": "Cell"}, {"end": 185, "start": 173, "tag": "Cell"}, {"end": 201, "start": 186, "tag": "Cell"}, {"end": 214, "start": 212, "tag": "HealthCareActivity"}, {"end": 42, "start": 14, "tag": "ResearchActivity"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "Substance"}, {"end": 13, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 63, "tag": "CellFunction"}, {"end": 127, "start": 107, "tag": "ResearchActivity"}, {"end": 152, "start": 136, "tag": "CellFunction"}]}
{"id": "1446_9", "text": "In conclusion, our results suggest core pathways involved in both AD and VD, and they identify REPS1 as a potential biomarker of both diseases.", "tags": [{"end": 48, "start": 35, "tag": "CellFunction"}, {"end": 100, "start": 95, "tag": "GeneOrGenome"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "CellFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 106, "tag": "ClinicalAttribute"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1446_10", "text": "This protein may aid in early diagnosis, monitoring of treatment response, and even efforts to prevent these debilitating disorders.", "tags": [{"end": 73, "start": 55, "tag": "ClinicalAttribute"}, {"end": 131, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "ResearchActivity"}, {"end": 39, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 73, "start": 65, "tag": "OrganismAttribute"}, {"end": 39, "start": 24, "tag": "HealthCareActivity"}]}
{"id": "1447_0", "text": "IMPORTANCE There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD).", "tags": [{"end": 137, "start": 122, "tag": "TemporalConcept"}, {"end": 29, "start": 20, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "Finding"}, {"end": 158, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 55, "tag": "ClinicalAttribute"}, {"end": 108, "start": 96, "tag": "Finding"}, {"end": 91, "start": 79, "tag": "ResearchActivity"}]}
{"id": "1447_1", "text": "OBJECTIVE To describe longitudinal [F-18]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.", "tags": [{"end": 278, "start": 268, "tag": "ResearchActivity"}, {"end": 267, "start": 253, "tag": "ResearchActivity"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 226, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 151, "tag": "ClinicalAttribute"}, {"end": 84, "start": 81, "tag": "HealthCareActivity"}, {"end": 233, "start": 230, "tag": "HealthCareActivity"}, {"end": 79, "start": 51, "tag": "HealthCareActivity"}, {"end": 46, "start": 35, "tag": "Chemical"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}]}
{"id": "1447_2", "text": "DESIGN, SETTING, AND PARTICIPANTS This longitudinal cohort study consecutively enrolled amyloid-beta (A beta)-negative cognitively unimpaired (CU) participants, A beta-positive CU individuals, A beta-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish BioFINDER-2 (discovery cohort) and BioFINDER-1 (validation cohort) studies.", "tags": [{"end": 64, "start": 39, "tag": "ResearchActivity"}, {"end": 349, "start": 342, "tag": "PopulationGroup"}, {"end": 141, "start": 119, "tag": "Finding"}, {"end": 408, "start": 398, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "BiologicFunction"}, {"end": 282, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 147, "tag": "PopulationGroup"}, {"end": 191, "start": 180, "tag": "PopulationGroup"}, {"end": 220, "start": 209, "tag": "PopulationGroup"}, {"end": 274, "start": 263, "tag": "PopulationGroup"}, {"end": 424, "start": 417, "tag": "ResearchActivity"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 291, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 372, "start": 363, "tag": "ResearchActivity"}, {"end": 100, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 379, "start": 373, "tag": "PopulationGroup"}, {"end": 415, "start": 409, "tag": "PopulationGroup"}, {"end": 361, "start": 350, "tag": "ResearchActivity"}, {"end": 396, "start": 385, "tag": "ResearchActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1447_3", "text": "EXPOSURES Baseline plasma and cerebrospinal fluid A beta 42/A beta 40, tau phosphorylated at threonine-217 (p-tau217), p-tau181 and neurofilament light, magnetic resonance imaging, amyloid PET ([F-18]flutemetamol), and tau PET ([F-18]RO948 in the BioFINDER-2 study; [F-18]flortaucipir in the BioFINDER-1 study).", "tags": [{"end": 151, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 75, "tag": "CellFunction"}, {"end": 284, "start": 266, "tag": "Chemical"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 247, "tag": "ResearchActivity"}, {"end": 309, "start": 292, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 226, "start": 223, "tag": "HealthCareActivity"}, {"end": 179, "start": 153, "tag": "HealthCareActivity"}, {"end": 69, "start": 30, "tag": "ClinicalAttribute"}, {"end": 106, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 228, "tag": "Chemical"}, {"end": 212, "start": 194, "tag": "Chemical"}]}
{"id": "1447_4", "text": "MAIN OUTCOMES AND MEASURES Baseline tau PET standardized uptake value ratio (SUVR) and annual percent change in tau PET SUVR across regions of interest derived using a data-driven approach combining clustering and event-based modeling.", "tags": [{"end": 234, "start": 214, "tag": "ResearchActivity"}, {"end": 151, "start": 132, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 168, "tag": "ResearchActivity"}, {"end": 93, "start": 87, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 119, "start": 116, "tag": "HealthCareActivity"}, {"end": 75, "start": 44, "tag": "ResearchActivity"}, {"end": 81, "start": 77, "tag": "ResearchActivity"}, {"end": 124, "start": 120, "tag": "ResearchActivity"}]}
{"id": "1447_5", "text": "Regression models were used to examine associations between individual biomarkers and longitudinal tau PET and to identify which combinations best predicted longitudinal tau PET.", "tags": [{"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 70, "start": 60, "tag": "OrganismAttribute"}, {"end": 106, "start": 103, "tag": "HealthCareActivity"}, {"end": 177, "start": 157, "tag": "HealthCareActivity"}]}
{"id": "1447_6", "text": "These combinations were then entered in a power analysis to examine how their use as an enrichment strategy would affect sample size in a simulated clinical trial.", "tags": [{"end": 162, "start": 148, "tag": "ResearchActivity"}, {"end": 132, "start": 128, "tag": "OrganismAttribute"}, {"end": 56, "start": 42, "tag": "ResearchActivity"}, {"end": 127, "start": 121, "tag": "Substance"}, {"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1447_7", "text": "RESULTS Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female.", "tags": [{"end": 98, "start": 92, "tag": "OrganismAttribute"}, {"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 46, "start": 43, "tag": "OrganismAttribute"}, {"end": 69, "start": 64, "tag": "TemporalConcept"}, {"end": 41, "start": 39, "tag": "ResearchActivity"}]}
{"id": "1447_8", "text": "The clustering/event-based modeling-based approach identified 5 regions of interest (stages).", "tags": [{"end": 50, "start": 4, "tag": "ResearchActivity"}, {"end": 91, "start": 85, "tag": "TemporalConcept"}, {"end": 83, "start": 64, "tag": "ResearchActivity"}]}
{"id": "1447_9", "text": "In A beta-positive CU individuals, the largest annual increase in tau PET SUVR was seen in stage I (entorhinal cortex, hippocampus, and amygdala; 4.04% [95% CI, 2.67%-5.32%]).", "tags": [{"end": 117, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 22, "tag": "PopulationGroup"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}, {"end": 159, "start": 157, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 91, "tag": "TemporalConcept"}, {"end": 96, "start": 91, "tag": "ClinicalAttribute"}, {"end": 78, "start": 74, "tag": "ResearchActivity"}]}
{"id": "1447_10", "text": "In A beta-positive individuals with MCI and with AD dementia, the greatest increases were seen in stages II (temporal cortical regions; 4.45% [95% CI, 3.41%-5.49%]) and IV (certain frontal regions; 5.22% [95% CI, 3.95%-6.49%]), respectively.", "tags": [{"end": 134, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 19, "tag": "PopulationGroup"}, {"end": 60, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "ResearchActivity"}, {"end": 211, "start": 209, "tag": "ResearchActivity"}, {"end": 196, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1447_11", "text": "In A beta-negative CU individuals and those with MCI, modest change was seen in stage I (1.38% [95% CI, 0.78%-1.99%] and 1.80% [95% CI, 0.76%-2.84%], respectively).", "tags": [{"end": 33, "start": 22, "tag": "PopulationGroup"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "ResearchActivity"}, {"end": 134, "start": 132, "tag": "ResearchActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 85, "start": 80, "tag": "ClinicalAttribute"}, {"end": 67, "start": 54, "tag": "Finding"}]}
{"id": "1447_12", "text": "When looking at individual predictors and longitudinal tau PET in the stages that showed most change, plasma p-tau217 (R-2 = 0.27, P < .005), tau PET (stage I baseline SUVR; R-2 = 0.13, P < .05) and amyloid PET (R-2 = 0.10, P < .05) were significantly associated with longitudinal tau PET in stage I in A beta-positive CU individuals.", "tags": [{"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 37, "start": 27, "tag": "Finding"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 284, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 284, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 333, "start": 322, "tag": "PopulationGroup"}, {"end": 206, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 16, "tag": "PopulationGroup"}, {"end": 26, "start": 16, "tag": "OrganismAttribute"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}, {"end": 149, "start": 146, "tag": "HealthCareActivity"}, {"end": 210, "start": 207, "tag": "HealthCareActivity"}, {"end": 288, "start": 285, "tag": "HealthCareActivity"}, {"end": 309, "start": 303, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 268, "tag": "ResearchActivity"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 297, "start": 292, "tag": "TemporalConcept"}, {"end": 156, "start": 151, "tag": "ClinicalAttribute"}, {"end": 297, "start": 292, "tag": "ClinicalAttribute"}, {"end": 117, "start": 102, "tag": "ClinicalAttribute"}, {"end": 172, "start": 168, "tag": "ResearchActivity"}]}
{"id": "1447_13", "text": "In A beta-positive individuals with MCI, plasma p-tau217 (R-2 = 0.24, P < .005) and tau PET (stage II baseline SUVR; R-2 = 0.44, P < .001) were significantly associated with longitudinal tau PET in stage II.", "tags": [{"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 19, "tag": "PopulationGroup"}, {"end": 39, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "HealthCareActivity"}, {"end": 194, "start": 174, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 93, "tag": "TemporalConcept"}, {"end": 203, "start": 198, "tag": "TemporalConcept"}, {"end": 98, "start": 93, "tag": "ClinicalAttribute"}, {"end": 203, "start": 198, "tag": "ClinicalAttribute"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 111, "tag": "ResearchActivity"}]}
{"id": "1447_14", "text": "Findings were replicated in BioFINDER-1 using longitudinal [F-18]flortaucipir.", "tags": [{"end": 77, "start": 59, "tag": "Chemical"}, {"end": 39, "start": 28, "tag": "ResearchActivity"}]}
{"id": "1447_15", "text": "For the power analysis component, plasma p-tau217 with tau PET resulted in sample size reductions of 43% (95% CI, 34%-46%; P < .005) in A beta-positive CU individuals and of 68% (95% CI, 61%-73%; P < .001) in A beta-positive individuals with MCI.", "tags": [{"end": 97, "start": 87, "tag": "NaturalPhenomenonOrProcess"}, {"end": 97, "start": 87, "tag": "HealthCareActivity"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 155, "tag": "PopulationGroup"}, {"end": 236, "start": 225, "tag": "PopulationGroup"}, {"end": 245, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "OrganismAttribute"}, {"end": 112, "start": 110, "tag": "ResearchActivity"}, {"end": 185, "start": 183, "tag": "ResearchActivity"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}, {"end": 62, "start": 59, "tag": "HealthCareActivity"}, {"end": 142, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 75, "tag": "Substance"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 34, "tag": "ClinicalAttribute"}]}
{"id": "1447_16", "text": "CONCLUSIONS AND RELEVANCE In trials using tau PET as the outcome, plasma p-tau217 with tau PET may prove optimal for enrichment in preclinical and prodromal AD.", "tags": [{"end": 64, "start": 57, "tag": "Finding"}, {"end": 127, "start": 117, "tag": "ResearchActivity"}, {"end": 159, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 81, "start": 66, "tag": "ClinicalAttribute"}]}
{"id": "1447_17", "text": "However, plasma p-tau217 was most important in preclinical AD, while tau PET was more important in prodromal AD.", "tags": [{"end": 111, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 24, "start": 9, "tag": "ClinicalAttribute"}, {"end": 76, "start": 69, "tag": "ClinicalAttribute"}]}
{"id": "1448_0", "text": "Introduction: Amyloid beta (A beta) deposition was identified to precede tau pathology and neurodegeneration in familial Alzheimer's disease (AD).", "tags": [{"end": 120, "start": 112, "tag": "PopulationGroup"}, {"end": 140, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 73, "tag": "PathologicFunction"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 61, "start": 51, "tag": "Finding"}, {"end": 26, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1448_1", "text": "But the divergence between sporadic and familial AD limits the extension of these findings to sporadic AD.", "tags": [{"end": 48, "start": 40, "tag": "PopulationGroup"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "TemporalConcept"}]}
{"id": "1448_2", "text": "Methods: Longitudinal changes of biomarkers among different stages were assessed using linear mixed-effects models.", "tags": [{"end": 21, "start": 9, "tag": "ResearchActivity"}, {"end": 114, "start": 87, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "TemporalConcept"}, {"end": 43, "start": 33, "tag": "ClinicalAttribute"}, {"end": 107, "start": 100, "tag": "Finding"}, {"end": 107, "start": 100, "tag": "PathologicFunction"}]}
{"id": "1448_3", "text": "The slopes of the models were used to estimate rates of change to calculate the biomarker trajectories in sporadic AD.", "tags": [{"end": 117, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 80, "tag": "ClinicalAttribute"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "TemporalConcept"}]}
{"id": "1448_4", "text": "Results: Cerebrospinal fluid (CSF) A beta was estimated to decline 45.2 years (abnormal: 27.8 years) before dementia, and A beta deposition seemed to increase 31.7 years (abnormal: 26.7 years) before dementia.", "tags": [{"end": 99, "start": 92, "tag": "TemporalConcept"}, {"end": 28, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "Finding"}, {"end": 179, "start": 171, "tag": "Finding"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 199, "start": 193, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 99, "start": 94, "tag": "TemporalConcept"}, {"end": 169, "start": 164, "tag": "TemporalConcept"}, {"end": 191, "start": 186, "tag": "TemporalConcept"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 122, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1448_5", "text": "It was estimated to take 29.0 years (CSF t-tau), 12.2 years (memory), 11.6 years (hippocampus), 9.3 years (hypometabolism), and 6.1 years (cognition) to move from normal to dementia.", "tags": [{"end": 121, "start": 107, "tag": "Finding"}, {"end": 80, "start": 73, "tag": "TemporalConcept"}, {"end": 169, "start": 163, "tag": "Finding"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "TemporalConcept"}, {"end": 59, "start": 54, "tag": "TemporalConcept"}, {"end": 80, "start": 75, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "TemporalConcept"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 148, "start": 139, "tag": "BiologicFunction"}, {"end": 93, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "BiologicFunction"}]}
{"id": "1448_6", "text": "Discussion: The trajectory in sporadic AD is led by A beta accumulation, followed by CSF t-tau increase, memory deficits, brain atrophy, hypometabolism, and cognitive decline.", "tags": [{"end": 120, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 137, "tag": "Finding"}, {"end": 135, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 91, "tag": "Finding"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 30, "tag": "TemporalConcept"}, {"end": 58, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 111, "start": 105, "tag": "BiologicFunction"}]}
{"id": "1449_0", "text": "Posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA) are clinical syndromes that commonly have underlying Alzheimer's disease (AD), although non-AD pathologies have also been reported.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "ResearchActivity"}, {"end": 179, "start": 168, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 18, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 37, "tag": "DiseaseOrSyndrome"}]}
{"id": "1449_1", "text": "PET imaging allows for identification of beta-amyloid (A beta) and tau in AD, so we aimed to assess these in a large cohort to identify patients that do not have evidence for biomarker-defined AD.", "tags": [{"end": 11, "start": 0, "tag": "HealthCareActivity"}, {"end": 53, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 4, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 175, "tag": "ClinicalAttribute"}, {"end": 144, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 117, "tag": "PopulationGroup"}]}
{"id": "1449_2", "text": "Eight-one patients, 47 PCA and 34 LPA, underwent extensive neurological and neuropsychological testing, [C-11] Pittsburgh compound B, [F-18] flortaucipir and [F-18] fluorodeoxyglucose PETs.", "tags": [{"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "Chemical"}, {"end": 26, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 23, "tag": "ResearchActivity"}, {"end": 102, "start": 76, "tag": "HealthCareActivity"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 102, "start": 95, "tag": "HealthCareActivity"}, {"end": 94, "start": 76, "tag": "HealthCareActivity"}, {"end": 132, "start": 104, "tag": "Chemical"}, {"end": 183, "start": 158, "tag": "Chemical"}, {"end": 188, "start": 184, "tag": "HealthCareActivity"}]}
{"id": "1449_3", "text": "Global A beta and tau-PET standardized uptake value ratios (SUVRs) were plotted for all patients and outliers, and patients with abnormally low SUVRs compared to the biomarker-classic cohort were identified.", "tags": [{"end": 143, "start": 140, "tag": "Finding"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 166, "tag": "ClinicalAttribute"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "HealthCareActivity"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 184, "tag": "PopulationGroup"}, {"end": 58, "start": 26, "tag": "ResearchActivity"}, {"end": 65, "start": 60, "tag": "ResearchActivity"}, {"end": 149, "start": 144, "tag": "ResearchActivity"}]}
{"id": "1449_4", "text": "Six (7.4%) biomarker-outlier cases were identified, and three patterns were observed: (i) negative/borderline A beta-PET and striking widespread tau-PET uptake (two LPA); (ii) negative/borderline A beta-PET and low tau-PET uptake (three PCA) and (iii) elevated A beta-PET uptake but mild focal tau-PET uptake (one LPA).", "tags": [{"end": 168, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 237, "tag": "ResearchActivity"}, {"end": 214, "start": 211, "tag": "Finding"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 297, "start": 294, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 294, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 11, "tag": "ClinicalAttribute"}, {"end": 120, "start": 117, "tag": "HealthCareActivity"}, {"end": 152, "start": 149, "tag": "HealthCareActivity"}, {"end": 206, "start": 203, "tag": "HealthCareActivity"}, {"end": 222, "start": 219, "tag": "HealthCareActivity"}, {"end": 271, "start": 268, "tag": "HealthCareActivity"}, {"end": 301, "start": 298, "tag": "HealthCareActivity"}, {"end": 116, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 267, "start": 261, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 283, "tag": "Finding"}, {"end": 70, "start": 62, "tag": "ResearchActivity"}, {"end": 159, "start": 153, "tag": "BiologicFunction"}, {"end": 229, "start": 223, "tag": "BiologicFunction"}, {"end": 278, "start": 272, "tag": "BiologicFunction"}, {"end": 308, "start": 302, "tag": "BiologicFunction"}, {"end": 159, "start": 153, "tag": "CellFunction"}, {"end": 229, "start": 223, "tag": "CellFunction"}, {"end": 278, "start": 272, "tag": "CellFunction"}, {"end": 308, "start": 302, "tag": "CellFunction"}]}
{"id": "1449_5", "text": "Among the unusual patients in group ii, two patients showed no abnormal tau uptake suggesting non-AD pathology, with one developing features of cortico-basal syndrome and the other dementia with Lewy bodies.", "tags": [{"end": 71, "start": 63, "tag": "Finding"}, {"end": 206, "start": 195, "tag": "CellComponent"}, {"end": 206, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 189, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 101, "tag": "PathologicFunction"}, {"end": 110, "start": 101, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 30, "tag": "PopulationGroup"}, {"end": 82, "start": 76, "tag": "BiologicFunction"}, {"end": 82, "start": 76, "tag": "CellFunction"}]}
{"id": "1449_6", "text": "The remaining patient showed very mild focal tau uptake.", "tags": [{"end": 21, "start": 14, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 34, "tag": "Finding"}, {"end": 55, "start": 49, "tag": "BiologicFunction"}, {"end": 55, "start": 49, "tag": "CellFunction"}]}
{"id": "1449_7", "text": "This study demonstrates that a small minority (similar to 8%) of PCA and LPA patients do not show the typical striking patterns of A beta and tau PET uptake, with only 2% showing absence of both proteins.", "tags": [{"end": 45, "start": 37, "tag": "PopulationGroup"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "ResearchActivity"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 77, "tag": "PatientOrDisabledGroup"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 203, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 146, "tag": "HealthCareActivity"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 119, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "BiologicFunction"}, {"end": 156, "start": 150, "tag": "CellFunction"}]}
{"id": "1449_8", "text": "These findings will help inform the use of molecular PET in clinical treatment trials that include patients with atypical phenotypes of AD.", "tags": [{"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 60, "tag": "ResearchActivity"}, {"end": 132, "start": 122, "tag": "OrganismAttribute"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 56, "start": 53, "tag": "HealthCareActivity"}, {"end": 78, "start": 60, "tag": "HealthCareActivity"}]}
{"id": "1450_0", "text": "INTRODUCTIONSecernin-1 (SCRN1) is a neuronal protein that co-localizes with neurofibrillary tangles in Alzheimer's disease (AD), but not with tau inclusions in corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), or Pick's disease.", "tags": [{"end": 52, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 76, "tag": "CellComponent"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "Cell"}, {"end": 99, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 156, "start": 142, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1450_1", "text": "METHODSWe measured SCRN1 concentration in cerebrospinal fluid (CSF) using a novel mass spectrometric parallel reaction monitoring method in three clinical cohorts comprising patients with neurochemically characterized AD (n = 25) and controls (n = 28), clinically diagnosed Parkinson's disease (PD; n = 38), multiple system atrophy (MSA; n = 31), PSP (n = 20), CBD (n = 8), healthy controls (n = 37), and neuropathology-confirmed AD (n = 47).", "tags": [{"end": 38, "start": 25, "tag": "BiologicFunction"}, {"end": 331, "start": 308, "tag": "PathologicFunction"}, {"end": 336, "start": 333, "tag": "PathologicFunction"}, {"end": 350, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 364, "start": 361, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 432, "start": 430, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 234, "tag": "PopulationGroup"}, {"end": 182, "start": 174, "tag": "PatientOrDisabledGroup"}, {"end": 419, "start": 405, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 419, "start": 405, "tag": "PathologicFunction"}, {"end": 381, "start": 374, "tag": "OrganismAttribute"}, {"end": 273, "start": 264, "tag": "HealthCareActivity"}, {"end": 293, "start": 274, "tag": "DiseaseOrSyndrome"}, {"end": 297, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 155, "tag": "PopulationGroup"}, {"end": 390, "start": 374, "tag": "PopulationGroup"}, {"end": 136, "start": 82, "tag": "ResearchActivity"}, {"end": 136, "start": 82, "tag": "HealthCareActivity"}, {"end": 24, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 19, "tag": "GeneOrGenome"}, {"end": 24, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 19, "tag": "ClinicalAttribute"}]}
{"id": "1450_2", "text": "RESULTSCSF SCRN1 was significantly increased in AD (P < 0.01, fold change = 1.4) compared to controls (receiver operating characteristic area under the curve = 0.78) but not in CBD, PSP, PD, or MSA.", "tags": [{"end": 180, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "PathologicFunction"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 93, "tag": "PopulationGroup"}, {"end": 44, "start": 21, "tag": "Finding"}, {"end": 157, "start": 137, "tag": "ResearchActivity"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 7, "tag": "ClinicalAttribute"}]}
{"id": "1450_3", "text": "CSF SCRN1 positively correlated with CSF total tau (R = 0.78, P = 1.1 x 10(-13)), phosphorylated tau(181) (R = 0.64, P = 3.2 x 10(-8)), and Braak stage and negatively correlated with Mini-Mental State Examination score.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 183, "tag": "HealthCareActivity"}, {"end": 151, "start": 140, "tag": "HealthCareActivity"}, {"end": 50, "start": 37, "tag": "ClinicalAttribute"}, {"end": 218, "start": 213, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1450_4", "text": "DISCUSSIONCSF SCRN1 is a candidate biomarker of AD, reflecting tau pathology.", "tags": [{"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 35, "tag": "ClinicalAttribute"}, {"end": 76, "start": 63, "tag": "PathologicFunction"}, {"end": 19, "start": 10, "tag": "ClinicalAttribute"}]}
{"id": "1450_5", "text": "HIGHLIGHTSWe developed a parallel reaction monitoring assay to measure secernin-1 (SCRN1) in cerebrospinal fluid (CSF).CSF SCRN1 was increased in Alzheimer's disease compared to healthy controls.CSF SCRN1 remained unchanged in Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration compared to controls.CSF SCRN1 correlated strongly with CSF phosphorylated tau and total tau.CSF SCRN1 increased across Braak stages and negatively correlated with Mini-Mental State Examination score.", "tags": [{"end": 223, "start": 214, "tag": "Finding"}, {"end": 271, "start": 248, "tag": "PathologicFunction"}, {"end": 303, "start": 285, "tag": "DiseaseOrSyndrome"}, {"end": 466, "start": 454, "tag": "HealthCareActivity"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 358, "start": 355, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 393, "start": 390, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 354, "start": 346, "tag": "PopulationGroup"}, {"end": 284, "start": 273, "tag": "TemporalConcept"}, {"end": 426, "start": 417, "tag": "AminoAcidPeptideOrProtein"}, {"end": 426, "start": 417, "tag": "BiologicallyActiveSubstance"}, {"end": 412, "start": 394, "tag": "AminoAcidPeptideOrProtein"}, {"end": 412, "start": 394, "tag": "BiologicallyActiveSubstance"}, {"end": 527, "start": 498, "tag": "HealthCareActivity"}, {"end": 185, "start": 178, "tag": "OrganismAttribute"}, {"end": 246, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 178, "tag": "PopulationGroup"}, {"end": 59, "start": 25, "tag": "HealthCareActivity"}, {"end": 533, "start": 528, "tag": "Finding"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "GeneOrGenome"}, {"end": 128, "start": 119, "tag": "ClinicalAttribute"}, {"end": 204, "start": 195, "tag": "ClinicalAttribute"}, {"end": 333, "start": 308, "tag": "DiseaseOrSyndrome"}, {"end": 364, "start": 355, "tag": "ClinicalAttribute"}, {"end": 436, "start": 427, "tag": "ClinicalAttribute"}]}
{"id": "1451_0", "text": "While heart disease remains a common cause of mortality, cerebrovascular disease also increases with age, and has been implicated in Alzheimer's disease and related dementias (ADRD).", "tags": [{"end": 19, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 46, "tag": "Finding"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 101, "tag": "OrganismAttribute"}, {"end": 174, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 176, "tag": "DiseaseOrSyndrome"}]}
{"id": "1451_1", "text": "We have described hydrogen sulfide (H2S), a signaling molecule important in vascular homeostasis, as a biomarker of cardiovascular disease.", "tags": [{"end": 34, "start": 18, "tag": "Chemical"}, {"end": 62, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 44, "tag": "CellFunction"}, {"end": 138, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "Chemical"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 112, "start": 103, "tag": "ClinicalAttribute"}, {"end": 84, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "InjuryOrPoisoning"}, {"end": 34, "start": 18, "tag": "InjuryOrPoisoning"}, {"end": 39, "start": 36, "tag": "Chemical"}]}
{"id": "1451_2", "text": "We hypothesize that plasma H2S and its metabolites also relate to vascular and cognitive dysfunction in ADRD.", "tags": [{"end": 100, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 27, "tag": "Chemical"}, {"end": 30, "start": 27, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 20, "tag": "ClinicalAttribute"}]}
{"id": "1451_3", "text": "We used analytical biochemical methods to measure plasma H2S metabolites and MRI to evaluate indicators of microvascular disease in ADRD.", "tags": [{"end": 103, "start": 93, "tag": "Chemical"}, {"end": 128, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 136, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 8, "tag": "ResearchActivity"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}]}
{"id": "1451_4", "text": "Levels of total H2S and specific metabolites were increased in ADRD versus controls.", "tags": [{"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 75, "tag": "PopulationGroup"}, {"end": 67, "start": 63, "tag": "DiseaseOrSyndrome"}]}
{"id": "1451_5", "text": "Cognition and microvascular disease indices were correlated with H2S levels.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 35, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "ClinicalAttribute"}]}
{"id": "1451_6", "text": "Total plasma sulfide was the strongest indicator of ADRD, and partially drove the relationship between cognitive dysfunction and white matter lesion volume, an indicator of microvascular disease.", "tags": [{"end": 20, "start": 13, "tag": "Chemical"}, {"end": 48, "start": 39, "tag": "Chemical"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 194, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 142, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 82, "tag": "Finding"}, {"end": 56, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 129, "tag": "ClinicalAttribute"}, {"end": 148, "start": 129, "tag": "Finding"}]}
{"id": "1451_7", "text": "Our findings show that H2S is dysregulated in dementia, providing a potential biomarker for diagnosis and intervention.", "tags": [{"end": 42, "start": 30, "tag": "PathologicFunction"}, {"end": 87, "start": 68, "tag": "ClinicalAttribute"}, {"end": 54, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "HealthCareActivity"}, {"end": 26, "start": 23, "tag": "Chemical"}, {"end": 26, "start": 23, "tag": "InjuryOrPoisoning"}]}
{"id": "1452_0", "text": "The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology.", "tags": [{"end": 36, "start": 22, "tag": "CellFunction"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 44, "tag": "Substance"}, {"end": 176, "start": 161, "tag": "PathologicFunction"}, {"end": 176, "start": 161, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1452_1", "text": "Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown.", "tags": [{"end": 18, "start": 4, "tag": "CellFunction"}, {"end": 128, "start": 119, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 84, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 37, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1452_2", "text": "Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts (n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders.", "tags": [{"end": 148, "start": 137, "tag": "Finding"}, {"end": 221, "start": 212, "tag": "TemporalConcept"}, {"end": 260, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 260, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 149, "tag": "PopulationGroup"}, {"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 22, "tag": "ResearchActivity"}, {"end": 65, "start": 60, "tag": "ResearchActivity"}, {"end": 108, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 100, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1452_3", "text": "Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-beta negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92-0.94).", "tags": [{"end": 71, "start": 58, "tag": "CellFunction"}, {"end": 126, "start": 104, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 144, "start": 132, "tag": "PopulationGroup"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 155, "tag": "Finding"}, {"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 165, "tag": "ResearchActivity"}, {"end": 144, "start": 138, "tag": "PopulationGroup"}, {"end": 154, "start": 150, "tag": "Finding"}, {"end": 15, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1452_4", "text": "Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-beta negative MCI patients (AUC = 0.89).", "tags": [{"end": 100, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 138, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "ResearchActivity"}, {"end": 170, "start": 167, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1452_5", "text": "In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life.", "tags": [{"end": 199, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 287, "tag": "TemporalConcept"}, {"end": 199, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 151, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 260, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 234, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 5, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 147, "start": 133, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 19, "start": 5, "tag": "PathologicFunction"}, {"end": 147, "start": 133, "tag": "PathologicFunction"}, {"end": 269, "start": 261, "tag": "DiseaseOrSyndrome"}, {"end": 279, "start": 270, "tag": "HealthCareActivity"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 76, "tag": "TemporalConcept"}, {"end": 26, "start": 20, "tag": "PopulationGroup"}, {"end": 204, "start": 201, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}, {"end": 54, "start": 47, "tag": "Substance"}, {"end": 54, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1452_6", "text": "Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [F-18]MK-6240 positron emission tomography (PET), and brain amyloidosis by [F-18]AZD469 PET.", "tags": [{"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}, {"end": 157, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 130, "tag": "HealthCareActivity"}, {"end": 177, "start": 174, "tag": "HealthCareActivity"}, {"end": 128, "start": 100, "tag": "HealthCareActivity"}, {"end": 15, "start": 0, "tag": "ClinicalAttribute"}, {"end": 55, "start": 43, "tag": "ClinicalAttribute"}, {"end": 99, "start": 86, "tag": "Chemical"}, {"end": 173, "start": 161, "tag": "Chemical"}]}
{"id": "1452_7", "text": "Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [F-18]AZD469 amyloid-beta PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-beta PET positivity and the increase of plasma p-tau181.", "tags": [{"end": 77, "start": 69, "tag": "BiologicFunction"}, {"end": 77, "start": 69, "tag": "OrganismAttribute"}, {"end": 77, "start": 69, "tag": "CellFunction"}, {"end": 192, "start": 184, "tag": "HealthCareActivity"}, {"end": 234, "start": 224, "tag": "ResearchActivity"}, {"end": 178, "start": 171, "tag": "TemporalConcept"}, {"end": 63, "start": 53, "tag": "Finding"}, {"end": 91, "start": 81, "tag": "TemporalConcept"}, {"end": 112, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 207, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 261, "start": 255, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 118, "tag": "HealthCareActivity"}, {"end": 223, "start": 220, "tag": "HealthCareActivity"}, {"end": 203, "start": 193, "tag": "Finding"}, {"end": 141, "start": 135, "tag": "BiologicFunction"}, {"end": 141, "start": 135, "tag": "CellFunction"}, {"end": 270, "start": 255, "tag": "ClinicalAttribute"}, {"end": 51, "start": 36, "tag": "ClinicalAttribute"}]}
{"id": "1452_8", "text": "Furthermore, plasma p-tau231 was significantly increased in amyloid-beta PET quartiles 2-4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3-4 and 4, respectively.", "tags": [{"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 33, "tag": "Finding"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 28, "start": 13, "tag": "ClinicalAttribute"}, {"end": 112, "start": 100, "tag": "ClinicalAttribute"}, {"end": 132, "start": 117, "tag": "ClinicalAttribute"}]}
{"id": "1452_9", "text": "Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I-II, which was not observed for plasma p-tau181.", "tags": [{"end": 115, "start": 108, "tag": "TemporalConcept"}, {"end": 90, "start": 70, "tag": "HealthCareActivity"}, {"end": 51, "start": 40, "tag": "PopulationGroup"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 9, "tag": "ClinicalAttribute"}, {"end": 115, "start": 102, "tag": "HealthCareActivity"}, {"end": 128, "start": 121, "tag": "HealthCareActivity"}, {"end": 147, "start": 137, "tag": "HealthCareActivity"}, {"end": 191, "start": 176, "tag": "ClinicalAttribute"}]}
{"id": "1452_10", "text": "To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-beta deposition, prior to the threshold for amyloid-beta PET positivity has been attained, and also in response to early brain tau deposition.", "tags": [{"end": 225, "start": 216, "tag": "Finding"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 82, "start": 70, "tag": "ClinicalAttribute"}, {"end": 257, "start": 247, "tag": "ResearchActivity"}, {"end": 76, "start": 61, "tag": "TemporalConcept"}, {"end": 156, "start": 149, "tag": "TemporalConcept"}, {"end": 316, "start": 313, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 313, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 87, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 101, "start": 87, "tag": "PathologicFunction"}, {"end": 312, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 242, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 306, "start": 301, "tag": "TemporalConcept"}, {"end": 246, "start": 243, "tag": "HealthCareActivity"}, {"end": 297, "start": 289, "tag": "OrganismAttribute"}, {"end": 201, "start": 178, "tag": "PathologicFunction"}, {"end": 327, "start": 313, "tag": "PathologicFunction"}, {"end": 39, "start": 24, "tag": "ClinicalAttribute"}, {"end": 133, "start": 118, "tag": "ClinicalAttribute"}]}
{"id": "1452_11", "text": "Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-beta positivity or apparent entorhinal tau deposition.", "tags": [{"end": 181, "start": 172, "tag": "Finding"}, {"end": 52, "start": 37, "tag": "ClinicalAttribute"}, {"end": 208, "start": 198, "tag": "ResearchActivity"}, {"end": 161, "start": 150, "tag": "PopulationGroup"}, {"end": 126, "start": 111, "tag": "ResearchActivity"}, {"end": 231, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 235, "start": 232, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 232, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 43, "tag": "ClinicalAttribute"}, {"end": 192, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 171, "start": 168, "tag": "HealthCareActivity"}, {"end": 246, "start": 232, "tag": "PathologicFunction"}, {"end": 21, "start": 6, "tag": "ClinicalAttribute"}]}
{"id": "1453_0", "text": "Alterations in Alzheimer's disease (AD) biomarkers have been observed decades before the onset of dementia.", "tags": [{"end": 77, "start": 70, "tag": "TemporalConcept"}, {"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 40, "tag": "ClinicalAttribute"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 94, "start": 89, "tag": "TemporalConcept"}]}
{"id": "1453_1", "text": "Cognitive dysfunction, while central to the clinical diagnosis of AD, has long been considered as a late-stage phenomenon.", "tags": [{"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 100, "tag": "TemporalConcept"}, {"end": 21, "start": 10, "tag": "PathologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 53, "tag": "HealthCareActivity"}, {"end": 62, "start": 44, "tag": "HealthCareActivity"}, {"end": 110, "start": 105, "tag": "TemporalConcept"}, {"end": 110, "start": 105, "tag": "ClinicalAttribute"}]}
{"id": "1453_2", "text": "This assumption is currently challenged and signals on some cognitive tests are now being observed within the preclinical stage.", "tags": [{"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 75, "start": 60, "tag": "HealthCareActivity"}, {"end": 75, "start": 60, "tag": "ResearchActivity"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 75, "start": 70, "tag": "HealthCareActivity"}, {"end": 127, "start": 122, "tag": "TemporalConcept"}, {"end": 127, "start": 122, "tag": "ClinicalAttribute"}, {"end": 127, "start": 110, "tag": "TemporalConcept"}, {"end": 51, "start": 44, "tag": "CellFunction"}]}
{"id": "1453_3", "text": "As part of the European Prevention of Alzheimer's Dementia (EPAD) project, a battery of cognitive tests has been proposed (the EPAD Neuropsychological Examination, ENE) which is designed to detect cognitive changes in persons without clinical signs of AD but who are at high risk.", "tags": [{"end": 58, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 77, "tag": "ManufacturedObject"}, {"end": 279, "start": 270, "tag": "Finding"}, {"end": 248, "start": 234, "tag": "SignOrSymptom"}, {"end": 225, "start": 218, "tag": "PopulationGroup"}, {"end": 214, "start": 197, "tag": "Finding"}, {"end": 73, "start": 66, "tag": "ResearchActivity"}, {"end": 58, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 88, "tag": "HealthCareActivity"}, {"end": 103, "start": 88, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "HealthCareActivity"}, {"end": 23, "start": 15, "tag": "PopulationGroup"}, {"end": 274, "start": 270, "tag": "Finding"}, {"end": 58, "start": 15, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "ResearchActivity"}, {"end": 162, "start": 127, "tag": "ResearchActivity"}, {"end": 167, "start": 164, "tag": "ResearchActivity"}]}
{"id": "1453_4", "text": "Analysis of results from the 361 participants with complete measures and without dementia recruited into the EPAD Longitudinal Cohort Study showed that the majority have elevated biomarker levels, with significant associations between an episodic verbal memory task and tau, while amyloid-beta (A beta) was associated with a central executive task.", "tags": [{"end": 246, "start": 238, "tag": "TemporalConcept"}, {"end": 260, "start": 247, "tag": "BiologicFunction"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 273, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 179, "tag": "ClinicalAttribute"}, {"end": 45, "start": 33, "tag": "PopulationGroup"}, {"end": 288, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 260, "start": 254, "tag": "BiologicFunction"}, {"end": 139, "start": 109, "tag": "ResearchActivity"}, {"end": 265, "start": 238, "tag": "ResearchActivity"}, {"end": 347, "start": 325, "tag": "ResearchActivity"}]}
{"id": "1453_5", "text": "These preliminary findings suggest that profiles of cognitive performance may be specific to a given biomarker, with a primarily hippocampal task being associated with higher levels of tau and a frontal executive task being associated with higher levels of A beta.", "tags": [{"end": 17, "start": 6, "tag": "TemporalConcept"}, {"end": 188, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 101, "tag": "ClinicalAttribute"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 73, "start": 52, "tag": "Finding"}, {"end": 263, "start": 257, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 145, "start": 129, "tag": "ResearchActivity"}, {"end": 217, "start": 195, "tag": "ResearchActivity"}, {"end": 188, "start": 175, "tag": "ClinicalAttribute"}, {"end": 263, "start": 247, "tag": "ClinicalAttribute"}]}
{"id": "1453_6", "text": "While previous research has focused on the relationship between cognition and levels of A beta, our findings suggest that p-tau may potentially be a more significant correlate.", "tags": [{"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "BiologicFunction"}, {"end": 55, "start": 43, "tag": "Finding"}, {"end": 127, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 78, "tag": "ClinicalAttribute"}]}
{"id": "1454_0", "text": "Huntington disease (HD) is a neurodegenerative disease caused by a trinucleotide repeat expansion in the HTT gene encoding an elongated polyglutamine tract in the huntingtin (HTT) protein.", "tags": [{"end": 87, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 126, "tag": "Finding"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 113, "start": 105, "tag": "GeneOrGenome"}, {"end": 155, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 178, "start": 175, "tag": "GeneOrGenome"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 67, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_1", "text": "Expanded mutant HTT (mHTT) is toxic and leads to regional atrophy and neuronal cell loss in the brain, which occurs earliest in the striatum.", "tags": [{"end": 19, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 124, "start": 116, "tag": "TemporalConcept"}, {"end": 83, "start": 70, "tag": "Cell"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 58, "tag": "PathologicFunction"}, {"end": 65, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 21, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 70, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_2", "text": "Therapeutic lowering of mHTT in the central nervous system (CNS) has shown promise in preclinical studies, with multiple approaches currently in clinical development for HD.", "tags": [{"end": 28, "start": 0, "tag": "HealthCareActivity"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 86, "tag": "ResearchActivity"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "TemporalConcept"}, {"end": 165, "start": 154, "tag": "BiologicFunction"}, {"end": 165, "start": 154, "tag": "CellFunction"}]}
{"id": "1454_3", "text": "Quantitation of mHTT in the cerebrospinal fluid (CSF) is being used as a clinical pharmacodynamic biomarker of target engagement in the CNS.", "tags": [{"end": 97, "start": 82, "tag": "BiologicFunction"}, {"end": 97, "start": 82, "tag": "ResearchActivity"}, {"end": 139, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 111, "tag": "Finding"}, {"end": 128, "start": 118, "tag": "Finding"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 47, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "1454_4", "text": "We have previously shown that the CNS is a major source of mHTT in the CSF.", "tags": [{"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_5", "text": "However, little is known about the specific brain regions and cell types that contribute to CSF mHTT.", "tags": [{"end": 72, "start": 62, "tag": "Cell"}, {"end": 57, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 92, "tag": "ClinicalAttribute"}]}
{"id": "1454_6", "text": "Therefore, a better understanding of the origins of CSF mHTT and whether therapies targeting mHTT in the striatum would be expected to be associated with significant lowering of mHTT in the CSF is needed.", "tags": [{"end": 113, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "HealthCareActivity"}, {"end": 48, "start": 41, "tag": "TemporalConcept"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 20, "tag": "BiologicFunction"}, {"end": 60, "start": 52, "tag": "ClinicalAttribute"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 182, "start": 178, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_7", "text": "Here, we use complementary pharmacological and genetic-based approaches to either restrict expression of mHTT to the striatum or selectively deplete mHTT in the striatum to evaluate the contribution of this brain region to mHTT in the CSF.", "tags": [{"end": 125, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 27, "tag": "ResearchActivity"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "CellOrMolecularDysfunction"}, {"end": 153, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 227, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 223, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_8", "text": "We show that viral expression of a mHTT fragment restricted to the striatum leads to detectable mHTT in the CSF.", "tags": [{"end": 29, "start": 13, "tag": "CellFunction"}, {"end": 75, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 85, "tag": "ClinicalAttribute"}, {"end": 48, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_9", "text": "We demonstrate that targeted lowering of mHTT selectively in the striatum using an antisense oligonucleotide leads to a significant reduction of mHTT in the CSF of HD mice.", "tags": [{"end": 73, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 108, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 83, "tag": "Chemical"}, {"end": 141, "start": 120, "tag": "Finding"}, {"end": 171, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 141, "start": 132, "tag": "Finding"}, {"end": 141, "start": 132, "tag": "NaturalPhenomenonOrProcess"}, {"end": 160, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 167, "tag": "Eukaryote"}, {"end": 45, "start": 20, "tag": "HealthCareActivity"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_10", "text": "Furthermore, using a transgenic mouse model of HD that expresses full length human mHTT and wild type HTT, we show that genetic inactivation of mHTT selectively in the striatum results in a significant reduction of mHTT in the CSF.", "tags": [{"end": 101, "start": 92, "tag": "GeneOrGenome"}, {"end": 101, "start": 92, "tag": "ResearchActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 140, "start": 128, "tag": "CellFunction"}, {"end": 176, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 102, "tag": "GeneOrGenome"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 190, "tag": "Finding"}, {"end": 49, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 76, "start": 70, "tag": "ResearchActivity"}, {"end": 211, "start": 202, "tag": "Finding"}, {"end": 211, "start": 202, "tag": "NaturalPhenomenonOrProcess"}, {"end": 230, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "Eukaryote"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 219, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 215, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_11", "text": "Taken together, our data supports the conclusion that the striatum contributes sufficiently to the pool of mHTT in the CSF that therapeutic levels of mHTT lowering in the striatum can be detected by this measure in HD mice.", "tags": [{"end": 103, "start": 99, "tag": "ClinicalAttribute"}, {"end": 66, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 215, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 222, "start": 218, "tag": "Eukaryote"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 107, "tag": "CellOrMolecularDysfunction"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1454_12", "text": "This suggests that CSF mHTT may represent a pharmacodynamic biomarker for therapies that lower mHTT in the striatum.", "tags": [{"end": 59, "start": 44, "tag": "BiologicFunction"}, {"end": 59, "start": 44, "tag": "ResearchActivity"}, {"end": 115, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "HealthCareActivity"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 27, "start": 19, "tag": "ClinicalAttribute"}, {"end": 99, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 95, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1455_0", "text": "Background: The hippocampus, entorhinal cortex (EC), and basal forebrain (BF) are among the earliest regions affected by Alzheimer's disease (AD) pathology.", "tags": [{"end": 72, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 92, "tag": "TemporalConcept"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "PathologicFunction"}, {"end": 155, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 27, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1455_1", "text": "They play an essential role in spatial pattern separation, a process critical for accurate discrimination between similar locations.", "tags": [{"end": 57, "start": 31, "tag": "BiologicFunction"}, {"end": 131, "start": 91, "tag": "BiologicFunction"}]}
{"id": "1455_2", "text": "Objective: We examined differences in spatial pattern separation performance between older adults with amnestic mild cognitive impairment (aMCI) with AD versus those with non-Alzheimer's pathologic change (non-AD) and interrelations between volumes of the hippocampal, EC subregions and BF nuclei projecting to these subregions (medial septal nuclei and vertical limb of the diagonal band of Broca - Ch1-2 nuclei) with respect to performance.", "tags": [{"end": 296, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 349, "start": 329, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 296, "start": 290, "tag": "CellComponent"}, {"end": 282, "start": 269, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 271, "start": 269, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PopulationGroup"}, {"end": 143, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 23, "tag": "Finding"}, {"end": 76, "start": 65, "tag": "Finding"}, {"end": 441, "start": 430, "tag": "Finding"}, {"end": 137, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 112, "tag": "Finding"}, {"end": 97, "start": 91, "tag": "PopulationGroup"}, {"end": 267, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 38, "tag": "BiologicFunction"}, {"end": 204, "start": 187, "tag": "PathologicFunction"}, {"end": 327, "start": 317, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 412, "start": 354, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1455_3", "text": "Methods: Hundred and eighteen older adults were recruited from the Czech Brain Aging Study.", "tags": [{"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "TemporalConcept"}, {"end": 42, "start": 30, "tag": "PopulationGroup"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 90, "start": 67, "tag": "ResearchActivity"}]}
{"id": "1455_4", "text": "Participants with AD aMCI (n = 37), non-AD aMCI (n = 26), mild AD dementia (n = 26), and cognitively normal older adults (CN; n = 29) underwent spatial pattern separation testing, cognitive assessment and brain magnetic resonance imaging.", "tags": [{"end": 25, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "Finding"}, {"end": 124, "start": 122, "tag": "Finding"}, {"end": 113, "start": 108, "tag": "TemporalConcept"}, {"end": 120, "start": 108, "tag": "PopulationGroup"}, {"end": 25, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 171, "tag": "HealthCareActivity"}, {"end": 74, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 180, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 107, "start": 89, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "Finding"}, {"end": 120, "start": 114, "tag": "PopulationGroup"}, {"end": 237, "start": 211, "tag": "HealthCareActivity"}, {"end": 170, "start": 144, "tag": "BiologicFunction"}]}
{"id": "1455_5", "text": "Results: The AD aMCI group had less accurate spatial pattern separation performance than the non-AD aMCI (p = 0.039) and CN (p < 0.001) groups.", "tags": [{"end": 20, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 121, "tag": "Finding"}, {"end": 20, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 72, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 142, "start": 136, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "PopulationGroup"}, {"end": 71, "start": 45, "tag": "BiologicFunction"}]}
{"id": "1455_6", "text": "The AD aMCI and non-AD groups did not differ in other cognitive tests.", "tags": [{"end": 11, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 7, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 23, "tag": "PopulationGroup"}, {"end": 69, "start": 54, "tag": "HealthCareActivity"}, {"end": 69, "start": 54, "tag": "ResearchActivity"}]}
{"id": "1455_7", "text": "Decreased BF Ch1-2 volume was indirectly associated with worse performance through reduced hippocampal tail volume and reduced posteromedial EC and hippocampal tail or body volumes operating in serial.", "tags": [{"end": 9, "start": 0, "tag": "Finding"}, {"end": 12, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 143, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "Finding"}, {"end": 172, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 63, "tag": "Finding"}, {"end": 164, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 10, "tag": "ClinicalAttribute"}, {"end": 114, "start": 91, "tag": "ClinicalAttribute"}, {"end": 180, "start": 168, "tag": "ClinicalAttribute"}, {"end": 159, "start": 148, "tag": "ClinicalAttribute"}, {"end": 180, "start": 173, "tag": "ClinicalAttribute"}, {"end": 164, "start": 148, "tag": "ClinicalAttribute"}]}
{"id": "1455_8", "text": "Conclusion: The study demonstrates that spatial pattern separation testing differentiates AD biomarker positive and negative older adults with aMCI and provides evidence that BF Ch1-2 nuclei influence spatial pattern separation through the posteromedial EC and the posterior hippocampus.", "tags": [{"end": 256, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 240, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "TemporalConcept"}, {"end": 137, "start": 125, "tag": "PopulationGroup"}, {"end": 147, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "ClinicalAttribute"}, {"end": 74, "start": 67, "tag": "HealthCareActivity"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 169, "start": 161, "tag": "Finding"}, {"end": 286, "start": 265, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 131, "tag": "PopulationGroup"}, {"end": 190, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 201, "tag": "BiologicFunction"}, {"end": 66, "start": 40, "tag": "BiologicFunction"}]}
{"id": "1456_0", "text": "Multiple biomarkers can capture different facets of Alzheimer's disease.", "tags": [{"end": 71, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1456_1", "text": "However, statistical models of biomarkers to predict outcomes in Alzheimer's rarely model nonlinear interactions between these measures.", "tags": [{"end": 61, "start": 45, "tag": "HealthCareActivity"}, {"end": 76, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 90, "tag": "Finding"}, {"end": 41, "start": 31, "tag": "ClinicalAttribute"}, {"end": 61, "start": 53, "tag": "Finding"}, {"end": 89, "start": 84, "tag": "ResearchActivity"}, {"end": 27, "start": 9, "tag": "ResearchActivity"}]}
{"id": "1456_2", "text": "Here, we used Gaussian Processes to address this, modelling nonlinear interactions to predict progression from mild cognitive impairment (MCI) to Alzheimer's over 3 years, using Alzheimer's Disease Neuroimaging Initiative (ADNI) data.", "tags": [{"end": 59, "start": 50, "tag": "ResearchActivity"}, {"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 178, "tag": "ResearchActivity"}, {"end": 221, "start": 178, "tag": "HealthCareRelatedOrganization"}, {"end": 82, "start": 60, "tag": "Finding"}, {"end": 227, "start": 223, "tag": "HealthCareRelatedOrganization"}, {"end": 227, "start": 223, "tag": "ResearchActivity"}, {"end": 233, "start": 229, "tag": "ResearchActivity"}, {"end": 136, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 94, "tag": "PathologicFunction"}, {"end": 105, "start": 94, "tag": "TemporalConcept"}, {"end": 170, "start": 165, "tag": "TemporalConcept"}, {"end": 136, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 111, "tag": "Finding"}, {"end": 32, "start": 14, "tag": "ResearchActivity"}]}
{"id": "1456_3", "text": "Measures included: demographics, APOE4 genotype, CSF (amyloid-beta 42, total tau, phosphorylated tau), [18(F)]florbetapir, hippocampal volume and brain-age.", "tags": [{"end": 96, "start": 82, "tag": "CellFunction"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 47, "start": 39, "tag": "OrganismAttribute"}, {"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 123, "tag": "ClinicalAttribute"}, {"end": 121, "start": 104, "tag": "Chemical"}]}
{"id": "1456_4", "text": "We examined: (a) the independent value of each biomarker; and (b) whether modelling nonlinear interactions between biomarkers improved predictions.", "tags": [{"end": 83, "start": 74, "tag": "ResearchActivity"}, {"end": 134, "start": 126, "tag": "Finding"}, {"end": 106, "start": 84, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "ClinicalAttribute"}, {"end": 125, "start": 115, "tag": "ClinicalAttribute"}]}
{"id": "1456_5", "text": "Each measured added complementary information when predicting conversion to Alzheimer's.", "tags": [{"end": 87, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "Finding"}]}
{"id": "1456_6", "text": "A linear model classifying stable from progressive MCI explained over half the variance (R-2= 0.51,p < .001); the strongest independently contributing biomarker was hippocampal volume (R-2= 0.13).", "tags": [{"end": 14, "start": 2, "tag": "ResearchActivity"}, {"end": 160, "start": 151, "tag": "ClinicalAttribute"}, {"end": 50, "start": 39, "tag": "TemporalConcept"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 165, "tag": "ClinicalAttribute"}, {"end": 87, "start": 79, "tag": "ResearchActivity"}]}
{"id": "1456_7", "text": "When comparing sensitivity of different models to progressive MCI (independent biomarker models, additive models, nonlinear interaction models), we observed a significant improvement (p < .001) for various two-way interaction models.", "tags": [{"end": 88, "start": 79, "tag": "ClinicalAttribute"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 65, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 46, "start": 40, "tag": "ResearchActivity"}, {"end": 95, "start": 89, "tag": "ResearchActivity"}, {"end": 112, "start": 106, "tag": "ResearchActivity"}, {"end": 142, "start": 114, "tag": "ResearchActivity"}, {"end": 232, "start": 206, "tag": "ResearchActivity"}]}
{"id": "1456_8", "text": "The best performing model included an interaction between amyloid-beta-PET and P-tau, while accounting for hippocampal volume (sensitivity = 0.77, AUC = 0.826).", "tags": [{"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 127, "tag": "Finding"}, {"end": 70, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 74, "start": 71, "tag": "HealthCareActivity"}, {"end": 150, "start": 147, "tag": "ResearchActivity"}, {"end": 125, "start": 107, "tag": "ClinicalAttribute"}]}
{"id": "1456_9", "text": "Closely related biomarkers contributed uniquely to predict conversion to Alzheimer's.", "tags": [{"end": 84, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 69, "start": 59, "tag": "Finding"}]}
{"id": "1456_10", "text": "Nonlinear biomarker interactions were also implicated, and results showed that although for some patients adding additional biomarkers may add little value (i.e., when hippocampal volume is high), for others (i.e., with low hippocampal volume) further invasive and expensive examination may be warranted.", "tags": [{"end": 286, "start": 275, "tag": "HealthCareActivity"}, {"end": 274, "start": 265, "tag": "Finding"}, {"end": 260, "start": 252, "tag": "Finding"}, {"end": 32, "start": 20, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 223, "start": 220, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "ClinicalAttribute"}, {"end": 105, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 124, "tag": "ClinicalAttribute"}, {"end": 186, "start": 168, "tag": "ClinicalAttribute"}, {"end": 242, "start": 224, "tag": "ClinicalAttribute"}, {"end": 194, "start": 190, "tag": "Finding"}]}
{"id": "1456_11", "text": "Our framework enables visualisation of these interactions, in individual patient biomarker 'space', providing information for personalised or stratified healthcare or clinical trial design.", "tags": [{"end": 181, "start": 167, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 57, "start": 45, "tag": "Finding"}, {"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 72, "start": 62, "tag": "PopulationGroup"}, {"end": 72, "start": 62, "tag": "OrganismAttribute"}, {"end": 188, "start": 182, "tag": "ResearchActivity"}, {"end": 188, "start": 182, "tag": "HealthCareActivity"}, {"end": 163, "start": 126, "tag": "HealthCareActivity"}]}
{"id": "1457_0", "text": "Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 39, "start": 30, "tag": "CellFunction"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 40, "tag": "OrganismAttribute"}]}
{"id": "1457_1", "text": "Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-beta (A beta) and tau pathologies.", "tags": [{"end": 94, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 96, "tag": "GeneOrGenome"}, {"end": 132, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 186, "tag": "DiseaseOrSyndrome"}]}
{"id": "1457_2", "text": "We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for A beta ([F-18]AZD4694) and tau ([F-18]MK-6240), as well as CSF GFAP and YKL-40 measures.", "tags": [{"end": 123, "start": 110, "tag": "HealthCareActivity"}, {"end": 195, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 191, "tag": "GeneOrGenome"}, {"end": 206, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "BiologicFunction"}, {"end": 44, "start": 39, "tag": "CellFunction"}, {"end": 158, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 16, "tag": "PopulationGroup"}, {"end": 108, "start": 105, "tag": "HealthCareActivity"}, {"end": 134, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 75, "tag": "HealthCareActivity"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 149, "start": 136, "tag": "Chemical"}, {"end": 174, "start": 160, "tag": "Chemical"}, {"end": 195, "start": 187, "tag": "ClinicalAttribute"}, {"end": 206, "start": 200, "tag": "ClinicalAttribute"}, {"end": 190, "start": 187, "tag": "ClinicalAttribute"}]}
{"id": "1457_3", "text": "We observed that higher CSF GFAP levels were associated with elevated A beta-PET but not tau-PET load.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 96, "start": 93, "tag": "HealthCareActivity"}, {"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 24, "tag": "ClinicalAttribute"}]}
{"id": "1457_4", "text": "By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not A beta-PET burden.", "tags": [{"end": 30, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 90, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "ResearchActivity"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}]}
{"id": "1457_5", "text": "Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of A beta and tau, respectively, on hippocampal atrophy, which was further associated with cognitive impairment.", "tags": [{"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 62, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 75, "tag": "Finding"}, {"end": 92, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 119, "tag": "PathologicFunction"}, {"end": 138, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "ClinicalAttribute"}, {"end": 62, "start": 56, "tag": "ClinicalAttribute"}, {"end": 46, "start": 43, "tag": "ClinicalAttribute"}]}
{"id": "1457_6", "text": "Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain A beta and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.", "tags": [{"end": 218, "start": 197, "tag": "PathologicFunction"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 232, "start": 219, "tag": "Finding"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "ClinicalAttribute"}, {"end": 97, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 251, "start": 240, "tag": "PathologicFunction"}, {"end": 251, "start": 240, "tag": "TemporalConcept"}, {"end": 168, "start": 155, "tag": "BiologicFunction"}, {"end": 104, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "Finding"}]}
{"id": "1458_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive loss of memory and cognitive decline.", "tags": [{"end": 55, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 75, "tag": "TemporalConcept"}, {"end": 123, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 87, "tag": "SignOrSymptom"}, {"end": 101, "start": 95, "tag": "BiologicFunction"}]}
{"id": "1458_1", "text": "Over the last decade, it has been found that defects in sensory systems could be highly associated with AD.", "tags": [{"end": 71, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 9, "tag": "TemporalConcept"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}]}
{"id": "1458_2", "text": "Hearing is an important neural sense.", "tags": [{"end": 7, "start": 0, "tag": "BiologicFunction"}, {"end": 36, "start": 24, "tag": "BiologicFunction"}]}
{"id": "1458_3", "text": "However, little is known about hearing functional changes in AD.", "tags": [{"end": 38, "start": 31, "tag": "BiologicFunction"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 39, "tag": "Finding"}]}
{"id": "1458_4", "text": "In this study, APP/PS1 AD mice (Jackson Lab: Stack No.", "tags": [{"end": 43, "start": 32, "tag": "HealthCareRelatedOrganization"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 30, "start": 15, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_5", "text": "004462) were used.", "tags": []}
{"id": "1458_6", "text": "Hearing function was assessed by auditory brainstem response (ABR), distortion product otoacoustic emission (DPOAE), and cochlear microphonics (CM) recordings.", "tags": [{"end": 16, "start": 0, "tag": "BiologicFunction"}, {"end": 60, "start": 33, "tag": "ClinicalAttribute"}, {"end": 65, "start": 62, "tag": "ClinicalAttribute"}, {"end": 158, "start": 148, "tag": "HealthCareActivity"}, {"end": 107, "start": 68, "tag": "HealthCareActivity"}, {"end": 158, "start": 148, "tag": "HealthCareActivity"}, {"end": 142, "start": 121, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "HealthCareActivity"}]}
{"id": "1458_7", "text": "Wild-type (WT) littermates served as control.", "tags": [{"end": 13, "start": 11, "tag": "ResearchActivity"}, {"end": 44, "start": 37, "tag": "PopulationGroup"}, {"end": 26, "start": 15, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1458_8", "text": "We found that APP/PS1 AD mice measured as ABR threshold had hearing loss.", "tags": [{"end": 45, "start": 42, "tag": "ClinicalAttribute"}, {"end": 72, "start": 60, "tag": "Finding"}, {"end": 55, "start": 46, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 14, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_9", "text": "The hearing loss appeared at high frequency as early as 2 months old, prior to the reported occurrence of spatial learning deficit at 6-7 months of age in this AD mouse model.", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 122, "start": 106, "tag": "BiologicFunction"}, {"end": 102, "start": 92, "tag": "TemporalConcept"}, {"end": 43, "start": 34, "tag": "TemporalConcept"}, {"end": 151, "start": 148, "tag": "OrganismAttribute"}, {"end": 52, "start": 47, "tag": "TemporalConcept"}, {"end": 64, "start": 58, "tag": "TemporalConcept"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 33, "start": 29, "tag": "Finding"}, {"end": 174, "start": 160, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_10", "text": "The hearing loss was progressive and extended from high frequency to low frequency.", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 72, "start": 69, "tag": "Finding"}, {"end": 32, "start": 21, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "TemporalConcept"}, {"end": 82, "start": 73, "tag": "TemporalConcept"}, {"end": 55, "start": 51, "tag": "Finding"}]}
{"id": "1458_11", "text": "At 3-4 months old, the hearing loss appeared in the whole-frequency range.", "tags": [{"end": 35, "start": 23, "tag": "Finding"}, {"end": 67, "start": 58, "tag": "TemporalConcept"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}]}
{"id": "1458_12", "text": "Moreover, the wave IV and V in the super-threshold ABR were eliminated, indicating substantial impairment in inferior colliculus, nuclei of lateral lemniscus, and medial geniculate body in the upper brainstem.", "tags": [{"end": 54, "start": 51, "tag": "ClinicalAttribute"}, {"end": 105, "start": 95, "tag": "Finding"}, {"end": 128, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 41, "tag": "Finding"}]}
{"id": "1458_13", "text": "DPOAE in APP/PS1 AD mice was also reduced.", "tags": [{"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 24, "start": 9, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_14", "text": "However, there was no reduction in CM in APP/PS1 mice.", "tags": [{"end": 31, "start": 22, "tag": "Finding"}, {"end": 31, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 53, "start": 41, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_15", "text": "These data demonstrate that unlike age-related hearing loss APP/PS1 AD mice have early onset of hearing loss.", "tags": [{"end": 59, "start": 35, "tag": "PathologicFunction"}, {"end": 108, "start": 96, "tag": "Finding"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}, {"end": 75, "start": 60, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1458_16", "text": "These data also suggest that hearing function testing could provide a simple, sensitive, non-invasive screen-tool for early detecting AD and localizing lesion.", "tags": [{"end": 158, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 87, "start": 78, "tag": "PathologicFunction"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 53, "start": 46, "tag": "HealthCareActivity"}, {"end": 123, "start": 118, "tag": "TemporalConcept"}, {"end": 113, "start": 89, "tag": "HealthCareActivity"}, {"end": 113, "start": 89, "tag": "ResearchActivity"}, {"end": 45, "start": 29, "tag": "BiologicFunction"}]}
{"id": "1459_0", "text": "Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings.", "tags": [{"end": 75, "start": 53, "tag": "Finding"}, {"end": 96, "start": 87, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "IndividualBehavior"}, {"end": 33, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "ResearchActivity"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 82, "start": 76, "tag": "PopulationGroup"}]}
{"id": "1459_1", "text": "Yet, US Food and Drug Administration approval of a disease-modifying treatment for symptomatic individuals, improved understanding of the preclinical phase of disease, and advancements toward more accessible biomarker tests suggest such disclosure will increase in frequency, eventually becoming routine in clinical practice.", "tags": [{"end": 36, "start": 8, "tag": "HealthCareRelatedOrganization"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 78, "start": 51, "tag": "HealthCareActivity"}, {"end": 303, "start": 296, "tag": "TemporalConcept"}, {"end": 247, "start": 237, "tag": "IndividualBehavior"}, {"end": 324, "start": 307, "tag": "HealthCareActivity"}, {"end": 155, "start": 138, "tag": "TemporalConcept"}, {"end": 217, "start": 208, "tag": "ClinicalAttribute"}, {"end": 106, "start": 83, "tag": "PopulationGroup"}, {"end": 274, "start": 265, "tag": "TemporalConcept"}, {"end": 130, "start": 117, "tag": "BiologicFunction"}, {"end": 223, "start": 218, "tag": "ResearchActivity"}, {"end": 223, "start": 218, "tag": "HealthCareActivity"}]}
{"id": "1459_2", "text": "The changing landscape in AD research to focus on biomarkers has generated debate on the validity and clinical utility of disclosure to cognitively unimpaired adults.", "tags": [{"end": 132, "start": 122, "tag": "IndividualBehavior"}, {"end": 158, "start": 136, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 97, "start": 89, "tag": "Finding"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}, {"end": 165, "start": 159, "tag": "PopulationGroup"}, {"end": 118, "start": 102, "tag": "Finding"}, {"end": 22, "start": 4, "tag": "Finding"}]}
{"id": "1459_3", "text": "This article explores the broader social implications of more widespread AD biomarker disclosure-that is, of individuals learning their risk for developing dementia caused by AD.", "tags": [{"end": 96, "start": 86, "tag": "IndividualBehavior"}, {"end": 155, "start": 136, "tag": "Finding"}, {"end": 129, "start": 121, "tag": "BiologicFunction"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 120, "start": 109, "tag": "PopulationGroup"}, {"end": 164, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 53, "start": 34, "tag": "Finding"}]}
{"id": "1459_4", "text": "We identify 10 challenges and offer preliminary solutions.", "tags": [{"end": 57, "start": 48, "tag": "Substance"}, {"end": 25, "start": 15, "tag": "HealthCareActivity"}, {"end": 47, "start": 36, "tag": "TemporalConcept"}]}
{"id": "1459_5", "text": "As the field continues to evolve, it is essential to anticipate and address these broader ethical, legal, and social implications of disclosure.", "tags": [{"end": 143, "start": 133, "tag": "IndividualBehavior"}, {"end": 129, "start": 110, "tag": "Finding"}, {"end": 129, "start": 117, "tag": "Finding"}, {"end": 97, "start": 90, "tag": "Finding"}, {"end": 129, "start": 117, "tag": "Finding"}, {"end": 104, "start": 99, "tag": "Finding"}]}
{"id": "1460_0", "text": "The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD.", "tags": [{"end": 240, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 249, "tag": "PopulationGroup"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 201, "tag": "ClinicalAttribute"}, {"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 298, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 165, "tag": "Finding"}, {"end": 221, "start": 215, "tag": "PopulationGroup"}, {"end": 7, "start": 4, "tag": "HealthCareRelatedOrganization"}, {"end": 61, "start": 15, "tag": "HealthCareRelatedOrganization"}, {"end": 109, "start": 79, "tag": "HealthCareRelatedOrganization"}, {"end": 69, "start": 63, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1460_1", "text": "These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials.", "tags": [{"end": 113, "start": 105, "tag": "Finding"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}, {"end": 155, "start": 140, "tag": "ResearchActivity"}]}
{"id": "1460_2", "text": "This paper considers how these data can be integrated in clinical trials for individuals with DS.", "tags": [{"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "ResearchActivity"}, {"end": 72, "start": 57, "tag": "ResearchActivity"}, {"end": 88, "start": 77, "tag": "PopulationGroup"}]}
{"id": "1460_3", "text": "The Alzheimer's Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.", "tags": [{"end": 57, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 246, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "ResearchActivity"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 152, "tag": "ResearchActivity"}, {"end": 57, "start": 4, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}]}
{"id": "1461_0", "text": "Objective There is still an urgent need for supportive minimally invasive and cost-effective biomarkers for early diagnosis of Alzheimer's disease (AD).", "tags": [{"end": 73, "start": 55, "tag": "Finding"}, {"end": 146, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 123, "start": 108, "tag": "HealthCareActivity"}]}
{"id": "1461_1", "text": "Previous work in our lab has identified Kallikrein-8 (KLK8) as a potential candidate since it shows an excessive increase in human brain in preclinical disease stages.", "tags": [{"end": 24, "start": 21, "tag": "HealthCareRelatedOrganization"}, {"end": 166, "start": 152, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 52, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "GeneOrGenome"}]}
{"id": "1461_2", "text": "The aim of this study was to evaluate the diagnostic performance of cerebrospinal fluid (CSF) and blood KLK8 for AD and mild cognitive impairment (MCI) due to AD.", "tags": [{"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 150, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 42, "tag": "Finding"}, {"end": 145, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 98, "tag": "ClinicalAttribute"}]}
{"id": "1461_3", "text": "Methods In this multi-centre trans-sectional study, clinical and laboratory data as well as CSF and/or blood serum samples of 237 participants, including 98 patients with mild AD, 21 with MCI due to AD and 118 controls were collected.", "tags": [{"end": 122, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 210, "tag": "PopulationGroup"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 52, "tag": "ResearchActivity"}, {"end": 142, "start": 130, "tag": "PopulationGroup"}, {"end": 50, "start": 16, "tag": "ResearchActivity"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 171, "tag": "Finding"}]}
{"id": "1461_4", "text": "CSF and/or serum KLK8 levels were analysed by ELISA.", "tags": [{"end": 51, "start": 46, "tag": "ResearchActivity"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 11, "tag": "ClinicalAttribute"}, {"end": 28, "start": 17, "tag": "ClinicalAttribute"}, {"end": 3, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1461_5", "text": "The diagnostic accuracy of KLK8 in CSF and blood was determined using receiver operating characteristic (ROC) analyses and compared with that of CSF core biomarkers A beta 42, P-tau and T-tau.", "tags": [{"end": 191, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 4, "tag": "Finding"}, {"end": 108, "start": 105, "tag": "ResearchActivity"}, {"end": 181, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 154, "tag": "ClinicalAttribute"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 48, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 103, "start": 70, "tag": "ResearchActivity"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}]}
{"id": "1461_6", "text": "Results The diagnostic accuracy of CSF KLK8 was as good as that of core CSF biomarkers for AD (area under the curve (AUC)=0.89) and in case of MCI (AUC=0.97) even superior to CSF A beta 42.", "tags": [{"end": 188, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 12, "tag": "Finding"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 95, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "ClinicalAttribute"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 135, "tag": "ManufacturedObject"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 120, "start": 117, "tag": "ResearchActivity"}, {"end": 151, "start": 148, "tag": "ResearchActivity"}, {"end": 43, "start": 35, "tag": "ClinicalAttribute"}, {"end": 188, "start": 175, "tag": "ClinicalAttribute"}]}
{"id": "1461_7", "text": "Blood KLK8 was a similarly strong discriminator for MCI (AUC=0.94) but slightly weaker for AD (AUC=0.83).", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "ResearchActivity"}, {"end": 98, "start": 95, "tag": "ResearchActivity"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1461_8", "text": "Conclusions This is the first study to demonstrate the potential clinical utility of blood and CSF KLK8 as a biomarker for incipient AD.", "tags": [{"end": 132, "start": 123, "tag": "TemporalConcept"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "ClinicalAttribute"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "ClinicalAttribute"}]}
{"id": "1461_9", "text": "Future prospective validation studies are warranted.", "tags": [{"end": 18, "start": 7, "tag": "BiologicFunction"}, {"end": 29, "start": 19, "tag": "ResearchActivity"}, {"end": 37, "start": 30, "tag": "ResearchActivity"}]}
{"id": "1462_0", "text": "Alzheimer's disease (AD) begins with an asymptomatic preclinical phase, in which abnormal biomarkers indicate risk for developing cognitive impairment.", "tags": [{"end": 52, "start": 40, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 90, "tag": "ClinicalAttribute"}, {"end": 70, "start": 53, "tag": "TemporalConcept"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "Finding"}]}
{"id": "1462_1", "text": "Biomarker information is increasingly being disclosed in research settings, and is moving toward clinical settings with the development of cheaper and non-invasive testing.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 171, "start": 151, "tag": "HealthCareActivity"}, {"end": 114, "start": 97, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 135, "start": 124, "tag": "BiologicFunction"}, {"end": 135, "start": 124, "tag": "CellFunction"}]}
{"id": "1462_2", "text": "Limited research has focused on the safety and psychological effects of disclosing biomarker results to cognitively unimpaired adults.", "tags": [{"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 92, "start": 83, "tag": "ClinicalAttribute"}, {"end": 133, "start": 127, "tag": "PopulationGroup"}, {"end": 68, "start": 47, "tag": "Finding"}, {"end": 126, "start": 104, "tag": "Finding"}]}
{"id": "1462_3", "text": "However, less is known about how to ensure equitable access and robust counseling for decision-making before testing, and how to effectively provide long-term follow-up and risk management after testing.", "tags": [{"end": 81, "start": 71, "tag": "HealthCareActivity"}, {"end": 188, "start": 173, "tag": "HealthCareActivity"}, {"end": 116, "start": 109, "tag": "HealthCareActivity"}, {"end": 202, "start": 195, "tag": "HealthCareActivity"}, {"end": 158, "start": 149, "tag": "TemporalConcept"}, {"end": 101, "start": 86, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}]}
{"id": "1462_4", "text": "Using the framework of Huntington's disease, which is based on extensive experience with disclosing and managing risk for a progressive neurodegenerative condition, this article proposes a conceptual model of pre-disclosure, disclosure, and post-disclosure phases for AD biomarker testing.", "tags": [{"end": 235, "start": 225, "tag": "IndividualBehavior"}, {"end": 177, "start": 170, "tag": "ResearchActivity"}, {"end": 288, "start": 281, "tag": "HealthCareActivity"}, {"end": 43, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 136, "tag": "CellOrMolecularDysfunction"}, {"end": 153, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 124, "tag": "TemporalConcept"}, {"end": 270, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 271, "tag": "ClinicalAttribute"}, {"end": 205, "start": 200, "tag": "ResearchActivity"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 245, "start": 241, "tag": "TemporalConcept"}, {"end": 117, "start": 104, "tag": "HealthCareActivity"}]}
{"id": "1462_5", "text": "Addressing research questions in each phase will facilitate the transition of biomarker testing into clinical practice.", "tags": [{"end": 74, "start": 64, "tag": "Finding"}, {"end": 95, "start": 88, "tag": "HealthCareActivity"}, {"end": 118, "start": 101, "tag": "HealthCareActivity"}, {"end": 43, "start": 38, "tag": "TemporalConcept"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}]}
{"id": "1463_0", "text": "Background: The typical approach to identify blood-derived gene expression signatures as a biomarker for Alzheimer's disease (AD) have relied on training classification models using AD and healthy controls only.", "tags": [{"end": 85, "start": 64, "tag": "ResearchActivity"}, {"end": 74, "start": 59, "tag": "CellFunction"}, {"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "ClinicalAttribute"}, {"end": 196, "start": 189, "tag": "OrganismAttribute"}, {"end": 205, "start": 197, "tag": "PopulationGroup"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 145, "tag": "MachineActivity"}]}
{"id": "1463_1", "text": "This may inadvertently result in the identification of markers for general illness rather than being disease-specific.", "tags": [{"end": 62, "start": 55, "tag": "ClinicalAttribute"}, {"end": 82, "start": 75, "tag": "SignOrSymptom"}]}
{"id": "1463_2", "text": "Objective: Investigate whether incorporating additional related disorders in the classification model development process can lead to the discovery of an AD-specific gene expression signature.", "tags": [{"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 191, "start": 182, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 102, "tag": "BiologicFunction"}, {"end": 113, "start": 102, "tag": "CellFunction"}, {"end": 147, "start": 138, "tag": "ResearchActivity"}, {"end": 101, "start": 81, "tag": "ResearchActivity"}]}
{"id": "1463_3", "text": "Methods: Two types of XGBoost classification models were developed.", "tags": [{"end": 51, "start": 22, "tag": "MachineActivity"}]}
{"id": "1463_4", "text": "The first used 160 AD and 127 healthy controls and the second used the same 160 AD with 6,318 upsampled mixed controls consisting of Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, bipolar disorder, schizophrenia, coronary artery disease, rheumatoid arthritis, chronic obstructive pulmonary disease, and cognitively healthy subjects.", "tags": [{"end": 221, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 285, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 110, "tag": "PopulationGroup"}, {"end": 37, "start": 30, "tag": "OrganismAttribute"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PopulationGroup"}, {"end": 356, "start": 348, "tag": "PopulationGroup"}, {"end": 347, "start": 328, "tag": "OrganismAttribute"}]}
{"id": "1463_5", "text": "Both classification models were evaluated in an independent cohort consisting of 127 AD and 687 mixed controls.", "tags": [{"end": 59, "start": 48, "tag": "Finding"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PopulationGroup"}, {"end": 66, "start": 60, "tag": "PopulationGroup"}, {"end": 26, "start": 5, "tag": "ResearchActivity"}]}
{"id": "1463_6", "text": "Results: The AD versus healthy control models resulted in an average 48.7% sensitivity (95% CI = 34.7-64.6), 41.9% specificity (95% CI = 26.8-54.3), 13.6% PPV (95% CI = 9.9-18.5), and 81.1% NPV (95% CI = 73.3-87.7).", "tags": [{"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 23, "tag": "OrganismAttribute"}, {"end": 86, "start": 75, "tag": "Finding"}, {"end": 126, "start": 115, "tag": "Finding"}, {"end": 38, "start": 31, "tag": "PopulationGroup"}, {"end": 94, "start": 92, "tag": "ResearchActivity"}, {"end": 134, "start": 132, "tag": "ResearchActivity"}, {"end": 166, "start": 164, "tag": "ResearchActivity"}, {"end": 201, "start": 199, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 39, "tag": "ResearchActivity"}]}
{"id": "1463_7", "text": "In contrast, the mixed control models resulted in an average of 40.8% sensitivity (95% CI = 27.5-52.0), 95.3% specificity (95% CI = 93.3-97.1), 61.4% PPV (95% CI = 53.8-69.6), and 89.7% NPV (95% CI = 87.8-91.4).", "tags": [{"end": 81, "start": 70, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "ResearchActivity"}, {"end": 129, "start": 127, "tag": "ResearchActivity"}, {"end": 161, "start": 159, "tag": "ResearchActivity"}, {"end": 197, "start": 195, "tag": "ResearchActivity"}, {"end": 37, "start": 17, "tag": "ResearchActivity"}]}
{"id": "1463_8", "text": "Conclusions: This early work demonstrates the value of incorporating additional related disorders into the classification model developmental process, which can result in models with improved ability to distinguish AD from a heterogeneous aging population.", "tags": [{"end": 141, "start": 128, "tag": "BiologicFunction"}, {"end": 141, "start": 128, "tag": "TemporalConcept"}, {"end": 191, "start": 183, "tag": "Finding"}, {"end": 238, "start": 225, "tag": "OrganismAttribute"}, {"end": 97, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 245, "tag": "PopulationGroup"}, {"end": 244, "start": 239, "tag": "BiologicFunction"}, {"end": 244, "start": 239, "tag": "CellFunction"}, {"end": 199, "start": 192, "tag": "OrganismAttribute"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 161, "tag": "Finding"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}, {"end": 127, "start": 107, "tag": "ResearchActivity"}, {"end": 177, "start": 171, "tag": "ResearchActivity"}]}
{"id": "1463_9", "text": "However, further improvement to the sensitivity of the test is still required.", "tags": [{"end": 47, "start": 36, "tag": "Finding"}, {"end": 59, "start": 55, "tag": "ResearchActivity"}, {"end": 59, "start": 55, "tag": "HealthCareActivity"}]}
{"id": "1464_0", "text": "IntroductionWe examined longitudinal cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker changes among cognitively normal individuals with 10.7 years follow-up, on average.", "tags": [{"end": 82, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 131, "tag": "PopulationGroup"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}, {"end": 130, "start": 112, "tag": "Finding"}, {"end": 36, "start": 24, "tag": "ResearchActivity"}, {"end": 105, "start": 98, "tag": "Finding"}]}
{"id": "1464_1", "text": "MethodsAnalyses included 278 participants (M age = 57.5 years); 94 have progressed from normal cognition to mild cognitive impairment (MCI).", "tags": [{"end": 44, "start": 43, "tag": "TemporalConcept"}, {"end": 94, "start": 88, "tag": "Finding"}, {"end": 104, "start": 88, "tag": "Finding"}, {"end": 41, "start": 29, "tag": "PopulationGroup"}, {"end": 138, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 61, "start": 56, "tag": "TemporalConcept"}, {"end": 104, "start": 95, "tag": "BiologicFunction"}, {"end": 133, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "ResearchActivity"}]}
{"id": "1464_2", "text": "Amyloid beta (A beta)(42)/A beta(40), phosphorylated tau(181) (p-tau(181)), and total tau (t-tau) were measured using automated electrochemiluminescence assays.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 13, "tag": "ClinicalAttribute"}, {"end": 61, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 118, "tag": "ResearchActivity"}]}
{"id": "1464_3", "text": "ResultsApolipoprotein E (APOE) epsilon 4 carriers had lower baseline A beta(42)/A beta(40), but longitudinal A beta(42)/A beta(40) decreases did not differ by APOE epsilon 4 after accounting for A beta(42)/A beta(40) positivity.", "tags": [{"end": 227, "start": 217, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 41, "tag": "PopulationGroup"}, {"end": 173, "start": 159, "tag": "GeneOrGenome"}, {"end": 40, "start": 31, "tag": "GeneOrGenome"}, {"end": 23, "start": 7, "tag": "GeneOrGenome"}, {"end": 90, "start": 69, "tag": "ClinicalAttribute"}, {"end": 130, "start": 109, "tag": "ClinicalAttribute"}, {"end": 216, "start": 195, "tag": "ClinicalAttribute"}]}
{"id": "1464_4", "text": "Lower baseline A beta(42)/A beta(40) was associated with greater increases in tau (more strongly in males), and APOE epsilon 4 genotype was associated with greater tau increases after reaching A beta(42)/A beta(40) positivity.", "tags": [{"end": 105, "start": 100, "tag": "OrganismAttribute"}, {"end": 225, "start": 215, "tag": "ResearchActivity"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 127, "tag": "OrganismAttribute"}, {"end": 126, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 15, "tag": "ClinicalAttribute"}, {"end": 214, "start": 193, "tag": "ClinicalAttribute"}]}
{"id": "1464_5", "text": "Participants who progressed to MCI had more abnormal biomarker levels and greater tau increases prior to MCI symptom onset.", "tags": [{"end": 52, "start": 44, "tag": "Finding"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 34, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 122, "start": 109, "tag": "TemporalConcept"}, {"end": 116, "start": 109, "tag": "SignOrSymptom"}]}
{"id": "1464_6", "text": "Biomarkers were more abnormal among older adults, but unrelated to sex or education.", "tags": [{"end": 29, "start": 21, "tag": "Finding"}, {"end": 70, "start": 67, "tag": "OrganismAttribute"}, {"end": 41, "start": 36, "tag": "TemporalConcept"}, {"end": 48, "start": 36, "tag": "PopulationGroup"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 83, "start": 74, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 48, "start": 42, "tag": "PopulationGroup"}]}
{"id": "1464_7", "text": "DiscussionOur results confirm accelerated biomarker changes during preclinical AD and highlight the important role of amyloid levels in tau accelerations.", "tags": [{"end": 132, "start": 118, "tag": "ClinicalAttribute"}, {"end": 139, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 125, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 52, "tag": "Finding"}]}
{"id": "1465_0", "text": "We aimed to evaluate the specificity of neurogranin (Ng) for Alzheimer's disease (AD) in a dementia cohort.", "tags": [{"end": 55, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 25, "tag": "Finding"}, {"end": 106, "start": 100, "tag": "PopulationGroup"}]}
{"id": "1465_1", "text": "Cerebrospinal fluid (CSF) Ng was measured (ELISA) in two independent cohorts: (1) clinical (n = 116; age 72 +/- 11 years): AD, non-AD (+ high T-tau), and controls; and (2) autopsy-confirmed (n = 97; age 71 +/- 11 years): AD and non-AD, and 50 controls (age 60 +/- 6 years).", "tags": [{"end": 28, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 43, "tag": "ResearchActivity"}, {"end": 147, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 154, "tag": "PopulationGroup"}, {"end": 251, "start": 243, "tag": "PopulationGroup"}, {"end": 76, "start": 69, "tag": "PopulationGroup"}, {"end": 104, "start": 101, "tag": "OrganismAttribute"}, {"end": 202, "start": 199, "tag": "OrganismAttribute"}, {"end": 256, "start": 253, "tag": "OrganismAttribute"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 218, "start": 213, "tag": "TemporalConcept"}, {"end": 271, "start": 266, "tag": "TemporalConcept"}, {"end": 141, "start": 137, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "ClinicalAttribute"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}, {"end": 179, "start": 172, "tag": "HealthCareActivity"}]}
{"id": "1465_2", "text": "In 16 autopsy-confirmed AD and 8 control subjects, Ng was measured in tissue (BA6 + BA22).", "tags": [{"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "PopulationGroup"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 6, "tag": "HealthCareActivity"}]}
{"id": "1465_3", "text": "Ng was compared across diagnostic groups or neu-ropathological staging using multilinear regression models.", "tags": [{"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 63, "tag": "TemporalConcept"}, {"end": 106, "start": 77, "tag": "ResearchActivity"}, {"end": 40, "start": 34, "tag": "PopulationGroup"}, {"end": 33, "start": 23, "tag": "HealthCareActivity"}]}
{"id": "1465_4", "text": "Median[IQR] Ng concentrations were elevated in AD (414[315-499]pg/mL) and non-AD (464[319- 699]pg/mL) compared to controls (260[193-306]pg/mL), but highest in AD-high-T-tau (874[716, 1148] pg/mL) and Creutzfeldt-Jakob disease (CJD; 828[703-1373]pg/mL) in cohort 1 ( p < 0.01), but not in co-hort 2: AD: 358[249-470]pg/mL; non-AD:245[137-416]pg/mL; controls: 259[193-370]pg/mL.", "tags": [{"end": 225, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 299, "tag": "DiseaseOrSyndrome"}, {"end": 328, "start": 326, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "PopulationGroup"}, {"end": 356, "start": 348, "tag": "PopulationGroup"}, {"end": 261, "start": 255, "tag": "PopulationGroup"}, {"end": 166, "start": 162, "tag": "Finding"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1465_5", "text": "Ng and tau biomarkers strongly correlated (r = 0.4-0.9, p < 0.05), except in CJD.", "tags": [{"end": 80, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 11, "tag": "ClinicalAttribute"}]}
{"id": "1465_6", "text": "CSF Ng concentrations were not associated with neuropathological AD hallmarks, nor with tissue Ng concentrations.", "tags": [{"end": 6, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "Finding"}, {"end": 64, "start": 47, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}, {"end": 112, "start": 88, "tag": "ClinicalAttribute"}]}
{"id": "1465_7", "text": "CSF Ng is a general biomarker for synaptic degeneration, strongly correlating with CSF tau, but with-out added value for AD differential diagnosis.", "tags": [{"end": 55, "start": 34, "tag": "CellOrMolecularDysfunction"}, {"end": 6, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 124, "tag": "HealthCareActivity"}, {"end": 90, "start": 83, "tag": "ClinicalAttribute"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 146, "start": 137, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1465_8", "text": "(C) 2021 The Authors.", "tags": []}
{"id": "1465_9", "text": "Published by Elsevier Inc.", "tags": []}
{"id": "1466_0", "text": "Background: Although numerous microRNAs (miRNAs) have been discovered to participate in the progression of Alzheimer's disease (AD), they are still difficult to apply in clinical work.", "tags": [{"end": 39, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}]}
{"id": "1466_1", "text": "Thus, the identification of novel miRNAs and clarification of their clinical significance are importing for improving the diagnosis and treatment of AD.", "tags": [{"end": 89, "start": 68, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 136, "tag": "HealthCareActivity"}, {"end": 145, "start": 136, "tag": "ResearchActivity"}, {"end": 131, "start": 122, "tag": "HealthCareActivity"}]}
{"id": "1466_2", "text": "The purpose of this study was to analyze the expression of miR-128 and its diagnostic value in patients with AD.", "tags": [{"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 75, "tag": "Finding"}]}
{"id": "1466_3", "text": "Patients and Methods: In this study, 117 AD patients and 106 controls were enrolled, and the demographic data, biochemical parameters and serum miR-128 levels were collected.", "tags": [{"end": 109, "start": 93, "tag": "ResearchActivity"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 158, "start": 138, "tag": "ClinicalAttribute"}]}
{"id": "1466_4", "text": "These data were then used to build a logistic regression model, and receiver operating characteristic (ROC) curves were drawn to evaluate the diagnostic value of miR-128.", "tags": [{"end": 62, "start": 37, "tag": "ResearchActivity"}, {"end": 106, "start": 103, "tag": "ResearchActivity"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 169, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 162, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 108, "tag": "ResearchActivity"}, {"end": 101, "start": 68, "tag": "ResearchActivity"}, {"end": 158, "start": 142, "tag": "Finding"}]}
{"id": "1466_5", "text": "The relationships between miR-128 and inflammatory factors (IL-113/TNF-alpha) were also analyzed from clinical serum data.", "tags": [{"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 117, "tag": "ResearchActivity"}, {"end": 17, "start": 4, "tag": "Finding"}, {"end": 33, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 33, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 38, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1466_6", "text": "Results: Our study found that miR-128 was significantly upregulated in the serum samples of AD patients compared with controls, and that this upregulation was negatively correlated with Mini-Mental State Examination (MMSE) scores (r = -0.687, P< 0.01).", "tags": [{"end": 154, "start": 142, "tag": "CellFunction"}, {"end": 221, "start": 217, "tag": "HealthCareActivity"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 229, "start": 223, "tag": "Finding"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "PopulationGroup"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 215, "start": 186, "tag": "HealthCareActivity"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "Substance"}, {"end": 88, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}]}
{"id": "1466_7", "text": "ROC curve showed that the area under the curve of miR-128 was 0.831.", "tags": [{"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 46, "start": 26, "tag": "ResearchActivity"}, {"end": 57, "start": 50, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 57, "start": 50, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1466_8", "text": "Logistic regression analyses showed that glycosylated hemoglobin (HbA1c) levels, low-density lipoprotein (LDL) levels, MMSE scores and serum miR-128 levels were statistically significant (P< 0.01), and the ROC curve of the combined detection of these variables was 0.906.", "tags": [{"end": 64, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "HealthCareActivity"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 241, "start": 232, "tag": "HealthCareActivity"}, {"end": 155, "start": 135, "tag": "ClinicalAttribute"}, {"end": 104, "start": 81, "tag": "Chemical"}, {"end": 104, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 206, "tag": "ResearchActivity"}]}
{"id": "1466_9", "text": "The serum miR-128 levels in AD patients were positively correlated with the serum IL-113 (r=0.798, P<0.01) and serum TNF-alpha levels (r=0.733, P<0.01).", "tags": [{"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 31, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 111, "tag": "ClinicalAttribute"}, {"end": 24, "start": 4, "tag": "ClinicalAttribute"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "ClinicalAttribute"}]}
{"id": "1466_10", "text": "Conclusion: Serum miR-128 is a candidate diagnostic biomarker in AD patients who achieved good diagnostic performance when used alone or in combination with other factors and may have the potential to be a novel therapeutic target for neuroinflammation.", "tags": [{"end": 230, "start": 206, "tag": "Finding"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 41, "tag": "ClinicalAttribute"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 252, "start": 235, "tag": "PathologicFunction"}, {"end": 117, "start": 95, "tag": "Finding"}, {"end": 25, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1467_0", "text": "IntroductionDespite increasing evidence of a role of rare genetic variation in the risk of Alzheimer's disease (AD), limited attention has been paid to its contribution to AD-related biomarker traits indicative of AD-relevant pathophysiological processes.", "tags": [{"end": 75, "start": 58, "tag": "NaturalPhenomenonOrProcess"}, {"end": 199, "start": 193, "tag": "OrganismAttribute"}, {"end": 254, "start": 226, "tag": "BiologicFunction"}, {"end": 39, "start": 20, "tag": "Finding"}, {"end": 134, "start": 125, "tag": "BiologicFunction"}, {"end": 30, "start": 20, "tag": "Finding"}, {"end": 110, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 183, "tag": "ClinicalAttribute"}, {"end": 39, "start": 31, "tag": "Finding"}, {"end": 57, "start": 53, "tag": "TemporalConcept"}, {"end": 87, "start": 83, "tag": "Finding"}]}
{"id": "1467_1", "text": "MethodsWe performed whole-exome gene-based rare-variant association studies (RVASs) of 17 AD-related traits on whole-exome sequencing (WES) data generated in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study (n = 450) and whole-genome sequencing (WGS) data from ADNI (n = 808).", "tags": [{"end": 107, "start": 101, "tag": "OrganismAttribute"}, {"end": 133, "start": 111, "tag": "ResearchActivity"}, {"end": 138, "start": 135, "tag": "ResearchActivity"}, {"end": 334, "start": 330, "tag": "HealthCareRelatedOrganization"}, {"end": 334, "start": 330, "tag": "ResearchActivity"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 140, "tag": "ResearchActivity"}, {"end": 324, "start": 320, "tag": "ResearchActivity"}, {"end": 75, "start": 20, "tag": "ResearchActivity"}, {"end": 275, "start": 270, "tag": "ResearchActivity"}, {"end": 200, "start": 162, "tag": "HealthCareRelatedOrganization"}, {"end": 255, "start": 205, "tag": "ResearchActivity"}, {"end": 268, "start": 257, "tag": "ResearchActivity"}, {"end": 313, "start": 290, "tag": "ResearchActivity"}, {"end": 82, "start": 77, "tag": "ResearchActivity"}]}
{"id": "1467_2", "text": "ResultsMutation screening revealed a novel probably pathogenic mutation (PSEN1 p.Leu232Phe).", "tags": [{"end": 78, "start": 73, "tag": "GeneOrGenome"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 52, "tag": "PathologicFunction"}, {"end": 25, "start": 7, "tag": "ResearchActivity"}, {"end": 90, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1467_3", "text": "Gene-based RVAS revealed the exome-wide significant contribution of rare coding variation in RBKS and OR7A10 to cognitive performance and protection against left hippocampal atrophy, respectively.", "tags": [{"end": 97, "start": 93, "tag": "GeneOrGenome"}, {"end": 108, "start": 102, "tag": "GeneOrGenome"}, {"end": 181, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 112, "tag": "Finding"}, {"end": 72, "start": 68, "tag": "TemporalConcept"}, {"end": 15, "start": 11, "tag": "ResearchActivity"}]}
{"id": "1467_4", "text": "DiscussionThe identification of these novel gene-trait associations offers new perspectives into the role of rare coding variation in the distinct pathophysiological processes culminating in AD, which may lead to identification of novel therapeutic and diagnostic targets.", "tags": [{"end": 175, "start": 147, "tag": "BiologicFunction"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 263, "start": 253, "tag": "HealthCareActivity"}, {"end": 113, "start": 109, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "OrganismAttribute"}, {"end": 48, "start": 44, "tag": "GeneOrGenome"}, {"end": 271, "start": 231, "tag": "Finding"}]}
{"id": "1468_0", "text": "Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development.", "tags": [{"end": 58, "start": 38, "tag": "PathologicFunction"}, {"end": 122, "start": 110, "tag": "TemporalConcept"}, {"end": 122, "start": 116, "tag": "TemporalConcept"}, {"end": 86, "start": 69, "tag": "CellFunction"}, {"end": 185, "start": 169, "tag": "ResearchActivity"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 174, "tag": "BiologicFunction"}, {"end": 185, "start": 174, "tag": "CellFunction"}, {"end": 24, "start": 14, "tag": "ClinicalAttribute"}, {"end": 173, "start": 169, "tag": "PharmacologicSubstance"}]}
{"id": "1468_1", "text": "Methods: A targeted, stable isotope, quantitative mass spectrometry-based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline.", "tags": [{"end": 35, "start": 21, "tag": "Chemical"}, {"end": 372, "start": 369, "tag": "DiseaseOrSyndrome"}, {"end": 324, "start": 322, "tag": "Finding"}, {"end": 320, "start": 302, "tag": "Finding"}, {"end": 241, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 165, "tag": "ClinicalAttribute"}, {"end": 217, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 207, "tag": "Substance"}, {"end": 87, "start": 74, "tag": "ResearchActivity"}, {"end": 278, "start": 266, "tag": "PopulationGroup"}, {"end": 212, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 367, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 367, "start": 342, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 37, "tag": "ResearchActivity"}, {"end": 265, "start": 222, "tag": "ResearchActivity"}]}
{"id": "1468_2", "text": "Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs.", "tags": [{"end": 83, "start": 63, "tag": "GeneOrGenome"}, {"end": 83, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 85, "tag": "GeneOrGenome"}, {"end": 90, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 219, "tag": "PopulationGroup"}, {"end": 235, "start": 233, "tag": "Finding"}, {"end": 36, "start": 26, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 208, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 90, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "CellFunction"}, {"end": 83, "start": 42, "tag": "ClinicalAttribute"}]}
{"id": "1468_3", "text": "MCI participants; AD pathology positive vs.", "tags": [{"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "PathologicFunction"}, {"end": 30, "start": 21, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}]}
{"id": "1468_4", "text": "negative defined by phosphorylated tau181/amyloid beta1-42 ratio; and clinical progressors vs.", "tags": [{"end": 58, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 70, "tag": "PopulationGroup"}]}
{"id": "1468_5", "text": "non-progressors).", "tags": [{"end": 15, "start": 0, "tag": "PopulationGroup"}]}
{"id": "1468_6", "text": "The rate of change of NPTX2 also significantly correlated with declining cognition.", "tags": [{"end": 27, "start": 22, "tag": "GeneOrGenome"}, {"end": 27, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 82, "start": 73, "tag": "BiologicFunction"}]}
{"id": "1468_7", "text": "Discussion: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.", "tags": [{"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 15, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 48, "tag": "ClinicalAttribute"}, {"end": 111, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 136, "tag": "Finding"}, {"end": 35, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1469_0", "text": "Introduction: Brain cells secrete extracellular microvesicles (EVs) that cross the blood-brain barrier.", "tags": [{"end": 25, "start": 14, "tag": "Cell"}, {"end": 61, "start": 34, "tag": "CellComponent"}, {"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 63, "tag": "CellComponent"}, {"end": 102, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1469_1", "text": "Involved in cell-to-cell communication, EVs contain surface markers and a biologically active cargo of molecules specific to their tissue (and cell) of origin, reflecting the tissue or cell's physiological state.", "tags": [{"end": 147, "start": 143, "tag": "Cell"}, {"end": 112, "start": 103, "tag": "Substance"}, {"end": 158, "start": 152, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 99, "start": 74, "tag": "CellFunction"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 12, "tag": "CellFunction"}]}
{"id": "1469_2", "text": "Isolation of brain-secreted EVs (BEVs) from blood provides a minimally invasive way to sample components of brain tissue in Alzheimer's disease (AD), and is considered a form of liquid biopsy.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 83, "start": 61, "tag": "Finding"}, {"end": 191, "start": 178, "tag": "HealthCareActivity"}, {"end": 104, "start": 94, "tag": "CellComponent"}, {"end": 120, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "CellComponent"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 33, "tag": "CellComponent"}, {"end": 31, "start": 13, "tag": "CellComponent"}]}
{"id": "1469_3", "text": "Methods: We performed a comprehensive review of the PubMed literature to assess the biomarker and therapeutic potential of blood-isolated BEVs in AD.", "tags": [{"end": 69, "start": 59, "tag": "ResearchActivity"}, {"end": 119, "start": 98, "tag": "HealthCareActivity"}, {"end": 58, "start": 52, "tag": "HealthCareRelatedOrganization"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 44, "start": 38, "tag": "HealthCareActivity"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 142, "start": 138, "tag": "CellComponent"}]}
{"id": "1469_4", "text": "Results: We summarize methods used for BEV isolation, validation, and novel biomarker discovery, as well as provide insights from 26 studies in humans on the biomarker potential in AD of four cell-specific BEVs isolated from blood: neuron-, neural precursor-, astrocyte-, and brain vasculature-derived BEVs.", "tags": [{"end": 52, "start": 43, "tag": "ResearchActivity"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 238, "start": 232, "tag": "Cell"}, {"end": 269, "start": 260, "tag": "Cell"}, {"end": 150, "start": 144, "tag": "Eukaryote"}, {"end": 281, "start": 276, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 140, "start": 133, "tag": "ResearchActivity"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 70, "tag": "ClinicalAttribute"}, {"end": 52, "start": 43, "tag": "HealthCareActivity"}, {"end": 210, "start": 206, "tag": "CellComponent"}, {"end": 293, "start": 282, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 306, "start": 302, "tag": "CellComponent"}, {"end": 257, "start": 241, "tag": "Cell"}]}
{"id": "1469_5", "text": "Of these, neuron-derived BEVs has been investigated on several fronts, and these include levels of amyloid-beta and tau proteins, as well as synaptic proteins.", "tags": [{"end": 128, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 10, "tag": "Cell"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 10, "tag": "CellComponent"}, {"end": 111, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 116, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1469_6", "text": "In addition, we provide a synopsis of the current landscape of BEV-based evaluation/monitoring of AD therapeutics based on two published trials and a review of registered clinical trials.", "tags": [{"end": 83, "start": 73, "tag": "HealthCareActivity"}, {"end": 83, "start": 73, "tag": "ResearchActivity"}, {"end": 113, "start": 101, "tag": "HealthCareActivity"}, {"end": 156, "start": 150, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "HealthCareActivity"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 171, "tag": "ResearchActivity"}, {"end": 94, "start": 84, "tag": "HealthCareActivity"}, {"end": 49, "start": 42, "tag": "TemporalConcept"}, {"end": 66, "start": 63, "tag": "CellComponent"}, {"end": 143, "start": 127, "tag": "ResearchActivity"}]}
{"id": "1469_7", "text": "Discussion: Blood-isolated BEVs have emerged as a novel player in the study of AD, with enormous potential as a diagnostic, evaluation of therapeutics, and treatment tool.", "tags": [{"end": 122, "start": 112, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "ResearchActivity"}, {"end": 150, "start": 138, "tag": "HealthCareActivity"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 156, "tag": "HealthCareActivity"}, {"end": 165, "start": 156, "tag": "ResearchActivity"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 12, "tag": "CellComponent"}]}
{"id": "1469_8", "text": "The literature has largely concentrated on neuron-derived BEVs in the blood in AD.", "tags": [{"end": 49, "start": 43, "tag": "Cell"}, {"end": 14, "start": 4, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 43, "tag": "CellComponent"}]}
{"id": "1469_9", "text": "Given the multifactorial pathophysiology of AD, additional studies, in neuron-derived and other brain cell-specific BEVs are warranted to establish BEVs as a robust blood-based biomarker of AD.", "tags": [{"end": 24, "start": 10, "tag": "Finding"}, {"end": 77, "start": 71, "tag": "Cell"}, {"end": 106, "start": 96, "tag": "Cell"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 177, "tag": "ClinicalAttribute"}, {"end": 40, "start": 25, "tag": "PathologicFunction"}, {"end": 40, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 120, "start": 116, "tag": "CellComponent"}, {"end": 152, "start": 148, "tag": "CellComponent"}]}
{"id": "1470_0", "text": "Exosomes are small extracellular vesicles (EVs) present in human biofluids that can transport specific disease-associated molecules.", "tags": [{"end": 93, "start": 84, "tag": "CellFunction"}, {"end": 131, "start": 122, "tag": "Substance"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 41, "start": 19, "tag": "CellComponent"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 41, "start": 13, "tag": "CellComponent"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 74, "start": 65, "tag": "Substance"}]}
{"id": "1470_1", "text": "Consequently blood-derived exosomes have emerged as important peripheral biomarker sources for a wide range of diseases, among them Alzheimer's disease (AD).", "tags": [{"end": 90, "start": 83, "tag": "Finding"}, {"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 151, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 72, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1470_2", "text": "Although there is no effective cure for AD, an accurate diagnosis, relying on easily accessible peripheral biofluids, is still necessary to discriminate this disease from other dementias, test potential therapies and even monitor rate of disease progression.", "tags": [{"end": 186, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 222, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "ManufacturedObject"}, {"end": 35, "start": 31, "tag": "Finding"}, {"end": 35, "start": 31, "tag": "ResearchActivity"}, {"end": 234, "start": 230, "tag": "TemporalConcept"}, {"end": 257, "start": 246, "tag": "PathologicFunction"}, {"end": 257, "start": 246, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 203, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 257, "start": 238, "tag": "PathologicFunction"}]}
{"id": "1470_3", "text": "The ultimate goal is to produce a cost-effective and widely available alternative, which can also be employed as a first clinical screen.", "tags": [{"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 136, "start": 121, "tag": "HealthCareActivity"}]}
{"id": "1470_4", "text": "In this study, EVs with exosome-like characteristics were isolated from serum of Controls and AD cases through precipitation- and column-based methods, followed by mass spectrometry analysis.", "tags": [{"end": 181, "start": 164, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "CellComponent"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 150, "start": 130, "tag": "ResearchActivity"}, {"end": 150, "start": 137, "tag": "ResearchActivity"}, {"end": 125, "start": 111, "tag": "ResearchActivity"}]}
{"id": "1470_5", "text": "The resulting proteomes were characterized by Gene Ontology (GO) and multivariate analyses.", "tags": [{"end": 23, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 46, "tag": "ResearchActivity"}, {"end": 63, "start": 61, "tag": "ResearchActivity"}, {"end": 90, "start": 69, "tag": "ResearchActivity"}]}
{"id": "1470_6", "text": "Although GO terms were similar for exosomes' proteomes of Controls and ADs, using both methodologies, a clear segregation of disease cases was obtained when using the precipitation-based method.", "tags": [{"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 167, "tag": "ResearchActivity"}, {"end": 43, "start": 35, "tag": "CellComponent"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}]}
{"id": "1470_7", "text": "Nine significantly different abundant proteins were identified between Controls and AD cases, representing putative biomarker candidate targets.", "tags": [{"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "ClinicalAttribute"}]}
{"id": "1470_8", "text": "Among them are AACT and C4BP alpha, two A beta-binding proteins, whose exosome levels were further validated in individuals from independent cohorts using antibody-based approaches.", "tags": [{"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 78, "start": 71, "tag": "CellComponent"}, {"end": 54, "start": 47, "tag": "CellFunction"}, {"end": 63, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 141, "tag": "PopulationGroup"}, {"end": 123, "start": 112, "tag": "PopulationGroup"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 24, "tag": "GeneOrGenome"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 155, "tag": "ResearchActivity"}]}
{"id": "1470_9", "text": "The findings discussed represent an important contribution to the identification of novel exosomal biomarker candidates useful as potential blood-based tools for AD diagnosis.", "tags": [{"end": 174, "start": 165, "tag": "HealthCareActivity"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 90, "tag": "ClinicalAttribute"}]}
{"id": "1471_0", "text": "Random Forest (RF) is a bagging ensemble model and has many important advantages, such as robustness to noise, an effective structure for complex multimodal data and parallel computing, and also provides important features that help investigate biomarkers.", "tags": [{"end": 255, "start": 245, "tag": "ClinicalAttribute"}, {"end": 161, "start": 146, "tag": "ResearchActivity"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "MachineActivity"}, {"end": 17, "start": 15, "tag": "MachineActivity"}]}
{"id": "1471_1", "text": "Despite these benefits, RF is not used actively to predict Alzheimer's disease (AD) with brain MRIs.", "tags": [{"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 95, "tag": "ManufacturedObject"}, {"end": 99, "start": 95, "tag": "HealthCareActivity"}, {"end": 26, "start": 24, "tag": "MachineActivity"}]}
{"id": "1471_2", "text": "Recent studies have reported RF's effectiveness in predicting AD, but the test sample sizes were too small to draw any solid conclusions.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 47, "start": 34, "tag": "Finding"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 29, "tag": "MachineActivity"}, {"end": 85, "start": 79, "tag": "Substance"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "OrganismAttribute"}]}
{"id": "1471_3", "text": "Thus, it is timely to compare RF with other learning model methods, including deep learning, particularly with large amounts of data.", "tags": [{"end": 91, "start": 78, "tag": "MachineActivity"}, {"end": 132, "start": 128, "tag": "ResearchActivity"}, {"end": 66, "start": 53, "tag": "ResearchActivity"}, {"end": 52, "start": 44, "tag": "BiologicFunction"}, {"end": 91, "start": 83, "tag": "BiologicFunction"}, {"end": 32, "start": 30, "tag": "MachineActivity"}]}
{"id": "1471_4", "text": "In this study, we tested RF and various machine learning models with regional volumes from 2250 brain MRIs: 687 normal controls (NC), 1094 mild cognitive impairment (MCI), and 469 AD that ADNI (Alzheimer's Disease Neuroimaging Initiative database) provided.", "tags": [{"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 194, "tag": "ResearchActivity"}, {"end": 118, "start": 112, "tag": "Finding"}, {"end": 213, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 40, "tag": "MachineActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "PopulationGroup"}, {"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "BiologicFunction"}, {"end": 63, "start": 57, "tag": "ResearchActivity"}, {"end": 164, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 25, "tag": "MachineActivity"}, {"end": 106, "start": 102, "tag": "ManufacturedObject"}, {"end": 106, "start": 102, "tag": "HealthCareActivity"}]}
{"id": "1471_5", "text": "Three types of features sets (63, 29, and 22 features) were selected, and classification accuracies were computed with RF, Support vector machine (SVM), Multi-layer perceptron (MLP), and Convolutional neural network (CNN).", "tags": [{"end": 121, "start": 119, "tag": "MachineActivity"}, {"end": 145, "start": 123, "tag": "MachineActivity"}, {"end": 150, "start": 147, "tag": "MachineActivity"}, {"end": 175, "start": 153, "tag": "MachineActivity"}, {"end": 180, "start": 177, "tag": "MachineActivity"}, {"end": 215, "start": 187, "tag": "MachineActivity"}, {"end": 220, "start": 217, "tag": "MachineActivity"}]}
{"id": "1471_6", "text": "As a result, RF, MLP, and CNN showed high performances of 90.2%, 89.6%, and 90.5% with 63 features.", "tags": [{"end": 11, "start": 5, "tag": "Finding"}, {"end": 54, "start": 42, "tag": "IndividualBehavior"}, {"end": 15, "start": 13, "tag": "MachineActivity"}, {"end": 20, "start": 17, "tag": "MachineActivity"}, {"end": 29, "start": 26, "tag": "MachineActivity"}]}
{"id": "1471_7", "text": "Interestingly, when 22 features were used, RF showed the smallest decrease in accuracy, -3.8%, and the standard deviation did not change significantly, while MLP and CNN yielded decreases in accuracy of -6.8% and -4.5% with changes in the standard deviation from 3.3% to 4.0% for MLP and 2.1% to 7.0% for CNN, indicating that RF predicts AD more reliably with fewer features.", "tags": [{"end": 340, "start": 338, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 43, "tag": "MachineActivity"}, {"end": 328, "start": 326, "tag": "MachineActivity"}, {"end": 283, "start": 280, "tag": "MachineActivity"}, {"end": 308, "start": 305, "tag": "MachineActivity"}, {"end": 86, "start": 78, "tag": "Finding"}, {"end": 121, "start": 103, "tag": "ResearchActivity"}, {"end": 161, "start": 158, "tag": "MachineActivity"}, {"end": 169, "start": 166, "tag": "MachineActivity"}, {"end": 199, "start": 191, "tag": "Finding"}, {"end": 257, "start": 239, "tag": "ResearchActivity"}]}
{"id": "1471_8", "text": "In addition, we investigated the importance of the features that RF provides, and identified the hippocampus, amygdala, and inferior lateral ventricle as the major contributors in classifying NC, MCI, and AD.", "tags": [{"end": 118, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 65, "tag": "MachineActivity"}, {"end": 150, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 192, "tag": "PopulationGroup"}]}
{"id": "1471_9", "text": "On average, AD showed smaller hippocampus and amygdala volumes and a larger volume of inferior lateral ventricle than those of MCI and NC.", "tags": [{"end": 54, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 135, "tag": "PopulationGroup"}, {"end": 61, "start": 46, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "ClinicalAttribute"}, {"end": 41, "start": 30, "tag": "ClinicalAttribute"}, {"end": 112, "start": 76, "tag": "ClinicalAttribute"}]}
{"id": "1472_0", "text": "IntroductionAlthough many lesion-based MRI biomarkers in multiple sclerosis (MS) patients were investigated, none of the previous studies dealt with the signal intensity variations (SIVs) of MS lesions.", "tags": [{"end": 137, "start": 130, "tag": "ResearchActivity"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 201, "start": 194, "tag": "InjuryOrPoisoning"}, {"end": 32, "start": 26, "tag": "InjuryOrPoisoning"}, {"end": 180, "start": 153, "tag": "ResearchActivity"}, {"end": 186, "start": 182, "tag": "ResearchActivity"}]}
{"id": "1472_1", "text": "In this study, the SIVs of MS lesions on direct myelin imaging and standard clinical sequences as possible MRI biomarkers for disability in MS patients were assessed.", "tags": [{"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 121, "start": 111, "tag": "ClinicalAttribute"}, {"end": 151, "start": 143, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "HealthCareActivity"}, {"end": 37, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 55, "tag": "HealthCareActivity"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 48, "tag": "CellComponent"}, {"end": 136, "start": 126, "tag": "Finding"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}]}
{"id": "1472_2", "text": "MethodsTwenty seven MS patients were included in this prospective study.", "tags": [{"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}]}
{"id": "1472_3", "text": "IR-UTE, FLAIR, and MPRAGE sequences were employed on a 3T scanner.", "tags": [{"end": 13, "start": 8, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 35, "start": 19, "tag": "HealthCareActivity"}, {"end": 65, "start": 55, "tag": "HealthCareActivity"}, {"end": 65, "start": 55, "tag": "ManufacturedObject"}]}
{"id": "1472_4", "text": "Regions of interest (ROIs) were manually drawn within the MS lesions, and the cerebrospinal fluid (CSF) and signal intensity ratios (SIR) were calculated from the derived values.", "tags": [{"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 92, "tag": "Substance"}, {"end": 68, "start": 61, "tag": "InjuryOrPoisoning"}, {"end": 97, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 131, "start": 108, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "ResearchActivity"}]}
{"id": "1472_5", "text": "Variations coefficients were determined from the standard deviations (Coeff 1) and the absolute differences (Coeff 2) of the SIRs.", "tags": [{"end": 129, "start": 125, "tag": "ResearchActivity"}, {"end": 23, "start": 0, "tag": "ResearchActivity"}, {"end": 68, "start": 49, "tag": "ResearchActivity"}, {"end": 107, "start": 87, "tag": "ResearchActivity"}]}
{"id": "1472_6", "text": "Disability grade was assessed by the expanded disability status scale (EDSS).", "tags": [{"end": 56, "start": 46, "tag": "Finding"}, {"end": 69, "start": 37, "tag": "HealthCareActivity"}, {"end": 75, "start": 71, "tag": "HealthCareActivity"}, {"end": 16, "start": 0, "tag": "Finding"}]}
{"id": "1472_7", "text": "Cortical/gray matter, subcortical, infratentorial, and spinal lesions were excluded.", "tags": [{"end": 49, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 62, "tag": "InjuryOrPoisoning"}, {"end": 8, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1472_8", "text": "ResultsThe mean diameter of the lesions was 7.8 +/- 1.97 mm, while the mean EDSS score was 4.5 +/- 1.73.", "tags": [{"end": 39, "start": 32, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 76, "tag": "HealthCareActivity"}, {"end": 86, "start": 76, "tag": "HealthCareActivity"}]}
{"id": "1472_9", "text": "We found moderate correlations between the EDSS and Coeff 1 and 2 on IR-UTE and MPRAGE images.", "tags": [{"end": 93, "start": 80, "tag": "HealthCareActivity"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 30, "start": 18, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "HealthCareActivity"}]}
{"id": "1472_10", "text": "Accordingly, Pearson's correlations on IR-UTE were R = 0.51 (p = 0.007) and R = 0.49 (p = 0.01) for Coeff 1 and 2, respectively.", "tags": [{"end": 35, "start": 13, "tag": "ResearchActivity"}, {"end": 45, "start": 39, "tag": "HealthCareActivity"}]}
{"id": "1472_11", "text": "For MPRAGE, Pearson's correlations were R = 0.5 (p = 0.008) and R = 0.48 (p = 0.012) for Coeff 1 and 2, respectively.", "tags": [{"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 34, "start": 12, "tag": "ResearchActivity"}]}
{"id": "1472_12", "text": "For FLAIR, only poor correlations could be found.", "tags": [{"end": 9, "start": 4, "tag": "Chemical"}, {"end": 9, "start": 4, "tag": "HealthCareActivity"}, {"end": 33, "start": 21, "tag": "ResearchActivity"}]}
{"id": "1472_13", "text": "ConclusionThe SIVs of MS lesions on IR-UTE and MPRAGE images, assessed by Coeff 1 and 2, could be used as novel potential MRI biomarkers for patients' disability.", "tags": [{"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 136, "start": 126, "tag": "ClinicalAttribute"}, {"end": 149, "start": 141, "tag": "PatientOrDisabledGroup"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 32, "start": 25, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 151, "tag": "Finding"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "HealthCareActivity"}]}
{"id": "1473_0", "text": "BackgroundSpatial navigation impairment is a promising cognitive marker of Alzheimer's disease (AD) that can reflect the underlying pathology.", "tags": [{"end": 94, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "PathologicFunction"}, {"end": 141, "start": 132, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 71, "start": 65, "tag": "ClinicalAttribute"}, {"end": 39, "start": 10, "tag": "SignOrSymptom"}, {"end": 28, "start": 10, "tag": "BiologicFunction"}]}
{"id": "1473_1", "text": "ObjectivesWe assessed spatial navigation performance in AD biomarker positive older adults with amnestic mild cognitive impairment (AD aMCI) vs.", "tags": [{"end": 90, "start": 78, "tag": "PopulationGroup"}, {"end": 52, "start": 22, "tag": "ClinicalAttribute"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 59, "tag": "ClinicalAttribute"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 90, "start": 84, "tag": "PopulationGroup"}, {"end": 130, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 22, "tag": "BiologicFunction"}]}
{"id": "1473_2", "text": "those AD biomarker negative (non-AD aMCI), and examined associations between navigation performance, MRI measures of brain atrophy, and cerebrospinal fluid (CSF) biomarkers.", "tags": [{"end": 99, "start": 77, "tag": "ClinicalAttribute"}, {"end": 130, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 162, "tag": "ClinicalAttribute"}, {"end": 8, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 9, "tag": "ClinicalAttribute"}, {"end": 160, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 150, "tag": "Substance"}, {"end": 104, "start": 101, "tag": "HealthCareActivity"}, {"end": 155, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1473_3", "text": "MethodsA total of 122 participants with AD aMCI (n = 33), non-AD aMCI (n = 31), mild AD dementia (n = 28), and 30 cognitively normal older adults (CN) underwent cognitive assessment, brain MRI (n = 100 had high-quality images for volumetric analysis) and three virtual navigation tasks focused on route learning (body-centered navigation), wayfinding (world-centered navigation) and perspective taking/wayfinding.", "tags": [{"end": 84, "start": 80, "tag": "Finding"}, {"end": 181, "start": 161, "tag": "HealthCareActivity"}, {"end": 192, "start": 183, "tag": "HealthCareActivity"}, {"end": 249, "start": 230, "tag": "ResearchActivity"}, {"end": 285, "start": 261, "tag": "HealthCareActivity"}, {"end": 401, "start": 383, "tag": "BiologicFunction"}, {"end": 145, "start": 133, "tag": "PopulationGroup"}, {"end": 149, "start": 147, "tag": "Finding"}, {"end": 132, "start": 126, "tag": "Finding"}, {"end": 317, "start": 313, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 206, "tag": "ResearchActivity"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 138, "start": 133, "tag": "TemporalConcept"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 145, "start": 139, "tag": "PopulationGroup"}, {"end": 311, "start": 297, "tag": "BiologicFunction"}, {"end": 337, "start": 313, "tag": "BiologicFunction"}, {"end": 350, "start": 340, "tag": "BiologicFunction"}, {"end": 377, "start": 352, "tag": "BiologicFunction"}, {"end": 412, "start": 402, "tag": "BiologicFunction"}]}
{"id": "1473_4", "text": "Cognitively impaired participants underwent CSF biomarker assessment [amyloid-beta(1-42), total tau, and phosphorylated tau(181) (p-tau(181))] and amyloid PET imaging (n = 47 and n = 45, respectively), with a subset having both (n = 19).", "tags": [{"end": 158, "start": 155, "tag": "HealthCareActivity"}, {"end": 166, "start": 155, "tag": "HealthCareActivity"}, {"end": 99, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 48, "tag": "ClinicalAttribute"}, {"end": 88, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 159, "tag": "HealthCareActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 154, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 130, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1473_5", "text": "ResultsIn route learning, AD aMCI performed worse than non-AD aMCI (p < 0.001), who performed similarly to CN.", "tags": [{"end": 33, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 10, "tag": "BiologicFunction"}]}
{"id": "1473_6", "text": "In wayfinding, aMCI participants performed worse than CN (both p <= 0.009) and AD aMCI performed worse than non-AD aMCI in the second task session (p = 0.032).", "tags": [{"end": 86, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 20, "tag": "PopulationGroup"}, {"end": 13, "start": 3, "tag": "BiologicFunction"}, {"end": 19, "start": 15, "tag": "DiseaseOrSyndrome"}]}
{"id": "1473_7", "text": "In perspective taking/wayfinding, aMCI participants performed worse than CN (both p <= 0.001).", "tags": [{"end": 21, "start": 3, "tag": "BiologicFunction"}, {"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 32, "start": 22, "tag": "BiologicFunction"}, {"end": 38, "start": 34, "tag": "DiseaseOrSyndrome"}]}
{"id": "1473_8", "text": "AD aMCI and non-AD aMCI did not differ in conventional cognitive tests.", "tags": [{"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 70, "start": 42, "tag": "ResearchActivity"}, {"end": 70, "start": 65, "tag": "ResearchActivity"}, {"end": 70, "start": 65, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "DiseaseOrSyndrome"}]}
{"id": "1473_9", "text": "Route learning was associated with parietal thickness and amyloid-beta(1-42), wayfinding was associated with posterior medial temporal lobe (MTL) volume and p-tau(181) and perspective taking/wayfinding was correlated with MRI measures of several brain regions and all CSF biomarkers.", "tags": [{"end": 144, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 172, "tag": "BiologicFunction"}, {"end": 53, "start": 35, "tag": "ClinicalAttribute"}, {"end": 259, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 282, "start": 272, "tag": "ClinicalAttribute"}, {"end": 76, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 271, "start": 268, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 222, "tag": "HealthCareActivity"}, {"end": 76, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 88, "start": 78, "tag": "BiologicFunction"}, {"end": 139, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 191, "tag": "BiologicFunction"}, {"end": 152, "start": 146, "tag": "ClinicalAttribute"}, {"end": 139, "start": 109, "tag": "ClinicalAttribute"}]}
{"id": "1473_10", "text": "ConclusionAD biomarker positive and negative older adults with aMCI had different profiles of spatial navigation deficits that were associated with posterior MTL and parietal atrophy and reflected AD pathology.", "tags": [{"end": 161, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 166, "tag": "AnatomicalAbnormality"}, {"end": 57, "start": 45, "tag": "PopulationGroup"}, {"end": 90, "start": 82, "tag": "ResearchActivity"}, {"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "ClinicalAttribute"}, {"end": 209, "start": 200, "tag": "PathologicFunction"}, {"end": 209, "start": 200, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 45, "tag": "TemporalConcept"}, {"end": 57, "start": 51, "tag": "PopulationGroup"}, {"end": 67, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 94, "tag": "BiologicFunction"}, {"end": 121, "start": 94, "tag": "SignOrSymptom"}]}
{"id": "1474_0", "text": "Background: Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer's disease (AD).", "tags": [{"end": 19, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}, {"end": 94, "start": 66, "tag": "HealthCareActivity"}, {"end": 99, "start": 96, "tag": "HealthCareActivity"}, {"end": 174, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 141, "tag": "ClinicalAttribute"}]}
{"id": "1474_1", "text": "Retinal thinning is hypothesized to be a result of retrograde atrophy and/or parallel neurodegenerative processes.", "tags": [{"end": 7, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 41, "tag": "Finding"}, {"end": 69, "start": 52, "tag": "PathologicFunction"}, {"end": 16, "start": 0, "tag": "Finding"}]}
{"id": "1474_2", "text": "Changes in the visual pathway are of particular interest in posterior cortical atrophy (PCA), the most common atypical AD phenotype predominantly affecting the parietal-occipital cortices.", "tags": [{"end": 29, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 131, "start": 122, "tag": "OrganismAttribute"}, {"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "ResearchActivity"}]}
{"id": "1474_3", "text": "We therefore evaluated retinal thickness as non-invasive biomarker of neurodegeneration in well-characterized participants with posterior cortical atrophy (PCA) and typical Alzheimer's disease (tAD).", "tags": [{"end": 154, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "ResearchActivity"}, {"end": 87, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 57, "tag": "ClinicalAttribute"}, {"end": 122, "start": 110, "tag": "PopulationGroup"}, {"end": 30, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 44, "tag": "ClinicalAttribute"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}]}
{"id": "1474_4", "text": "Methods: Retinal thickness measures were acquired from 48 patient participants (N = 25 PCA; N = 23 tAD) fulfilling consensus diagnostic criteria and 70 age-matched controls.", "tags": [{"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 87, "tag": "ResearchActivity"}, {"end": 155, "start": 152, "tag": "OrganismAttribute"}, {"end": 172, "start": 164, "tag": "PopulationGroup"}, {"end": 144, "start": 125, "tag": "HealthCareActivity"}, {"end": 78, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 9, "tag": "ClinicalAttribute"}, {"end": 90, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 99, "tag": "DiseaseOrSyndrome"}]}
{"id": "1474_5", "text": "Participants were recruited between 2014 and 2016.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}]}
{"id": "1474_6", "text": "All participants underwent optical coherence tomography (OCT) imaging, including measurement of peripapillary retinal nerve fiber layer (pRNFL) thickness and total macular thickness (mRT).", "tags": [{"end": 142, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 164, "tag": "ClinicalAttribute"}, {"end": 181, "start": 164, "tag": "SignOrSymptom"}, {"end": 135, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 27, "tag": "HealthCareActivity"}, {"end": 60, "start": 57, "tag": "HealthCareActivity"}, {"end": 92, "start": 81, "tag": "ResearchActivity"}, {"end": 92, "start": 81, "tag": "HealthCareActivity"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 117, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1474_7", "text": "Participants did not show evidence of any significant ophthalmological conditions.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 81, "start": 54, "tag": "DiseaseOrSyndrome"}]}
{"id": "1474_8", "text": "Subgroup analyses were performed in participants with available MRI and CSF measures, providing evidence of neurodegeneration and underlying AD pathology respectively.", "tags": [{"end": 125, "start": 108, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}, {"end": 153, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 36, "tag": "PopulationGroup"}, {"end": 67, "start": 64, "tag": "HealthCareActivity"}, {"end": 104, "start": 96, "tag": "Finding"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1474_9", "text": "Results: There was no evidence of overall between-group differences in pRNFL thickness (mean PCA 98.7 +/- 12.2; tAD 99.9 +/- 8.7; controls 99.6 +/- 10.0 mu m, one-way analysis of variance (ANOVA) p = 0.92) or total mRT (mean PCA 266.9 +/- 16.3; tAD 267.8 +/- 13.6; controls 269.3 +/- 13.6 mu m, one-way ANOVA p = 0.75).", "tags": [{"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 93, "tag": "ResearchActivity"}, {"end": 228, "start": 225, "tag": "ResearchActivity"}, {"end": 67, "start": 50, "tag": "Finding"}, {"end": 67, "start": 56, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 273, "start": 265, "tag": "PopulationGroup"}, {"end": 55, "start": 50, "tag": "PopulationGroup"}, {"end": 187, "start": 159, "tag": "ResearchActivity"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 86, "start": 71, "tag": "ClinicalAttribute"}, {"end": 96, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 189, "tag": "ResearchActivity"}, {"end": 228, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 308, "start": 295, "tag": "ResearchActivity"}]}
{"id": "1474_10", "text": "Similarly, subgroup analysis with MRI biomarkers (PCA = 18, tAD = 17, controls = 31) showing neurodegeneration, and CSF biomarkers (PCA = 18, tAD = 14, controls = 13) supporting underlying AD pathology did not provide evidence of overall between-group differences in pRNFL or mRT measures (all p > 0.3).", "tags": [{"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 50, "tag": "ResearchActivity"}, {"end": 135, "start": 132, "tag": "ResearchActivity"}, {"end": 263, "start": 246, "tag": "Finding"}, {"end": 263, "start": 252, "tag": "Finding"}, {"end": 110, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 130, "start": 120, "tag": "ClinicalAttribute"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 192, "tag": "PathologicFunction"}, {"end": 201, "start": 192, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "PopulationGroup"}, {"end": 160, "start": 152, "tag": "PopulationGroup"}, {"end": 37, "start": 34, "tag": "HealthCareActivity"}, {"end": 251, "start": 246, "tag": "PopulationGroup"}, {"end": 28, "start": 11, "tag": "ResearchActivity"}, {"end": 226, "start": 218, "tag": "Finding"}]}
{"id": "1474_11", "text": "Conclusions: Retinal thickness did not discriminate tAD and PCA from controls or from one another despite unequivocal differences on standard clinical, neuro-imaging and CSF measures.", "tags": [{"end": 20, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 173, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 174, "tag": "HealthCareActivity"}, {"end": 165, "start": 152, "tag": "HealthCareActivity"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 30, "start": 13, "tag": "ClinicalAttribute"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}]}
{"id": "1474_12", "text": "Findings from this well-characterized sample, including cases with PCA, do not support the hypothesis that retinal neurodegeneration, measured using conventional OCT, is a useful biomarker for AD or PCA.", "tags": [{"end": 44, "start": 38, "tag": "Substance"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "ResearchActivity"}, {"end": 202, "start": 199, "tag": "ResearchActivity"}, {"end": 165, "start": 149, "tag": "HealthCareActivity"}, {"end": 132, "start": 115, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 179, "tag": "ClinicalAttribute"}, {"end": 114, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "DiseaseOrSyndrome"}]}
{"id": "1475_0", "text": "The search for new, robust, and reproducible biomarkers for Alzheimer's disease (AD) diagnosis is a challenge.", "tags": [{"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 55, "start": 45, "tag": "ClinicalAttribute"}]}
{"id": "1475_1", "text": "We recently reported that salivary lactoferrin (Lf) could be presented as new biomarker candidate for AD, being both non-invasive and cost-effective, as well as having appropriate diagnostic performance for the clinical detection of AD subjects.", "tags": [{"end": 50, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}, {"end": 202, "start": 191, "tag": "Finding"}, {"end": 244, "start": 236, "tag": "PopulationGroup"}, {"end": 229, "start": 211, "tag": "HealthCareActivity"}, {"end": 11, "start": 3, "tag": "TemporalConcept"}, {"end": 190, "start": 180, "tag": "HealthCareActivity"}, {"end": 46, "start": 26, "tag": "ClinicalAttribute"}]}
{"id": "1475_2", "text": "Saliva is an attractive sample type for biomarker-based testing approaches for several other diseases; however, its composition may change under certain circumstances.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 40, "tag": "ClinicalAttribute"}, {"end": 74, "start": 56, "tag": "HealthCareActivity"}, {"end": 30, "start": 24, "tag": "Substance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1475_3", "text": "It is therefore critical to maintain a consistent salivary handling protocol, considering possible extrinsic factors that may influence salivary Lf concentration.", "tags": [{"end": 147, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 50, "tag": "HealthCareActivity"}, {"end": 161, "start": 136, "tag": "ClinicalAttribute"}]}
{"id": "1475_4", "text": "In this work, we analyzed salivary Lf concentration under different handling conditions and donor-dependent factors including age, inter-diurnal variations, physical activity, and pharmacological treatments.", "tags": [{"end": 97, "start": 92, "tag": "PopulationGroup"}, {"end": 206, "start": 180, "tag": "HealthCareActivity"}, {"end": 206, "start": 180, "tag": "ResearchActivity"}, {"end": 37, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "Finding"}, {"end": 174, "start": 157, "tag": "BiologicFunction"}, {"end": 129, "start": 126, "tag": "OrganismAttribute"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 51, "start": 26, "tag": "ClinicalAttribute"}, {"end": 87, "start": 68, "tag": "HealthCareActivity"}]}
{"id": "1475_5", "text": "Our aim was to evaluate the influence of such conditions on salivary Lf concentration.", "tags": [{"end": 71, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 60, "tag": "ClinicalAttribute"}]}
{"id": "1475_6", "text": "In conclusion, we found that most of these extrinsic factors should be considered in the future when using Lf as a predictive biomarker for AD.", "tags": [{"end": 135, "start": 115, "tag": "ClinicalAttribute"}, {"end": 109, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 95, "start": 89, "tag": "TemporalConcept"}]}
{"id": "1476_0", "text": "Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease.", "tags": [{"end": 58, "start": 44, "tag": "CellFunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 143, "tag": "HealthCareActivity"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}, {"end": 203, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 204, "tag": "ClinicalAttribute"}, {"end": 94, "start": 73, "tag": "Finding"}]}
{"id": "1476_1", "text": "However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau.", "tags": [{"end": 69, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "ClinicalAttribute"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 156, "tag": "ClinicalAttribute"}]}
{"id": "1476_2", "text": "Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources.", "tags": [{"end": 101, "start": 94, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}]}
{"id": "1476_3", "text": "We sought to address this challenge by generating an anti-tau antibody that selectively binds brain-derived tau and avoids the peripherally expressed 'big tau' isoform.", "tags": [{"end": 167, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "CellFunction"}, {"end": 70, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 26, "tag": "HealthCareActivity"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 140, "tag": "CellFunction"}, {"end": 99, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1476_4", "text": "We applied this antibody to develop an ultrasensitive blood-based assay for brain-derived tau, and validated it in five independent cohorts (n = 609) including a blood-to-autopsy cohort, CSF biomarker-classified cohorts and memory clinic cohorts.", "tags": [{"end": 24, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 24, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 191, "tag": "ClinicalAttribute"}, {"end": 139, "start": 132, "tag": "PopulationGroup"}, {"end": 219, "start": 212, "tag": "PopulationGroup"}, {"end": 245, "start": 238, "tag": "PopulationGroup"}, {"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 179, "tag": "PopulationGroup"}, {"end": 230, "start": 224, "tag": "BiologicFunction"}, {"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 178, "start": 171, "tag": "HealthCareActivity"}, {"end": 237, "start": 224, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1476_5", "text": "In paired samples, serum and CSF brain-derived tau were significantly correlated (rho = 0.85, P < 0.0001), while serum and CSF total-tau were not (rho = 0.23, P = 0.3364).", "tags": [{"end": 24, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 10, "tag": "Substance"}, {"end": 17, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 123, "tag": "ClinicalAttribute"}, {"end": 136, "start": 127, "tag": "ClinicalAttribute"}, {"end": 118, "start": 113, "tag": "ClinicalAttribute"}, {"end": 50, "start": 29, "tag": "ClinicalAttribute"}]}
{"id": "1476_6", "text": "Blood-based brain-derived tau showed equivalent diagnostic performance as CSF total-tau and CSF brain-derived tau to separate biomarker-positive Alzheimer's disease participants from biomarker-negative controls.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ClinicalAttribute"}, {"end": 192, "start": 183, "tag": "ClinicalAttribute"}, {"end": 210, "start": 202, "tag": "PopulationGroup"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 165, "tag": "PopulationGroup"}, {"end": 70, "start": 48, "tag": "Finding"}, {"end": 87, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 74, "tag": "ClinicalAttribute"}, {"end": 113, "start": 92, "tag": "ClinicalAttribute"}]}
{"id": "1476_7", "text": "Furthermore, plasma brain-derived tau accurately distinguished autopsy-confirmed Alzheimer's disease from other neurodegenerative diseases (area under the curve = 86.4%) while neurofilament light did not (area under the curve = 54.3%).", "tags": [{"end": 195, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 140, "tag": "ResearchActivity"}, {"end": 225, "start": 205, "tag": "ResearchActivity"}, {"end": 25, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 13, "tag": "ClinicalAttribute"}, {"end": 70, "start": 63, "tag": "HealthCareActivity"}]}
{"id": "1476_8", "text": "These performances were independent of the presence of concomitant pathologies.", "tags": [{"end": 35, "start": 24, "tag": "Finding"}, {"end": 66, "start": 55, "tag": "TemporalConcept"}, {"end": 18, "start": 6, "tag": "IndividualBehavior"}, {"end": 78, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "Finding"}]}
{"id": "1476_9", "text": "Plasma brain-derived tau (rho = 0.52-0.67, P = 0.003), but not neurofilament light (rho = -0.14-0.17, P = 0.501), was associated with global and regional amyloid plaque and neurofibrillary tangle counts.", "tags": [{"end": 82, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 154, "tag": "AnatomicalAbnormality"}, {"end": 188, "start": 173, "tag": "CellComponent"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 0, "tag": "ClinicalAttribute"}, {"end": 195, "start": 173, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1476_10", "text": "These results were further verified in two memory clinic cohorts where serum brain-derived tau differentiated Alzheimer's disease from a range of other neurodegenerative disorders, including frontotemporal lobar degeneration and atypical parkinsonian disorders (area under the curve up to 99.6%).", "tags": [{"end": 205, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 212, "tag": "PathologicFunction"}, {"end": 179, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 282, "start": 262, "tag": "ResearchActivity"}, {"end": 64, "start": 57, "tag": "PopulationGroup"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 229, "tag": "Finding"}, {"end": 49, "start": 43, "tag": "BiologicFunction"}, {"end": 94, "start": 71, "tag": "ClinicalAttribute"}]}
{"id": "1476_11", "text": "Notably, plasma/serum brain-derived tau correlated with neurofilament light only in Alzheimer's disease but not in the other neurodegenerative diseases.", "tags": [{"end": 75, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1476_12", "text": "Across cohorts, plasma/serum brain-derived tau was associated with CSF and plasma AT(N) biomarkers and cognitive function.", "tags": [{"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 7, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 82, "tag": "ClinicalAttribute"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 103, "tag": "BiologicFunction"}]}
{"id": "1476_13", "text": "Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer's disease-type neurodegeneration.", "tags": [{"end": 114, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "ClinicalAttribute"}, {"end": 133, "start": 122, "tag": "Finding"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 162, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 66, "tag": "ClinicalAttribute"}]}
{"id": "1476_14", "text": "Thus, brain-derived tau demonstrates potential to complete the AT(N) scheme in blood, and will be useful to evaluate Alzheimer's disease-dependent neurodegenerative processes for clinical and research purposes.", "tags": [{"end": 174, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 192, "tag": "ResearchActivity"}, {"end": 84, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1476_15", "text": "A blood-based biomarker that tracks neurodegeneration in Alzheimer's disease and differentiates it from other dementias is lacking.", "tags": [{"end": 35, "start": 29, "tag": "ManufacturedObject"}, {"end": 119, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 14, "tag": "ClinicalAttribute"}, {"end": 7, "start": 2, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 36, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1476_16", "text": "Gonzalez et al.", "tags": []}
{"id": "1476_17", "text": "report the discovery and clinical validation of plasma brain-derived tau, an improved total-tau assay that specifically targets CNS tau in blood.", "tags": [{"end": 131, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 25, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 95, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 48, "tag": "ClinicalAttribute"}]}
{"id": "1477_0", "text": "Amyloid-beta (A beta) deposition in the brain parenchyma is one of the pathological hallmarks of Alzheimer disease (AD).", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "Finding"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1477_1", "text": "We have previously identified amyloid precursor protein (APP)669-711 (a.k.a.", "tags": [{"end": 68, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 30, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1477_2", "text": "A beta(-3)-40) in human plasma using immunoprecipitation combined with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (IP-MALDI-MS).", "tags": [{"end": 56, "start": 37, "tag": "ResearchActivity"}, {"end": 147, "start": 71, "tag": "ResearchActivity"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 18, "tag": "Eukaryote"}, {"end": 119, "start": 115, "tag": "TemporalConcept"}, {"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 149, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_3", "text": "Furthermore, we found that the level of a composite biomarker, i.e., a combination of APP669-711/A beta 1-42 ratio and A beta 1-40/A beta 1-42 ratio in human plasma, correlates with the amyloid PET status of AD patients.", "tags": [{"end": 204, "start": 198, "tag": "Finding"}, {"end": 197, "start": 194, "tag": "HealthCareActivity"}, {"end": 210, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 211, "tag": "PatientOrDisabledGroup"}, {"end": 61, "start": 52, "tag": "ClinicalAttribute"}, {"end": 157, "start": 152, "tag": "Eukaryote"}, {"end": 193, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 131, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_4", "text": "However, the production mechanism of APP669-711 has remained unclear.", "tags": [{"end": 47, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 37, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_5", "text": "Using in vitro and in vivo assays, we identified A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, type 4 (ADAMTS4) as a responsible enzyme for APP669-711 production.", "tags": [{"end": 62, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 67, "tag": "GeneOrGenome"}, {"end": 136, "start": 129, "tag": "GeneOrGenome"}, {"end": 136, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}, {"end": 33, "start": 19, "tag": "ResearchActivity"}, {"end": 127, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 92, "tag": "GeneOrGenome"}, {"end": 161, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_6", "text": "ADAMTS4 cleaves APP directly to generate the C-terminal stub c102, which is subsequently proteolyzed by gamma-secretase to release APP669-711.", "tags": [{"end": 7, "start": 0, "tag": "GeneOrGenome"}, {"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "GeneOrGenome"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 131, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_7", "text": "Genetic knockout of ADAMTS4 reduced the production of endogenous APP669-711 by 30% to 40% in cultured cells as well as mouse plasma, irrespectively of A beta levels.", "tags": [{"end": 27, "start": 20, "tag": "GeneOrGenome"}, {"end": 27, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 93, "tag": "Cell"}, {"end": 107, "start": 93, "tag": "ResearchActivity"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 119, "tag": "Eukaryote"}, {"end": 157, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1477_8", "text": "Finally, we found that the endogenous murine APP669-711/A beta 1-42 ratio was increased in aged AD model mice, which shows A beta deposition as observed in human patients.", "tags": [{"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 156, "tag": "Eukaryote"}, {"end": 67, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 38, "tag": "Eukaryote"}, {"end": 55, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 91, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1477_9", "text": "These data suggest that ADAMTS4 is involved in the production of APP669-711, and a plasma biomarker determined by IP-MALDI-MS can be used to estimate the level of A beta deposition in the brain of mouse models.", "tags": [{"end": 31, "start": 24, "tag": "GeneOrGenome"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 90, "tag": "ClinicalAttribute"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 202, "start": 197, "tag": "Eukaryote"}, {"end": 169, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 203, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 114, "tag": "ResearchActivity"}]}
{"id": "1478_0", "text": "Aim: Identify a global resting-state functional connectivity (gFC) signature in mutation carriers (MC) from the Dominantly Inherited Alzheimer Network (DIAN).", "tags": [{"end": 97, "start": 80, "tag": "PopulationGroup"}, {"end": 101, "start": 99, "tag": "PopulationGroup"}, {"end": 60, "start": 37, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 142, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 112, "tag": "HealthCareRelatedOrganization"}, {"end": 156, "start": 152, "tag": "HealthCareRelatedOrganization"}, {"end": 76, "start": 67, "tag": "ClinicalAttribute"}, {"end": 60, "start": 16, "tag": "ClinicalAttribute"}, {"end": 65, "start": 62, "tag": "ClinicalAttribute"}]}
{"id": "1478_1", "text": "Assess the gFC with regard to amyloid (A), tau (T), and neurodegeneration (N) biomarkers, and estimated years to symptom onset (EYO).", "tags": [{"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 56, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 78, "tag": "ClinicalAttribute"}, {"end": 126, "start": 94, "tag": "TemporalConcept"}, {"end": 37, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 11, "tag": "ClinicalAttribute"}, {"end": 131, "start": 128, "tag": "TemporalConcept"}]}
{"id": "1478_2", "text": "Introduction: Cross-sectional measures were assessed in MC (n = 171) and mutation noncarrier (NC) (n = 70) participants.", "tags": [{"end": 58, "start": 56, "tag": "PopulationGroup"}, {"end": 119, "start": 107, "tag": "PopulationGroup"}, {"end": 81, "start": 73, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1478_3", "text": "A functional connectivity (FC) matrix that encompassed multiple resting-state networks was computed for each participant.", "tags": [{"end": 120, "start": 109, "tag": "PopulationGroup"}, {"end": 25, "start": 2, "tag": "BiologicFunction"}, {"end": 86, "start": 64, "tag": "BiologicFunction"}]}
{"id": "1478_4", "text": "Methods: A global FC was compiled as a single index indicating FC strength.", "tags": [{"end": 20, "start": 11, "tag": "ClinicalAttribute"}]}
{"id": "1478_5", "text": "The gFC signature was modeled as a nonlinear function of EYO.", "tags": [{"end": 17, "start": 4, "tag": "ClinicalAttribute"}, {"end": 60, "start": 57, "tag": "TemporalConcept"}]}
{"id": "1478_6", "text": "The gFC was linearly associated with other biomarkers used for assessing the AT(N) framework, including cerebrospinal fluid (CSF), positron emission tomography (PET) molecular biomarkers, and structural magnetic resonance imaging.", "tags": [{"end": 186, "start": 166, "tag": "ClinicalAttribute"}, {"end": 159, "start": 131, "tag": "HealthCareActivity"}, {"end": 229, "start": 192, "tag": "HealthCareActivity"}, {"end": 229, "start": 192, "tag": "ManufacturedObject"}, {"end": 159, "start": 131, "tag": "ManufacturedObject"}, {"end": 164, "start": 161, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 186, "start": 176, "tag": "ClinicalAttribute"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 118, "tag": "Substance"}, {"end": 229, "start": 203, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "HealthCareActivity"}, {"end": 229, "start": 203, "tag": "ManufacturedObject"}, {"end": 123, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}]}
{"id": "1478_7", "text": "Results: The gFC was reduced in MC compared with NC participants.", "tags": [{"end": 34, "start": 32, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 64, "start": 52, "tag": "PopulationGroup"}, {"end": 16, "start": 13, "tag": "ClinicalAttribute"}]}
{"id": "1478_8", "text": "When MC participants were differentiated by clinical dementia rating (CDR), the gFC was significantly decreased in MC CDR >0 (demented) compared with either MC CDR 0 (cognitively normal) or NC participants.", "tags": [{"end": 7, "start": 5, "tag": "PopulationGroup"}, {"end": 117, "start": 115, "tag": "PopulationGroup"}, {"end": 134, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "PopulationGroup"}, {"end": 185, "start": 179, "tag": "Finding"}, {"end": 61, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 8, "tag": "PopulationGroup"}, {"end": 205, "start": 193, "tag": "PopulationGroup"}, {"end": 68, "start": 44, "tag": "HealthCareActivity"}, {"end": 73, "start": 70, "tag": "HealthCareActivity"}, {"end": 83, "start": 80, "tag": "ClinicalAttribute"}, {"end": 121, "start": 118, "tag": "HealthCareActivity"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}]}
{"id": "1478_9", "text": "The gFC varied nonlinearly with EYO and initially decreased at EYO = -24 years, followed by a stable period followed by a further decline near EYO = 0 years.", "tags": [{"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 78, "start": 73, "tag": "TemporalConcept"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 35, "start": 32, "tag": "TemporalConcept"}, {"end": 66, "start": 63, "tag": "TemporalConcept"}, {"end": 146, "start": 143, "tag": "TemporalConcept"}]}
{"id": "1478_10", "text": "Irrespective of EYO, a lower gFC associated with values of amyloid PET, CSF A beta(1-42), CSF p-tau, CSF t-tau, 18F-fluorodeoxyglucose, and hippocampal volume.", "tags": [{"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "Cell"}, {"end": 70, "start": 67, "tag": "HealthCareActivity"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 112, "tag": "Chemical"}, {"end": 158, "start": 140, "tag": "ClinicalAttribute"}, {"end": 19, "start": 16, "tag": "TemporalConcept"}, {"end": 32, "start": 29, "tag": "ClinicalAttribute"}, {"end": 88, "start": 76, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1478_11", "text": "Conclusions: The gFC correlated with biomarkers used for defining the AT(N) framework.", "tags": [{"end": 47, "start": 37, "tag": "ClinicalAttribute"}, {"end": 20, "start": 17, "tag": "ClinicalAttribute"}]}
{"id": "1478_12", "text": "A biphasic change in the gFC suggested early changes associated with CSF amyloid and later changes associated with hippocampal volume.", "tags": [{"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 115, "tag": "Cell"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 115, "tag": "ClinicalAttribute"}, {"end": 28, "start": 25, "tag": "ClinicalAttribute"}]}
{"id": "1479_0", "text": "Objective To determine the ordering of changes in Alzheimer disease (AD) biomarkers among cognitively normal individuals.", "tags": [{"end": 108, "start": 102, "tag": "Finding"}, {"end": 67, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 73, "tag": "ClinicalAttribute"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 109, "tag": "PopulationGroup"}]}
{"id": "1479_1", "text": "Methods Cross-sectional data, including CSF analytes, molecular imaging of cerebral fibrillar beta-amyloid (A beta) with PET using the [C-11] benzothiazole tracer Pittsburgh compound B (PiB), MRI-based brain structures, and clinical/cognitive outcomes harmonized from 8 studies, collectively involving 3,284 cognitively normal individuals 18 to 101 years of age, were analyzed.", "tags": [{"end": 52, "start": 44, "tag": "Substance"}, {"end": 71, "start": 54, "tag": "HealthCareActivity"}, {"end": 189, "start": 186, "tag": "Chemical"}, {"end": 218, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 135, "tag": "Chemical"}, {"end": 326, "start": 320, "tag": "Finding"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}, {"end": 361, "start": 358, "tag": "OrganismAttribute"}, {"end": 354, "start": 349, "tag": "TemporalConcept"}, {"end": 277, "start": 270, "tag": "ResearchActivity"}, {"end": 28, "start": 8, "tag": "ResearchActivity"}, {"end": 43, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 192, "tag": "HealthCareActivity"}, {"end": 71, "start": 64, "tag": "HealthCareActivity"}, {"end": 338, "start": 327, "tag": "PopulationGroup"}, {"end": 114, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 75, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1479_2", "text": "The age at which each marker exhibited an accelerated change (called the change point) was estimated and compared across the markers.", "tags": [{"end": 7, "start": 4, "tag": "OrganismAttribute"}, {"end": 28, "start": 22, "tag": "ClinicalAttribute"}]}
{"id": "1479_3", "text": "Results Accelerated changes in CSF A beta(1-42) (A beta(42)) occurred at 48.28 years of age and in A beta(42)/A beta(40) ratio at 46.02 years, followed by PiB mean cortical standardized uptake value ratio (SUVR) with a change point at 54.47 years.", "tags": [{"end": 158, "start": 155, "tag": "Chemical"}, {"end": 172, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "OrganismAttribute"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 141, "start": 136, "tag": "TemporalConcept"}, {"end": 246, "start": 241, "tag": "TemporalConcept"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 155, "tag": "ResearchActivity"}]}
{"id": "1479_4", "text": "CSF total tau (Tau) and tau phosphorylated at threonine 181 (Ptau) had a change point at approximate to 60 years, similar to those for MRI hippocampal volume and cortical thickness.", "tags": [{"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 162, "tag": "ClinicalAttribute"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 135, "tag": "HealthCareActivity"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 135, "tag": "ClinicalAttribute"}]}
{"id": "1479_5", "text": "The change point for a cognitive composite occurred at 62.41 years.", "tags": [{"end": 66, "start": 61, "tag": "TemporalConcept"}]}
{"id": "1479_6", "text": "The change points for CSF A beta(42) and A beta(42)/A beta(40) ratio, albeit not significantly different from that for PiB SUVR, occurred significantly earlier than that for CSF Tau, Ptau, MRI markers, and the cognitive composite.", "tags": [{"end": 122, "start": 119, "tag": "Chemical"}, {"end": 181, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 189, "tag": "HealthCareActivity"}, {"end": 36, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 152, "tag": "TemporalConcept"}, {"end": 36, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 183, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1479_7", "text": "Adjusted analyses confirmed that accelerated changes in CSF Tau, Ptau, MRI markers, and the cognitive composite occurred at ages not significantly different from each other.", "tags": [{"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 124, "tag": "TemporalConcept"}, {"end": 59, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "HealthCareActivity"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1479_8", "text": "Conclusions Our findings support the hypothesized early changes of amyloid in preclinical AD and suggest that changes in neuronal injury and neurodegeneration markers occur close in time to cognitive decline.", "tags": [{"end": 129, "start": 121, "tag": "Cell"}, {"end": 158, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 182, "tag": "TemporalConcept"}, {"end": 136, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 190, "tag": "DiseaseOrSyndrome"}]}
{"id": "1480_0", "text": "An efficient method to identify whether mild cognitive impairment (MCI) has progressed to Alzheimer's disease (AD) will be beneficial to patient care.", "tags": [{"end": 149, "start": 137, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 149, "start": 145, "tag": "HealthCareActivity"}, {"end": 109, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 137, "tag": "PatientOrDisabledGroup"}, {"end": 65, "start": 40, "tag": "DiseaseOrSyndrome"}]}
{"id": "1480_1", "text": "Previous studies have shown that magnetic resonance imaging (MRI) has enabled the assessment of AD progression based on imaging findings.", "tags": [{"end": 92, "start": 82, "tag": "HealthCareActivity"}, {"end": 92, "start": 82, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 110, "start": 99, "tag": "PathologicFunction"}, {"end": 110, "start": 99, "tag": "TemporalConcept"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 61, "tag": "HealthCareActivity"}, {"end": 59, "start": 33, "tag": "HealthCareActivity"}, {"end": 59, "start": 52, "tag": "HealthCareActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 59, "start": 33, "tag": "ManufacturedObject"}]}
{"id": "1480_2", "text": "The present work aimed to establish an algorithm based on three features, namely, volume, surface area, and surface curvature within the hippocampal subfields, to model variations, including atrophy and structural changes to the cortical surface.", "tags": [{"end": 102, "start": 90, "tag": "OrganismAttribute"}, {"end": 158, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 229, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 163, "tag": "ResearchActivity"}, {"end": 198, "start": 191, "tag": "PathologicFunction"}, {"end": 198, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 39, "tag": "MachineActivity"}, {"end": 158, "start": 108, "tag": "ClinicalAttribute"}]}
{"id": "1480_3", "text": "In this study, a new biomarker, the ratio of principal curvatures (RPC), was proposed to characterize the folding patterns of the cortical gyrus and sulcus.", "tags": [{"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 65, "start": 36, "tag": "ClinicalAttribute"}, {"end": 70, "start": 67, "tag": "ClinicalAttribute"}, {"end": 144, "start": 106, "tag": "BiologicFunction"}]}
{"id": "1480_4", "text": "Along with volumes and surface areas, these morphological features associated with the hippocampal subfields were assessed in terms of their sensitivity to the changes in cognitive capacity by two different feature selection methods.", "tags": [{"end": 36, "start": 23, "tag": "OrganismAttribute"}, {"end": 108, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 141, "tag": "Finding"}, {"end": 232, "start": 207, "tag": "ResearchActivity"}]}
{"id": "1480_5", "text": "Either the extracted features were statistically significantly different, or the features were selected through a random forest model.", "tags": [{"end": 133, "start": 114, "tag": "MachineActivity"}]}
{"id": "1480_6", "text": "The identified subfields and their structural indices that are sensitive to the changes characteristic of the progression from MCI to AD were further assessed with a multilayer perceptron classifier to help facilitate the diagnosis.", "tags": [{"end": 130, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 110, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 231, "start": 222, "tag": "HealthCareActivity"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 166, "tag": "MachineActivity"}]}
{"id": "1480_7", "text": "The accuracy of the classification based on the proposed method to distinguish whether a MCI patient enters the AD stage amounted to 79.95%, solely using the information from the features selected by a logical feature selection method.", "tags": [{"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ClinicalAttribute"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 57, "tag": "ResearchActivity"}, {"end": 234, "start": 202, "tag": "ResearchActivity"}, {"end": 63, "start": 57, "tag": "HealthCareActivity"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 12, "start": 4, "tag": "Finding"}]}
{"id": "1481_0", "text": "BackgroundMacrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine.", "tags": [{"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "GeneOrGenome"}, {"end": 85, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 21, "tag": "CellFunction"}, {"end": 76, "start": 60, "tag": "PathologicFunction"}, {"end": 20, "start": 10, "tag": "Cell"}, {"end": 48, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1481_1", "text": "Chronic inflammation induced by amyloid proteins (A) is one prominent neuropathological feature in Alzheimer's disease (AD) brain.MethodsElisa, Western blot, and immunohistochemical staining analysis were performed to examine the level of MIF protein in CSF and brain tissues.", "tags": [{"end": 20, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 144, "tag": "ResearchActivity"}, {"end": 275, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 257, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 8, "tag": "PathologicFunction"}, {"end": 48, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 162, "tag": "ResearchActivity"}, {"end": 142, "start": 137, "tag": "ResearchActivity"}, {"end": 257, "start": 230, "tag": "ClinicalAttribute"}]}
{"id": "1481_2", "text": "MTT and LDH assays were used to examine the neurotoxicity, and the Morris Water Maze test was performed to examine the cognitive function in the MIF+/-/APP23 transgenic mice.ResultsMIF expression was upregulated in the brain of AD patients and AD model mice.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 57, "start": 44, "tag": "InjuryOrPoisoning"}, {"end": 89, "start": 67, "tag": "ResearchActivity"}, {"end": 137, "start": 119, "tag": "BiologicFunction"}, {"end": 173, "start": 158, "tag": "Eukaryote"}, {"end": 173, "start": 158, "tag": "ResearchActivity"}, {"end": 239, "start": 231, "tag": "PatientOrDisabledGroup"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 247, "tag": "ResearchActivity"}, {"end": 173, "start": 169, "tag": "Eukaryote"}, {"end": 257, "start": 253, "tag": "Eukaryote"}, {"end": 18, "start": 8, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "ResearchActivity"}, {"end": 173, "start": 145, "tag": "ExperimentalModelOfDisease"}, {"end": 184, "start": 181, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1481_3", "text": "Elevated MIF concentration was detected in the cerebrospinal fluid of AD patients but not in that of the patients suffering from mild cognitive impairment and vascular dementia.", "tags": [{"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 123, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 61, "tag": "Substance"}, {"end": 176, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "Finding"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1481_4", "text": "Reduced MIF expression impaired learning and memory in the AD model mice.", "tags": [{"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 8, "tag": "GeneOrGenome"}, {"end": 51, "start": 32, "tag": "BiologicFunction"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 32, "tag": "BiologicFunction"}, {"end": 67, "start": 62, "tag": "ResearchActivity"}, {"end": 72, "start": 68, "tag": "Eukaryote"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1481_5", "text": "MIF expression largely associates with A deposits and microglia.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 63, "start": 54, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1481_6", "text": "The binding assay revealed a direct association between MIF and A oligomers.", "tags": [{"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "GeneOrGenome"}, {"end": 17, "start": 4, "tag": "ResearchActivity"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1481_7", "text": "Neurons instead of glial cells were responsible for the secretion of MIF upon stimulation by A oligomers.", "tags": [{"end": 7, "start": 0, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "GeneOrGenome"}, {"end": 89, "start": 78, "tag": "HealthCareActivity"}, {"end": 89, "start": 78, "tag": "NaturalPhenomenonOrProcess"}, {"end": 30, "start": 19, "tag": "Cell"}, {"end": 24, "start": 19, "tag": "Cell"}, {"end": 104, "start": 95, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1481_8", "text": "In addition, overexpression of MIF significantly protected neuronal cells from A-induced cytotoxicity.ConclusionOur study suggests that neuronal secretion of MIF may serve as a defense mechanism to compensate for declined cognitive function in AD, and increased MIF level could be a potential AD biomarker.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 31, "tag": "GeneOrGenome"}, {"end": 161, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 158, "tag": "GeneOrGenome"}, {"end": 240, "start": 222, "tag": "BiologicFunction"}, {"end": 265, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 265, "start": 262, "tag": "GeneOrGenome"}, {"end": 73, "start": 59, "tag": "Cell"}, {"end": 194, "start": 177, "tag": "BiologicFunction"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 295, "start": 293, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 296, "tag": "ClinicalAttribute"}, {"end": 121, "start": 116, "tag": "ResearchActivity"}, {"end": 34, "start": 13, "tag": "Finding"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 154, "start": 136, "tag": "CellFunction"}, {"end": 101, "start": 89, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 271, "start": 262, "tag": "ClinicalAttribute"}, {"end": 34, "start": 31, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1482_0", "text": "Introduction Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively.", "tags": [{"end": 32, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 216, "start": 195, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 102, "tag": "ClinicalAttribute"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 168, "tag": "CellFunction"}, {"end": 166, "start": 153, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1482_1", "text": "Methods We performed genome-wide association studies (GWAS) using DNA and cerebrospinal fluid (CSF) samples from the EMIF-AD Multimodal Biomarker Discovery study for discovery, and the Alzheimer's Disease Neuroimaging Initiative study for validation analyses.", "tags": [{"end": 52, "start": 21, "tag": "ResearchActivity"}, {"end": 258, "start": 239, "tag": "ResearchActivity"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 69, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 27, "start": 21, "tag": "GeneOrGenome"}, {"end": 204, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 117, "tag": "ResearchActivity"}, {"end": 234, "start": 185, "tag": "ResearchActivity"}, {"end": 175, "start": 166, "tag": "ResearchActivity"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 88, "tag": "Substance"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1482_2", "text": "GWAS were performed for all three CSF biomarkers using linear regression models adjusting for relevant covariates.", "tags": [{"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 55, "tag": "ResearchActivity"}]}
{"id": "1482_3", "text": "Results We identify novel genome-wide significant associations between DNA variants in TMEM106B and CSF levels of NfL, and between CPOX and YKL-40.", "tags": [{"end": 95, "start": 87, "tag": "GeneOrGenome"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 74, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 32, "start": 26, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 146, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 131, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1482_4", "text": "We confirm previous work suggesting that YKL-40 levels are associated with DNA variants in CHI3L1.", "tags": [{"end": 97, "start": 91, "tag": "GeneOrGenome"}, {"end": 97, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1482_5", "text": "Discussion Our study provides important new insights into the genetic architecture underlying interindividual variation in three AD-related CSF biomarkers.", "tags": [{"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 154, "start": 144, "tag": "ClinicalAttribute"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1482_6", "text": "In particular, our data shed light on the sequence of events regarding the initiation and progression of neuropathological processes relevant in AD.", "tags": [{"end": 101, "start": 90, "tag": "PathologicFunction"}, {"end": 101, "start": 90, "tag": "TemporalConcept"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}, {"end": 85, "start": 75, "tag": "TemporalConcept"}, {"end": 132, "start": 105, "tag": "PathologicFunction"}]}
{"id": "1483_0", "text": "Salivary A beta 40, A beta 42, t-tau, and p-tau 181 are commonly employed in Alzheimer's disease (AD) investigations.", "tags": [{"end": 116, "start": 102, "tag": "ResearchActivity"}, {"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}, {"end": 36, "start": 31, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 8, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1483_1", "text": "However, the collection method of these biomarkers can affect their levels.", "tags": [{"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 50, "start": 40, "tag": "ClinicalAttribute"}]}
{"id": "1483_2", "text": "To assess the impact of saliva collection methods on biomarkers in this study, 15 healthy people were employed in the morning with six saliva collection methods.", "tags": [{"end": 125, "start": 118, "tag": "TemporalConcept"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 82, "tag": "OrganismAttribute"}, {"end": 63, "start": 53, "tag": "ClinicalAttribute"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}, {"end": 96, "start": 90, "tag": "PopulationGroup"}, {"end": 49, "start": 31, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ResearchActivity"}]}
{"id": "1483_3", "text": "The chosen methods were then applied in 30 AD patients and 30 non-AD controls.", "tags": [{"end": 45, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}]}
{"id": "1483_4", "text": "The levels of salivary biomarkers were calculated by a specific enzyme-linked immunosorbent assay.", "tags": [{"end": 97, "start": 64, "tag": "ResearchActivity"}, {"end": 70, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 23, "tag": "ClinicalAttribute"}]}
{"id": "1483_5", "text": "The receiver operating characteristic was utilized to assess salivary biomarkers in AD patients.", "tags": [{"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 70, "tag": "ClinicalAttribute"}, {"end": 37, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1483_6", "text": "The results demonstrated that the highest levels of salivary A beta 40, A beta 42, t-tau, and p-tau were in different saliva collection methods.", "tags": [{"end": 70, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "ClinicalAttribute"}, {"end": 143, "start": 125, "tag": "ResearchActivity"}]}
{"id": "1483_7", "text": "The correlations between different saliva biomarkers in the same collection method were different.", "tags": [{"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 65, "tag": "ResearchActivity"}, {"end": 52, "start": 42, "tag": "ClinicalAttribute"}, {"end": 16, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1483_8", "text": "Salivary A beta 40, A beta 42, t-tau, and p-tau had no significant association.", "tags": [{"end": 78, "start": 52, "tag": "Finding"}, {"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1483_9", "text": "Salivary A beta 42 was higher in AD than in non-AD controls.", "tags": [{"end": 18, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 51, "tag": "PopulationGroup"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1483_10", "text": "However, p-tau/t-tau and A beta 42/A beta 40 had some relevance.", "tags": [{"end": 20, "start": 9, "tag": "ClinicalAttribute"}, {"end": 44, "start": 25, "tag": "ClinicalAttribute"}]}
{"id": "1483_11", "text": "The area under the curve for four biomarkers combined in AD diagnosis was 92.11%.", "tags": [{"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 4, "tag": "ResearchActivity"}, {"end": 69, "start": 60, "tag": "HealthCareActivity"}, {"end": 44, "start": 34, "tag": "ClinicalAttribute"}]}
{"id": "1483_12", "text": "An alternate saliva collection method (e.g., USS in A beta 40, UPS in A beta 42, t-tau, SSS in p-tau 181) was demonstrated in this study.", "tags": [{"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 20, "tag": "ResearchActivity"}, {"end": 136, "start": 131, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 45, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "ResearchActivity"}, {"end": 91, "start": 88, "tag": "ResearchActivity"}]}
{"id": "1483_13", "text": "Moreover, combining numerous biomarkers improves AD diagnosis.", "tags": [{"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "HealthCareActivity"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}]}
{"id": "1484_0", "text": "BackgroundReduced F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer's disease (AD) biological definition.", "tags": [{"end": 97, "start": 81, "tag": "BiologicFunction"}, {"end": 211, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "ClinicalAttribute"}, {"end": 79, "start": 72, "tag": "HealthCareActivity"}, {"end": 79, "start": 76, "tag": "HealthCareActivity"}, {"end": 41, "start": 18, "tag": "Chemical"}, {"end": 148, "start": 131, "tag": "CellOrMolecularDysfunction"}, {"end": 164, "start": 156, "tag": "TemporalConcept"}, {"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 187, "start": 174, "tag": "HealthCareActivity"}]}
{"id": "1484_1", "text": "However, accumulating evidence suggested it is an independent biomarker, which is denoted as F in the very study.MethodsA total of 551 A+T+ individuals from the Alzheimer's Disease Neuroimaging Initiative database were recruited and then further divided into four groups based on the biomarker positivity as 132 A+T+N-F-, 102 A+T+N-F+, 113 A+T+N+F-, and 204 A+T+N+F+.", "tags": [{"end": 61, "start": 50, "tag": "Finding"}, {"end": 213, "start": 205, "tag": "ResearchActivity"}, {"end": 30, "start": 9, "tag": "Finding"}, {"end": 204, "start": 161, "tag": "ResearchActivity"}, {"end": 204, "start": 161, "tag": "HealthCareRelatedOrganization"}, {"end": 304, "start": 294, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 293, "start": 284, "tag": "ClinicalAttribute"}, {"end": 151, "start": 140, "tag": "PopulationGroup"}, {"end": 112, "start": 107, "tag": "ResearchActivity"}, {"end": 270, "start": 264, "tag": "PopulationGroup"}]}
{"id": "1484_2", "text": "Frequency distributions of the groups were compared, as well as the clinical progression [measured by the longitudinal changes in cognition and brain structure, and mild cognitive impairment (MCI) to AD dementia conversion] between every pair of F+ and F- groups.ResultsThe prevalence of A+T+N+F+ profile was 66.24% in clinically diagnosed AD dementia patients; similarly, the majority of individuals with reduced FDG-PET were AD dementia subjects.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 10, "tag": "BiologicFunction"}, {"end": 159, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 68, "tag": "TemporalConcept"}, {"end": 126, "start": 106, "tag": "ResearchActivity"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 342, "start": 340, "tag": "DiseaseOrSyndrome"}, {"end": 429, "start": 427, "tag": "DiseaseOrSyndrome"}, {"end": 360, "start": 352, "tag": "PatientOrDisabledGroup"}, {"end": 339, "start": 330, "tag": "HealthCareActivity"}, {"end": 400, "start": 389, "tag": "PopulationGroup"}, {"end": 421, "start": 414, "tag": "HealthCareActivity"}, {"end": 211, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 351, "start": 343, "tag": "DiseaseOrSyndrome"}, {"end": 438, "start": 430, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "PopulationGroup"}, {"end": 262, "start": 256, "tag": "PopulationGroup"}, {"end": 139, "start": 130, "tag": "BiologicFunction"}, {"end": 421, "start": 418, "tag": "HealthCareActivity"}, {"end": 190, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 447, "start": 439, "tag": "PopulationGroup"}, {"end": 222, "start": 212, "tag": "Finding"}]}
{"id": "1484_3", "text": "Among the 551 individuals that included, 537 had at least one follow-up (varied from 1 to 8years).", "tags": [{"end": 25, "start": 14, "tag": "PopulationGroup"}, {"end": 71, "start": 62, "tag": "HealthCareActivity"}, {"end": 71, "start": 62, "tag": "TemporalConcept"}]}
{"id": "1484_4", "text": "Individuals in F+ groups performed worse and dropped faster in Mini-Mental State Examination scale and had faster shrinking middle temporal lobe than those in F- groups (all p<0.05).", "tags": [{"end": 98, "start": 63, "tag": "HealthCareActivity"}, {"end": 40, "start": 35, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 92, "start": 63, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "PopulationGroup"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 144, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1484_5", "text": "Moreover, in MCI patients, reduced FDG-PET exerted 2.47 to 4.08-fold risk of AD dementia progression compared with those without significantly impaired FDG-PET (both p<0.001).ConclusionsBased on the analyses, separating FDG-PET from N biomarker to build the ATN(F) system is necessary and well-founded.", "tags": [{"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 235, "tag": "ClinicalAttribute"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 42, "start": 35, "tag": "HealthCareActivity"}, {"end": 159, "start": 152, "tag": "HealthCareActivity"}, {"end": 227, "start": 220, "tag": "HealthCareActivity"}, {"end": 88, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 89, "tag": "PathologicFunction"}, {"end": 100, "start": 89, "tag": "TemporalConcept"}, {"end": 207, "start": 199, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 159, "start": 156, "tag": "HealthCareActivity"}, {"end": 227, "start": 224, "tag": "HealthCareActivity"}, {"end": 73, "start": 69, "tag": "Finding"}, {"end": 271, "start": 258, "tag": "HealthCareActivity"}]}
{"id": "1484_6", "text": "The analysis from this study could be a complement to the original ATN framework for AD's biological definition.", "tags": [{"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 80, "start": 67, "tag": "HealthCareActivity"}]}
{"id": "1485_0", "text": "BackgroundGrowing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the blood of AD subjects.", "tags": [{"end": 70, "start": 66, "tag": "CellFunction"}, {"end": 137, "start": 133, "tag": "CellFunction"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 149, "start": 138, "tag": "Finding"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 185, "tag": "PopulationGroup"}, {"end": 52, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 18, "tag": "Finding"}]}
{"id": "1485_1", "text": "Most studies have correlated blood DNAm with the clinical diagnosis of AD in living individuals.", "tags": [{"end": 39, "start": 35, "tag": "CellFunction"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 77, "tag": "PopulationGroup"}, {"end": 67, "start": 49, "tag": "HealthCareActivity"}]}
{"id": "1485_2", "text": "However, as the pathophysiological process of AD can begin many years before the onset of clinical symptoms, there is often disagreement between neuropathology in the brain and clinical phenotypes.", "tags": [{"end": 107, "start": 90, "tag": "SignOrSymptom"}, {"end": 159, "start": 145, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 145, "tag": "PathologicFunction"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 69, "start": 64, "tag": "TemporalConcept"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 16, "tag": "PathologicFunction"}, {"end": 196, "start": 177, "tag": "ClinicalAttribute"}]}
{"id": "1485_3", "text": "Therefore, blood DNAm associated with AD neuropathology, rather than with clinical data, would provide more relevant information on AD pathogenesis.MethodsWe performed a comprehensive analysis to identify blood DNAm associated with cerebrospinal fluid (CSF) pathological biomarkers for AD.", "tags": [{"end": 21, "start": 17, "tag": "CellFunction"}, {"end": 215, "start": 211, "tag": "CellFunction"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 55, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 41, "tag": "PathologicFunction"}, {"end": 281, "start": 271, "tag": "ClinicalAttribute"}, {"end": 256, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 288, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 74, "tag": "ResearchActivity"}, {"end": 192, "start": 184, "tag": "ResearchActivity"}]}
{"id": "1485_4", "text": "Our study included matched samples of whole blood DNA methylation, CSF A beta(42), phosphorylated tau(181) (pTau(181)), and total tau (tTau) biomarkers data, measured on the same subjects and at the same clinical visits from a total of 202 subjects (123 CN or cognitively normal, 79 AD) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.", "tags": [{"end": 49, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 50, "tag": "CellFunction"}, {"end": 151, "start": 141, "tag": "ClinicalAttribute"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 351, "start": 345, "tag": "PopulationGroup"}, {"end": 285, "start": 283, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 156, "start": 152, "tag": "ResearchActivity"}, {"end": 117, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 248, "start": 240, "tag": "PopulationGroup"}, {"end": 278, "start": 260, "tag": "Finding"}, {"end": 313, "start": 294, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "Finding"}, {"end": 337, "start": 294, "tag": "ResearchActivity"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 337, "start": 294, "tag": "HealthCareRelatedOrganization"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 135, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1485_5", "text": "To validate our findings, we also examined the association between premortem blood DNAm and postmortem brain neuropathology measured on a group of 69 subjects in the London dataset.ResultsWe identified a number of novel associations between blood DNAm and CSF biomarkers, demonstrating that changes in pathological processes in the CSF are reflected in the blood epigenome.", "tags": [{"end": 87, "start": 83, "tag": "CellFunction"}, {"end": 123, "start": 103, "tag": "PathologicFunction"}, {"end": 251, "start": 247, "tag": "CellFunction"}, {"end": 372, "start": 363, "tag": "GeneOrGenome"}, {"end": 102, "start": 92, "tag": "TemporalConcept"}, {"end": 324, "start": 302, "tag": "PathologicFunction"}, {"end": 270, "start": 260, "tag": "ClinicalAttribute"}, {"end": 259, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 335, "start": 332, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 246, "start": 241, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 357, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 150, "tag": "PopulationGroup"}, {"end": 143, "start": 138, "tag": "PopulationGroup"}, {"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 180, "start": 173, "tag": "ResearchActivity"}]}
{"id": "1485_6", "text": "Overall, the CSF biomarker-associated DNAm is relatively distinct in CN and AD subjects, highlighting the importance of analyzing omics data measured on cognitively normal subjects (which includes preclinical AD subjects) to identify diagnostic biomarkers, and considering disease stages in the development and testing of AD treatment strategies.", "tags": [{"end": 42, "start": 38, "tag": "CellFunction"}, {"end": 287, "start": 273, "tag": "ClinicalAttribute"}, {"end": 345, "start": 325, "tag": "HealthCareActivity"}, {"end": 318, "start": 311, "tag": "HealthCareActivity"}, {"end": 135, "start": 130, "tag": "ResearchActivity"}, {"end": 345, "start": 325, "tag": "ResearchActivity"}, {"end": 255, "start": 245, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 324, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 17, "tag": "ClinicalAttribute"}, {"end": 211, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 136, "tag": "ResearchActivity"}, {"end": 306, "start": 295, "tag": "BiologicFunction"}, {"end": 306, "start": 295, "tag": "CellFunction"}, {"end": 287, "start": 281, "tag": "TemporalConcept"}, {"end": 87, "start": 79, "tag": "PopulationGroup"}, {"end": 180, "start": 172, "tag": "PopulationGroup"}, {"end": 220, "start": 212, "tag": "PopulationGroup"}, {"end": 171, "start": 153, "tag": "Finding"}, {"end": 255, "start": 234, "tag": "ClinicalAttribute"}, {"end": 71, "start": 69, "tag": "Finding"}]}
{"id": "1485_7", "text": "Moreover, our analysis revealed biological processes associated with early brain impairment relevant to AD are marked by DNAm in the blood, and blood DNAm at several CpGs in the DMR on HOXA5 gene are associated with pTau(181) in the CSF, as well as tau-pathology and DNAm in the brain, nominating DNAm at this locus as a promising candidate AD biomarker.ConclusionsOur study provides a valuable resource for future mechanistic and biomarker studies of DNAm in AD.", "tags": [{"end": 125, "start": 121, "tag": "CellFunction"}, {"end": 154, "start": 150, "tag": "CellFunction"}, {"end": 195, "start": 185, "tag": "GeneOrGenome"}, {"end": 271, "start": 267, "tag": "CellFunction"}, {"end": 301, "start": 297, "tag": "CellFunction"}, {"end": 456, "start": 452, "tag": "CellFunction"}, {"end": 52, "start": 32, "tag": "BiologicFunction"}, {"end": 414, "start": 408, "tag": "TemporalConcept"}, {"end": 236, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 262, "start": 249, "tag": "PathologicFunction"}, {"end": 448, "start": 441, "tag": "ResearchActivity"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 343, "start": 341, "tag": "DiseaseOrSyndrome"}, {"end": 462, "start": 460, "tag": "DiseaseOrSyndrome"}, {"end": 353, "start": 344, "tag": "ClinicalAttribute"}, {"end": 440, "start": 431, "tag": "ClinicalAttribute"}, {"end": 374, "start": 369, "tag": "ResearchActivity"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 284, "start": 279, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 216, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 14, "tag": "ResearchActivity"}, {"end": 170, "start": 166, "tag": "NucleicAcidNucleosideOrNucleotide"}]}
{"id": "1486_0", "text": "BACKGROUND: Amyloid-beta (A beta) likely plays a primary role in Alzheimer's disease pathogenesis, but longitudinal A beta, tau, and neurodegeneration (A/T/N) measurements in the same individuals have rarely been examined to verify the temporal dynamics of these biomarkers.", "tags": [{"end": 244, "start": 236, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 253, "start": 245, "tag": "NaturalPhenomenonOrProcess"}, {"end": 115, "start": 103, "tag": "ResearchActivity"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 133, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 263, "tag": "ClinicalAttribute"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 184, "tag": "PopulationGroup"}, {"end": 32, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 159, "tag": "HealthCareActivity"}]}
{"id": "1486_1", "text": "METHODS: In this study, we investigated the temporal ordering of A beta, tau, and neurodegeneration using longitudinal biomarkers in nondemented elderly individuals.", "tags": [{"end": 52, "start": 44, "tag": "TemporalConcept"}, {"end": 118, "start": 106, "tag": "ResearchActivity"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 119, "tag": "ClinicalAttribute"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 164, "start": 153, "tag": "PopulationGroup"}, {"end": 144, "start": 133, "tag": "PopulationGroup"}, {"end": 152, "start": 145, "tag": "PopulationGroup"}, {"end": 71, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1486_2", "text": "A total of 395 cognitively unimpaired individuals and 204 individuals with mild cognitive impairment (320 [53%] were female) were classified into 8 A +/-/T +/-/N +/- categories according to the abnormal (+)/normal (-) status of A beta (F-18-flor betapir or F-18-florbeta ben) positron emission tomography (PET), F-18-flortaucipir PET, and adjusted hippocampal volume (aHCV).", "tags": [{"end": 202, "start": 194, "tag": "Finding"}, {"end": 123, "start": 117, "tag": "OrganismAttribute"}, {"end": 224, "start": 218, "tag": "Finding"}, {"end": 213, "start": 207, "tag": "Finding"}, {"end": 49, "start": 15, "tag": "PopulationGroup"}, {"end": 69, "start": 58, "tag": "PopulationGroup"}, {"end": 309, "start": 306, "tag": "HealthCareActivity"}, {"end": 333, "start": 330, "tag": "HealthCareActivity"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 276, "tag": "HealthCareActivity"}, {"end": 359, "start": 348, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 359, "start": 348, "tag": "Cell"}, {"end": 304, "start": 276, "tag": "ManufacturedObject"}, {"end": 366, "start": 339, "tag": "ClinicalAttribute"}, {"end": 253, "start": 236, "tag": "Chemical"}, {"end": 274, "start": 257, "tag": "Chemical"}, {"end": 329, "start": 312, "tag": "Chemical"}, {"end": 372, "start": 368, "tag": "ClinicalAttribute"}]}
{"id": "1486_3", "text": "Follow-up A beta PET, tau PET, and aHCV measurements at 0.6 to 4.1 years were available for 35% to 63% of the sample.", "tags": [{"end": 116, "start": 110, "tag": "Substance"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}, {"end": 29, "start": 26, "tag": "HealthCareActivity"}, {"end": 16, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 40, "tag": "HealthCareActivity"}, {"end": 39, "start": 35, "tag": "ClinicalAttribute"}]}
{"id": "1486_4", "text": "Baseline A beta, tau, and aHCV were compared between different A/T/N profiles.", "tags": [{"end": 20, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 69, "tag": "ResearchActivity"}, {"end": 30, "start": 26, "tag": "ClinicalAttribute"}]}
{"id": "1486_5", "text": "We investigated the associations of baseline and longitudinal A beta, tau, and neurodegeneration in relation to one another conti nuously.", "tags": [{"end": 61, "start": 49, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 79, "tag": "CellOrMolecularDysfunction"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1486_6", "text": "RESULTS: Among T- participants, tau was higher for A+/T-/N- individuals compared with the A-/T-/N- group (p = .02).", "tags": [{"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 18, "tag": "PopulationGroup"}, {"end": 71, "start": 60, "tag": "PopulationGroup"}, {"end": 104, "start": 99, "tag": "PopulationGroup"}]}
{"id": "1486_7", "text": "Among N- participants, neurodegeneration was worse among A+/T+/N- individuals compared with the A-/T-/N- group (p = .001).", "tags": [{"end": 40, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}, {"end": 77, "start": 66, "tag": "PopulationGroup"}, {"end": 110, "start": 105, "tag": "PopulationGroup"}]}
{"id": "1486_8", "text": "High baseline A beta was associated (p , .001) with subsequent tau increase and high baseline tau was associated (p = .002) with subsequent aHCV decrease, whereas high tau and low aHCV at baseline were not associated with subsequent A beta increase.", "tags": [{"end": 153, "start": 140, "tag": "Finding"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 176, "tag": "Finding"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 140, "tag": "ClinicalAttribute"}, {"end": 75, "start": 63, "tag": "Finding"}]}
{"id": "1486_9", "text": "CONCLUSIONS: These findings define a sequence of pathological events in Alzheimer's disease that support a current model of Alzheimer's disease pathogenesis in which A beta appears early, followed by deposition of abnormal tau aggregates and subsequent neurodegeneration.", "tags": [{"end": 237, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 144, "tag": "PathologicFunction"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 253, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 115, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "TemporalConcept"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 49, "tag": "PathologicFunction"}, {"end": 186, "start": 181, "tag": "TemporalConcept"}, {"end": 237, "start": 200, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1487_0", "text": "Background and purpose We investigated plasma neurofilament light chain concentration (pNfL) as a biomarker for neuroaxonal damage and disease activity using data from Phase 3 trials of ozanimod in relapsing multiple sclerosis (RMS).", "tags": [{"end": 182, "start": 168, "tag": "ResearchActivity"}, {"end": 175, "start": 168, "tag": "TemporalConcept"}, {"end": 194, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 162, "start": 158, "tag": "ResearchActivity"}, {"end": 65, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 135, "tag": "HealthCareActivity"}, {"end": 226, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 112, "tag": "InjuryOrPoisoning"}, {"end": 71, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 39, "tag": "ClinicalAttribute"}, {"end": 91, "start": 87, "tag": "ClinicalAttribute"}]}
{"id": "1487_1", "text": "Methods pNfL was measured before and after ozanimod 0.46 mg or 0.92 mg daily or interferon beta-1a 30 mu g weekly in the randomized, double-blind SUNBEAM and RADIANCE trials.", "tags": [{"end": 51, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 107, "tag": "TemporalConcept"}, {"end": 131, "start": 121, "tag": "ResearchActivity"}, {"end": 131, "start": 121, "tag": "Finding"}, {"end": 173, "start": 167, "tag": "ResearchActivity"}, {"end": 145, "start": 133, "tag": "ResearchActivity"}, {"end": 76, "start": 71, "tag": "TemporalConcept"}, {"end": 25, "start": 17, "tag": "HealthCareActivity"}, {"end": 12, "start": 8, "tag": "ClinicalAttribute"}, {"end": 51, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 167, "tag": "ResearchActivity"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 172, "start": 158, "tag": "ResearchActivity"}, {"end": 98, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 80, "tag": "PharmacologicSubstance"}]}
{"id": "1487_2", "text": "In these post hoc analyses, we investigated relationships between pNfL (at baseline and median percentage change from baseline to Month 12 [SUNBEAM] or 24 [RADIANCE]) and clinical and magnetic resonance imaging outcomes.", "tags": [{"end": 135, "start": 130, "tag": "TemporalConcept"}, {"end": 57, "start": 44, "tag": "Finding"}, {"end": 210, "start": 184, "tag": "HealthCareActivity"}, {"end": 210, "start": 203, "tag": "HealthCareActivity"}, {"end": 210, "start": 184, "tag": "ManufacturedObject"}, {"end": 126, "start": 88, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "TemporalConcept"}, {"end": 70, "start": 66, "tag": "ClinicalAttribute"}, {"end": 26, "start": 9, "tag": "ResearchActivity"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 164, "start": 156, "tag": "ResearchActivity"}]}
{"id": "1487_3", "text": "Results Median (Q1, Q3) baseline pNfL, available in 1244 of 1346 SUNBEAM participants, was 14.70 (10.16, 23.26) pg/ml and in 1109 of 1313 RADIANCE participants was 13.35 (9.42, 20.41) pg/ml.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 73, "tag": "PopulationGroup"}, {"end": 159, "start": 147, "tag": "PopulationGroup"}, {"end": 37, "start": 33, "tag": "ClinicalAttribute"}, {"end": 72, "start": 65, "tag": "ResearchActivity"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}]}
{"id": "1487_4", "text": "Baseline gadolinium-enhancing (GdE) and T2 lesion counts increased and brain volume decreased with increasing baseline pNfL.", "tags": [{"end": 49, "start": 43, "tag": "Finding"}, {"end": 29, "start": 9, "tag": "Finding"}, {"end": 34, "start": 31, "tag": "Finding"}, {"end": 123, "start": 119, "tag": "ClinicalAttribute"}, {"end": 83, "start": 71, "tag": "ClinicalAttribute"}]}
{"id": "1487_5", "text": "Baseline pNfL was higher in those with versus without on-treatment relapse.", "tags": [{"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 74, "start": 67, "tag": "TemporalConcept"}, {"end": 74, "start": 67, "tag": "Finding"}, {"end": 13, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1487_6", "text": "Median percentage reduction in pNfL at 12 months in SUNBEAM (n = 1238) and 24 months in RADIANCE (n = 1088) was greater for ozanimod (20%-27%) than interferon beta-1a (13%-16%; p < 0.01).", "tags": [{"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 39, "tag": "TemporalConcept"}, {"end": 27, "start": 18, "tag": "Finding"}, {"end": 27, "start": 18, "tag": "NaturalPhenomenonOrProcess"}, {"end": 48, "start": 42, "tag": "TemporalConcept"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 35, "start": 31, "tag": "ClinicalAttribute"}, {"end": 59, "start": 52, "tag": "ResearchActivity"}, {"end": 96, "start": 88, "tag": "ResearchActivity"}, {"end": 132, "start": 124, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 148, "tag": "PharmacologicSubstance"}]}
{"id": "1487_7", "text": "Greater pNfL reduction was associated with fewer GdE lesions, fewer new/enlarging T2 lesions per scan, less loss of brain volume, lower annualized relapse rate (ARR), and no evidence of disease activity.", "tags": [{"end": 60, "start": 49, "tag": "Finding"}, {"end": 101, "start": 97, "tag": "HealthCareActivity"}, {"end": 101, "start": 97, "tag": "Finding"}, {"end": 182, "start": 174, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 202, "start": 186, "tag": "HealthCareActivity"}, {"end": 60, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 92, "start": 82, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 8, "tag": "ClinicalAttribute"}, {"end": 128, "start": 116, "tag": "ClinicalAttribute"}, {"end": 159, "start": 136, "tag": "HealthCareActivity"}, {"end": 164, "start": 161, "tag": "HealthCareActivity"}]}
{"id": "1487_8", "text": "The following models predicted ARR: 0.5111 + 0.0116 x Delta NfL at 12 months (SUNBEAM) and 0.4079 + 0.0088 x Delta NfL at 24 months (RADIANCE).", "tags": [{"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "TemporalConcept"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 34, "start": 31, "tag": "HealthCareActivity"}, {"end": 85, "start": 78, "tag": "ResearchActivity"}, {"end": 141, "start": 133, "tag": "ResearchActivity"}]}
{"id": "1487_9", "text": "Conclusions pNfL was associated with clinical and radiologic measures of disease and treatment effects in RMS, supporting its use as a biomarker.", "tags": [{"end": 69, "start": 50, "tag": "ClinicalAttribute"}, {"end": 102, "start": 85, "tag": "Finding"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 135, "tag": "ClinicalAttribute"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 16, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1488_0", "text": "The A/T/N research framework has been proposed for the diagnosis and prognosis of Alzheimer's disease (AD).", "tags": [{"end": 78, "start": 69, "tag": "HealthCareActivity"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 4, "tag": "ResearchActivity"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}]}
{"id": "1488_1", "text": "However, the spatial distribution of ATN biomarkers and their relationship with cognitive impairment and neuropsychiatric symptoms (NPS) need further clarification in patients with AD.", "tags": [{"end": 135, "start": 132, "tag": "SignOrSymptom"}, {"end": 130, "start": 105, "tag": "SignOrSymptom"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 37, "tag": "ClinicalAttribute"}, {"end": 74, "start": 62, "tag": "Finding"}]}
{"id": "1488_2", "text": "We scanned 83 AD patients and 38 cognitively normal controls who independently completed the mini-mental state examination and Neuropsychiatric Inventory scales.", "tags": [{"end": 10, "start": 3, "tag": "HealthCareActivity"}, {"end": 122, "start": 93, "tag": "HealthCareActivity"}, {"end": 51, "start": 45, "tag": "Finding"}, {"end": 60, "start": 45, "tag": "PopulationGroup"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 33, "tag": "Finding"}, {"end": 160, "start": 127, "tag": "HealthCareActivity"}]}
{"id": "1488_3", "text": "Tau, Ap, and hypometabolism spatial patterns were characterized using Statistical Parametric Mapping together with [18F]flortaucipir, [18F]florbetapir, and [18F]FDG positron emission tomography.", "tags": [{"end": 27, "start": 13, "tag": "Finding"}, {"end": 150, "start": 134, "tag": "Chemical"}, {"end": 132, "start": 115, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 165, "tag": "HealthCareActivity"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 100, "start": 70, "tag": "HealthCareActivity"}, {"end": 164, "start": 156, "tag": "Chemical"}]}
{"id": "1488_4", "text": "Piecewise linear regression, two-sample t-tests, and support vector machine algorithms were used to explore the relationship between tau, A beta, and hypometabolism and cognition, NPS, and AD diagnosis.", "tags": [{"end": 164, "start": 150, "tag": "Finding"}, {"end": 183, "start": 180, "tag": "SignOrSymptom"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}, {"end": 86, "start": 53, "tag": "MachineActivity"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 192, "tag": "HealthCareActivity"}, {"end": 178, "start": 169, "tag": "BiologicFunction"}, {"end": 124, "start": 112, "tag": "Finding"}, {"end": 47, "start": 29, "tag": "ResearchActivity"}, {"end": 144, "start": 138, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1488_5", "text": "The results showed that regions with tau deposition are region-specific and mainly occurred in inferior temporal lobes in AD, which extensively overlaps with the hypometabolic regions.", "tags": [{"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 37, "tag": "PathologicFunction"}]}
{"id": "1488_6", "text": "While the deposition regions of A beta were unique and the regions affected by hypometabolism were widely distributed.", "tags": [{"end": 93, "start": 79, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1488_7", "text": "Unlike A beta, tau and hypometabolism build up monotonically with increasing cognitive impairment in the late stages of AD.", "tags": [{"end": 37, "start": 23, "tag": "Finding"}, {"end": 116, "start": 105, "tag": "TemporalConcept"}, {"end": 116, "start": 110, "tag": "TemporalConcept"}, {"end": 122, "start": 110, "tag": "ClinicalAttribute"}, {"end": 76, "start": 66, "tag": "Finding"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1488_8", "text": "In addition, NPS in AD were associated with tau deposition closely, followed by hypometabolism, but not with A beta.", "tags": [{"end": 16, "start": 13, "tag": "SignOrSymptom"}, {"end": 94, "start": 80, "tag": "Finding"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 44, "tag": "PathologicFunction"}]}
{"id": "1488_9", "text": "Finally, hypometabolism and tau had higher accuracy in differentiating the AD patients from controls (accuracy = 0.88, accuracy = 0.85) than A beta (accuracy = 0.81), and the combined three were the highest (accuracy = 0.95).", "tags": [{"end": 23, "start": 9, "tag": "Finding"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}, {"end": 86, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 51, "start": 43, "tag": "Finding"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 127, "start": 119, "tag": "Finding"}, {"end": 157, "start": 149, "tag": "Finding"}, {"end": 216, "start": 208, "tag": "Finding"}, {"end": 147, "start": 141, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1488_10", "text": "These findings suggest tau pathology is superior over A beta and glucose metabolism to identify cognitive impairment and NPS.", "tags": [{"end": 124, "start": 121, "tag": "SignOrSymptom"}, {"end": 83, "start": 65, "tag": "CellFunction"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 83, "start": 73, "tag": "CellFunction"}, {"end": 26, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 23, "tag": "PathologicFunction"}, {"end": 72, "start": 65, "tag": "Chemical"}, {"end": 72, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 54, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1488_11", "text": "Its results support tau accumulation can be used as a biomarker of clinical impairment in AD.", "tags": [{"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 54, "tag": "ClinicalAttribute"}, {"end": 36, "start": 24, "tag": "Finding"}, {"end": 86, "start": 67, "tag": "SignOrSymptom"}]}
{"id": "1489_0", "text": "Introduction: Amyloid beta (A beta) oligomers are one of the most toxic structural forms of the A beta protein and are hypothesized to cause synaptotoxicity and memory failure as they build up in Alzheimer's disease (AD) patients' brain tissue.", "tags": [{"end": 71, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 221, "tag": "PatientOrDisabledGroup"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 161, "tag": "BiologicFunction"}, {"end": 45, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 141, "tag": "InjuryOrPoisoning"}, {"end": 175, "start": 161, "tag": "PathologicFunction"}]}
{"id": "1489_1", "text": "We previously demonstrated that antagonists of the sigma-2 receptor complex effectively block A beta oligomer toxicity.", "tags": [{"end": 43, "start": 32, "tag": "Chemical"}, {"end": 75, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 51, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1489_2", "text": "CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers.", "tags": [{"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 50, "tag": "Chemical"}, {"end": 99, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 156, "tag": "PopulationGroup"}, {"end": 155, "start": 148, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 107, "start": 65, "tag": "Chemical"}, {"end": 107, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 164, "tag": "PopulationGroup"}]}
{"id": "1489_3", "text": "We tested CT1812's effect on A beta oligomer pathobiology in preclinical AD models and evaluated CT1812's impact on cerebrospinal fluid (CSF) protein biomarkers in mild to moderate AD patients in a clinical trial (ClinicalTrials.gov NCT02907567).", "tags": [{"end": 232, "start": 214, "tag": "HealthCareRelatedOrganization"}, {"end": 212, "start": 198, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ClinicalAttribute"}, {"end": 192, "start": 184, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 76, "tag": "ResearchActivity"}, {"end": 75, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 130, "tag": "Substance"}, {"end": 44, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 10, "tag": "Chemical"}, {"end": 16, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 97, "tag": "Chemical"}, {"end": 57, "start": 45, "tag": "PathologicFunction"}, {"end": 244, "start": 233, "tag": "ResearchActivity"}]}
{"id": "1489_4", "text": "Methods: Experiments were performed to measure the impact of CT1812 versus vehicle on A beta oligomer binding to synapses in vitro, to human AD patient post mortem brain tissue ex vivo, and in living APP(S)(we)/PS1dE9 transgenic mice in vivo.", "tags": [{"end": 20, "start": 9, "tag": "ResearchActivity"}, {"end": 121, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 233, "start": 218, "tag": "Eukaryote"}, {"end": 233, "start": 218, "tag": "ResearchActivity"}, {"end": 241, "start": 234, "tag": "ResearchActivity"}, {"end": 203, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 200, "tag": "GeneOrGenome"}, {"end": 203, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 229, "tag": "Eukaryote"}, {"end": 176, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 102, "tag": "CellFunction"}, {"end": 140, "start": 135, "tag": "Eukaryote"}, {"end": 101, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 122, "tag": "ResearchActivity"}, {"end": 151, "start": 144, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 152, "tag": "TemporalConcept"}, {"end": 67, "start": 61, "tag": "Chemical"}, {"end": 67, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 184, "start": 177, "tag": "ResearchActivity"}, {"end": 233, "start": 200, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1489_5", "text": "Additional experiments were performed to measure the impact of CT1812 versus vehicle on A beta oligomer-induced deficits in membrane trafficking rate, synapse number, and protein expression in mature hippocampal/cortical neurons in vitro.", "tags": [{"end": 158, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 212, "tag": "Cell"}, {"end": 22, "start": 11, "tag": "ResearchActivity"}, {"end": 132, "start": 124, "tag": "CellComponent"}, {"end": 189, "start": 171, "tag": "CellFunction"}, {"end": 199, "start": 193, "tag": "TemporalConcept"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 149, "start": 145, "tag": "TemporalConcept"}, {"end": 103, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 229, "tag": "ResearchActivity"}, {"end": 211, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 200, "tag": "Cell"}, {"end": 69, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 63, "tag": "Chemical"}, {"end": 144, "start": 124, "tag": "CellFunction"}]}
{"id": "1489_6", "text": "The impact of CT1812 on cognitive function was measured in transgenic Thy1 huAPP(Swe/Lnd+) and wild-type littermates.", "tags": [{"end": 42, "start": 24, "tag": "BiologicFunction"}, {"end": 69, "start": 59, "tag": "GeneOrGenome"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 116, "start": 95, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "Chemical"}, {"end": 20, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 59, "tag": "ExperimentalModelOfDisease"}]}
{"id": "1489_7", "text": "A multicenter, double-blind, placebo-controlled parallel group trial was performed to evaluate the safety, tolerability, and impact on protein biomarker expression of CT1812 or placebo given once daily for 28 days to AD patients (Mini-Mental State Examination 18-26).", "tags": [{"end": 13, "start": 2, "tag": "ResearchActivity"}, {"end": 27, "start": 15, "tag": "ResearchActivity"}, {"end": 47, "start": 29, "tag": "ResearchActivity"}, {"end": 119, "start": 107, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "HealthCareActivity"}, {"end": 184, "start": 177, "tag": "HealthCareActivity"}, {"end": 105, "start": 99, "tag": "HealthCareActivity"}, {"end": 213, "start": 209, "tag": "TemporalConcept"}, {"end": 228, "start": 220, "tag": "PatientOrDisabledGroup"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 135, "tag": "ClinicalAttribute"}, {"end": 62, "start": 57, "tag": "PopulationGroup"}, {"end": 201, "start": 196, "tag": "TemporalConcept"}, {"end": 259, "start": 230, "tag": "HealthCareActivity"}, {"end": 173, "start": 167, "tag": "Chemical"}, {"end": 173, "start": 167, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}]}
{"id": "1489_8", "text": "CSF protein expression was measured by liquid chromatography with tandem mass spectrometry or enzyme-linked immunosorbent assay in samples drawn prior to dosing (Day 0) and at end of dosing (Day 28) and compared within each patient and between pooled treated versus placebo-treated dosing groups.", "tags": [{"end": 60, "start": 39, "tag": "ResearchActivity"}, {"end": 90, "start": 66, "tag": "ResearchActivity"}, {"end": 127, "start": 94, "tag": "ResearchActivity"}, {"end": 165, "start": 162, "tag": "TemporalConcept"}, {"end": 194, "start": 191, "tag": "TemporalConcept"}, {"end": 22, "start": 4, "tag": "CellFunction"}, {"end": 273, "start": 266, "tag": "HealthCareActivity"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 289, "tag": "PopulationGroup"}, {"end": 90, "start": 73, "tag": "ResearchActivity"}, {"end": 100, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 224, "tag": "PatientOrDisabledGroup"}]}
{"id": "1489_9", "text": "Results: CT1812 significantly and dose-dependently displaced A beta oligomers bound to synaptic receptors in three independent preclinical models of AD, facilitated oligomer clearance into the CSF, increased synaptic number and protein expression in neurons, and improved cognitive performance in transgenic mice.", "tags": [{"end": 105, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 174, "tag": "NaturalPhenomenonOrProcess"}, {"end": 312, "start": 297, "tag": "Eukaryote"}, {"end": 246, "start": 228, "tag": "CellFunction"}, {"end": 312, "start": 297, "tag": "ResearchActivity"}, {"end": 293, "start": 272, "tag": "Finding"}, {"end": 196, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 127, "tag": "ResearchActivity"}, {"end": 312, "start": 308, "tag": "Eukaryote"}, {"end": 77, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 250, "tag": "Cell"}, {"end": 15, "start": 9, "tag": "Chemical"}, {"end": 15, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 208, "tag": "CellFunction"}]}
{"id": "1489_10", "text": "CT1812 significantly increased CSF concentrations of A beta oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF.", "tags": [{"end": 231, "start": 210, "tag": "PathologicFunction"}, {"end": 30, "start": 7, "tag": "Finding"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 6, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 69, "start": 31, "tag": "ClinicalAttribute"}]}
{"id": "1489_11", "text": "Discussion: These preclinical studies demonstrate the novel disease-modifying mechanism of action of CT1812 against AD and A beta oligomers.", "tags": [{"end": 37, "start": 18, "tag": "ResearchActivity"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 101, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "PharmacologicSubstance"}]}
{"id": "1489_12", "text": "The clinical results are consistent with preclinical data and provide evidence of target engagement and impact on fundamental disease-related signaling pathways in AD patients, supporting further development of CT1812.", "tags": [{"end": 160, "start": 142, "tag": "CellFunction"}, {"end": 175, "start": 167, "tag": "PatientOrDisabledGroup"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "ResearchActivity"}, {"end": 207, "start": 196, "tag": "BiologicFunction"}, {"end": 207, "start": 196, "tag": "CellFunction"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 99, "start": 82, "tag": "Finding"}, {"end": 217, "start": 211, "tag": "PharmacologicSubstance"}, {"end": 217, "start": 211, "tag": "Chemical"}]}
{"id": "1490_0", "text": "Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined.", "tags": [{"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 70, "tag": "ClinicalAttribute"}]}
{"id": "1490_1", "text": "Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples.", "tags": [{"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 43, "tag": "ResearchActivity"}, {"end": 33, "start": 25, "tag": "PopulationGroup"}, {"end": 96, "start": 89, "tag": "Substance"}, {"end": 96, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1490_2", "text": "Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 155, "start": 133, "tag": "Finding"}, {"end": 43, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "PopulationGroup"}, {"end": 164, "start": 156, "tag": "PopulationGroup"}]}
{"id": "1490_3", "text": "We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL).", "tags": [{"end": 127, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 68, "tag": "CellFunction"}, {"end": 11, "start": 3, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}, {"end": 93, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1490_4", "text": "Median CSF sampling interval was 2.1 years.", "tags": [{"end": 10, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 28, "start": 20, "tag": "TemporalConcept"}, {"end": 19, "start": 7, "tag": "HealthCareActivity"}]}
{"id": "1490_5", "text": "Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <.", "tags": [{"end": 52, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 77, "tag": "TemporalConcept"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 101, "tag": "PopulationGroup"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 97, "start": 94, "tag": "OrganismAttribute"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1490_6", "text": "001).", "tags": []}
{"id": "1490_7", "text": "In AD, t-tau levels were 1% lower (P <.", "tags": [{"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 7, "tag": "ClinicalAttribute"}]}
{"id": "1490_8", "text": "001) and p-tau levels did not change per each year of baseline age.", "tags": [{"end": 50, "start": 46, "tag": "TemporalConcept"}, {"end": 14, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "OrganismAttribute"}, {"end": 14, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1490_9", "text": "Longitudinally, only NfL (P <.", "tags": [{"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1490_10", "text": "001) and YKL-40 (P <.", "tags": [{"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1490_11", "text": "02) increased during the study period.", "tags": [{"end": 37, "start": 31, "tag": "TemporalConcept"}, {"end": 30, "start": 25, "tag": "ResearchActivity"}]}
{"id": "1490_12", "text": "Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau.", "tags": [{"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 95, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}]}
{"id": "1490_13", "text": "(C) 2019 the Alzheimer's Association.", "tags": [{"end": 36, "start": 13, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1490_14", "text": "Published by Elsevier Inc.", "tags": []}
{"id": "1490_15", "text": "All rights reserved.", "tags": []}
{"id": "1491_0", "text": "Observational studies suggest that angiotcnsin receptor blockers in hypertensive adults are associated with lower post-mortem indicators of Alzheimer's disease pathology.", "tags": [{"end": 80, "start": 68, "tag": "Finding"}, {"end": 55, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 152, "tag": "PathologicFunction"}, {"end": 159, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 118, "start": 114, "tag": "TemporalConcept"}, {"end": 125, "start": 114, "tag": "TemporalConcept"}, {"end": 87, "start": 68, "tag": "PatientOrDisabledGroup"}]}
{"id": "1491_1", "text": "Candesartan, an angiotensin receptor blocker, has a positive cognitive effect in mild cognitive impairment with hypertension.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 44, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 112, "tag": "Finding"}, {"end": 36, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}]}
{"id": "1491_2", "text": "However, its safety and effects in non, hypertensive individuals with Alzheimer's disease are unclear.", "tags": [{"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 35, "tag": "PopulationGroup"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 31, "start": 24, "tag": "Finding"}]}
{"id": "1491_3", "text": "This is the first double-blind randomized placebo-controlled trial aimed to assess safety and effects of 1-year therapy of candesartan on biomarkers and clinical indicators of Alzheimer's disease in non-hypertensive individuals with biomarker-confirmed prodromal Alzheimer's disease, Seventy-seven non-hypertensive participants 50 years or older (mean age: 68.1 years; 62% women; 20% African American) with mild cognitive impairment and biomarker confirmed Alzheimer's disease were randomized to escalating doses of once daily oral candesartan (up to 32 mg) or matched placebo.", "tags": [{"end": 134, "start": 123, "tag": "Chemical"}, {"end": 520, "start": 516, "tag": "TemporalConcept"}, {"end": 543, "start": 532, "tag": "Chemical"}, {"end": 282, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 391, "start": 384, "tag": "PopulationGroup"}, {"end": 345, "start": 340, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 111, "start": 107, "tag": "TemporalConcept"}, {"end": 400, "start": 384, "tag": "PopulationGroup"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 282, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 476, "start": 457, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 233, "tag": "ClinicalAttribute"}, {"end": 446, "start": 437, "tag": "ClinicalAttribute"}, {"end": 327, "start": 315, "tag": "PopulationGroup"}, {"end": 227, "start": 199, "tag": "PopulationGroup"}, {"end": 148, "start": 138, "tag": "ClinicalAttribute"}, {"end": 378, "start": 373, "tag": "PopulationGroup"}, {"end": 355, "start": 352, "tag": "OrganismAttribute"}, {"end": 89, "start": 83, "tag": "HealthCareActivity"}, {"end": 336, "start": 331, "tag": "TemporalConcept"}, {"end": 367, "start": 362, "tag": "TemporalConcept"}, {"end": 66, "start": 18, "tag": "ResearchActivity"}, {"end": 576, "start": 569, "tag": "HealthCareActivity"}, {"end": 101, "start": 94, "tag": "Finding"}, {"end": 119, "start": 112, "tag": "HealthCareActivity"}, {"end": 432, "start": 407, "tag": "DiseaseOrSyndrome"}, {"end": 526, "start": 521, "tag": "TemporalConcept"}, {"end": 134, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 531, "start": 527, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 543, "start": 532, "tag": "PharmacologicSubstance"}]}
{"id": "1491_4", "text": "Main outcomes included safety and tolerability of candesartan, cerebrospinal fluid biomarkers (amyloid-beta 42, amyloid-beta 40, total tau and phospho-tau).", "tags": [{"end": 61, "start": 50, "tag": "Chemical"}, {"end": 46, "start": 34, "tag": "ResearchActivity"}, {"end": 154, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 29, "start": 23, "tag": "HealthCareActivity"}, {"end": 61, "start": 50, "tag": "PharmacologicSubstance"}]}
{"id": "1491_5", "text": "Additional exploratory outcomes included PET imaging (Pittsburgh Compound-B (C-11-PiB) and F-18-flortaucipir), brain MRI (structural and connectivity measures) and cognitive functioning.", "tags": [{"end": 185, "start": 164, "tag": "BiologicFunction"}, {"end": 52, "start": 41, "tag": "HealthCareActivity"}, {"end": 120, "start": 111, "tag": "HealthCareActivity"}, {"end": 85, "start": 82, "tag": "Chemical"}, {"end": 52, "start": 45, "tag": "HealthCareActivity"}, {"end": 108, "start": 91, "tag": "Chemical"}, {"end": 31, "start": 23, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 149, "start": 137, "tag": "BiologicFunction"}, {"end": 75, "start": 54, "tag": "Chemical"}]}
{"id": "1491_6", "text": "Analyses used intentionto-treat approach with group comparisons of safety measures using Chi-square test, and repeated measures mixed effects models were used to assess candesartan effects on main and exploratory outcomes (ClinicalTrials.gov , NCT02646982).", "tags": [{"end": 180, "start": 169, "tag": "Chemical"}, {"end": 241, "start": 223, "tag": "HealthCareRelatedOrganization"}, {"end": 221, "start": 213, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "HealthCareActivity"}, {"end": 188, "start": 181, "tag": "Finding"}, {"end": 148, "start": 110, "tag": "ResearchActivity"}, {"end": 51, "start": 46, "tag": "PopulationGroup"}, {"end": 104, "start": 89, "tag": "ResearchActivity"}, {"end": 104, "start": 100, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 56, "start": 55, "tag": "ResearchActivity"}, {"end": 180, "start": 169, "tag": "PharmacologicSubstance"}]}
{"id": "1491_7", "text": "Candesartan was found to be safe with no significant difference in safety measures: symptoms of hypotension, renal failure or hyperkalemia.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 107, "start": 96, "tag": "Finding"}, {"end": 122, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 126, "tag": "Finding"}, {"end": 92, "start": 84, "tag": "SignOrSymptom"}, {"end": 63, "start": 38, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "HealthCareActivity"}, {"end": 4, "start": 3, "tag": "PharmacologicSubstance"}]}
{"id": "1491_8", "text": "Candesartan was also found to be associated with increases in cerebrospinal fluid A beta 40 (between-group mean difference: 1211.95 pg/ml, 95% confidence interval: 313.27, 2110.63) and A beta 42 (49.51 pg/ml, 95% confidence interval: - 98.05, -0.98) reflecting lower brain amyloid accumulation.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 91, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 143, "tag": "ResearchActivity"}, {"end": 232, "start": 213, "tag": "ResearchActivity"}, {"end": 81, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 280, "start": 273, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 273, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 101, "tag": "PopulationGroup"}, {"end": 293, "start": 281, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}]}
{"id": "1491_9", "text": "Candesartan was associated with decreased 1 C-PiB in the parahippocampal region (-0.1104, 95% confidence interval: -0.19, -0.029) which remained significant after false discovery rate correction, and with an increase in functional network connectivity in the subcortical networks.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 279, "start": 271, "tag": "CellFunction"}, {"end": 41, "start": 32, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "Chemical"}, {"end": 270, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 94, "tag": "ResearchActivity"}, {"end": 194, "start": 163, "tag": "ResearchActivity"}, {"end": 251, "start": 220, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1491_10", "text": "Candesartan was further associated with improved executive function (Trail Making Test Part B) performance (-11.41 s, 95% confidence interval: -11.94, -10.89) and trended for an improved global cognitive functioning reflected by a composite cognitive score (0.002, 95% confidence interval: -0.0002, 0.005).", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 67, "start": 49, "tag": "BiologicFunction"}, {"end": 215, "start": 194, "tag": "BiologicFunction"}, {"end": 48, "start": 40, "tag": "Finding"}, {"end": 186, "start": 178, "tag": "Finding"}, {"end": 141, "start": 122, "tag": "ResearchActivity"}, {"end": 288, "start": 269, "tag": "ResearchActivity"}, {"end": 256, "start": 251, "tag": "Finding"}, {"end": 106, "start": 95, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 69, "tag": "HealthCareActivity"}]}
{"id": "1491_11", "text": "We did not observe significant effects on tau levels, hippocampal volume or other cognitive measures (memory or clinical dementia rating scale-sum of boxes).", "tags": [{"end": 155, "start": 112, "tag": "HealthCareActivity"}, {"end": 100, "start": 82, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 31, "tag": "Finding"}, {"end": 108, "start": 102, "tag": "BiologicFunction"}, {"end": 72, "start": 54, "tag": "ClinicalAttribute"}, {"end": 52, "start": 42, "tag": "ClinicalAttribute"}]}
{"id": "1491_12", "text": "In conclusion, among non-hypertensive prodromal Alzheimer's disease, candesartan is safe and likely decreases brain amyloid biomarkers, enhances subcortical brain connectivity and has favourable cognitive effects.", "tags": [{"end": 80, "start": 69, "tag": "Chemical"}, {"end": 67, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 124, "tag": "ClinicalAttribute"}, {"end": 212, "start": 184, "tag": "Finding"}, {"end": 175, "start": 163, "tag": "BiologicFunction"}, {"end": 80, "start": 69, "tag": "PharmacologicSubstance"}]}
{"id": "1491_13", "text": "These findings suggest that candesartan may have an important therapeutic role in Alzheimer's disease, and warrant further investigation given the lack of clear treatment options for this devastating illness.", "tags": [{"end": 39, "start": 28, "tag": "Chemical"}, {"end": 207, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 123, "tag": "ResearchActivity"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "HealthCareActivity"}, {"end": 170, "start": 161, "tag": "ResearchActivity"}, {"end": 39, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 78, "start": 62, "tag": "Finding"}]}
{"id": "1492_0", "text": "IntroductionAlzheimer's disease (AD) is a public health priority.", "tags": [{"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 49, "tag": "HealthCareActivity"}, {"end": 55, "start": 42, "tag": "HealthCareActivity"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}]}
{"id": "1492_1", "text": "AD biomarkers may vary based on race, but the recruitment of diverse participants has been challenging.", "tags": [{"end": 36, "start": 32, "tag": "PopulationGroup"}, {"end": 13, "start": 3, "tag": "ClinicalAttribute"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 69, "tag": "PopulationGroup"}]}
{"id": "1492_2", "text": "MethodsThree groups of Black and White participants with and without prior research advocacy or participation were interviewed individually or in focus groups to better understand perspectives related to AD biomarker research participation.", "tags": [{"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 28, "start": 23, "tag": "PopulationGroup"}, {"end": 158, "start": 146, "tag": "PopulationGroup"}, {"end": 92, "start": 75, "tag": "ResearchActivity"}, {"end": 239, "start": 217, "tag": "ResearchActivity"}, {"end": 206, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 207, "tag": "ClinicalAttribute"}, {"end": 51, "start": 39, "tag": "PopulationGroup"}, {"end": 51, "start": 33, "tag": "PopulationGroup"}, {"end": 109, "start": 96, "tag": "ResearchActivity"}, {"end": 83, "start": 75, "tag": "ResearchActivity"}]}
{"id": "1492_3", "text": "A rapid qualitative data analytic approach was used to analyze the data.", "tags": [{"end": 42, "start": 8, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "ResearchActivity"}]}
{"id": "1492_4", "text": "ResultsIdentified barriers to AD biomarker research participation included hesitancy due to fear, distrust of research and researchers, lack of relevant knowledge, and lack of research test results disclosure.", "tags": [{"end": 84, "start": 75, "tag": "SignOrSymptom"}, {"end": 162, "start": 136, "tag": "Finding"}, {"end": 134, "start": 123, "tag": "ResearchActivity"}, {"end": 65, "start": 43, "tag": "ResearchActivity"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 197, "start": 176, "tag": "ResearchActivity"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}, {"end": 96, "start": 92, "tag": "BiologicFunction"}, {"end": 118, "start": 98, "tag": "Finding"}, {"end": 208, "start": 168, "tag": "Finding"}]}
{"id": "1492_5", "text": "Drivers for engagement in biomarker research procedures included knowledge about research, AD, and related clinical procedures, perceived benefits of participation, and outreach from trusted sources.", "tags": [{"end": 7, "start": 0, "tag": "ManufacturedObject"}, {"end": 7, "start": 0, "tag": "PopulationGroup"}, {"end": 22, "start": 12, "tag": "Finding"}, {"end": 198, "start": 191, "tag": "Finding"}, {"end": 74, "start": 65, "tag": "Finding"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 26, "tag": "ClinicalAttribute"}, {"end": 126, "start": 107, "tag": "HealthCareActivity"}, {"end": 177, "start": 169, "tag": "ResearchActivity"}, {"end": 163, "start": 138, "tag": "Finding"}]}
{"id": "1492_6", "text": "DiscussionParticipants' comments related to the need for diversity in research and desire for results disclosure suggest opportunities to engage Black individuals.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 150, "start": 145, "tag": "PopulationGroup"}, {"end": 78, "start": 70, "tag": "ResearchActivity"}, {"end": 112, "start": 94, "tag": "ResearchActivity"}, {"end": 162, "start": 151, "tag": "PopulationGroup"}]}
{"id": "1492_7", "text": "HighlightsBlack Americans experience more salient barriers to Alzheimer's disease (AD) biomarker research participation.Concerns about research diversity influence research participation decisions.Research test disclosure may affect research participation and retention.", "tags": [{"end": 25, "start": 10, "tag": "PopulationGroup"}, {"end": 36, "start": 26, "tag": "BiologicFunction"}, {"end": 196, "start": 187, "tag": "BiologicFunction"}, {"end": 221, "start": 197, "tag": "ResearchActivity"}, {"end": 119, "start": 97, "tag": "ResearchActivity"}, {"end": 143, "start": 135, "tag": "ResearchActivity"}, {"end": 186, "start": 164, "tag": "ResearchActivity"}, {"end": 255, "start": 233, "tag": "ResearchActivity"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "ClinicalAttribute"}, {"end": 269, "start": 260, "tag": "ResearchActivity"}, {"end": 241, "start": 233, "tag": "ResearchActivity"}]}
{"id": "1493_0", "text": "Introduction Batch differences in cerebrospinal fluid (CSF) biomarker measurement can introduce bias into analyses for Alzheimer's disease studies.", "tags": [{"end": 146, "start": 139, "tag": "ResearchActivity"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 48, "tag": "Substance"}, {"end": 53, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 13, "tag": "Finding"}, {"end": 114, "start": 106, "tag": "ResearchActivity"}]}
{"id": "1493_1", "text": "We evaluated and adjusted for batch differences using statistical methods.", "tags": [{"end": 73, "start": 54, "tag": "ResearchActivity"}, {"end": 47, "start": 30, "tag": "Finding"}]}
{"id": "1493_2", "text": "Methods A total of 792 CSF samples from 528 participants were assayed in three batches for 12 biomarkers and 3 biomarker ratios.", "tags": [{"end": 104, "start": 94, "tag": "ClinicalAttribute"}, {"end": 120, "start": 111, "tag": "ClinicalAttribute"}, {"end": 26, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 44, "tag": "PopulationGroup"}]}
{"id": "1493_3", "text": "Batch differences were assessed using Bland-Altman plot, paired t test, Pitman-Morgan test, and linear regression.", "tags": [{"end": 17, "start": 0, "tag": "Finding"}, {"end": 55, "start": 38, "tag": "ResearchActivity"}, {"end": 70, "start": 57, "tag": "ResearchActivity"}, {"end": 90, "start": 72, "tag": "ResearchActivity"}, {"end": 113, "start": 96, "tag": "ResearchActivity"}]}
{"id": "1493_4", "text": "Generalized linear models were applied to convert CSF values between batches.", "tags": [{"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1493_5", "text": "Results We found statistically significant batch differences for all biomarkers and ratios, except that neurofilament light was comparable between batches 1 and 2.", "tags": [{"end": 79, "start": 69, "tag": "ClinicalAttribute"}, {"end": 123, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 60, "start": 43, "tag": "Finding"}]}
{"id": "1493_6", "text": "The conversion models generally had high R-2 except for converting P-tau between batches 1 and 3.", "tags": [{"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1493_7", "text": "Discussion Between-batch conversion allows harmonized CSF values to be used in the same analysis.", "tags": [{"end": 96, "start": 88, "tag": "ResearchActivity"}, {"end": 57, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 11, "tag": "ResearchActivity"}]}
{"id": "1493_8", "text": "Such method may be applied to adjust for other sources of variability in measuring CSF or other types of biomarkers.", "tags": [{"end": 69, "start": 47, "tag": "Finding"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 115, "start": 105, "tag": "ClinicalAttribute"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1494_0", "text": "Introduction: We aimed to estimate the frequency of each AT(N) (beta-amyloid deposition [A], pathologic tau [T], and neurodegeneration [N]) profile in different clinical diagnosis groups and to describe the longitudinal change in clinical outcomes of individuals in each group.", "tags": [{"end": 186, "start": 180, "tag": "PopulationGroup"}, {"end": 179, "start": 161, "tag": "HealthCareActivity"}, {"end": 76, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 170, "tag": "HealthCareActivity"}, {"end": 134, "start": 117, "tag": "CellOrMolecularDysfunction"}, {"end": 247, "start": 230, "tag": "ClinicalAttribute"}, {"end": 262, "start": 251, "tag": "PopulationGroup"}, {"end": 276, "start": 271, "tag": "PopulationGroup"}, {"end": 226, "start": 207, "tag": "ResearchActivity"}, {"end": 48, "start": 39, "tag": "TemporalConcept"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 57, "tag": "ResearchActivity"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 87, "start": 64, "tag": "PathologicFunction"}]}
{"id": "1494_1", "text": "Methods: Longitudinal change in clinical outcomes and conversion risk of AT(N) profiles are assessed using linear mixed-effects models and multivariate Cox proportional-hazard models, respectively.", "tags": [{"end": 87, "start": 73, "tag": "ResearchActivity"}, {"end": 49, "start": 32, "tag": "ClinicalAttribute"}, {"end": 134, "start": 107, "tag": "ResearchActivity"}, {"end": 182, "start": 139, "tag": "ResearchActivity"}, {"end": 28, "start": 9, "tag": "ResearchActivity"}, {"end": 69, "start": 54, "tag": "ClinicalAttribute"}]}
{"id": "1494_2", "text": "Results: Participants with A+T+N+ showed faster clinical progression than those with A-T-N- and A+T +/- N-.", "tags": [{"end": 68, "start": 48, "tag": "TemporalConcept"}, {"end": 68, "start": 57, "tag": "PathologicFunction"}, {"end": 68, "start": 57, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 21, "start": 9, "tag": "PopulationGroup"}]}
{"id": "1494_3", "text": "Compared with A-T-N-, participants with A+T+N +/- had an increased risk of conversion from cognitively normal (CN) to incident prodromal stage of Alzheimer's disease (AD), and from MCI to AD dementia.", "tags": [{"end": 184, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "Finding"}, {"end": 109, "start": 103, "tag": "Finding"}, {"end": 142, "start": 127, "tag": "TemporalConcept"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 85, "start": 67, "tag": "ClinicalAttribute"}]}
{"id": "1494_4", "text": "A+T +N+ showed an increased conversion risk when compared with A+T +/- N-.", "tags": [{"end": 43, "start": 28, "tag": "ClinicalAttribute"}]}
{"id": "1494_5", "text": "Discussion: The 2018 research framework may provide prognostic information of clinical change and progression.", "tags": [{"end": 109, "start": 98, "tag": "PathologicFunction"}, {"end": 109, "start": 98, "tag": "TemporalConcept"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 93, "start": 78, "tag": "ClinicalAttribute"}]}
{"id": "1494_6", "text": "It may also be useful for targeted recruitment of participants with AD into clinical trials.", "tags": [{"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 76, "tag": "ResearchActivity"}, {"end": 62, "start": 50, "tag": "PopulationGroup"}]}
{"id": "1494_7", "text": "(C) 2019 the Alzheimer's Association.", "tags": [{"end": 36, "start": 13, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1494_8", "text": "Published by Elsevier Inc.", "tags": []}
{"id": "1494_9", "text": "All rights reserved.", "tags": []}
{"id": "1495_0", "text": "Introduction: The accumulation of endogenous formaldehyde is considered a pathogenic factor in Alzheimer's disease (AD).", "tags": [{"end": 57, "start": 45, "tag": "Chemical"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}, {"end": 30, "start": 18, "tag": "Finding"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 45, "tag": "InjuryOrPoisoning"}]}
{"id": "1495_1", "text": "The purpose of this study was to investigate the relationship between urinary formic acid and plasma biomarkers in AD.Materials and methods: Five hundred and seventy-four participants were divided into five groups according to their diagnosis: 71 with normal cognitive (NC), 101 with subjective cognitive decline (SCD), 131 with cognitive impairment without mild cognitive impairment (CINM), 158 with mild cognitive impairment (MCI), and 113 with AD.Results: With the progression of the disease, urinary formic acid levels showed an overall upward trend.", "tags": [{"end": 213, "start": 207, "tag": "PopulationGroup"}, {"end": 389, "start": 385, "tag": "DiseaseOrSyndrome"}, {"end": 431, "start": 428, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 252, "tag": "Finding"}, {"end": 494, "start": 468, "tag": "PathologicFunction"}, {"end": 494, "start": 468, "tag": "TemporalConcept"}, {"end": 61, "start": 49, "tag": "Finding"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 479, "start": 468, "tag": "PathologicFunction"}, {"end": 479, "start": 468, "tag": "TemporalConcept"}, {"end": 242, "start": 233, "tag": "HealthCareActivity"}, {"end": 111, "start": 101, "tag": "ClinicalAttribute"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 449, "start": 447, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 457, "start": 450, "tag": "ResearchActivity"}, {"end": 183, "start": 171, "tag": "PopulationGroup"}, {"end": 349, "start": 329, "tag": "DiseaseOrSyndrome"}, {"end": 383, "start": 363, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 406, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 383, "start": 358, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 401, "tag": "DiseaseOrSyndrome"}, {"end": 522, "start": 496, "tag": "ClinicalAttribute"}, {"end": 515, "start": 504, "tag": "Chemical"}, {"end": 89, "start": 78, "tag": "Chemical"}, {"end": 77, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 503, "start": 496, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1495_2", "text": "Urinary formic acid was significantly correlated with Mini-Mental State Examination (MMSE) scores, the Chinese version of Addenbrooke's Cognitive Examination III (ACE-III) scores, and Montreal Cognitive Assessment-Basic (MoCA-B) time.", "tags": [{"end": 110, "start": 103, "tag": "PopulationGroup"}, {"end": 83, "start": 54, "tag": "HealthCareActivity"}, {"end": 219, "start": 184, "tag": "HealthCareActivity"}, {"end": 227, "start": 221, "tag": "HealthCareActivity"}, {"end": 233, "start": 229, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 8, "tag": "Chemical"}, {"end": 89, "start": 85, "tag": "HealthCareActivity"}, {"end": 161, "start": 122, "tag": "HealthCareActivity"}, {"end": 170, "start": 163, "tag": "HealthCareActivity"}]}
{"id": "1495_3", "text": "The areas under the receiver operating characteristic curves (AUC) of urinary formic acid in distinguishing NC from AD was 0.797, which was similar to that of plasma neurofilament light chain (NfL; AUC = 0.768) and better than other plasma biomarkers (A beta 40, A beta 42, A beta 42/A beta 40, T-tau, P-tau181, and P-tau181/T-tau).", "tags": [{"end": 300, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 330, "start": 325, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 240, "tag": "ClinicalAttribute"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 239, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "ResearchActivity"}, {"end": 201, "start": 198, "tag": "ResearchActivity"}, {"end": 185, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 300, "start": 295, "tag": "BiologicallyActiveSubstance"}, {"end": 330, "start": 325, "tag": "BiologicallyActiveSubstance"}, {"end": 261, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 272, "start": 263, "tag": "AminoAcidPeptideOrProtein"}, {"end": 283, "start": 274, "tag": "AminoAcidPeptideOrProtein"}, {"end": 293, "start": 284, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 4, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 78, "tag": "Chemical"}, {"end": 261, "start": 252, "tag": "BiologicallyActiveSubstance"}, {"end": 272, "start": 263, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 274, "tag": "BiologicallyActiveSubstance"}, {"end": 293, "start": 284, "tag": "BiologicallyActiveSubstance"}, {"end": 310, "start": 302, "tag": "BiologicallyActiveSubstance"}, {"end": 310, "start": 302, "tag": "AminoAcidPeptideOrProtein"}, {"end": 324, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 324, "start": 316, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1495_4", "text": "We also found that using urinary formic acid and formaldehyde levels could improve the accuracy of using plasma biomarkers to determine AD disease stage.Discussion: Our study revealed the possibility of urinary formic acid as a potential novel biomarker for the early diagnosis of AD.", "tags": [{"end": 61, "start": 49, "tag": "Chemical"}, {"end": 277, "start": 262, "tag": "HealthCareActivity"}, {"end": 174, "start": 169, "tag": "ResearchActivity"}, {"end": 277, "start": 268, "tag": "HealthCareActivity"}, {"end": 122, "start": 112, "tag": "ClinicalAttribute"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 253, "start": 244, "tag": "ClinicalAttribute"}, {"end": 152, "start": 139, "tag": "ClinicalAttribute"}, {"end": 152, "start": 139, "tag": "TemporalConcept"}, {"end": 253, "start": 238, "tag": "ClinicalAttribute"}, {"end": 32, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "Chemical"}, {"end": 95, "start": 87, "tag": "Finding"}, {"end": 210, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 211, "tag": "Chemical"}, {"end": 61, "start": 49, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 49, "tag": "PharmacologicSubstance"}]}
{"id": "1496_0", "text": "The identification of biomarkers of Alzheimer's disease (AD) is an important and urgent area of study, not only to aid in the early diagnosis of AD, but also to evaluate potentially new anti-AD drugs.", "tags": [{"end": 141, "start": 126, "tag": "HealthCareActivity"}, {"end": 199, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 96, "tag": "ResearchActivity"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 22, "tag": "ClinicalAttribute"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}]}
{"id": "1496_1", "text": "The aim of this study was to explore cofilin 2 in serum as a novel biomarker for AD.", "tags": [{"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 37, "tag": "GeneOrGenome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 67, "tag": "ClinicalAttribute"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 61, "tag": "ClinicalAttribute"}, {"end": 46, "start": 37, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1496_2", "text": "The upregulation was observed in AD patients and different AD animal models compared to the controls, as well as in AD cell models.", "tags": [{"end": 16, "start": 4, "tag": "CellFunction"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 92, "tag": "PopulationGroup"}, {"end": 75, "start": 59, "tag": "ExperimentalModelOfDisease"}, {"end": 130, "start": 116, "tag": "ExperimentalModelOfDisease"}, {"end": 68, "start": 62, "tag": "Eukaryote"}]}
{"id": "1496_3", "text": "Memantine and donepezil can attenuate the upregulation of cofilin 2 expression in APP/PS1 mice.", "tags": [{"end": 23, "start": 14, "tag": "Chemical"}, {"end": 54, "start": 42, "tag": "CellFunction"}, {"end": 67, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 58, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 82, "tag": "ExperimentalModelOfDisease"}, {"end": 94, "start": 90, "tag": "Eukaryote"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1496_4", "text": "The serum levels of cofilin 2 in AD or mild cognitive impairment (MCI) patients were significantly higher compared to controls (AD: 167.9 +/- 35.3 pg/mL; MCI: 115.9 +/- 15.4 pg/mL; Control: 90.5 +/- 27.1 pg/mL; p < 0.01).", "tags": [{"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 118, "tag": "PopulationGroup"}, {"end": 64, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 4, "tag": "ClinicalAttribute"}]}
{"id": "1496_5", "text": "A significant correlation between cofilin 2 levels and cognitive decline was observed (r = -0.792; p < 0.001).", "tags": [{"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "GeneOrGenome"}, {"end": 72, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1496_6", "text": "The receiver operating characteristic curve (ROC) analysis showed the area under the curve (AUC) of cofilin 2 was 0.957, and the diagnostic accuracy was 80%, with 93% sensitivity and 87% specificity.", "tags": [{"end": 109, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "GeneOrGenome"}, {"end": 198, "start": 187, "tag": "Finding"}, {"end": 58, "start": 4, "tag": "ResearchActivity"}, {"end": 178, "start": 167, "tag": "Finding"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 148, "start": 129, "tag": "Finding"}, {"end": 90, "start": 70, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1496_7", "text": "The optimal cut-off value was 130.4 pg/ml.", "tags": [{"end": 25, "start": 4, "tag": "Finding"}]}
{"id": "1496_8", "text": "Our results indicate the possibility of serum cofilin 2 as a novel and non-invasive biomarker for AD.", "tags": [{"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 45, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 71, "tag": "ClinicalAttribute"}, {"end": 55, "start": 40, "tag": "ClinicalAttribute"}]}
{"id": "1496_9", "text": "In addition, the expression of cofilin 2 was found to be significantly increased in AD compared to vascular dementia (VaD), and only an increased trend but not significant was detected in VaD compared to the controls.", "tags": [{"end": 40, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 31, "tag": "GeneOrGenome"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 208, "tag": "PopulationGroup"}, {"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 31, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1496_10", "text": "ROC analysis between AD and VaD showed that the AUC was 0.824, which could indicate a role of cofilin 2 as a biomarker in the differential diagnosis between AD and VaD.", "tags": [{"end": 103, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 94, "tag": "GeneOrGenome"}, {"end": 148, "start": 139, "tag": "HealthCareActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "ResearchActivity"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 148, "start": 126, "tag": "HealthCareActivity"}, {"end": 103, "start": 94, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1497_0", "text": "INTRODUCTION: Brain cell-derived small extracellular vesicles (sEVs) in blood offer unique cellular and molecular information related to the onset and progression of Alzheimer's disease (AD).", "tags": [{"end": 67, "start": 63, "tag": "CellComponent"}, {"end": 24, "start": 14, "tag": "Cell"}, {"end": 162, "start": 151, "tag": "PathologicFunction"}, {"end": 162, "start": 151, "tag": "TemporalConcept"}, {"end": 61, "start": 39, "tag": "CellComponent"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 33, "tag": "CellComponent"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}]}
{"id": "1497_1", "text": "We simultaneously enriched six specific sEV subtypes from the plasma and analyzed a selected panel of microRNAs (miRNAs) in older adults with/without cognitive impairment.METHODS: Total sEVs were isolated from the plasma of participants with normal cognition (CN; n = 11), mild cognitive impairment (MCI; n = 11), MCI conversion to AD dementia (MCI-AD; n = 6), and AD dementia (n = 11).", "tags": [{"end": 111, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 111, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 186, "tag": "CellComponent"}, {"end": 17, "start": 3, "tag": "TemporalConcept"}, {"end": 136, "start": 124, "tag": "PopulationGroup"}, {"end": 303, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 348, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 258, "start": 242, "tag": "Finding"}, {"end": 262, "start": 260, "tag": "Finding"}, {"end": 248, "start": 242, "tag": "Finding"}, {"end": 334, "start": 332, "tag": "DiseaseOrSyndrome"}, {"end": 351, "start": 349, "tag": "DiseaseOrSyndrome"}, {"end": 367, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 343, "start": 335, "tag": "DiseaseOrSyndrome"}, {"end": 376, "start": 368, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 249, "tag": "BiologicFunction"}, {"end": 129, "start": 124, "tag": "TemporalConcept"}, {"end": 236, "start": 224, "tag": "PopulationGroup"}, {"end": 136, "start": 130, "tag": "PopulationGroup"}, {"end": 170, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 273, "tag": "DiseaseOrSyndrome"}]}
{"id": "1497_2", "text": "Various brain cell-derived sEVs (from neurons, astrocytes, microglia, oligodendrocytes, pericytes, and endothelial cells) were enriched and analyzed for specific miRNAs.RESULTS: miRNAs in sEV subtypes differentially expressed in MCI, MCI-AD, and AD dementia compared to the CN group clearly distinguished dementia status, with an area under the curve (AUC) > 0.90 and correlated with the temporal cortical region thickness on magnetic resonance imaging (MRI).DISCUSSION: miRNA analyses in specific sEVs could serve as a novel blood-based molecular biomarker for AD.Highlights", "tags": [{"end": 320, "start": 314, "tag": "Finding"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 31, "start": 27, "tag": "CellComponent"}, {"end": 502, "start": 498, "tag": "CellComponent"}, {"end": 232, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 70, "tag": "Cell"}, {"end": 97, "start": 88, "tag": "Cell"}, {"end": 120, "start": 103, "tag": "Cell"}, {"end": 18, "start": 8, "tag": "Cell"}, {"end": 422, "start": 388, "tag": "ClinicalAttribute"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 225, "start": 201, "tag": "Finding"}, {"end": 412, "start": 388, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 557, "start": 538, "tag": "ClinicalAttribute"}, {"end": 191, "start": 188, "tag": "CellComponent"}, {"end": 276, "start": 274, "tag": "Finding"}, {"end": 114, "start": 103, "tag": "Cell"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 564, "start": 562, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 162, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 184, "start": 178, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 168, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 531, "start": 526, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 476, "start": 471, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 476, "start": 471, "tag": "BiologicallyActiveSubstance"}, {"end": 557, "start": 548, "tag": "ClinicalAttribute"}, {"end": 257, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 313, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 355, "start": 352, "tag": "ResearchActivity"}, {"end": 225, "start": 216, "tag": "CellFunction"}, {"end": 457, "start": 454, "tag": "HealthCareActivity"}, {"end": 452, "start": 426, "tag": "HealthCareActivity"}, {"end": 452, "start": 445, "tag": "HealthCareActivity"}, {"end": 452, "start": 426, "tag": "ManufacturedObject"}, {"end": 68, "start": 59, "tag": "Cell"}, {"end": 148, "start": 140, "tag": "ResearchActivity"}, {"end": 282, "start": 277, "tag": "PopulationGroup"}, {"end": 350, "start": 330, "tag": "ResearchActivity"}, {"end": 485, "start": 477, "tag": "ResearchActivity"}]}
{"id": "1498_0", "text": "IntroductionLoss of entorhinal cortex (EC) layer II neurons represents the earliest Alzheimer's disease (AD) lesion in the brain.", "tags": [{"end": 59, "start": 52, "tag": "Cell"}, {"end": 51, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 75, "tag": "TemporalConcept"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 109, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 16, "start": 12, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1498_1", "text": "Research suggests differing functional roles between two EC subregions, the anterolateral EC (aLEC) and the posteromedial EC (pMEC).", "tags": [{"end": 70, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 92, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1498_2", "text": "MethodsWe use joint label fusion to obtain aLEC and pMEC cortical thickness measurements from serial magnetic resonance imaging scans of 775 ADNI-1 participants (219 healthy; 380 mild cognitive impairment; 176 AD) and use linear mixed-effects models to analyze longitudinal associations among cortical thickness, disease status, and cognitive measures.", "tags": [{"end": 32, "start": 14, "tag": "HealthCareActivity"}, {"end": 88, "start": 76, "tag": "HealthCareActivity"}, {"end": 133, "start": 101, "tag": "HealthCareActivity"}, {"end": 65, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 293, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 57, "tag": "ClinicalAttribute"}, {"end": 311, "start": 293, "tag": "ClinicalAttribute"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 166, "tag": "OrganismAttribute"}, {"end": 127, "start": 101, "tag": "HealthCareActivity"}, {"end": 127, "start": 120, "tag": "HealthCareActivity"}, {"end": 127, "start": 101, "tag": "ManufacturedObject"}, {"end": 160, "start": 148, "tag": "PopulationGroup"}, {"end": 286, "start": 261, "tag": "ResearchActivity"}, {"end": 204, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 222, "tag": "ResearchActivity"}, {"end": 204, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 327, "start": 313, "tag": "ClinicalAttribute"}, {"end": 351, "start": 333, "tag": "ClinicalAttribute"}]}
{"id": "1498_3", "text": "ResultsGroup status is reliably predicted by aLEC thickness, which also exhibits greater associations with cognitive outcomes than does pMEC thickness.", "tags": [{"end": 150, "start": 136, "tag": "ClinicalAttribute"}, {"end": 59, "start": 45, "tag": "ClinicalAttribute"}, {"end": 125, "start": 107, "tag": "ClinicalAttribute"}]}
{"id": "1498_4", "text": "Change in aLEC thickness is also associated with cerebrospinal fluid amyloid and tau levels.", "tags": [{"end": 6, "start": 0, "tag": "Finding"}, {"end": 24, "start": 10, "tag": "ClinicalAttribute"}, {"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 63, "tag": "Substance"}, {"end": 68, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 81, "tag": "ClinicalAttribute"}]}
{"id": "1498_5", "text": "DiscussionThinning of aLEC is a sensitive structural biomarker that changes over short durations in the course of AD and tracks disease severity-it is a strong candidate biomarker for detection of early AD.", "tags": [{"end": 41, "start": 32, "tag": "PathologicFunction"}, {"end": 127, "start": 121, "tag": "ManufacturedObject"}, {"end": 96, "start": 87, "tag": "TemporalConcept"}, {"end": 144, "start": 128, "tag": "ClinicalAttribute"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 179, "start": 170, "tag": "ClinicalAttribute"}, {"end": 193, "start": 184, "tag": "HealthCareActivity"}, {"end": 144, "start": 128, "tag": "Finding"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 26, "start": 10, "tag": "Finding"}]}
{"id": "1499_0", "text": "Cholecystokinin (CCK) is a satiety hormone that is highly expressed in brain regions like the hippocampus.", "tags": [{"end": 15, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 27, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1499_1", "text": "CCK is integral for maintaining or enhancing memory and thus may be a useful marker of cognitive and neural integrity in participants with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 117, "start": 108, "tag": "IndividualBehavior"}, {"end": 155, "start": 139, "tag": "Finding"}, {"end": 207, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "BiologicFunction"}, {"end": 83, "start": 77, "tag": "ClinicalAttribute"}, {"end": 133, "start": 121, "tag": "PopulationGroup"}, {"end": 182, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 101, "tag": "Finding"}]}
{"id": "1499_2", "text": "Cerebrospinal fluid (CSF) CCK levels were examined in 287 subjects from the Alzheimer's Disease Neuroimaging Initiative.", "tags": [{"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 14, "tag": "Substance"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}, {"end": 36, "start": 26, "tag": "ClinicalAttribute"}, {"end": 119, "start": 76, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1499_3", "text": "Linear or voxelwise regression was used to examine associations between CCK, regional gray matter, CSF AD biomarkers, and cognitive outcomes.", "tags": [{"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 106, "tag": "ClinicalAttribute"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 10, "tag": "ResearchActivity"}, {"end": 30, "start": 20, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 140, "start": 122, "tag": "ClinicalAttribute"}]}
{"id": "1499_4", "text": "Briefly, higher CCK was related to a decreased likelihood of having mild cognitive impairment or AD, better global and memory scores, and more gray matter volume primarily spanning posterior cingulate cortex, parahippocampal gyrus, and medial prefrontal cortex.", "tags": [{"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 236, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 37, "tag": "Finding"}, {"end": 154, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 143, "tag": "ClinicalAttribute"}, {"end": 125, "start": 119, "tag": "BiologicFunction"}]}
{"id": "1499_5", "text": "CSF CCK was also strongly related to higher CSF total tau (R-2 = 0.342) and p-tau-181 (R-2 = 0.256) but not A beta 1-42.", "tags": [{"end": 7, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1499_6", "text": "Tau levels partially mediated CCK and cognition associations.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 38, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1499_7", "text": "In conclusion, CCK levels may reflect compensatory protection as AD pathology progresses.", "tags": [{"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 77, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 15, "tag": "ClinicalAttribute"}]}
{"id": "1499_8", "text": "(C) 2019 Elsevier Inc.", "tags": []}
{"id": "1499_9", "text": "All rights reserved.", "tags": []}
{"id": "1500_0", "text": "Objective To determine whether the Alzheimer disease (AD) dementia conversion-related pattern (ADCRP) on [F-18]FDG PET can serve as a valid predictor for the development of AD dementia, the individual expression of the ADCRP (subject score) and its prognostic value were examined in patients with mild cognitive impairment (MCI) and biologically defined AD.", "tags": [{"end": 52, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 356, "start": 354, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 283, "tag": "PatientOrDisabledGroup"}, {"end": 169, "start": 158, "tag": "BiologicFunction"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 66, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 324, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 190, "tag": "PopulationGroup"}, {"end": 200, "start": 190, "tag": "OrganismAttribute"}, {"end": 118, "start": 105, "tag": "HealthCareActivity"}, {"end": 322, "start": 297, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 67, "tag": "Finding"}, {"end": 265, "start": 249, "tag": "Finding"}, {"end": 93, "start": 35, "tag": "ClinicalAttribute"}, {"end": 100, "start": 95, "tag": "ClinicalAttribute"}, {"end": 240, "start": 219, "tag": "ClinicalAttribute"}, {"end": 224, "start": 186, "tag": "ClinicalAttribute"}]}
{"id": "1500_1", "text": "Methods A total of 269 patients with available [F-18]FDG PET, [F-18]AV-45 PET, phosphorylated and total tau in CSF, and neurofilament light chain in plasma were included.", "tags": [{"end": 139, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 79, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 77, "start": 62, "tag": "HealthCareActivity"}, {"end": 145, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 120, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1500_2", "text": "Following the AT(N) classification scheme, where AD is defined biologically by in vivo biomarkers of beta-amyloid (A beta) deposition (A) and pathologic tau (T), patients were categorized to the A-T-, A+T-, A+T+ (AD), and A-T+ groups.", "tags": [{"end": 133, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 142, "tag": "CellOrMolecularDysfunction"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 87, "tag": "ClinicalAttribute"}, {"end": 233, "start": 227, "tag": "PopulationGroup"}, {"end": 121, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 41, "start": 14, "tag": "HealthCareActivity"}]}
{"id": "1500_3", "text": "Results The mean subject score of the ADCRP was significantly higher in the A+T+ group compared to each of the other group (all p < 0.05) but was similar among the latter (all p > 0.1).", "tags": [{"end": 30, "start": 12, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "PopulationGroup"}, {"end": 122, "start": 117, "tag": "PopulationGroup"}, {"end": 43, "start": 38, "tag": "ClinicalAttribute"}]}
{"id": "1500_4", "text": "Within the A+T+ group, the subject score of ADCRP was a significant predictor of conversion to dementia (hazard ratio, 2.02 per z score increase; p < 0.001), with higher predictive value than of alternative biomarkers of neurodegeneration (total tau and neurofilament light chain).", "tags": [{"end": 186, "start": 170, "tag": "Finding"}, {"end": 273, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 240, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 240, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 130, "tag": "Finding"}, {"end": 103, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 207, "tag": "ClinicalAttribute"}, {"end": 21, "start": 16, "tag": "PopulationGroup"}, {"end": 238, "start": 221, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 81, "tag": "Finding"}, {"end": 279, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 279, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 27, "tag": "ClinicalAttribute"}]}
{"id": "1500_5", "text": "Stratification of A+T+ patients by the subject score of ADCRP yielded well-separated groups of high, medium, and low conversion risks.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 107, "start": 101, "tag": "Substance"}, {"end": 107, "start": 101, "tag": "Finding"}, {"end": 116, "start": 113, "tag": "Finding"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 91, "start": 85, "tag": "PopulationGroup"}, {"end": 133, "start": 117, "tag": "Finding"}, {"end": 99, "start": 95, "tag": "Finding"}, {"end": 61, "start": 39, "tag": "ClinicalAttribute"}]}
{"id": "1500_6", "text": "Conclusions The ADCRP is a valuable biomarker of neurodegeneration in patients with MCI and biologically defined AD.", "tags": [{"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 36, "tag": "ClinicalAttribute"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 16, "tag": "ClinicalAttribute"}]}
{"id": "1500_7", "text": "It shows great potential for stratifying the risk and estimating the time to conversion to dementia in patients with MCI and underlying AD (A+T+).", "tags": [{"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 99, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 87, "start": 77, "tag": "Finding"}, {"end": 49, "start": 45, "tag": "Finding"}]}
{"id": "1500_8", "text": "Classification of Evidence This study provides Class I evidence that [F-18]FDG PET predicts the development of AD dementia in individuals with MCI and underlying AD as defined by the AT(N) framework.", "tags": [{"end": 54, "start": 47, "tag": "Finding"}, {"end": 54, "start": 47, "tag": "GeneOrGenome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 126, "tag": "PopulationGroup"}, {"end": 107, "start": 96, "tag": "BiologicFunction"}, {"end": 107, "start": 96, "tag": "CellFunction"}, {"end": 122, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 32, "tag": "ResearchActivity"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 55, "tag": "Finding"}, {"end": 82, "start": 69, "tag": "HealthCareActivity"}, {"end": 198, "start": 183, "tag": "HealthCareActivity"}, {"end": 26, "start": 18, "tag": "Finding"}]}
{"id": "1501_0", "text": "Objective This study was mainly conducted to explore the expression changes of GSDMD and conventional markers (including T-Tau, Tau181p, and A beta(1-42)) in the cerebrospinal fluid among patients with Alzheimer's disease (AD) and vascular dementia (VD), followed by determination of role of GSDMD in diagnosing and identifying AD and VD.", "tags": [{"end": 84, "start": 79, "tag": "GeneOrGenome"}, {"end": 101, "start": 89, "tag": "HealthCareActivity"}, {"end": 297, "start": 292, "tag": "GeneOrGenome"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 337, "start": 335, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 311, "start": 301, "tag": "HealthCareActivity"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 330, "start": 328, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 153, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 102, "tag": "ClinicalAttribute"}, {"end": 135, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 292, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 292, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1501_1", "text": "Methods In this study, 60 patients with VD, 60 patients with AD, and 50 healthy controls were enrolled.", "tags": [{"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 72, "tag": "OrganismAttribute"}, {"end": 88, "start": 72, "tag": "PopulationGroup"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}]}
{"id": "1501_2", "text": "Lumbar puncture was performed to collect cerebrospinal fluid samples.", "tags": [{"end": 15, "start": 0, "tag": "HealthCareActivity"}, {"end": 60, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "Substance"}]}
{"id": "1501_3", "text": "Patients with VD and patients with AD were evaluated using the Mini-Mental State Examination (MMSE) scale, Montreal Cognitive Assessment (MoCA) scale, Clinical Dementia Rating (CDR) scale, Activity of Daily Living (ADL) scale, and Neuropsychiatric Inventory (NPI) questionnaire, aiming to determine the behavioral ability of patients.", "tags": [{"end": 225, "start": 220, "tag": "HealthCareActivity"}, {"end": 213, "start": 189, "tag": "HealthCareActivity"}, {"end": 142, "start": 138, "tag": "HealthCareActivity"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 94, "tag": "HealthCareActivity"}, {"end": 321, "start": 314, "tag": "OrganismAttribute"}, {"end": 149, "start": 144, "tag": "HealthCareActivity"}, {"end": 136, "start": 107, "tag": "HealthCareActivity"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 333, "start": 325, "tag": "PatientOrDisabledGroup"}, {"end": 105, "start": 100, "tag": "HealthCareActivity"}, {"end": 92, "start": 63, "tag": "HealthCareActivity"}, {"end": 187, "start": 182, "tag": "HealthCareActivity"}, {"end": 175, "start": 151, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 180, "start": 177, "tag": "HealthCareActivity"}, {"end": 277, "start": 264, "tag": "HealthCareActivity"}, {"end": 257, "start": 231, "tag": "HealthCareActivity"}]}
{"id": "1501_4", "text": "ELISA kit was purchased to determine the levels of GSDMD, T-Tau, Tau181p, and A beta(1-42) in cerebrospinal fluid, and the expression of inflammatory factors, IL-1 beta and IL-6, was also detected.", "tags": [{"end": 56, "start": 51, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 173, "tag": "GeneOrGenome"}, {"end": 177, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 78, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1501_5", "text": "Results (1) The levels of GSDMD, T-Tau, and Tau181p in the cerebrospinal fluid were higher in patients with AD than those of patients with VD and healthy controls, while the levels of A beta(1-42) in the cerebrospinal fluid were lower in patients with AD than that in healthy controls and patients with VD.", "tags": [{"end": 31, "start": 26, "tag": "GeneOrGenome"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 303, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 246, "start": 238, "tag": "PatientOrDisabledGroup"}, {"end": 297, "start": 289, "tag": "PatientOrDisabledGroup"}, {"end": 162, "start": 146, "tag": "PopulationGroup"}, {"end": 284, "start": 268, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 196, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1501_6", "text": "(2) GSDMD had good diagnostic accuracy in AD.", "tags": [{"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 38, "start": 19, "tag": "Finding"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1501_7", "text": "Additionally, GSDMD, T-Tau, Tau181p, and A beta(1-42) had good discrimination accuracy in distinguishing AD and VD.", "tags": [{"end": 19, "start": 14, "tag": "GeneOrGenome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 63, "tag": "Finding"}, {"end": 53, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 41, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1501_8", "text": "(3) The expression levels of inflammatory factors (IL-1 beta and IL-6) in cerebrospinal fluid were higher in patients with AD than those of healthy controls and patients with VD, which were positively correlated with GSDMD expression.", "tags": [{"end": 222, "start": 217, "tag": "GeneOrGenome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 109, "tag": "PatientOrDisabledGroup"}, {"end": 169, "start": 161, "tag": "PatientOrDisabledGroup"}, {"end": 156, "start": 140, "tag": "PopulationGroup"}, {"end": 222, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 233, "start": 223, "tag": "CellFunction"}, {"end": 18, "start": 8, "tag": "CellFunction"}]}
{"id": "1501_9", "text": "Conclusion The expression of GSDMD was increased in patients with AD, which could be used as a biomarker for AD diagnosis and identification from VD.", "tags": [{"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 95, "tag": "ClinicalAttribute"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 112, "tag": "HealthCareActivity"}, {"end": 25, "start": 15, "tag": "CellFunction"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1502_0", "text": "Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD).", "tags": [{"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 108, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 12, "tag": "Finding"}]}
{"id": "1502_1", "text": "These associations are often observed only in the later stages of decline.", "tags": [{"end": 62, "start": 56, "tag": "TemporalConcept"}, {"end": 55, "start": 50, "tag": "TemporalConcept"}]}
{"id": "1502_2", "text": "This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD.", "tags": [{"end": 134, "start": 128, "tag": "Finding"}, {"end": 236, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 128, "tag": "PopulationGroup"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 46, "tag": "ResearchActivity"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}, {"end": 169, "start": 157, "tag": "PopulationGroup"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 134, "start": 116, "tag": "Finding"}, {"end": 249, "start": 244, "tag": "TemporalConcept"}, {"end": 199, "start": 190, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 23, "tag": "ClinicalAttribute"}, {"end": 93, "start": 69, "tag": "Finding"}]}
{"id": "1502_3", "text": "A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS-13) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores.", "tags": [{"end": 199, "start": 163, "tag": "HealthCareActivity"}, {"end": 158, "start": 154, "tag": "HealthCareActivity"}, {"end": 59, "start": 16, "tag": "ResearchActivity"}, {"end": 59, "start": 16, "tag": "HealthCareRelatedOrganization"}, {"end": 267, "start": 261, "tag": "Finding"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 60, "tag": "PopulationGroup"}, {"end": 35, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 214, "tag": "HealthCareActivity"}, {"end": 259, "start": 253, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "PopulationGroup"}, {"end": 208, "start": 201, "tag": "HealthCareActivity"}]}
{"id": "1502_4", "text": "In a sub-analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD-; 390).", "tags": [{"end": 166, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 67, "tag": "HealthCareActivity"}, {"end": 50, "start": 44, "tag": "Finding"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 43, "start": 37, "tag": "BiologicFunction"}, {"end": 107, "start": 102, "tag": "HealthCareActivity"}]}
{"id": "1502_5", "text": "Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD.", "tags": [{"end": 110, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 69, "tag": "BiologicFunction"}, {"end": 65, "start": 46, "tag": "ClinicalAttribute"}, {"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 93, "start": 82, "tag": "TemporalConcept"}]}
{"id": "1502_6", "text": "Lower global cognition, as measured by increased ADAS-13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01).", "tags": [{"end": 152, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "BiologicFunction"}, {"end": 101, "start": 99, "tag": "PopulationGroup"}, {"end": 97, "start": 78, "tag": "ClinicalAttribute"}, {"end": 56, "start": 49, "tag": "HealthCareActivity"}]}
{"id": "1502_7", "text": "Lower global cognition as measured increased CDR-SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001).", "tags": [{"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "HealthCareActivity"}, {"end": 91, "start": 72, "tag": "ClinicalAttribute"}]}
{"id": "1502_8", "text": "Lower RAVLT performance was associated with hippocampal grading in SCD- (p < .05) and SCD+ (p < .05).", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 12, "tag": "Finding"}, {"end": 11, "start": 6, "tag": "HealthCareActivity"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}
{"id": "1502_9", "text": "These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD.", "tags": [{"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 74, "tag": "BiologicFunction"}, {"end": 89, "start": 87, "tag": "PopulationGroup"}, {"end": 47, "start": 28, "tag": "ClinicalAttribute"}]}
{"id": "1502_10", "text": "Early changes in episodic memory during pre-clinical AD are associated with changes in hippocampal grading.", "tags": [{"end": 32, "start": 17, "tag": "BiologicFunction"}, {"end": 52, "start": 40, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 6, "tag": "Finding"}, {"end": 106, "start": 87, "tag": "ClinicalAttribute"}]}
{"id": "1502_11", "text": "Hippocampal grading may be sensitive to progressive changes early in the disease course.", "tags": [{"end": 36, "start": 27, "tag": "PathologicFunction"}, {"end": 87, "start": 73, "tag": "TemporalConcept"}, {"end": 51, "start": 40, "tag": "TemporalConcept"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1503_0", "text": "Introduction Synaptic degeneration is a key part of the pathophysiology of neurodegenerative diseases, and biomarkers reflecting the pathological alterations are greatly needed.", "tags": [{"end": 34, "start": 13, "tag": "PathologicFunction"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 107, "tag": "ClinicalAttribute"}, {"end": 71, "start": 56, "tag": "PathologicFunction"}, {"end": 71, "start": 56, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 157, "start": 133, "tag": "PathologicFunction"}]}
{"id": "1503_1", "text": "Method Seventeen synaptic proteins were quantified in a pathology-confirmed cerebrospinal fluid cohort of patients with Alzheimer's disease (AD; n = 63), frontotemporal lobar degeneration (FTLD; n = 53), and Lewy body spectrum of disorders (LBD; n = 21), as well as healthy controls (HC; n = 48).", "tags": [{"end": 187, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 286, "start": 284, "tag": "PopulationGroup"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 282, "start": 266, "tag": "PopulationGroup"}, {"end": 65, "start": 56, "tag": "PathologicFunction"}, {"end": 65, "start": 56, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 102, "start": 96, "tag": "PopulationGroup"}, {"end": 239, "start": 208, "tag": "DiseaseOrSyndrome"}]}
{"id": "1503_2", "text": "Results Comparisons revealed four distinct patterns: markers decreased across all neurodegenerative conditions compared to HC (the neuronal pentraxins), markers increased across all neurodegenerative conditions (14-3-3 zeta/delta), markers selectively increased in AD compared to other neurodegenerative conditions (neurogranin and beta-synuclein), and markers selectively decreased in LBD and FTLD compared to HC and AD (AP2B1 and syntaxin-1B).", "tags": [{"end": 389, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 398, "start": 394, "tag": "DiseaseOrSyndrome"}, {"end": 427, "start": 422, "tag": "GeneOrGenome"}, {"end": 427, "start": 422, "tag": "AminoAcidPeptideOrProtein"}, {"end": 443, "start": 432, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 346, "start": 332, "tag": "AminoAcidPeptideOrProtein"}, {"end": 327, "start": 316, "tag": "AminoAcidPeptideOrProtein"}, {"end": 327, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 346, "start": 337, "tag": "AminoAcidPeptideOrProtein"}, {"end": 346, "start": 337, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 123, "tag": "PopulationGroup"}, {"end": 413, "start": 411, "tag": "PopulationGroup"}, {"end": 267, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 420, "start": 418, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 60, "start": 53, "tag": "ClinicalAttribute"}, {"end": 160, "start": 153, "tag": "ClinicalAttribute"}, {"end": 239, "start": 232, "tag": "ClinicalAttribute"}, {"end": 360, "start": 353, "tag": "ClinicalAttribute"}, {"end": 19, "start": 8, "tag": "ResearchActivity"}, {"end": 150, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 427, "start": 422, "tag": "BiologicallyActiveSubstance"}, {"end": 443, "start": 432, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 212, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1503_3", "text": "Discussion Several of the synaptic proteins may serve as biomarkers for synaptic dysfunction in AD, LBD, and FTLD.", "tags": [{"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}]}
{"id": "1503_4", "text": "Additionally, differential patterns of synaptic protein alterations seem to be present across neurodegenerative diseases.", "tags": [{"end": 120, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 56, "tag": "Finding"}]}
{"id": "1503_5", "text": "Highlights A panel of synaptic proteins were quantified in the cerebrospinal fluid using mass spectrometry.", "tags": [{"end": 39, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 89, "tag": "ResearchActivity"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1503_6", "text": "We compared Alzheimer's disease, frontotemporal degeneration, and Lewy body spectrum of disorders.", "tags": [{"end": 60, "start": 33, "tag": "PathologicFunction"}, {"end": 60, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}]}
{"id": "1503_7", "text": "Pathology was confirmed by autopsy or familial mutations.", "tags": [{"end": 9, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 9, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 27, "tag": "HealthCareActivity"}, {"end": 46, "start": 38, "tag": "PopulationGroup"}, {"end": 56, "start": 47, "tag": "CellFunction"}, {"end": 56, "start": 47, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1503_8", "text": "We discovered synaptic biomarkers for synaptic degeneration and cognitive decline.", "tags": [{"end": 59, "start": 38, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 14, "tag": "ClinicalAttribute"}, {"end": 81, "start": 64, "tag": "DiseaseOrSyndrome"}]}
{"id": "1503_9", "text": "We found differential patterns of synaptic proteins across neurodegenerative diseases.", "tags": [{"end": 51, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}]}
{"id": "1504_0", "text": "Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide.", "tags": [{"end": 68, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 91, "tag": "PopulationGroup"}]}
{"id": "1504_1", "text": "Progressive and relentless efforts are being made for therapeutic development by way of advancing understanding of non-invasive imaging modalities for the causal molecular process of AD.", "tags": [{"end": 77, "start": 54, "tag": "ResearchActivity"}, {"end": 111, "start": 98, "tag": "BiologicFunction"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 115, "tag": "HealthCareActivity"}, {"end": 77, "start": 66, "tag": "BiologicFunction"}, {"end": 77, "start": 66, "tag": "CellFunction"}]}
{"id": "1504_2", "text": "We present a Hadoop-based big data framework integrating non-invasive magnetic resonance imaging (MRI), MR spectroscopy (MRS) as well as neuropsychological test outcomes to identify early diagnostic biomarkers of AD.", "tags": [{"end": 119, "start": 104, "tag": "HealthCareActivity"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}, {"end": 169, "start": 137, "tag": "HealthCareActivity"}, {"end": 209, "start": 188, "tag": "ClinicalAttribute"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 13, "tag": "ResearchActivity"}, {"end": 101, "start": 98, "tag": "HealthCareActivity"}, {"end": 96, "start": 70, "tag": "HealthCareActivity"}, {"end": 96, "start": 89, "tag": "HealthCareActivity"}, {"end": 96, "start": 70, "tag": "ManufacturedObject"}]}
{"id": "1504_3", "text": "This big data framework for AD incorporates the three Vs (volume, variety, velocity) with advanced data mining, machine learning, and statistical modeling algorithms.", "tags": [{"end": 165, "start": 134, "tag": "ResearchActivity"}, {"end": 128, "start": 112, "tag": "MachineActivity"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 5, "tag": "ResearchActivity"}, {"end": 110, "start": 90, "tag": "ResearchActivity"}, {"end": 128, "start": 120, "tag": "BiologicFunction"}, {"end": 84, "start": 44, "tag": "ResearchActivity"}]}
{"id": "1504_4", "text": "A large volume of longitudinal information from non-invasive imaging modalities with colligated parametric variety and speed for both data acquisition and processing as velocity complete the fundamental requirements of this big data framework for early AD diagnosis.", "tags": [{"end": 265, "start": 256, "tag": "HealthCareActivity"}, {"end": 255, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 134, "tag": "ResearchActivity"}, {"end": 242, "start": 224, "tag": "ResearchActivity"}, {"end": 68, "start": 48, "tag": "HealthCareActivity"}, {"end": 42, "start": 18, "tag": "ResearchActivity"}, {"end": 165, "start": 155, "tag": "ResearchActivity"}, {"end": 138, "start": 134, "tag": "ResearchActivity"}, {"end": 114, "start": 85, "tag": "ResearchActivity"}]}
{"id": "1504_5", "text": "Brain structural, neurochemical, and behavioral features are extracted from MRI, MRS, and neuropsychological scores, respectively.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 76, "tag": "HealthCareActivity"}, {"end": 84, "start": 81, "tag": "HealthCareActivity"}, {"end": 115, "start": 90, "tag": "HealthCareActivity"}]}
{"id": "1504_6", "text": "Subsequently, feature selection and ensemble-based classification are proposed and their outputs are fused based on the combination rule for final accurate classification and validation from clinicians.", "tags": [{"end": 185, "start": 175, "tag": "ResearchActivity"}, {"end": 201, "start": 191, "tag": "HealthCareActivity"}, {"end": 65, "start": 36, "tag": "HealthCareActivity"}]}
{"id": "1504_7", "text": "A multi-modality-based decision framework (BHARAT) for classification of early AD will be immensely helpful.", "tags": [{"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 2, "tag": "HealthCareActivity"}, {"end": 49, "start": 43, "tag": "HealthCareActivity"}]}
{"id": "1505_0", "text": "We aimed to evaluate the value of ATN biomarker classification system (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) for predicting conversion from mild cognitive impairment (MCI) to dementia.", "tags": [{"end": 99, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 103, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 113, "tag": "CellOrMolecularDysfunction"}, {"end": 171, "start": 167, "tag": "Finding"}, {"end": 83, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 151, "tag": "Finding"}, {"end": 69, "start": 34, "tag": "HealthCareActivity"}, {"end": 47, "start": 34, "tag": "ClinicalAttribute"}]}
{"id": "1505_1", "text": "In a sample of people with MCI (n = 415) we assessed predictive performance of ATN classification using empirical knowledge-based cut-offs for each component of ATN and compared it to two data-driven approaches, logistic regression and RUSBoost machine learning classifiers, which used continuous clinical or biomarker scores.", "tags": [{"end": 164, "start": 161, "tag": "HealthCareActivity"}, {"end": 231, "start": 212, "tag": "ResearchActivity"}, {"end": 123, "start": 114, "tag": "Finding"}, {"end": 273, "start": 236, "tag": "MachineActivity"}, {"end": 325, "start": 319, "tag": "Finding"}, {"end": 296, "start": 286, "tag": "TemporalConcept"}, {"end": 318, "start": 309, "tag": "ClinicalAttribute"}, {"end": 210, "start": 188, "tag": "ResearchActivity"}, {"end": 30, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 64, "tag": "Finding"}, {"end": 21, "start": 15, "tag": "PopulationGroup"}, {"end": 11, "start": 5, "tag": "Substance"}, {"end": 11, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 79, "tag": "HealthCareActivity"}, {"end": 138, "start": 104, "tag": "ResearchActivity"}]}
{"id": "1505_2", "text": "In data-driven approaches, we identified ATN features that distinguish normals from individuals with dementia and used them to classify persons with MCI into dementia-like and normal groups.", "tags": [{"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 143, "start": 136, "tag": "PopulationGroup"}, {"end": 182, "start": 176, "tag": "Finding"}, {"end": 25, "start": 3, "tag": "ResearchActivity"}, {"end": 95, "start": 84, "tag": "PopulationGroup"}, {"end": 109, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 183, "tag": "PopulationGroup"}]}
{"id": "1505_3", "text": "Both data-driven classification methods performed better than the empirical cut-offs for ATN biomarkers in predicting conversion to dementia.", "tags": [{"end": 39, "start": 5, "tag": "ResearchActivity"}, {"end": 140, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 89, "tag": "ClinicalAttribute"}, {"end": 128, "start": 118, "tag": "Finding"}, {"end": 84, "start": 66, "tag": "ResearchActivity"}]}
{"id": "1505_4", "text": "Classifiers that used clinical features performed as well as classifiers that used ATN biomarkers for prediction of progression to dementia.", "tags": [{"end": 39, "start": 22, "tag": "ClinicalAttribute"}, {"end": 139, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 83, "tag": "ClinicalAttribute"}, {"end": 127, "start": 116, "tag": "PathologicFunction"}, {"end": 127, "start": 116, "tag": "TemporalConcept"}, {"end": 112, "start": 102, "tag": "Finding"}, {"end": 72, "start": 61, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1505_5", "text": "We discuss that data-driven modeling approaches can improve our ability to predict disease progression and might have implications in future clinical trials.", "tags": [{"end": 47, "start": 28, "tag": "ResearchActivity"}, {"end": 156, "start": 141, "tag": "ResearchActivity"}, {"end": 71, "start": 64, "tag": "OrganismAttribute"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 102, "start": 91, "tag": "PathologicFunction"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 102, "start": 83, "tag": "PathologicFunction"}, {"end": 140, "start": 134, "tag": "TemporalConcept"}]}
{"id": "1506_0", "text": "Red blood cells (RBCs) are characterized by a remarkable elasticity, which allows them to undergo very large deformation when passing through small vessels and capillaries.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 21, "start": 17, "tag": "Cell"}, {"end": 67, "start": 57, "tag": "NaturalPhenomenonOrProcess"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}, {"end": 171, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1506_1", "text": "This extreme deformability is altered in various clinical conditions, suggesting that the analysis of red blood cell (RBC) mechanics has potential applications in the search for non-invasive and cost-effective blood biomarkers.", "tags": [{"end": 26, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 116, "start": 102, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "Cell"}, {"end": 132, "start": 123, "tag": "NaturalPhenomenonOrProcess"}, {"end": 132, "start": 123, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 147, "tag": "HealthCareActivity"}, {"end": 173, "start": 167, "tag": "ResearchActivity"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 190, "start": 178, "tag": "ClinicalAttribute"}, {"end": 116, "start": 106, "tag": "Cell"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 209, "start": 195, "tag": "ClinicalAttribute"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 216, "tag": "ClinicalAttribute"}, {"end": 215, "start": 210, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}]}
{"id": "1506_2", "text": "Here, we provide a comparative study of the mechanical response of RBCs in patients with Alzheimer's disease (AD) and healthy subjects.", "tags": [{"end": 36, "start": 19, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "Cell"}, {"end": 134, "start": 118, "tag": "PopulationGroup"}, {"end": 108, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 118, "tag": "OrganismAttribute"}, {"end": 134, "start": 126, "tag": "PopulationGroup"}, {"end": 63, "start": 55, "tag": "OrganismAttribute"}]}
{"id": "1506_3", "text": "For this purpose, RBC viscoelastic response was investigated using atomic force microscopy (AFM) in the force spectroscopy mode.", "tags": [{"end": 21, "start": 18, "tag": "Cell"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}, {"end": 95, "start": 92, "tag": "ManufacturedObject"}, {"end": 90, "start": 67, "tag": "ResearchActivity"}, {"end": 43, "start": 22, "tag": "Finding"}, {"end": 127, "start": 104, "tag": "ResearchActivity"}, {"end": 60, "start": 48, "tag": "HealthCareActivity"}, {"end": 43, "start": 35, "tag": "OrganismAttribute"}]}
{"id": "1506_4", "text": "Two types of analyses were performed: (i) a conventional analysis of AFM force-distance (FD) curves, which allowed us to retrieve the apparent Young's modulus, E; and (ii) a more in-depth analysis of time-dependent relaxation curves in the framework of the standard linear solid (SLS) model, which allowed us to estimate cell viscosity and elasticity, independently.", "tags": [{"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ManufacturedObject"}, {"end": 335, "start": 326, "tag": "NaturalPhenomenonOrProcess"}, {"end": 350, "start": 340, "tag": "NaturalPhenomenonOrProcess"}, {"end": 350, "start": 340, "tag": "ClinicalAttribute"}, {"end": 290, "start": 257, "tag": "ResearchActivity"}, {"end": 65, "start": 44, "tag": "ResearchActivity"}, {"end": 99, "start": 73, "tag": "ResearchActivity"}, {"end": 158, "start": 143, "tag": "ResearchActivity"}, {"end": 232, "start": 215, "tag": "ResearchActivity"}, {"end": 325, "start": 321, "tag": "Cell"}, {"end": 214, "start": 205, "tag": "Finding"}, {"end": 204, "start": 200, "tag": "TemporalConcept"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 196, "start": 188, "tag": "ResearchActivity"}]}
{"id": "1506_5", "text": "Our data demonstrate that, while conventional analysis of AFM FD curves fails in distinguishing the two groups, the mechanical parameters obtained with the SLS model show a very good classification ability.", "tags": [{"end": 61, "start": 58, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "ManufacturedObject"}, {"end": 165, "start": 156, "tag": "ResearchActivity"}, {"end": 54, "start": 33, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "ResearchActivity"}, {"end": 205, "start": 198, "tag": "OrganismAttribute"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "PopulationGroup"}, {"end": 54, "start": 46, "tag": "ResearchActivity"}]}
{"id": "1506_6", "text": "The diagnostic performance of mechanical parameters was assessed using receiving operator characteristic (ROC) curves, showing very large areas under the curves (AUC) for selected biomarkers (AUC > 0.9).", "tags": [{"end": 117, "start": 72, "tag": "ResearchActivity"}, {"end": 160, "start": 138, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 180, "tag": "ClinicalAttribute"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 165, "start": 162, "tag": "ResearchActivity"}, {"end": 195, "start": 192, "tag": "ResearchActivity"}]}
{"id": "1506_7", "text": "Taken all together, the data presented here demonstrate that RBC mechanics are significantly altered in AD, also highlighting the key role played by viscous forces.", "tags": [{"end": 64, "start": 61, "tag": "Cell"}, {"end": 74, "start": 65, "tag": "NaturalPhenomenonOrProcess"}, {"end": 74, "start": 65, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 24, "tag": "ResearchActivity"}]}
{"id": "1506_8", "text": "These RBC abnormalities in AD, which include both a modified elasticity and viscosity, could be considered a potential source of plasmatic biomarkers in the field of liquid biopsy to be used in combination with more established indicators of the pathology.", "tags": [{"end": 9, "start": 6, "tag": "Cell"}, {"end": 71, "start": 61, "tag": "NaturalPhenomenonOrProcess"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 85, "start": 76, "tag": "NaturalPhenomenonOrProcess"}, {"end": 149, "start": 129, "tag": "ClinicalAttribute"}, {"end": 179, "start": 166, "tag": "HealthCareActivity"}, {"end": 23, "start": 6, "tag": "CellOrMolecularDysfunction"}, {"end": 238, "start": 228, "tag": "Chemical"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "ClinicalAttribute"}, {"end": 255, "start": 246, "tag": "PathologicFunction"}, {"end": 255, "start": 246, "tag": "BiomedicalOccupationOrDiscipline"}]}
{"id": "1507_0", "text": "Introduction: We examined factors related to willingness to enroll in hypothetical Alzheimer disease (AD) biomarker studies.", "tags": [{"end": 100, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 45, "tag": "BiologicFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 123, "start": 116, "tag": "ResearchActivity"}]}
{"id": "1507_1", "text": "Methods: Using linear regression, we assessed the relationship among enrollment willingness and demographics, family dementia history, research attitudes, concern about AD, experiences of discrimination, and belief in AD risk modifiability.", "tags": [{"end": 91, "start": 69, "tag": "Finding"}, {"end": 133, "start": 110, "tag": "Finding"}, {"end": 184, "start": 173, "tag": "BiologicFunction"}, {"end": 202, "start": 188, "tag": "BiologicFunction"}, {"end": 214, "start": 208, "tag": "BiologicFunction"}, {"end": 153, "start": 135, "tag": "ResearchActivity"}, {"end": 239, "start": 221, "tag": "Finding"}, {"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 91, "start": 80, "tag": "BiologicFunction"}, {"end": 133, "start": 126, "tag": "Finding"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 135, "tag": "ResearchActivity"}, {"end": 125, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "HealthCareActivity"}, {"end": 62, "start": 50, "tag": "Finding"}]}
{"id": "1507_2", "text": "Inductive coding was used to assess qualitative data.", "tags": [{"end": 52, "start": 36, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 52, "start": 48, "tag": "ResearchActivity"}]}
{"id": "1507_3", "text": "Results: In middle-aged and older adult AD research participants ( n = 334), willingness to enroll in biomarker studies was driven by biomarker collection method, research attitudes, and disclosure of personal results.", "tags": [{"end": 23, "start": 12, "tag": "PopulationGroup"}, {"end": 39, "start": 28, "tag": "PopulationGroup"}, {"end": 39, "start": 34, "tag": "PopulationGroup"}, {"end": 181, "start": 163, "tag": "ResearchActivity"}, {"end": 98, "start": 77, "tag": "Finding"}, {"end": 197, "start": 187, "tag": "IndividualBehavior"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 209, "start": 201, "tag": "OrganismAttribute"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 143, "start": 134, "tag": "ClinicalAttribute"}, {"end": 161, "start": 155, "tag": "ResearchActivity"}, {"end": 161, "start": 155, "tag": "HealthCareActivity"}, {"end": 64, "start": 52, "tag": "PopulationGroup"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 171, "start": 163, "tag": "ResearchActivity"}, {"end": 119, "start": 112, "tag": "ResearchActivity"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1507_4", "text": "Predictors of willingness were similar for Black and White participants.", "tags": [{"end": 71, "start": 53, "tag": "PopulationGroup"}, {"end": 48, "start": 43, "tag": "PopulationGroup"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 71, "start": 59, "tag": "PopulationGroup"}]}
{"id": "1507_5", "text": "Themes associated with increased willingness included a desire to learn biomarker results and support research.", "tags": [{"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 44, "start": 33, "tag": "BiologicFunction"}, {"end": 81, "start": 72, "tag": "ClinicalAttribute"}, {"end": 110, "start": 102, "tag": "ResearchActivity"}]}
{"id": "1507_6", "text": "Discussion: Research attitudes were an important predictor of biomarker study willingness regardless of race.", "tags": [{"end": 108, "start": 104, "tag": "PopulationGroup"}, {"end": 30, "start": 12, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 89, "start": 78, "tag": "BiologicFunction"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}]}
{"id": "1507_7", "text": "As seen elsewhere, Black participants were more hesitant to participate in biomarker research.", "tags": [{"end": 37, "start": 19, "tag": "PopulationGroup"}, {"end": 24, "start": 19, "tag": "PopulationGroup"}, {"end": 84, "start": 75, "tag": "ClinicalAttribute"}, {"end": 37, "start": 25, "tag": "PopulationGroup"}, {"end": 93, "start": 85, "tag": "ResearchActivity"}]}
{"id": "1507_8", "text": "Disclosure of biomarker results/risk can bolster willingness to enroll in biomarker studies, particularly for Black participants.", "tags": [{"end": 128, "start": 110, "tag": "PopulationGroup"}, {"end": 70, "start": 49, "tag": "Finding"}, {"end": 10, "start": 0, "tag": "IndividualBehavior"}, {"end": 115, "start": 110, "tag": "PopulationGroup"}, {"end": 60, "start": 49, "tag": "BiologicFunction"}, {"end": 23, "start": 14, "tag": "ClinicalAttribute"}, {"end": 83, "start": 74, "tag": "ClinicalAttribute"}, {"end": 128, "start": 116, "tag": "PopulationGroup"}, {"end": 91, "start": 84, "tag": "ResearchActivity"}]}
{"id": "1508_0", "text": "Background Synaptic dysfunction is an early core feature of Alzheimer's disease (AD), closely associated with cognitive symptoms.", "tags": [{"end": 79, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 110, "tag": "SignOrSymptom"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 20, "tag": "PathologicFunction"}]}
{"id": "1508_1", "text": "Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the development and maintenance of synaptic transmission.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 58, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 113, "tag": "CellFunction"}, {"end": 134, "start": 113, "tag": "BiologicFunction"}, {"end": 31, "start": 25, "tag": "BiologicFunction"}, {"end": 109, "start": 98, "tag": "BiologicFunction"}, {"end": 51, "start": 36, "tag": "CellFunction"}, {"end": 93, "start": 82, "tag": "BiologicFunction"}, {"end": 93, "start": 82, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 36, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1508_2", "text": "Previous reports have shown that changes in cerebrospinal fluid (CSF) NRG1 concentration are associated with cognitive status and biomarker evidence of AD pathology.", "tags": [{"end": 74, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 16, "start": 9, "tag": "HealthCareActivity"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 125, "start": 109, "tag": "BiologicFunction"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 155, "tag": "PathologicFunction"}, {"end": 164, "start": 155, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 130, "tag": "ClinicalAttribute"}, {"end": 63, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 148, "start": 140, "tag": "Finding"}, {"end": 88, "start": 70, "tag": "ClinicalAttribute"}, {"end": 63, "start": 44, "tag": "ClinicalAttribute"}]}
{"id": "1508_3", "text": "Plasma biomarkers reflecting synaptic impairment would be of great clinical interest.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 7, "tag": "ClinicalAttribute"}, {"end": 48, "start": 29, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 61, "tag": "Finding"}]}
{"id": "1508_4", "text": "Objective To measure plasma NRG1 concentration in AD patients in comparison with other neurodegenerative disorders and neurological controls (NC) and to study its association with cerebrospinal fluid (CSF) core AD and synaptic biomarkers.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 237, "start": 218, "tag": "ClinicalAttribute"}, {"end": 27, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 204, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 153, "tag": "ResearchActivity"}, {"end": 199, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 132, "tag": "PopulationGroup"}, {"end": 114, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "ResearchActivity"}, {"end": 144, "start": 142, "tag": "PopulationGroup"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 21, "tag": "ClinicalAttribute"}]}
{"id": "1508_5", "text": "Methods This retrospective study enrolled 127 participants including patients with AD at mild cognitive impairment stage (AD-MCI, n = 27) and at dementia stage (n = 35), non-AD dementia (n = 26, A beta-negative), non-AD MCI (n = 19), and neurological controls (n=20).", "tags": [{"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 46, "tag": "PopulationGroup"}, {"end": 259, "start": 251, "tag": "PopulationGroup"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ClinicalAttribute"}, {"end": 128, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 154, "tag": "ClinicalAttribute"}]}
{"id": "1508_6", "text": "Plasma and CSF NRG1, as well as CSF core AD biomarkers (A beta 42/A beta 40 ratio, phospho-tau, and total tau), were measured using ELISA.", "tags": [{"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 137, "start": 132, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1508_7", "text": "CSF synaptic markers were measured using ELISA for GAP-43 and neurogranin and through immunoprecipitation mass spectrometry for SNAP-25.", "tags": [{"end": 57, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "GeneOrGenome"}, {"end": 135, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 106, "tag": "ResearchActivity"}, {"end": 105, "start": 86, "tag": "ResearchActivity"}, {"end": 135, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 4, "tag": "ClinicalAttribute"}, {"end": 57, "start": 51, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1508_8", "text": "Results Plasma NRG1 concentration was higher in AD-MCI and AD dementia patients compared with neurological controls (respectively P = 0.005 and P < 0.001).", "tags": [{"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 14, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 8, "tag": "ClinicalAttribute"}]}
{"id": "1508_9", "text": "Plasma NRG1 differentiated AD MCI patients from neurological controls with an area under the curve of 88.3%, and AD dementia patients from NC with an area under the curve of 87.3%.", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 34, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 98, "start": 78, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "ResearchActivity"}, {"end": 33, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 139, "tag": "PopulationGroup"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1508_10", "text": "Plasma NRG1 correlated with CSF NRG1 (beta = 0.372, P = 0.0056, adjusted on age and sex).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 76, "tag": "OrganismAttribute"}, {"end": 87, "start": 84, "tag": "OrganismAttribute"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 36, "start": 28, "tag": "ClinicalAttribute"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1508_11", "text": "Plasma NRG1 was associated with AD CSF core biomarkers in the whole cohort and in A beta-positive patients (beta = -0.197-0.423).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 106, "start": 98, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1508_12", "text": "Plasma NRG1 correlated with CSF GAP-43, neurogranin, and SNAP-25 (beta = 0.278-0.355).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "GeneOrGenome"}, {"end": 64, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1508_13", "text": "Plasma NRG1 concentration correlated inversely with MMSE in the whole cohort and in A beta-positive patients (all, beta = -0.188, P = 0.038; A beta+: beta = -0.255, P = 0.038).", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 70, "tag": "PopulationGroup"}, {"end": 90, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 52, "tag": "HealthCareActivity"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1508_14", "text": "Conclusion Plasma NRG1 concentration is increased in AD patients and correlates with CSF core AD and synaptic biomarkers and cognitive status.", "tags": [{"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "GeneOrGenome"}, {"end": 141, "start": 125, "tag": "BiologicFunction"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 101, "tag": "ClinicalAttribute"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 11, "tag": "ClinicalAttribute"}]}
{"id": "1508_15", "text": "Thus, plasma NRG1 is a promising non-invasive biomarker to monitor synaptic impairment in AD.", "tags": [{"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "HealthCareActivity"}, {"end": 66, "start": 59, "tag": "ManufacturedObject"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 6, "tag": "ClinicalAttribute"}]}
{"id": "1509_0", "text": "Background: Oligomeric amyloid-beta (A beta) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); A beta oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric A beta (MDS-OA beta) after incubation with spiked synthetic A beta.", "tags": [{"end": 260, "start": 250, "tag": "IndividualBehavior"}, {"end": 260, "start": 250, "tag": "ResearchActivity"}, {"end": 122, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 129, "tag": "CellFunction"}, {"end": 229, "start": 186, "tag": "HealthCareActivity"}, {"end": 242, "start": 231, "tag": "HealthCareActivity"}, {"end": 99, "start": 85, "tag": "PathologicFunction"}]}
{"id": "1509_1", "text": "Objective: We evaluated the clinical sensitivity and specificity of the MDS-OA beta values for prediction of AD.", "tags": [{"end": 48, "start": 28, "tag": "Finding"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "Finding"}, {"end": 83, "start": 72, "tag": "HealthCareActivity"}, {"end": 105, "start": 95, "tag": "Finding"}]}
{"id": "1509_2", "text": "Methods: The MDS-OA beta values measured using in Blood (TM) OA beta test in heparin-treated plasma samples from 52ADpatients in comparison with 52 community-based subjects with normal cognition (NC).", "tags": [{"end": 157, "start": 148, "tag": "HealthCareRelatedOrganization"}, {"end": 59, "start": 57, "tag": "CellComponent"}, {"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 178, "tag": "Finding"}, {"end": 194, "start": 178, "tag": "Finding"}, {"end": 194, "start": 185, "tag": "BiologicFunction"}, {"end": 172, "start": 164, "tag": "PopulationGroup"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 196, "tag": "PopulationGroup"}, {"end": 40, "start": 32, "tag": "HealthCareActivity"}, {"end": 24, "start": 13, "tag": "HealthCareActivity"}]}
{"id": "1509_3", "text": "The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.", "tags": [{"end": 130, "start": 123, "tag": "TemporalConcept"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 140, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "TemporalConcept"}, {"end": 163, "start": 157, "tag": "TemporalConcept"}, {"end": 100, "start": 94, "tag": "TemporalConcept"}, {"end": 149, "start": 131, "tag": "HealthCareActivity"}, {"end": 23, "start": 4, "tag": "ResearchActivity"}, {"end": 56, "start": 44, "tag": "HealthCareActivity"}]}
{"id": "1509_4", "text": "Results: The MDS-OA beta values were 1.43 +/- 0.30 ng/ml in AD and 0.45 +/- 0.19 (p < 0.001) in NC, respectively.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "PopulationGroup"}, {"end": 24, "start": 13, "tag": "HealthCareActivity"}]}
{"id": "1509_5", "text": "Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity.", "tags": [{"end": 74, "start": 63, "tag": "Finding"}, {"end": 97, "start": 86, "tag": "Finding"}]}
{"id": "1509_6", "text": "Conclusion: MDS-OA beta to measure plasma A beta oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.", "tags": [{"end": 152, "start": 136, "tag": "Finding"}, {"end": 168, "start": 136, "tag": "Finding"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "ClinicalAttribute"}, {"end": 84, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 141, "tag": "Finding"}, {"end": 123, "start": 105, "tag": "HealthCareActivity"}, {"end": 168, "start": 157, "tag": "Finding"}, {"end": 23, "start": 12, "tag": "HealthCareActivity"}, {"end": 64, "start": 35, "tag": "ClinicalAttribute"}]}
{"id": "1510_0", "text": "Introduction There has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD).", "tags": [{"end": 124, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 67, "tag": "ClinicalAttribute"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 51, "start": 40, "tag": "CellFunction"}, {"end": 101, "start": 88, "tag": "PathologicFunction"}]}
{"id": "1510_1", "text": "However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate.", "tags": [{"end": 55, "start": 45, "tag": "ClinicalAttribute"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 64, "tag": "HealthCareActivity"}]}
{"id": "1510_2", "text": "Multimer Detection System-Oligomeric Amyloid-beta (MDS-OA beta) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.Main text We suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OA beta with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis.", "tags": [{"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 293, "start": 270, "tag": "HealthCareActivity"}, {"end": 158, "start": 141, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 346, "start": 339, "tag": "AminoAcidPeptideOrProtein"}, {"end": 346, "start": 339, "tag": "BiologicallyActiveSubstance"}, {"end": 357, "start": 355, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "ClinicalAttribute"}, {"end": 228, "start": 219, "tag": "ClinicalAttribute"}, {"end": 300, "start": 295, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 332, "start": 329, "tag": "HealthCareActivity"}, {"end": 350, "start": 347, "tag": "HealthCareActivity"}, {"end": 367, "start": 358, "tag": "HealthCareActivity"}, {"end": 327, "start": 301, "tag": "HealthCareActivity"}, {"end": 49, "start": 0, "tag": "HealthCareActivity"}, {"end": 62, "start": 51, "tag": "HealthCareActivity"}, {"end": 264, "start": 253, "tag": "HealthCareActivity"}, {"end": 246, "start": 233, "tag": "PathologicFunction"}, {"end": 120, "start": 112, "tag": "Finding"}]}
{"id": "1510_3", "text": "Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.Discussion A systematic interpretation strategy could support accurate diagnosis and staging of AD.", "tags": [{"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 24, "start": 20, "tag": "HealthCareActivity"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 156, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 25, "tag": "Finding"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 55, "tag": "TemporalConcept"}, {"end": 254, "start": 245, "tag": "HealthCareActivity"}, {"end": 266, "start": 259, "tag": "TemporalConcept"}, {"end": 126, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 55, "tag": "ClinicalAttribute"}]}
{"id": "1510_4", "text": "Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OA beta on amyloid-beta oligomerization tendency can complement to gain advanced insights on amyloid-beta dynamics in AD.", "tags": [{"end": 111, "start": 97, "tag": "AnatomicalAbnormality"}, {"end": 234, "start": 226, "tag": "NaturalPhenomenonOrProcess"}, {"end": 41, "start": 31, "tag": "ClinicalAttribute"}, {"end": 225, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 127, "start": 116, "tag": "HealthCareActivity"}, {"end": 67, "start": 54, "tag": "PathologicFunction"}, {"end": 159, "start": 131, "tag": "CellFunction"}, {"end": 168, "start": 160, "tag": "Finding"}, {"end": 209, "start": 192, "tag": "Finding"}]}
{"id": "1511_0", "text": "Background: While cutoffs for abnormal levels of the cerebrospinal fluid (CSF) biomarkers amyloid-beta 1-42 (A beta(1-42)), total tau (t-tau), phosphorylated tau (p-tau), and the ratios of t-tau/A beta(1-42) and p-tau/A beta(1-42), have been established in Alzheimer's disease (AD), biologically relevant cutoffs have not been studied extensively in Parkinson's disease (PD).", "tags": [{"end": 45, "start": 30, "tag": "Finding"}, {"end": 140, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 276, "start": 257, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "ClinicalAttribute"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 369, "start": 350, "tag": "DiseaseOrSyndrome"}, {"end": 373, "start": 371, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 217, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 217, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 179, "tag": "ClinicalAttribute"}, {"end": 230, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 312, "start": 305, "tag": "ResearchActivity"}]}
{"id": "1511_1", "text": "Objective: Assess the suitability and diagnostic accuracy of established AD-derived CSF biomarker cutoffs in the PD population.", "tags": [{"end": 87, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 126, "start": 116, "tag": "PopulationGroup"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 38, "tag": "Finding"}, {"end": 33, "start": 22, "tag": "Finding"}, {"end": 105, "start": 98, "tag": "ResearchActivity"}]}
{"id": "1511_2", "text": "Methods: Baseline and longitudinal data on CSF biomarkers, cognitive diagnoses, and PET amyloid imaging in 423 newly diagnosed patients with PD from the Parkinson's Progression Markers Initiative (PPMI) cohort were used to evaluate established AD biomarker cutoffs compared with optimal cutoffs derived from the PPMI cohort.", "tags": [{"end": 57, "start": 47, "tag": "ClinicalAttribute"}, {"end": 135, "start": 127, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 203, "tag": "PopulationGroup"}, {"end": 323, "start": 317, "tag": "PopulationGroup"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 247, "tag": "ClinicalAttribute"}, {"end": 103, "start": 96, "tag": "HealthCareActivity"}, {"end": 39, "start": 22, "tag": "ResearchActivity"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "HealthCareActivity"}, {"end": 195, "start": 153, "tag": "HealthCareRelatedOrganization"}, {"end": 201, "start": 197, "tag": "HealthCareRelatedOrganization"}, {"end": 316, "start": 312, "tag": "HealthCareRelatedOrganization"}, {"end": 294, "start": 279, "tag": "ResearchActivity"}, {"end": 39, "start": 35, "tag": "ResearchActivity"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 264, "start": 257, "tag": "ResearchActivity"}]}
{"id": "1511_3", "text": "Results: Using PET amyloid imaging as the gold standard for AD pathology, the optimal cutoff of A beta(1-42) was higher than the AD cutoff, the optimal cutoffs of t-tau/A beta(1-42) and p-tau/A beta(1-42) were lower than the AD cutoffs, and their confidence intervals (CIs) did not overlap with the AD cutoffs.", "tags": [{"end": 55, "start": 42, "tag": "ResearchActivity"}, {"end": 289, "start": 282, "tag": "TemporalConcept"}, {"end": 168, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 63, "tag": "PathologicFunction"}, {"end": 72, "start": 63, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 299, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 27, "tag": "HealthCareActivity"}, {"end": 18, "start": 15, "tag": "HealthCareActivity"}, {"end": 108, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 132, "tag": "ResearchActivity"}, {"end": 92, "start": 78, "tag": "ResearchActivity"}, {"end": 108, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 144, "tag": "ResearchActivity"}, {"end": 181, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 247, "tag": "ResearchActivity"}, {"end": 272, "start": 269, "tag": "ResearchActivity"}, {"end": 309, "start": 302, "tag": "ResearchActivity"}, {"end": 235, "start": 228, "tag": "ResearchActivity"}]}
{"id": "1511_4", "text": "Optimal cutoffs for t-tau and p-tau to predict cognitive impairment were significantly lower than the AD cutoffs, and their CIs did not overlap with the AD cutoffs.", "tags": [{"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 136, "tag": "TemporalConcept"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "ResearchActivity"}, {"end": 127, "start": 124, "tag": "ResearchActivity"}, {"end": 163, "start": 156, "tag": "ResearchActivity"}]}
{"id": "1511_5", "text": "Conclusion: Optimal cutoffs for the PPMI cohort for A beta(1-42), t-tau/A beta(1-42), and p-tau/A beta(1-42) to predict amyloid-PET positivity and for t-tau and p-tau to predict cognitive impairment differ significantly from cutoffs derived from AD populations.", "tags": [{"end": 142, "start": 132, "tag": "ResearchActivity"}, {"end": 156, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 249, "tag": "PopulationGroup"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "PopulationGroup"}, {"end": 127, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 128, "tag": "HealthCareActivity"}, {"end": 198, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 12, "tag": "ResearchActivity"}, {"end": 40, "start": 36, "tag": "HealthCareRelatedOrganization"}, {"end": 64, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 225, "tag": "ResearchActivity"}, {"end": 84, "start": 72, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1511_6", "text": "The presence of additional pathologies such as alpha-synuclein in PD may lead to disease-specific CSF biomarker characteristics.", "tags": [{"end": 12, "start": 4, "tag": "Finding"}, {"end": 38, "start": 27, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 62, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 62, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}]}
{"id": "1512_0", "text": "Background Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-beta peptide deposition and progressive neuron loss.", "tags": [{"end": 145, "start": 134, "tag": "TemporalConcept"}, {"end": 30, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 146, "tag": "Cell"}, {"end": 67, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 84, "tag": "CellOrMolecularDysfunction"}, {"end": 157, "start": 146, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1512_1", "text": "Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process.", "tags": [{"end": 112, "start": 97, "tag": "Cell"}, {"end": 47, "start": 30, "tag": "PathologicFunction"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 92, "start": 82, "tag": "Cell"}, {"end": 106, "start": 97, "tag": "Cell"}]}
{"id": "1512_2", "text": "Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson's disease patients.", "tags": [{"end": 45, "start": 0, "tag": "GeneOrGenome"}, {"end": 45, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "GeneOrGenome"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 207, "tag": "TemporalConcept"}, {"end": 103, "start": 95, "tag": "TemporalConcept"}, {"end": 273, "start": 265, "tag": "PatientOrDisabledGroup"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 145, "tag": "PathologicFunction"}, {"end": 264, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 207, "tag": "TemporalConcept"}]}
{"id": "1512_3", "text": "Methods The present study describes the partial fit for purpose validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF).", "tags": [{"end": 114, "start": 103, "tag": "ResearchActivity"}, {"end": 74, "start": 64, "tag": "ResearchActivity"}, {"end": 184, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 179, "start": 140, "tag": "ClinicalAttribute"}]}
{"id": "1512_4", "text": "We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively.", "tags": [{"end": 46, "start": 41, "tag": "GeneOrGenome"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 52, "tag": "ClinicalAttribute"}, {"end": 195, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 134, "start": 125, "tag": "ClinicalAttribute"}, {"end": 163, "start": 154, "tag": "HealthCareActivity"}, {"end": 182, "start": 170, "tag": "HealthCareActivity"}, {"end": 103, "start": 96, "tag": "PopulationGroup"}, {"end": 224, "start": 196, "tag": "HealthCareActivity"}, {"end": 163, "start": 145, "tag": "HealthCareActivity"}]}
{"id": "1512_5", "text": "Results The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels.", "tags": [{"end": 44, "start": 39, "tag": "GeneOrGenome"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 193, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 175, "tag": "BiologicFunction"}, {"end": 180, "start": 175, "tag": "CellFunction"}, {"end": 51, "start": 35, "tag": "ClinicalAttribute"}, {"end": 200, "start": 185, "tag": "ClinicalAttribute"}]}
{"id": "1512_6", "text": "Conclusions The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals.", "tags": [{"end": 59, "start": 54, "tag": "GeneOrGenome"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 142, "tag": "ResearchActivity"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 106, "tag": "ClinicalAttribute"}, {"end": 38, "start": 33, "tag": "ResearchActivity"}, {"end": 187, "start": 168, "tag": "PopulationGroup"}, {"end": 105, "start": 95, "tag": "HealthCareActivity"}, {"end": 167, "start": 160, "tag": "OrganismAttribute"}]}
{"id": "1513_0", "text": "Background: Elevated blood pressure is linked to cognitive impairment and Alzheimer's disease (AD) biomarker abnormality.", "tags": [{"end": 35, "start": 12, "tag": "Finding"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "ClinicalAttribute"}, {"end": 69, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 21, "tag": "BiologicFunction"}, {"end": 120, "start": 109, "tag": "Finding"}]}
{"id": "1513_1", "text": "However, blood pressure levels vary over time.", "tags": [{"end": 45, "start": 41, "tag": "TemporalConcept"}, {"end": 30, "start": 9, "tag": "ClinicalAttribute"}]}
{"id": "1513_2", "text": "Less is known about the role of long-term blood pressure variability in cognitive impairment and AD pathophysiology.", "tags": [{"end": 56, "start": 42, "tag": "BiologicFunction"}, {"end": 41, "start": 32, "tag": "TemporalConcept"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 100, "tag": "PathologicFunction"}, {"end": 115, "start": 100, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 68, "start": 57, "tag": "Finding"}]}
{"id": "1513_3", "text": "Objective: Determine whether long-term blood pressure variability is elevated across the clinical and biomarker spectrum of AD.", "tags": [{"end": 53, "start": 39, "tag": "BiologicFunction"}, {"end": 120, "start": 102, "tag": "ResearchActivity"}, {"end": 38, "start": 29, "tag": "TemporalConcept"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "ClinicalAttribute"}, {"end": 65, "start": 54, "tag": "Finding"}]}
{"id": "1513_4", "text": "Methods: Alzheimer's Disease Neuroimaging Initiative participants (cognitively normal, mild cognitive impairment, AD [n = 1,421]) underwent baseline exam, including blood pressure measurement at 0, 6, and 12 months.", "tags": [{"end": 153, "start": 149, "tag": "HealthCareActivity"}, {"end": 179, "start": 165, "tag": "BiologicFunction"}, {"end": 191, "start": 180, "tag": "ResearchActivity"}, {"end": 191, "start": 180, "tag": "HealthCareActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 53, "tag": "PopulationGroup"}, {"end": 85, "start": 67, "tag": "Finding"}, {"end": 112, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 9, "tag": "ResearchActivity"}, {"end": 214, "start": 208, "tag": "TemporalConcept"}, {"end": 52, "start": 9, "tag": "HealthCareRelatedOrganization"}]}
{"id": "1513_5", "text": "A subset (n = 318) underwent baseline lumbar puncture to determine cerebrospinal fluid amyloid-beta and phosphorylated tau levels.", "tags": [{"end": 99, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 38, "tag": "HealthCareActivity"}, {"end": 122, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 104, "tag": "ClinicalAttribute"}]}
{"id": "1513_6", "text": "Clinical groups and biomarker-confirmed AD groups were compared on blood pressure variability over 12 months.", "tags": [{"end": 81, "start": 67, "tag": "BiologicFunction"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 20, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "PopulationGroup"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 93, "start": 82, "tag": "Finding"}]}
{"id": "1513_7", "text": "Results: Systolic blood pressure variability was elevated in clinically diagnosed AD dementia (VIM: F-2,F-1195 = 6.657, p = 0.001, eta(2) = 0.01) compared to cognitively normal participants (p = 0.001), and in mild cognitive impairment relative to cognitively normal participants (p = 0.01).", "tags": [{"end": 32, "start": 9, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 177, "tag": "PopulationGroup"}, {"end": 279, "start": 267, "tag": "PopulationGroup"}, {"end": 176, "start": 158, "tag": "Finding"}, {"end": 266, "start": 248, "tag": "Finding"}, {"end": 81, "start": 72, "tag": "HealthCareActivity"}, {"end": 235, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 33, "tag": "Finding"}]}
{"id": "1513_8", "text": "Findings were maintained in biomarker-confirmed AD (VIM: F-2,F-850 = 5.216, p = 0.006, eta(2) = 0.01), such that systolic blood pressure variability was elevated in biomarker-confirmed dementia due to AD relative to cognitively normal participants (p = 0.005) and in biomarker-confirmed mild cognitive impairment due to AD compared to cognitively normal participants (p = 0.04).", "tags": [{"end": 136, "start": 113, "tag": "ClinicalAttribute"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 320, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 28, "tag": "ClinicalAttribute"}, {"end": 174, "start": 165, "tag": "ClinicalAttribute"}, {"end": 276, "start": 267, "tag": "ClinicalAttribute"}, {"end": 193, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 235, "tag": "PopulationGroup"}, {"end": 366, "start": 354, "tag": "PopulationGroup"}, {"end": 234, "start": 216, "tag": "Finding"}, {"end": 353, "start": 335, "tag": "Finding"}, {"end": 312, "start": 287, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 137, "tag": "Finding"}]}
{"id": "1513_9", "text": "Conclusion: Long-term systolic blood pressure variability is elevated in cognitive impairment due to AD.", "tags": [{"end": 21, "start": 12, "tag": "TemporalConcept"}, {"end": 21, "start": 12, "tag": "HealthCareActivity"}, {"end": 45, "start": 22, "tag": "ClinicalAttribute"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 46, "tag": "Finding"}]}
{"id": "1513_10", "text": "Blood pressure variability may represent an understudied aspect of vascular dysfunction in AD with potential clinical implications.", "tags": [{"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 76, "tag": "PathologicFunction"}, {"end": 26, "start": 15, "tag": "Finding"}]}
{"id": "1514_0", "text": "T The blood-brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen.", "tags": [{"end": 57, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 75, "tag": "Finding"}, {"end": 30, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 58, "tag": "BiologicFunction"}, {"end": 110, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 100, "tag": "PharmacologicSubstance"}]}
{"id": "1514_1", "text": "Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML).", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 127, "start": 107, "tag": "Finding"}, {"end": 132, "start": 129, "tag": "Finding"}, {"end": 119, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 120, "tag": "InjuryOrPoisoning"}, {"end": 96, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 98, "tag": "DiseaseOrSyndrome"}]}
{"id": "1514_2", "text": "Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer's disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD.", "tags": [{"end": 110, "start": 102, "tag": "Finding"}, {"end": 64, "start": 52, "tag": "PathologicFunction"}, {"end": 171, "start": 152, "tag": "ClinicalAttribute"}, {"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 162, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 17, "tag": "PathologicFunction"}, {"end": 133, "start": 125, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1514_3", "text": "We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HP tau) and amyloid-beta (A beta), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage.", "tags": [{"end": 132, "start": 121, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 243, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 69, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 278, "start": 266, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 94, "tag": "BiologicFunction"}, {"end": 105, "start": 94, "tag": "CellFunction"}, {"end": 197, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 25, "tag": "ClinicalAttribute"}]}
{"id": "1514_4", "text": "Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HP tau, A beta, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM).", "tags": [{"end": 23, "start": 12, "tag": "TemporalConcept"}, {"end": 250, "start": 247, "tag": "Finding"}, {"end": 210, "start": 204, "tag": "ResearchActivity"}, {"end": 195, "start": 182, "tag": "PathologicFunction"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 284, "start": 272, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 290, "start": 286, "tag": "ClinicalAttribute"}, {"end": 126, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 255, "tag": "Finding"}, {"end": 87, "start": 66, "tag": "PopulationGroup"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 156, "tag": "ClinicalAttribute"}, {"end": 164, "start": 156, "tag": "Finding"}, {"end": 47, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 6, "tag": "Eukaryote"}, {"end": 134, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 180, "start": 166, "tag": "ClinicalAttribute"}, {"end": 238, "start": 214, "tag": "ClinicalAttribute"}]}
{"id": "1514_5", "text": "SVD severity was determined by calculating sclerotic indices.", "tags": [{"end": 52, "start": 43, "tag": "PathologicFunction"}, {"end": 12, "start": 4, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}]}
{"id": "1514_6", "text": "WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HP tau or A beta pathology, or any measures of white matter damage.", "tags": [{"end": 31, "start": 25, "tag": "ResearchActivity"}, {"end": 125, "start": 119, "tag": "ResearchActivity"}, {"end": 188, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 9, "tag": "ClinicalAttribute"}, {"end": 135, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 146, "tag": "PathologicFunction"}, {"end": 155, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 135, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 79, "tag": "PopulationGroup"}, {"end": 145, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Finding"}, {"end": 24, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 24, "start": 14, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1514_7", "text": "Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only.", "tags": [{"end": 109, "start": 103, "tag": "ResearchActivity"}, {"end": 91, "start": 87, "tag": "ClinicalAttribute"}, {"end": 136, "start": 128, "tag": "PopulationGroup"}, {"end": 19, "start": 11, "tag": "ClinicalAttribute"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 26, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 92, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1514_8", "text": "In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05).", "tags": [{"end": 48, "start": 42, "tag": "ResearchActivity"}, {"end": 30, "start": 26, "tag": "ClinicalAttribute"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 31, "tag": "PharmacologicSubstance"}]}
{"id": "1514_9", "text": "BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies.", "tags": [{"end": 101, "start": 95, "tag": "ResearchActivity"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 48, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1514_10", "text": "BBB dysfunction was strongly associated with SVD but only in the non-demented controls.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 77, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "DiseaseOrSyndrome"}]}
{"id": "1514_11", "text": "In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA.", "tags": [{"end": 119, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 31, "tag": "PathologicFunction"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}]}
{"id": "1514_12", "text": "In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.", "tags": [{"end": 86, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 134, "start": 126, "tag": "Finding"}, {"end": 148, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 66, "tag": "Finding"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 193, "tag": "PathologicFunction"}, {"end": 202, "start": 193, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 169, "tag": "ClinicalAttribute"}, {"end": 104, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 15, "tag": "ClinicalAttribute"}, {"end": 148, "start": 138, "tag": "PharmacologicSubstance"}]}
{"id": "1515_0", "text": "Background: A clinical diagnosis of cognitive impairment is traditionally based on a single cognitive exam, but serial cognitive testing can be sensitive to subtle cognitive changes in asymptomatic individuals and inform cognitive trajectory.", "tags": [{"end": 197, "start": 185, "tag": "Finding"}, {"end": 136, "start": 129, "tag": "HealthCareActivity"}, {"end": 209, "start": 198, "tag": "PopulationGroup"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 14, "tag": "HealthCareActivity"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}]}
{"id": "1515_1", "text": "Objective: We evaluated the prognostic utility of identifying longitudinal neuropsychological decline along with single cognitive exam and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in predicting dementia.", "tags": [{"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 190, "tag": "ClinicalAttribute"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 28, "tag": "Finding"}, {"end": 101, "start": 62, "tag": "PathologicFunction"}, {"end": 134, "start": 120, "tag": "HealthCareActivity"}]}
{"id": "1515_2", "text": "We also examined brain volumetric differences based on decline trajectories.", "tags": [{"end": 33, "start": 23, "tag": "HealthCareActivity"}, {"end": 45, "start": 34, "tag": "Finding"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1515_3", "text": "Method: Regression models quantified 12-month neuropsychological decline relative to normative expectations among nondemented older adults (N = 1,074).", "tags": [{"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 138, "start": 132, "tag": "PopulationGroup"}, {"end": 25, "start": 8, "tag": "ResearchActivity"}, {"end": 131, "start": 126, "tag": "TemporalConcept"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "PopulationGroup"}, {"end": 72, "start": 46, "tag": "PathologicFunction"}]}
{"id": "1515_4", "text": "Progression to dementia over follow-up (18-120 months) was diagnosed using independent modes of assessment.", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 23, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 29, "tag": "HealthCareActivity"}, {"end": 38, "start": 29, "tag": "TemporalConcept"}, {"end": 68, "start": 59, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "ResearchActivity"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}]}
{"id": "1515_5", "text": "Results: In Cox regression models controlling for age, sex, education, apolipoprotein E4, and baseline cognitive diagnosis, neuropsychological decline predicted increased dementia risk, chi(2) = 69.861, p < 0.001, odds ratio = 2.841, even after correction for CSF biomarkers (amyloid-beta, phosphorylated tau, total tau), chi(2) = 26.365, p < 0.001, odds ratio = 2.283.", "tags": [{"end": 88, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 71, "tag": "GeneOrGenome"}, {"end": 274, "start": 264, "tag": "ClinicalAttribute"}, {"end": 288, "start": 276, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 179, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 12, "tag": "ResearchActivity"}, {"end": 308, "start": 290, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 94, "tag": "HealthCareActivity"}, {"end": 308, "start": 290, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 60, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 58, "start": 55, "tag": "OrganismAttribute"}, {"end": 319, "start": 310, "tag": "AminoAcidPeptideOrProtein"}, {"end": 319, "start": 310, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 124, "tag": "PathologicFunction"}]}
{"id": "1515_6", "text": "Voxel-based morphometry analysis indicated smaller hippocampal and medial temporal volume in participants with neuropsychological decline.", "tags": [{"end": 105, "start": 93, "tag": "PopulationGroup"}, {"end": 32, "start": 0, "tag": "ResearchActivity"}, {"end": 89, "start": 83, "tag": "ClinicalAttribute"}, {"end": 62, "start": 51, "tag": "ClinicalAttribute"}, {"end": 89, "start": 67, "tag": "ClinicalAttribute"}, {"end": 137, "start": 111, "tag": "PathologicFunction"}]}
{"id": "1515_7", "text": "Conclusions: Longitudinal diagnosis of neuropsychological decline improved prognostic accuracy beyond single cognitive exam diagnoses and AD CSF biomarkers, even in asymptomatic older adults.", "tags": [{"end": 133, "start": 124, "tag": "HealthCareActivity"}, {"end": 177, "start": 165, "tag": "Finding"}, {"end": 155, "start": 145, "tag": "ClinicalAttribute"}, {"end": 144, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 184, "tag": "PopulationGroup"}, {"end": 183, "start": 178, "tag": "TemporalConcept"}, {"end": 35, "start": 13, "tag": "HealthCareActivity"}, {"end": 94, "start": 86, "tag": "Finding"}, {"end": 190, "start": 178, "tag": "PopulationGroup"}, {"end": 65, "start": 39, "tag": "PathologicFunction"}, {"end": 123, "start": 102, "tag": "HealthCareActivity"}]}
{"id": "1515_8", "text": "Older adults with a trajectory of neuropsychological decline exhibit smaller medial temporal and hippocampal brain volume.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 12, "start": 6, "tag": "PopulationGroup"}, {"end": 121, "start": 97, "tag": "ClinicalAttribute"}, {"end": 121, "start": 109, "tag": "ClinicalAttribute"}, {"end": 60, "start": 34, "tag": "PathologicFunction"}, {"end": 121, "start": 109, "tag": "ClinicalAttribute"}, {"end": 92, "start": 77, "tag": "ClinicalAttribute"}]}
{"id": "1515_9", "text": "Longitudinal diagnostic approaches may benefit selection and randomization procedures for AD clinical trials in asymptomatic individuals.", "tags": [{"end": 124, "start": 112, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 125, "tag": "PopulationGroup"}, {"end": 108, "start": 93, "tag": "ResearchActivity"}, {"end": 34, "start": 0, "tag": "HealthCareActivity"}]}
{"id": "1516_0", "text": "BackgroundElectroencephalogram (EEG) has emerged as a non-invasive tool to detect the aberrant neuronal activity related to different stages of Alzheimer's disease (AD).", "tags": [{"end": 35, "start": 32, "tag": "HealthCareActivity"}, {"end": 163, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 134, "tag": "TemporalConcept"}, {"end": 30, "start": 10, "tag": "HealthCareActivity"}, {"end": 112, "start": 86, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1516_1", "text": "However, the effectiveness of EEG in the precise diagnosis and assessment of AD and its preclinical stage, amnestic mild cognitive impairment (MCI), has yet to be fully elucidated.", "tags": [{"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 88, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "ClinicalAttribute"}, {"end": 58, "start": 49, "tag": "HealthCareActivity"}, {"end": 146, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 13, "tag": "Finding"}, {"end": 141, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 63, "tag": "HealthCareActivity"}, {"end": 73, "start": 63, "tag": "ResearchActivity"}]}
{"id": "1516_2", "text": "In this study, we aimed to identify key EEG biomarkers that are effective in distinguishing patients at the early stage of AD and monitoring the progression of AD.MethodsA total of 890 participants, including 189 patients with MCI, 330 patients with AD, 125 patients with other dementias (frontotemporal dementia, dementia with Lewy bodies, and vascular cognitive impairment), and 246 healthy controls (HC) were enrolled.", "tags": [{"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 119, "start": 108, "tag": "TemporalConcept"}, {"end": 374, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 289, "tag": "DiseaseOrSyndrome"}, {"end": 339, "start": 328, "tag": "CellComponent"}, {"end": 401, "start": 385, "tag": "PopulationGroup"}, {"end": 54, "start": 44, "tag": "ClinicalAttribute"}, {"end": 100, "start": 92, "tag": "PatientOrDisabledGroup"}, {"end": 221, "start": 213, "tag": "PatientOrDisabledGroup"}, {"end": 244, "start": 236, "tag": "PatientOrDisabledGroup"}, {"end": 266, "start": 258, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 252, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 185, "tag": "PopulationGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 353, "start": 345, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 119, "start": 114, "tag": "ClinicalAttribute"}, {"end": 156, "start": 145, "tag": "PathologicFunction"}, {"end": 156, "start": 145, "tag": "TemporalConcept"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 374, "start": 354, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 130, "tag": "HealthCareActivity"}, {"end": 287, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 392, "start": 385, "tag": "OrganismAttribute"}]}
{"id": "1516_3", "text": "Biomarkers were extracted from resting-state EEG recordings for a three-level classification of HC, MCI, and AD.", "tags": [{"end": 48, "start": 45, "tag": "HealthCareActivity"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 59, "start": 31, "tag": "ResearchActivity"}, {"end": 92, "start": 66, "tag": "HealthCareActivity"}]}
{"id": "1516_4", "text": "The optimal EEG biomarkers were then identified based on the classification performance.", "tags": [{"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 87, "start": 76, "tag": "Finding"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}]}
{"id": "1516_5", "text": "Random forest regression was used to train a series of models by combining participants' EEG biomarkers, demographic information (i.e., sex, age), CSF biomarkers, and APOE phenotype for assessing the disease progression and individual's cognitive function.ResultsThe identified EEG biomarkers achieved over 70% accuracy in the three-level classification of HC, MCI, and AD.", "tags": [{"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 92, "start": 89, "tag": "HealthCareActivity"}, {"end": 255, "start": 237, "tag": "BiologicFunction"}, {"end": 281, "start": 278, "tag": "HealthCareActivity"}, {"end": 181, "start": 172, "tag": "OrganismAttribute"}, {"end": 42, "start": 37, "tag": "BiologicFunction"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 161, "start": 151, "tag": "ClinicalAttribute"}, {"end": 292, "start": 282, "tag": "ClinicalAttribute"}, {"end": 150, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 141, "tag": "OrganismAttribute"}, {"end": 372, "start": 370, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 75, "tag": "PopulationGroup"}, {"end": 61, "start": 55, "tag": "ResearchActivity"}, {"end": 219, "start": 208, "tag": "PathologicFunction"}, {"end": 219, "start": 208, "tag": "TemporalConcept"}, {"end": 139, "start": 136, "tag": "OrganismAttribute"}, {"end": 319, "start": 311, "tag": "Finding"}, {"end": 364, "start": 361, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 219, "start": 200, "tag": "PathologicFunction"}, {"end": 353, "start": 327, "tag": "HealthCareActivity"}]}
{"id": "1516_6", "text": "Among all six groups, the most prominent effects of AD-linked neurodegeneration on EEG metrics were localized at parieto-occipital regions.", "tags": [{"end": 48, "start": 41, "tag": "PathologicFunction"}, {"end": 86, "start": 83, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "Chemical"}, {"end": 79, "start": 62, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 14, "tag": "PopulationGroup"}]}
{"id": "1516_7", "text": "In the cross-validation predictive analyses, the optimal EEG features were more effective than the CSF + APOE biomarkers in predicting the age of onset and disease course, whereas the combination of EEG + CSF + APOE measures achieved the best performance for all targets of prediction.ConclusionsOur study indicates that EEG can be used as a useful screening tool for the diagnosis and disease progression evaluation of MCI and AD.", "tags": [{"end": 60, "start": 57, "tag": "HealthCareActivity"}, {"end": 202, "start": 199, "tag": "HealthCareActivity"}, {"end": 324, "start": 321, "tag": "HealthCareActivity"}, {"end": 151, "start": 139, "tag": "TemporalConcept"}, {"end": 170, "start": 156, "tag": "TemporalConcept"}, {"end": 254, "start": 243, "tag": "Finding"}, {"end": 120, "start": 110, "tag": "ClinicalAttribute"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 430, "start": 428, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 300, "tag": "ResearchActivity"}, {"end": 405, "start": 394, "tag": "PathologicFunction"}, {"end": 405, "start": 394, "tag": "TemporalConcept"}, {"end": 381, "start": 372, "tag": "HealthCareActivity"}, {"end": 423, "start": 420, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 416, "start": 406, "tag": "HealthCareActivity"}, {"end": 416, "start": 406, "tag": "ResearchActivity"}, {"end": 405, "start": 386, "tag": "PathologicFunction"}, {"end": 43, "start": 7, "tag": "ResearchActivity"}, {"end": 284, "start": 274, "tag": "Finding"}]}
{"id": "1517_0", "text": "This study characterizes individuals in the Alzheimer's Disease Neuroimaging Initiative (ADNI) data set with tau abnormality indicated by cerebrospinal fluid assay or positron emission tomography.", "tags": [{"end": 87, "start": 44, "tag": "ResearchActivity"}, {"end": 87, "start": 44, "tag": "HealthCareRelatedOrganization"}, {"end": 93, "start": 89, "tag": "HealthCareRelatedOrganization"}, {"end": 93, "start": 89, "tag": "ResearchActivity"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 95, "tag": "ResearchActivity"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 157, "start": 152, "tag": "Substance"}, {"end": 63, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 195, "start": 167, "tag": "HealthCareActivity"}, {"end": 124, "start": 113, "tag": "Finding"}, {"end": 195, "start": 167, "tag": "ManufacturedObject"}]}
{"id": "1517_1", "text": "Question Do cerebrospinal fluid (CSF) and positron emission tomography (PET) measures provide different information about Alzheimer disease-related tau pathology? Findings In this cohort study using the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, one-third of participants had abnormal CSF tau or were tau positive on both CSF assay and PET, while tau-PET positivity alone was relatively rare.", "tags": [{"end": 348, "start": 343, "tag": "ResearchActivity"}, {"end": 246, "start": 203, "tag": "ResearchActivity"}, {"end": 246, "start": 203, "tag": "HealthCareRelatedOrganization"}, {"end": 301, "start": 293, "tag": "Finding"}, {"end": 382, "start": 372, "tag": "ResearchActivity"}, {"end": 309, "start": 302, "tag": "ClinicalAttribute"}, {"end": 252, "start": 248, "tag": "HealthCareRelatedOrganization"}, {"end": 252, "start": 248, "tag": "ResearchActivity"}, {"end": 139, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 309, "start": 306, "tag": "AminoAcidPeptideOrProtein"}, {"end": 321, "start": 318, "tag": "AminoAcidPeptideOrProtein"}, {"end": 367, "start": 364, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 305, "start": 302, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 342, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 306, "tag": "BiologicallyActiveSubstance"}, {"end": 321, "start": 318, "tag": "BiologicallyActiveSubstance"}, {"end": 367, "start": 364, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 148, "tag": "PathologicFunction"}, {"end": 288, "start": 276, "tag": "PopulationGroup"}, {"end": 31, "start": 26, "tag": "Substance"}, {"end": 222, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 187, "tag": "ResearchActivity"}, {"end": 261, "start": 254, "tag": "ResearchActivity"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 356, "start": 353, "tag": "HealthCareActivity"}, {"end": 371, "start": 368, "tag": "HealthCareActivity"}, {"end": 70, "start": 42, "tag": "HealthCareActivity"}, {"end": 186, "start": 180, "tag": "PopulationGroup"}, {"end": 408, "start": 404, "tag": "TemporalConcept"}, {"end": 70, "start": 42, "tag": "ManufacturedObject"}]}
{"id": "1517_2", "text": "Individuals whose CSF was tau positive had a history of accelerated CSF tau accrual, but only persons with tau-PET abnormality showed a similar significant decline in cognition.", "tags": [{"end": 101, "start": 94, "tag": "PopulationGroup"}, {"end": 126, "start": 111, "tag": "ClinicalAttribute"}, {"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 75, "start": 68, "tag": "ClinicalAttribute"}, {"end": 52, "start": 45, "tag": "Finding"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 167, "tag": "BiologicFunction"}, {"end": 114, "start": 111, "tag": "HealthCareActivity"}, {"end": 126, "start": 115, "tag": "Finding"}]}
{"id": "1517_3", "text": "Meaning Cerebrospinal fluid tau abnormality may be detected earlier in the AD pathogenetic process than flortaucipir-PET positivity and may occur before measurable cognitive decline.", "tags": [{"end": 27, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 104, "tag": "Chemical"}, {"end": 131, "start": 121, "tag": "ResearchActivity"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}, {"end": 31, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 22, "tag": "Substance"}, {"end": 152, "start": 146, "tag": "TemporalConcept"}, {"end": 181, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 117, "tag": "HealthCareActivity"}, {"end": 43, "start": 32, "tag": "Finding"}]}
{"id": "1517_4", "text": "Importance Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease.", "tags": [{"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "Substance"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}, {"end": 143, "start": 137, "tag": "TemporalConcept"}, {"end": 60, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 129, "tag": "TemporalConcept"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 117, "start": 107, "tag": "ClinicalAttribute"}]}
{"id": "1517_5", "text": "Objective To characterize individuals with tau abnormality indicated by cerebrospinal fluid (CSF) assay or positron emission tomography (PET).", "tags": [{"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "Substance"}, {"end": 140, "start": 137, "tag": "HealthCareActivity"}, {"end": 135, "start": 107, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "Finding"}, {"end": 135, "start": 107, "tag": "ManufacturedObject"}]}
{"id": "1517_6", "text": "Design, Setting, and Participants Between 2010 and 2019, 322 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent CSF and PET assessments of tau pathology.", "tags": [{"end": 165, "start": 154, "tag": "HealthCareActivity"}, {"end": 124, "start": 81, "tag": "ResearchActivity"}, {"end": 124, "start": 81, "tag": "HealthCareRelatedOrganization"}, {"end": 130, "start": 126, "tag": "HealthCareRelatedOrganization"}, {"end": 130, "start": 126, "tag": "ResearchActivity"}, {"end": 172, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}, {"end": 73, "start": 61, "tag": "PopulationGroup"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 8, "tag": "BiologicFunction"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}]}
{"id": "1517_7", "text": "Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (>= 26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio >= 1.37) indicated participants' tau status as CSF-/PET-, CSF+/PET-, CSF-/PET+, and CSF+/PET+.", "tags": [{"end": 66, "start": 52, "tag": "CellFunction"}, {"end": 112, "start": 100, "tag": "Chemical"}, {"end": 141, "start": 122, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 213, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 249, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 213, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 196, "tag": "PopulationGroup"}, {"end": 116, "start": 113, "tag": "HealthCareActivity"}, {"end": 232, "start": 229, "tag": "HealthCareActivity"}, {"end": 243, "start": 240, "tag": "HealthCareActivity"}, {"end": 254, "start": 251, "tag": "HealthCareActivity"}, {"end": 269, "start": 266, "tag": "HealthCareActivity"}, {"end": 43, "start": 33, "tag": "Finding"}, {"end": 220, "start": 214, "tag": "Finding"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 164, "start": 158, "tag": "BiologicFunction"}, {"end": 164, "start": 158, "tag": "CellFunction"}]}
{"id": "1517_8", "text": "Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded).", "tags": [{"end": 52, "start": 40, "tag": "Chemical"}, {"end": 12, "start": 8, "tag": "HealthCareRelatedOrganization"}, {"end": 12, "start": 8, "tag": "ResearchActivity"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 13, "tag": "PopulationGroup"}, {"end": 63, "start": 53, "tag": "HealthCareActivity"}, {"end": 63, "start": 53, "tag": "ResearchActivity"}]}
{"id": "1517_9", "text": "Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis.", "tags": [{"end": 77, "start": 65, "tag": "Chemical"}, {"end": 85, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 86, "tag": "HealthCareActivity"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}]}
{"id": "1517_10", "text": "Of these, 213 were cognitively unimpaired (CU); 98 had mild cognitive impairment (MCI); and 11 had AD dementia.", "tags": [{"end": 41, "start": 19, "tag": "Finding"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 55, "tag": "Finding"}]}
{"id": "1517_11", "text": "Main Outcomes and Measures We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid beta-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs.", "tags": [{"end": 106, "start": 98, "tag": "HealthCareActivity"}, {"end": 231, "start": 227, "tag": "ResearchActivity"}, {"end": 187, "start": 175, "tag": "Chemical"}, {"end": 199, "start": 192, "tag": "CellFunction"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 207, "tag": "HealthCareActivity"}, {"end": 153, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 162, "start": 159, "tag": "HealthCareActivity"}, {"end": 191, "start": 188, "tag": "HealthCareActivity"}, {"end": 158, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 163, "tag": "ResearchActivity"}, {"end": 218, "start": 213, "tag": "TemporalConcept"}, {"end": 218, "start": 213, "tag": "ClinicalAttribute"}]}
{"id": "1517_12", "text": "We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning.", "tags": [{"end": 99, "start": 87, "tag": "Chemical"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 100, "tag": "HealthCareActivity"}, {"end": 55, "start": 43, "tag": "Finding"}, {"end": 42, "start": 33, "tag": "ClinicalAttribute"}]}
{"id": "1517_13", "text": "Results Among the 322 study participants, 180 were women (56%), and the mean (SD) age was 73.08 (7.37) years.", "tags": [{"end": 40, "start": 28, "tag": "PopulationGroup"}, {"end": 27, "start": 22, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 85, "start": 82, "tag": "OrganismAttribute"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 80, "start": 78, "tag": "ResearchActivity"}]}
{"id": "1517_14", "text": "Two hundred ten participants were CSF-/PET- (65%); 63 were CSF+/PET- (19.5%); 15 were CSF-/PET+ (4.6%); and 34 were CSF+/PET+ (10.5%).", "tags": [{"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 16, "tag": "PopulationGroup"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 67, "start": 64, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 124, "start": 121, "tag": "HealthCareActivity"}]}
{"id": "1517_15", "text": "Most CSF-/PET+ participants had measures near CSF or PET tau thresholds.", "tags": [{"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 13, "start": 10, "tag": "HealthCareActivity"}, {"end": 56, "start": 53, "tag": "HealthCareActivity"}, {"end": 71, "start": 61, "tag": "Finding"}]}
{"id": "1517_16", "text": "The CSF+/PET- participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF-/PET- participants.", "tags": [{"end": 123, "start": 119, "tag": "ResearchActivity"}, {"end": 123, "start": 113, "tag": "ResearchActivity"}, {"end": 91, "start": 79, "tag": "Chemical"}, {"end": 103, "start": 96, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 64, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 14, "tag": "PopulationGroup"}, {"end": 187, "start": 175, "tag": "PopulationGroup"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 173, "start": 170, "tag": "HealthCareActivity"}, {"end": 142, "start": 136, "tag": "BiologicFunction"}, {"end": 150, "start": 136, "tag": "DiseaseOrSyndrome"}]}
{"id": "1517_17", "text": "Tau-positive individuals by either measure showed increased amyloid beta-PET burden.", "tags": [{"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 13, "tag": "PopulationGroup"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 77, "tag": "ResearchActivity"}]}
{"id": "1517_18", "text": "All CSF+/PET+ individuals were amyloid-positive, and 26 had MCI or AD dementia (76%).", "tags": [{"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 14, "tag": "PopulationGroup"}, {"end": 38, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 9, "tag": "HealthCareActivity"}]}
{"id": "1517_19", "text": "Compared with the CSF-/PET- group, CSF+/PET+ individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment.", "tags": [{"end": 152, "start": 134, "tag": "BiologicFunction"}, {"end": 152, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 175, "tag": "BiologicFunction"}, {"end": 222, "start": 210, "tag": "Chemical"}, {"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 107, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 45, "tag": "PopulationGroup"}, {"end": 237, "start": 227, "tag": "HealthCareActivity"}, {"end": 237, "start": 227, "tag": "ResearchActivity"}, {"end": 206, "start": 202, "tag": "TemporalConcept"}, {"end": 26, "start": 23, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "HealthCareActivity"}, {"end": 226, "start": 223, "tag": "HealthCareActivity"}, {"end": 33, "start": 28, "tag": "PopulationGroup"}, {"end": 129, "start": 123, "tag": "BiologicFunction"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 119, "start": 112, "tag": "Finding"}]}
{"id": "1517_20", "text": "Conclusions and Relevance Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance.", "tags": [{"end": 71, "start": 59, "tag": "Chemical"}, {"end": 87, "start": 72, "tag": "ClinicalAttribute"}, {"end": 50, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 115, "tag": "BiologicFunction"}, {"end": 126, "start": 115, "tag": "CellFunction"}, {"end": 149, "start": 144, "tag": "TemporalConcept"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 214, "start": 185, "tag": "Finding"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 108, "start": 103, "tag": "ClinicalAttribute"}, {"end": 87, "start": 76, "tag": "Finding"}, {"end": 165, "start": 154, "tag": "Finding"}, {"end": 50, "start": 41, "tag": "ClinicalAttribute"}, {"end": 126, "start": 112, "tag": "PathologicFunction"}]}
{"id": "1517_21", "text": "Persons with both tau CSF and PET abnormality appear to have reduced cognitive capacities resulting from faster antecedent cognitive decline.", "tags": [{"end": 7, "start": 0, "tag": "PopulationGroup"}, {"end": 89, "start": 61, "tag": "Finding"}, {"end": 45, "start": 30, "tag": "ClinicalAttribute"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 45, "start": 34, "tag": "Finding"}]}
{"id": "1517_22", "text": "Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 54, "start": 42, "tag": "Chemical"}, {"end": 69, "start": 59, "tag": "ResearchActivity"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "PathologicFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 137, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 95, "tag": "PathologicFunction"}, {"end": 58, "start": 55, "tag": "HealthCareActivity"}, {"end": 22, "start": 13, "tag": "ClinicalAttribute"}]}
{"id": "1518_0", "text": "Introduction The aim of this study was to investigate retinal thickness as a biomarker for identifying patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).", "tags": [{"end": 172, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "ClinicalAttribute"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 54, "tag": "ClinicalAttribute"}]}
{"id": "1518_1", "text": "Methods The retinal thickness, utilizing the spectral domain optical coherence tomography, was compared among 73 patients with AD, 51 patients with MCI, 67 cognitive normal control (NC) subjects.", "tags": [{"end": 89, "start": 45, "tag": "HealthCareActivity"}, {"end": 89, "start": 61, "tag": "HealthCareActivity"}, {"end": 121, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 134, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 166, "tag": "Finding"}, {"end": 194, "start": 186, "tag": "PopulationGroup"}, {"end": 151, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 182, "tag": "PopulationGroup"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1518_2", "text": "Results The retinal thickness of ganglion cell complex and peripapillary retinal nerve fiber layer decreased in both AD and MCI patients, in comparison with NC subjects (AD vs.", "tags": [{"end": 98, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 33, "tag": "Cell"}, {"end": 136, "start": 128, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 46, "start": 42, "tag": "Cell"}, {"end": 159, "start": 157, "tag": "PopulationGroup"}, {"end": 29, "start": 12, "tag": "ClinicalAttribute"}]}
{"id": "1518_3", "text": "NC, P < .01; MCI vs.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 2, "start": 0, "tag": "PopulationGroup"}]}
{"id": "1518_4", "text": "NC, P < .01).", "tags": [{"end": 2, "start": 0, "tag": "PopulationGroup"}]}
{"id": "1518_5", "text": "The inner retinal layers in macular area in MCI exhibited significant thinning compared with NC (P < .001).", "tags": [{"end": 24, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "PopulationGroup"}, {"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 58, "tag": "Finding"}]}
{"id": "1518_6", "text": "Remarkable association was found between the retinal thickness and brain volume (P < .05).", "tags": [{"end": 79, "start": 67, "tag": "ClinicalAttribute"}, {"end": 62, "start": 45, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "Finding"}]}
{"id": "1518_7", "text": "Better correlation was seen between the inner perifovea retinal thickness and the hippocampal and entorhinal cortex volume (r: 0.427-0.644, P < .01).", "tags": [{"end": 73, "start": 40, "tag": "ClinicalAttribute"}, {"end": 122, "start": 98, "tag": "ClinicalAttribute"}, {"end": 122, "start": 116, "tag": "ClinicalAttribute"}, {"end": 93, "start": 82, "tag": "ClinicalAttribute"}, {"end": 18, "start": 0, "tag": "Finding"}]}
{"id": "1518_8", "text": "Discussion The retinal thickness, especially the inner retinal layer thickness, is a potentially early AD marker indicating neurodegeneration.", "tags": [{"end": 141, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 106, "tag": "ClinicalAttribute"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}, {"end": 78, "start": 49, "tag": "ClinicalAttribute"}]}
{"id": "1519_0", "text": "Abnormal tau inclusions are hallmarks of Alzheimer's disease and predictors of clinical decline.", "tags": [{"end": 23, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 60, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "Finding"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 95, "start": 79, "tag": "Finding"}]}
{"id": "1519_1", "text": "Several tau PET tracers are available for neurodegenerative disease research, opening avenues for molecular diagnosis in vivo.", "tags": [{"end": 117, "start": 98, "tag": "ResearchActivity"}, {"end": 67, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 118, "tag": "ResearchActivity"}, {"end": 11, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 68, "tag": "ResearchActivity"}, {"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 23, "start": 16, "tag": "Chemical"}]}
{"id": "1519_2", "text": "However, few have been approved for clinical use.", "tags": [{"end": 48, "start": 36, "tag": "HealthCareActivity"}]}
{"id": "1519_3", "text": "Understanding the neurobiological basis of PET signal validation remains problematic because it requires a large-scale, voxel-to-voxel correlation between PET and (immuno) histological signals.", "tags": [{"end": 192, "start": 185, "tag": "CellFunction"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "HealthCareActivity"}, {"end": 158, "start": 155, "tag": "HealthCareActivity"}, {"end": 146, "start": 120, "tag": "ResearchActivity"}, {"end": 192, "start": 163, "tag": "HealthCareActivity"}, {"end": 192, "start": 163, "tag": "ResearchActivity"}]}
{"id": "1519_4", "text": "Large dimensionality of whole human brains, tissue deformation impacting co-registration, and computing requirements to process terabytes of information preclude proper validation.", "tags": [{"end": 179, "start": 169, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "Eukaryote"}, {"end": 88, "start": 73, "tag": "ResearchActivity"}, {"end": 116, "start": 94, "tag": "MachineActivity"}, {"end": 62, "start": 44, "tag": "Finding"}]}
{"id": "1519_5", "text": "We developed a computational pipeline to identify and segment particles of interest in billion-pixel digital pathology images to generate quantitative, 3D density maps.", "tags": [{"end": 71, "start": 62, "tag": "Chemical"}, {"end": 118, "start": 109, "tag": "PathologicFunction"}, {"end": 118, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 167, "start": 152, "tag": "ResearchActivity"}, {"end": 37, "start": 15, "tag": "MachineActivity"}, {"end": 125, "start": 87, "tag": "ResearchActivity"}]}
{"id": "1519_6", "text": "The proposed convolutional neural network for immunohistochemistry samples, IHCNet, is at the pipeline's core.", "tags": [{"end": 66, "start": 46, "tag": "ResearchActivity"}, {"end": 41, "start": 13, "tag": "MachineActivity"}, {"end": 82, "start": 76, "tag": "ResearchActivity"}]}
{"id": "1519_7", "text": "We have successfully processed and immunostained over 500 slides from two whole human brains with three phospho-tau antibodies (AT100, AT8, and MC1), spanning several terabytes of images.", "tags": [{"end": 92, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 80, "tag": "Eukaryote"}, {"end": 126, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 58, "tag": "ManufacturedObject"}]}
{"id": "1519_8", "text": "Our artificial neural network estimated tau inclusion from brain images, which performs with ROC AUC of 0.87, 0.85, and 0.91 for AT100, AT8, and MC1, respectively.", "tags": [{"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "ResearchActivity"}, {"end": 29, "start": 4, "tag": "MachineActivity"}, {"end": 134, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 71, "start": 59, "tag": "ResearchActivity"}]}
{"id": "1519_9", "text": "Introspection studies further assessed the ability of our trained model to learn tau-related features.", "tags": [{"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 71, "start": 66, "tag": "ResearchActivity"}, {"end": 50, "start": 43, "tag": "OrganismAttribute"}]}
{"id": "1519_10", "text": "We present an end-to-end pipeline to create terabytes-large 3D tau inclusion density maps co-registered to MRI as a means to facilitate validation of PET tracers.", "tags": [{"end": 146, "start": 136, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "HealthCareActivity"}, {"end": 161, "start": 154, "tag": "Chemical"}, {"end": 89, "start": 60, "tag": "ResearchActivity"}, {"end": 33, "start": 14, "tag": "ResearchActivity"}, {"end": 76, "start": 63, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1520_0", "text": "Background The progression rates of Alzheimer's disease (AD) are variable and dynamic, yet the mechanisms that contribute to heterogeneity in progression rates remain ill-understood.", "tags": [{"end": 138, "start": 125, "tag": "Finding"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "PathologicFunction"}, {"end": 153, "start": 142, "tag": "PathologicFunction"}, {"end": 26, "start": 15, "tag": "TemporalConcept"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 32, "start": 27, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "TemporalConcept"}]}
{"id": "1520_1", "text": "Particularly, the role of synergies in pathological processes reflected by biomarkers for amyloid-beta ('A'), tau ('T'), and neurodegeneration ('N') in progression along the AD continuum is not fully understood.", "tags": [{"end": 186, "start": 177, "tag": "TemporalConcept"}, {"end": 61, "start": 39, "tag": "PathologicFunction"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 102, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 152, "tag": "PathologicFunction"}, {"end": 163, "start": 152, "tag": "TemporalConcept"}, {"end": 142, "start": 125, "tag": "CellOrMolecularDysfunction"}]}
{"id": "1520_2", "text": "Methods Here, we used a combination of model and data-driven approaches to address this question.", "tags": [{"end": 53, "start": 49, "tag": "ResearchActivity"}, {"end": 44, "start": 39, "tag": "ResearchActivity"}]}
{"id": "1520_3", "text": "Working with a large dataset (N = 321 across the training and testing cohorts), we first applied unsupervised clustering on longitudinal cognitive assessments to divide individuals on the AD continuum into those showing fast vs.", "tags": [{"end": 200, "start": 191, "tag": "HealthCareActivity"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 70, "tag": "PopulationGroup"}, {"end": 180, "start": 169, "tag": "PopulationGroup"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 28, "start": 21, "tag": "ResearchActivity"}, {"end": 120, "start": 97, "tag": "ResearchActivity"}, {"end": 158, "start": 124, "tag": "HealthCareActivity"}, {"end": 224, "start": 220, "tag": "Finding"}]}
{"id": "1520_4", "text": "moderate decline.", "tags": [{"end": 16, "start": 0, "tag": "Finding"}, {"end": 16, "start": 9, "tag": "Finding"}]}
{"id": "1520_5", "text": "Next, we developed a deep learning model that differentiated fast vs.", "tags": [{"end": 65, "start": 61, "tag": "Finding"}, {"end": 34, "start": 21, "tag": "MachineActivity"}, {"end": 34, "start": 26, "tag": "BiologicFunction"}, {"end": 40, "start": 35, "tag": "ResearchActivity"}]}
{"id": "1520_6", "text": "moderate decline using baseline AT(N) biomarkers.", "tags": [{"end": 16, "start": 9, "tag": "Finding"}, {"end": 16, "start": 0, "tag": "Finding"}, {"end": 48, "start": 32, "tag": "ClinicalAttribute"}]}
{"id": "1520_7", "text": "Results Training the model with AT(N) biomarker combination revealed more prognostic utility than any individual biomarkers alone.", "tags": [{"end": 92, "start": 74, "tag": "Finding"}, {"end": 47, "start": 32, "tag": "ClinicalAttribute"}, {"end": 123, "start": 113, "tag": "ClinicalAttribute"}, {"end": 112, "start": 102, "tag": "PopulationGroup"}, {"end": 112, "start": 102, "tag": "OrganismAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 21, "tag": "ResearchActivity"}, {"end": 16, "start": 8, "tag": "BiologicFunction"}]}
{"id": "1520_8", "text": "We additionally found little overlap between the model-driven progression phenotypes and established atrophy-based AD subtypes.", "tags": [{"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 74, "tag": "OrganismAttribute"}, {"end": 73, "start": 62, "tag": "PathologicFunction"}, {"end": 73, "start": 62, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "ResearchActivity"}, {"end": 108, "start": 101, "tag": "PathologicFunction"}, {"end": 108, "start": 101, "tag": "DiseaseOrSyndrome"}]}
{"id": "1520_9", "text": "Our model showed that the combination of all AT(N) biomarkers had the most prognostic utility in predicting progression along the AD continuum.", "tags": [{"end": 142, "start": 133, "tag": "TemporalConcept"}, {"end": 93, "start": 75, "tag": "Finding"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 45, "tag": "ClinicalAttribute"}, {"end": 119, "start": 108, "tag": "PathologicFunction"}, {"end": 119, "start": 108, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}
{"id": "1520_10", "text": "A comprehensive AT(N) model showed better predictive performance than biomarker pairs (A(N) and T(N)) and individual biomarkers (A, T, or N).", "tags": [{"end": 79, "start": 70, "tag": "ClinicalAttribute"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 64, "start": 42, "tag": "Finding"}, {"end": 116, "start": 106, "tag": "PopulationGroup"}, {"end": 116, "start": 106, "tag": "OrganismAttribute"}, {"end": 27, "start": 16, "tag": "ResearchActivity"}]}
{"id": "1520_11", "text": "Conclusions This study combined data and model-driven methods to uncover the role of AT(N) biomarker synergies in the progression of cognitive decline along the AD continuum.", "tags": [{"end": 173, "start": 164, "tag": "TemporalConcept"}, {"end": 163, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 85, "tag": "ClinicalAttribute"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "PathologicFunction"}, {"end": 129, "start": 118, "tag": "TemporalConcept"}, {"end": 150, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}]}
{"id": "1520_12", "text": "The results suggest a synergistic relationship between AT(N) biomarkers in determining this progression, extending previous evidence of A-T synergistic mechanisms.", "tags": [{"end": 71, "start": 55, "tag": "ClinicalAttribute"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 132, "start": 124, "tag": "Finding"}, {"end": 46, "start": 34, "tag": "Finding"}]}
{"id": "1521_0", "text": "Mitochondrial dysfunction plays a key role in the pathogenesis of Alzheimer's disease (AD).", "tags": [{"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 50, "tag": "PathologicFunction"}, {"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}]}
{"id": "1521_1", "text": "The translocase of the outer membrane (TOM) complex controls the input of mitochondrial precursor proteins to maintain mitochondrial function under pathophysiological conditions.", "tags": [{"end": 51, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 74, "tag": "CellComponent"}, {"end": 141, "start": 119, "tag": "CellFunction"}, {"end": 177, "start": 148, "tag": "PathologicFunction"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 106, "start": 88, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1521_2", "text": "However, its role in AD development remains unclear.", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 24, "tag": "BiologicFunction"}, {"end": 35, "start": 24, "tag": "CellFunction"}]}
{"id": "1521_3", "text": "TOM70 is an important translocase present in the TOM complex.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 33, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 49, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1521_4", "text": "In the current study, we found that TOM70 levels were reduced in the peripheral blood and hippocampus of the APP/PS1 mice.", "tags": [{"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 85, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1521_5", "text": "In addition, we examined the whole-blood mRNA levels of TOM70 in patients with AD, dementia with Lewy bodies (DLB), and post-stroke dementia (PSD).", "tags": [{"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 113, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 108, "start": 97, "tag": "CellComponent"}, {"end": 73, "start": 65, "tag": "PatientOrDisabledGroup"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 120, "tag": "TemporalConcept"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}]}
{"id": "1521_6", "text": "Our study revealed that the mRNA level of TOM70 was decreased in the blood samples of patients with AD, which was also correlated with the progression of clinical stages.", "tags": [{"end": 47, "start": 42, "tag": "GeneOrGenome"}, {"end": 169, "start": 154, "tag": "TemporalConcept"}, {"end": 32, "start": 28, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 82, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 139, "tag": "PathologicFunction"}, {"end": 150, "start": 139, "tag": "TemporalConcept"}]}
{"id": "1521_7", "text": "Therefore, we proposed that the expression of TOM70 could be a promising biomarker for AD diagnosis and monitoring of disease progression.", "tags": [{"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 137, "start": 126, "tag": "PathologicFunction"}, {"end": 137, "start": 126, "tag": "TemporalConcept"}, {"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 114, "start": 104, "tag": "HealthCareActivity"}, {"end": 137, "start": 118, "tag": "PathologicFunction"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1522_0", "text": "Alzheimer's disease (AD) is an accelerating neurodegenerative disorder.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 44, "tag": "DiseaseOrSyndrome"}]}
{"id": "1522_1", "text": "Dysfunction of mitochondria and oxidative stress contributes to the pathogenesis of AD.", "tags": [{"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 15, "tag": "CellComponent"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}]}
{"id": "1522_2", "text": "Sirtuins play a role in this pathway and can be a potential marker to study neurodegenerative changes.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "CellFunction"}, {"end": 101, "start": 76, "tag": "PathologicFunction"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "ClinicalAttribute"}]}
{"id": "1522_3", "text": "This study evaluated serum levels of all seven sirtuin (SIRT1-SIRT7) proteins in three study groups: AD, mild cognitive impairment (MCI) and geriatric control (GC) by surface plasmon resonance (SPR) technique.", "tags": [{"end": 33, "start": 21, "tag": "ResearchActivity"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 167, "tag": "ResearchActivity"}, {"end": 208, "start": 199, "tag": "ResearchActivity"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 92, "start": 87, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 93, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 141, "tag": "PopulationGroup"}, {"end": 197, "start": 194, "tag": "ResearchActivity"}]}
{"id": "1522_4", "text": "Further, it was validated by the Western blot experiment.", "tags": [{"end": 56, "start": 33, "tag": "ResearchActivity"}]}
{"id": "1522_5", "text": "ROC analysis was performed to differentiate the study group based on the concentration of serum SIRT proteins.", "tags": [{"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}, {"end": 95, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 109, "start": 73, "tag": "ClinicalAttribute"}, {"end": 109, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 96, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1522_6", "text": "Out of seven sirtuins, serum SIRT1, SIRT3 and SIRT6 levels (mean +/- SD) were significantly decreased in AD (1.65 +/- 0.56, 3.15 +/- 0.28, 3.36 +/- 0.32 ng/mu l), compared to MCI (2.17 +/- 0.39, 3.60 +/- 0.51, 3.73 +/- 0.48 ng/mu l) and GC (2.84 +/- 0.47, 4.55 +/- 0.48, 4.65 +/- 0.55 ng/mu l).", "tags": [{"end": 21, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 71, "start": 69, "tag": "ResearchActivity"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 237, "tag": "PopulationGroup"}]}
{"id": "1522_7", "text": "ROC analysis showed the cut-off value with high sensitivity and specificity for cognitive impairment (AD and MCI).", "tags": [{"end": 75, "start": 43, "tag": "Finding"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}]}
{"id": "1522_8", "text": "The concentration declined significantly with the disease progression.", "tags": [{"end": 69, "start": 58, "tag": "PathologicFunction"}, {"end": 69, "start": 58, "tag": "TemporalConcept"}, {"end": 69, "start": 50, "tag": "PathologicFunction"}]}
{"id": "1522_9", "text": "No specific difference was observed in the case of other SIRTs between the study groups.", "tags": [{"end": 62, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 43, "tag": "ManufacturedObject"}, {"end": 80, "start": 75, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 22, "start": 0, "tag": "Finding"}, {"end": 62, "start": 57, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1522_10", "text": "This study reveals an inverse relation of serum SIRT1, SIRT3 and SIRT6 concentration with AD.", "tags": [{"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 55, "tag": "GeneOrGenome"}, {"end": 60, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 65, "tag": "GeneOrGenome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 22, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1522_11", "text": "ROC analysis showed that these serum proteins have greater accuracy in diagnosing of AD.", "tags": [{"end": 81, "start": 71, "tag": "HealthCareActivity"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 59, "tag": "Finding"}, {"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}]}
{"id": "1522_12", "text": "This is the first report of estimation of all seven serum sirtuins and the clinical relevance of SIRT3 and SIRT6 as serum protein markers for AD.", "tags": [{"end": 102, "start": 97, "tag": "GeneOrGenome"}, {"end": 102, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "GeneOrGenome"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 75, "tag": "Finding"}, {"end": 102, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 116, "tag": "ClinicalAttribute"}]}
{"id": "1523_0", "text": "Huntington's disease (HD) is an autosomal-dominant neurodegenerative movement disorder that presents with prominent cognitive and psychiatric dysfunction.", "tags": [{"end": 86, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 116, "tag": "PathologicFunction"}]}
{"id": "1523_1", "text": "Brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of HD, as well as other neurodegenerative and psychiatric disorders, and epigenetic alterations in the complex BDNF promoter have been associated with its deregulation in pathological conditions.", "tags": [{"end": 33, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 204, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 282, "start": 259, "tag": "PathologicFunction"}, {"end": 255, "start": 243, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 72, "tag": "PathologicFunction"}, {"end": 87, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 33, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 161, "tag": "Finding"}, {"end": 212, "start": 204, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1523_2", "text": "BDNF has gained increased attention as a potential biomarker of disease; but currently, the conflicting results from measurements of BDNF in different biofluids difficult the assessment of its utility as a biomarker for HD.", "tags": [{"end": 35, "start": 26, "tag": "BiologicFunction"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 41, "tag": "ClinicalAttribute"}, {"end": 86, "start": 77, "tag": "TemporalConcept"}, {"end": 215, "start": 206, "tag": "ClinicalAttribute"}, {"end": 160, "start": 151, "tag": "Substance"}, {"end": 185, "start": 175, "tag": "HealthCareActivity"}, {"end": 185, "start": 175, "tag": "ResearchActivity"}, {"end": 129, "start": 117, "tag": "HealthCareActivity"}]}
{"id": "1523_3", "text": "Here, we measured BDNF protein levels in plasma (n = 85) and saliva (n = 81) samples from premanifest and manifest HD patients and normal controls using ELISA assays.", "tags": [{"end": 30, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 153, "tag": "ResearchActivity"}, {"end": 126, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 106, "tag": "SignOrSymptom"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 131, "tag": "Finding"}, {"end": 146, "start": 138, "tag": "PopulationGroup"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 18, "tag": "ClinicalAttribute"}]}
{"id": "1523_4", "text": "We further examined DNA methylation levels of BDNF promoter IV using DNA derived from whole blood of HD patients and healthy controls (n = 40) using pyrosequencing.", "tags": [{"end": 97, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 149, "tag": "ResearchActivity"}, {"end": 35, "start": 20, "tag": "CellFunction"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 117, "tag": "PopulationGroup"}, {"end": 112, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 72, "start": 69, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 124, "start": 117, "tag": "OrganismAttribute"}, {"end": 62, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}]}
{"id": "1523_5", "text": "BDNF protein levels were not significantly different in plasma samples across diagnostic groups.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 89, "tag": "PopulationGroup"}, {"end": 88, "start": 78, "tag": "HealthCareActivity"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1523_6", "text": "Plasma BDNF was significantly correlated with age in control subjects but not in HD patients, nor were significant gender effects observed.", "tags": [{"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 115, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 46, "tag": "OrganismAttribute"}, {"end": 69, "start": 53, "tag": "PopulationGroup"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1523_7", "text": "Similar to plasma, salivary BDNF was correlated with age only in control subjects, with no gender effects observed.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "OrganismAttribute"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 81, "start": 65, "tag": "PopulationGroup"}, {"end": 27, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 19, "tag": "ClinicalAttribute"}]}
{"id": "1523_8", "text": "Importantly, we detected significantly lower levels of salivary BDNF in premanifest and manifest HD patients compared to control subjects, with lower BDNF levels being observed in premanifest patients within a predicted 10 years to disease onset.", "tags": [{"end": 245, "start": 232, "tag": "TemporalConcept"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 88, "tag": "SignOrSymptom"}, {"end": 228, "start": 223, "tag": "TemporalConcept"}, {"end": 200, "start": 192, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 121, "tag": "PopulationGroup"}, {"end": 63, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 55, "tag": "ClinicalAttribute"}]}
{"id": "1523_9", "text": "Salivary and plasma BDNF levels were not significantly correlated with one another, suggesting different origins.", "tags": [{"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 13, "tag": "ClinicalAttribute"}]}
{"id": "1523_10", "text": "DNA methylation at four out of the 12 CpG sites studied in promoter IV were significantly altered in HD patients in comparison to controls.", "tags": [{"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 112, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 138, "start": 130, "tag": "PopulationGroup"}, {"end": 126, "start": 116, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}]}
{"id": "1523_11", "text": "Interestingly, methylation at three of these CpG sites was inversely correlated to the Hospital Anxiety and Depression Scale (HADS) scores.", "tags": [{"end": 26, "start": 15, "tag": "CellFunction"}, {"end": 124, "start": 87, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "HealthCareActivity"}]}
{"id": "1523_12", "text": "BDNF promoter methylation was not correlated with motor or cognitive scores in HD patients, and was not associated with sex or age in neither disease nor control groups.", "tags": [{"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 154, "tag": "PopulationGroup"}, {"end": 90, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 130, "start": 127, "tag": "OrganismAttribute"}, {"end": 123, "start": 120, "tag": "OrganismAttribute"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 25, "start": 5, "tag": "CellFunction"}]}
{"id": "1523_13", "text": "Conclusion: Our studies show that BDNF protein levels are decreased in saliva; and BDNF promoter methylation increased in blood in HD subjects when compared to controls.", "tags": [{"end": 142, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 127, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 88, "tag": "CellFunction"}]}
{"id": "1523_14", "text": "These findings suggest that salivary BDNF measures may represent an early marker of disease onset and DNA methylation at the BDNF promoter IV, could represent a biomarker of psychiatric symptoms in HD patients.", "tags": [{"end": 97, "start": 84, "tag": "TemporalConcept"}, {"end": 194, "start": 174, "tag": "SignOrSymptom"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 198, "tag": "PatientOrDisabledGroup"}, {"end": 170, "start": 161, "tag": "ClinicalAttribute"}, {"end": 36, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 74, "tag": "ClinicalAttribute"}, {"end": 105, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 28, "tag": "ClinicalAttribute"}, {"end": 73, "start": 68, "tag": "TemporalConcept"}, {"end": 141, "start": 130, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 141, "start": 130, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1524_0", "text": "Objective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS).", "tags": [{"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "ResearchActivity"}, {"end": 232, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 172, "tag": "Finding"}, {"end": 138, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 183, "tag": "ClinicalAttribute"}, {"end": 145, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 140, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1524_1", "text": "Methods: Twenty-four patients with 5-year RRMS evolution and eleven healthy control subjects entered the study.", "tags": [{"end": 46, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 47, "tag": "TemporalConcept"}, {"end": 56, "start": 47, "tag": "BiologicFunction"}, {"end": 29, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 105, "tag": "ResearchActivity"}, {"end": 41, "start": 37, "tag": "TemporalConcept"}, {"end": 92, "start": 76, "tag": "PopulationGroup"}, {"end": 75, "start": 68, "tag": "OrganismAttribute"}]}
{"id": "1524_2", "text": "None of the participants had an inflammatory systemic or metabolic disease.", "tags": [{"end": 74, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 12, "tag": "PopulationGroup"}, {"end": 74, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 32, "tag": "DiseaseOrSyndrome"}]}
{"id": "1524_3", "text": "Disability progression was evaluated using the Expanded Disability Status Scale.", "tags": [{"end": 79, "start": 47, "tag": "HealthCareActivity"}, {"end": 22, "start": 11, "tag": "PathologicFunction"}, {"end": 22, "start": 11, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "Finding"}]}
{"id": "1524_4", "text": "Serum level of pNF-H, the anti-inflammatory cytokine transforming growth factor-beta 1 (TGF-beta 1), and the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17A (IL-17A), monocyte chemotactic protein-1 (MCP-1), and soluble intercellular cell-adhesion molecule 1 (sICAM-1) were quantified using enzyme-linked immunosorbent assay (ELISA).", "tags": [{"end": 98, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 88, "tag": "GeneOrGenome"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 136, "tag": "GeneOrGenome"}, {"end": 195, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 224, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 224, "tag": "GeneOrGenome"}, {"end": 228, "start": 224, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 250, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 250, "start": 246, "tag": "GeneOrGenome"}, {"end": 268, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 268, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 276, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 279, "tag": "AminoAcidPeptideOrProtein"}, {"end": 309, "start": 279, "tag": "BiologicallyActiveSubstance"}, {"end": 316, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 316, "start": 311, "tag": "GeneOrGenome"}, {"end": 330, "start": 323, "tag": "CellComponent"}, {"end": 369, "start": 331, "tag": "AminoAcidPeptideOrProtein"}, {"end": 369, "start": 331, "tag": "BiologicallyActiveSubstance"}, {"end": 435, "start": 402, "tag": "ResearchActivity"}, {"end": 43, "start": 26, "tag": "BiologicFunction"}, {"end": 43, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 206, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 197, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 109, "tag": "PathologicFunction"}, {"end": 442, "start": 437, "tag": "ResearchActivity"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "ClinicalAttribute"}, {"end": 86, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 195, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 270, "tag": "GeneOrGenome"}, {"end": 378, "start": 371, "tag": "ClinicalAttribute"}, {"end": 369, "start": 323, "tag": "ClinicalAttribute"}]}
{"id": "1524_5", "text": "Results: The patients had higher serum level of TGF-beta 1, IL-6, sICAM-1, and pNF-H.", "tags": [{"end": 58, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 48, "tag": "GeneOrGenome"}, {"end": 58, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 13, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 66, "tag": "ClinicalAttribute"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1524_6", "text": "Based on these findings, a sample of at least 49 controls and 89 recent-onset RRMS patients is required to find an at least 1-point between-group difference in pNF-H with a power of 80% and an alpha error = 0.05.", "tags": [{"end": 33, "start": 27, "tag": "Substance"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 65, "tag": "TemporalConcept"}, {"end": 82, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 57, "start": 49, "tag": "PopulationGroup"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 165, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 160, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1524_7", "text": "The progression of the disease was correlated with the level of pNF-H (Spearman rho = 0.624, p = 0.006), but not with the cytokines'.", "tags": [{"end": 131, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 15, "start": 4, "tag": "TemporalConcept"}, {"end": 30, "start": 4, "tag": "PathologicFunction"}, {"end": 30, "start": 4, "tag": "TemporalConcept"}, {"end": 69, "start": 55, "tag": "ClinicalAttribute"}, {"end": 83, "start": 71, "tag": "ResearchActivity"}]}
{"id": "1524_8", "text": "Conclusions: The serum level of pNF-H, EDSS score-correlated, might stand for a potential biomarker of disability in RRMS reflecting progressive axonal damage and cumulative neurological deterioration.", "tags": [{"end": 151, "start": 145, "tag": "CellComponent"}, {"end": 200, "start": 174, "tag": "Finding"}, {"end": 144, "start": 133, "tag": "TemporalConcept"}, {"end": 121, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 80, "tag": "ClinicalAttribute"}, {"end": 121, "start": 117, "tag": "HealthCareActivity"}, {"end": 99, "start": 90, "tag": "ClinicalAttribute"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "Finding"}, {"end": 43, "start": 39, "tag": "HealthCareActivity"}, {"end": 49, "start": 39, "tag": "HealthCareActivity"}, {"end": 158, "start": 145, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 17, "tag": "ClinicalAttribute"}]}
{"id": "1524_9", "text": "The novelty of these results warrants conducting a larger confirmatory trial.", "tags": [{"end": 76, "start": 58, "tag": "ResearchActivity"}]}
{"id": "1525_0", "text": "Background: Myeloperoxidase (MPO), a neutrophil-derived pro-inflammatory protein, co-localizes with amyloid-beta (A beta) plaques in Alzheimer's disease (AD).", "tags": [{"end": 27, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 12, "tag": "Chemical"}, {"end": 27, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "GeneOrGenome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 122, "tag": "AnatomicalAbnormality"}, {"end": 112, "start": 100, "tag": "AnatomicalAbnormality"}, {"end": 72, "start": 56, "tag": "PathologicFunction"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 37, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1525_1", "text": "Anti-dementia treatment may facilitate efflux of A beta and associated plaque proteins from the brain to the peripheral circulation, therefore providing potential biomarkers for the monitoring of donor response to drug treatment.", "tags": [{"end": 131, "start": 109, "tag": "BiologicFunction"}, {"end": 201, "start": 196, "tag": "PopulationGroup"}, {"end": 45, "start": 39, "tag": "CellFunction"}, {"end": 228, "start": 214, "tag": "HealthCareActivity"}, {"end": 228, "start": 214, "tag": "ResearchActivity"}, {"end": 77, "start": 71, "tag": "AnatomicalAbnormality"}, {"end": 192, "start": 182, "tag": "HealthCareActivity"}, {"end": 218, "start": 214, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 228, "start": 219, "tag": "HealthCareActivity"}, {"end": 228, "start": 219, "tag": "ResearchActivity"}, {"end": 13, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 153, "tag": "ClinicalAttribute"}, {"end": 210, "start": 202, "tag": "OrganismAttribute"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1525_2", "text": "Objective: We investigated the diagnostic utility of MPO as a biomarker of AD, and how anti-dementia treatment alters plasma MPO concentration.", "tags": [{"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "Chemical"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 125, "tag": "Chemical"}, {"end": 128, "start": 125, "tag": "GeneOrGenome"}, {"end": 128, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 110, "start": 87, "tag": "HealthCareActivity"}, {"end": 100, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 14, "tag": "ResearchActivity"}, {"end": 49, "start": 31, "tag": "Finding"}, {"end": 142, "start": 118, "tag": "ClinicalAttribute"}, {"end": 56, "start": 53, "tag": "GeneOrGenome"}]}
{"id": "1525_3", "text": "Methods: Thirty-two AD patients were recruited, and plasma collected pre-drug administration (baseline), and 1- and 6-months post-treatment.", "tags": [{"end": 92, "start": 73, "tag": "ResearchActivity"}, {"end": 92, "start": 73, "tag": "HealthCareActivity"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 139, "start": 130, "tag": "ResearchActivity"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "TemporalConcept"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}]}
{"id": "1525_4", "text": "All patients received cholinesterase inhibitors (ChEIs).", "tags": [{"end": 47, "start": 22, "tag": "Chemical"}, {"end": 47, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 54, "start": 49, "tag": "Chemical"}, {"end": 54, "start": 49, "tag": "PharmacologicSubstance"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}]}
{"id": "1525_5", "text": "At baseline and 6 months, patients underwent neuropsychological assessment.", "tags": [{"end": 74, "start": 45, "tag": "HealthCareActivity"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 24, "start": 18, "tag": "TemporalConcept"}]}
{"id": "1525_6", "text": "Forty-nine elderly healthy individuals with normal cognitive status served as controls.", "tags": [{"end": 67, "start": 44, "tag": "Finding"}, {"end": 38, "start": 19, "tag": "PopulationGroup"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 18, "start": 11, "tag": "PopulationGroup"}]}
{"id": "1525_7", "text": "Plasma MPO concentration was measured by ELISA.", "tags": [{"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "Chemical"}, {"end": 10, "start": 7, "tag": "GeneOrGenome"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1525_8", "text": "Results: AD drug naive patients had similar plasma MPO concentration to their control counterparts (p > 0.05).", "tags": [{"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 78, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 68, "start": 44, "tag": "ClinicalAttribute"}]}
{"id": "1525_9", "text": "Baseline MPO levels positively correlated with Neuropsychiatric Inventory score (r = 0.5080; p = 0.011) and carer distress (r = 0.5022; p = 0.012).", "tags": [{"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "Chemical"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 79, "start": 74, "tag": "Finding"}, {"end": 79, "start": 47, "tag": "HealthCareActivity"}, {"end": 113, "start": 108, "tag": "PopulationGroup"}]}
{"id": "1525_10", "text": "Following 1-month ChEI treatment, 84.4% of AD patients exhibited increased plasma MPO levels (p < 0.001), which decreased at 6 months (p < 0.001).", "tags": [{"end": 85, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 82, "tag": "Chemical"}, {"end": 85, "start": 82, "tag": "GeneOrGenome"}, {"end": 85, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 23, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "ResearchActivity"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 12, "tag": "TemporalConcept"}, {"end": 133, "start": 127, "tag": "TemporalConcept"}, {"end": 22, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 18, "tag": "Chemical"}, {"end": 92, "start": 75, "tag": "ClinicalAttribute"}]}
{"id": "1525_11", "text": "MPO concentration at 1 month was greatest in AD patients whose memory deteriorated during the study period (p = 0.028), and for AD patients with deterioration in Cornell assessment score (p = 0.044).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 70, "tag": "Finding"}, {"end": 158, "start": 145, "tag": "Finding"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "PatientOrDisabledGroup"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 186, "start": 181, "tag": "Finding"}, {"end": 106, "start": 100, "tag": "TemporalConcept"}, {"end": 99, "start": 94, "tag": "ResearchActivity"}, {"end": 186, "start": 162, "tag": "HealthCareActivity"}, {"end": 180, "start": 170, "tag": "ResearchActivity"}, {"end": 28, "start": 23, "tag": "TemporalConcept"}, {"end": 69, "start": 63, "tag": "BiologicFunction"}, {"end": 17, "start": 0, "tag": "ClinicalAttribute"}]}
{"id": "1525_12", "text": "Conclusion: Whereas baseline MPO levels did not differentiate between healthy and AD populations, baseline MPO positively correlated with initial Neuropsychiatric Inventory evaluation.", "tags": [{"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "GeneOrGenome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "Chemical"}, {"end": 110, "start": 107, "tag": "GeneOrGenome"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 96, "start": 85, "tag": "PopulationGroup"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 70, "tag": "OrganismAttribute"}, {"end": 145, "start": 138, "tag": "TemporalConcept"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 183, "start": 146, "tag": "HealthCareActivity"}]}
{"id": "1525_13", "text": "Post-treatment, transient MPO upregulation in ChEI-treated patients may reflect worse therapeutic outcome.", "tags": [{"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "Chemical"}, {"end": 29, "start": 26, "tag": "GeneOrGenome"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 16, "tag": "TemporalConcept"}, {"end": 42, "start": 30, "tag": "CellFunction"}, {"end": 105, "start": 80, "tag": "Finding"}, {"end": 67, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 5, "tag": "HealthCareActivity"}, {"end": 14, "start": 5, "tag": "ResearchActivity"}, {"end": 14, "start": 0, "tag": "TemporalConcept"}, {"end": 50, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 46, "tag": "Chemical"}]}
{"id": "1525_14", "text": "Further studies are required to assess the potential of plasma MPO as an AD therapeutic biomarker.", "tags": [{"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "Chemical"}, {"end": 66, "start": 63, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 73, "tag": "HealthCareActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 56, "tag": "ClinicalAttribute"}]}
{"id": "1526_0", "text": "Background Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer's disease (AD).", "tags": [{"end": 93, "start": 83, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 61, "tag": "HealthCareActivity"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 18, "tag": "ClinicalAttribute"}]}
{"id": "1526_1", "text": "However, profiles of the biomarkers and the associations with cognition across a spectrum of cognitive stages have seldom been reported.", "tags": [{"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 109, "start": 103, "tag": "TemporalConcept"}, {"end": 35, "start": 25, "tag": "ClinicalAttribute"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}]}
{"id": "1526_2", "text": "Methods We recruited 320 individuals with cognitive impairment and 131 cognitively normal participants from a memory clinic and a community cohort.", "tags": [{"end": 139, "start": 130, "tag": "HealthCareRelatedOrganization"}, {"end": 102, "start": 90, "tag": "PopulationGroup"}, {"end": 36, "start": 25, "tag": "PopulationGroup"}, {"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 71, "tag": "Finding"}, {"end": 146, "start": 140, "tag": "PopulationGroup"}, {"end": 116, "start": 110, "tag": "BiologicFunction"}]}
{"id": "1526_3", "text": "Participants were classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and clinical diagnosis, including AD, amnestic mild cognitive impairment (aMCI), and normal cognition (NC).", "tags": [{"end": 197, "start": 181, "tag": "Finding"}, {"end": 95, "start": 89, "tag": "Finding"}, {"end": 174, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 82, "start": 58, "tag": "HealthCareActivity"}, {"end": 168, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 84, "tag": "HealthCareActivity"}, {"end": 118, "start": 100, "tag": "HealthCareActivity"}]}
{"id": "1526_4", "text": "A battery of neuropsychological tests was used to assess the global and domain-specific cognition.", "tags": [{"end": 9, "start": 2, "tag": "ManufacturedObject"}, {"end": 37, "start": 13, "tag": "HealthCareActivity"}, {"end": 97, "start": 88, "tag": "BiologicFunction"}]}
{"id": "1526_5", "text": "Plasma A beta(1-40), A beta(1-42), A beta(1-42)/A beta(1-40), total tau (t-tau), neurofilament protein light chain (NfL), and phosphorylated tau at threonine 181 (p-tau181) were quantified using the single-molecule array (Simoa) platform.", "tags": [{"end": 114, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 229, "tag": "ResearchActivity"}, {"end": 220, "start": 199, "tag": "ResearchActivity"}, {"end": 140, "start": 126, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}, {"end": 33, "start": 21, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}, {"end": 60, "start": 35, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "ClinicalAttribute"}, {"end": 161, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 222, "tag": "ResearchActivity"}]}
{"id": "1526_6", "text": "Results All the plasma markers (A beta(1-40), A beta(1-42), A beta(1-42)/A beta(1-40), t-tau, NfL, p-tau181) showed certain discrepancies among NC, aMCI, and AD groups.", "tags": [{"end": 137, "start": 124, "tag": "Finding"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "PopulationGroup"}, {"end": 44, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 144, "tag": "PopulationGroup"}, {"end": 30, "start": 23, "tag": "ClinicalAttribute"}, {"end": 44, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 60, "tag": "ClinicalAttribute"}, {"end": 58, "start": 46, "tag": "AminoAcidPeptideOrProtein"}]}
{"id": "1526_7", "text": "The p-tau181 level showed a continuous escalating trend as the CDR scores increased from 0 (NC group) to 3 (severe AD).", "tags": [{"end": 73, "start": 67, "tag": "Finding"}, {"end": 38, "start": 28, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "PopulationGroup"}, {"end": 66, "start": 63, "tag": "HealthCareActivity"}, {"end": 114, "start": 108, "tag": "Finding"}, {"end": 94, "start": 92, "tag": "PopulationGroup"}]}
{"id": "1526_8", "text": "Compared with other biomarkers, p-tau181 had correlations with broader cognitive domains, covering global cognition (r = -0.536, P < 0.0001), memory (r = -0.481, P < 0.0001), attention (r = -0.437, P < 0.0001), visuospatial function (r = -0.385, P < 0.0001), and language (r = -0.177, P = 0.0003).", "tags": [{"end": 271, "start": 263, "tag": "BiologicFunction"}, {"end": 184, "start": 175, "tag": "BiologicFunction"}, {"end": 30, "start": 20, "tag": "ClinicalAttribute"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 106, "tag": "BiologicFunction"}, {"end": 148, "start": 142, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "ResearchActivity"}, {"end": 232, "start": 211, "tag": "BiologicFunction"}, {"end": 88, "start": 71, "tag": "Finding"}]}
{"id": "1526_9", "text": "Among participants with CDR >= 1, higher p-tau181 was correlated with worse global cognition (r = -0.301, P < 0.001).", "tags": [{"end": 75, "start": 70, "tag": "Finding"}, {"end": 18, "start": 6, "tag": "PopulationGroup"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 83, "tag": "BiologicFunction"}, {"end": 27, "start": 24, "tag": "HealthCareActivity"}]}
{"id": "1526_10", "text": "Conclusions Plasma p-tau181 had correlations with broader cognitive domains, suggesting its potential as a promising clinical-relevant blood-based biomarker.", "tags": [{"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 147, "tag": "ClinicalAttribute"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 12, "tag": "ClinicalAttribute"}, {"end": 75, "start": 58, "tag": "Finding"}]}
{"id": "1527_0", "text": "Background: Cerebrospinal Fluid (CSF) biomarkers are associated with conversion from mild cognitive impairment to Alzheimer's Disease (AD), but their predictive value for later end-points has been less evaluated with inconsistent results.", "tags": [{"end": 31, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 150, "tag": "Finding"}, {"end": 176, "start": 171, "tag": "TemporalConcept"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "ClinicalAttribute"}, {"end": 110, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 85, "tag": "Finding"}, {"end": 79, "start": 69, "tag": "Finding"}]}
{"id": "1527_1", "text": "Objective: We investigated potential relationships between CSF amyloid-beta(1-42) (A beta(42)), Phosphorylated tau (P-tau), and Total tau (T-tau) with time to Nursing Home Placement (NHP) and life expectancy after diagnosis.", "tags": [{"end": 110, "start": 96, "tag": "CellFunction"}, {"end": 186, "start": 183, "tag": "HealthCareActivity"}, {"end": 196, "start": 192, "tag": "TemporalConcept"}, {"end": 144, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 192, "tag": "TemporalConcept"}, {"end": 81, "start": 59, "tag": "ClinicalAttribute"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 37, "tag": "Finding"}, {"end": 70, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 214, "tag": "HealthCareActivity"}, {"end": 75, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "TemporalConcept"}, {"end": 26, "start": 14, "tag": "HealthCareActivity"}, {"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 159, "tag": "HealthCareActivity"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1527_2", "text": "Methods: This prospective observational study included 129 outpatients clinically diagnosed with mild-to-moderate AD who underwent a lumbar puncture.", "tags": [{"end": 70, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 45, "start": 26, "tag": "ResearchActivity"}, {"end": 113, "start": 105, "tag": "Finding"}, {"end": 148, "start": 133, "tag": "HealthCareActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 82, "tag": "HealthCareActivity"}, {"end": 101, "start": 97, "tag": "Finding"}]}
{"id": "1527_3", "text": "The CSF biomarkers were analysed with xMAP technology.", "tags": [{"end": 7, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}, {"end": 53, "start": 38, "tag": "ResearchActivity"}]}
{"id": "1527_4", "text": "Dates of institutionalisation and death were recorded.", "tags": [{"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 39, "start": 34, "tag": "BiologicFunction"}, {"end": 39, "start": 34, "tag": "PathologicFunction"}, {"end": 39, "start": 34, "tag": "CellFunction"}, {"end": 29, "start": 9, "tag": "HealthCareActivity"}]}
{"id": "1527_5", "text": "Results: After 20 years of follow-up, 123 patients (95%) were deceased.", "tags": [{"end": 70, "start": 62, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 27, "tag": "HealthCareActivity"}, {"end": 36, "start": 27, "tag": "TemporalConcept"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}]}
{"id": "1527_6", "text": "The participants with abnormal P-tau and T-tau (A+ T+ (N)+) died earlier than those with normal P-tau/abnormal T-tau (A+ T-(N)+) (mean, 80.5 vs.", "tags": [{"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 89, "tag": "Finding"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 72, "start": 65, "tag": "TemporalConcept"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}]}
{"id": "1527_7", "text": "85.4 years).", "tags": [{"end": 10, "start": 5, "tag": "TemporalConcept"}]}
{"id": "1527_8", "text": "Linear associations were demonstrated between lower A beta(42) and shorter time to NHP (p = 0.017), and higher P-tau and younger age at death (p = 0.016).", "tags": [{"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "Eukaryote"}, {"end": 141, "start": 136, "tag": "BiologicFunction"}, {"end": 141, "start": 136, "tag": "PathologicFunction"}, {"end": 141, "start": 136, "tag": "CellFunction"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 75, "tag": "TemporalConcept"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 62, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 121, "tag": "TemporalConcept"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1527_9", "text": "No correlations were detected between survival after AD diagnosis and CSF biomarkers.", "tags": [{"end": 73, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 84, "start": 74, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "CellFunction"}, {"end": 15, "start": 3, "tag": "ResearchActivity"}]}
{"id": "1527_10", "text": "In sex and-age-adjusted Cox regression models, higher P-tau and T-tau were independent predictors of shorter lifespan after diagnosis.", "tags": [{"end": 117, "start": 109, "tag": "TemporalConcept"}, {"end": 69, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "OrganismAttribute"}, {"end": 45, "start": 24, "tag": "ResearchActivity"}, {"end": 97, "start": 87, "tag": "Finding"}, {"end": 45, "start": 28, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 124, "tag": "HealthCareActivity"}, {"end": 14, "start": 11, "tag": "OrganismAttribute"}]}
{"id": "1527_11", "text": "In multivariate Cox models, older age and lower baseline cognitive status, but not elevated tau, significantly precipitated both institutionalisation and death.", "tags": [{"end": 73, "start": 57, "tag": "BiologicFunction"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 159, "start": 154, "tag": "BiologicFunction"}, {"end": 159, "start": 154, "tag": "PathologicFunction"}, {"end": 159, "start": 154, "tag": "CellFunction"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 48, "tag": "Finding"}, {"end": 37, "start": 34, "tag": "OrganismAttribute"}, {"end": 25, "start": 3, "tag": "ResearchActivity"}, {"end": 73, "start": 67, "tag": "Finding"}, {"end": 149, "start": 129, "tag": "HealthCareActivity"}]}
{"id": "1527_12", "text": "Conclusion: These findings suggest that CSF biomarker levels plateau in the dementia phase of AD, which may limit their possible relationships with clinical end-points, such as NHP and survival time.", "tags": [{"end": 198, "start": 185, "tag": "ClinicalAttribute"}, {"end": 198, "start": 185, "tag": "TemporalConcept"}, {"end": 180, "start": 177, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "ClinicalAttribute"}, {"end": 142, "start": 129, "tag": "Finding"}, {"end": 84, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "TemporalConcept"}, {"end": 167, "start": 148, "tag": "ClinicalAttribute"}]}
{"id": "1527_13", "text": "However, the biomarkers reflect the central pathophysiologies of AD.", "tags": [{"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 13, "tag": "ClinicalAttribute"}, {"end": 61, "start": 44, "tag": "PathologicFunction"}]}
{"id": "1527_14", "text": "In particular, pathologic tau is associated with more advanced disease, younger age at onset, and earlier death.", "tags": [{"end": 25, "start": 15, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 29, "start": 15, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 106, "tag": "BiologicFunction"}, {"end": 111, "start": 106, "tag": "PathologicFunction"}, {"end": 111, "start": 106, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "TemporalConcept"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 80, "tag": "OrganismAttribute"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}, {"end": 79, "start": 72, "tag": "TemporalConcept"}]}
{"id": "1528_0", "text": "Background: Because dementia is an emerging problem in the world, biochemical markers of cerebrospinal fluid (CSF) and radio-isotopic analyses are helpful for diagnosing Alzheimer's disease (AD).", "tags": [{"end": 51, "start": 44, "tag": "Finding"}, {"end": 169, "start": 159, "tag": "HealthCareActivity"}, {"end": 189, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 59, "tag": "PopulationGroup"}, {"end": 28, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 119, "tag": "ResearchActivity"}, {"end": 85, "start": 66, "tag": "ClinicalAttribute"}]}
{"id": "1528_1", "text": "Although blood sample is more feasible and plausible than CSF or radiological biomarkers for screening potential AD, measurements of serum amyloid-beta(A beta), plasma tau, and serum antibodies for A beta(1-42 )are not yet well established.", "tags": [{"end": 21, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "HealthCareActivity"}, {"end": 102, "start": 93, "tag": "ResearchActivity"}, {"end": 146, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 65, "tag": "ClinicalAttribute"}, {"end": 167, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 117, "tag": "HealthCareActivity"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 133, "tag": "ClinicalAttribute"}, {"end": 171, "start": 161, "tag": "ClinicalAttribute"}, {"end": 211, "start": 177, "tag": "ClinicalAttribute"}]}
{"id": "1528_2", "text": "Objective: We aimed to identify a new serum biomarker to detect mild cognitive impairment (MCI) and AD in comparison to cognitively healthy control by a new peptidome technology.", "tags": [{"end": 116, "start": 106, "tag": "ResearchActivity"}, {"end": 43, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "ClinicalAttribute"}, {"end": 139, "start": 132, "tag": "OrganismAttribute"}, {"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 140, "tag": "PopulationGroup"}, {"end": 89, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 120, "tag": "OrganismAttribute"}, {"end": 68, "start": 64, "tag": "Finding"}, {"end": 177, "start": 157, "tag": "ResearchActivity"}]}
{"id": "1528_3", "text": "Methods: With only 1.5 mu l of serum, we examined a new target plate BLOTCHIP (R) plus a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) to discriminate control (n = 100), MCI (n = 60), and AD (n = 99).", "tags": [{"end": 165, "start": 89, "tag": "ResearchActivity"}, {"end": 179, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 148, "tag": "ResearchActivity"}, {"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 63, "tag": "ManufacturedObject"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 204, "start": 197, "tag": "PopulationGroup"}, {"end": 179, "start": 167, "tag": "ResearchActivity"}, {"end": 77, "start": 69, "tag": "ResearchActivity"}]}
{"id": "1528_4", "text": "In some subjects, cognitive Mini-Mental State Examination (MMSE) were compared to positron emission tomography (PET) with Pittsburgh compound B (PiB) and the serum probability of dementia (SPD).", "tags": [{"end": 143, "start": 122, "tag": "Chemical"}, {"end": 148, "start": 145, "tag": "Chemical"}, {"end": 63, "start": 59, "tag": "HealthCareActivity"}, {"end": 163, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 28, "tag": "HealthCareActivity"}, {"end": 187, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "HealthCareActivity"}, {"end": 16, "start": 8, "tag": "PopulationGroup"}, {"end": 110, "start": 82, "tag": "HealthCareActivity"}]}
{"id": "1528_5", "text": "The mother proteins of candidate serum peptides were examined in autopsied AD brains.", "tags": [{"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 47, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1528_6", "text": "Results: Apart from A beta or tau, the present study discovered a new diagnostic 4-peptides-set biomarker for discriminating control, MCI, and AD with 87% of sensitivity and 65% of specificity between control and AD (***p < 0.001).", "tags": [{"end": 91, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "ClinicalAttribute"}, {"end": 52, "start": 47, "tag": "ResearchActivity"}, {"end": 137, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 158, "tag": "Finding"}, {"end": 192, "start": 181, "tag": "Finding"}, {"end": 132, "start": 125, "tag": "PopulationGroup"}, {"end": 208, "start": 201, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 70, "tag": "HealthCareActivity"}]}
{"id": "1528_7", "text": "MMSE score was well correlated to brain A beta deposition and to SPD of AD.", "tags": [{"end": 4, "start": 0, "tag": "HealthCareActivity"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "Finding"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 40, "tag": "PathologicFunction"}]}
{"id": "1528_8", "text": "The mother proteins of the four peptides were upregulated for coagulation, complement, and plasticity (three proteins), and was downregulated for anti-inflammation (one protein) in AD brains.", "tags": [{"end": 10, "start": 4, "tag": "PopulationGroup"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 85, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 163, "start": 146, "tag": "PharmacologicSubstance"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 151, "tag": "PathologicFunction"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1528_9", "text": "Conclusion: The present serum biomarker set provides a new, rapid, non-invasive, highly quantitative and low-cost clinical application for dementia screening, and also suggests an alternative pathomechanism of AD for neuroinflammation and neurovascular unit damage.", "tags": [{"end": 134, "start": 114, "tag": "HealthCareActivity"}, {"end": 257, "start": 239, "tag": "Cell"}, {"end": 79, "start": 67, "tag": "ClinicalAttribute"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 206, "start": 192, "tag": "PathologicFunction"}, {"end": 29, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "Finding"}, {"end": 212, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 30, "tag": "ClinicalAttribute"}, {"end": 234, "start": 217, "tag": "PathologicFunction"}, {"end": 157, "start": 148, "tag": "HealthCareActivity"}, {"end": 157, "start": 148, "tag": "ResearchActivity"}, {"end": 147, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 264, "start": 258, "tag": "InjuryOrPoisoning"}]}
{"id": "1529_0", "text": "Background: Progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia can be predicted by clinical features and a combination of biomarkers may increase the predictive power.", "tags": [{"end": 133, "start": 116, "tag": "ClinicalAttribute"}, {"end": 23, "start": 12, "tag": "PathologicFunction"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 155, "tag": "ClinicalAttribute"}, {"end": 57, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 27, "tag": "Finding"}, {"end": 199, "start": 183, "tag": "Finding"}]}
{"id": "1529_1", "text": "In the present study, we investigated whether the combination of olfactory function and plasma neuronal-derived exosome (NDE) A beta(1-42) can best predict progression to AD dementia.", "tags": [{"end": 119, "start": 112, "tag": "CellComponent"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "Cell"}, {"end": 182, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 156, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "TemporalConcept"}, {"end": 37, "start": 25, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 65, "tag": "BiologicFunction"}, {"end": 138, "start": 126, "tag": "ClinicalAttribute"}, {"end": 119, "start": 88, "tag": "ClinicalAttribute"}, {"end": 124, "start": 121, "tag": "CellComponent"}]}
{"id": "1529_2", "text": "Methods: 87 MCI patients were enrolled and received the cognitive assessment at 2-year and 3-year follow-up to reevaluate cognition.", "tags": [{"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 97, "start": 93, "tag": "TemporalConcept"}, {"end": 24, "start": 16, "tag": "PatientOrDisabledGroup"}, {"end": 15, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 66, "tag": "HealthCareActivity"}, {"end": 76, "start": 66, "tag": "ResearchActivity"}, {"end": 76, "start": 56, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "TemporalConcept"}, {"end": 131, "start": 122, "tag": "BiologicFunction"}]}
{"id": "1529_3", "text": "In the meanwhile, 80 healthy controls and 88 AD dementia patients were enrolled at baseline as well to evaluate the diagnose value in cross-section.", "tags": [{"end": 124, "start": 116, "tag": "HealthCareActivity"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 21, "tag": "OrganismAttribute"}, {"end": 37, "start": 21, "tag": "PopulationGroup"}, {"end": 56, "start": 48, "tag": "DiseaseOrSyndrome"}]}
{"id": "1529_4", "text": "Olfactory function was evaluated with the sniffin sticks (SS-16) and A beta(1-42) levels in NDEs were determined by ELISA.", "tags": [{"end": 121, "start": 116, "tag": "ResearchActivity"}, {"end": 81, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 56, "start": 42, "tag": "ManufacturedObject"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 96, "start": 69, "tag": "ClinicalAttribute"}]}
{"id": "1529_5", "text": "Logistic regression was performed to evaluate the risk factors for cognitive decline in MCI at 2-year and 3-year revisits.", "tags": [{"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 101, "start": 97, "tag": "TemporalConcept"}, {"end": 112, "start": 108, "tag": "TemporalConcept"}, {"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 50, "tag": "Finding"}]}
{"id": "1529_6", "text": "Results: In the cross cohort, lower SS-16 scores and higher A beta(1-42) levels in NDEs were found in MCI and AD dementia compared to healthy controls.", "tags": [{"end": 48, "start": 42, "tag": "Finding"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 134, "tag": "OrganismAttribute"}, {"end": 150, "start": 134, "tag": "PopulationGroup"}, {"end": 121, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 72, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 22, "tag": "PopulationGroup"}, {"end": 87, "start": 60, "tag": "ClinicalAttribute"}, {"end": 72, "start": 60, "tag": "BiologicallyActiveSubstance"}]}
{"id": "1529_7", "text": "For the longitudinal set, 8 MCI individuals developed AD dementia within 2 years, and 16 MCI individuals developed AD dementia within 3 years.", "tags": [{"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 32, "tag": "PopulationGroup"}, {"end": 104, "start": 93, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 75, "tag": "TemporalConcept"}, {"end": 141, "start": 136, "tag": "TemporalConcept"}, {"end": 20, "start": 8, "tag": "ResearchActivity"}]}
{"id": "1529_8", "text": "The two parameter-combination of SS-16 scores and A beta(1-42) level in NDEs showed better prediction in the conversion of MCI to AD dementia at 2-year and 3-year revisit.", "tags": [{"end": 151, "start": 147, "tag": "TemporalConcept"}, {"end": 162, "start": 158, "tag": "TemporalConcept"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "Finding"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 109, "tag": "Finding"}, {"end": 45, "start": 33, "tag": "HealthCareActivity"}, {"end": 76, "start": 50, "tag": "ClinicalAttribute"}]}
{"id": "1529_9", "text": "Moreover, after a 3-year follow-up, SS-16 scores also significantly predicted the conversion to AD dementia, where lower scores were associated with a 10-fold increased risk of developing AD dementia (p = 0.006).", "tags": [{"end": 24, "start": 20, "tag": "TemporalConcept"}, {"end": 127, "start": 121, "tag": "Finding"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 34, "start": 25, "tag": "TemporalConcept"}, {"end": 173, "start": 159, "tag": "Finding"}, {"end": 92, "start": 82, "tag": "Finding"}, {"end": 48, "start": 36, "tag": "HealthCareActivity"}]}
{"id": "1529_10", "text": "Similarly, higher A beta(1-42) levels in NDEs in patients with MCI increased the risk of developing AD dementia by 8.5-fold (p = 0.002).", "tags": [{"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 111, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 18, "tag": "ClinicalAttribute"}]}
{"id": "1529_11", "text": "Conclusion: A combination of two biomarkers of NDEs (A beta(1-42)) and SS-16 predicted the conversion of MCI to AD dementia more accurately in combination.", "tags": [{"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 33, "tag": "ClinicalAttribute"}, {"end": 108, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 91, "tag": "Finding"}, {"end": 76, "start": 71, "tag": "HealthCareActivity"}]}
{"id": "1529_12", "text": "These findings have critical implications for understanding the pathophysiology of AD dementia and for developing preventative treatments for cognitive decline.", "tags": [{"end": 137, "start": 114, "tag": "HealthCareActivity"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 64, "tag": "PathologicFunction"}, {"end": 79, "start": 64, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 159, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "BiologicFunction"}, {"end": 41, "start": 20, "tag": "Finding"}]}
{"id": "1530_0", "text": "Objective: To investigate variation in the characteristics of regional cerebral blood flow (rCBF), brain activity, and intrinsic functional connectivity (FC) across the Alzheimer's disease spectrum (ADS).", "tags": [{"end": 58, "start": 43, "tag": "OrganismAttribute"}, {"end": 113, "start": 99, "tag": "BiologicFunction"}, {"end": 156, "start": 154, "tag": "BiologicFunction"}, {"end": 197, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 62, "tag": "BiologicFunction"}, {"end": 96, "start": 92, "tag": "BiologicFunction"}, {"end": 152, "start": 129, "tag": "BiologicFunction"}]}
{"id": "1530_1", "text": "Methods: The study recruited 20 individuals in each of the following categories: Alzheimer's disease (AD), mild cognitive impairment (MCI), subjective cognitive decline (SCD), and healthy control (HC).", "tags": [{"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 43, "start": 32, "tag": "PopulationGroup"}, {"end": 168, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 180, "tag": "OrganismAttribute"}, {"end": 173, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 188, "tag": "PopulationGroup"}, {"end": 199, "start": 197, "tag": "PopulationGroup"}]}
{"id": "1530_2", "text": "All participants completed the 3.0T resting-state functional MRI (rs-fMRI) and arterial spin labeling scans in addition to neuropsychological tests.", "tags": [{"end": 147, "start": 123, "tag": "HealthCareActivity"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 64, "start": 31, "tag": "HealthCareActivity"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 147, "start": 142, "tag": "HealthCareActivity"}, {"end": 73, "start": 66, "tag": "HealthCareActivity"}, {"end": 107, "start": 79, "tag": "HealthCareActivity"}]}
{"id": "1530_3", "text": "Additionally, the normalized CBF, regional homogeneity (ReHo), and amplitude of low-frequency fluctuation (ALFF) of individual subjects were compared in the ADS.", "tags": [{"end": 32, "start": 29, "tag": "BiologicFunction"}, {"end": 160, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 54, "start": 34, "tag": "ResearchActivity"}, {"end": 105, "start": 67, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "ResearchActivity"}, {"end": 60, "start": 56, "tag": "ResearchActivity"}]}
{"id": "1530_4", "text": "Moreover, the changes in intrinsic FC were investigated across the ADS using the abnormal rCBF regions as seeds and behavioral correlations.", "tags": [{"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 94, "start": 90, "tag": "BiologicFunction"}, {"end": 139, "start": 127, "tag": "ResearchActivity"}]}
{"id": "1530_5", "text": "Finally, a support-vector classifier model of machine learning was used to distinguish individuals with ADS from HC.", "tags": [{"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 46, "tag": "MachineActivity"}, {"end": 42, "start": 11, "tag": "ResearchActivity"}, {"end": 98, "start": 87, "tag": "PopulationGroup"}, {"end": 115, "start": 113, "tag": "PopulationGroup"}]}
{"id": "1530_6", "text": "Results: Compared to the HC subjects, patients with AD showed the poorest level of rCBF in the left precuneus (LPCUN) and right middle frontal gyrus (RMFG) among all participants.", "tags": [{"end": 109, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 166, "tag": "PopulationGroup"}, {"end": 87, "start": 83, "tag": "HealthCareActivity"}, {"end": 36, "start": 28, "tag": "PopulationGroup"}]}
{"id": "1530_7", "text": "In addition, there was a significant decrease in the ALFF in the bilateral posterior cingulate cortex (PCC) and ReHo in the right PCC.", "tags": [{"end": 101, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 25, "tag": "Finding"}, {"end": 101, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "ResearchActivity"}, {"end": 116, "start": 112, "tag": "ResearchActivity"}]}
{"id": "1530_8", "text": "Moreover, RMFG- and LPCUN-based FC analysis revealed that the altered FCs were primarily located in the posterior brain regions.", "tags": [{"end": 43, "start": 35, "tag": "ResearchActivity"}, {"end": 127, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 70, "tag": "BiologicFunction"}, {"end": 34, "start": 32, "tag": "BiologicFunction"}]}
{"id": "1530_9", "text": "Finally, a combination of altered rCBF, ALFF, and ReHo in posterior cingulate cortex/precuneus (PCC/PCUN) showed a better ability to differentiate ADS from HC, AD from SCD and MCI, but not MCI from SCD.", "tags": [{"end": 150, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 122, "tag": "OrganismAttribute"}, {"end": 38, "start": 34, "tag": "BiologicFunction"}, {"end": 179, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 40, "tag": "ResearchActivity"}, {"end": 54, "start": 50, "tag": "ResearchActivity"}, {"end": 94, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 156, "tag": "PopulationGroup"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 198, "tag": "DiseaseOrSyndrome"}]}
{"id": "1530_10", "text": "Conclusions: The study demonstrated the significance of an altered rCBF and brain activity in the early stages of ADS.", "tags": [{"end": 90, "start": 76, "tag": "BiologicFunction"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 71, "start": 67, "tag": "HealthCareActivity"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 110, "start": 98, "tag": "TemporalConcept"}]}
{"id": "1530_11", "text": "These findings, therefore, present a potential diagnostic neuroimaging-based biomarker in ADS.", "tags": [{"end": 93, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "ClinicalAttribute"}, {"end": 70, "start": 58, "tag": "HealthCareActivity"}, {"end": 57, "start": 47, "tag": "HealthCareActivity"}]}
{"id": "1530_12", "text": "Additionally, the study provides a better understanding of the pathophysiology of AD.", "tags": [{"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 78, "start": 63, "tag": "PathologicFunction"}, {"end": 78, "start": 63, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 42, "tag": "BiologicFunction"}]}
{"id": "1531_0", "text": "Introduction: Previous in vivo optical coherence tomography studies have proposed the retinal choroid as a potential oculovascular biomarker for Alzheimer's disease (AD).", "tags": [{"end": 101, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 31, "tag": "HealthCareActivity"}, {"end": 93, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 14, "tag": "TemporalConcept"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 117, "tag": "ClinicalAttribute"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}]}
{"id": "1531_1", "text": "However, the clinical use of the choroid as a purported surrogate marker remains poorly understood.", "tags": [{"end": 40, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "PopulationGroup"}, {"end": 72, "start": 56, "tag": "ClinicalAttribute"}, {"end": 72, "start": 66, "tag": "ClinicalAttribute"}, {"end": 25, "start": 13, "tag": "Finding"}]}
{"id": "1531_2", "text": "We pursued a histopathological approach to assess choroidal thickness and vascular morphology in severe disease.", "tags": [{"end": 69, "start": 50, "tag": "ClinicalAttribute"}, {"end": 82, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 97, "tag": "Finding"}, {"end": 39, "start": 13, "tag": "ResearchActivity"}, {"end": 39, "start": 13, "tag": "HealthCareActivity"}, {"end": 93, "start": 74, "tag": "OrganismAttribute"}]}
{"id": "1531_3", "text": "Methods: Human postmortem tissues from 8 patients with AD (mean age: 80.1 +/- 12.7 years) and from 11 age-matched controls (mean age: 78.4 +/- 16.57 years) were analyzed.", "tags": [{"end": 33, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 114, "tag": "PopulationGroup"}, {"end": 49, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 67, "start": 64, "tag": "OrganismAttribute"}, {"end": 105, "start": 102, "tag": "OrganismAttribute"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 154, "start": 149, "tag": "TemporalConcept"}, {"end": 25, "start": 15, "tag": "TemporalConcept"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}, {"end": 14, "start": 9, "tag": "Eukaryote"}]}
{"id": "1531_4", "text": "Thickness, area, and vascularity of the retinal choroid and its sublayers were measured from the nasal and temporal quadrants of the superior retina.", "tags": [{"end": 55, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 55, "start": 33, "tag": "ClinicalAttribute"}, {"end": 15, "start": 11, "tag": "ClinicalAttribute"}, {"end": 55, "start": 21, "tag": "ClinicalAttribute"}]}
{"id": "1531_5", "text": "Results: Nasally, the choroid was thinner in the patients with AD than in the controls (22% thickness reduction; P < .001), but to our surprise, the choroid was thicker in the patients with AD than in the controls (similar to 60% increase; P < .03) within the macula, temporally.", "tags": [{"end": 29, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 266, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 92, "tag": "Finding"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "PopulationGroup"}, {"end": 213, "start": 205, "tag": "PopulationGroup"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 184, "start": 176, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1531_6", "text": "The choroidal area was also significantly greater in the patients with AD than in the controls (similar to 60% increase; P < .03).", "tags": [{"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 18, "start": 4, "tag": "ClinicalAttribute"}]}
{"id": "1531_7", "text": "Choroidal thickening in AD was strongly correlated with the stromal vessel number (R-2 = 0.96, P < .001).", "tags": [{"end": 74, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "Finding"}, {"end": 81, "start": 60, "tag": "ClinicalAttribute"}]}
{"id": "1531_8", "text": "Discussion: We found significant differences in the retinal choroid by layer and by region, nasally and temporally with respect to the optic nerve.", "tags": [{"end": 67, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 99, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}
{"id": "1531_9", "text": "Intriguingly, the choroid was markedly thicker in the central macular region and was strongly associated with vessel number in the stromal vascular layer.", "tags": [{"end": 25, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 110, "tag": "ClinicalAttribute"}]}
{"id": "1531_10", "text": "These quantified histological findings in severe disease expand our understanding of vascular pathology in AD and suggest vascularity as a potential biomarker supplementary to thickness when evaluating the retinal choroid in AD.", "tags": [{"end": 221, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "ClinicalAttribute"}, {"end": 103, "start": 94, "tag": "PathologicFunction"}, {"end": 103, "start": 94, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 68, "tag": "BiologicFunction"}, {"end": 158, "start": 139, "tag": "ClinicalAttribute"}, {"end": 56, "start": 42, "tag": "Finding"}, {"end": 133, "start": 122, "tag": "ClinicalAttribute"}]}
{"id": "1531_13", "text": "on behalf of the Alzheimer's Association.", "tags": [{"end": 40, "start": 17, "tag": "HealthCareRelatedOrganization"}]}